FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Stineman, MG Streim, JE Pan, Q Kurichi, JE Rose, SMSF Xie, DW AF Stineman, Margaret G. Streim, Joel E. Pan, Qiang Kurichi, Jibby E. Rose, Sophia Miryam Schuessler-Fiorenza Xie, Dawei TI Activity Limitation Stages Empirically Derived for Activities of Daily Living (ADL) and Instrumental ADL in the US Adult Community-Dwelling Medicare Population SO PM&R LA English DT Article ID HOME ACCESSIBILITY FEATURES; HEALTH-CARE UTILIZATION; SELF-RATED HEALTH; FUNCTIONAL DISABILITY; ELDERLY-PEOPLE; INDEPENDENCE; IMPACT; REHABILITATION; IMPROVEMENT; MORTALITY AB Background: Stages quantify severity like conventional measures but further specify the activities that people are still able to perform without difficulty. Objective: To develop Activity Limitation Stages for defining and monitoring groups of adult community-dwelling Medicare beneficiaries. Design: Cross-sectional. Setting: Community. Participants: There were 14,670 respondents to the 2006 Medicare Current Beneficiary Survey. Methods: Stages were empirically derived for the Activities of Daily Living (ADLs) and the Instrumental Activities of Daily Living (IADLs) by profiling the distribution of performance difficulties as reported by beneficiaries or their proxies. Stage prevalence estimates were determined, and associations with demographic and health variables were examined for all community-dwelling Medicare beneficiaries. Main Outcome Measurements: ADL and IADL stage prevalence. Results: Stages (0-IV) define 5 groups across the separate ADL and IADL domains according to hierarchically organized profiles of retained abilities and difficulties. For example, at ADL-I, people are guaranteed to be able to eat, toilet, dress, and bathe/shower without difficulty, whereas they experience limitations getting in and out of bed or chairs and/or difficulties walking. In 2006, an estimated 6.0, 2.9, 2.2, and 0.5 million beneficiaries had mild (ADL-I), moderate (ADL-II), severe (ADL-III), and complete (ADL-IV) difficulties, respectively, with estimates for IADL stages even higher. ADL and IADL stages showed expected associations with age and health-related concepts, supporting construct validity. Stages showed the strongest associations with conditions that impair cognition. Conclusions: Stages as aggregate measures reveal the ADLs and IADLs that people are still able to do without difficulty, along with those activities in which they report having difficulty, consequently emphasizing how groups of people with difficulties can still participate in their own lives. Over the coming decades, stages applied to populations served by vertically integrated clinical practices could facilitate large-scale planning, with the goal of maximizing personal autonomy among groups of community-dwelling people with disabilities. C1 [Stineman, Margaret G.; Pan, Qiang; Xie, Dawei] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Stineman, Margaret G.] Univ Penn, Perelman Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA. [Streim, Joel E.] Univ Penn, Perelman Sch Med, Dept Psychiat, Geriatr Psychiat Sect, Philadelphia, PA 19104 USA. [Streim, Joel E.; Rose, Sophia Miryam Schuessler-Fiorenza] Philadelphia Vet Affairs Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA. [Kurichi, Jibby E.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Rose, Sophia Miryam Schuessler-Fiorenza] VA Healthcare Syst Palo Alto, Spinal Cord Injury Serv, Palo Alto, CA USA. RP Kurichi, JE (reprint author), Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, 423 Guardian Dr,907 Blockley Hall, Philadelphia, PA 19104 USA. EM jkurichi@mail.med.upenn.edu RI Schussler-Fiorenza Rose, Sophia Miryam/E-6411-2013 OI Schussler-Fiorenza Rose, Sophia Miryam/0000-0002-6311-6671 FU National Institute of Aging of the National Institutes of Health [AG032420-01A1, R01 AG 040105-01A1] FX The research for this manuscript was supported by grants from the National Institute of Aging of the National Institutes of Health (AG032420-01A1 and R01 AG 040105-01A1). NR 42 TC 9 Z9 9 U1 4 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 EI 1934-1563 J9 PM&R JI PM&R PD NOV PY 2014 VL 6 IS 11 BP 976 EP 987 DI 10.1016/j.pmrj.2014.05.001 PG 12 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA AU4YJ UT WOS:000345614000003 PM 24798263 ER PT J AU Grubaugh, AL Gros, KS Davidson, TM Frueh, BC Ruggiero, KJ AF Grubaugh, Anouk L. Gros, Kirstin Stauffacher Davidson, Tatiana M. Frueh, B. Christopher Ruggiero, Kenneth J. TI Providers' Perspectives Regarding the Feasibility and Utility of an Internet-Based Mental Health Intervention for Veterans SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY LA English DT Article DE Internet-based intervention; web-based intervention; PTSD; mental health; veterans; qualitative ID POSTTRAUMATIC-STRESS-DISORDER; CARE; IRAQ; AFGHANISTAN; BARRIERS; COMBAT; PTSD; DISSEMINATION; PERCEPTIONS; DEPLOYMENT AB Although support for Internet-based interventions (IBIs) has grown significantly in the past decade, few interventions are designed specifically for veterans with posttraumatic stress disorder and other mental health problems. Additionally, research guiding IBI development is limited. We solicited feedback from providers familiar with the needs and preferences of Operation Iraqi Freedom and Operation Enduring Freedom (OIF/OEF) veterans with mental health problems to inform the development of an IBI. Thematic interviews were conducted with 17 Veterans Affairs providers to (a) gain insight into the unique problems and needs of OIF/OEF veterans, (b) obtain feedback on the content and presentation of the IBI, and (c) generate suggestions regarding the effective delivery of the IBI. Providers were receptive to the use of IBIs and were vocal in their need for novel approaches and tools to address the mental health needs of their patients. They noted several advantages to IBIs such as their ability to circumvent access-to-care barriers and their ease of use and likely appeal to OIF/OEF veterans. They also noted challenges associated with IBIs, including obtaining sufficient motivation and buy-in from veterans given the distal nature of IBIs. Finally, providers offered several recommendations regarding the content and design of the IBI, as well as strategies for effective marketing and dissemination. Provider feedback was valuable in the development of an IBI that is responsive to the mental health needs of OIF/OEF veterans and in learning about how best to promote IBIs. Similar approaches can be used by stakeholders interested in developing IBIs for novel populations and settings. C1 [Grubaugh, Anouk L.; Gros, Kirstin Stauffacher; Ruggiero, Kenneth J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Grubaugh, Anouk L.; Gros, Kirstin Stauffacher; Davidson, Tatiana M.; Ruggiero, Kenneth J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Honolulu, HI 96822 USA. [Frueh, B. Christopher] Menninger Clin, Houston, TX USA. RP Grubaugh, AL (reprint author), Ralph H Johnson Vet Affairs Med Ctr, 109 Bee St, Charleston, SC 29401 USA. EM grubaugh@musc.edu NR 25 TC 1 Z9 1 U1 0 U2 4 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1942-9681 EI 1942-969X J9 PSYCHOL TRAUMA-US JI Psychol. Trauma PD NOV PY 2014 VL 6 IS 6 BP 624 EP 631 DI 10.1037/a0035772 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AU2NC UT WOS:000345454200005 ER PT J AU Yilmaz, E Hough, KA Gebhart, GF Williams, BA Gold, MS AF Yilmaz, Eser Hough, Karen A. Gebhart, Gerald F. Williams, Brian A. Gold, Michael S. TI Mechanisms Underlying Midazolam-Induced Peripheral Nerve Block and Neurotoxicity SO REGIONAL ANESTHESIA AND PAIN MEDICINE LA English DT Article ID TRANSLOCATOR PROTEIN TSPO; ROOT GANGLION NEURONS; INTRATHECAL MIDAZOLAM; BUPIVACAINE IMPROVES; GABA(A) RECEPTORS; RAT; ANALGESIA; INFLAMMATION; ANESTHETICS; ADJUVANTS AB Background and Objectives: The benzodiazepine midazolam has been reported to facilitate the actions of spinally administrated local anesthetics. Interestingly, despite the lack of convincing evidence for the presence of gamma-aminobutyric acid type A (GABA(A)) receptors along peripheral nerve axons, midazolam also has been shown to have analgesic efficacy when applied alone to peripheral nerves. These observations suggest midazolam-induced nerve block is due to another site of action. Furthermore, because of evidence indicating that midazolam has equal potency at the benzodiazepine site on the GABA(A) receptor and the 18-kd translocator protein (TSPO), it is possible that at least the nerve-blocking actions of midazolam are mediated by this alternative site of action. Methods: We used the benzodiazepine receptor antagonist flumazenil, and the TSPO antagonist PK11195, with midazolam on rat sciatic nerves and isolated sensory neurons to determine if either receptor mediates midazolam-induced nerve block and/or neurotoxicity. Results: Midazolam (300 mu M)-induced block of nerve conduction was reversed by PK11195 (3 mu M), but not flumazenil (30 mu M). Midazolam-induced neurotoxicity was blocked by neither PK11195 nor flumazenil. Midazolam also causes the release of Ca2+ from internal stores in sensory neurons, and there was a small but significant attenuation of midazolam-induced neurotoxicity by the Ca2+ chelator, BAPTA. BAPTA (30 mu M) significantly attenuated midazolam-induced nerve block. Conclusions: Our results indicate that processes underlying midazolam-induced nerve block and neurotoxicity are separable, and suggest that selective activation of TSPO may facilitate modality-selective nerve block while minimizing the potential for neurotoxicity. C1 [Yilmaz, Eser; Hough, Karen A.; Gebhart, Gerald F.; Williams, Brian A.; Gold, Michael S.] Univ Pittsburgh, Sch Med, Ctr Pain Res, Pittsburgh, PA USA. [Yilmaz, Eser; Hough, Karen A.; Gebhart, Gerald F.; Williams, Brian A.; Gold, Michael S.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA. [Williams, Brian A.] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. RP Gold, MS (reprint author), 3500 Terrace St,Room E1440 BST, Pittsburgh, PA 15139 USA. EM msg22@pitt.edu OI Gold, Michael/0000-0002-2083-6206 FU Department of Defense [OR090012] FX This research is supported by the Department of Defense grant OR090012 to B.A.W., M.S.G., and G.F.G. NR 25 TC 6 Z9 6 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1098-7339 EI 1532-8651 J9 REGION ANESTH PAIN M JI Region. Anesth. Pain Med. PD NOV-DEC PY 2014 VL 39 IS 6 BP 525 EP 533 DI 10.1097/AAP.0000000000000176 PG 9 WC Anesthesiology SC Anesthesiology GA AT4SZ UT WOS:000344933500014 PM 25304479 ER PT J AU Nishio, I AF Nishio, Isuta TI Cervical Transforaminal Epidural Steroid Injections A Proposal for Optimizing the Preprocedural Evaluation With Available Imaging SO REGIONAL ANESTHESIA AND PAIN MEDICINE LA English DT Article ID VERTEBRAL ARTERY; COMPLICATIONS; HYPOPLASIA AB Cervical transforaminal epidural steroid injection (CTFESI) has been used to treat cervical radicular pain; however, rare but serious complications such as cerebellar or spinal cord infarction have been reported. The most probable causes of the serious complications include vertebral artery trauma, spasm, or accidental arterial injection of particulate steroid. Several recommendations have been made to improve the safety of CTFESI; however, evaluation and risk assessment of the patient's anatomy by the interventionist have not been sufficiently emphasized. Significant correlations between foraminal narrowing and proximity of the vertebral artery to the target of needle have been reported. This correlation is particularly problematic for interventionists because patients considered or referred for CTFESI are more likely to have foraminal narrowing at the level concerned. Without knowing the patient's anatomy, a common practice of rotating the C-arm obliquely to obtain a full view of the target foramen may carry significant risk of needle's encounter with the vertebral artery. Risk assessment through careful preprocedural review of the patient's magnetic resonance imaging by the interventionist is a worthwhile practice to optimize safety. Special attention should be paid to the vital structures such as the vertebral artery, neural foramen, and carotid artery. A preprocedural roadmap for the safest predicted needle trajectory can be created by simulation using the patient's available magnetic resonance imaging scans. These considerations may guide and help the interventionist to minimize the risk of inadvertent needle placement involving vital structures such as the vertebral artery or carotid artery. C1 [Nishio, Isuta] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98108 USA. RP Nishio, I (reprint author), Univ Washington, Dept Anesthesiol & Pain Med, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-112 Anes, Seattle, WA 98108 USA. EM nishioi@uw.edu NR 17 TC 3 Z9 3 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1098-7339 EI 1532-8651 J9 REGION ANESTH PAIN M JI Region. Anesth. Pain Med. PD NOV-DEC PY 2014 VL 39 IS 6 BP 546 EP 549 DI 10.1097/AAP.0000000000000164 PG 4 WC Anesthesiology SC Anesthesiology GA AT4SZ UT WOS:000344933500017 PM 25304477 ER PT J AU Jindai, K Kunzer, B Van, TT Striker, R AF Jindai, Kazuaki Kunzer, Bethaney Van, Tam T. Striker, Rob TI Human immunodeficiency virus testing pitfalls and clinical suspicion SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID ACUTE HIV-INFECTION; PERFORMANCE; ALGORITHM AB Universal human immunodeficiency virus (HIV) screening was recommended in 2012, and major improvements in HIV testing have occurred in the past decade, but identification of HIV infected individuals remains inadequate in the United States. We report the case of a seronegative HIV-infected man who despite clinical and laboratory findings of acquired immunodeficiency syndrome, repeatedly tested nonreactive to third-generation HIV enzyme immunoassays (EIAs) and Western blot testing. Serologic diagnosis in this case required fourth-generation EIA testing due to the seronegativity of standard testing. The fourth-generation HIV EIA was positive presumably because it detects p24 HIV antigen as well as antibodies, unlike rapid HIV tests and third-generation HIV EIAs. This case highlights not only the importance of frontline providers to understand the different testing methodologies for HIV screening and their limitations but the importance of clinical suspicion as well. C1 [Jindai, Kazuaki; Kunzer, Bethaney; Striker, Rob] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Infect Dis Sect, Madison, WI 53706 USA. [Van, Tam T.] Univ Wisconsin, Wisconsin State Lab Hyg, Madison, WI 53706 USA. [Striker, Rob] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Jindai, K (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Infect Dis Sect, Madison, WI 53706 USA. EM rstriker@wisc.edu NR 10 TC 0 Z9 0 U1 1 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 EI 1532-8171 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD NOV PY 2014 VL 32 IS 11 AR 1442.e1 DI 10.1016/j.ajem.2014.04.017 PG 2 WC Emergency Medicine SC Emergency Medicine GA AT4ZC UT WOS:000344951600056 PM 24856744 ER PT J AU Prieto-Centurion, V Rolle, AJ Au, DH Carson, SS Henderson, AG Lee, TA Lindenauer, PK McBurnie, MA Mularski, RA Naureckas, ET Vollmer, WM Joese, BJ Krishnan, JA AF Prieto-Centurion, Valentin Rolle, Andrew J. Au, David H. Carson, Shannon S. Henderson, Ashley G. Lee, Todd A. Lindenauer, Peter K. McBurnie, Mary A. Mularski, Richard A. Naureckas, Edward T. Vollmer, William M. Joese, Binoy J. Krishnan, Jerry A. CA CONCERT Consortium TI Multicenter Study Comparing Case Definitions Used to Identify Patients with Chronic Obstructive Pulmonary Disease SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE COPD; spirometry; ICD-9-CM; comparative effectiveness; case definitions ID AIRWAY-OBSTRUCTION; UNITED-STATES; PRIMARY-CARE; COPD; EXACERBATIONS; DIAGNOSIS; VALIDITY; SPIROMETRY; HOSPITALIZATIONS; PREVENTION AB Rationale: Clinical trials in chronic obstructive pulmonary disease (COPD) usually require evidence of airflow obstruction and clinical risk factors. International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes or patient-reported physician diagnoses are often used for epidemiologic studies and performance improvement programs. Objectives: To evaluate agreement between these case definitions for COPD and to assess the comparability of study populations identified as having COPD not using the clinical trial reference standard. Methods: We recruited patients from the COPD Outcomes-based Network for Clinical Effectiveness and Research Translation multicenter clinical registry in a cross-sectional study. Demographics, clinical, and post-bronchodilator spirometry data were collected at an in-person study visit. The kappa statistic (kappa) was used to evaluate agreement. A multivariable logistic regression model was used to identify patient characteristics associated with meeting the trial reference standard. Measurements and Main Results: A total of 998 (82.8%) of 1,206 study participants met at least one case definition for COPD (of the 998: 91% using ICD-9 codes, 73% using patient reported physician diagnosis, 56% using trial reference standard); agreement between case definitions was poor (kappa = 0.20-0.26). Lack of airflow obstruction was the principal (89%) reason patients identified as having COPD did not meet the trial reference standard. Patients who were black (vs white), obese (vs normal weight), or had depression (vs. not) were less likely to meet the trial reference standard (odds ratio [95% CI], 0.37 [0.26-0.53], 0.51 [0.34-0.75], 0.53 [0.40-0.71], respectively). Conclusions: Findings highlight concerns about the applicability of findings in clinical trials to patients meeting other case definitions for COPD. C1 [Prieto-Centurion, Valentin; Rolle, Andrew J.; Krishnan, Jerry A.] Univ Illinois, Div Pulm Crit Care Sleep & Allergy, Chicago, IL 60612 USA. [Lee, Todd A.] Univ Illinois, Dept Pharm Syst Outcomes & Policy, Chicago, IL 60612 USA. [Au, David H.] Univ Washington, VA Puget Sound, Seattle, WA 98195 USA. [Carson, Shannon S.; Henderson, Ashley G.] Univ N Carolina, Div Pulm & Crit Care Med, Chapel Hill, NC USA. [Lindenauer, Peter K.] Baystate Med Ctr, Dept Med, Springfield, MA 01199 USA. [Lindenauer, Peter K.] Baystate Med Ctr, Ctr Qual Care Res, Springfield, MA 01199 USA. [Lindenauer, Peter K.] Tufts Univ, Sch Med, Boston, MA 02111 USA. [McBurnie, Mary A.; Mularski, Richard A.; Vollmer, William M.] Kaiser Permanente, Ctr Hlth Res, Portland, OR USA. [Naureckas, Edward T.] Univ Chicago Med, Sect Pulm & Crit Care, Chicago, IL USA. [Joese, Binoy J.; Krishnan, Jerry A.] Univ Illinois Hosp & Hlth Sci Syst, Populat Hlth Sci Program, Chicago, IL USA. RP Prieto-Centurion, V (reprint author), Univ Illinois, 912 South Wood St,MC 719, Chicago, IL 60612 USA. EM vprieto@uic.edu FU National Heart, Lung, and Blood Institute [RC2 HL101618]; National Institutes of Health [2T32HL082547]; Patient-Centered Outcomes Research Institute [IH-12-11-4365, CE-1304-6490, PPRN-1306-04748] FX Supported by the National Heart, Lung, and Blood Institute (RC2 HL101618) for CONCERT; National Institutes of Health T32 (2T32HL082547) institutional training grant (V.P.-C.); and Patient-Centered Outcomes Research Institute contracts IH-12-11-4365, CE-1304-6490, and PPRN-1306-04748 (J.A.K.). NR 31 TC 8 Z9 8 U1 1 U2 6 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD NOV 1 PY 2014 VL 190 IS 9 BP 989 EP 995 DI 10.1164/rccm.201406-1166OC PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AT8RN UT WOS:000345199900009 PM 25192554 ER PT J AU Restrepo, MI Anzueto, A AF Restrepo, Marcos I. Anzueto, Antonio TI Azithromycin: We're There! Reply SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Letter ID EXACERBATIONS; PREVENTION C1 [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, San Antonio, TX 78258 USA. Univ Texas San Antonio, Hlth Sci Ctr, San Antonio, TX USA. RP Restrepo, MI (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX 78258 USA. NR 5 TC 1 Z9 1 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD NOV 1 PY 2014 VL 190 IS 9 BP 1075 EP 1076 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AT8RN UT WOS:000345199900021 PM 25360733 ER PT J AU Odden, MC Shlipak, MG Whitson, HE Katz, R Kearney, PM Defilippi, C Shastri, S Sarnak, MJ Siscovick, DS Cushman, M Psaty, BM Newman, AB AF Odden, Michelle C. Shlipak, Michael G. Whitson, Heather E. Katz, Ronit Kearney, Patricia M. defilippi, Chris Shastri, Shani Sarnak, Mark J. Siscovick, David S. Cushman, Mary Psaty, Bruce M. Newman, Anne B. TI Risk factors for cardiovascular disease across the spectrum of older age: The Cardiovascular Health Study SO ATHEROSCLEROSIS LA English DT Article DE Aging; Epidemiology; Risk factors ID CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; BODY-MASS INDEX; BLOOD-PRESSURE; MORTALITY RISK; CYSTATIN-C; MYOCARDIAL-INFARCTION; CHOLESTEROL LEVELS; FOLLOW-UP; ASSOCIATION AB Objective: The associations of some risk factors with cardiovascular disease (CVD) are attenuated in older age; whereas others appear robust. The present study aimed to compare CVD risk factors across older age. Methods: Participants (n = 4883) in the Cardiovascular Health Study free of prevalent CVD, were stratified into three age groups: 65-74, 75-84, 85+ years. Traditional risk factors included systolic blood pressure (BP), LDL-cholesterol, HDL-cholesterol, obesity, and diabetes. Novel risk factors included kidney function, C-reactive protein (CRP), and N-terminal pro-B-type natriuretic peptide (NT pro-BNP). Results: There were 1498 composite CVD events (stroke, myocardial infarction, and cardiovascular death) over 5 years. The associations of high systolic BP and diabetes appeared strongest, though both were attenuated with age (p-values for interaction = 0.01 and 0.002, respectively). The demographic-adjusted hazard ratios (HR) for elevated systolic BP were 1.79 (95% confidence interval: 1.49, 2.15), 1.59 (1.37, 1.85) and 1.10 (0.86, 1.41) in participants aged 65-74, 75-84, 85+, and for diabetes, 2.36 (1.89, 2.95), 1.55 (1.27, 1.89), 1.51 (1.10, 2.09). The novel risk factors had consistent associations with the outcome across the age spectrum; low kidney function: 1.69 (1.31, 2.19), 1.61 (1.36, 1.90), and 1.57 (1.16, 2.14) for 65-74, 75-84, and 85+ years, respectively; elevated CRP: 1.54 (1.28, 1.87), 1.33 (1.13, 1.55), and 1.51 (1.15, 1.97); elevated NT pro-BNP: 2.67 (1.96, 3.64), 2.71 (2.25, 3.27), and 2.18 (1.43, 3.45). Conclusions: The associations of most traditional risk factors with CVD were minimal in the oldest old, whereas diabetes, eGFR, CRP, and NT pro-BNP were associated with CVD across older age. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 [Odden, Michelle C.] Oregon State Univ, Sch Biol & Populat Hlth Sci, Corvallis, OR 97331 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Gen Internal Med, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Whitson, Heather E.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Whitson, Heather E.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA. [Whitson, Heather E.] Geriatr Res Educ & Clin Ctr, Durham VA Med Ctr, Durham, NC USA. [Katz, Ronit] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Kearney, Patricia M.] Natl Univ Ireland Univ Coll Cork, Dept Epidemiol & Publ Hlth, Cork, Ireland. [defilippi, Chris] Univ Maryland, Div Cardiovasc Med, Baltimore, MD 21201 USA. [Shastri, Shani] Univ Texas SW Med Ctr Dallas, Div Nephrol, Dallas, TX 75390 USA. [Sarnak, Mark J.] Tufts Med Ctr, Dept Med, Div Nephrol, Boston, MA USA. [Siscovick, David S.; Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Siscovick, David S.; Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA USA. [Siscovick, David S.; Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Siscovick, David S.] New York Acad Med, New York, NY USA. [Cushman, Mary] Univ Vermont, Dept Med, Burlington, VT USA. [Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. [Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. RP Odden, MC (reprint author), Oregon State Univ, Sch Biol & Populat Hlth Sci, 141B Milam Hall, Corvallis, OR 97331 USA. EM Michelle.Odden@oregonstate.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU National Heart, Lung, and Blood Institute (NHLBI) [HHSN268201200036C, N01HC85239, N01 HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, HL080295]; National Institute on Aging (NIA) [R01AG023629, R01AG027002, K01AG039387, K23AG032867, P30AG028716, R01AG043438]; American Heart Association Western States Affiliate [11CRP7210088] FX This research was supported by contracts HHSN268201200036C, N01HC85239, N01 HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grant HL080295 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629 and R01AG027002 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org/PI.htm.; Dr. Odden is supported by the American Heart Association Western States Affiliate (11CRP7210088) and the National Institute on Aging (K01AG039387). Dr. Whitson is supported by the National Institute on Aging K23AG032867, P30AG028716, and R01AG043438. NR 39 TC 12 Z9 13 U1 2 U2 9 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 EI 1879-1484 J9 ATHEROSCLEROSIS JI Atherosclerosis PD NOV PY 2014 VL 237 IS 1 BP 336 EP 342 DI 10.1016/j.atherosclerosis.2014.09.012 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AT5WT UT WOS:000345011300050 PM 25303772 ER PT J AU Allott, EH Howard, LE Cooperberg, MR Kane, CJ Aronson, WJ Terris, MK Amling, CL Freedland, SJ AF Allott, Emma H. Howard, Lauren E. Cooperberg, Matthew R. Kane, Christopher J. Aronson, William J. Terris, Martha K. Amling, Christopher L. Freedland, Stephen J. TI Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID HIGH-DENSITY-LIPOPROTEIN; METABOLIC SYNDROME; HDL CHOLESTEROL; STATIN USE; COHORT; GRADE; ASSOCIATION; PREVENTION; MORTALITY; OBESITY AB Background: Evidence for an association between total cholesterol, low- and high-density lipoproteins (LDL and HDL, respectively), triglycerides, and prostate cancer is conflicting. Given that prostate cancer and dyslipidemia affect large proportions of Western society, understanding these associations has public health importance. Methods: We conducted a retrospective cohort analysis of 843 radical prostatectomy (RP) patients who never used statins before surgery within the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Multivariable Cox proportional hazards analysis was used to investigate the association between cholesterol, LDL, HDL, and triglycerides and biochemical recurrence risk. In secondary analysis, we explored these associations in patients with dyslipidemia, defined using National Cholesterol Education Program guidelines. Results: Elevated serum triglycerides were associated with increased risk of prostate cancer recurrence [HRper 10mg/dl, 1.03; 95% confidence interval (CI), 1.01-1.05] but associations between total cholesterol, LDL and HDL, and recurrence risk were null. However, among men with dyslipidemia, each 10 mg/dl increase in cholesterol and HDL was associated with 9% increased recurrence risk (HR, 1.09; 95% CI, 1.01-1.17) and 39% reduced recurrence risk (HR, 0.61; 95% CI, 0.41-0.91), respectively. Conclusions: Elevated serum triglycerides were associated with increased risk of prostate cancer recurrence. Cholesterol, LDL, or HDL were not associated with recurrence risk among all men. However, among men with dyslipidemia, elevated cholesterol and HDL levels were associated with increased and decreased risk of recurrence, respectively. Impact: These findings, coupled with evidence that statin use is associated with reduced recurrence risk, suggest that lipid levels should be explored as a modifiable risk factor for prostate cancer recurrence. (C) 2014 AACR. C1 [Allott, Emma H.; Howard, Lauren E.; Freedland, Stephen J.] Duke Univ, Sch Med, Dept Surg, Div Urol, Durham, NC 27710 USA. [Allott, Emma H.] Duke Canc Inst, Canc Prevent Detect & Control Program, Durham, NC USA. [Allott, Emma H.; Howard, Lauren E.; Freedland, Stephen J.] Vet Affairs Med Ctr Durham, Div Urol, Durham, NC USA. [Howard, Lauren E.] Duke Univ, Sch Med, Dept Biostat & Bioinformat, Durham, NC 27710 USA. [Cooperberg, Matthew R.] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Urol, San Francisco, CA USA. [Kane, Christopher J.] Univ Calif San Diego Hlth Syst, Dept Urol, San Diego, CA USA. [Aronson, William J.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA. [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. [Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA. [Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. [Amling, Christopher L.] Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97201 USA. [Freedland, Stephen J.] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA. RP Freedland, SJ (reprint author), Duke Univ, Sch Med, DUMC 2626,571 Res Dr, Durham, NC 27710 USA. EM steve.freedland@duke.edu OI Terris, Martha/0000-0002-3843-7270 FU NCI [5R25-CA126938-03]; NIH [1-R01-CA131235-01A1, 1K24CA160653] FX This study was supported by grants from the NCI (5R25-CA126938-03; to E.H. Allott) and NIH (1-R01-CA131235-01A1 and 1K24CA160653; to S.J. Freedland). NR 33 TC 18 Z9 19 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD NOV PY 2014 VL 23 IS 11 BP 2349 EP 2356 DI 10.1158/1055-9965.EPI-14-0458 PG 8 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA AT9YL UT WOS:000345279600017 PM 25304929 ER PT J AU Jhund, PS Claggett, BL Voors, AA Zile, MR Packer, M Pieske, BM Kraigher-Krainer, E Shah, AM Prescott, MF Shi, V Lefkowitz, M McMurray, JJV Solomon, SD AF Jhund, Pardeep S. Claggett, Brian L. Voors, Adriaan A. Zile, Michael R. Packer, Milton Pieske, Burkert M. Kraigher-Krainer, Elisabeth Shah, Amil M. Prescott, Margaret F. Shi, Victor Lefkowitz, Marty McMurray, John J. V. Solomon, Scott D. CA PARAMOUNT Investigators TI Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696 SO CIRCULATION-HEART FAILURE LA English DT Article DE heart failure; neprilysin; troponin T ID SYSTOLIC FUNCTION; NATRIURETIC PEPTIDE; PREVALENCE; TRIAL; HYPERTROPHY; ASSOCIATION; RELAXATION; BIOMARKERS; DEATH; RISK AB Background-Elevated high-sensitivity troponin is associated with increasing disease severity in patients with stable heart failure with reduced ejection fraction, but less is known about the association in heart failure with preserved ejection fraction. Methods and Results-We examined the prevalence of elevated high-sensitivity troponin T (hs-TnT) in 298 patients with heart failure with preserved ejection fraction enrolled in the Prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin receptor blocker on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) trial, in which the angiotensin receptor neprilysin inhibitor LCZ696 reduced markers of heart failure severity compared with valsartan. We assessed the association between hs-TnT and cardiac structure and function, and the effect of LCZ696, compared with valsartan, on hs-TnT over 36 weeks. Elevated hs-TnT in the myocardial injury range (>0.014 mu g/L) was found in 55% of patients and was associated with older age, history of diabetes mellitus, higher N-terminal pro-brain natriuretic peptide, lower estimated glomerular filtration rate, and larger left atrial size, left ventricular volume, and mass. LCZ696 treatment reduced hs-TnT to a greater extent at 12 weeks (12% reduction; P=0.05) and at 36 weeks (14% reduction; P=0.03) compared with valsartan. Conclusions-Troponin T was elevated in a substantial number of patients enrolled in a heart failure with preserved ejection fraction clinical trial and was associated with abnormalities of cardiac structure, function, and elevated baseline N-terminal pro-brain natriuretic peptide. Decreases in hs-TnT with LCZ696 in parallel with improvement in N-terminal pro-brain natriuretic peptide and left atrial size suggest that the angiotensin receptor neprilysin inhibitor LCZ696 may reduce this measure of myocardial injury in heart failure with preserved ejection fraction. C1 [Jhund, Pardeep S.; Claggett, Brian L.; Shah, Amil M.; Solomon, Scott D.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. [Jhund, Pardeep S.; McMurray, John J. V.] Univ Glasgow, Inst Cardiovasc & Med Sci, BHF Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Zile, Michael R.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC USA. [Packer, Milton] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. [Pieske, Burkert M.; Kraigher-Krainer, Elisabeth] Med Univ Graz, Dept Cardiol, Graz, Austria. [Prescott, Margaret F.; Shi, Victor; Lefkowitz, Marty] Novartis Pharmaceut, E Hanover, NJ USA. RP Solomon, SD (reprint author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA. EM ssolomon@rics.bwh.harvard.edu RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Jhund, Pardeep/0000-0003-4306-5317; mcmurray, john/0000-0002-6317-3975 FU Novartis Pharmaceuticals, East Hanover, NJ FX The PARAMOUNT trial was funded by Novartis Pharmaceuticals, East Hanover, NJ. NR 28 TC 22 Z9 24 U1 3 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD NOV PY 2014 VL 7 IS 6 BP 953 EP U129 DI 10.1161/CIRCHEARTFAILURE.114.001427 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AU0BS UT WOS:000345288800013 PM 25277997 ER PT J AU Oluleye, OW Rector, TS Win, S McMurray, JJV Zile, MR Komajda, M McKelvie, RS Massie, B Carson, PE Anand, IS AF Oluleye, Oludamilola W. Rector, Thomas S. Win, Sithu McMurray, John J. V. Zile, Michael R. Komajda, Michel McKelvie, Robert S. Massie, Barry Carson, Peter E. Anand, Inder S. TI History of Atrial Fibrillation as a Risk Factor in Patients With Heart Failure and Preserved Ejection Fraction SO CIRCULATION-HEART FAILURE LA English DT Article DE atrial fibrillation; heart failure; preserved ejection fraction; prognosis; stroke ID VENTRICULAR SYSTOLIC DYSFUNCTION; ACC/AHA/ESC 2006 GUIDELINES; EUROPEAN-SOCIETY; TASK-FORCE; MANAGEMENT; STROKE; ASSOCIATION; MORTALITY; INSIGHTS; MORBIDITY AB Background-Atrial fibrillation (AFib) is common in heart failure (HF) with preserved ejection fraction (HFpEF). Current AFib stroke risk prediction models include the presence of HF but do not specifically include HFpEF as a risk factor. Whether a history of AFib should be used to identify patients with HFpEF who are at risk has not been established. Methods and Results-Baseline characteristics and outcomes of patients with HFpEF in the Irbesartan in Heart Failure with Preserved Ejection Fraction Trial were analyzed in relation to AFib. At baseline, 1209 (29.3%) had a history of AFib. Of these 557 (13.5%) had history of AFib alone, whereas 670 (16.2%) had both a history and AFib on ECG; 2901 (70.3%) had neither. There were no significant differences in the risk of stroke between the 2 groups with a history of AFib who did or did not have AFib present on baseline ECG. During a median follow-up of 53 months, a fatal or nonfatal stroke occurred in 6.5% (79/1209) patients with history of AFib compared with 3.9% (114/2901) with no AFib. Having a history of AFib was independently associated with higher risk of stroke (hazard ratio, 2.2; 95% confidence interval, 1.6-3.2; P<0.0001) compared with those with no history of AFib. Conclusions-In patients with HFpEF, a history of AFib was common and independently associated with increased risk of stroke, regardless of whether AFib was present on ECG. Patients with HFpEF and a history of AFib should be considered at risk. Further studies are needed to determine whether this risk can be safely reduced. C1 [Oluleye, Oludamilola W.; Rector, Thomas S.; Win, Sithu; Anand, Inder S.] VA Med Ctr, Dept Med, Minneapolis, MN 55417 USA. [Oluleye, Oludamilola W.; Rector, Thomas S.; Win, Sithu; Anand, Inder S.] Univ Minnesota, Minneapolis, MN USA. [McMurray, John J. V.] British Heart Fdn, Glasgow Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland. [Zile, Michael R.] Med Univ S Carolina, Dept Med, RHJ Dept Vet Affairs Med Ctr, Charleston, SC USA. [Komajda, Michel] Univ Paris 06, Pitie Salpetriere Hosp, Inst Cardiol, Paris, France. [McKelvie, Robert S.] McMaster Univ, Dept Med, Populat Hlth Res Inst, Hamilton, ON, Canada. [Massie, Barry] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, San Francisco, CA USA. [Carson, Peter E.] Washington VAMC, Dept Med, Washington, DC USA. [Carson, Peter E.] Georgetown Univ, Washington, DC USA. RP Anand, IS (reprint author), VA Med Ctr, One Vet Dr, Minneapolis, MN 55417 USA. EM anand001@umn.edu OI mcmurray, john/0000-0002-6317-3975 FU Bristol-Myers Squibb FX Bristol-Myers Squibb sponsored the Irbesartan in Heart Failure with Preserved Ejection Fraction Trial (I-PRESERVE). Dr Rector was supported by resources and facilities of the Minneapolis VA Healthcare System. The views expressed herein do not necessarily represent the views of the Department of Veterans Affairs or the US Government. NR 22 TC 11 Z9 11 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD NOV PY 2014 VL 7 IS 6 BP 960 EP 966 DI 10.1161/CIRCHEARTFAILURE.114.001523 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AU0BS UT WOS:000345288800014 PM 25225241 ER PT J AU Farmer, AS Gros, DF McCabe, RE Antony, MM AF Farmer, Antonina S. Gros, Daniel F. McCabe, Randi E. Antony, Martin M. TI Clinical predictors of diagnostic status in individuals with social anxiety disorder SO COMPREHENSIVE PSYCHIATRY LA English DT Article ID NATIONAL COMORBIDITY SURVEY; NEGATIVE EVALUATION SCALE; STRESS SCALES; PSYCHOMETRIC PROPERTIES; SURVEY REPLICATION; MOOD DISORDERS; PHOBIA; DEPRESSION; FEAR; UNCERTAINTY AB Objective: In psychiatric patients, comorbidity tends to be the rule, rather than the exception. This is especially true for patients with social anxiety disorder (SAD), but research on the implications of diagnostic status has been limited This study aimed to examine the frequency of SAD as: (1) the only diagnosis, (2) a principal diagnosis with comorbid conditions, or (3) a comorbid condition when another diagnosis is principal in a treatment-seeking population. The study also sought to identify clinical features that distinguish people in these diagnostic groups. Method: Our sample included 684 adult participants presenting for treatment in a specialty clinic for anxiety disorders. We established diagnoses with semistructured clinical interviews, and participants completed self-report measures of social anxiety, associated transdiagnostic symptoms, general distress, and impairment due to psychological difficulties. We analyzed group differences and investigated predictors of principal SAD diagnosis. Results: Over half of participants reported symptoms that met criteria for a SAD diagnosis (51.8%). Of these, 8.8% had SAD only (no comorbid psychiatric diagnoses), 48.6% had multiple conditions with SAD as the principal diagnosis, and 42.7% had multiple conditions with SAD as an additional diagnosis. SAD-only was associated with less severe impairment and transdiagnostic symptoms. Among participants with comorbid conditions, greater fear of negative evaluation, behavioral avoidance, and coping with substances predicted a principal SAD diagnosis, whereas SAD as an additional diagnosis was more likely when participants presented with greater anxiety sensitivity, intolerance of uncertainty, and thought avoidance. Conclusions: Our fmdings suggest that principal diagnosis of SAD is common in a treatment-seeking population and is associated with more severe disorder-specific symptoms and less severe transdiagnostic features related to anxiety. Implications for assessment and treatment planning in clinical practice are discussed. (C) 2014 Elsevier Inc. All rights reserved. C1 [Farmer, Antonina S.; Gros, Daniel F.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Farmer, Antonina S.; Gros, Daniel F.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [McCabe, Randi E.] St Josephs Healthcare, Anxiety Treatment & Res Ctr, Hamilton, ON, Canada. [McCabe, Randi E.] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada. [Antony, Martin M.] Ryerson Univ, Dept Psychol, Toronto, ON, Canada. RP Farmer, AS (reprint author), Randolph Macon Coll, Dept Psychol, Ashland, VA 23005 USA. EM antoninafarmer@rmc.edu FU Department of Veteran Affairs Clinical Sciences Research and Development Career Development Award [CX000845]; Ralph H. Johnson VAMC FX This study is supported by Department of Veteran Affairs Clinical Sciences Research and Development Career Development Award CX000845 (PI: Gros). This material is the result of work supported with resources and the use of facilities at the Ralph H. Johnson VAMC. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. Submitted for publication to Comprehensive Psychiatry (May 2014). NR 44 TC 0 Z9 0 U1 9 U2 19 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0010-440X EI 1532-8384 J9 COMPR PSYCHIAT JI Compr. Psychiat. PD NOV PY 2014 VL 55 IS 8 BP 1906 EP 1913 DI 10.1016/j.comppsych.2014.07.019 PG 8 WC Psychiatry SC Psychiatry GA AT5HS UT WOS:000344975200016 PM 25236968 ER PT J AU Dubin, RF Beatty, AL Teerlink, JR Schiller, NB Alokozai, D Johansen, KL AF Dubin, Ruth F. Beatty, Alexis L. Teerlink, John R. Schiller, Nelson B. Alokozai, Dean Johansen, Kirsten L. TI Associations of Tissue Doppler Imaging with NT-proBNP and hs-TnT: A Pilot Study in End-Stage Renal Disease SO ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES LA English DT Article DE Doppler tissue imaging; end-stage renal disease ID CARDIAC TROPONIN-T; VENTRICULAR DIASTOLIC FUNCTION; CHRONIC-HEMODIALYSIS PATIENTS; PRESERVED EJECTION FRACTION; C-REACTIVE PROTEIN; NATRIURETIC PEPTIDE; HEART-FAILURE; FILLING PRESSURES; ALL-CAUSE; DYSFUNCTION AB BackgroundDiastolic dysfunction is common and associated with higher mortality in the end-stage renal disease (ESRD) population. E/E, a measure derived from tissue Doppler imaging (TDI), is a correlate of left ventricular (LV) filling pressures. E/E may be viewed as a confirmatory marker of diastolic dysfunction, but it is not routinely used to quantify diastolic dysfunction. Whether E/E is associated with N-terminal brain natriuretic peptide (NT-proBNP) or high sensitivity troponin T (hs-TnT) in this population is not known. MethodsWe performed echocardiograms and serology prior to the 2nd or 3rd dialysis session of the week on 35 chronic hemodialysis patients. We compared TDI parameters (E/E and E alone), traditional categories of diastolic function (normal, impaired, pseudonormal or restrictive), and ejection fraction (EF) as potential predictors of the outcomes NT-proBNP and hs-TnT. ResultsHigher E/E was associated with higher NT-proBNP (rho 0.48, P=0.004) and hs-TnT (rho 0.37, P=0.03). EF did not have statistically significant associations with NT-proBNP (rho -0.2, P=0.4) or hs-TnT (rho -0.24, P=0.16). As compared to patients with normal diastolic function, those with impaired or pseudonormal filling patterns did not have significantly different levels of NT-proBNP (P=0.46); patients in traditional categories of worsened diastolic function actually had lower hs-TnT (P=0.02). The associations of E/E with higher NT-proBNP and hs-TnT persisted after multivariate adjustment for EF, LV mass, and volume status. ConclusionsTissue Doppler imaging may be more useful in evaluating cardiac function than traditional measures of diastolic dysfunction in the ESRD population. C1 [Dubin, Ruth F.; Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med Nephrol, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Beatty, Alexis L.; Teerlink, John R.; Schiller, Nelson B.] Univ Calif San Francisco, Dept Med Cardiol, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Alokozai, Dean] Cardiocore, San Francisco, CA USA. RP Dubin, RF (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 111A1, San Francisco, CA 94121 USA. EM ruth.dubin@ucsf.edu FU University of California San Francisco Academic Senate, San Francisco, CA; Research Evaluation and Allocation Committee in the University of California San Francisco, School of Medicine Dean's Office, San Francisco, CA; National Institute of Diabetes and Digestive and Kidney Diseases [1K24-DK085153-02, 1K23-DK092354-01A1]; UCSF Clinical and Translational Science Institute [UL1 TR000004.4]; Roche Diagnostics Corporation, Indianapolis FX Funding for this project came from the following sources. 1. Individual Investigator Grant, University of California San Francisco Academic Senate, San Francisco, CA 2. Grant Huntington Fund provided by the Research Evaluation and Allocation Committee in the University of California San Francisco, School of Medicine Dean's Office, San Francisco, CA. 3. National Institute of Diabetes and Digestive and Kidney Diseases, 1K24-DK085153-02 4. National Institute of Diabetes and Digestive and Kidney Diseases, 1K23-DK092354-01A1 5. UCSF Clinical and Translational Science Institute Grant Number UL1 TR000004.4. Roche Diagnostics Corporation, Indianapolis, Indiana supplied reagents for the NT-proBNP and hs-TnT assays, but did not provide study funding. Conflict of Interest: Nelson Schiller is a consultant to Cardiocore for projects unrelated to the current manuscript. NR 28 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0742-2822 EI 1540-8175 J9 ECHOCARDIOGR-J CARD JI Echocardiography-J. Cardiovasc. Ultrasound Allied Tech. PD NOV PY 2014 VL 31 IS 10 BP 1205 EP 1212 DI 10.1111/echo.12552 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AT3ST UT WOS:000344854600014 PM 24828699 ER PT J AU Mata, IF Leverenz, JB Weintraub, D Trojanowski, JQ Hurtig, HI Van Deerlin, VM Ritz, B Rausch, R Rhodes, SL Factor, SA Wood-Siverio, C Quinn, JF Chung, KA Peterson, AL Espay, AJ Revilla, FJ Devoto, J Hu, SC Cholerton, BA Wan, JY Montine, TJ Edwards, KL Zabetian, CP AF Mata, Ignacio F. Leverenz, James B. Weintraub, Daniel Trojanowski, John Q. Hurtig, Howard I. Van Deerlin, Vivianna M. Ritz, Beate Rausch, Rebecca Rhodes, Shannon L. Factor, Stewart A. Wood-Siverio, Cathy Quinn, Joseph F. Chung, Kathryn A. Peterson, Amie L. Espay, Alberto J. Revilla, Fredy J. Devoto, Johnna Hu, Shu-Ching Cholerton, Brenna A. Wan, Jia Y. Montine, Thomas J. Edwards, Karen L. Zabetian, Cyrus P. TI APOE, MAPT, and SNCA Genes and Cognitive Performance in Parkinson Disease SO JAMA NEUROLOGY LA English DT Article ID APOLIPOPROTEIN-E GENOTYPE; VERBAL FLUENCY; DEMENTIA; IMPAIRMENT; ASSOCIATION; DECLINE; RISK; METAANALYSIS; INCIDENT; SUBTYPES AB IMPORTANCE Cognitive impairment is a common and disabling problem in Parkinson disease (PD) that is not well understood and is difficult to treat. Identification of genetic variants that influence the rate of cognitive decline or pattern of early cognitive deficits in PD might provide a clearer understanding of the etiopathogenesis of this important nonmotor feature. OBJECTIVE To determine whether common variation in the APOE, MAPT, and SNCA genes is associated with cognitive performance in patients with PD. DESIGN, SETTING, AND PARTICIPANTS We studied 1079 PD patients from 6 academic centers in the United States who underwent assessments of memory (Hopkins Verbal Learning Test-Revised [HVLT-R]), attention and executive function (Letter-Number Sequencing Test and Trail Making Test), language processing (semantic and phonemic verbal fluency tests), visuospatial skills (Benton Judgment of Line Orientation test), and global cognitive function (Montreal Cognitive Assessment). Participants underwent genotyping for the APOE epsilon 2/epsilon 3/epsilon 4 alleles, MAPT H1/H2 haplotypes, and SNCA rs356219. We used linear regression to test for association between genotype and baseline cognitive performance with adjustment for age, sex, years of education, disease duration, and site. We used a Bonferroni correction to adjust for the 9 comparisons that were performed for each gene. MAIN OUTCOMES AND MEASURES Nine variables derived from 7 psychometric tests. RESULTS The APOE epsilon 4 allele was associated with lower performance on the HVLT-R Total Recall (P = 6.7 x 10(-6); corrected P [P-c] = 6.0 x 10(-5)), Delayed Recall (P = .001; P-c = .009), and Recognition Discrimination Index (P =.004; P-c = .04); a semantic verbal fluency test (P = .002; P-c = .02); the Letter-Number Sequencing Test (P = 1 x 10(-5); P-c = 9 x 10(-5)); and Trail Making Test B minus Trail Making Test A (P = .002; P-c = .02). In a subset of 645 patients without dementia, the APOE epsilon 4 allele was associated with lower scores on the HVLT-R Total Recall (P =.005; P-c = .045) and the semantic verbal fluency (P = .005; P-c = .045) measures. Variants of MAPT and SNCA were not associated with scores on any tests. CONCLUSIONS AND RELEVANCE Our data indicate that the APOE epsilon 4 allele is an important predictor of cognitive function in PD across multiple domains. Among PD patients without dementia, the APOE epsilon 4 allele was only associated with lower performance on word list learning and semantic verbal fluency, a pattern more typical of the cognitive deficits seen in early Alzheimer disease than PD. C1 [Mata, Ignacio F.; Leverenz, James B.; Hu, Shu-Ching; Cholerton, Brenna A.; Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Leverenz, James B.; Hu, Shu-Ching; Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Mata, Ignacio F.; Leverenz, James B.; Hu, Shu-Ching; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Leverenz, James B.; Cholerton, Brenna A.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Weintraub, Daniel; Hurtig, Howard I.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Trojanowski, John Q.; Van Deerlin, Vivianna M.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA. [Trojanowski, John Q.] Univ Penn, Inst Aging, Philadelphia, PA 19104 USA. [Ritz, Beate; Rhodes, Shannon L.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA. [Ritz, Beate] Univ Calif Los Angeles, Sch Publ Hlth, Dept Environm Hlth Sci, Los Angeles, CA 90024 USA. [Ritz, Beate; Rausch, Rebecca] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Factor, Stewart A.; Wood-Siverio, Cathy] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Quinn, Joseph F.; Chung, Kathryn A.; Peterson, Amie L.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Portland, OR USA. [Quinn, Joseph F.; Chung, Kathryn A.; Peterson, Amie L.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Espay, Alberto J.; Revilla, Fredy J.; Devoto, Johnna] Univ Cincinnati, Dept Neurol & Rehabil Med, Cincinnati, OH USA. [Revilla, Fredy J.] Cincinnati Vet Affairs Med Ctr, Dept Neurol, Cincinnati, OH USA. [Wan, Jia Y.; Edwards, Karen L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Montine, Thomas J.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. RP Zabetian, CP (reprint author), Vet Affairs Puget Sound Hlth Care Syst, GRECC S-182,1660 S Columbian Way, Seattle, WA 98108 USA. EM zabetian@u.washington.edu RI Ritz, Beate/E-3043-2015 OI Zabetian, Cyrus/0000-0002-7739-4306 FU Department of Veterans Affairs [1I01BX000531]; NIH [P50 NS062684, P50 NS053488, P50 NS038367, R01 NS065070]; Consolidated Anti-Aging Foundation; Jane and Lee Seidman Fund FX This study was supported by grant 1I01BX000531 from the Department of Veterans Affairs, grants P50 NS062684, P50 NS053488, P50 NS038367, and R01 NS065070 from the NIH, by the Consolidated Anti-Aging Foundation, and by the Jane and Lee Seidman Fund. NR 50 TC 34 Z9 37 U1 1 U2 13 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD NOV PY 2014 VL 71 IS 11 BP 1405 EP 1412 DI 10.1001/jamaneurol.2014.1455 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA AT7WN UT WOS:000345145300010 PM 25178429 ER PT J AU Pietrzak, RH Naganawa, M Huang, YY Corsi-Travali, S Zheng, MQ Stein, MB Henry, S Lim, K Ropchan, J Lin, SF Carson, RE Neumeister, A AF Pietrzak, Robert H. Naganawa, Mika Huang, Yiyun Corsi-Travali, Stefani Zheng, Ming-Qiang Stein, Murray B. Henry, Shannan Lim, Keunpoong Ropchan, Jim Lin, Shu-fei Carson, Richard E. Neumeister, Alexander TI Association of In Vivo K-Opioid Receptor Availability and the Transdiagnostic Dimensional Expression of Trauma-Related Psychopathology SO JAMA PSYCHIATRY LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; GENERALIZED ANXIETY DISORDER; PLACEBO-CONTROLLED TRIAL; ADMINISTERED PTSD SCALE; CENTRAL-NERVOUS-SYSTEM; MAJOR DEPRESSION; PSYCHOLOGICAL DISTRESS; CORTISOL-LEVELS; ACTIVATION; RATS AB IMPORTANCE Exposure to trauma increases the risk for developing threat (ie, fear) symptoms, such as reexperiencing and hyperarousal symptoms, and loss (ie, dysphoria) symptoms, such as emotional numbing and depressive symptoms. While preclinical data have implicated the activated dynorphin/K-opioid receptor (KOR) system in relation to these symptoms, the role of the KOR system in mediating these phenotypes in humans is unknown. Elucidation of molecular targets implicated in threat and loss symptoms is important because it can help inform the development of novel, mechanism-based treatments for trauma-related psychopathology. OBJECTIVE To use the newly developed [C-11]LY2795050 radiotracer and high-resolution positron emission tomography to evaluate the relation between in vivo KOR availability in an amygdala-anterior cingulate cortex-ventral striatal neural circuit and the severity of threat and loss symptoms. We additionally evaluated the role of 24-hour urinary cortisol levels in mediating this association. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional positron emission tomography study under resting conditions was conducted at an academic medical center. Thirty-five individuals representing a broad transdiagnostic and dimensional spectrum of trauma-related psychopathology, ranging from nontrauma-exposed psychiatrically healthy adults to trauma-exposed adults with severe trauma-related psychopathology (ie, posttraumatic stress disorder, major depressive disorder, and/or generalized anxiety disorder). MAIN OUTCOMES AND MEASURES [C-11]LY2795050 volume of distribution values in amygdala-anterior cingulate cortex-ventral striatal neural circuit; composite measures of threat (ie, reexperiencing, avoidance, and hyperarousal symptoms) and loss (ie, emotional numbing, major depressive disorder, and generalized anxiety disorder symptoms) symptoms as assessed using the Clinician-Administered PTSD Scale, Hamilton Depression Rating Scale, and Hamilton Rating Scale for Anxiety; and 24-hour urinary cortisol levels. RESULTS [C-11]LY2795050 volume of distribution values in an amygdala-anterior cingulate cortex-ventral striatal neural circuit were negatively associated with severity of loss (r = -0.39; 95% CI, -0.08 to -0.66), but not threat (r = -0.03; 95% CI, -0.30 to 0.27), symptoms; this association was most pronounced for dysphoria symptoms (r = -0.45; 95% CI, -0.10 to -0.70). Path analysis revealed that lower [C-11]LY2795050 volume of distribution values in this circuit was directly associated with greater severity of loss symptoms and indirectly mediated by 24-hour urinary cortisol levels. CONCLUSIONS AND RELEVANCE Results of this study suggest that KOR availability in an amygdala-anterior cingulate cortex-ventral striatal neural circuit mediates the phenotypic expression of trauma-related loss (ie, dysphoria) symptoms. They further suggest that an activated corticotropin-releasing factor/hypothalamic-pituitary-adrenal axis system, as assessed by 24-hour urinary cortisol levels, may indirectly mediate this association. These results may help inform the development of more targeted, mechanism-based transdiagnostic treatments for loss (ie, dysphoric) symptoms. C1 [Pietrzak, Robert H.] US Dept Vet Affairs, VA Connecticut Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, West Haven, CT USA. [Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Naganawa, Mika; Huang, Yiyun; Zheng, Ming-Qiang; Henry, Shannan; Lim, Keunpoong; Ropchan, Jim; Lin, Shu-fei; Carson, Richard E.] Yale Univ, Sch Med, Dept Diagnost Radiol, New Haven, CT 06510 USA. [Corsi-Travali, Stefani; Neumeister, Alexander] NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA. [Corsi-Travali, Stefani; Neumeister, Alexander] NYU, Sch Med, Dept Radiol, New York, NY 10016 USA. [Stein, Murray B.] Univ Calif San Diego, Sch Med, Dept Psychiat, San Diego, CA 92103 USA. [Stein, Murray B.] Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, San Diego, CA 92103 USA. [Neumeister, Alexander] Steven & Alexandra Cohen Vet Ctr, New York, NY USA. RP Neumeister, A (reprint author), NYU, Sch Med, 1 Pk Ave,8th Floor 225, New York, NY 10016 USA. EM alexander.neumeister@nyumc.org RI Carson, Richard/H-3250-2011 OI Carson, Richard/0000-0002-9338-7966 FU National Institutes of Health (NIH) [R21MH096105, R21MH085627, RO1MH096876, RO1MH102566]; National Center for Research Resources [UL1 RR024139]; National Center for Advancing Translational Science, components of the NIH; NIH Roadmap for Medical Research; Clinical Neurosciences Division of the US Department of Veterans Affairs National Center for Posttraumatic Stress Disorder; Eli Lilly Inc [[11C]LY2795050] FX This project was supported by the National Institutes of Health (NIH) through the following grants: R21MH096105, R21MH085627, RO1MH096876, and RO1MH102566. This was also supported by Clinical and Translational Science Award grant UL1 RR024139 from the National Center for Research Resources and the National Center for Advancing Translational Science, components of the NIH, NIH Roadmap for Medical Research, and Clinical Neurosciences Division of the US Department of Veterans Affairs National Center for Posttraumatic Stress Disorder. We acknowledge grant support from Eli Lilly Inc for support in the development of [11C]LY2795050. NR 67 TC 13 Z9 13 U1 2 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD NOV PY 2014 VL 71 IS 11 BP 1262 EP 1270 DI 10.1001/jamapsychiatry.2014.1221 PG 9 WC Psychiatry SC Psychiatry GA AT5NH UT WOS:000344989100008 PM 25229257 ER PT J AU Anestis, MD Joiner, T Hanson, JE Gutierrez, PM AF Anestis, Michael D. Joiner, Thomas Hanson, Jetta E. Gutierrez, Peter M. TI The Modal Suicide Decedent Did Not Consume Alcohol Just Prior to the Time of Death: An Analysis With Implications for Understanding Suicidal Behavior SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE suicide decedents; blood alcohol content; meta-analysis ID DEPENDENCE; TRENDS; ABUSE AB We identified and analyzed a total of 92 studies, representing 167,894 suicide decedents, to determine if there is evidence to support what appears to be a widely held cultural, clinical, and scholarly view that many people who die by suicide had been drinking at the time of death. It was determined that, based on weighted averages, approximately 27% of suicide decedents had above-zero blood alcohol concentrations (BACs) at the time of death. We emphasize that it was not 27% who were intoxicated at the time of death; rather, 27% had above-zero BACs and 73% had BACs of 0.00%. Among studies of suicide decedents, BACs differed as a function of race (higher in non-White individuals). We conclude that the role of alcohol use at the time of death may be less than some assume, and this interpretation can inform clinical practice and theories of suicide. Important unanswered questions are posed which will help refine research in this area going forward. C1 [Anestis, Michael D.] Univ So Mississippi, Dept Psychol, Hattiesburg, MS 39406 USA. [Joiner, Thomas] Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA. [Joiner, Thomas; Hanson, Jetta E.] Mil Suicide Res Consortium, Tallahassee, FL USA. [Gutierrez, Peter M.] Denver VA Med Ctr, MIRECC, Denver, CO 80220 USA. [Gutierrez, Peter M.] Mil Suicide Res Consortium, Denver, CO USA. [Gutierrez, Peter M.] Univ Colorado, Sch Med, Dept Psychiat, Boulder, CO 80309 USA. RP Gutierrez, PM (reprint author), Denver VA Med Ctr, MIRECC, 1055 Clermont St, Denver, CO 80220 USA. EM peter.gutierrez@va.gov OI Gutierrez, Peter/0000-0001-8981-8404 NR 17 TC 11 Z9 11 U1 0 U2 2 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X EI 1939-1846 J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD NOV PY 2014 VL 123 IS 4 BP 835 EP 840 DI 10.1037/a0037480 PG 6 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA AT7ZM UT WOS:000345153400015 PM 25286371 ER PT J AU Kaplan, KA McQuaid, J Primich, C Rosenlicht, N AF Kaplan, Katherine A. McQuaid, John Primich, Charles Rosenlicht, Nicholas TI An Evidence-Based Review of Insomnia Treatment in Early Recovery SO JOURNAL OF ADDICTION MEDICINE LA English DT Review DE abstinence; cognitive behavioral therapy; insomnia; recovery; sleep ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; ALCOHOL DEPENDENCE; SLEEP DISTURBANCE; OLDER-ADULTS; PSYCHIATRIC-DISORDERS; DOUBLE-BLIND; NONPHARMACOLOGIC TREATMENT; COMPARATIVE METAANALYSIS; SUBSTANCE DEPENDENCE AB Accruing evidence indicates that insomnia is prevalent and persistent in early recovery from substance use disorders and may predict relapse. As such, insomnia treatment after abstinence represents an important area for intervention. This article reviews the literature on insomnia predicting new-onset alcohol and substance use disorders, along with evidence for insomnia predicting relapse in recovering populations. Pharmacological and psychological treatment options are presented, and cognitive-behavioral therapy for insomnia applied to recovering populations is described in detail. C1 [Kaplan, Katherine A.] Stanford Univ, Sch Med, Dept Psychiat, Stanford, CA 94305 USA. [McQuaid, John; Rosenlicht, Nicholas] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [McQuaid, John; Primich, Charles; Rosenlicht, Nicholas] San Francisco VA Med Ctr, San Francisco, CA USA. RP Rosenlicht, N (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St, San Francisco, CA 94121 USA. EM Nicholas.Rosenlicht@ucsf.edu NR 70 TC 2 Z9 2 U1 2 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD NOV-DEC PY 2014 VL 8 IS 6 BP 389 EP 394 DI 10.1097/ADM.0000000000000052 PG 6 WC Substance Abuse SC Substance Abuse GA AT7LD UT WOS:000345117200001 PM 25369938 ER PT J AU Kaplan, KA McQuaid, J Batki, SL Rosenlicht, N AF Kaplan, Katherine A. McQuaid, John Batki, Steven L. Rosenlicht, Nicholas TI Behavioral Treatment of Insomnia in Early Recovery SO JOURNAL OF ADDICTION MEDICINE LA English DT Article ID ALCOHOL DEPENDENCE; GABAPENTIN; TRIAL AB This clinical case discussion focuses on a veteran with alcohol dependence in early partial remission and comorbid insomnia. The case illustrates the use of cognitive behavioral therapy for insomnia (CBT-I) to treat sleep disturbance. After the case presentation, expert clinicians provide commentary on the case. C1 [Kaplan, Katherine A.] Stanford Univ, Sch Med, Dept Psychiat, Stanford, CA 94305 USA. [McQuaid, John; Batki, Steven L.; Rosenlicht, Nicholas] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Rosenlicht, N (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr 116C, Dept Psychiat, 4150 Clement St, San Francisco, CA 94121 USA. EM Nicholas.Rosenlicht@ucsf.edu NR 14 TC 3 Z9 3 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD NOV-DEC PY 2014 VL 8 IS 6 BP 395 EP 398 DI 10.1097/ADM.0000000000000058 PG 4 WC Substance Abuse SC Substance Abuse GA AT7LD UT WOS:000345117200002 PM 25369939 ER PT J AU Alexander, ES Martin, LJ Collins, MH Kottyan, LC Sucharew, H He, H Mukkada, VA Succop, PA Abonia, JP Foote, H Eby, MD Grotjan, TM Greenler, AJ Dellon, ES Demain, JG Furuta, GT Gurian, LE Harley, JB Hopp, RJ Kagalwalla, A Kaul, A Nadeau, KC Noel, RJ Putnam, PE von Tiehl, KF Rothenberg, ME AF Alexander, Eileen S. Martin, Lisa J. Collins, Margaret H. Kottyan, Leah C. Sucharew, Heidi He, Hua Mukkada, Vincent A. Succop, Paul A. Abonia, J. Pablo Foote, Heather Eby, Michael D. Grotjan, Tommie M. Greenler, Alexandria J. Dellon, Evan S. Demain, Jeffrey G. Furuta, Glenn T. Gurian, Larry E. Harley, John B. Hopp, Russell J. Kagalwalla, Amir Kaul, Ajay Nadeau, Kari C. Noel, Richard J. Putnam, Philip E. von Tiehl, Karl F. Rothenberg, Marc E. TI Twin and family studies reveal strong environmental and weaker genetic cues explaining heritability of eosinophilic esophagitis SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Eosinophilia; food allergy; medical genetics; twins; immune system diseases; heritability; gene-environment interaction; drug hypersensitivity; gastrointestinal diseases; skin diseases ID MISSING HERITABILITY; SEASONAL-VARIATION; MOLECULAR CHARACTERIZATION; PROVIDES INSIGHT; LINKAGE ANALYSIS; CROHNS-DISEASE; EARLY-LIFE; CHILDREN; ASSOCIATION; EXPRESSION AB Background: Eosinophilic esophagitis (EoE) is a chronic antigen-driven allergic inflammatory disease, likely involving the interplay of genetic and environmental factors, yet their respective contributions to heritability are unknown. Objective: To quantify the risk associated with genes and environment on familial clustering of EoE. Methods: Family history was obtained from a hospital-based cohort of 914 EoE probands (n = 2192 first-degree "Nuclear-Family" relatives) and an international registry of monozygotic and dizygotic twins/triplets (n = 63 EoE "Twins" probands). Frequencies, recurrence risk ratios (RRRs), heritability, and twin concordance were estimated. Environmental exposures were preliminarily examined. Results: Analysis of the Nuclear-Family-based cohort revealed that the rate of EoE, in first-degree relatives of a proband, was 1.8% (unadjusted) and 2.3% (sex-adjusted). RRRs ranged from 10 to 64, depending on the family relationship, and were higher in brothers (64.0; P = .04), fathers (42.9; P = .004), and males (50.7; P < .001) than in sisters, mothers, and females, respectively. The risk of EoE for other siblings was 2.4%. In the Nuclear-Family cohort, combined gene and common environment heritability was 72.0% 6 2.7% (P < .001). In the Twins cohort, genetic heritability was 14.5% +/- 4.0% (P < .001), and common family environment contributed 81.0% +/- 4% (P < .001) to phenotypic variance. Probandwise concordance in monozygotic co-twins was 57.9% +/- 9.5% compared with 36.4% +/- 9.3% in dizygotic co-twins (P = .11). Greater birth weight difference between twins (P = .01), breast-feeding (P = .15), and fall birth season (P = .02) were associated with twin discordance in disease status. Conclusions: EoE RRRs are increased 10- to 64-fold compared with the general population. EoE in relatives is 1.8% to 2.4%, depending on relationship and sex. Nuclear-Family heritability appeared to be high (72.0%). However, the Twins cohort analysis revealed a powerful role for common environment (81.0%) compared with additive genetic heritability (14.5%). C1 [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; Mukkada, Vincent A.; Succop, Paul A.; Abonia, J. Pablo; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA. [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; Mukkada, Vincent A.; Succop, Paul A.; Abonia, J. Pablo; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA. [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; Mukkada, Vincent A.; Succop, Paul A.; Abonia, J. Pablo; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Dept Pathol, Cincinnati, OH USA. [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; Mukkada, Vincent A.; Succop, Paul A.; Abonia, J. Pablo; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Dept Lab Med, Cincinnati, OH USA. [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; He, Hua; Mukkada, Vincent A.; Abonia, J. Pablo; Foote, Heather; Eby, Michael D.; Grotjan, Tommie M.; Greenler, Alexandria J.; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA. [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; He, Hua; Mukkada, Vincent A.; Abonia, J. Pablo; Foote, Heather; Eby, Michael D.; Grotjan, Tommie M.; Greenler, Alexandria J.; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA. [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; He, Hua; Mukkada, Vincent A.; Abonia, J. Pablo; Foote, Heather; Eby, Michael D.; Grotjan, Tommie M.; Greenler, Alexandria J.; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Pathol, Cincinnati, OH 45229 USA. [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; He, Hua; Mukkada, Vincent A.; Abonia, J. Pablo; Foote, Heather; Eby, Michael D.; Grotjan, Tommie M.; Greenler, Alexandria J.; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Div Rheumatol, Cincinnati, OH 45229 USA. [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; He, Hua; Mukkada, Vincent A.; Abonia, J. Pablo; Foote, Heather; Eby, Michael D.; Grotjan, Tommie M.; Greenler, Alexandria J.; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol, Cincinnati, OH 45229 USA. [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; He, Hua; Mukkada, Vincent A.; Abonia, J. Pablo; Foote, Heather; Eby, Michael D.; Grotjan, Tommie M.; Greenler, Alexandria J.; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Hepatol & Nutr, Cincinnati, OH 45229 USA. [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; He, Hua; Mukkada, Vincent A.; Abonia, J. Pablo; Foote, Heather; Eby, Michael D.; Grotjan, Tommie M.; Greenler, Alexandria J.; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA. [Alexander, Eileen S.] Xavier Univ, Dept Hlth Serv Adm, Cincinnati, OH 45207 USA. [Dellon, Evan S.] Univ N Carolina, Sch Med, Esophageal Dis & Swallowing, Div Gastroenterol & Hepatol, Chapel Hill, NC USA. [Demain, Jeffrey G.] Allergy Asthma & Immunol Ctr Alaska, Anchorage, AK USA. [Furuta, Glenn T.] Univ Colorado, Sch Med, Digest Hlth Inst, Gastrointestinal Eosinophil Dis Program,Childrens, Aurora, CO USA. [Gurian, Larry E.] Ferrell Duncan Clin & CoxHlth, Springfield, MO USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Hopp, Russell J.] Creighton Univ, Dept Pediat, Div Allergy & Immunol, Omaha, NE 68178 USA. [Kagalwalla, Amir] Ann & Robert H Lurie Childrens Hosp Chicago, Div Gastroenterol Hepatol & Nutr, Chicago, IL USA. [Kagalwalla, Amir] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Nadeau, Kari C.] Stanford Med Sch, Stanford, CA USA. [Nadeau, Kari C.] Stanford Med Ctr, Div Allergy & Immunol, Stanford, CA USA. [Nadeau, Kari C.] Lucille Packard Childrens Hosp, Stanford, CA USA. [Noel, Richard J.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA. [Noel, Richard J.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [von Tiehl, Karl F.] Huntington Mem Hosp, Pasadena, CA USA. RP Rothenberg, ME (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, MLC 7028,3333 Burnet Ave, Cincinnati, OH 45229 USA. EM Rothenberg@cchmc.org RI Sucharew, Heidi/M-4338-2015; Martin, Lisa/E-2425-2016 OI Martin, Lisa/0000-0001-8702-9946; Kottyan, Leah/0000-0003-3979-2220; Abonia, Juan/0000-0003-3788-6485 FU Cincinnati Children's Division of Biostatistics and Epidemiology; University of Cincinnati Research Council; Campaign Urging Research for Eosinophilic Diseases (CURED); Food Allergy Research and Education (FARE); Buckeye Foundation; National Institutes of Health (NIH) [T32-ES10957]; NIEHS [P30-ES006096]; CTSA; NCATS; NCRR/NIH [UL1-RR026314-01]; UAB Section on Statistical Genetics [1R25GM093044-01]; [NIH-1K24DK100303] FX This study was supported in part by the: Frank C. Woodside, Dinsmore& Shohl Fellowship through Cincinnati Children's Division of Biostatistics and Epidemiology; University of Cincinnati Research Council; Campaign Urging Research for Eosinophilic Diseases (CURED); Food Allergy Research and Education (FARE); Buckeye Foundation; National Institutes of Health (NIH) grants: T32-ES10957 Molecular Epidemiology in Children's Environmental Health Fellowship 2011-2013; NIEHS P30-ES006096 Center for Environmental Genetics New Investigator Scholar and PI Mentee/Mentor; NIH 8 UL1-TR000077-04 Center for Clinical and Translational Science and Training, CTSA, NCATS Just in Time; CCTST REDCap UL1-RR026314-01 NCRR/NIH; 1R25GM093044-01 UAB Section on Statistical Genetics; NIH-1K24DK100303 (GTF). This work was completed in partial fulfillment of the Doctor of Philosophy degree in Epidemiology in the Department of Environmental Health, Division of Epidemiology and Biostatistics, University of Cincinnati College of Medicine. NR 72 TC 23 Z9 25 U1 3 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD NOV PY 2014 VL 134 IS 5 BP 1084 EP + DI 10.1016/j.jaci.2014.07.021 PG 10 WC Allergy; Immunology SC Allergy; Immunology GA AT4UN UT WOS:000344938900013 PM 25258143 ER PT J AU Friedlander, AH Liebeskind, DS Tran, HQ Mallya, SM AF Friedlander, Arthur H. Liebeskind, David S. Tran, Huy Q. Mallya, Sanjay M. TI What Are the Potential Implications of Identifying Intracranial Internal Carotid Artery Atherosclerotic Lesions on Cone-Beam Computed Tomography? A Systematic Review and Illustrative Case Studies SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID DIGITAL-SUBTRACTION-ANGIOGRAPHY; SMALL VESSEL DISEASE; RISK-FACTORS; INCIDENTAL FINDINGS; CORONARY; STROKE; CALCIFICATIONS; PREVALENCE; OUTCOMES; STENOSIS AB Purpose: A systematic literature review was performed to examine the clinical implications of intracranial internal carotid artery calcific atherosclerotic lesions (IICACALs) detected at cone-beam computed tomographic (CBCT) examinations. Materials and Methods: The PubMed database was queried in 2 separate searches using the linked search terms non-contrast enhanced cone beam computed tomography and calcified intracranial vascular lesions and non-contrast enhanced computed tomography and calcified intracranial vascular lesions. Reviewed were all English-language articles using CBCT or CT imaging that enrolled neurologically asymptomatic and symptomatic patients. Excluded were studies describing patients with hemorrhagic stroke. Illustrative cases describing incidentally detected IICACALs on CBCT scans are provided. Results: Three articles described identification of IICACALs on CBCT scans of almost 1,500 dental patients. Two of these fully addressed the subject, with 1 noting that IICACALs were benign and another urging patient referral for further workup. Five non-contrast-enhanced CT studies were evaluated in detail; all confirmed IICACALs as a substantive risk marker of advanced stenotic disease in the cerebral circulation, central brain atrophy, concomitant advanced atherosclerotic disease in the cardiovascular circulation, and an indicator of future ischemic events. Five CBCT examinations showing IICACALs in the cavernous and ophthalmic segments are presented. Conclusion: Few studies have denoted the importance of identifying IICACALs on CBCT scans. However, all non-contrast-enhanced CT studies emphasized the clinical significance of these lesions in relation to cerebral and cardiovascular disease. Therefore, IICACALs seen on CBCT and CT scans present the same risk and should prompt referral for further evaluation. (C) 2014 American Association of Oral and Maxillofacial Surgeons C1 [Friedlander, Arthur H.] Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Assoc, Los Angeles, CA USA. [Friedlander, Arthur H.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Qual Assurance Hosp Dent Serv, Ronald Reagan UCLA Med Ctr, Los Angeles, CA 90095 USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Sect Oral & Maxillofacial Surg, Sch Dent, Los Angeles, CA 90095 USA. [Liebeskind, David S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Clin Neurol, Los Angeles, CA 90095 USA. [Liebeskind, David S.] Univ Calif Los Angeles, David Geffen Sch Med, Stroke Program, Los Angeles, CA 90095 USA. [Tran, Huy Q.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA. [Mallya, Sanjay M.] Univ Calif Los Angeles, Div Diagnost & Surg Sci, Sect Oral & Maxillofacial Radiol, Sch Dent, Los Angeles, CA 90095 USA. RP Mallya, SM (reprint author), Univ Calif Los Angeles, Residency Program, Sect Oral & Maxillofacial Radiol, Sch Dent, Los Angeles, CA 90095 USA. EM smallya@dentistry.ucla.edu NR 29 TC 6 Z9 6 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 EI 1531-5053 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD NOV PY 2014 VL 72 IS 11 BP 2167 EP 2177 DI 10.1016/j.joms.2014.06.437 PG 11 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA AT9CE UT WOS:000345224800020 PM 25438276 ER PT J AU Gaither, JR Goulet, JL Becker, WC Crystal, S Edelman, EJ Gordon, K Kerns, RD Rimland, D Skanderson, M Weisberg, DF Justice, AC Fiellin, DA AF Gaither, Julie R. Goulet, Joseph L. Becker, William C. Crystal, Stephen Edelman, E. Jennifer Gordon, Kirsha Kerns, Robert D. Rimland, David Skanderson, Melissa Weisberg, Daniel F. Justice, Amy C. Fiellin, David A. TI Guideline-Concordant Management of Opioid Therapy Among Human Immunodeficiency Virus (HIV)-Infected and Uninfected Veterans SO JOURNAL OF PAIN LA English DT Article DE Opioid analgesics; practice guideline; quality of health care; chronic pain; HIV ID CHRONIC NONCANCER PAIN; HIV-INFECTED PATIENTS; UNITED-STATES; CLINICAL GUIDELINES; HEALTH-CARE; PRESCRIBING PRACTICES; PRESCRIPTION OPIOIDS; AGING COHORT; QUALITY; ABUSE AB Whether patients receive guideline-concordant opioid therapy (OT) is largely unknown and may vary based on provider and patient characteristics. We assessed the extent to which human immunodeficiency virus (HIV)-infected and uninfected patients initiating long-term (>= 90 days) OT received care concordant with American Pain Society/American Academy of Pain Medicine and Department of Veterans Affairs/Department of Defense guidelines by measuring receipt of 17 indicators during the first 6 months of OT. Of 20,753 patients, HIV-infected patients (n = 6,604) were more likely than uninfected patients to receive a primary care provider visit within 1 month (52.0% vs 30.9%) and 6 months (90.7% vs 73.7%) and urine drug tests within 1 month (14.8% vs 11.5%) and 6 months (19.5% vs 15.4%; all P < .001). HIV-infected patients were also more likely to receive OT concurrent with sedatives (24.6% vs 19.6%) and a current substance use disorder (21.6% vs 17.2%). Among both patient groups, only modest changes in guideline concordance were observed over time: urine drug tests and OT concurrent with current substance use disorders increased, whereas sedative coprescriptions decreased (all Ps for trend <.001). Over a 10-year period, on average, patients received no more than 40% of recommended care. OT guideline-concordant care is rare in primary care, varies by patient/provider characteristics, and has undergone few changes over time. Perspective: The promulgation of OT clinical guidelines has not resulted in substantive changes over time in OT management, which falls well short of the standard recommended by leading medical societies. Strategies are needed to increase the provision of OT guideline-concordant care for all patients. (C) 2014 by the American Pain Society. Published by Elsevier Inc. All rights reserved C1 [Gaither, Julie R.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA. [Edelman, E. Jennifer; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Publ Hlth, Yale Ctr Interdisciplinary Res AIDS, New Haven, CT 06520 USA. [Goulet, Joseph L.; Kerns, Robert D.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. [Becker, William C.; Edelman, E. Jennifer; Weisberg, Daniel F.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA. [Goulet, Joseph L.; Becker, William C.; Gordon, Kirsha; Kerns, Robert D.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Crystal, Stephen] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA. [Rimland, David] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA. [Rimland, David] Atlanta VA Med Ctr, Decatur, GA USA. [Skanderson, Melissa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Gaither, JR (reprint author), Yale Univ, Sch Publ Hlth, POB 208034,60 Coll St, New Haven, CT 06520 USA. EM julie.gaither@yale.edu OI Gaither, Julie/0000-0001-6053-8505; Fiellin, David/0000-0002-4006-010X; Goulet, Joseph/0000-0002-0842-804X FU National Institute on Drug Abuse [F31DA035567]; National Institute on Alcohol Abuse and Alcoholism [U10AA013566, U01AA020790, U24AA020794]; National Institute of Mental Health [P30MH062294]; VA Health Services Research and Development Research Enhancement Award Program [REA 08-266]; Agency for Healthcare Research and Quality [U19HS21112] FX Research reported in this paper was supported by grants from the National Institute on Drug Abuse (grant no. F31DA035567), National Institute on Alcohol Abuse and Alcoholism (grant nos. U10AA013566, U01AA020790, and U24AA020794), National Institute of Mental Health (grant no. P30MH062294), VA Health Services Research and Development Research Enhancement Award Program (grant no. REA 08-266), and the Agency for Healthcare Research and Quality (grant no. U19HS21112). NR 54 TC 8 Z9 9 U1 2 U2 3 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD NOV PY 2014 VL 15 IS 11 BP 1130 EP 1140 DI 10.1016/j.jpain.2014.08.004 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AT4LZ UT WOS:000344912200007 PM 25152300 ER PT J AU Krebs, EE Bergman, AA Coffing, JM Campbell, SR Frankel, RM Matthias, MS AF Krebs, Erin E. Bergman, Alicia A. Coffing, Jessica M. Campbell, Steffanie R. Frankel, Richard M. Matthias, Marianne S. TI Barriers to Guideline-Concordant Opioid Management in Primary Care-A Qualitative Study SO JOURNAL OF PAIN LA English DT Article DE Chronic pain; opioid analgesics; qualitative research; primary care; guidelines ID RISK REDUCTION STRATEGIES; CHRONIC NONCANCER PAIN; CLINICAL GUIDELINES; THERAPY; TIME; ADHERENCE; NETWORK; MISUSE AB Prior studies have demonstrated poor physician adherence to opioid management guidelines in primary care. The objectives of this qualitative study were to understand physicians' and patients' perspectives on recommended opioid management practices and to identify potential barriers to and facilitators of guideline-concordant opioid management in primary care. Individual semistructured interviews were conducted with 14 primary care physicians and 26 of their patients receiving long-term opioid therapy. Data were analyzed using a qualitative immersion/crystallization approach. We identified 3 major barriers to and 1 facilitator of use of recommended opioid management practices. Major barriers were inadequate time and resources available; relying on general impressions of risk for opioid misuse; and viewing opioid monitoring as a "law enforcement" activity. The third barrier was most apparent for physicians in the context of drug testing and for patients in the context of opioid agreements. Beliefs about the need to protect patients from opioid-related harm emerged as a major facilitator, especially among patients. We hypothesize that future interventions to improve opioid management in primary care will be more effective if they address identified barriers and use a patient-centered framework, in which prevention of opioid-related harm to patients is emphasized as the primary goal. Perspective: This article describes primary care perspectives on guideline-recommended opioid management practices. Barriers identified in this study may contribute to underuse of recommended opioid management practices. Consideration of barriers and facilitators to guideline-concordant care could improve effectiveness of future interventions aimed at improving opioid management in primary care. Published by Elsevier Inc. on behalf of the American Pain Society C1 [Krebs, Erin E.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Krebs, Erin E.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55417 USA. [Bergman, Alicia A.] VA Greater Los Angeles Syst, Ctr Study Healthcare Innovat Implementat & Policy, Los Angeles, CA USA. [Coffing, Jessica M.; Frankel, Richard M.; Matthias, Marianne S.] Roudebush VA Med Ctr, Ctr Hlth Informat & Commun, Indianapolis, IN USA. [Campbell, Steffanie R.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Frankel, Richard M.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA. [Frankel, Richard M.; Matthias, Marianne S.] Regenstrief Inst Inc, Indianapolis, IN USA. [Matthias, Marianne S.] Indiana Univ Purdue Univ, Dept Commun Studies, Indianapolis, IN 46202 USA. RP Krebs, EE (reprint author), Univ Minnesota, Sch Med, Minneapolis VA Hlth Care Syst, Dept Med,Ctr Chron Dis Outcomes Res, Minneapolis VAMC 152,One Vet Dr, Minneapolis, MN 55417 USA. EM erin.krebs@va.gov FU U.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Career Development Awards [CDA 07-215, CDA 10-034] FX This work was supported by the U.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Career Development Awards to E.E.K. (CDA 07-215) and M.S.M. (CDA 10-034). NR 37 TC 14 Z9 14 U1 2 U2 4 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD NOV PY 2014 VL 15 IS 11 BP 1148 EP 1155 DI 10.1016/j.jpain.2014.08.006 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AT4LZ UT WOS:000344912200009 PM 25179150 ER PT J AU Warms, CA Backus, D Rajan, S Bombardier, CH Schomer, KG Burns, SP AF Warms, Catherine A. Backus, Deborah Rajan, Suparna Bombardier, Charles H. Schomer, Katherine G. Burns, Stephen P. TI Adverse events in cardiovascular-related training programs in people with spinal cord injury: A systematic review SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Review DE Aerobic exercise; Functional electric stimulation; Locomotor training; Gait training; Treadmill training; Ergometry; Wheelchair exercise; Spinal cord injuries; Tetraplegia; Paraplegia ID FUNCTIONAL ELECTRICAL-STIMULATION; PARASTEP(R)1 AMBULATION SYSTEM; ARM CRANKING EXERCISE; PHYSICAL-ACTIVITY; PHYSIOLOGICAL-RESPONSES; WHEELCHAIR ERGOMETER; TETRAPLEGIC PATIENTS; CLINICAL-EVALUATION; BODY-COMPOSITION; INDIVIDUALS AB Context: There are anecdotal reports of adverse events (AEs) associated with exercise in people with spinal cord injury (SCI) and consequent concern by people with SCI and their providers about potential risks of exercise. Enumeration of specific events has never been performed and the extent of risk of exercise to people with SCI is not understood. Objective: To systematically review published evidence to identify and enumerate reports of adverse events or AEs associated with training in persons with SCI. Methods: Review was limited to peer-reviewed studies published in English from 1970 to 2011: (1) in adults with SCI, (2) evaluating training protocols consisting of repeated sessions over at least 4 weeks to maintain or improve cardiovascular health, (3) including volitional exercise modalities and functional electrical stimulation (FES)-enhanced exercise modalities, and (4) including a specific statement about AEs. Trained reviewers initially identified a total of 145 studies. After further screening, 38 studies were included in the review. Quality of evidence was evaluated using established procedures. Results: There were no serious AEs reported. There were no common AEs reported across most types of interventions, except for musculoskeletal AEs related to FES walking. There were few AEs in volitional exercise studies. Conclusion: There is no evidence to suggest that cardiovascular exercise done according to guidelines and established safety precautions is harmful. To improve the strength of these conclusions, future publications should include definition of AEs, information about pre-intervention screening, and statements of the nature and extent of AEs. C1 [Warms, Catherine A.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Warms, Catherine A.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Backus, Deborah] Shepherd Ctr, Atlanta, GA USA. [Rajan, Suparna; Burns, Stephen P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Bombardier, Charles H.; Schomer, Katherine G.; Burns, Stephen P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Warms, CA (reprint author), Univ Washington, Med Ctr, Seattle, WA 98195 USA. EM cwarms@u.washington.edu FU National Institute for Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education, Washington, DC [H133A060070]; University of Washington Northwest Regional Spinal Cord Injury System [H133N060033] FX This work was funded in part by grants from the National Institute for Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education, Washington, DC to the University of Washington Model Systems Knowledge Translation Center (H133A060070) and the University of Washington Northwest Regional Spinal Cord Injury System (H133N060033). NR 57 TC 1 Z9 1 U1 2 U2 20 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD NOV PY 2014 VL 37 IS 6 BP 672 EP 692 DI 10.1179/2045772313Y.0000000115 PG 21 WC Clinical Neurology SC Neurosciences & Neurology GA AT9AE UT WOS:000345219200004 PM 24090603 ER PT J AU Emmons, RR Cirnigliaro, CM Kirshblum, SC Bauman, WA AF Emmons, Racine R. Cirnigliaro, Christopher M. Kirshblum, Steven C. Bauman, William A. TI The relationship between the postprandial lipemic response and lipid composition in persons with spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Postprandial lipemia; Lipid particle size; Spinal cord injury; Abdominal fat; Apolipoprotein B ID LOW-DENSITY-LIPOPROTEIN; VISCERAL FAT; REMNANT LIPOPROTEINS; APOLIPOPROTEIN B-48; METABOLIC SYNDROME; RISK-FACTORS; CORONARY; ULTRASONOGRAPHY; ATHEROSCLEROSIS; ATHEROGENESIS AB Objective: To determine the influence of lipid concentration, lipid particle size, and total abdominal fat (TAF) on postprandial lipemic response (PPLr) in persons with spinal cord injury (SCI). Methods: Thirty-five persons with SCI (17 paraplegia, 18 tetraplegia) and 18 able-bodied (AB) individuals participated. Following a 10-hour fast, blood was drawn for lipids, apolipoprotein (apo) A1 and B concentrations, and low-density (LSP) and high-density (HSP) lipoprotein particle sizes. A high-fat milkshake was consumed (similar to 1.3 g fat/kg). Blood was drawn at 2, 4, and 6 hours to determine PPLr, (triglyceride (TG) area under the curve). TAF and visceral (VF) fat were measured by ultrasonography; total body fat (TBF) by dual-energy X-ray absorptiometry. Differences between the groups were determined by independent sample t-tests. Pearson correlation coefficients determined the relationship among PPLr and lipids, and TAF. Results: There were no significant differences in fasting TG, low-density lipoprotein (LDL), apoB, TAF, or PPLr values between the groups. In SCI, PPLr significantly correlated with: apoB (r = 0.63, P < 0.01, LSP (r = 0.57, P < 0.01), and TAF (r = 0.36, P < 0.01). After controlling for age and duration of injury, PPLr significantly correlated with apoB (r = 0.66, P = 0.001), TBF (r = 0.45, P = 0.03), VF (r = 0.66, P = 0.02), and TAF (r = 0.56, P = 0.007). Conclusions: Although concentrations of LDL cholesterol and apoB were not different between SCI and AB groups, LSP, apoB, and TAF correlated with PPLr in persons with SCI. ApoB was associated with a greater PPLr in those with motor complete SCI, after controlling for age and duration of injury. C1 [Emmons, Racine R.] William Paterson Univ, Dept Kinesiol, Wayne, NJ 07470 USA. [Emmons, Racine R.; Cirnigliaro, Christopher M.; Bauman, William A.] James J Peters VA Med Ctr, Rehabil Res & Dev Natl Ctr Excellence Med Consequ, Dept Vet Affairs, Bronx, NY USA. [Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA. [Kirshblum, Steven C.] Rutgers New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA. [Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP Emmons, RR (reprint author), William Paterson Univ, Dept Kinesiol, 300 Pompton Rd, Wayne, NJ 07470 USA. EM emmonshindelongr@wpunj.edu FU Veteran Affairs Rehabilitation Research and Development Service [B4162C]; James J. Peters VA Medical Center FX This research was supported by the Veteran Affairs Rehabilitation Research and Development Service (#B4162C) and the James J. Peters VA Medical Center. NR 30 TC 0 Z9 0 U1 0 U2 3 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD NOV PY 2014 VL 37 IS 6 BP 765 EP 773 DI 10.1179/2045772314Y.0000000231 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA AT9AE UT WOS:000345219200013 PM 24961488 ER PT J AU Yang, HQ Trbovich, M Harrow, J AF Yang, Huiqing Trbovich, Michelle Harrow, Jeffrey TI Secondary adrenal insufficiency after glucocorticosteroid administration in acute spinal cord injury: A case report SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Acute spinal cord injury; Steroid; Adrenal insufficiency; Cosyntropin stimulation test ID ORTHOSTATIC HYPOTENSION; ILL PATIENTS; METHYLPREDNISOLONE; STIMULATION; PREVALENCE; DIAGNOSIS; THERAPY; TESTS; MEN AB Context/background: A 61-year-old female with cervical stenosis underwent an elective cervical laminectomy with post-op worsening upper extremity weakness. Over the first 3 weeks post-op, she received two separate courses of intravenous steroids. Two days after cessation of steroids, she presented with non-specific symptoms of adrenal insufficiency (AI). Initial formal diagnostic tests of random cortisol level and 250 mu g cosyntropin challenge were non-diagnostic; however, symptoms resolved with the initiation of empiric treatment with hydrocortisone. Ten days later, repeat cosyntropin (adrenocortocotropic hormone stimulation) test confirmed the diagnosis of AI. Findings: AI is a potentially life-threatening complication of acute spinal cord injury (ASCI), especially in those receiving steroids acutely. Only three cases have been reported to date of AI occurring in ASCI after steroid treatment. The presenting symptoms can be non-specific (as in this patient) and easily confused with other common sequelae of ASCI such as orthostasis and diffuse weakness. The 250 mu g cosyntropin simulation test may not the most sensitive test to diagnose AI in ASCI. Conclusion: The non-specific presentations and variability of diagnosis criteria make diagnosis more difficult. One microgram cosyntropin simulation test may be more sensitive than higher dose. Clinicians should be aware that AI can be a potential life-threatening complication of ASCI post-steroid treatment. Prompt diagnosis and treatment can reverse symptoms and minimize mortality. C1 [Yang, Huiqing; Trbovich, Michelle; Harrow, Jeffrey] Univ Texas Hlth Sci Ctr San Antonio, Dept Phys Med & Rehabil, San Antonio, TX 78229 USA. [Trbovich, Michelle; Harrow, Jeffrey] Audie L Murphy Mem Vet Affairs Hosp, Spinal Cord Injury Serv, San Antonio, TX USA. RP Trbovich, M (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Med, Mail Code 7798,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM Michelle.Trbovich@va.gov NR 28 TC 0 Z9 0 U1 1 U2 4 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD NOV PY 2014 VL 37 IS 6 BP 786 EP 790 DI 10.1179/2045772314Y.0000000223 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA AT9AE UT WOS:000345219200016 PM 24969098 ER PT J AU Ahroni, JH AF Ahroni, Jessie H. TI Developing a Wound and Skin Care Program SO JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING LA English DT Article DE program development; skin care; wound care AB The purpose of this article is to review the process used in a large Veterans Affairs facility to unite a group of diverse wound care specialists together into a coordinated program. Program development is an iterative, interactive process requiring continued recycling of efforts until projects are completed. The Program Development Cycle is presented as an example of intentional planning that has been divided into 4 phases: (1) identifying the agency culture, (2) engaging in targeted project development, (3) developing operational strategies, and (4) conducting follow-up analysis. Specific examples of developing a mission, program goals, and wound care champions are discussed. Discussion also incorporates suggestions for changing organizational culture, developing policies and procedures, using best practices and guidelines, creating a wound fair, and incorporating a skin bundle and the challenges of outcome assessment. C1 [Ahroni, Jessie H.] VA Puget Sound Hlth Care Syst, Wound & Skin Care Program, Seattle, WA 98108 USA. [Ahroni, Jessie H.] Univ Washington, Sch Nursing, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. RP Ahroni, JH (reprint author), VA Puget Sound Hlth Care Syst, Wound & Skin Care Program, Mail Stop S-118-NEO,1660 South Columbian Way, Seattle, WA 98108 USA. EM Jessie.Ahroni@VA.gov NR 16 TC 2 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1071-5754 EI 1528-3976 J9 J WOUND OSTOMY CONT JI J. Wound Ostomy Cont. Nurs. PD NOV-DEC PY 2014 VL 41 IS 6 BP 549 EP 555 DI 10.1097/WON.0000000000000085 PG 7 WC Nursing SC Nursing GA AT7RF UT WOS:000345134400009 PM 25377104 ER PT J AU Findlay, VJ Wang, C Nogueira, LM Hurst, K Quirk, D Ethier, SP O'Carroll, KFS Watson, DK Camp, ER AF Findlay, Victoria J. Wang, Cindy Nogueira, Lourdes M. Hurst, Katie Quirk, Daniel Ethier, Stephen P. O'Carroll, Kevin F. Staveley Watson, Dennis K. Camp, E. Ramsay TI SNAI2 Modulates Colorectal Cancer 5-Fluorouracil Sensitivity through miR145 Repression SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID EMBRYONIC STEM-CELLS; EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR SNAIL; RECTAL-CANCER; COLON-CANCER; PANCREATIC-CANCER; TUMOR-REGRESSION; DRUG-RESISTANCE; GENE-EXPRESSION; C-MYC AB Epithelial-to-mesenchymal transition (EMT) has been associated with poor treatment outcomes in various malignancies and is inversely associated with miRNA145 expression. Therefore, we hypothesized that SNAI2 (Slug) may mediate 5-fluorouracil (5FU) chemotherapy resistance through inhibition of miR145 in colorectal cancer and thus represents a novel therapeutic target to enhance current colorectal cancer treatment strategies. Compared with parental DLD1 colon cancer cells, 5FU-resistant (5FUr) DLD1 cells demonstrated features of EMT, including >2-fold enhanced invasion (P < 0.001) and migration, suppressed E-cadherin expression, and 2-fold increased SNAI2 expression. DLD1 and HCT116 cells with stable expression of SNAI2 (DLD1/SNAI2; HCT116/SNAI2) also demonstrated EMT features such as the decreased E-cadherin as well as significantly decreased miR145 expression, as compared with control empty vector cells. On the basis of an miR145 luciferase promoter assay, we demonstrated that SNAI2 repressed activity of the miR145 promoter in the DLD1 and HCT116 cells. In addition, the ectopic expressing SNAI2 cell lines demonstrated decreased 5FU sensitivity, and, conversely, miR145 replacement significantly enhanced 5FU sensitivity. In the parental SW620 colon cancer cell line with high SNAI2 and low miR145 levels, inhibition of SNAI2 directly with short hairpin sequence for SNAI2 and miR145 replacement therapy both decreased vimentin expression and increased in vitro 5FU sensitivity. In pretreatment rectal cancer patient biopsy samples, low miR145 expression levels correlated with poor response to neoadjuvant 5FU-based chemoradiation. These results suggested that the SNAI2: miR145 pathway may represent a novel clinical therapeutic target in colorectal cancer and may serve as a response predictor to chemoradiation therapy. (C) 2014 AACR. C1 [Findlay, Victoria J.; Nogueira, Lourdes M.; Ethier, Stephen P.; Watson, Dennis K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Findlay, Victoria J.; Ethier, Stephen P.; O'Carroll, Kevin F. Staveley; Watson, Dennis K.; Camp, E. Ramsay] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Wang, Cindy; Hurst, Katie; Quirk, Daniel; O'Carroll, Kevin F. Staveley; Camp, E. Ramsay] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. [O'Carroll, Kevin F. Staveley; Camp, E. Ramsay] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Watson, Dennis K.] Med Univ S Carolina, Dept Biochem Mol Biol, Charleston, SC 29425 USA. RP Camp, ER (reprint author), Med Univ S Carolina, Dept Surg, 25 Courtenay Dr,Room 7018,MSC 295, Charleston, SC 29425 USA. EM findlay@musc.edu; campe@musc.edu FU NIH grant [5R 1K08CA142904]; Hollings Cancer Center Translational Research Award; American Cancer Society FX The study was supported by NIH grant 5R 1K08CA142904 (E.R. Camp), Hollings Cancer Center Translational Research Award (E.R. Camp), and American Cancer Society: Institutional Research Grant (E.R. Camp). NR 42 TC 4 Z9 5 U1 0 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 EI 1538-8514 J9 MOL CANCER THER JI Mol. Cancer Ther. PD NOV PY 2014 VL 13 IS 11 BP 2713 EP 2726 DI 10.1158/1535-7163.MCT-14-0207 PG 14 WC Oncology SC Oncology GA AT5BB UT WOS:000344957600021 PM 25249558 ER PT J AU Brewster, PWH Melrose, RJ Marquine, MJ Johnson, JK Napoles, A MacKay-Brandt, A Farias, S Reed, B Mungas, D AF Brewster, Paul W. H. Melrose, Rebecca J. Marquine, Maria J. Johnson, Julene K. Napoles, Anna MacKay-Brandt, Anna Farias, Sarah Reed, Bruce Mungas, Dan TI Life Experience and Demographic Influences on Cognitive Function in Older Adults SO NEUROPSYCHOLOGY LA English DT Article DE aging; cognitive change; individual differences; minority and diverse populations; recreational activity ID NEUROPSYCHOLOGICAL ASSESSMENT SCALES; ETHNICALLY DIVERSE ELDERS; PHYSICAL-ACTIVITY; SOCIOECONOMIC-STATUS; ALZHEIMERS-DISEASE; AFRICAN-AMERICAN; TEST-PERFORMANCE; READING LEVEL; LEISURE-TIME; DECLINE AB Objective: We examined the influence of a broad spectrum of life experiences on longitudinal cognitive trajectories in a demographically diverse sample of older adults. Method: Participants were 333 educationally, ethnically, and cognitively diverse older adults enrolled in a longitudinal aging study. Mixed-effects regression was used to measure baseline status in episodic memory, executive functioning, and semantic memory and change in a global cognition factor defined by change in these 3 domain-specific measures. We examined effects of life experience variables (literacy, childhood socioeconomic status, morphometric measures of physical development, life course physical and recreational activity) on longitudinal cognitive trajectories, covarying for age, apolipoprotein E (APOE) genotype and demographics (education, ethnicity, language). Results: Non-Latino Whites had higher baseline cognition, but life experience variables attenuated ethnic differences in cognitive scores. Age, literacy, childhood socioeconomic status, and physical activity significantly influenced baseline cognition. Age, APOE epsilon 4, and decline in intellectually and socially stimulating recreational activity from mid to late life were independently associated with increased late life cognitive decline. Higher literacy and late life recreational activity were associated with less decline. Literacy had similar effects for English and Spanish readers/speakers. Bilingual English and Spanish speakers did not differ from English Speakers in cognitive performance. Conclusions: Life experience variables, especially literacy level, were strongly related to baseline cognition and substantially attenuated effects of race/ethnicity and education. Cognitive change was best explained by age, APOE epsilon 4, literacy, and current recreational activities. Literacy had robust associations with baseline cognition and cognitive change in both English and Spanish speakers. C1 [Brewster, Paul W. H.] Univ Victoria, Dept Psychol, Victoria, BC, Canada. [Melrose, Rebecca J.] VA Greater Los Angeles Healthcare Syst, Brain Behav & Aging Res Ctr, Los Angeles, CA USA. [Melrose, Rebecca J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Marquine, Maria J.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Johnson, Julene K.] Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA 94143 USA. [Johnson, Julene K.; Napoles, Anna] Univ Calif San Francisco, Ctr Aging Div Commun, Dept Med, San Francisco, CA 94143 USA. [MacKay-Brandt, Anna] Nathan S Kline Inst Psychiat Res, Dept Outpatient Res, Orangeburg, NY USA. [Farias, Sarah; Reed, Bruce; Mungas, Dan] Univ Calif Davis, Sch Med, Dept Neurol, Davis, CA USA. RP Brewster, PWH (reprint author), Univ Victoria, Dept Psychol, Victoria, BC, Canada. EM pbrew@uvic.ca FU National Institute on Aging (NIA) [R13 AG030995, R01 AG042526, P30 AG15272]; NIA [P30 AG15272, R01 AG10220, P30 AG10129, R01 AG021028, R01 AG031252, R01 AG031563]; NIA Resource Centers for Minority Aging Research grant [P30 AG043097]; VA Career Development Award; Canadian Institutes for Health Research; Research Training in Late-Life Neuropsychiatric Disorders [T32 MH02004]; Training in Research on Addictions in Interdisciplinary NeuroAIDS (TRAIN) [T32 DA031098] FX This work was developed as part of a conference supported by the National Institute on Aging (NIA; R13 AG030995, Dan Mungas, PI). Data collection for this research was supported by multiple grants from the NIA (R01 AG10220, Dan Mungas, PI; P30 AG10129 and R01 AG021028, C. DeCarli, PI; R01 AG031252 Sarah Tomaszewski Farias, PI; R01 AG031563 Bruce Reed, PI), and analysis and manuscript development was supported by a NIA Resource Centers for Minority Aging Research grant (P30 AG043097, L. Hinton, PI). Rebecca J. Melrose was supported by a VA Career Development Award. Paul W. H. Brewster was funded by a Doctoral Research Award from the Canadian Institutes for Health Research. Anna Napoles was supported by NIA grant P30 AG15272. Anna MacKay-Brandt was funded by T32 MH02004, Research Training in Late-Life Neuropsychiatric Disorders. Maria J. Marquine was funded by T32 DA031098, Training in Research on Addictions in Interdisciplinary NeuroAIDS (TRAIN). Julene K. Johnson was funded by the National Institute on Aging grants R01 AG042526 and P30 AG15272. NR 69 TC 12 Z9 12 U1 1 U2 19 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0894-4105 EI 1931-1559 J9 NEUROPSYCHOLOGY JI Neuropsychology PD NOV PY 2014 VL 28 IS 6 SI SI BP 846 EP 858 DI 10.1037/neu0000098 PG 13 WC Psychology, Clinical; Neurosciences; Psychology SC Psychology; Neurosciences & Neurology GA AT8BI UT WOS:000345158400005 PM 24933483 ER PT J AU Gupta, SR Steele, EA Solomon, AR AF Gupta, Seema R. Steele, Eric A. Solomon, Alvin R. TI Idiopathic Lymphoplasmacellular Mucositis-Dermatitis of the Eyelid SO OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article AB Idiopathic lymphoplasmacellular mucositis-dermatitis is a rare mucosal or cutaneous disorder characterized clinically by papules or plaques with variable erosion and microscopically by dense dermal inflammatory cell infiltrates with numerous plasma cells. It has been described in the oral and upper aerodigestive tracts, male and female genitalia, and other mucosal surfaces. In this article, the authors describe a case of idiopathic lymphoplasmacellular mucositis-dermatitis occurring in the skin of the eyelid that was removed by excisional biopsy and has not recurred in the 19-month follow-up period. C1 [Gupta, Seema R.; Steele, Eric A.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, Portland, OR 97201 USA. [Steele, Eric A.; Solomon, Alvin R.] Portland VA Med Ctr, Operat Care Div, Portland, OR USA. [Solomon, Alvin R.] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA. [Solomon, Alvin R.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. RP Gupta, SR (reprint author), Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA. EM steeleer@ohsu.edu FU Research to Prevent Blindness to Casey Eye Institute FX Funded, in part, from an unrestricted grant from Research to Prevent Blindness to Casey Eye Institute. NR 5 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0740-9303 EI 1537-2677 J9 OPHTHAL PLAST RECONS JI Ophthalmic Plast. Reconstr. Surg. PD NOV-DEC PY 2014 VL 30 IS 6 BP E149 EP E151 DI 10.1097/01.iop.0000440707.52043.87 PG 4 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA AT7PJ UT WOS:000345129600006 PM 24836448 ER PT J AU Levine, MS Yee, J AF Levine, Marc S. Yee, Judy TI History, Evolution, and Current Status of Radiologic Imaging Tests for Colorectal Cancer Screening SO RADIOLOGY LA English DT Article ID CONTRAST BARIUM ENEMA; COMPUTED-TOMOGRAPHIC COLONOGRAPHY; MAGNETIC-RESONANCE COLONOGRAPHY; LUMEN MR COLONOGRAPHY; AVERAGE-RISK PATIENTS; ROW CT COLONOGRAPHY; WORK-IN-PROGRESS; AIDED DETECTION; CONVENTIONAL COLONOSCOPY; COLONIC DISTENSION AB Colorectal cancer screening is thought to be an effective tool with which to reduce the mortality from colorectal cancer through early detection and removal of colonic adenomas and early colon cancers. In this article, we review the history, evolution, and current status of imaging tests of the colon-including single-contrast barium enema, double-contrast barium enema, computed tomographic (CT) colonography, and magnetic resonance (MR) colonography-for colorectal cancer screening. Despite its documented value in the detection of colonic polyps, the double-contrast barium enema has largely disappeared as a screening test because it is widely perceived as a labor-intensive, time-consuming, and technically demanding procedure. In the past decade, the barium enema has been supplanted by CT colonography as the major imaging test in colorectal cancer screening in the United States, with MR colonography emerging as another viable option in Europe. Although MR colonography does not require ionizing radiation, the radiation dose for CT colonography has decreased substantially, and regular screening with this technique has a high benefit-to-risk ratio. In recent years, CT colonography has been validated as an effective tool for use in colorectal cancer screening that is increasingly being disseminated. (C)RSNA, 2014 C1 [Levine, Marc S.] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Yee, Judy] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Levine, MS (reprint author), Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA. EM marc.levine@uphs.upenn.edu NR 169 TC 4 Z9 4 U1 1 U2 3 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD NOV PY 2014 VL 273 IS 2S BP S160 EP S180 DI 10.1148/radiol.14140531 PG 21 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AT9UR UT WOS:000345272400010 PM 25340435 ER PT J AU Williams, RM Turner, AP Norvell, DC Henderson, AW Hakimi, KN Czerniecki, JM AF Williams, Rhonda M. Turner, Aaron P. Norvell, Daniel C. Henderson, Alison W. Hakimi, Kevin N. Czerniecki, Joseph M. TI The Role of Expectations in Pain After Dysvascular Lower Extremity Amputation SO REHABILITATION PSYCHOLOGY LA English DT Article DE expectations; satisfaction; amputation; pain ID LOWER-LIMB AMPUTATION; PATIENT EXPECTATIONS; PHANTOM PAIN; BACK-PAIN; SATISFACTION; ARTHROPLASTY; DISABILITY; SECONDARY; MODERATE; MILD AB Objective: The objective was to determine the relationship between pain expectations assessed prior to surgery and satisfaction with pain 4 and 12 months after major dysvascular lower extremity amputation. Research Method: The study included a prospective cohort of male (n = 19) veterans experiencing their first lower extremity amputation due to complications of diabetes mellitus or peripheral arterial disease. Measures included presurgical expectations of pain at 4 and 12 months postamputation, actual average pain and satisfaction with pain at 4 and 12 months postamputation, and agreement between expected and actual pain. Results: Sixty-eight percent of participants expected to experience no or minimal pain at 4 months; 95% expected to experience no or minimal pain at 12 months. Thirty-two percent and 58% of participants had more pain than they expected at 4 and 12 months, respectively. Participants whose pain expectations were met reported higher satisfaction with their actual level of pain at 12 months postamputation, even after adjusting for current pain levels. Conclusion: The results underscore the potential value of fostering realistic expectations about the degree to which amputation may impact average pain. C1 [Williams, Rhonda M.] VA Puget Sound Hlth Care Syst, Ctr Polytrauma Care, Rehabil Care Serv, Seattle, WA 98108 USA. [Williams, Rhonda M.; Turner, Aaron P.; Hakimi, Kevin N.; Czerniecki, Joseph M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Turner, Aaron P.; Hakimi, Kevin N.] VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98108 USA. [Norvell, Daniel C.] Spectrum Res Inc, Tacoma, WA USA. [Henderson, Alison W.] VA Puget Sound Hlth Care Syst, VA Res Ctr Excellence Limb Loss Prevent & Prosthe, Seattle, WA 98108 USA. [Czerniecki, Joseph M.] VA Puget Sound Hlth Care Syst, VA Res Ctr Excellence Limb Loss Prevent & Prosthe, Rehabil Care Serv, Seattle, WA 98108 USA. RP Williams, RM (reprint author), VA Puget Sound Hlth Care Syst, RCS 117,1660 S Columbian Way, Seattle, WA 98108 USA. EM Rhonda.Williams1@va.gov OI Turner, Aaron/0000-0001-6897-8003 NR 21 TC 2 Z9 2 U1 1 U2 3 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0090-5550 EI 1939-1544 J9 REHABIL PSYCHOL JI Rehabil. Psychol. PD NOV PY 2014 VL 59 IS 4 BP 459 EP 463 DI 10.1037/rep0000014 PG 5 WC Psychology, Clinical; Rehabilitation SC Psychology; Rehabilitation GA AT8BQ UT WOS:000345159200011 PM 25313581 ER PT J AU Yoon, JH Westphal, AJ Minzenberg, MJ Niendam, T Ragland, JD Lesh, T Solomon, M Carter, CS AF Yoon, Jong H. Westphal, Andrew J. Minzenberg, Michael J. Niendam, Tara Ragland, J. Daniel Lesh, Tyler Solomon, Marjorie Carter, Cameron S. TI Task-evoked substantia nigra hyperactivity associated with prefrontal hypofunction, prefrontonigral disconnectivity and nigrostriatal connectivity predicting psychosis severity in medication naive first episode schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Psychosis; fMRI; Substantia nigra; Prefrontal cortex; Striatum; Dopamine; Basal ganglia ID CONTEXT-PROCESSING DEFICITS; PRESYNAPTIC DOPAMINE FUNCTION; DOUBLE-BLIND PET; FUNCTIONAL CONNECTIVITY; CORTEX DYSFUNCTION; BASAL GANGLIA; BRAIN; STRIATUM; SYMPTOMS; SPECIFICITY AB The widely cited prefrontal dysfunction - excess subcortical dopamine model of schizophrenia posits that prefrontal deficits give rise to cognitive impairments and the disinhibition of subcortical dopamine release underlying psychosis. While this has been one of the most influential schizophrenia models, only a handful of studies have provided evidence supporting it directly in patients with schizophrenia. We previously demonstrated task-evoked substantia nigra hyperactivity in the context of prefrontal hypofunction and prefrontonigral functional disconnectivity. In addition, nigrostriatal functional connectivity was identified as a potential marker of psychosis. Because patients in this prior study had chronic schizophrenia and were treated with antipsychotics, in the present study we tested whether these findings were confounded by illness chronicity and medication effects by seeking to reproduce these findings in an independent sample of antipsychotic naive, first episode (FE) patients. We compared event-related fMRI activations from 12 FE patients with 15 demographically matched healthy control subjects during cognitive testing. We found substantia nigra hyperactivity associated with prefrontal hypofunction and prefrontonigral functional disconnectivity, as well as the magnitude of nigrostriatal functional connectivity positively correlating with severity of psychosis. This study adds to the body of evidence supporting the prefrontal-dopamine model of schizophrenia and further validates nigrostriatal functional connectivity as a marker of psychosis. Published by Elsevier B.V. C1 [Yoon, Jong H.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Yoon, Jong H.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Westphal, Andrew J.; Niendam, Tara; Ragland, J. Daniel; Lesh, Tyler; Solomon, Marjorie; Carter, Cameron S.] Univ Calif Davis, Dept Psychiat, Davis, CA USA. [Minzenberg, Michael J.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Minzenberg, Michael J.] San Francisco VA Med Ctr, San Francisco, CA USA. [Solomon, Marjorie] Univ Calif Davis, MIND Inst, Davis, CA USA. [Carter, Cameron S.] Univ Calif Davis, Ctr Neurosci, Davis, CA USA. RP Yoon, JH (reprint author), VA Palo Alto Hlth Care Syst, 3801 Miranda Ave,Bldg 4,2nd Floor, Palo Alto, CA 94304 USA. RI Niendam, Tara/K-8475-2015 OI Niendam, Tara/0000-0003-2285-5002 FU NIH FX The funding source for this study was entirely derived from investigator initiated NIH grants. Therefore, the conduct of the study was solely directed by the authors of this manuscript. NR 45 TC 3 Z9 3 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD NOV PY 2014 VL 159 IS 2-3 BP 521 EP 526 DI 10.1016/j.schres.2014.09.022 PG 6 WC Psychiatry SC Psychiatry GA AT9DX UT WOS:000345229200042 PM 25266549 ER PT J AU Bastian, LA Trentalange, M Murphy, TE Brandt, C Bean-Mayberry, B Maisel, NC Wright, SM Gaetano, VS Allore, H Skanderson, M Reyes-Harvey, E Yano, EM Rose, D Haskell, S AF Bastian, Lori A. Trentalange, Mark Murphy, Terrence E. Brandt, Cynthia Bean-Mayberry, Bevanne Maisel, Natalya C. Wright, Steven M. Gaetano, Vera S. Allore, Heather Skanderson, Melissa Reyes-Harvey, Evelyn Yano, Elizabeth M. Rose, Danielle Haskell, Sally TI Association between Women Veterans' Experiences with VA Outpatient Health Care and Designation as a Women's Health Provider in Primary Care Clinics SO WOMENS HEALTH ISSUES LA English DT Article ID QUALITY-OF-CARE; PATIENT SATISFACTION; MEDICAL-CARE; PREFERENCES; PERCEPTIONS; SERVICES; VHA AB Background: Women veterans comprise a small percentage of Department of Veterans Affairs (VA) health care users. Prior research on women veterans' experiences with primary care has focused on VA site differences and not individual provider characteristics. In 2010, the VA established policy requiring the provision of comprehensive women's health care by designated women's health providers (DWHPs). Little is known about the quality of health care delivered by DWHPs and women veterans' experience with care from these providers. Methods: Secondary data were obtained from the VA Survey of Healthcare Experience of Patients (SHEP) using the Consumer Assessment of Healthcare Providers and Systems (CAHPS) patient-centered medical home (PCMH) survey from March 2012 through February 2013, a survey designed to measure patient experience with care and the DWHPs Assessment of Workforce Capacity that discerns between DWHPs versus non-DWHPs. Findings: Of the 28,994 surveys mailed to women veterans, 24,789 were seen by primary care providers and 8,151 women responded to the survey (response rate, 32%). A total of 3,147 providers were evaluated by the SHEP-CAHPS-PCMH survey (40%; n = 1,267 were DWHPs). In a multivariable model, patients seen by DWHPs (relative risk, 1.02; 95% CI, 1.01-1.04) reported higher overall experiences with care compared with patients seen by non-DWHPs. Conclusions: The main finding is that women veterans' overall experiences with outpatient health care are slightly better for those receiving care from DWHPs compared with those receiving care from non-DWHPs. Our findings have important policy implications for how to continue to improve women veterans' experiences. Our work provides support to increase access to DWHPs at VA primary care clinics. Published by Elsevier Inc. C1 [Bastian, Lori A.; Trentalange, Mark; Murphy, Terrence E.; Brandt, Cynthia; Gaetano, Vera S.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Bastian, Lori A.; Allore, Heather] Univ Connecticut, Ctr Hlth, Farmington, CT USA. [Bean-Mayberry, Bevanne; Yano, Elizabeth M.; Rose, Danielle] VA Greater Los Angeles Healthcare Syst, Vet Hlth Adm Hlth Serv Res & Dev, Ctr Study Healthcare Innovat Implementat & Policy, Sepulveda, CA USA. [Maisel, Natalya C.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA USA. [Wright, Steven M.] Dept Vet Affairs, Off Performance Measurement, Providence, RI USA. [Skanderson, Melissa] Dept Vet Affairs, Pittsburgh, PA USA. [Reyes-Harvey, Evelyn] Off Analyt & Business Intelligence, Off Performance Measurement, Durham, NC USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Haskell, Sally] Yale Univ, Sch Med, VA Connecticut Healthcare Syst, Womens Hlth Serv,Patient Care Serv,VA Cent Off, West Haven, CT 06516 USA. RP Bastian, LA (reprint author), VA Connecticut Healthcare Syst, 555 Willard Ave, Newington, CT 06011 USA. EM lori.bastian@va.gov OI Gaetano, Vera/0000-0002-0723-7671; Allore, Heather/0000-0001-7685-8175 FU NIA NIH HHS [P30 AG021342] NR 33 TC 8 Z9 8 U1 3 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD NOV-DEC PY 2014 VL 24 IS 6 BP 605 EP 612 DI 10.1016/j.whi.2014.07.005 PG 8 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA AT8BD UT WOS:000345157900005 PM 25442706 ER PT J AU Liang, PS Dominitz, JA AF Liang, Peter S. Dominitz, Jason A. TI Bowel Preparation: Is Fair Good Enough? SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Editorial Material ID ADENOMA DETECTION RATE; SOCIETY TASK-FORCE; COLORECTAL-CANCER; COLONOSCOPY; QUALITY; RECOMMENDATIONS; PERFORMANCE; VALIDATION; ENDOSCOPY; IMPACT AB The effectiveness of colonoscopy in reducing colorectal cancer incidence and mortality has been shown to be associated with an endoscopist's adenoma detection rate, although the ability to detect adenomas depends, in part, on the quality of bowel preparation. Many endoscopists routinely recommend shorter examination intervals for colonoscopies with a fair or intermediate-quality bowel preparation, assuming that the preparation is insufficient for the purpose of colorectal cancer screening. In this issue, Clark et al. performed a systematic review and meta-analysis to assess the adequacy of a fair-quality bowel preparation, finding no difference in the adenoma detection rate of colonoscopies with an intermediate-quality bowel preparation relative to those with a high-quality preparation. Although this finding has potentially significant implications for patient care and healthcare costs, the limitations of the adenoma detection rate as a performance measure and variability in the application of bowel preparation ratings are important issues that must be considered. C1 [Liang, Peter S.; Dominitz, Jason A.] Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. [Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Gastroenterol Sect, Seattle, WA 98108 USA. RP Dominitz, JA (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,111 Gastro, Seattle, WA 98108 USA. EM jason.dominitz@va.gov OI Liang, Peter/0000-0002-4160-421X FU NIDDK NIH HHS [T32 DK007742] NR 18 TC 4 Z9 4 U1 2 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD NOV PY 2014 VL 109 IS 11 BP 1725 EP 1727 DI 10.1038/ajg.2014.328 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS7UZ UT WOS:000344461300005 PM 25373582 ER PT J AU Abbas, AM Almukhtar, RM Loftus, EV Lichtenstein, GR Khan, N AF Abbas, Ali M. Almukhtar, Rawaa M. Loftus, Edward V., Jr. Lichtenstein, Gary R. Khan, Nabeel TI Risk of Melanoma and Non-Melanoma Skin Cancer in Ulcerative Colitis Patients Treated With Thiopurines: A Nationwide Retrospective Cohort SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; ORGAN TRANSPLANT RECIPIENTS; BASAL-CELL CARCINOMAS; RECEIVE THIOPURINES; CLAIMS DATA; DNA-DAMAGE; US WOMEN; AZATHIOPRINE; POPULATION; THERAPY AB OBJECTIVES: There are limited data on the risk of non-melanoma skin cancer (NMSC) and melanoma skin cancer (MSC) among thiopurine-treated patients with ulcerative colitis (UC). Our aim was to investigate the risk while on, by cumulative years, and after stopping thiopurine therapy. METHODS: Nationwide data were obtained from the Veterans Affairs (VA) health-care system during 2001-2011. We performed a retrospective cohort study evaluating patients with UC. Cox regression was used to investigate the association between thiopurines use and time to NMSC while adjusting for demographics, ultraviolet radiation exposure, and VA visiting frequency. A matched nested case-control study was conducted to investigate the association between thiopurine use and MSC. RESULTS: We included 14,527 patients with UC in the analysis, with a median follow-up of 8.1 years. A total of 3,346 (23%) patients used thiopurines for a median duration of 1.6 years. We identified 421 NMSC and 45 MSC cases. The adjusted hazard ratios of developing NMSC while on and after stopping thiopurines were 2.1 (P<0.0001) and 0.7 (P=0.07), respectively, as compared with unexposed patients. The incidence rate of NMSC among those who never used thiopurines was 3.7 compared with 5.8, 7.9, 8.3, 7.8, and 13.6 per 1,000 person-years for the 1st, 2nd, 3th, 4th, and 5th year of thiopurine use, respectively. No statistically significant association was observed between thiopurine use and MSC, odds ratio 0.8 (P=0.6). CONCLUSIONS: In this predominantly white male nationwide cohort, there was a twofold increase in the risk of NMSC while on thiopurines. The incidence rate of NMSC significantly increased with subsequent years of cumulative exposure to thiopurines. Stopping thiopurines reduced the risk of NMSC to pre-exposure levels irrespective of the prior exposure duration. C1 [Abbas, Ali M.; Khan, Nabeel] Southeast Louisiana Vet Hlth Care Syst, Gastroenterol Sect, New Orleans, LA USA. [Abbas, Ali M.] Univ Florida, Dept Med, Gainesville, FL 32610 USA. [Almukhtar, Rawaa M.] Louisiana State Univ, Sch Publ Hlth, Hlth Sci Ctr, Dept Epidemiol, New Orleans, LA USA. [Loftus, Edward V., Jr.] Mayo Clin, Div Gastroenterol & Hepatol, Dept Internal Med, Rochester, MN USA. [Lichtenstein, Gary R.; Khan, Nabeel] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia VA Med Ctr,Div Gastroenterol, Philadelphia, PA 19104 USA. RP Abbas, AM (reprint author), Univ Florida, Dept Med, 1600 SW Archer Rd, Gainesville, FL 32610 USA. EM Ali.Abbas@medicine.ufl.edu RI Loftus, Edward/E-8304-2011 FU Department of Veterans Affairs, Veterans Health Administration - Office of Research & Development Health Services [VA Project No. 425] FX Financial support: This study was funded in full by the Department of Veterans Affairs, Veterans Health Administration - Office of Research & Development Health Services. Grant number (VA Project No. 425). NR 68 TC 14 Z9 15 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD NOV PY 2014 VL 109 IS 11 BP 1781 EP 1793 DI 10.1038/ajg.2014.298 PG 13 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS7UZ UT WOS:000344461300012 PM 25244964 ER PT J AU Spiegel, BMR Hays, RD Bolus, R Melmed, GY Chang, L Whitman, C Khanna, PP Paz, SH Hays, T Reise, S Khanna, D AF Spiegel, Brennan M. R. Hays, Ron D. Bolus, Roger Melmed, Gil Y. Chang, Lin Whitman, Cynthia Khanna, Puja P. Paz, Sylvia H. Hays, Tonya Reise, Steve Khanna, Dinesh TI Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Gastrointestinal Symptom Scales SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID QUALITY-OF-LIFE; IRRITABLE-BOWEL-SYNDROME; VISCERAL SENSITIVITY INDEX; CLINICAL-PRACTICE; CHRONIC ILLNESS; VALIDATION; DISEASE; QUESTIONNAIRE; INSTRUMENT; GASTROENTEROLOGY AB OBJECTIVES: The National Institutes of Health (NIH) Patient-Reported Outcomes Measurement Information System (PROMIS (R)) is a standardized set of patient-reported outcomes (PROs) that cover physical, mental, and social health. The aim of this study was to develop the NIH PROMIS gastrointestinal (GI) symptom measures. METHODS: We first conducted a systematic literature review to develop a broad conceptual model of GI symptoms. We complemented the review with 12 focus groups including 102 GI patients. We developed PROMIS items based on the literature and input from the focus groups followed by cognitive debriefing in 28 patients. We administered the items to diverse GI patients (irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), systemic sclerosis (SSc), and other common GI disorders) and a census-based US general population (GP) control sample. We created scales based on confirmatory factor analyses and item response theory modeling, and evaluated the scales for reliability and validity. RESULTS: A total of 102 items were developed and administered to 865 patients with GI conditions and 1,177 GP participants. Factor analyses provided support for eight scales: gastroesophageal reflux (13 items), disrupted swallowing (7 items), diarrhea (5 items), bowel incontinence/soilage (4 items), nausea and vomiting (4 items), constipation (9 items), belly pain (6 items), and gas/bloat/flatulence (12 items). The scales correlated significantly with both generic and disease-targeted legacy instruments, and demonstrate evidence of reliability. CONCLUSIONS: Using the NIH PROMIS framework, we developed eight GI symptom scales that can now be used for clinical care and research across the full range of GI disorders. C1 [Spiegel, Brennan M. R.; Melmed, Gil Y.] Cedars Sinai Med Ctr, Dept Gastroenterol, Los Angeles, CA 90048 USA. [Spiegel, Brennan M. R.; Bolus, Roger; Whitman, Cynthia] Cedars Sinai Ctr Outcomes Res & Educ, Los Angeles, CA USA. [Spiegel, Brennan M. R.] VA Greater Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA. [Spiegel, Brennan M. R.; Hays, Ron D.; Paz, Sylvia H.; Hays, Tonya] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Hays, Ron D.; Chang, Lin] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Chang, Lin] Univ Calif Los Angeles, David Geffen Sch Med, Gail & Gerald Oppenheimer Family Ctr Neurobiol St, Los Angeles, CA 90095 USA. [Khanna, Puja P.; Khanna, Dinesh] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA. [Reise, Steve] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. RP Spiegel, BMR (reprint author), Univ Michigan, Scleroderma Program, Div Rheumatol, Dept Internal Med, 300 North Ingalls St,Suite 7C27, Ann Arbor, MI 48109 USA. EM bspiegel@ucla.edu; khannad@med.umich.edu FU NIH/NIAMS [U01 AR057936A]; National Institutes of Health through the NIH Roadmap for Medical Research grant [AR052177]; Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training grant NIAMS [1 T32 AR053463]; ACR Research and Education Foundation Clinical Investigator Fellowship Award; NIAMS [K24 AR063120]; NIH/NIA [P30-AG028748, P30-AG021684]; NCMHD [2P20MD000182]; NIDDK [P50 DK64539] FX Financial support : This study was supported by NIH/NIAMS U01 AR057936A, the National Institutes of Health through the NIH Roadmap for Medical Research grant (AR052177). Puja P. Khanna was supported by Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training grant NIAMS 1 T32 AR053463 and ACR Research and Education Foundation Clinical Investigator Fellowship Award 2009-11. Dinesh Khanna was also supported by NIAMS K24 AR063120. Ron D. Hays was also supported by NIH/NIA grants P30-AG028748 and P30-AG021684, and NCMHD grant 2P20MD000182. Lin Chang was also supported by NIDDK P50 DK64539. NR 29 TC 18 Z9 18 U1 1 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD NOV PY 2014 VL 109 IS 11 BP 1804 EP 1814 DI 10.1038/ajg.2014.237 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS7UZ UT WOS:000344461300014 PM 25199473 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Therapy Without Diagnosis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter ID IRRITABLE-BOWEL-SYNDROME C1 [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Div Gastroenterol Hepatol, Portland VA Med Ctr, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Div Gastroenterol Hepatol, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 5 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD NOV PY 2014 VL 109 IS 11 BP 1837 EP 1838 DI 10.1038/ajg.2014.291 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS7UZ UT WOS:000344461300023 PM 25373591 ER PT J AU Whittle, J Schapira, MM Fletcher, KE Hayes, A Morzinski, J Laud, P Eastwood, D Ertl, K Patterson, L Mosack, KE AF Whittle, Jeff Schapira, Marilyn M. Fletcher, Kathlyn E. Hayes, Avery Morzinski, Jeffrey Laud, Purushottam Eastwood, Dan Ertl, Kristyn Patterson, Leslie Mosack, Katie E. TI A Randomized Trial of Peer-Delivered Self-Management Support for Hypertension SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article DE blood pressure; hypertension; patient participation; randomized clinical trial; self-help groups ID CHRONIC DISEASE; BLOOD-PRESSURE; CARE MANAGEMENT; HEART-DISEASE; PROGRAMS; EDUCATION; VETERANS; ORGANIZATIONS; INTERVENTIONS; QUESTIONNAIRE AB Peer-led interventions to improve chronic disease self-management can improve health outcomes but are not widely used. Therefore, we tested a peer-led hypertension self-management intervention delivered at regular meetings of community veterans' organizations. We randomized 58 organizational units ("posts") of veterans' organizations in southeast Wisconsin to peer-led vs. professionally delivered self-management education. Volunteer peer leaders at peer-led posts delivered monthly presentations regarding hypertension self-management during regular post meetings. Volunteer post representatives at seminar posts encouraged post members to attend 3 didactic seminars delivered by health professionals at a time separate from the post meeting. Volunteers in both groups encouraged members to self-monitor using blood pressure cuffs, weight scales, and pedometers. Our primary outcome was change in systolic blood pressure (SBP) at 12 months. We measured SBP in 404 participants at baseline and in 379 participants at 12 months. SBP decreased significantly (4.4mm Hg; P < 0.0001) overall; the decrease was similar in peer-led and seminar posts (3.5mm Hg vs. 5.4mm Hg; P = 0.24). Among participants with uncontrolled BP at baseline, SBP decreased by 10.1mm Hg from baseline to 12 months but was again similar in the 2 groups. This pattern was also seen at 6 months and with diastolic blood pressure. Our peer-led educational intervention was not more effective than didactic seminars for SBP control. Although peer-led educational programs have had important impacts in a number of studies, we did not find our intervention superior to a similar intervention delivered by healthcare professionals. ClinicalTrials.gov NCT00571038. C1 [Whittle, Jeff; Fletcher, Kathlyn E.; Hayes, Avery] Clement J Zablocki VA Med Ctr, Primary Care Div, Milwaukee, WI 53295 USA. [Whittle, Jeff; Fletcher, Kathlyn E.; Laud, Purushottam; Ertl, Kristyn] Med Coll Wisconsin, Ctr Patient Care Outcomes Res, Milwaukee, WI 53226 USA. [Whittle, Jeff; Fletcher, Kathlyn E.] Med Coll Wisconsin, Dept Med, Div Gen Internal Med, Milwaukee, WI 53226 USA. [Schapira, Marilyn M.] Univ Penn, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.] Philadelphia VA, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Morzinski, Jeffrey; Patterson, Leslie] Med Coll Wisconsin, Dept Family & Community Med, Milwaukee, WI 53226 USA. [Laud, Purushottam; Eastwood, Dan] Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI 53226 USA. [Mosack, Katie E.] Univ Wisconsin, Dept Psychol, Milwaukee, WI 53201 USA. RP Whittle, J (reprint author), Clement J Zablocki VA Med Ctr, Primary Care Div, Milwaukee, WI 53295 USA. EM jeffrey.whittle@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development [IAB 06-086-2] FX This work was supported by a grant from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development (Project IAB 06-086-2, Working with Veterans Service Organizations to Improve Blood Pressure). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. This work was reviewed and approved by the Human Studies Subcommittee (IRB) of the Milwaukee VA Medical Center. Data from this article were presented in poster format at the National VA HSRD Meeting, Washington, DC, 17 February 2011. NR 37 TC 2 Z9 4 U1 1 U2 13 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0895-7061 EI 1941-7225 J9 AM J HYPERTENS JI Am. J. Hypertens. PD NOV PY 2014 VL 27 IS 11 BP 1416 EP 1423 DI 10.1093/ajh/hpu058 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AT0BF UT WOS:000344601100012 PM 24755206 ER PT J AU McKinley, L Moriarty, H Short, TH Hagle, M Ranum, A Valentine, S Safdar, N AF McKinley, Linda Moriarty, Helene Short, Thomas H. Hagle, Mary Ranum, Abigail Valentine, Susan Safdar, Nasia TI Regional differences in vancomycin-resistant Enterococcus colonization rates in critically ill veterans SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Health care-associated infection; Antibiotic-resistant organism ID STAPHYLOCOCCUS-AUREUS; INFECTIONS; PATHOGENS; PRESSURE AB Screening for vancomycin-resistant Enterococcus (VRE) has not been universally implemented within the Department of Veterans Affairs (VA). A prospective study was conducted to identify the admission prevalence rate of VRE in patients admitted to the intensive care unit in 2 VA facilities. Significant regional differences were found between the 2 facilities. Further studies are needed to account for regional differences in VRE admission prevalence, to optimize infection control interventions. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [McKinley, Linda; Valentine, Susan; Safdar, Nasia] William S Middleton Mem VA Hosp, Madison, WI USA. [Moriarty, Helene] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Moriarty, Helene] Villanova Univ, Coll Nursing, Villanova, PA 19085 USA. [Short, Thomas H.] John Carroll Univ, University Hts, OH USA. [Hagle, Mary; Ranum, Abigail; Valentine, Susan] Milwaukee VA Med Ctr, Milwaukee, WI USA. [Safdar, Nasia] Univ Wisconsin, Madison, WI USA. RP McKinley, L (reprint author), 2500 Overlook Terrace, Madison, WI 53705 USA. EM Linda.mckinley2@va.gov OI McKinley, Linda/0000-0002-6172-7700 FU Health Services Research and Development Service of the VA Office of Research and Development [NRI 03-068] FX This material is based on work supported by NRI 03-068 from the Health Services Research and Development Service of the VA Office of Research and Development. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government. NR 8 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD NOV PY 2014 VL 42 IS 11 BP 1226 EP 1228 DI 10.1016/j.ajic.2014.07.030 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AT2FI UT WOS:000344747900019 PM 25444269 ER PT J AU Sheshadri, N Catanzaro, JM Bott, AJ Sun, Y Ullman, E Chen, EI Pan, JA Wu, S Crawford, HC Zhang, JH Zong, WX AF Sheshadri, Namratha Catanzaro, Joseph M. Bott, Alex J. Sun, Yu Ullman, Erica Chen, Emily I. Pan, Ji-An Wu, Song Crawford, Howard C. Zhang, Jianhua Zong, Wei-Xing TI SCCA1/SERPINB3 Promotes Oncogenesis and Epithelial-Mesenchymal Transition via the Unfolded Protein Response and IL6 Signaling SO CANCER RESEARCH LA English DT Article ID SQUAMOUS-CELL CARCINOMA; ENDOPLASMIC-RETICULUM STRESS; NF-KAPPA-B; TUMOR-GROWTH; STEM-CELLS; ER STRESS; ANTIGEN 1; CANCER; EXPRESSION; APOPTOSIS AB The serine/cysteine protease inhibitor SCCA1 (SERPINB3) is upregulated in many advanced cancers with poor prognosis, but there is limited information about whether it makes functional contributions to malignancy. Here, we show that SCCA1 expression promoted oncogenic transformation and epithelial-mesenchymal transition (EMT) in mammary epithelial cells, and that SCCA1 silencing in breast cancer cells halted their proliferation. SCCA1 overexpression in neu(+) mammary tumors increased the unfolded protein response (UPR), IL6 expression, and inflammatory phenotypes. Mechanistically, SCCA1 induced a prolonged nonlethal increase in the UPR that was sufficient to activate NF-kappa B and expression of the protumorigenic cytokine IL6. Overall, our findings established that SCCA1 contributes to tumorigenesis by promoting EMT and a UPR-dependent induction of NF-kappa B and IL6 autocrine signaling that promotes a protumorigenic inflammation. (C) 2014 AACR. C1 [Sheshadri, Namratha; Catanzaro, Joseph M.; Bott, Alex J.; Sun, Yu; Ullman, Erica; Pan, Ji-An; Zong, Wei-Xing] SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA. [Chen, Emily I.] SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA. [Wu, Song] SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA. [Crawford, Howard C.] Mayo Clin, Dept Canc Biol, Jacksonville, FL 32224 USA. [Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Zong, WX (reprint author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA. EM weixing.zong@stonybrook.edu OI Bott, Alex/0000-0003-2273-8922 FU NIH [R01CA129536, R01GM97355]; Carol Baldwin Breast Cancer Research Foundation; NCI T32 training grant [T32CA009176]; VA merit award; [NIHR01-NS064090] FX This work was supported by grants from NIH (R01CA129536 and R01GM97355) and the Carol Baldwin Breast Cancer Research Foundation to WXZ. J.M. Catanzaro was supported by the NCI T32 training grant (T32CA009176). J. Zhang was supported by NIHR01-NS064090 and a VA merit award. NR 50 TC 13 Z9 13 U1 0 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD NOV 1 PY 2014 VL 74 IS 21 BP 6318 EP 6329 DI 10.1158/0008-5472.CAN-14-0798 PG 12 WC Oncology SC Oncology GA AT2IF UT WOS:000344756800036 PM 25213322 ER PT J AU Pullicino, PM Qian, M Sacco, RL Freudenberger, R Graham, S Teerlink, JR Mann, D Di Tullio, MR Ponikowski, P Lok, DJ Anker, SD Lip, GYH Estol, CJ Levin, B Mohr, JP Thompson, JLP Homma, S AF Pullicino, Patrick M. Qian, Min Sacco, Ralph L. Freudenberger, Ron Graham, Susan Teerlink, John R. Mann, Douglas Di Tullio, Marco R. Ponikowski, Piotr Lok, Dirk J. Anker, Stefan D. Lip, Gregory Y. H. Estol, Conrado J. Levin, Bruce Mohr, Jay P. Thompson, John L. P. Homma, Shunichi CA WARCEF Investigators TI Recurrent Stroke in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial SO CEREBROVASCULAR DISEASES LA English DT Article DE Heart failure; Stroke; Ejection fraction ID HEART-FAILURE; ATRIAL-FIBRILLATION; SINUS RHYTHM; ISCHEMIC-STROKE; RISK; PREVENTION; THERAPY AB Background and Purpose: WARCEF randomized 2,305 patients in sinus rhythm with ejection fraction (EF) <= 35% to warfarin (INR 2.0-3.5) or aspirin 325 mg. Warfarin reduced the incident ischemic stroke (IIS) hazard rate by 48% over aspirin in a secondary analysis. The IIS rate in heart failure (HF) is too low to warrant routine anticoagulation but epidemiologic studies show that prior stroke increases the stroke risk in HF. In this study, we explore IIS rates in WARCEF patients with and without baseline stroke to look for risk factors for IIS and determine if a subgroup with an IIS rate high enough to give a clinically relevant stroke risk reduction can be identified. Methods: We compared potential stroke risk factors between patients with baseline stroke and those without using the exact conditional score test for Poisson variables. We looked for risk factors for IIS, by comparing IIS rates between different risk factors. For EF we tried cut-off points of 10, 15 and 20%. The cut-off point 15% was used as it was the highest EF that was associated with a significant increase in IIS rate. IIS and EF strata were balanced as to warfarin/ aspirin assignment by the stratified randomized design. A multiple Poisson regression examined the simultaneous effects of all risk factors on IIS rate. IIS rates per hundred patient years (/100PY) were calculated in patient groups with significant risk factors. Missing values were assigned the modal value. Results: Twenty of 248 (8.1%) patients with baseline stroke and 64 of 2,048 (3.1%) without had IIS. IIS rate in patients with baseline stroke (2.37/100PY) was greater than patients without (0.89/100PY) (rate ratio 2.68, p < 0.001). Fourteen of 219 (6.4%) patients with ejection fraction (EF) < 15% and 70 of 2,079 (3.4%) with EF >= 15% had IIS. In the multiple regression analysis stroke at baseline (p < 0.001) and EF < 15% vs. >= 15% (p = 0.005) remained significant predictors of IIS. IIS rate was 2.04/100PY in patients with EF < 15% and 0.95/100PY in patients with EF >= 15% (p = 0.009). IIS rate in patients with baseline stroke and reduced EF was 5.88/100PY with EF < 15% decreasing to 2.62/100PY with EF < 30%. Conclusions: In a WARCEF exploratory analysis, prior stroke and EF < 15% were risk factors for IIS. Further research is needed to determine if a clinically relevant stroke risk reduction is obtainable with warfarin in HF patients with prior stroke and reduced EF. (C) 2014 S. Karger AG, Basel C1 [Pullicino, Patrick M.] Univ Kent, Canterbury CT2 7PD, Kent, England. [Qian, Min; Di Tullio, Marco R.; Levin, Bruce; Mohr, Jay P.; Thompson, John L. P.; Homma, Shunichi] Columbia Univ, New York, NY USA. [Sacco, Ralph L.] Univ Miami, Miami, FL USA. [Freudenberger, Ron] LeHigh Valley Hosp, Allentown, PA USA. [Graham, Susan] SUNY Buffalo, Buffalo, NY 14260 USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Mann, Douglas] Washington Univ, St Louis, MO USA. [Ponikowski, Piotr] Med Univ, Wroclaw, Poland. [Lok, Dirk J.] Hosp Deventer, Deventer, Netherlands. [Anker, Stefan D.] Charite, Campus Virchow Klinikum, D-13353 Berlin, Germany. [Lip, Gregory Y. H.] Univ Birmingham, Ctr Cardiovasc Sci, Birmingham, W Midlands, England. [Estol, Conrado J.] Ctr Neurol Tratamiento & Rehabil, Buenos Aires, DF, Argentina. RP Pullicino, PM (reprint author), Univ Kent, KentHlth, Rutherford Bldg, Canterbury CT2 7PD, Kent, England. EM P.Pullicino@kent.ac.uk RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Beran, David/0000-0001-7229-3920; Mann, Douglas /0000-0002-2516-0145; Kohsaka, Shun/0000-0003-3779-2972 FU NINDS [U01-NS-043975, U01-NS-039143] FX NINDS U01-NS-043975 and U01-NS-039143. NR 14 TC 5 Z9 5 U1 1 U2 5 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1015-9770 EI 1421-9786 J9 CEREBROVASC DIS JI Cerebrovasc. Dis. PD NOV PY 2014 VL 38 IS 3 BP 176 EP 181 DI 10.1159/000365502 PG 6 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA AT1ZJ UT WOS:000344729400004 PM 25300706 ER PT J AU Domsic, RT Dezfulian, C Shoushtari, A Ivanco, D Kenny, E Kwoh, CK Medsger, TA Champion, HC AF Domsic, R. T. Dezfulian, C. Shoushtari, A. Ivanco, D. Kenny, E. Kwoh, C. K. Medsger, T. A., Jr. Champion, H. C. TI Endothelial dysfunction is present only in the microvasculature and microcirculation of early diffuse systemic sclerosis patients SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY LA English DT Article DE scleroderma; systemic; diffuse; endothelium; vascular; laser speckle contrast analysis ID PULMONARY ARTERIAL-HYPERTENSION; RAYNAUDS-PHENOMENON SECONDARY; STIFFNESS PARAMETERS; BRACHIAL-ARTERY; WOMEN; COMPLICATIONS; VASODILATION; INVOLVEMENT; REACTIVITY; RELEVANCE AB Objective. To evaluate endothelial function and vascular stiffness in large, medium, small and microcirculatory blood vessels in very early diffuse systemic sclerosis (SSc). Methods. We studied consecutive early diffuse SSc patients, defined as <2 years from first SSc symptom who did not have a prior cardiovascular event. Age, gender and race-matched controls were recruited. All underwent assessment of aortic pulse wave velocity (PWV), carotid intima-media thickness (IMT) brachial flow-mediated dilation (FMD), digital peripheral artery tonometer (EndoPAT) assessment and laser speckle contrast imaging (LSCI). Results. Fifteen early diffuse SSc and controls were evaluated. The average age was 49 years, 63% were female and 93% were Caucasian. There were no ferences in body mass index, hypertension, diabetes or hyperlipidaemia between controls and SSc patients. Mean SSc disease duration was 1.3 years. In the large central vessels, there was no difference in aortic PWV (p=0.71) or carotid IMT (p=0.92) between SSc patients and controls. Similarly, there was no difference in endothelial dysfunction with brachial artery FMD after ischaemia (p=0.55) and nitroglycerin administration (p=0.74). There were significantly lower values for digital EndoPAT measures (p=0.0001) in SSc patients. LSCI revealed a distinct pattern of microcirculatory abnormalities in response to ischaemia in SSc patients compared to controls. Imaging demonstrated a blunted microcirculatory hyperaemia of the hand with greater subsequent response to nitroglycerin. Conclusions. These findings suggest that the earliest endothelial changes occur in smaller arterioles and microvascular beds, but not in medium or macrovascular beds, in early diffuse SSc. C1 [Domsic, R. T.; Ivanco, D.; Kwoh, C. K.; Medsger, T. A., Jr.] Univ Pittsburgh, Div Rheumatol & Clin Immunol, Dept Med, Sch Med, Pittsburgh, PA 15261 USA. [Dezfulian, C.; Kenny, E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15261 USA. [Dezfulian, C.; Shoushtari, A.] Univ Pittsburgh, Div Crit Care Med, Dept Crit Care Med, Pittsburgh, PA 15261 USA. [Champion, H. C.] Univ Pittsburgh, Vas Med Inst, Pittsburgh, PA 15261 USA. [Kwoh, C. K.] VA Pittsburgh Healthcare, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Champion, H. C.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Med Ctr, Heart & Vasc Inst, Pittsburgh, PA 15261 USA. RP Domsic, RT (reprint author), Univ Pittsburgh, Div Rheumatol & Clin Immunol, Dept Med, S724 Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15261 USA. EM rtd4@pitt.edu FU National Institutes of Health (NIAMS grant) [P60-AR054731]; National Institutes of Health (NIAMS) [K23AR057485]; National Institutes of Health (NINDS grant) [K08 -NS069817] FX this work was supported by a grant from the National Institutes of Health (NIAMS grant P60-AR054731). R.T. Domsic is supported by a grant from the National Institutes of Health (NIAMS grant K23AR057485);; C. Dezfulian is supported by a grant from the National Institutes of Health (NINDS grant K08 -NS069817). NR 27 TC 6 Z9 6 U1 0 U2 3 PU CLINICAL & EXPER RHEUMATOLOGY PI PISA PA VIA SANTA MARIA 31, 56126 PISA, ITALY SN 0392-856X J9 CLIN EXP RHEUMATOL JI Clin. Exp. Rheumatol. PD NOV-DEC PY 2014 VL 32 IS 6 SU 86 BP S154 EP S160 PG 7 WC Rheumatology SC Rheumatology GA AT1WJ UT WOS:000344721500026 ER PT J AU Lucas, GM Ross, MJ Stock, PG Shlipak, MG Wyatt, CM Gupta, SK Atta, MG Wools-Kaloustian, KK Pham, PA Bruggeman, LA Lennox, JL Ray, PE Kalayjian, RC AF Lucas, Gregory M. Ross, Michael J. Stock, Peter G. Shlipak, Michael G. Wyatt, Christina M. Gupta, Samir K. Atta, Mohamed G. Wools-Kaloustian, Kara K. Pham, Paul A. Bruggeman, Leslie A. Lennox, Jeffrey L. Ray, Patricio E. Kalayjian, Robert C. TI Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE HIV-1; chronic kidney disease; clinical practice guideline; HIV-associated nephropathy; kidney transplantation ID GRADE; RECOMMENDATIONS; CONSENSUS; QUALITY AB It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances. C1 [Lucas, Gregory M.; Atta, Mohamed G.; Pham, Paul A.] Johns Hopkins Sch Med, Baltimore, MD USA. [Ross, Michael J.; Wyatt, Christina M.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Stock, Peter G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. [Gupta, Samir K.; Wools-Kaloustian, Kara K.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Bruggeman, Leslie A.; Kalayjian, Robert C.] Case Western Reserve Univ, MetroHlth Med Ctr, Cleveland, OH 44106 USA. [Lennox, Jeffrey L.] Emory Univ, Sch Med, Atlanta, GA USA. [Ray, Patricio E.] Childrens Natl Med Ctr, Washington, DC 20010 USA. RP Lucas, GM (reprint author), Johns Hopkins Univ, Dept Med, 1830 E Monument St,4th Floor, Baltimore, MD 21287 USA. EM glucas@jhmi.edu FU Infectious Diseases Society of America; National Institutes of Health (NIH) [R01 DA026770, K24 DA035684, P30 AI094189, AI 036219, PO1 DK 056492, RO1 KD 078510, P30 AI050409, AI 69501]; Veterans Administration: VISN10 Geriatric Research Educational and Clinical Centers; Veterans Administration: Louis Stokes Cleveland Veterans Administration Medical Center FX Support for this guideline was provided by the Infectious Diseases Society of America. The following authors were supported by the National Institutes of Health (NIH): G. M. L. (grant numbers R01 DA026770, K24 DA035684, and P30 AI094189); L. A. B (AI 036219); M. J. R., C. M. W., and M. G. A. (PO1 DK 056492); M. A. R (RO1 KD 078510); J. L. L (P30 AI050409); R. C. K. (AI 69501, AI 036219). Support was also received from the Veterans Administration: VISN10 Geriatric Research Educational and Clinical Centers, Louis Stokes Cleveland Veterans Administration Medical Center. NR 8 TC 3 Z9 4 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2014 VL 59 IS 9 BP 1203 EP 1207 DI 10.1093/cid/ciu730 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AT0TG UT WOS:000344647100003 ER PT J AU Lucas, GM Ross, MJ Stock, PG Shlipak, MG Wyatt, CM Gupta, SK Atta, MG Wools-Kaloustian, KK Pham, PA Bruggeman, LA Lennox, JL Ray, PE Kalayjian, RC AF Lucas, Gregory M. Ross, Michael J. Stock, Peter G. Shlipak, Michael G. Wyatt, Christina M. Gupta, Samir K. Atta, Mohamed G. Wools-Kaloustian, Kara K. Pham, Paul A. Bruggeman, Leslie A. Lennox, Jeffrey L. Ray, Patricio E. Kalayjian, Robert C. TI Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE HIV-1; chronic kidney disease; clinical practice guideline; HIV-associated nephropathy; kidney transplantation ID HUMAN-IMMUNODEFICIENCY-VIRUS; GLOMERULAR-FILTRATION-RATE; STAGE RENAL-DISEASE; ACTIVE ANTIRETROVIRAL THERAPY; TENOFOVIR DISOPROXIL FUMARATE; HEPATITIS-C VIRUS; AMBULATORY PERITONEAL-DIALYSIS; SOLID-ORGAN TRANSPLANTATION; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; SERVICES TASK-FORCE AB It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances. C1 [Lucas, Gregory M.; Atta, Mohamed G.; Pham, Paul A.] Johns Hopkins Sch Med, Baltimore, MD USA. [Ross, Michael J.; Wyatt, Christina M.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Stock, Peter G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. [Gupta, Samir K.; Wools-Kaloustian, Kara K.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Bruggeman, Leslie A.; Kalayjian, Robert C.] Case Western Reserve Univ, MetroHlth Med Ctr, Cleveland, OH 44106 USA. [Lennox, Jeffrey L.] Emory Univ, Sch Med, Atlanta, GA USA. [Ray, Patricio E.] Childrens Natl Med Ctr, Washington, DC 20010 USA. RP Lucas, GM (reprint author), Johns Hopkins Univ, Dept Med, 1830 E Monument St,4th Floor, Baltimore, MD 21287 USA. EM glucas@jhmi.edu FU Infectious Diseases Society of America; National Institutes of Health (NIH) [R01 DA026770, K24 DA035684, P30 AI094189, AI 036219, PO1 DK 056492, RO1 KD 078510, P30 AI050409, AI 69501]; Veterans Administration: VISN10 Geriatric Research Educational and Clinical Centers; Veterans Administration: Louis Stokes Cleveland Veterans Administration Medical Center FX Support for this guideline was provided by the Infectious Diseases Society of America. The following authors were supported by the National Institutes of Health (NIH): G. M. L. (grant numbers R01 DA026770, K24 DA035684, and P30 AI094189); L. A. B (AI 036219); M. J. R., C. M. W., and M. G. A. (PO1 DK 056492); M. A. R (RO1 KD 078510); J. L. L (P30 AI050409); R. C. K. (AI 69501, AI 036219). Support was also received from the Veterans Administration: VISN10 Geriatric Research Educational and Clinical Centers, Louis Stokes Cleveland Veterans Administration Medical Center. NR 439 TC 53 Z9 55 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2014 VL 59 IS 9 BP E96 EP E138 DI 10.1093/cid/ciu617 PG 43 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AT0TG UT WOS:000344647100001 PM 25234519 ER PT J AU Nguyen, HM Labreche, MJ Graber, CJ AF Nguyen, Hien M. Labreche, Matthew J. Graber, Christopher J. TI Making Sense of Cephalosporin and Amoxicillin/Clavulanate Susceptibility Testing for Uropathogens SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID UNCOMPLICATED CYSTITIS; ORAL CEPHALOSPORINS; ENTEROBACTERIACEAE; WOMEN C1 [Nguyen, Hien M.; Labreche, Matthew J.] Kaiser Permanente Northwest, Portland, OR USA. [Graber, Christopher J.] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA. [Graber, Christopher J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. RP Nguyen, HM (reprint author), Kaiser Permanente Northwest, 9900 SE Sunnyside Rd, Clackamas, OR 97015 USA. EM hien.m.nguyen@kp.org NR 8 TC 0 Z9 0 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2014 VL 59 IS 9 DI 10.1093/cid/ciu574 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AT0TG UT WOS:000344647100026 ER PT J AU Loewy, R Fulford, D Pearson, R Hua, J Schlosser, D Stuart, B Wolkowitz, O Epel, E Mathalon, D Vinogradov, S AF Loewy, Rachel Fulford, Daniel Pearson, Rahel Hua, Jessica Schlosser, Danielle Stuart, Barbara Wolkowitz, Owen Epel, Elissa Mathalon, Daniel Vinogradov, Sophia TI Mechanisms of psychosis risk: childhood trauma and cortisol dysregulation SO EARLY INTERVENTION IN PSYCHIATRY LA English DT Meeting Abstract C1 [Loewy, Rachel; Fulford, Daniel; Pearson, Rahel; Hua, Jessica; Schlosser, Danielle; Stuart, Barbara; Wolkowitz, Owen; Epel, Elissa; Mathalon, Daniel; Vinogradov, Sophia] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Mathalon, Daniel; Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1751-7885 EI 1751-7893 J9 EARLY INTERV PSYCHIA JI Early Interv. Psychiatry PD NOV PY 2014 VL 8 SU 1 SI SI BP 57 EP 57 PG 1 WC Psychiatry SC Psychiatry GA AT2SM UT WOS:000344785700210 ER PT J AU Schlosser, D Vergani, S Kim, D Campellone, T Vinogradov, S AF Schlosser, Danielle Vergani, Silvia Kim, Daniel Campellone, Tim Vinogradov, Sophia TI PRIME: A neuroscience-informed mobile app intervention to treat reward processing impairments and improve quality of life in recent onset schizophrenia SO EARLY INTERVENTION IN PSYCHIATRY LA English DT Meeting Abstract C1 [Schlosser, Danielle; Kim, Daniel; Campellone, Tim; Vinogradov, Sophia] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Vergani, Silvia] IDEO, Palo Alto, CA USA. [Campellone, Tim] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1751-7885 EI 1751-7893 J9 EARLY INTERV PSYCHIA JI Early Interv. Psychiatry PD NOV PY 2014 VL 8 SU 1 SI SI MA C94 BP 157 EP 157 PG 1 WC Psychiatry SC Psychiatry GA AT2SM UT WOS:000344785700583 ER PT J AU Adabag, S Rector, TS Anand, IS McMurray, JJ Zile, M Komajda, M McKelvie, RS Massie, B Carson, PE AF Adabag, Selcuk Rector, Thomas S. Anand, Inder S. McMurray, John J. Zile, Michael Komajda, Michel McKelvie, Robert S. Massie, Barry Carson, Peter E. TI A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Death; sudden; Heart failure; Risk factors; Prognosis ID ACUTE MYOCARDIAL-INFARCTION; BRAIN NATRIURETIC PEPTIDE; POPULATION; SURVIVAL; RISK; IRBESARTAN; METAANALYSIS; DYSFUNCTION; COMMUNITY; LESSONS AB AimsSudden cardiac death (SCD) accounts for approximate to 25% of all deaths in heart failure with preserved ejection fraction (HFpEF). However, strategies to identify HFpEF patients at a higher risk of SCD have not been developed. Methods and resultsWe studied 4128 patients with HFpEF enrolled in the Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction (I-PRESERVE) trial. All SCDs were adjudicated by a clinical endpoint committee. Cumulative incidences of SCD were estimated counting other deaths as competing risks. Cox regression analysis was used to generate a risk model for SCD. During a mean follow-up of 4.1 years, 231 (5.6%) patients died suddenly and 650 (15.7%) died non-suddenly. A multivariable model in 3480 patients including age, gender, history of diabetes and myocardial infarction, LBBB on ECG, and the natural logarithm of NT-proBNP identified a subgroup of 837 (24%) patients with 10% cumulative incidence of SCD over 5 years, accounting for other deaths as competing risk (Harrell's C index 0.75). The 5-year cumulative incidences of SCD in the higher and lower risk groups were 11% and 4%, respectively. In the higher risk group, 32% of deaths were SCD compared with 26% in the entire I-PRESERVE cohort. ConclusionsA multivariable prediction model identified patients with HFpEF who have a 10% risk of SCD over 5 years, similar to the risk of SCD in the Sudden Cardiac Death in Heart Failure (SCD-Heft) trial. This model may be useful for selecting patients with HFpEF for SCD prevention trials. C1 [Adabag, Selcuk; Rector, Thomas S.; Anand, Inder S.] Vet Affairs Hlth Care Syst, Minneapolis, MN USA. [Adabag, Selcuk; Rector, Thomas S.; Anand, Inder S.] Univ Minnesota, Minneapolis, MN 55455 USA. [McMurray, John J.] British Heart Fdn Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland. [Zile, Michael] RHJ Dept Vet Affairs Med Ctr, Charleston, SC USA. [Zile, Michael] Med Univ S Carolina, Charleston, SC 29425 USA. [Komajda, Michel] Univ Paris 06, Pitie Salpetriere Hosp, Paris, France. [McKelvie, Robert S.] Populat Hlth Res Inst, Hamilton, ON, Canada. [McKelvie, Robert S.] McMaster Univ, Hamilton, ON, Canada. [Massie, Barry] San Francisco VA Med Ctr, San Francisco, CA USA. [Massie, Barry] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Carson, Peter E.] Washington Vet Affairs Med Ctr, Washington, DC USA. [Carson, Peter E.] Georgetown Univ, Washington, DC USA. RP Anand, IS (reprint author), VA Med Ctr, One Vet Dr, Minneapolis, MN 55417 USA. EM anand001@umn.edu OI Adabag, Selcuk/0000-0003-2154-8596; mcmurray, john/0000-0002-6317-3975 FU Bristol-Myers Squibb; Veterans Health Administration Health Services Research & Development Center of Innovation Grant [HFP-98-001]; Center for Epidemiology and Clinical Research at the Minneapolis VA Medical Center FX Bristol-Myers Squibb sponsored the I-PRESERVE Trial. T. S. R. was supported by Veterans Health Administration Health Services Research & Development Center of Innovation Grant HFP-98-001 and the Center for Epidemiology and Clinical Research at the Minneapolis VA Medical Center. The views expressed herein do not necessarily represent the views of the Department of Veterans Affairs. NR 38 TC 13 Z9 13 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD NOV PY 2014 VL 16 IS 11 BP 1175 EP 1182 DI 10.1002/ejhf.172 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AT0JB UT WOS:000344621500005 PM 25302657 ER PT J AU Kim, E Kinney, WH Ovrutsky, AR Vo, D Bai, XY Honda, JR Marx, G Peck, E Lindberg, L Falkinham, JO May, RM Chan, ED AF Kim, Eun Kinney, William H. Ovrutsky, Alida R. Vo, Danthy Bai, Xiyuan Honda, Jennifer R. Marx, Grace Peck, Emily Lindberg, Leslie Falkinham, Joseph O., III May, Rhea M. Chan, Edward D. TI A surface with a biomimetic micropattern reduces colonization of Mycobacterium abscessus SO FEMS MICROBIOLOGY LETTERS LA English DT Article DE nontuberculous mycobacteria; biofilm; bioengineered surfaces; bacterial colonization ID ENGINEERED ANTIFOULING MICROTOPOGRAPHIES; BIOFILM FORMATION; AVIUM-COMPLEX; NONTUBERCULOUS MYCOBACTERIA; PULMONARY-DISEASE; CELL ATTACHMENT; LUNG-DISEASE; INFECTION; SUSCEPTIBILITY; CONTAMINATION AB Nontuberculous mycobacteria (NTM) are ubiquitous organisms found in soil, water, and biofilms. Engineered surface topography has been proposed as a method to reduce microbial biofilm formation. The Sharklet((R)) micropattern silicone surface has been shown to reduce biofilm formation of pyogenic bacteria. We hypothesized that this micropattern surface will also reduce colonization by Mycobacterium abscessus, a human pathogen. Smooth and micropattern silicone samples were incubated with 1x10(6)M.abscessusmL(-1) for 2 and 4days. After processing to optimize recovery of adhered mycobacteria, there was a 75% and 50% reduction in the number of viable M.abscessus recovered from the micropattern surfaces compared to the smooth surfaces at 2 and 4days after inoculation, respectively. Ziehl-Neelsen staining after measures to remove the adherent microorganisms revealed fewer residual M.abscessus on the micropattern samples as compared to smooth samples, validating the quantitative culture results. Microscopic observation of 2, 4, and 8day M.abscessus cultures on micropattern samples showed that the organisms preferentially colonized within the channels between the rectangular features. In summary, a micropattern surface reduces the colonization of a pathogenic NTM. It remains to be seen whether this micropattern can reduce infections in humans. C1 [Kim, Eun; Kinney, William H.; Ovrutsky, Alida R.; Vo, Danthy; Bai, Xiyuan; Honda, Jennifer R.; Peck, Emily; Chan, Edward D.] Natl Jewish Hlth, Dept Med & Acad Affairs, Denver, CO 80206 USA. [Bai, Xiyuan; Honda, Jennifer R.; Chan, Edward D.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Aurora, CO USA. [Marx, Grace] Univ Colorado Denver, Div Infect Dis, Aurora, CO USA. [Lindberg, Leslie; Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Falkinham, Joseph O., III] Virginia Tech, Dept Biol Sci, Blacksburg, VA USA. [May, Rhea M.] Sharklet Technol, Aurora, CO USA. RP Chan, ED (reprint author), Natl Jewish Hlth, D509,Neustadt Bldg,1400 Jackson St, Denver, CO 80206 USA. EM chane@njhealth.org NR 35 TC 4 Z9 4 U1 3 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0378-1097 EI 1574-6968 J9 FEMS MICROBIOL LETT JI FEMS Microbiol. Lett. PD NOV PY 2014 VL 360 IS 1 BP 17 EP 22 DI 10.1111/1574-6968.12587 PG 6 WC Microbiology SC Microbiology GA AT4OJ UT WOS:000344919000004 PM 25155501 ER PT J AU Larson, ER Porterfield, JE Sagar, S Marmol-Velez, J Panday, M Escobedo, D Michalek, J Ouyang, YJ Valvano, JW Pearce, JA Feldman, MD AF Larson, Erik R. Porterfield, John E. Sagar, Sandeep Marmol-Velez, Juan Panday, Manoj Escobedo, Daniel Michalek, Joel Ouyang, Yongjian Valvano, Jonathan W. Pearce, John A. Feldman, Marc D. TI Admittance to detect alterations in left ventricular stroke volume SO HEART RHYTHM LA English DT Article DE Shock reduction; Biventricular pacing/defibrillation; Ventricular tachycardia; Ventricular fibrillation; Inappropriate shocks ID CARDIOVERTER-DEFIBRILLATOR SHOCKS; CONDUCTANCE CATHETER; INAPPROPRIATE; THERAPY; MORTALITY; TRIAL AB BACKGROUND Implantable cardioverter-defibrillators monitor intracardiac electrograms (EGMs) to discriminate between ventricular and supraventricular tachycardias. The incidence of inappropriate shocks remains high because of misclassification of the tachycardia in an otherwise hemodynamically stable individual. Coupling EGMs with an assessment of left ventricular (LV) stroke volume (SV) could help in gauging hemodynamics during an arrhythmia and reducing inappropriate shocks. OBJECTIVE The purpose of this study was to use the admittance method to accurately derive LV SV. METHODS Ultrasonic flow probe and LV endocardial crystals were used in canines (n = 12) as the standard for LV SV. Biventricular pacing leads were inserted to obtain admittance measurements. A tetrapolar, complex impedance measurement was made between the Bi-V leads. The real and imaginary components of impedance were used to discard the myocardial component from the blood component to derive instantaneous blood conductance (G(b)). Alterations in SV were measured during right ventricular pacing, dopamine infusion, and inferior vena cava occlusion. RESULTS G(b) tracks steady-state changes in SV more accurately than traditional magnitude (ie. IYI, without removal of the muscle signal) during right ventricular pacing and dopamine infusion (P = .004). Instantaneous LV volume also was tracked more accurately by G(b) than vertical bar Y vertical bar in the subset of subjects that underwent inferior vena cava occlusions (n = 5, P = .025). Finite element modeling demonstrates that admittance shifts more sensitivity of the measurement to the LV blood chamber as the mechanism for improvement (see Online Appendix). CONCLUSION Monitoring LV SV is possible using the admittance method with biventricular pacing leads. The technique could be piggybacked to complement EGMs to determine if arrhythmias are hemodynamically unstable. C1 [Larson, Erik R.; Valvano, Jonathan W.; Pearce, John A.] Univ Texas Austin, Dept Elect Engn, Austin, TX 78712 USA. [Porterfield, John E.; Feldman, Marc D.] Admittance Technol, Austin, TX USA. [Sagar, Sandeep; Marmol-Velez, Juan; Panday, Manoj; Escobedo, Daniel; Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, Div Cardiol, San Antonio, TX 78229 USA. [Michalek, Joel; Ouyang, Yongjian] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Feldman, Marc D.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Feldman, MD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78248 USA. EM feldmanm@uthscsa.edu OI Marmol-Velez, Juan/0000-0002-7450-9817 FU Janey and Dolph Briscoe Center for Cardiovascular Research; CTSA [UL1RR025767] FX Support was provided by the Janey and Dolph Briscoe Center for Cardiovascular Research and a CTSA grant (UL1RR025767). Supplies were provided by Transonic Systems and St. Jude Medical. NR 20 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1547-5271 EI 1556-3871 J9 HEART RHYTHM JI Heart Rhythm PD NOV PY 2014 VL 11 IS 11 BP 2075 EP 2083 DI 10.1016/j.hrthm.2014.06.034 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AS8DI UT WOS:000344480000034 PM 24981870 ER PT J AU Pan, C Zhou, Y Dator, R Ginghina, C Zhao, YC Movius, J Peskind, E Zabetian, CP Quinn, J Galasko, D Stewart, T Shi, M Zhang, J AF Pan, Catherine Zhou, Yong Dator, Romel Ginghina, Carmen Zhao, Yanchun Movius, James Peskind, Elaine Zabetian, Cyrus P. Quinn, Joseph Galasko, Douglas Stewart, Tessandra Shi, Min Zhang, Jing TI Targeted Discovery and Validation of Plasma Biomarkers of Parkinson's Disease SO JOURNAL OF PROTEOME RESEARCH LA English DT Article DE Parkinsons disease; targeted mass spectrometry; peripheral biomarkers; selected reaction monitoring ID BLOOD-BRAIN-BARRIER; ALPHA-SYNUCLEIN; PRION PROTEIN; NEURODEGENERATIVE DISEASES; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; MASS-SPECTROMETRY; GROWTH-FACTOR; GLYCOPROTEINS; PROTEOMICS AB Despite extensive research, an unmet need remains for protein biomarkers of Parkinson's disease (PD) in peripheral body fluids, especially blood, which is easily accessible clinically. The discovery of such biomarkers is challenging, however, due to the enormous complexity and huge dynamic range of human blood proteins, which are derived from nearly all organ systems, with those originating specifically from the central nervous system (CNS) being exceptionally low in abundance. In this investigation of a relatively large cohort (similar to 300 subjects), selected reaction monitoring (SRM) assays (a targeted approach) were used to probe plasma peptides derived from glycoproteins previously found to be altered in the CNS based on PD diagnosis or severity. Next, the detected peptides were interrogated for their diagnostic sensitivity and specificity as well as the correlation with PD severity, as determined by the Unified Parkinson's Disease Rating Scale (UPDRS). The results revealed that 12 of the 50 candidate glycopeptides were reliably and consistently identified in plasma samples, with three of them displaying significant differences among diagnostic groups. A combination of four peptides (derived from PRNP, HSPG2, MEGF8, and NCAM1) provided an overall area under curve (AUC) of 0.753 (sensitivity: 90.4%; specificity: 50.0%). Additionally, combining two peptides (derived from MEGF8 and ICAM1) yielded significant correlation with PD severity, that is, UPDRS (r = 0.293, p = 0.004). The significance of these results is at least two-fold: (1) it is possible to use a targeted approach to identify otherwise very difficult to detect CNS related biomarkers in peripheral blood and (2) the novel biomarkers, if validated in independent cohorts, can be employed to assist with clinical diagnosis of PD as well as monitoring disease progression. C1 [Pan, Catherine; Dator, Romel; Ginghina, Carmen; Zhao, Yanchun; Movius, James; Stewart, Tessandra; Shi, Min; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA. [Pan, Catherine] Inarian Neurodiagnost, Mercer Isl, WA 98040 USA. [Zhou, Yong] Inst Syst Biol, Seattle, WA 98109 USA. [Peskind, Elaine] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Peskind, Elaine] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. [Quinn, Joseph] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Galasko, Douglas] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, 325 9th Ave,HMC 359635, Seattle, WA 98104 USA. EM zhangj@uw.edu RI Shi, Min/G-6165-2012 OI Shi, Min/0000-0002-6901-2558; Zabetian, Cyrus/0000-0002-7739-4306 FU University of Washington's Proteomics Resource [UWPR95794]; [R43NS065553]; [AG033398]; [AG05131]; [ES004696-5897]; [ES007033-6364]; [ES016873]; [ES019277]; [NS057567]; [NS062684]; [NS060252]; [NS062684-6221]; [NS082137] FX We deeply appreciate the generous participation and donation of samples by the patients in this study. The project described was supported by Award Number R43NS065553 (to C.P.) as well as Award Numbers AG033398, AG05131, ES004696-5897, ES007033-6364, ES016873, ES019277, NS057567, NS062684, NS060252, NS062684-6221, and NS082137 (to J.Z.). It was also partially supported by the University of Washington's Proteomics Resource (UWPR95794). The content is solely the responsibility of the authors and does not necessarily represent the official views of any funding agency. NR 58 TC 10 Z9 10 U1 4 U2 19 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1535-3893 EI 1535-3907 J9 J PROTEOME RES JI J. Proteome Res. PD NOV PY 2014 VL 13 IS 11 BP 4535 EP 4545 DI 10.1021/pr500421v PG 11 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA AT0PA UT WOS:000344636500006 PM 24853996 ER PT J AU Quick, ED Leser, JS Clarke, P Tyler, KL AF Quick, Eamon D. Leser, J. Smith Clarke, Penny Tyler, Kenneth L. TI Activation of Intrinsic Immune Responses and Microglial Phagocytosis in an Ex Vivo Spinal Cord Slice Culture Model of West Nile Virus Infection SO JOURNAL OF VIROLOGY LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; CD8(+) T-CELLS; JAPANESE ENCEPHALITIS; IN-VITRO; BRAIN; NEURONS; MINOCYCLINE; INNATE; PATHOGENESIS; REPLICATION AB West Nile virus (WNV) is a neurotropic flavivirus that causes significant neuroinvasive disease involving the brain and/or spinal cord. Experimental mouse models of WNV infection have established the importance of innate and adaptive immune responses in controlling the extent and severity of central nervous system (CNS) disease. However, differentiating between immune responses that are intrinsic to the CNS and those that are dependent on infiltrating inflammatory cells has proven difficult. We used a murine ex vivo spinal cord slice culture (SCSC) model to determine the innate immune processes specific to the CNS during WNV infections. By 7 days after ex vivo infection of SCSCs, the majority of neurons and a substantial percentage of astrocytes were infected with WNV, resulting in apoptotic cell death and astrogliosis. Microglia, the resident immune cells of the CNS, were activated by WNV infection, as exemplified by their amoeboid morphology, the development of filopodia and lamellipodia, and phagocytosis of WNV-infected cells and debris. Microglial cell activation was concomitant with increased expression of pro-inflammatory cytokines and chemokines, including CXCL10, CXCL1, CCL5, CCL3, CCL2, tumor necrosis factor alpha (TNF-alpha), TNF-related apoptosis-inducing ligand (TRAIL), and interleukin-6 (IL-6). The application of minocycline, an inhibitor of neuro-inflammation, altered the WNV-induced proinflammatory cytokine/chemokine expression profile, with inhibited production of CCL5, CCL2, and IL-6. Our findings establish that CNS-resident cells have the capacity to initiate a robust innate immune response against WNV infection in the absence of infiltrating inflammatory cells and systemic immune responses. IMPORTANCE There are no specific treatments of proven efficacy available for WNV neuroinvasive disease. A better understanding of the pathogenesis of WNV CNS infection is crucial for the rational development of novel therapies. Development of a spinal cord slice culture (SCSC) model facilitates the study of WNV pathogenesis and allows investigation of the intrinsic immune responses of the CNS. Our studies demonstrate that robust CNS innate immune responses, including microglial activation and proinflammatory cytokine/chemokine production, develop independently of contributions from the peripheral immune system and CNS-infiltrating inflammatory cells. C1 [Quick, Eamon D.; Tyler, Kenneth L.] Univ Colorado Denver, Neurosci Program, Aurora, CO USA. [Leser, J. Smith; Clarke, Penny; Tyler, Kenneth L.] Univ Colorado Denver, Dept Neurol, Aurora, CO 80045 USA. [Tyler, Kenneth L.] Univ Colorado Denver, Dept Immunol & Microbiol, Aurora, CO USA. [Tyler, Kenneth L.] Univ Colorado Denver, Dept Infect Dis, Aurora, CO USA. [Tyler, Kenneth L.] Univ Colorado Denver, Dept Med, Aurora, CO USA. [Tyler, Kenneth L.] Denver VA Med Ctr, Denver, CO USA. RP Clarke, P (reprint author), Univ Colorado Denver, Dept Neurol, Aurora, CO 80045 USA. EM Penny.Clarke@ucdenver.edu OI Tyler, Kenneth/0000-0003-3294-5888 FU NIH [R01 NS076512, R21/R33 AI101064]; VA merit grant FX The study described in this publication was supported by NIH grants R01 NS076512 (to K.L.T.) and R21/R33 AI101064 (to K.L.T.) and by a VA merit grant (to K.L.T.). K. L. Tyler is also supported by the Reuler-Lewin Family Professorship. NR 72 TC 8 Z9 8 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD NOV PY 2014 VL 88 IS 22 BP 13005 EP 13014 DI 10.1128/JVI.01994-14 PG 10 WC Virology SC Virology GA AT3CG UT WOS:000344812500007 PM 25165111 ER PT J AU Stroupe, KT Weaver, FM Cao, LS Ippolito, D Barton, BR Burnett-Zeigler, IE Holloway, RG Vickrey, BG Simuni, T Follett, KA AF Stroupe, Kevin T. Weaver, Frances M. Cao, Lishan Ippolito, Dolores Barton, Brandon R. Burnett-Zeigler, Inger E. Holloway, Robert G. Vickrey, Barbara G. Simuni, Tanya Follett, Kenneth A. TI Cost of Deep Brain Stimulation for the Treatment of Parkinson's Disease by Surgical Stimulation Sites SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; cost; deep brain stimulation ID RANDOMIZED CONTROLLED-TRIAL; SUBTHALAMIC NUCLEUS; MEDICAL THERAPY; GLOBUS-PALLIDUS; UNCERTAINTY AB ObjectiveTo assess costs and effectiveness of deep brain stimulation (DBS) of the internal globus pallidum (GPi) versus subthalamic nucleus (STN) from the provider and societal perspectives for Parkinson's disease (PD) patients in a multicenter randomized trial. MethodsAll costs from randomization to 36 months were included. Costs were from Department of Veterans Affairs (VA) and Medicare databases and clinical trial data. Quality adjusted life years (QALYs) were from Quality of Well Being questionnaires. ResultsProvider costs were similar for the 144 GPi and 130 STN patients (GPi: $138,044 vs. STN: $131,822; difference = $6,222, 95% confidence interval [CI]: -$42,125 to $45,343). Societal costs were also similar (GPi: $171,061 vs. STN: $167,706; difference = $3,356, 95% CI: -$57,371 to $60,294). The GPi patients had nonsignificantly more QALYs. ConclusionsThe QALYs and costs were similar; the level of uncertainty given the sample size suggests that these factors should not direct treatment or resource allocation decisions in selecting or making available either procedure for eligible PD patients. (c) 2014 International Parkinson and Movement Disorder Society C1 [Stroupe, Kevin T.; Weaver, Frances M.; Cao, Lishan; Ippolito, Dolores] Hines VA Hosp, Ctr Management Complex Chron Healthcare, Hines, IL USA. [Stroupe, Kevin T.; Weaver, Frances M.] Loyola Univ Stritch Sch Med, Maywood, IL USA. [Barton, Brandon R.] Rush Univ Med Ctr, Chicago, IL USA. [Barton, Brandon R.] Jesse Brown VA Med Ctr, Chicago, IL USA. [Burnett-Zeigler, Inger E.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Holloway, Robert G.] Univ Rochester Med Ctr, Rochester, NY USA. [Vickrey, Barbara G.] VA Southwest PADRECC, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Vickrey, Barbara G.] UCLA Dept Neurol, Los Angeles, CA USA. [Simuni, Tanya] Northwestern Univ, Parkinsons Dis & Movement Disorders Ctr, Chicago, IL 60611 USA. [Follett, Kenneth A.] Univ Nebraska Sch Med, Omaha, NE USA. RP Stroupe, KT (reprint author), Edward Hines Jr VA Hosp, Ctr Innovat Complex Chron Care, 5000 South 5th Ave 151H, Hines, IL 60141 USA. EM Kevin.Stroupe@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [IIR 08-124-2]; VA Research Career Scientist Award FX This study was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (Project Number: IIR 08-124-2). Dr. Weaver was also supported by a VA Research Career Scientist Award. NR 25 TC 8 Z9 8 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD NOV PY 2014 VL 29 IS 13 BP 1666 EP 1674 DI 10.1002/mds.26029 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA AT0TT UT WOS:000344648400014 PM 25220042 ER PT J AU Hsu, JJ Katz, R Ix, JH de Boer, IH Kestenbaum, B Shlipak, MG AF Hsu, Jeffrey J. Katz, Ronit Ix, Joachim H. de Boer, Ian H. Kestenbaum, Bryan Shlipak, Michael G. TI Association of fibroblast growth factor-23 with arterial stiffness in the Multi-Ethnic Study of Atherosclerosis SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE ABI; arterial elasticity; arterial stiffness; FGF-23; pulse pressure ID CHRONIC KIDNEY-DISEASE; ANKLE-BRACHIAL INDEX; CARDIOVASCULAR EVENTS; PULSE PRESSURE; ALL-CAUSE; MORTALITY; CALCIFICATION; HEART; RISK; COMMUNITY AB Serum fibroblast growth factor-23 (FGF-23) is associated with cardiovascular disease (CVD), yet the mechanisms remain uncertain. Our objective was to determine whether higher FGF-23 concentrations are associated with arterial stiffness. In this cross-sectional study, serum FGF-23 concentrations were measured in 5977 participants without known CVD in the Multi-Ethnic Study of Atherosclerosis. The primary outcomes of interest were large (LAE) and small artery elasticity (SAE), pulse pressure and ankle-brachial index (ABI) > 1.30. LAE and SAE were measured by pulse contour analysis of the radial artery. Pulse pressure was measured with an automated sphygmomanometer using the average of two resting blood pressure measurements. ABI was calculated as the ratio of the ankle and brachial systolic blood pressures. Serum FGF-23 concentrations were not significantly associated with LAE [relative difference (RD) per doubling: 0%; 95% confidence interval (CI): -2-1%], SAE (RD per doubling: 0%; 95% CI: -3-2%), pulse pressure (beta per doubling: 0.44; 95% CI: -0.31-1.19), or a high ABI (odds ratio per doubling: 1.14; 95% CI: 0.84-1.55). Findings were similar irrespective of chronic kidney disease status. Higher serum FGF-23 concentrations are not associated with arterial stiffness, as measured by pulse pressure, LAE, SAE or high ABI, in a community-based population without CVD. C1 [Hsu, Jeffrey J.; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA 94143 USA. [Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol, La Jolla, CA 92093 USA. [Katz, Ronit] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [de Boer, Ian H.; Kestenbaum, Bryan] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. RP Shlipak, MG (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA 94143 USA. EM michael.shlipak@ucsf.edu FU National Institute on Aging (NIA) [5R01-AG-027002-06]; National Heart, Lung and Blood Institute [5R01-AG-027002-06]; UCSF Department of Medicine FX The authors thank the other investigators, the staff and the participants of MESA for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. This research was supported by grants 5R01-AG-027002-06 from the National Institute on Aging (NIA) and R01-HL-096875 from the National Heart, Lung and Blood Institute, and the UCSF Department of Medicine. NR 33 TC 10 Z9 12 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD NOV PY 2014 VL 29 IS 11 BP 2099 EP 2105 DI 10.1093/ndt/gfu101 PG 7 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA AT0KP UT WOS:000344625400019 PM 24782533 ER PT J AU Light, G Greenwood, TA Swerdlow, NR Calkins, ME Freedman, R Green, MF Gur, RE Gur, RC Lazzeroni, LC Nuechterlein, KH Olincy, A Radant, AD Seidman, LJ Siever, LJ Silverman, JM Sprock, J Stone, WS Sugar, CA Tsuang, DW Tsuang, MT Turetsky, BI Braff, DL AF Light, Gregory Greenwood, Tiffany A. Swerdlow, Neal R. Calkins, Monica E. Freedman, Robert Green, Michael F. Gur, Raquel E. Gur, Ruben C. Lazzeroni, Laura C. Nuechterlein, Keith H. Olincy, Ann Radant, Allen D. Seidman, Larry J. Siever, Larry J. Silverman, Jeremy M. Sprock, Joyce Stone, William S. Sugar, Catherine A. Tsuang, Debby W. Tsuang, Ming T. Turetsky, Bruce I. Braff, David L. TI Comparison of the Heritability of Schizophrenia and Endophenotypes in the COGS-1 Family Study SO SCHIZOPHRENIA BULLETIN LA English DT Article DE schizophrenia; psychosis; endophenotypes; cognition; biomarkers; heritability ID GENOME-WIDE; PREPULSE INHIBITION; BIPOLAR DISORDER; GENE-EXPRESSION; ERNST RUDIN; FOLLOW-UP; IOWA 500; RISK; DEFICITS; TWIN AB Background: Twin and multiplex family studies have established significant heritability for schizophrenia (SZ), often summarized as 81%. The Consortium on the Genetics of Schizophrenia (COGS-1) family study was designed to deconstruct the genetic architecture of SZ using neurocognitive and neurophysiological endophenotypes, for which heritability estimates ranged from 18% to 50% (mean = 30%). This study assessed the heritability of SZ in these families to determine whether there is a "heritability gap" between the diagnosis and related endophenotypes. Methods: Nuclear families (N = 296) with a SZ proband, an unaffected sibling, and both parents (n = 1366 subjects; mean family size = 4.6) underwent comprehensive endophenotype and clinical characterization. The Family Interview for Genetic Studies was administered to all participants and used to obtain convergent psychiatric symptom information for additional first-degree relatives of interviewed subjects (N = 3304 subjects; mean family size = 11.2). Heritability estimates of psychotic disorders were computed for both nuclear and extended families. Results: The heritability of SZ was 31% and 44% for nuclear and extended families. The inclusion of bipolar disorder increased the heritability to 37% for the nuclear families. When major depression was added, heritability estimates dropped to 34% and 20% for nuclear and extended families, respectively. Conclusions: Endophenotypes and psychotic disorders exhibit comparable levels of heritability in the COGS-1 family sample. The ascertainment of families with discordant sibpairs to increase endophenotypic contrast may underestimate diagnostic heritability relative to other studies. However, population-based studies also report significantly lower heritability estimates for SZ. Collectively, these findings support the importance of endophenotype-based strategies and the dimensional view of psychosis. C1 [Light, Gregory; Greenwood, Tiffany A.; Swerdlow, Neal R.; Sprock, Joyce; Tsuang, Ming T.; Braff, David L.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Light, Gregory] San Diego Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 22, La Jolla, CA USA. [Calkins, Monica E.; Gur, Raquel E.; Gur, Ruben C.; Turetsky, Bruce I.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Freedman, Robert; Olincy, Ann] Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. [Green, Michael F.; Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Lazzeroni, Laura C.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Radant, Allen D.; Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Seidman, Larry J.; Stone, William S.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Seidman, Larry J.; Stone, William S.] Massachusetts Mental Hlth Ctr Publ Psychiat, Boston, MA USA. [Siever, Larry J.; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Siever, Larry J.; Silverman, Jeremy M.] James J Peters VA Med Ctr, New York, NY USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Tsuang, Ming T.] Univ Calif San Diego, Ctr Behav Genom, Inst Genom Med, La Jolla, CA 92093 USA. [Tsuang, Ming T.] Harvard Inst Psychiat Epidemiol & Genet, Boston, MA USA. RP Light, G (reprint author), Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. EM glight@ucsd.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894; Lazzeroni, Laura/0000-0002-1846-6920; Greenwood, Tiffany/0000-0002-6080-6503 FU Amgen; Pfizer; AstraZeneca; Ortho-McNeil Janssen Scientific Affairs FX The authors thank all of the COGS-1 participants and support staff that made this study possible, including the following key personnel: University of California San Diego (R01-MH065571; MH042228, MH079777, MH087889): Joyce Sprock, Katrin Meyer-Gomes, Barbara Haugeland, Kari Tweedale, Sheldrick Holmes, Marlena Pela, Maria Bongiovanni; Harvard University (RO1-MH065562; MH43518; Commonwealth Research Center of the Massachusetts Department of Mental Health): Stephen J. Glatt, Lynda Tucker, Monica Landi, Erica Lee, and Frances Schopick; Mount Sinai School of Medicine(RO1-MH065554): Rui Ferreira, Robert Fieo, Christopher Smith, and Rebecca West; University of California Los Angeles (RO1-MH65707): Mark McGee, William Horan and Mark Sergi; University of Colorado (RO1-MH65588): Jamey Ellis, Jeff Hollis, Vicki Pender, Bernadette Sullivan, Bettye Clement, Christopher Cason, and Alexis Ritvo; University of Pennsylvania (RO1-MH65578): Alexandra Duncan Ramos, Jarrod Gutman, CarlaAnn Henry, Paul Hughett, Jennifer Jackson, Adrienne Mishkin, J. Dan Ragland, Leslie Ramsey, David Rice, Jan Richard, Devon Seward, Felipe Silva, and Robert Witalec; University of Washington (R01-MH65558): Kate B. Alvey, Andrew C. David, Sean P. Meichle, and Denise O. Pritzl. The authors also thank Dr John Blangero for his expert advice and guidance with respect to the heritability analyses. Drs Greenwood, Braff, Calkins, Radant, Seidman, Siever, Silverman, Stone, Sugarb DW. Tsuang, and MT. Tsuang report no financial relationships with commercial interests. Dr Light reports having been a consultant to Neuroverse, Envivo, and Astellas. Dr Green reports having been a consultant to Abbott Laboratories (AbbVie), Biogen, and Roche; he is a member of the scientific board for Mnemosyne, and he has received research funds from Amgen. Drs Gur and Turetsky have received unrelated research support for investigator-initiated grants from Pfizer and AstraZeneca. Dr Nuechterlein has received unrelated research support from Ortho-McNeil Janssen Scientific Affairs and has consulted to Wyeth/Pfizer. Dr Swerdlow has been a paid consultant for Neurocine Inc. NR 67 TC 11 Z9 11 U1 2 U2 11 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD NOV PY 2014 VL 40 IS 6 BP 1404 EP 1411 DI 10.1093/schbul/sbu064 PG 8 WC Psychiatry SC Psychiatry GA AT0FF UT WOS:000344611900024 PM 24903414 ER PT J AU Ialynytchev, A Sear, AM Williams, AR Langland-Orban, B Zhang, NH AF Ialynytchev, Anna Sear, Alan M. Williams, Arthur R. Langland-Orban, Barbara Zhang, Nanhua TI Predictors of the Charges for Lumbar Fusion Surgery in Florida Hospitals SO SPINE LA English DT Article DE spinal fusion; lumbar fusion; hospital charges; low back ICD-9-CM diagnosis codes; low back ICD-9-CM procedure codes; low back surgery ID SPINE; TRENDS; COSTS AB Study Design. A mixed-effects model was used to evaluate the effects specific surgical procedure by International Classification of Diseases, Ninth Revision, Clinical Modification, procedure code, patient age, sex, ethnic group, payers for the inpatient hospital stay, and number of additional diagnoses beyond the principal diagnosis that led to the procedure (as a proxy for severity of illness) on the charges for lumbar fusion surgery. Objective. The present research examined the charges and the predictors of the charges for lumbar fusion surgery in Florida hospitals in 2010. Summary of Background Data. The number of spinal fusion surgical procedures in the United States has grown exponentially in recent years despite the procedure's high costs and questionable efficacy for many of the principal diagnoses associated with it. Methods. All records with any of the 5 International Classifi cation of Diseases, Ninth Revision, Clinical Modification, principal procedure codes for lumbar fusion were extracted (cases) from the Florida Agency for Health Care Administration (AHCA) hospital discharge data for the year 2010. A control group was obtained by taking all patients who had the same principal diagnoses as the cases, but who did not have fusion surgery. This produced 16,236 cases and 21,856 controls. Results. The total hospital charges for lumbar fusion surgery in Florida in 2010 were $2,095,413,584. Despite having the same principal diagnoses and a similar number of additional diagnoses, patients who underwent a fusion surgery had 3 times the charges as those incurred by the controls. The number of additional diagnoses, sex, age, payer, and principal procedure, were all found to be statistically significant predictors of charges. Ethnicity was not significant. Of all the predictors, the number of additional diagnoses was the most significant in the model (F = 2577, P < 0.0001). Conclusion. The high incidence and charges for fusion surgical procedures shown in this study emphasize the need for a better understanding of when these surgical procedures are justified and for which patients. C1 [Ialynytchev, Anna; Sear, Alan M.; Langland-Orban, Barbara] Univ S Florida, Dept Hlth Policy & Management, Tampa, FL 33612 USA. [Williams, Arthur R.] US Dept Vet Affairs, CINDRR, Tampa, FL USA. [Zhang, Nanhua] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA. [Zhang, Nanhua] Univ Cincinnati, Dept Pediat, Cincinnati, OH USA. RP Ialynytchev, A (reprint author), Univ S Florida, Dept Hlth Policy & Management, 13201 Bruce B Downs Blvd,MDC 56, Tampa, FL 33612 USA. EM annai@mail.usf.edu RI Zhang, Nanhua/L-7606-2015 NR 8 TC 2 Z9 2 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-2436 EI 1528-1159 J9 SPINE JI SPINE PD NOV 1 PY 2014 VL 39 IS 23 BP 1990 EP 1995 DI 10.1097/BRS.0000000000000582 PG 6 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA AT0DB UT WOS:000344606100019 PM 25365714 ER PT J AU Shi, Y Fung, KZ Freedland, SJ Hoffman, RM Tang, VL Walter, LC AF Shi, Ying Fung, Kathy Z. Freedland, Stephen J. Hoffman, Richard M. Tang, Victoria L. Walter, Louise C. TI Statin Medications Are Associated With a Lower Probability of Having an Abnormal Screening Prostate-specific Antigen Result SO UROLOGY LA English DT Article ID NUTRITION EXAMINATION SURVEY; NATIONAL-HEALTH; COA REDUCTASE; CANCER; MEN; INHIBITION; DISEASE; DRUGS AB OBJECTIVE To investigate how statin use is associated with the probability of having an abnormal screening prostate-specific antigen (PSA) result according to common PSA thresholds for biopsy (>2.5, >4.0, and >6.5 ng/mL). METHODS We conducted a cross-sectional study of 323,426 men aged >= 65 years who had a screening PSA test in 2003 at a Veterans Affairs facility. The primary predictor was the use of statin medications at the time of index screening PSA test. The main outcome was the screening PSA value. Poisson regressions were performed to calculate adjusted relative risks for having an abnormal screening PSA result according to statin usage. RESULTS Percentages of men with PSA results exceeding commonly used thresholds of >2.5, >4.0, and >6.5 ng/mL were 21.0%, 7.6%, and 1.6%, respectively. These percentages decreased with statin use, increasing statin dose, duration of statin use, and potency of the statin. For example, after adjusting for age, the percentage of men having a PSA level >4.0 ng/mL ranged from 8.2% in non-statin users to 6.2% in men prescribed with >40 mg of simvastatin dose. Adjusted relative risks of having a PSA level >4.0 ng/mL were 0.89 (95% confidence interval [CI], 0.86-0.93), 0.87 (95% CI, 0.84-0.91), and 0.83 (95% CI, 0.80-0.87), respectively for men on simvastatin dose of 5-20, >20-40, and >40 mg vs non-statin users. CONCLUSION Statin use is associated with a reduction in the probability that an older man will have an abnormal screening PSA result, regardless of the PSA threshold. This reduction is more pronounced with higher statin dose, longer statin duration, and higher statin potency. (C) 2014 Elsevier Inc. C1 Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. Duke Univ, Durham VA Med Ctr, Durham, NC USA. Duke Univ, Duke Prostate Ctr, Durham, NC USA. Univ New Mexico, New Mexico VA Hlth Care Syst, Albuquerque, NM 87131 USA. Univ New Mexico, Dept Med, Albuquerque, NM 87131 USA. RP Shi, Y (reprint author), Univ Calif San Francisco, VA Med Ctr, Div Geriatr, 181G,4150 Clement St, San Francisco, CA 94121 USA. EM Ying.Shi2@va.gov FU National Cancer Institute at the National Institutes of Health [R01 CA134425]; National Institute on Aging at the National Institutes of Health [K24AG041180, K24CA160653]; New Mexico Veterans Affairs Health Care System FX This work was supported by grant R01 CA134425 from the National Cancer Institute at the National Institutes of Health (Louise C. Walter, Stephen J. Freedland, and Richard M. Hoffman), by grant K24AG041180 from the National Institute on Aging at the National Institutes of Health (Louise C. Walter), by grant K24CA160653 from the National Cancer Institute at the National Institutes of Health (Stephen J. Freedland), and by the New Mexico Veterans Affairs Health Care System (Richard M. Hoffman). NR 29 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD NOV PY 2014 VL 84 IS 5 BP 1058 EP 1064 DI 10.1016/j.urology.2014.06.069 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA AS8CU UT WOS:000344478700024 PM 25443902 ER PT J AU Shi, Y Boscardin, WJ Walter, LC AF Shi, Ying Boscardin, W. John Walter, Louise C. TI Statin Medications Are Associated With a Lower Probability of Having an Abnormal Screening Prostate-specific Antigen Result REPLY SO UROLOGY LA English DT Editorial Material C1 [Shi, Ying] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Shi, Y (reprint author), San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD NOV PY 2014 VL 84 IS 5 BP 1065 EP 1065 DI 10.1016/j.urology.2014.06.072 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA AS8CU UT WOS:000344478700026 PM 25443904 ER PT J AU Shi, M Liu, CQ Cook, TJ Bullock, KM Zhao, YC Ginghina, C Li, YF Aro, P Dator, R He, CM Hipp, MJ Zabetian, CP Peskind, E Hu, SC Quinn, JF Galasko, DR Banks, WA Zhang, J AF Shi, Min Liu, Changqin Cook, Travis J. Bullock, Kristin M. Zhao, Yanchun Ginghina, Carmen Li, Yanfei Aro, Patrick Dator, Romel He, Chunmei Hipp, Michael J. Zabetian, Cyrus P. Peskind, Elaine R. Hu, Shu-Ching Quinn, Joseph F. Galasko, Douglas R. Banks, William A. Zhang, Jing TI Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson's disease SO ACTA NEUROPATHOLOGICA LA English DT Article DE Parkinson's disease; Exosome; alpha-synuclein; Biomarker; Plasma ID BLOOD-BRAIN-BARRIER; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; LEWY BODIES; NERVOUS-SYSTEM; AMYLOID-BETA; BIOMARKER; DJ-1; MICROVESICLES; REABSORPTION AB Extracellular alpha-synuclein is important in the pathogenesis of Parkinson's disease (PD) and also as a potential biomarker when tested in the cerebrospinal fluid (CSF). The performance of blood plasma or serum alpha-synuclein as a biomarker has been found to be inconsistent and generally ineffective, largely due to the contribution of peripherally derived alpha-synuclein. In this study, we discovered, via an intracerebroventricular injection of radiolabeled alpha-synuclein into mouse brain, that CSF alpha-synuclein was readily transported to blood, with a small portion being contained in exosomes that are relatively specific to the central nervous system (CNS). Consequently, we developed a technique to evaluate the levels of alpha-synuclein in these exosomes in individual plasma samples. When applied to a large cohort of clinical samples (267 PD, 215 controls), we found that in contrast to CSF alpha-synuclein concentrations, which are consistently reported to be lower in PD patients compared to controls, the levels of plasma exosomal alpha-synuclein were substantially higher in PD patients, suggesting an increased efflux of the protein to the peripheral blood of these patients. Furthermore, although no association was observed between plasma exosomal and CSF alpha-synuclein, a significant correlation between plasma exosomal alpha-synuclein and disease severity (r = 0.176, p = 0.004) was observed, and the diagnostic sensitivity and specificity achieved by plasma exosomal alpha-synuclein were comparable to those determined by CSF alpha-synuclein. Further studies are clearly needed to elucidate the mechanism involved in the transport of CNS alpha-synuclein to the periphery, which may lead to a more convenient and robust assessment of PD clinically. C1 [Shi, Min; Zhao, Yanchun; Ginghina, Carmen; Aro, Patrick; Dator, Romel; Hipp, Michael J.; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Liu, Changqin] Xiamen Univ, Affiliated Hosp 1, Dept Endocrinol & Diabet, Xiamen 361003, Fujian, Peoples R China. [Cook, Travis J.; Li, Yanfei] Univ Washington, Dept Environm & Occupat Hlth Sci, Sch Publ Hlth, Seattle, WA 98195 USA. [Bullock, Kristin M.; Zabetian, Cyrus P.; Hu, Shu-Ching; Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Bullock, Kristin M.; Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [He, Chunmei] Xiamen Univ, Affiliated Hosp 1, Dept Endocrinol & Diabet, Xiamen Diabet Inst, Xiamen 361003, Fujian, Peoples R China. [Zabetian, Cyrus P.; Hu, Shu-Ching] Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Zabetian, Cyrus P.; Hu, Shu-Ching] Univ Washington, Dept Neurol, Sch Med, Seattle, WA 98195 USA. [Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98195 USA. [Peskind, Elaine R.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, 325 9th Ave,HMC Box 359635, Seattle, WA 98195 USA. EM mshi70@u.washington.edu; zhangj@u.washington.edu RI Shi, Min/G-6165-2012 OI Shi, Min/0000-0002-6901-2558 FU National Institutes of Health (NIH) [U01 NS082137, P42 ES004696-5897, P30 ES007033-6364, R01 AG033398, R01 ES016873, R01 ES019277, R01 NS057567, P50 NS062684-6221, R01 NS065070, P50 AG005131]; NIH [P50 AG003156-30]; National Institute of Neurological Disorders and Stroke/NIH [R21 NS085425]; University of Washington's Proteomics Resource [UWPR95794] FX We thank Drs. Honglian Li and Sangwoo Jung for their kind help on EM method development, and Dr. Ane Korff for her assistance in Western blot confirmation. We also deeply appreciate the patients and participants for their generous participation and donation of samples. This study was supported by generous grants from the National Institutes of Health (NIH) (U01 NS082137, P42 ES004696-5897, P30 ES007033-6364, R01 AG033398, R01 ES016873, R01 ES019277, R01 NS057567, and P50 NS062684-6221 to JZ, R01 NS065070 to CPZ, and P50 AG005131 to DRG), and partially by a pilot study award from the NIH-sponsored ADRC at the UW (P50 AG003156-30) and a National Institute of Neurological Disorders and Stroke/NIH award R21 NS085425 to MS. It was also supported in part by the University of Washington's Proteomics Resource (UWPR95794). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. NR 73 TC 44 Z9 45 U1 4 U2 26 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-6322 EI 1432-0533 J9 ACTA NEUROPATHOL JI Acta Neuropathol. PD NOV PY 2014 VL 128 IS 5 BP 639 EP 650 DI 10.1007/s00401-014-1314-y PG 12 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA AS1RL UT WOS:000344058200003 PM 24997849 ER PT J AU Baker, JF Von Feldt, J Mostoufi-Moab, S Noaiseh, G Taratuta, E Kim, W Leonard, MB AF Baker, Joshua F. Von Feldt, Joan Mostoufi-Moab, Sogol Noaiseh, Ghaith Taratuta, Elena Kim, Woojin Leonard, Mary B. TI Deficits in Muscle Mass, Muscle Density, and Modified Associations With Fat in Rheumatoid Arthritis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID CHRONIC KIDNEY-DISEASE; METABOLIC RISK-FACTORS; BODY-COMPOSITION; BONE-STRUCTURE; ADIPOSITY; CACHEXIA; ADIPONECTIN; CHILDREN; OBESITY; PATHOPHYSIOLOGY AB Objective. To quantify muscle outcomes, independent of fat mass, in rheumatoid arthritis (RA) patients compared to healthy controls. Methods. Quantitative computed tomography scans measured calf muscle and fat cross-sectional area (CSA) and muscle density (an index of intramuscular adipose tissue), and isometric dynamometry was used to measure ankle muscle strength in 50 participants with RA ages 18-70 years and 500 healthy controls. Multivariable linear regression models assessed muscle deficits in RA after adjusting for group differences in adiposity and assessing for an altered muscle-fat association. Associations between RA disease characteristics and fat-adjusted muscle outcomes were also assessed. Results. Compared to controls, RA subjects had significantly greater body mass index (BMI) and fat area, and lower muscle area, muscle density, and muscle strength (P < 0.001 for all). Strength deficits were eliminated with adjustment for the smaller muscle area. The magnitude of muscle deficits, relative to controls, was significantly greater (P < 0.03 for interaction) in participants with lower fat area and BMI. Among those in the lower tertiles of adiposity, RA subjects demonstrated more significant deficits compared to controls with similar adiposity. In contrast, among those in the highest tertile for adiposity, RA was not associated with muscle deficits. Among RA, greater Sharp/van der Heijde scores were associated with lower muscle CSA and muscle density. Greater disease activity and disability were associated with low muscle density. Conclusion. Deficits in muscle area and muscle density are present in RA patients compared to controls and are most pronounced in subjects with low fat mass. Greater joint destruction is associated with greater muscle deficits. C1 [Baker, Joshua F.; Von Feldt, Joan] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Baker, Joshua F.; Von Feldt, Joan; Mostoufi-Moab, Sogol; Taratuta, Elena; Kim, Woojin; Leonard, Mary B.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Mostoufi-Moab, Sogol; Leonard, Mary B.] Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Noaiseh, Ghaith] Univ Pittsburgh, Pittsburgh, PA USA. RP Baker, JF (reprint author), Hosp Univ Penn, Dept Med, Div Rheumatol, 8 Penn Tower Bldg,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM bakerjo@uphs.upenn.edu FU University of Pennsylvania Clinical and Translational Research Center [UL1-RR024134] FX Supported by the University of Pennsylvania Clinical and Translational Research Center (UL1-RR024134). NR 35 TC 11 Z9 11 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD NOV PY 2014 VL 66 IS 11 BP 1612 EP 1618 DI 10.1002/acr.22328 PG 7 WC Rheumatology SC Rheumatology GA AS5UF UT WOS:000344334200003 PM 24664868 ER PT J AU Kerr, G Aujero, M Richards, J Sayles, H Davis, L Cannon, G Caplan, L Michaud, K Mikuls, T AF Kerr, Gail Aujero, Mireille Richards, John Sayles, Harlan Davis, Lisa Cannon, Grant Caplan, Liron Michaud, Kaleb Mikuls, Ted TI Associations of Hydroxychloroquine Use With Lipid Profiles in Rheumatoid Arthritis: Pharmacologic Implications SO ARTHRITIS CARE & RESEARCH LA English DT Article ID DENSITY-LIPOPROTEIN CHOLESTEROL; MODIFYING ANTIRHEUMATIC DRUGS; RISK-FACTORS; CARDIOVASCULAR RISK; DISEASE-ACTIVITY; VETERANS; ATHEROSCLEROSIS; METHOTREXATE; MANAGEMENT; THERAPY AB Objective. To evaluate the association of hydroxychloroquine (HCQ) use with lipid profiles in a Veterans Affairs Rheumatoid Arthritis (VARA) cohort. Methods. Lipid profiles in HCQ users were compared with HCQ nonusers, adjusting for potential confounders (age, sex, race, disease activity, prednisone, disease-modifying antirheumatic drugs, diabetes mellitus, and statin use). Applying current National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) guidelines for reduction of cardiovascular disease (CVD) events risk, the frequency of target lipid profiles with HCQ status was evaluated. Varied periods of HCQ exposure were compared to ascertain pharmacologic associations with lipid values. CVDs were compared between HCQ users and nonusers. Results. In an elderly, predominantly male VARA cohort, 1,011 patients had lipid profiles; 787 patients (77.8%) were white. Statin use was recorded in 11.6% of patients, diabetes mellitus in 33.5%, and CVD in 31.2%. HCQ users (n = 150) were older, had longer rheumatoid arthritis (RA) disease duration, and had lower disease activity. Optimum lipid profiles, including total cholesterol: high-density lipoprotein (HDL) and HDL: low-density lipoprotein ratios (P <= 0.001), were more frequent in HCQ users, with the exception of HDL (P = 0.165), and persisted in multivariate analyses. Similarly, more HCQ users had NCEP-ATP III target levels. Varied periods of HCQ exposure suggested lipid changes to occur early, but lost within a year of drug discontinuation. HCQ users had less prevalent CVD. Conclusion. In RA patients, HCQ use of at least 3 months' duration was associated with better lipid profiles irrespective of disease activity or statin use. Given the increased CVD risks in RA and the relative low cost and toxicity of HCQ, continued use, regardless of treatment regimen, should be considered. C1 [Kerr, Gail] Georgetown Univ, Washington DC Vet Affairs Med Ctr, Washington, DC USA. [Kerr, Gail] Howard Univ Hosp, Washington, DC USA. [Aujero, Mireille; Richards, John] Washington DC Vet Affairs Med Ctr, Washington, DC USA. [Richards, John] Georgetown Univ, Washington, DC USA. [Sayles, Harlan; Michaud, Kaleb; Mikuls, Ted] Univ Nebraska Med Ctr, Nebraska Arthrit Outcomes Res Ctr, Omaha, NE USA. [Davis, Lisa; Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA. [Davis, Lisa; Caplan, Liron] Univ Colorado, Denver, CO 80202 USA. [Cannon, Grant] George Whalen Vet Affairs Med Ctr, Salt Lake City, UT USA. [Mikuls, Ted] Univ Nebraska Med Ctr, Omaha Vet Affairs Med Ctr, Omaha, NE USA. RP Kerr, G (reprint author), Vet Affairs Med Ctr, Rheumatol Sect 151K, 50 Irving St NW, Washington, DC 20422 USA. EM gail.kerr@va.gov FU Nebraska Arthritis Outcomes Research Center at the University of Nebraska Medical Center; Veterans Affairs Health Services Research and Development Program of the Veterans Health Administration; Abbott Laboratories; Amgen; Bristol-Myers Squibb; Veterans Health Administration (Veterans Affairs Merit award); Veterans Affairs Health Services Research and Development Program Career Development Award [CDA 07-221] FX The Veterans Affairs Rheumatoid Arthritis Registry was supported by the Nebraska Arthritis Outcomes Research Center at the University of Nebraska Medical Center, the Veterans Affairs Health Services Research and Development Program of the Veterans Health Administration, and unrestricted grants from Abbott Laboratories, Amgen, and Bristol-Myers Squibb. Dr. Mikuls' work was supported by the Veterans Health Administration (Veterans Affairs Merit award) and a Veterans Affairs Health Services Research and Development Program Career Development Award (CDA 07-221). NR 45 TC 13 Z9 13 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD NOV PY 2014 VL 66 IS 11 BP 1619 EP 1626 DI 10.1002/acr.22341 PG 8 WC Rheumatology SC Rheumatology GA AS5UF UT WOS:000344334200004 PM 24692402 ER PT J AU Nagaraja, V Hays, RD Khanna, PP Spiegel, BMR Chang, L Melmed, GY Bolus, R Khanna, D AF Nagaraja, Vivek Hays, Ron D. Khanna, Puja P. Spiegel, Brennan M. R. Chang, Lin Melmed, Gil Y. Bolus, Roger Khanna, Dinesh TI Construct Validity of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptom Scales in Systemic Sclerosis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID QUALITY-OF-LIFE; TRACT INSTRUMENT; GASTROESOPHAGEAL-REFLUX; PHYSICAL FUNCTION; SCLERODERMA; PROMIS; VALIDATION; MANIFESTATIONS; INVOLVEMENT; MOTILITY AB Objective. Gastrointestinal (GI) involvement is common in patients with systemic sclerosis (SSc; scleroderma). The Patient-Reported Outcomes Measurement Information System (PROMIS) GI symptom item bank captures upper and lower GI symptoms (reflux, disrupted swallowing, nausea/vomiting, belly pain, gas/bloating/flatulence, diarrhea, constipation, and fecal incontinence). The objective of this study was to evaluate the construct validity of the PROMIS GI bank in SSc. Methods. A total of 167 patients with SSc were administered the PROMIS GI bank and the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (GIT 2.0) instrument. GIT 2.0 is a multi-item instrument that measures SSc-associated GI symptoms. Product-moment correlations and a multitrait-multimethod analysis of the PROMIS GI scales with the GIT 2.0 symptom scales were used to evaluate convergent and discriminant validity. Results. Patients with SSc GI involvement had PROMIS GI scale scores 0.2-0.7 SD worse than the US general population. Correlations among scales measuring the same domains for the PROMIS GI and GIT 2.0 measures were large, ranging from 0.61 to 0.87 (average r = 0.77). The average correlation between different symptom scales was 0.22, supporting discriminant validity. Conclusion. This study provides support for the construct validity of the PROMIS GI scales in SSc. Future research is needed to assess the responsiveness to change of these scales in patients with SSc. C1 [Nagaraja, Vivek; Khanna, Puja P.; Khanna, Dinesh] Univ Michigan, Ann Arbor, MI 48109 USA. [Hays, Ron D.] RAND Corp, Santa Monica, CA USA. [Hays, Ron D.; Bolus, Roger] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Spiegel, Brennan M. R.; Bolus, Roger] VA Ctr Outcomes Res & Educ, Los Angeles, CA USA. [Chang, Lin] Univ Calif Los Angeles, David Geffen Sch Med, Gail & Gerald Oppenheimer Family Ctr Neurobiol St, Los Angeles, CA 90095 USA. [Melmed, Gil Y.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. RP Khanna, D (reprint author), Univ Michigan Scleroderma Program, Div Rheumatol, Dept Internal Med, 300 North Ingalls St,Suite 7C27,SPC 5422, Ann Arbor, MI 48109 USA. EM khannad@med.umich.edu FU NIH Common Fund Initiative (Northwestern University) [U54-AR-057951, U01-AR-052177, U54-AR057943]; American Institutes for Research [U54-AR-057926]; State University of New York, Stony Brook [U01-AR-057948, U01-AR-052170]; University of Washington, Seattle [U01-AR-057954, U01-AR-052171]; University of North Carolina, Chapel Hill [U01-AR-052181]; Children's Hospital of Philadelphia [U01-AR-057956]; Stanford University [U01-AR-052158]; Boston University [U01-AR-057929]; University of California, Los Angeles [U01-AR-057936]; University of Pittsburgh [U01-AR-052155]; Georgetown University [U01-AR-057971]; Children's Hospital Medical Center, Cincinnati [U01-AR-057940]; University of Maryland, Baltimore [U01-AR-057967]; Duke University [U01-AR-052186]; NIH/National Institute on Aging [P30-AG-028748, P30-AG-021684]; National Center on Minority Health and Health Disparities [2P20-MD-000182]; NIH/National Institute for Arthritis and Musculoskeletal and Skin Disease [K24-AR-063120-02] FX PROMIS was funded with cooperative agreements from the NIH Common Fund Initiative (Northwestern University, grants U54-AR-057951, U01-AR-052177, and U54-AR057943; American Institutes for Research, grant U54-AR-057926; State University of New York, Stony Brook, grants U01-AR-057948 and U01-AR-052170; University of Washington, Seattle, grants U01-AR-057954 and U01-AR-052171; University of North Carolina, Chapel Hill, grant U01-AR-052181; Children's Hospital of Philadelphia, grant U01-AR-057956; Stanford University, grant U01-AR-052158; Boston University, grant U01-AR-057929; University of California, Los Angeles, grant U01-AR-057936; University of Pittsburgh, grant U01-AR-052155; Georgetown University, grant U01-AR-057971; Children's Hospital Medical Center, Cincinnati, grant U01-AR-057940; University of Maryland, Baltimore, grant U01-AR-057967; and Duke University, grant U01-AR-052186). See Appendix A for principal investigators and NIH science officers.; Dr. Hays's work was supported by the NIH/National Institute on Aging (grants P30-AG-028748 and P30-AG-021684) and the National Center on Minority Health and Health Disparities (grant 2P20-MD-000182). Dr. Dinesh Khanna's work was supported by the NIH/National Institute for Arthritis and Musculoskeletal and Skin Disease (grant K24-AR-063120-02). NR 31 TC 6 Z9 6 U1 13 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD NOV PY 2014 VL 66 IS 11 BP 1725 EP 1730 DI 10.1002/acr.22337 PG 6 WC Rheumatology SC Rheumatology GA AS5UF UT WOS:000344334200017 PM 24692332 ER PT J AU Baker, JF Smolen, JS Aletaha, D Shults, J Conaghan, PG Emery, P Baker, DG Ostergaard, M AF Baker, Joshua F. Smolen, Josef S. Aletaha, Daniel Shults, Justine Conaghan, Philip G. Emery, Paul Baker, Daniel G. Ostergaard, Mikkel TI Is the modified Disease Activity Score superior to the Disease Activity Score in early arthritis and rheumatoid arthritis? Comment on the article by Baker et al Reply SO ARTHRITIS & RHEUMATOLOGY LA English DT Letter ID JOINT DAMAGE C1 [Baker, Joshua F.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Baker, Joshua F.; Shults, Justine] Univ Penn, Philadelphia, PA 19104 USA. [Smolen, Josef S.; Aletaha, Daniel] Med Univ Vienna, Vienna, Austria. [Conaghan, Philip G.; Emery, Paul] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England. [Conaghan, Philip G.; Emery, Paul] NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England. [Baker, Daniel G.] Janssen Res & Dev LLC, Spring House, PA USA. [Ostergaard, Mikkel] Glostrup Cty Hosp, Copenhagen, Denmark. [Ostergaard, Mikkel] Univ Copenhagen, Copenhagen, Denmark. RP Baker, JF (reprint author), Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 3 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD NOV PY 2014 VL 66 IS 11 BP 3245 EP 3246 DI 10.1002/art.38810 PG 3 WC Rheumatology SC Rheumatology GA AS6BI UT WOS:000344349500037 PM 25132673 ER PT J AU Lindqvist, D Wolkowitz, OM Mellon, S Yehuda, R Flory, JD Henn-Haase, C Bierer, LM Abu-Amara, D Coy, M Neylan, TC Makotkine, L Reus, VI Yan, X Taylor, NM Marmar, CR Dhabhar, FS AF Lindqvist, Daniel Wolkowitz, Owen M. Mellon, Synthia Yehuda, Rachel Flory, Janine D. Henn-Haase, Clare Bierer, Linda M. Abu-Amara, Duna Coy, Michelle Neylan, Thomas C. Makotkine, Louri Reus, Victor I. Yan, Xiaodan Taylor, Nicole M. Marmar, Charles R. Dhabhar, Firdaus S. TI Proinflammatory milieu in combat-related PTSD is independent of depression and early life stress SO BRAIN BEHAVIOR AND IMMUNITY LA English DT Article DE Post-traumatic stress disorder (PTSD); Inflammation; Cytokines; Depression; Early life trauma; Combat ID C-REACTIVE PROTEIN; MAJOR DEPRESSION; GLUCOCORTICOID SENSITIVITY; MYOCARDIAL-INFARCTION; SERUM INTERLEUKIN-6; DISORDER; IMMUNE; INFLAMMATION; RISK; SYMPTOMS AB Background: Chronic inflammation may be involved in combat-related post-traumatic stress disorder (PTSD) and may help explain comorbid physical diseases. However, the extent to which combat exposure per se, depression, or early life trauma, all of which are associated with combat PTSD, may confound the relationship between PTSD and inflammation is unclear. Methods: We quantified interleukin (IL)-6, IL-1 beta, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, and C-reactive protein (CRP) in 51 combat-exposed males with PTSD and 51 combat-exposed males without PTSD, and assessed PTSD and depression severity as well as history of early life trauma. To decrease the possibility of Type I errors, we summed standardized scores of IL-1 beta, IL-6, TNF alpha, IFN gamma and CRP into a total "pro-inflammatory score". PTSD symptom severity was assessed with the Clinician Administered PTSD Scale (CAPS) rating scale. Results: Subjects with PTSD had significantly higher pro-inflammatory scores compared to combat-exposed subjects without PTSD (p = 0.006), and even after controlling for early life trauma, depression diagnosis and severity, body mass index, ethnicity, education, asthma/allergies, time since combat and the use of possibly confounding medications (p = 0.002). Within the PTSD group, the pro-inflammatory score was not significantly correlated with depressive symptom severity, CAPS total score, or with the number of early life traumas. Conclusions: Combat-related PTSD in males is associated with higher levels of pro-inflammatory cytokines, even after accounting for depression and early life trauma. These results, from one of the largest studies of inflammatory cytokines in PTSD to date, suggest that immune activation may be a core element of PTSD pathophysiology more so than a signature of combat exposure alone. (C) 2014 Published by Elsevier Inc. C1 [Lindqvist, Daniel; Wolkowitz, Owen M.; Coy, Michelle; Neylan, Thomas C.; Reus, Victor I.] Univ Calif San Francisco, Dept Psychiat, Sch Med, San Francisco, CA 94143 USA. [Lindqvist, Daniel] Lund Univ, Dept Clin Sci, Sect Psychiat, Lund, Sweden. [Mellon, Synthia] Univ Calif San Francisco, Sch Med, Dept OB GYN & Reprod Sci, San Francisco, CA 94143 USA. [Yehuda, Rachel; Flory, Janine D.; Bierer, Linda M.; Makotkine, Louri] James J Peters Vet Adm Med Ctr, MSSM, Dept Psychiat, New York, NY USA. [Henn-Haase, Clare; Abu-Amara, Duna; Yan, Xiaodan; Marmar, Charles R.] NYU, Dept Psychiat, Steven & Alexandra Cohen Vet Ctr Posttraumat Stre, New York, NY 10003 USA. [Taylor, Nicole M.; Dhabhar, Firdaus S.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. RP Wolkowitz, OM (reprint author), Univ Calif San Francisco, Dept Psychiat, Sch Med, 401 Parnassus Ave, San Francisco, CA 94143 USA. EM Owen.Wolkowitz@ucsf.edu; Charles.Marmar@nyumc.org RI reus, victor/I-7923-2015 OI reus, victor/0000-0002-8193-5697 FU U.S. Department of Defense [W81XWH-11-2-0223, W81XWH-10-1-0021]; Mental Illness Research, Education and Clinical Center (MIRECC); Swedish Society of Medicine; Sjobring Foundation; OM Persson Foundation; province of Scania (Sweden) FX This study was supported by the following grants: U.S. Department of Defense, W81XWH-11-2-0223 (PI: Charles Marmar); U.S. Department of Defense, W81XWH-10-1-0021 (PI: Owen M. Wolkowitz); The Mental Illness Research, Education and Clinical Center (MIRECC). Daniel Lindqvist received postdoc grants from the Swedish Society of Medicine; the Sjobring Foundation; the OM Persson Foundation and the province of Scania (Sweden) state grants (ALF). The authors declare no conflict of interest. NR 71 TC 33 Z9 33 U1 8 U2 21 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0889-1591 EI 1090-2139 J9 BRAIN BEHAV IMMUN JI Brain Behav. Immun. PD NOV PY 2014 VL 42 BP 81 EP 88 DI 10.1016/j.bbi.2014.06.003 PG 8 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA AS7IK UT WOS:000344429900012 PM 24929195 ER PT J AU Shores, MM Arnold, AM Biggs, ML Longstreth, WT Smith, NL Kizer, JR Cappola, AR Hirsch, CH Marck, BT Matsumoto, AM AF Shores, Molly M. Arnold, Alice M. Biggs, Mary L. Longstreth, W. T., Jr. Smith, Nicholas L. Kizer, Jorge R. Cappola, Anne R. Hirsch, Calvin H. Marck, Brett T. Matsumoto, Alvin M. TI Testosterone and dihydrotestosterone and incident ischaemic stroke in men in the Cardiovascular Health Study SO CLINICAL ENDOCRINOLOGY LA English DT Article ID HORMONE-BINDING GLOBULIN; SYMPTOMATIC ANDROGEN DEFICIENCY; OLDER MEN; ELDERLY-MEN; SERUM TESTOSTERONE; METABOLIC SYNDROME; ARTERIAL STIFFNESS; MASS-SPECTROMETRY; ESTRADIOL LEVELS; ALL-CAUSE AB ObjectiveIschaemic stroke is a major cause of morbidity and mortality in elderly men. Our main objective was to examine whether testosterone (T) or dihydrotestosterone (DHT) was associated with incident ischaemic stroke in elderly men. DesignCohort study. ParticipantsElderly men in the Cardiovascular Health Study who had no history of stroke, heart disease or prostate cancer as of 1994 and were followed until December 2010. MeasurementsAdjudicated ischaemic stroke. ResultsAmong 1032 men (mean age 76, range 66-97), followed for a median of 10years, 114 had an incident ischaemic stroke. Total T and free T were not significantly associated with stroke risk, while DHT had a nonlinear association with incident stroke (P=0006) in analyses adjusted for stroke risk factors. The lowest risk of stroke was at DHT levels of 50-75ng/dl, with greater risk of stroke at DHT levels above 75ng/dl or below 50ng/dl. Results were unchanged when SHBG was added to the model. Calculated free DHT had an inverse linear association with incident ischaemic stroke with HR 077 (95% CI, 061, 098) per standard deviation in analyses adjusted for stroke risk factors. ConclusionsDihydrotestosterone had a nonlinear association with stroke risk in which there was an optimal DHT level associated with the lowest stroke risk. Further studies are needed to confirm these results and to clarify whether there is an optimal androgen range associated with the least risk of adverse outcomes in elderly men. C1 [Shores, Molly M.; Smith, Nicholas L.; Marck, Brett T.; Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Shores, Molly M.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Arnold, Alice M.; Biggs, Mary L.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Longstreth, W. T., Jr.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Longstreth, W. T., Jr.; Smith, Nicholas L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Smith, Nicholas L.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. [Kizer, Jorge R.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [Cappola, Anne R.] Univ Penn, Dept Internal Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA. [Hirsch, Calvin H.] Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA. [Marck, Brett T.; Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98108 USA. [Matsumoto, Alvin M.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA. RP Shores, MM (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-116A, Seattle, WA 98108 USA. EM molly.shores@va.gov FU VA Research Service; VA Epidemiology Research and Information Center (ERIC); VA Geriatric Research and Information Center (GRECC); National Heart, Lung, and Blood Institute (NHLBI) [HHSN268201200036C, N01-HC-85239, N01 HC-55222, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85086, HL080295]; National Institute on Aging (NIA) [AG-023629]; [1R01HL091952] FX This project was supported by the VA Research Service, the VA Epidemiology Research and Information Center (ERIC), and the VA Geriatric Research and Information Center (GRECC) and by 1R01HL091952. This research was supported by contracts HHSN268201200036C, N01-HC-85239, N01 HC-55222, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85086 and Grant HL080295 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by AG-023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org. NR 47 TC 13 Z9 13 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0300-0664 EI 1365-2265 J9 CLIN ENDOCRINOL JI Clin. Endocrinol. PD NOV PY 2014 VL 81 IS 5 BP 746 EP 753 DI 10.1111/cen.12452 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AS3KR UT WOS:000344176900015 PM 24645738 ER PT J AU Weisbord, SD AF Weisbord, Steven D. TI AKI and Medical Care after Coronary Angiography: Renalism Revisited SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID CHRONIC KIDNEY-DISEASE; MYOCARDIAL-INFARCTION; MORTALITY; INTERVENTION; DECLINE; RISK C1 [Weisbord, Steven D.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Med Serv Line, Renal Sect, Pittsburgh, PA 15240 USA. [Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA. RP Weisbord, SD (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Med Serv Line, Renal Sect, 7E 111F U,Room 120, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu NR 12 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD NOV PY 2014 VL 9 IS 11 BP 1823 EP 1825 DI 10.2215/CJN.09430914 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA AS7OY UT WOS:000344446200001 PM 25318756 ER PT J AU Caska, CM Smith, TW Renshaw, KD Allen, SN Uchino, BN Birmingham, W Carlisle, M AF Caska, Catherine M. Smith, Timothy W. Renshaw, Keith D. Allen, Steven N. Uchino, Bert N. Birmingham, Wendy Carlisle, McKenzie TI Posttraumatic stress disorder and responses to couple conflict: Implications for cardiovascular risk SO HEALTH PSYCHOLOGY LA English DT Article DE medically unexplained symptoms; parental divorce; parental death; adolescence ID CORONARY-HEART-DISEASE; ANGER; VETERANS; PTSD; QUESTIONNAIRE; METAANALYSIS; REACTIVITY; HOSTILITY; DIAGNOSES; QUALITY AB Objective: Functional somatic symptoms (FSSs) are physical symptoms that cannot be (fully) explained by organic pathology. FSSs are very common among children and adolescents, yet their etiology is largely unknown. We hypothesize that (a) the experience of family disruption due to parental divorce or parental death increases FSSs in adolescents; (b) symptoms of depression and anxiety contribute to the relationship between family disruption and FSSs; (c) girls are more vulnerable to these effects than boys. Method: Data were obtained from the prospective population cohort of Dutch adolescents of the Tracking Adolescents' Individual Lives Survey (N = 2,230), aged 10 to 12 years at baseline. FSSs were assessed using the Somatic Complaints subscale of the Youth Self-Report. Parental divorce and parental death were assessed with self-reports. Both outcome and predictors were assessed during 3 assessment waves over the course of 5 years. Linear mixed models were used to investigate associations between both types of family disruption and FSSs. Results: An interaction with age was found for parental divorce (B = 0.01, p =.02) and parental death (B = 0.03, p =.04), indicating that the influence of family disruption on FSSs increases during adolescence. This relationship seems to be partly explained by symptoms of depression and anxiety. No gender differences were found with regard to the effects of family disruption on FSSs. Conclusions: Family disruption is associated with an increased level of FSSs in late adolescence in both genders. This relationship is partly explained by symptoms of depression and/or anxiety. C1 [Caska, Catherine M.; Smith, Timothy W.; Uchino, Bert N.; Birmingham, Wendy; Carlisle, McKenzie] Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA. [Renshaw, Keith D.] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA. [Allen, Steven N.] VA Salt Lake City Hlth Care Team, PTSD Clin Team, Salt Lake City, UT USA. RP Caska, CM (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div, 1660 S Columbian Way 116MHC, Seattle, WA 98108 USA. EM cmcaska@gmail.com FU National Institute of Mental Health [1F31MH091915-01A1] FX The research reported in this article was supported in part by National Institute of Mental Health Grant 1F31MH091915-01A1 and is based on the doctoral dissertation of Catherine M. Caska. We thank everyone who assisted in this investigation, especially Courtney Smith, the Utah National Guard, and the Salt Lake City VA's PTSD Clinical Team. NR 42 TC 7 Z9 7 U1 4 U2 16 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0278-6133 EI 1930-7810 J9 HEALTH PSYCHOL JI Health Psychol. PD NOV PY 2014 VL 33 IS 11 BP 1273 EP 1280 DI 10.1037/hea0000133 PG 8 WC Psychology, Clinical; Psychology SC Psychology GA AS1BC UT WOS:000344010300001 PM 25110851 ER PT J AU El-Serag, HB Kanwal, F AF El-Serag, Hashem B. Kanwal, Fasiha TI Epidemiology of Hepatocellular Carcinoma in the United States: Where Are We? Where Do We Go? SO HEPATOLOGY LA English DT Review ID CHRONIC HEPATITIS-B; C VIRUS-INFECTION; ADVANCED LIVER-DISEASE; RISK-FACTORS; ANTIVIRAL THERAPY; REDUCES RISK; METAANALYSIS; CANCER; CIRRHOSIS; PROGRESSION C1 [El-Serag, Hashem B.; Kanwal, Fasiha] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. [El-Serag, Hashem B.; Kanwal, Fasiha] Houston VA HSR&D Ctr Excellence Houston, Houston, TX USA. RP El-Serag, HB (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM hasheme@bcm.edu FU Houston VA HSR&D Center of Excellence [HFP90-020]; Texas Digestive Disease Center NIH [DK58338]; National Institute of Diabetes and Digestive and Kidney Diseases [K24-04-107] FX This work is funded, in part, by the Houston VA HSR&D Center of Excellence (HFP90-020) and the Texas Digestive Disease Center NIH DK58338. Dr. El-Serag is also supported by the National Institute of Diabetes and Digestive and Kidney Diseases (K24-04-107). NR 58 TC 83 Z9 85 U1 3 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD NOV PY 2014 VL 60 IS 5 BP 1767 EP 1775 DI 10.1002/hep.27222 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6CM UT WOS:000344352400033 PM 24839253 ER PT J AU Zhang, Z Adappa, ND Doghramji, LJ Chiu, AG Lautenbach, E Cohen, NA Palmer, JN AF Zhang, Zi Adappa, Nithin D. Doghramji, Laurel J. Chiu, Alexander G. Lautenbach, Ebbing Cohen, Noam A. Palmer, James N. TI Quality of life improvement from sinus surgery in chronic rhinosinusitis patients with asthma and nasal polyps SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE chronic rhinosinusitis; quality of life; asthma; nasal polyps; functional endoscopic sinus surgery ID EUROPEAN POSITION PAPER; OUTCOMES; BACTERIA; ALLERGY; LONG; CARE AB BackgroundIt is unclear whether chronic rhinosinusitis (CRS) patients with both nasal polyps and asthma have different quality of life (QOL) improvement after functional endoscopic sinus surgery (FESS). We aimed to determine whether CRS patients with asthma and nasal polyps had a greater QOL improvement after FESS compared to patients without asthma or polyps. MethodsThis retrospective analysis included adult CRS patients who underwent FESS between 2007 and 2011. QOL was measured using the 22-item Sino-Nasal Outcome Test (SNOT-22). Variables collected included baseline demographics, clinical factors, SNOT-22 scores before FESS, and 1 month, 3 months, and 6 months post-FESS. Groups tested were asthma alone, polyps alone, asthma and polyps, and no asthma or polyps. Linear mixed-effects regression model was performed to calculate -coefficients, which represent the adjusted mean QOL differences. ResultsAmong the 376 patients included, 40.16% had both asthma and polyps (n = 151), 14.36% had asthma alone (n = 54), 19.45% had polyps alone (n = 75), and 25.53% had no asthma or polyps (n = 96). After adjusting for all factors, there were significantly more QOL improvements in patients with both asthma and nasal polyps from baseline to 1-month (-coefficient = -10.05; 95% CI, -15.86 to -4.23; p = 0.001) and 3-month follow-up (-coefficient = -8.27; 95% CI, -14.98 to -1.56; p = 0.016), and patients with asthma alone from baseline to 6-month follow-up (-coefficient = -8.78; 95% CI, -17.45 to -0.11; p = 0.047), when compared to patients without asthma or nasal polyps. ConclusionCRS patients with both asthma and nasal polyps or asthma alone experience a larger QOL benefit from FESS immediately after FESS compared to CRS patients without asthma or polyps. C1 [Zhang, Zi; Lautenbach, Ebbing] Univ Penn, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Adappa, Nithin D.; Doghramji, Laurel J.; Cohen, Noam A.; Palmer, James N.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Perelman Sch Med, Philadelphia, PA 19104 USA. [Chiu, Alexander G.] Univ Arizona, Dept Surg, Tucson, AZ USA. [Lautenbach, Ebbing] Univ Penn, Perelman Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Zhang, Z (reprint author), 8th Floor,Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM zizhang@mail.med.upenn.edu OI Cohen, Noam/0000-0002-9462-3932 FU National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health [K24 AI080942/AI/NIAID NIH HHS/United States] FX National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (K24 AI080942/AI/NIAID NIH HHS/United States to E. L.). NR 27 TC 13 Z9 13 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD NOV PY 2014 VL 4 IS 11 BP 885 EP 892 DI 10.1002/alr.21406 PG 8 WC Otorhinolaryngology SC Otorhinolaryngology GA AS6GE UT WOS:000344361600005 PM 25256422 ER PT J AU Slane, JD Klump, KL McGue, M Iacono, WG AF Slane, Jennifer D. Klump, Kelly L. McGue, Matthew Iacono, William G. TI Developmental Trajectories of Disordered Eating from Early Adolescence to Young Adulthood: A Longitudinal Study SO INTERNATIONAL JOURNAL OF EATING DISORDERS LA English DT Article DE disordered eating; longitudinal; developmental; growth curve ID RISK-FACTORS; ADVERSE OUTCOMES; NATURAL-HISTORY; BODY-WEIGHT; GIRLS; BEHAVIORS; ATTITUDES; WOMEN; PREADOLESCENT; SYMPTOMS AB Objective: Research examining changes in eating disorder symptoms across adolescence suggests an increase in disordered eating from early to late adolescence. However, relevant studies have largely been cross-sectional in nature and most have not examined the changes in the attitudinal symptoms of eating disorders (e. g., weight concerns). This longitudinal study aimed to address gaps in the available data by examining the developmental trajectories of disordered eating in females from preadolescence into young adulthood. Method: Participants were 745 same-sex female twins from the Minnesota Twin Family Study. Disordered eating was assessed using the Total Score, Body Dissatisfaction subscale, Weight Preoccupation subscale, and a combined Binge Eating and Compensatory Behavior subscale from the Minnesota Eating Behavior Survey assessed at the ages of 11, 14, 18, 21, and 25. Several latent growth models were fit to the data to identify the trajectory that most accurately captures the changes in disordered eating symptoms from 11 to 25 years. Results: The best-fitting models for overall levels of disordered eating, body dissatisfaction, and weight preoccupation showed an increase in from 11 through 25 years. In contrast, bulimic behaviors increased to age of 18 and then stabilized to age of 25. Discussion: The findings expanded upon extant research by investigating longitudinal, symptom specific, within person changes and showing an increase in cognitive symptoms into young adulthood and the stability of disordered eating behaviors past late adolescence. (C) 2014 Wiley Periodicals, Inc. C1 [Slane, Jennifer D.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA. [Slane, Jennifer D.] Univ Pittsburgh, Dept Psychiat, Med Ctr, Pittsburgh, PA USA. [Klump, Kelly L.] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA. [McGue, Matthew; Iacono, William G.] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA. RP Slane, JD (reprint author), VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Univ Dr, Pittsburgh, PA 15261 USA. EM slane@msu.edu FU National Institute on Alcohol Abuse and Alcoholism [R01 AA009367] FX Supported by R01 AA009367 from National Institute on Alcohol Abuse and Alcoholism. NR 42 TC 3 Z9 4 U1 6 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0276-3478 EI 1098-108X J9 INT J EAT DISORDER JI Int. J. Eating Disord. PD NOV PY 2014 VL 47 IS 7 SI SI BP 793 EP 801 DI 10.1002/eat.22329 PG 9 WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology SC Psychology; Nutrition & Dietetics; Psychiatry GA AS6CO UT WOS:000344352600015 PM 24995824 ER PT J AU Kopacz, MS AF Kopacz, Marek S. TI Moral injury - A war trauma affecting current and former military personnel SO INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY LA English DT Letter ID EVENTS; COMBAT C1 US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA. RP Kopacz, MS (reprint author), US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM marek.kopacz@va.gov NR 12 TC 1 Z9 1 U1 0 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0020-7640 EI 1741-2854 J9 INT J SOC PSYCHIATR JI Int. J. Soc. Psychiatr. PD NOV PY 2014 VL 60 IS 7 BP 722 EP 723 DI 10.1177/0020764014547063 PG 2 WC Psychiatry SC Psychiatry GA AS4LD UT WOS:000344246500014 PM 25336198 ER PT J AU Gellad, WF Stein, BD Ruder, T Henderson, R Frazee, SG Mehrotra, A Donohue, JM AF Gellad, Walid F. Stein, Bradley D. Ruder, Teague Henderson, Rochelle Frazee, Sharon G. Mehrotra, Ateev Donohue, Julie M. TI Geographic Variation in Receipt of Psychotherapy in Children Receiving Attention-Deficit/Hyperactivity Disorder Medications SO JAMA PEDIATRICS LA English DT Letter ID ADHD C1 [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Gellad, Walid F.; Stein, Bradley D.; Ruder, Teague; Mehrotra, Ateev] RAND Corp, Pittsburgh, PA 15213 USA. [Gellad, Walid F.] Univ Pittsburgh, Div Gen Med, Pittsburgh, PA USA. [Gellad, Walid F.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA USA. [Stein, Bradley D.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Henderson, Rochelle; Frazee, Sharon G.] Express Scripts, St Louis, MO USA. [Mehrotra, Ateev] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA. RP Gellad, WF (reprint author), RAND Corp, 4570 Fifth Ave,Ste 600, Pittsburgh, PA 15213 USA. EM wgellad@rand.org OI Donohue, Julie/0000-0003-2418-6017 NR 6 TC 6 Z9 6 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD NOV PY 2014 VL 168 IS 11 BP 1074 EP 1076 DI 10.1001/jamapediatrics.2014.1647 PG 4 WC Pediatrics SC Pediatrics GA AT1NS UT WOS:000344701500024 PM 25243391 ER PT J AU McCormick, JA Yang, CL Zhang, C Davidge, B Blankenstein, KI Terker, AS Yarbrough, B Meermeier, NP Park, HJ McCully, B West, M Borschewski, A Himmerkus, N Bleich, M Bachmann, S Mutig, K Argaiz, ER Gamba, G Singer, JD Ellison, DH AF McCormick, James A. Yang, Chao-Ling Zhang, Chong Davidge, Brittney Blankenstein, Katharina I. Terker, Andrew S. Yarbrough, Bethzaida Meermeier, Nicholas P. Park, Hae J. McCully, Belinda West, Mark Borschewski, Aljona Himmerkus, Nina Bleich, Markus Bachmann, Sebastian Mutig, Kerim Argaiz, Eduardo R. Gamba, Gerardo Singer, Jeffrey D. Ellison, David H. TI Hyperkalemic hypertension-associated cullin 3 promotes WNK signaling by degrading KLHL3 SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID NA-CL COTRANSPORTER; PSEUDOHYPOALDOSTERONISM TYPE-II; SODIUM-CHLORIDE COTRANSPORTER; DISEASE-CAUSING MUTATIONS; BLOOD-PRESSURE; CYCLIN-E; DISTAL NEPHRON; UBIQUITINATION; DEGRADATION; EXPRESSION AB Familial hyperkalemic hypertension (FHHt) is a monogenic disease resulting from mutations in genes encoding WNK kinases, the ubiquitin scaffold protein cullin 3 (CUL3), or the substrate adaptor kelch-like 3 (KLHL3). Disease-associated CUL3 mutations abrogate WNK kinase degradation in cells, but it is not clear how mutant forms of CUL3 promote WNK stability. Here, we demonstrated that an FHHt-causing CUL3 mutant (CUL3 Delta 403-459) not only retains the ability to bind and ubiquitylate WNK kinases and KLHL3 in cells, but is also more heavily neddylated and activated than WT CUL3. In cells, activated CUL3 Delta 403-459 depleted KLHL3, preventing WNK degradation, despite increased CUL3-mediated WNK ubiquitylation; therefore, CUL3 loss in kidney should phenocopy FHHt in murine models. As predicted, nephron-specific deletion of Cul3 in mice did increase WNK kinase levels and the abundance of phosphorylated Na-Cl cotransporter (NCC). Over time, however, Cul3 deletion caused renal dysfunction, including hypochloremic alkalosis, diabetes insipidus, and salt-sensitive hypotension, with depletion of sodium potassium chloride cotransporter 2 and aquaporin 2. Moreover, these animals exhibited renal inflammation, fibrosis, and increased cyclin E. These results indicate that FHHt-associated CUL3 Delta 403-459 targets KLHL3 for degradation, thereby preventing WNK degradation, whereas general loss of CUL3 activity - while also impairing WNK degradation - has widespread toxic effects in the kidney. C1 [McCormick, James A.; Yang, Chao-Ling; Zhang, Chong; Terker, Andrew S.; Yarbrough, Bethzaida; Meermeier, Nicholas P.; Park, Hae J.; Ellison, David H.] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Dept Med, Portland, OR 97239 USA. [Zhang, Chong] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Nephrol, Shanghai 200030, Peoples R China. [Davidge, Brittney; West, Mark; Singer, Jeffrey D.] Portland State Univ, Dept Biol, Portland, OR 97207 USA. [Blankenstein, Katharina I.; Borschewski, Aljona; Bachmann, Sebastian; Mutig, Kerim; Ellison, David H.] Charite, Inst Vegetat Anat, Campus Charite Mitte, D-13353 Berlin, Germany. [McCully, Belinda] Oregon Hlth & Sci Univ, Dept Surg, Div Trauma Crit Care & Acute Care Surg, Portland, OR 97239 USA. [Himmerkus, Nina; Bleich, Markus] Univ Kiel, Inst Physiol, Kiel, Germany. [Argaiz, Eduardo R.; Gamba, Gerardo] Univ Nacl Autonoma Mexico, Mol Physiol Unit, Inst Invest Biomed, Mexico City 04510, DF, Mexico. [Argaiz, Eduardo R.; Gamba, Gerardo] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico. [Ellison, David H.] Portland VA Med Ctr, Portland, OR USA. RP Ellison, DH (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, CH12R,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM jsinger@pdx.edu; ellisond@ohsu.edu OI Terker, Andrew/0000-0003-1498-9043; Bleich, Markus/0000-0002-1745-2295; Gamba, Gerardo/0000-0002-4378-9043 FU NIH [R01 DK5149 6, K01 DK076617, R01 DK098141, R01 GM082940]; Department of Veterans Affairs [1I01BX002228-01A1]; Shanghai Municipal Education Commission; Shanghai Jiao Tong University K.C. Wong Medical Fellowship Fund; Conacyt; Europeans Union; American Heart Association [13PRE14090030] FX This work was supported by NIH grants R01 DK5149 6 (to D.H. Ellison), K01 DK076617 and R01 DK098141 (to J.A. McCormick), and R01 GM082940 (to J.D. Singer) as well as by Merit Review grant 1I01BX002228-01A1 from the Department of Veterans Affairs (to D.H. Ellison). C. Zhang was supported by the Shanghai Municipal Education Commission and a Shanghai Jiao Tong University K.C. Wong Medical Fellowship Fund. E.R. Argaiz was supported by a scholarship from Conacyt and is a graduate student in the biomedical science PhD program of Universidad Nacional Autonoma de Mexico. D.H. Ellison received a Marie Curie Fellowship from the Europeans Union during part of these studies. A.S. Terker is supported by a Predoctoral Fellowship from the American Heart Association (13PRE14090030). The authors appreciate the interpretation of the renal morphology and advice provided by Megan Troxell, and the helpful discussions with Juliette Hadchouel. NR 40 TC 35 Z9 37 U1 0 U2 7 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD NOV PY 2014 VL 124 IS 11 BP 4723 EP 4736 DI 10.1172/JCI76126 PG 14 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AS3UK UT WOS:000344203300010 PM 25250572 ER PT J AU Ganz, PA Petersen, L Castellon, SA Bower, JE Silverman, DHS Cole, SW Irwin, MR Belin, TR AF Ganz, Patricia A. Petersen, Laura Castellon, Steven A. Bower, Julienne E. Silverman, Daniel H. S. Cole, Steven W. Irwin, Michael R. Belin, Thomas R. TI Cognitive Function After the Initiation of Adjuvant Endocrine Therapy in Early-Stage Breast Cancer: An Observational Cohort Study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID STANDARD-DOSE CHEMOTHERAPY; HEALTH SURVEY SF-36; HORMONAL-THERAPY; WOMEN; MEMORY; TAMOXIFEN; ESTROGEN; DYSFUNCTION; IMPAIRMENT; BRAIN AB Purpose This report examines cognitive complaints and neuropsychological (NP) testing outcomes in patients with early-stage breast cancer after the initiation of endocrine therapy (ET) to determine whether this therapy plays any role in post-treatment cognitive complaints. Patients and Methods One hundred seventy-three participants from the Mind Body Study (MBS) observational cohort provided data from self-report questionnaires and NP testing obtained at enrollment (T1, before initiation of ET), and 6 months later (T2). Bivariate analyses compared demographic and treatment variables, cognitive complaints, depressive symptoms, quality of life, and NP functioning between those who received ET versus not. Multivariable linear regression models examined predictors of cognitive complaints at T2, including selected demographic variables, depressive symptoms, ET use, and other medical variables, along with NP domains that were identified in bivariate analyses. Results Seventy percent of the 173 MBS participants initiated ET, evenly distributed between tamoxifen or aromatase inhibitors. ET-treated participants reported significantly increased language and communication (LC) cognitive complaints at T2 (P = .003), but no significant differences in NP test performance. Multivariable regression on LC at T2 found higher LC complaints significantly associated with T1 LC score (P < .001), ET at T2 (P = .004), interaction between ET and past hormone therapy (HT) (P < .001), and diminished improvement in NP psychomotor function (P = .05). Depressive symptoms were not significant (P = .10). Conclusion Higher LC complaints are significantly associated with ET 6 months after starting treatment and reflect diminished improvements in some NP tests. Past HT is a significant predictor of higher LC complaints after initiation of ET. (C) 2014 by American Society of Clinical Oncology C1 [Ganz, Patricia A.; Belin, Thomas R.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA. [Ganz, Patricia A.; Petersen, Laura] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Ganz, Patricia A.; Silverman, Daniel H. S.; Cole, Steven W.; Irwin, Michael R.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Castellon, Steven A.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Castellon, Steven A.; Bower, Julienne E.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA. [Bower, Julienne E.; Cole, Steven W.; Irwin, Michael R.] Univ Calif Los Angeles, Semel Inst, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA 90095 USA. RP Ganz, PA (reprint author), Univ Calif Los Angeles, Div Canc Prevent & Control Res, Jonsson Comprehens Canc Ctr, A2-125 CHS,Box 956900, Los Angeles, CA 90095 USA. EM pganz@mednet.ucla.edu RI Irwin, Michael/H-4870-2013 OI Irwin, Michael/0000-0002-1502-8431 FU National Cancer Institute [R01-CA109650]; Breast Cancer Research Foundation [R01-AG034588, R01-AG026364, R01-CA119159, R01-HL079955, R01-HL095799, P30-AG028748, UL RR 033176]; Cousins Center for Psychoneuroimmunology FX Supported by funding from the National Cancer Institute Grant No. R01-CA109650 and the Breast Cancer Research Foundation (P.A.G.), Grants No. R01-AG034588, R01-AG026364, R01-CA119159, R01-HL079955, R01-HL095799, P30-AG028748, UL RR 033176 (M.R.I.), and the Cousins Center for Psychoneuroimmunology (M.R.I.). NR 48 TC 25 Z9 25 U1 0 U2 11 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2014 VL 32 IS 31 BP 3559 EP + DI 10.1200/JCO.2014.56.1662 PG 16 WC Oncology SC Oncology GA AS6MY UT WOS:000344378700018 PM 25267747 ER PT J AU Shimizu, T Takebayashi, T Sato, Y Niizeki, H Aoyama, Y Kitajima, Y Iwatsuki, K Hashimoto, T Yamagami, J Werth, VP Amagai, M Tanikawa, A AF Shimizu, Tomoko Takebayashi, Toru Sato, Yuji Niizeki, Hironori Aoyama, Yumi Kitajima, Yasuo Iwatsuki, Keiji Hashimoto, Takashi Yamagami, Jun Werth, Victoria P. Amagai, Masayuki Tanikawa, Akiko TI Grading criteria for disease severity by pemphigus disease area index SO JOURNAL OF DERMATOLOGY LA English DT Article DE clinical trial; Japanese pemphigus disease severity score; outcome instrument; pemphigus; pemphigus disease area index; severity index ID DISORDER INTENSITY SCORE AB Pemphigus is a group of autoimmune blistering diseases that affect the skin and mucous membranes. A reliable and accurate disease severity tool to assess pemphigus severity is crucial for managing pemphigus and for clinical trials. The purpose of this study was to compare the pemphigus disease area index activity score (PDAI), the Japanese pemphigus disease severity score (JPDSS) and the physician's subjective impression, and also to find appropriate severity grading cut-offs for the PDAI. We also evaluated the correlation between PDAI activity score and the JPDSS. Thirty-seven pemphigus patients and 110 assessments were analyzed in this study. The optimal points of pemphigus disease severity score in PDAI were: mild (0-8), moderate (9-24) and severe (25). In mild or moderate cases, the JPDSS was well correlated with the PDAI, but in severe cases the JPDSS reached a plateau at a PDAI score of approximately 30. The PDAI evaluates disease severity more accurately than the JPDSS, particularly in severe cases. The PDAI is not only a useful tool to measure the extent of cutaneous lesions, but also an excellent scoring system for evaluating pemphigus disease severity. C1 [Shimizu, Tomoko; Yamagami, Jun; Amagai, Masayuki; Tanikawa, Akiko] Keio Univ, Sch Med, Dept Dermatol, Tokyo 1608582, Japan. [Takebayashi, Toru] Keio Univ, Sch Med, Dept Prevent Med & Publ Hlth, Tokyo 1608582, Japan. [Sato, Yuji] Keio Univ, Sch Med, Clin Res Ctr, Tokyo 1608582, Japan. [Niizeki, Hironori] Natl Ctr Child Hlth & Dev, Dept Dermatol, Tokyo, Japan. [Niizeki, Hironori] Nara Med Univ, Sch Med, Nara, Japan. [Aoyama, Yumi; Iwatsuki, Keiji] Okayama Univ Hosp, Okayama, Japan. [Kitajima, Yasuo] Kizawa Mem Hosp, Gifu, Japan. [Hashimoto, Takashi] Kurume Univ, Sch Med, Fukuoka, Japan. [Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Werth, Victoria P.] Univ Penn, Philadelphia, PA 19104 USA. RP Tanikawa, A (reprint author), Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan. EM tanikawa@z3.keio.jp RI Takebayashi, Toru/K-7526-2013; Amagai, Masayuki/K-5325-2013 OI Takebayashi, Toru/0000-0002-8268-8026; Amagai, Masayuki/0000-0003-3314-7052 FU Ministry of Health, Labor and Welfare of Japan [H23-028] FX This work was supported by the Research on Measures for Intractable Diseases Project: matching fund subsidy (H23-028) from the Ministry of Health, Labor and Welfare of Japan. NR 10 TC 4 Z9 4 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0385-2407 EI 1346-8138 J9 J DERMATOL JI J. Dermatol. PD NOV PY 2014 VL 41 IS 11 BP 969 EP 973 DI 10.1111/1346-8138.12649 PG 5 WC Dermatology SC Dermatology GA AS5XN UT WOS:000344340000004 PM 25346300 ER PT J AU Mackesy, DZ Goalstone, ML AF Mackesy, Daniel Z. Goalstone, Marc L. TI Extracellular signal-regulated kinase-5: Novel mediator of insulin and tumor necrosis factor alpha-stimulated vascular cell adhesion molecule-1 expression in vascular cells SO JOURNAL OF DIABETES LA English DT Article DE extracellular signal-regulated kinase-5; hyperinsulinemia; tumor necrosis factor alpha; type-2 diabetes mellitus; vascular cell adhesion molecule-1 ID ENDOTHELIAL DYSFUNCTION; PROTEIN-KINASE; ERK5; ATHEROSCLEROSIS; MECHANISM; PATHWAY; MIGRATION; SURVIVAL; GROWTH; TISSUE AB Background: Atherosclerosis may be stimulated by the increased presence of insulin and tumor necrosis-factor-alpha (TNF alpha) with subsequent expression of vascular cell adhesion molecule-1 (VCAM-1). We hypothesized that extracellular signal-regulated kinase-5 (ERK5) plays an important role in insulin and TNF alpha-stimulated total and cell surface VCAM-1 expression. Methods: Rat aorta vascular endothelial cells were first transfected with either no inhibitory RNA, inactive (scrambled) inhibitory ERK5 RNA (scERK5) or active inhibitory ERK5 RNA (siERK5) and then treated with either (i) no analog; (ii) insulin (1 nM), or TNF alpha (1 ng/mL) alone, or (iii) insulin plus TNFa for 6 h. Thereafter either total VCAM-1 protein or surface VCAM-1 protein was determined. Results: Genetic inhibition of ERK5 decreased TNF alpha-stimulated total VCAM-1 expression by 57% and surface expression by 27%. In contrast, genetic inhibition of ERK5 did not significantly decrease insulin-stimulated total or surface VCAM-1 expression. Interestingly, genetic inhibition of ERK5 did not significantly decrease insulin plus TNFa-stimulated total VCAM-1 expression, but significantly (P < 0.05) decreased insulin plus TNFa-stimulated surface VCAM-1 expression 41%. Conclusions: We report here that ERK5 plays a minor role in insulin-stimulation of VCAM-1, but plays a significant role in TNF alpha-stimulation of both total and cell surface VCAM-1 protein expression. Taken together, these results demonstrate that not only does ERK5 have differential mediation of insulin and TNF alpha-stimulated VCAM-1 expression, but also has differential regulation of insulin plus TNF alpha-stimulated total and surface VCAM-1 expression, suggesting that other intermediates of the insulin and TNF alpha intracellular pathways are contributing to atherogenesis. C1 [Mackesy, Daniel Z.; Goalstone, Marc L.] Eastern Colorado Hlth Care Syst, Res Dept, Denver, CO USA. [Goalstone, Marc L.] Univ Colorado, Sch Med, Dept Endocrinol, Denver, CO USA. RP Goalstone, ML (reprint author), Denver VA Med Ctr, 1055 Clermont St,MS 151, Denver, CO 80220 USA. EM marc.goalstone@va.gov FU Research Service of the Department of Veterans Affairs; VA Career Development Award FX This work was supported by the Research Service of the Department of Veterans Affairs (to M.L.G.), in which Dr Goalstone is a recipient of a VA Career Development Award. We would also like to acknowledge the assistance of Harsh Pratap (Flow Cytometry technician for the Mucosal and Vaccine Research Colorado) of the Eastern Colorado Health Care Service (Denver VAMC). NR 30 TC 6 Z9 6 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1753-0393 EI 1753-0407 J9 J DIABETES JI J. Diabetes PD NOV PY 2014 VL 6 IS 6 BP 595 EP 602 DI 10.1111/1753-0407.12132 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AS6BS UT WOS:000344350500016 PM 24460840 ER PT J AU Richards, KA Negron, E Cohn, JA Steinberg, Z Eggener, SE Shalhav, AL AF Richards, Kyle A. Negron, Edris Cohn, Joshua A. Steinberg, Zoe Eggener, Scott E. Shalhav, Arieh L. TI The Impact of Body Mass Index on Renal Functional Outcomes Following Minimally Invasive Partial Nephrectomy SO JOURNAL OF ENDOUROLOGY LA English DT Article ID LAPAROSCOPIC PARTIAL NEPHRECTOMY; CHRONIC KIDNEY-DISEASE; INTRAABDOMINAL FAT; OBESITY; CANCER; PREDICTORS; EQUATION AB Objective: To assess the impact of body mass index (BMI) on perioperative and renal functional outcomes in patients undergoing minimally invasive partial nephrectomy (MIPN). Materials and Methods: In our IRB-approved, prospectively maintained clinical database, we identified 1206 patients who underwent kidney surgery from 2002 to 2013. Estimated glomerular filtration rate (eGFR) was obtained at baseline and each follow-up visit. From this group, patients who underwent MIPN with more than 12 months of follow-up were selected. Patients were separated into 4 cohorts based on BMI: normal weight (<25kg/m(2)), preobese (25-30kg/m(2)), obese class 1 (30-35kg/m(2)), and obese class >= 2 (>35kg/m(2)). Change in eGFR was compared across demographic and clinical variables through linear and logistic regression models. Results: A total of 235 patients met inclusion criteria with median follow-up of 29 months (interquartile range [IQR] 19, 45). There were no differences in demographic, perioperative, or pathologic features between BMI groups. While controlling for gender, race, Charlson comorbidity score, tumor size, and ischemia time, obese class 1 (odds ratio [OR] 4.68, p=0.019), obese class >= 2 (OR 4.27, p=0.033), and age (OR 1.06, p=0.014) were associated with increased risk of CKD stage >= 3; however, higher baseline eGFR (OR 0.91, p<0.001) was associated with a reduced risk of CKD stage >= 3. While controlling for the same variables, increasing BMI was associated with a significant absolute reduction in eGFR at 1 year (0.38mL/minute/1.73m(2) reduction in GFR per 1kg/m(2) increase in BMI, p=0.009). Conclusions: MIPN is technically feasible in obese patients with similar perioperative outcomes to nonobese patients. BMI is an independent risk factor for worsening kidney function following MIPN. C1 [Richards, Kyle A.; Negron, Edris; Cohn, Joshua A.; Steinberg, Zoe; Eggener, Scott E.; Shalhav, Arieh L.] Univ Chicago, Med Ctr, Dept Surg, Urol Sect, Chicago, IL 60637 USA. [Richards, Kyle A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Urol, Madison, WI 53705 USA. [Richards, Kyle A.] William S Middleton Mem Vet Adm Med Ctr, Dept Surg, Madison, WI USA. RP Richards, KA (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Third Floor,1685 Highland Ave, Madison, WI 53705 USA. EM richardsk@urology.wisc.edu OI Cohn, Joshua/0000-0002-4953-3321; Richards, Kyle/0000-0001-8773-6413 FU NCATS NIH HHS [UL1 TR000430] NR 26 TC 0 Z9 0 U1 0 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0892-7790 EI 1557-900X J9 J ENDOUROL JI J. Endourol. PD NOV 1 PY 2014 VL 28 IS 11 BP 1338 EP 1344 DI 10.1089/end.2014.0360 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA AS0PM UT WOS:000343979900016 PM 24935823 ER PT J AU Perissinotto, CM Covinsky, KE AF Perissinotto, Carla M. Covinsky, Kenneth E. TI Living Alone, Socially Isolated or Lonely-What are We Measuring? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE aging; loneliness; social isolation; geriatrics ID OLDER-ADULTS; LONELINESS; HEALTH; INTERVENTIONS; VALIDITY; PEOPLE C1 [Perissinotto, Carla M.; Covinsky, Kenneth E.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94143 USA. [Covinsky, Kenneth E.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Perissinotto, CM (reprint author), Univ Calif San Francisco, Div Geriatr, Dept Med, 3333 Calif St,Suite 380, San Francisco, CA 94143 USA. EM carla.perissinotto@ucsf.edu NR 13 TC 1 Z9 1 U1 2 U2 19 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2014 VL 29 IS 11 BP 1429 EP 1431 DI 10.1007/s11606-014-2977-8 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AS1ZC UT WOS:000344077900003 PM 25092012 ER PT J AU Piller, LB Simpson, LM Baraniuk, S Habib, GB Rahman, M Basile, JN Dart, RA Ellsworth, AJ Fendley, H Probstfield, JL Whelton, PK Davis, BR AF Piller, Linda B. Simpson, Lara M. Baraniuk, Sarah Habib, Gabriel B. Rahman, Mahboob Basile, Jan N. Dart, Richard A. Ellsworth, Allan J. Fendley, Herbert Probstfield, Jeffrey L. Whelton, Paul K. Davis, Barry R. CA ALLHAT Collaborative Res Grp TI Characteristics and Long-Term Follow-Up of Participants with Peripheral Arterial Disease During ALLHAT SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE cardiovascular disease; hypertension; clinical trials ID LIPID-LOWERING TREATMENT; HEART-ATTACK TRIAL; NUTRITION EXAMINATION SURVEY; JOINT NATIONAL COMMITTEE; HIGH BLOOD-PRESSURE; INTERMITTENT CLAUDICATION; LOWER-EXTREMITY; HYPERTENSION; MANAGEMENT; PREVALENCE AB Hypertension is a major risk factor for peripheral artery disease (PAD). Little is known about relative efficacy of antihypertensive treatments for preventing PAD. To compare, by randomized treatment groups, hospitalized or revascularized PAD rates and subsequent morbidity and mortality among participants in the Antihypertensive and Lipid-Lower Treatment to Prevent Heart Attack Trial (ALLHAT). Randomized, double-blind, active-control trial in high-risk hypertensive participants. Eight hundred thirty participants with specified secondary outcome of lower extremity PAD events during the randomized phase of ALLHAT. In-trial PAD events were reported during ALLHAT (1994-2002). Post-trial mortality data through 2006 were obtained from administrative databases. Mean follow-up was 8.8 years. Baseline characteristics and intermediate outcomes in three treatment groups, using the Kaplan-Meier method to calculate cumulative event rates and post-PAD mortality rates, Cox proportional hazards regression model for hazard ratios and 95 % confidence intervals, and multivariate Cox regression models to examine risk differences among treatment groups. Following adjustment for baseline characteristics, neither participants assigned to the calcium-channel antagonist amlodipine nor to the ACE-inhibitor lisinopril showed a difference in risk of clinically advanced PAD compared with those in the chlorthalidone arm (HR, 0.86; 95 % CI, 0.72-1.03 and HR, 0.98; 95 % CI, 0.83-1.17, respectively). Of the 830 participants with in-trial PAD events, 63 % died compared to 34 % of those without PAD; there were no significant treatment group differences for subsequent nonfatal myocardial infarction, coronary revascularizations, strokes, heart failure, or mortality. Neither amlodipine nor lisinopril showed superiority over chlorthalidone in reducing clinically advanced PAD risk. These findings reinforce the compelling need for comparative outcome trials examining treatment of PAD in high-risk hypertensive patients. Once PAD develops, cardiovascular event and mortality risk is high, regardless of type of antihypertensive treatment. C1 [Piller, Linda B.; Simpson, Lara M.; Baraniuk, Sarah; Davis, Barry R.] Univ Texas Sch Publ Hlth, Houston, TX 77030 USA. [Habib, Gabriel B.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Rahman, Mahboob] Case Western Reserve Univ, Louis Stokes Cleveland VA Med Ctr, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA. [Basile, Jan N.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Dart, Richard A.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Ellsworth, Allan J.] Univ Washington, Seattle, WA 98195 USA. [Fendley, Herbert] AHEC Family Practice Ctr, Pine Bluff, AR USA. [Probstfield, Jeffrey L.] Univ Washington, Sch Med, Div Cardiol, Seattle, WA USA. [Whelton, Paul K.] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA. RP Piller, LB (reprint author), Univ Texas Sch Publ Hlth, 1200 Herman Pressler St,W-906, Houston, TX 77030 USA. EM Linda.b.piller@uth.tmc.edu FU National Heart, Lung, and Blood Institute [NO1-HC-35130, HHSN268201100036C]; Pfizer, Inc. FX This research was supported by contracts NO1-HC-35130 and HHSN268201100036C from the National Heart, Lung, and Blood Institute. The ALLHAT investigators acknowledge contributions of study medications supplied by Pfizer, Inc. (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and Bristol-Myers Squibb (pravastatin) and financial support provided by Pfizer, Inc. NR 33 TC 4 Z9 5 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2014 VL 29 IS 11 BP 1475 EP 1483 DI 10.1007/s11606-014-2947-1 PG 9 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AS1ZC UT WOS:000344077900014 PM 25002161 ER PT J AU Collins, E Gu, F Qi, MS Molano, I Ruiz, P Sun, LY Gilkeson, GS AF Collins, Erin Gu, Fei Qi, Maosong Molano, Ivan Ruiz, Phillip Sun, Lingyun Gilkeson, Gary S. TI Differential Efficacy of Human Mesenchymal Stem Cells Based on Source of Origin SO JOURNAL OF IMMUNOLOGY LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; STROMAL CELLS; MEDIATED IMMUNOSUPPRESSION; INTERFERON-GAMMA; NITRIC-OXIDE; T-CELLS; TRANSPLANTATION; MICE; NEPHRITIS; SUPPRESSION AB Mesenchymal stem cells (MSCs) are useful in tissue repair but also possess immunomodulatory properties. Murine and uncontrolled human trials suggest efficacy of MSCs in treating lupus. Autologous cells are preferable; however, recent studies suggest that lupus-derived MSCs lack efficacy in treating disease. Thus, the optimum derivation of MSCs for use in lupus is unknown. It is also unknown which in vitro assays of MSC function predict in vivo efficacy. The objectives for this study were to provide insight into the optimum source of MSCs and to identify in vitro assays that predict in vivo efficacy. We derived MSCs from four umbilical cords, four healthy bone marrows (BMs), and four lupus BMs. In diseased MRL/lpr mice, MSCs from healthy BM and umbilical cords significantly decreased renal disease, whereas lupus BM MSCs only delayed disease. Current in vitro assays did not differentiate efficacy of the different MSCs. However, differences in MSC efficacy were observed in B cell proliferation assays. Our results suggest that autologous MSCs from lupus patients are not effective in treating disease. Furthermore, standard in vitro assays for MSC licensing are not predictive of in vivo efficacy, whereas inhibiting B cell proliferation appears to differentiate effective MSCs from ineffective MSCs. C1 [Collins, Erin; Gu, Fei; Qi, Maosong; Molano, Ivan; Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. [Gu, Fei; Sun, Lingyun] Nanjing Univ, Affiliated Hosp, Sch Med, Dept Rheumatol & Immunol,Nanjing Drum Tower Hosp, Nanjing 210008, Jiangsu, Peoples R China. [Ruiz, Phillip] Univ Miami, Sch Med, Dept Pathol, Miami, FL 33136 USA. [Gilkeson, Gary S.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC 29403 USA. RP Collins, E (reprint author), Med Univ S Carolina, Dept Med, 96 Jonathan Lucas St,Suite 912, Charleston, SC 29425 USA. EM collinel@musc.edu FU Lupus Foundation; National Institutes of Health [National Center for Research Resources] [UL1 RR029882]; National Institutes of Health [National Center for Advancing Translational Sciences] [UL1 TR000062]; Medical Research Service, Ralph H. Johnson Veterans Affairs Medical Center FX This work was supported by grants from the Lupus Foundation; the National Institutes of Health (UL1 RR029882 [National Center for Research Resources] and UL1 TR000062 [National Center for Advancing Translational Sciences]); and the Medical Research Service, Ralph H. Johnson Veterans Affairs Medical Center. NR 41 TC 7 Z9 9 U1 1 U2 10 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD NOV 1 PY 2014 VL 193 IS 9 BP 4381 EP 4390 DI 10.4049/jimmunol.1401636 PG 10 WC Immunology SC Immunology GA AS1ZS UT WOS:000344079500013 PM 25274529 ER PT J AU Wen, ZM Fan, LY Li, YH Zou, Z Scott, MJ Xiao, GZ Li, S Billiar, TR Wilson, MA Shi, XY Fan, J AF Wen, Zongmei Fan, Liyan Li, Yuehua Zou, Zui Scott, Melanie J. Xiao, Guozhi Li, Song Billiar, Timothy R. Wilson, Mark A. Shi, Xueyin Fan, Jie TI Neutrophils Counteract Autophagy-Mediated Anti-Inflammatory Mechanisms in Alveolar Macrophage: Role in Posthemorrhagic Shock Acute Lung Inflammation SO JOURNAL OF IMMUNOLOGY LA English DT Article ID NF-KAPPA-B; TLR2 UP-REGULATION; HEMORRHAGIC-SHOCK; NADPH OXIDASE; NLRP3 INFLAMMASOME; ENDOTHELIAL-CELLS; SIGNALING PATHWAYS; NAD(P)H OXIDASE; FAMILY-MEMBER; ORGAN INJURY AB Acute lung injury (ALI) is a major component of multiple organ dysfunction syndrome after hemorrhagic shock (HS) resulting from major surgery and trauma. The increased susceptibility in HS patients to the development of ALI suggests not yet fully elucidated mechanisms that enhance proinflammatory responses and/or suppress anti-inflammatory responses in the lung. Alveolar macrophages (AM phi) are at the center of the pathogenesis of ALI after HS. We have previously reported that HS-activated polymorphonuclear neutrophils (PMNs) interact with macrophages to influence inflammation progress. In this study, we explore a novel function of PMNs regulating AM phi anti-inflammatory mechanisms involving autophagy. Using a mouse "two-hit" model of HS/resuscitation followed by intratracheal injection of muramyl dipeptide, we demonstrate that HS initiates high mobility group box 1/TLR4 signaling, which upregulates NOD2 expression in AM phi and sensitizes them to subsequent NOD2 ligand muramyl dipeptide to augment lung inflammation. In addition, upregulated NOD2 signaling induces autophagy in AM phi, which negatively regulates lung inflammation through feedback suppression of NOD2-RIP2 signaling and inflammasome activation. Importantly, we further demonstrate that HS-activated PMNs that migrate in alveoli counteract the anti-inflammatory effect of autophagy in AM phi, possibly through NAD(P)H oxidase-mediated signaling to enhance I-kappa B kinase gamma phosphorylation, NF-kappa B activation, and nucleotide-binding oligomerization domain protein 3 inflammasome activation, and therefore augment post-HS lung inflammation. These findings explore a previously unidentified complexity in the mechanisms of ALI, which involves cell-cell interaction and receptor cross talk. C1 [Wen, Zongmei; Zou, Zui; Shi, Xueyin] Second Mil Med Univ, Changzheng Hosp, Dept Anesthesiol, Shanghai 200003, Peoples R China. [Wen, Zongmei] Tongji Univ, Sch Med, Dept Anesthesiol, Shanghai Pulm Hosp, Shanghai 200433, Peoples R China. [Wen, Zongmei; Li, Yuehua; Scott, Melanie J.; Billiar, Timothy R.; Wilson, Mark A.; Fan, Jie] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA. [Fan, Liyan] Univ Pittsburgh, Sch Arts & Sci, Dept Biol Sci, Pittsburgh, PA 15213 USA. [Xiao, Guozhi] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA. [Li, Song] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Ctr Pharmacogenet, Pittsburgh, PA 15261 USA. [Billiar, Timothy R.; Fan, Jie] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA. [Wilson, Mark A.; Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Fan, J (reprint author), Univ Pittsburgh, Sch Med, Dept Surg, 3500 Terrace St, Pittsburgh, PA 15213 USA. EM shixueyin1128@163.com; jif7@pitt.edu FU National Institutes of Health [R01-HL-079669, P50-GM-53789]; U.S. Department Veterans' Affairs merit award; 12th Five-Year Plan of the People's Liberation Army Key Project Grant [BWS12J027]; Natural Science Foundation of China [81372013, 81400052]; Project of Shanghai Leading Talent; Shanghai Pujiang Program [14PJD030] FX This work was supported by National Institutes of Health Grants R01-HL-079669 (to J.F. and M.A.W.) and P50-GM-53789 (to T.R.B. and J.F.), a U.S. Department Veterans' Affairs merit award (to J.F.), 12th Five-Year Plan of the People's Liberation Army Key Project Grant BWS12J027 (to X.S.), Natural Science Foundation of China Grant 81372013 (to X.S.), the Project of Shanghai Leading Talent (to X.S.), Natural Science Foundation of China Grant 81400052 (to Z.W.), and Shanghai Pujiang Program 14PJD030 (to Z.W.). NR 64 TC 11 Z9 11 U1 0 U2 10 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD NOV 1 PY 2014 VL 193 IS 9 BP 4623 EP 4633 DI 10.4049/jimmunol.1400899 PG 11 WC Immunology SC Immunology GA AS1ZS UT WOS:000344079500036 PM 25267975 ER PT J AU Way, D Smucker, WD AF Way, Deborah Smucker, William D. TI A Reflection on "Death as Harm" SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Letter ID CARE C1 [Way, Deborah] Philadelphia Vet Affairs Med Ctr, Palliat Care Serv, Philadelphia, PA USA. [Smucker, William D.] Summa Hlth Syst, Family Med Ctr Akron, Akron, OH 44304 USA. RP Smucker, WD (reprint author), Summa Hlth Syst, Family Med Ctr Akron, Akron, OH 44304 USA. EM Smuckerw@summahealth.org NR 3 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD NOV 1 PY 2014 VL 17 IS 11 BP 1196 EP 1196 DI 10.1089/jpm.2014.0289 PG 1 WC Health Care Sciences & Services SC Health Care Sciences & Services GA AS9XX UT WOS:000344592800002 PM 25302418 ER PT J AU Moghanaki, D Cheuk, AV Fosmire, H Anscher, MS Lutz, ST Hagan, MP Dawson, GA AF Moghanaki, Drew Cheuk, Alice V. Fosmire, Helen Anscher, Mitchell S. Lutz, Stephen T. Hagan, Michael P. Dawson, George A. CA US Vet Healthcare Adm Natl TI Availability of Single-Fraction Palliative Radiotherapy for Cancer Patients Receiving End-of-Life Care within the Veterans Healthcare Administration SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID BONE METASTASES; HOSPICE; DELIVERY; ONCOLOGY; SYSTEM AB Background: Surveys demonstrate <20% of radiation oncologists in the United States offer single-fraction palliative radiotherapy (RT) even though it is an acceptable standard of care. A study was conducted to investigate whether this held true for those practicing within the Veterans Healthcare Administration (VHA). Methods: All radiation oncologists currently practicing at VHA medical centers were surveyed. Comparisons and associations of responses were evaluated by Fisher's exact test. Results: The response rate was 90%. Half were full-time employees of the VHA, and the majority (70%) had thoroughly read guidelines on palliative RT for bone metastases recently published by either the American College of Radiology (ACR, 2009, 2012) or the American Society of Radiation Oncology (ASTRO, 2011). Single-fraction palliative RT for bone metastases had been prescribed by 76% of respondents, and 93% had prescribed a short course of <= 6 fractions. Respondents were less likely to have prescribed a single fraction for patients who had survival estimates of either >6 months or >12 months (66% versus 37%, p<0.0001).Those not offering single-fraction palliative RT (24%) were more likely to be >10 years out of training (37% versus 10%, p=0.01), and to have worked in a private practice setting at some point in their career (36% versus 12%, p=0.03). Conclusions: A majority of radiation oncologists within the VHA offer single-fraction therapy to their patients. These data ensure access to palliative RT is not limited within this health care system by a preference for prolonged treatment courses that may discourage patients and clinicians from seeking this care. C1 [Moghanaki, Drew] Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA 23249 USA. [Moghanaki, Drew; Anscher, Mitchell S.; Hagan, Michael P.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA. [Cheuk, Alice V.; Dawson, George A.] James J Peters Vet Affairs Med Ctr, New York, NY USA. [Cheuk, Alice V.; Dawson, George A.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Fosmire, Helen] Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA. [Lutz, Stephen T.] Blanchard Valley Reg Hlth Ctr, Findlay, OH USA. [Hagan, Michael P.] US Dept Vet Affairs, Natl Radiat Oncol Program, Richmond, VA USA. [Dawson, George A.] Vet Affairs New Jersey Healthcare Syst, E Orange, NJ USA. RP Moghanaki, D (reprint author), Hunter Holmes McGuire Vet Affairs Med Ctr, Dept Radiat Oncol, 1201 Broad Rock Blvd, Richmond, VA 23249 USA. EM drew.moghanaki@va.gov OI Anscher, Mitchell/0000-0003-4480-111X NR 22 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD NOV 1 PY 2014 VL 17 IS 11 BP 1221 EP 1225 DI 10.1089/jpm.2014.0041 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA AS9XX UT WOS:000344592800008 PM 25188468 ER PT J AU Quinones, AR Ramsey, K Newsom, JT Dorr, DA AF Quinones, Ana R. Ramsey, Katrina Newsom, Jason T. Dorr, David A. TI Racial and Ethnic Differences in Clinical Outcome Trajectories for Care Managed Patients SO MEDICAL CARE LA English DT Article DE racial/ethnic differences; complex care patients; multimorbidity; hemoglobin A1c; blood pressure; multilevel modeling ID RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE; MEXICAN-AMERICANS; MULTIMORBIDITY; QUALITY; HOSPITALIZATION; CONSEQUENCES; PREVALENCE; DISEASES; SENIORS AB Background: Care management has demonstrated improvements in quality of care for patients with complex care needs. The extent to which these interventions benefit race/ethnic minority populations is unclear. Objectives: To characterize race/ethnic differences in the longitudinal control of clinical outcomes for patients with complex care needs enrolled in Care Management Plus, a health information technology-enabled care coordination intervention. Research Design: Multilevel models of repeated observations from clinical encounters before and after program enrollment for 6 Oregon and California primary care clinics. Subjects: A total of 18,675 clinic patients were examined. We estimated multilevel models for 1481 and 5320 care-managed individuals with repeated hemoglobin A1c and blood pressure measurements, respectively. Measures: Primary outcomes were changes over time for 2 clinical markers of health status for complex care patients: (1) hemoglobin A1c for patients with diabetes; and (2) mid-blood pressure (BP) (average systolic and diastolic blood pressure). Results: We found significant reductions in A1c for patients with previously uncontrolled A1c (preperiod slope, b = 1.03 [0.83, 1.24]; postperiod slope, b = -0.63 [-0.91, -0.35]). For mid-BP we found increasing unconditional preperiod trajectories (b = 3.52 [2.39, 4.64]) and decreasing postperiod trajectories (b= -5.21 [-5.70, -4.72]). We also found the trajectories of A1c and mid-BP were not statistically different for black, Latino, and white patients. Conclusions: These analyses demonstrate some promising results for intermediate clinical outcomes for underrepresented patients with complex chronic care needs. It remains to be seen whether these health care system delivery redesigns yield long-term benefits for patients, such as improvements in function and quality of life. C1 [Quinones, Ana R.; Ramsey, Katrina] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. [Quinones, Ana R.] Portland VA Med Ctr, Portland, OR USA. [Newsom, Jason T.] Portland State Univ, Sch Community Hlth, Portland, OR 97207 USA. [Newsom, Jason T.] Portland State Univ, Inst Aging, Portland, OR 97207 USA. [Dorr, David A.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. RP Quinones, AR (reprint author), Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM quinones@ohsu.edu FU Medical Research Foundation of Oregon [MRF-1217]; American Diabetes Association [ADA 7-13-CD-08]; Programs to Increase Diversity among Individuals Engaged in Health Related-Research [NIH/NHLBI R25HL105430] FX Supported by the Medical Research Foundation of Oregon (MRF-1217, Quinones PI) and the American Diabetes Association (ADA 7-13-CD-08, Quinones PI). A.R.Q. was also supported by the Programs to Increase Diversity among Individuals Engaged in Health Related-Research (NIH/NHLBI R25HL105430). The views expressed in this article are those of the authors and do not necessarily represent the views of the Medical Research Foundation, the National Institutes of Health, or the American Diabetes Association. NR 33 TC 1 Z9 1 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD NOV PY 2014 VL 52 IS 11 BP 998 EP 1005 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AR9XL UT WOS:000343930300010 PM 25304019 ER PT J AU Kambayashi, T Laufer, TM AF Kambayashi, Taku Laufer, Terri M. TI Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell? SO NATURE REVIEWS IMMUNOLOGY LA English DT Review ID CD4(+) T-CELLS; INNATE LYMPHOID-CELLS; INTESTINAL EPITHELIAL-CELLS; ALLERGIC AIRWAY INFLAMMATION; HELPER TYPE-2 RESPONSE; HUMAN MAST-CELLS; FC-EPSILON-RI; IN-VIVO; HUMAN EOSINOPHILS; IL-4 PRODUCTION AB Dendritic cells, macrophages and B cells are regarded as the classical antigen-presenting cells of the immune system. However, in recent years, there has been a rapid increase in the number of cell types that are suggested to present antigens on MHC class II molecules to CD4(+) T cells. In this Review, we describe the key characteristics that define an antigen-presenting cell by examining the functions of dendritic cells. We then examine the functions of the haematopoietic cells and non-haematopoietic cells that can express MHC class II molecules and that have been suggested to represent 'atypical' antigen-presenting cells. We consider whether any of these cell populations can prime naive CD4(+) T cells and, if not, question the effects that they do have on the development of immune responses. C1 [Kambayashi, Taku] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kambayashi, Taku] Univ Penn, Div Rheumatol, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Laufer, Terri M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Laufer, TM (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. EM tlaufer@mail.med.upenn.edu FU VA Merit Award; US National Institutes of Health; American Asthma Foundation FX Work in the laboratory of T.M.L. is supported by a VA Merit Award. Research in the laboratory of T.K. is supported by funding from the US National Institutes of Health and the American Asthma Foundation. NR 159 TC 51 Z9 51 U1 2 U2 33 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1474-1733 EI 1474-1741 J9 NAT REV IMMUNOL JI Nat. Rev. Immunol. PD NOV PY 2014 VL 14 IS 11 BP 719 EP 730 DI 10.1038/nri3754 PG 12 WC Immunology SC Immunology GA AS8BQ UT WOS:000344475800008 PM 25324123 ER PT J AU Biczo, G Vegh, ET Shalbueva, N French, SW Elperin, J Lotshaw, E Mareninova, OA Hegyi, P Rakonczay, Z Gukovskaya, AS AF Biczo, G. Vegh, E. T. Shalbueva, N. French, S. W. Elperin, J. Lotshaw, E. Mareninova, O. A. Hegyi, P. Rakonczay, Z., Jr. Gukovskaya, A. S. TI Mitochondrial ATP Synthase Dysfunction Mediates L-arginine-Induced Pancreatitis SO PANCREAS LA English DT Meeting Abstract C1 [Biczo, G.; Vegh, E. T.; Shalbueva, N.; Elperin, J.; Lotshaw, E.; Mareninova, O. A.; Gukovskaya, A. S.] VA Greater Los Angeles, Los Angeles, CA USA. [Biczo, G.; Vegh, E. T.; Shalbueva, N.; Elperin, J.; Lotshaw, E.; Mareninova, O. A.; Gukovskaya, A. S.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Biczo, G.; Vegh, E. T.; Hegyi, P.; Rakonczay, Z., Jr.] Univ Szeged, Szeged, Hungary. [French, S. W.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2014 VL 43 IS 8 BP 1344 EP 1345 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6GO UT WOS:000344362600055 ER PT J AU Maertin, S Nitsche, CJ Elperin, JM Sendler, M Grippo, PJ Eibl, G Mayerle, J Lerch, MM Gukovskaya, AS AF Maertin, S. Nitsche, C. J. Elperin, J. M. Sendler, M. Grippo, P. J. Eibl, G. Mayerle, J. Lerch, M. M. Gukovskaya, A. S. TI Prosurvival Effect of Autophagy in Pancreatic Cancer Cells is Determined by Kras and p53 Mutational Status SO PANCREAS LA English DT Meeting Abstract C1 [Maertin, S.; Elperin, J. M.; Gukovskaya, A. S.] VA Greater Los Angeles, Los Angeles, CA USA. [Maertin, S.; Eibl, G.; Gukovskaya, A. S.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Maertin, S.; Nitsche, C. J.; Sendler, M.; Mayerle, J.; Lerch, M. M.] Ernst Moritz Arndt Univ Greifswald, Greifswald, Germany. [Grippo, P. J.] Univ Illinois, Chicago, IL USA. RI Lerch, Markus M./E-2206-2016 OI Lerch, Markus M./0000-0002-9643-8263 NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2014 VL 43 IS 8 BP 1386 EP 1386 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6GO UT WOS:000344362600228 ER PT J AU Pimienta, M Lee, GE Gukovskaya, AS Gukovsky, I Mareninova, OA AF Pimienta, M. Lee, G. E. Gukovskaya, A. S. Gukovsky, I. Mareninova, O. A. TI mTOR Mediates p62/SQSTM1 Synthesis in Pancreatic Acinar Cells SO PANCREAS LA English DT Meeting Abstract C1 Univ Calif Los Angeles, VA Greater Los Angeles, Los Angeles, CA USA. Southern Calif Res Ctr ALPD & Cirrhosis, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2014 VL 43 IS 8 BP 1401 EP 1401 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6GO UT WOS:000344362600289 ER PT J AU Wu, SV Pham, H Million, M Chen, MC Go, VLW Jiang, M AF Wu, S. V. Pham, H. Million, M. Chen, M. C. Go, V. L. W. Jiang, M. TI Expression and Functional Characterization of Bitter Taste Receptors in Rat Pancreas SO PANCREAS LA English DT Meeting Abstract C1 [Wu, S. V.; Chen, M. C.; Go, V. L. W.] Univ Calif Los Angeles, Ctr Excellence Pancreat Dis, Los Angeles, CA USA. [Pham, H.; Million, M.] Univ Calif Los Angeles, Dept Med, Div Digest Dis, Los Angeles, CA 90024 USA. [Jiang, M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pharmacol, Los Angeles, CA 90095 USA. [Wu, S. V.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2014 VL 43 IS 8 BP 1422 EP 1422 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6GO UT WOS:000344362600381 ER PT J AU Wu, SV Chen, MC Tache, Y Go, VLW AF Wu, S. V. Chen, M. C. Tache, Y. Go, V. L. W. TI Characterization of Corticotropin-Releasing Hormone (CRH) Type I System in Human Pancreatic Endocrine Tumors SO PANCREAS LA English DT Meeting Abstract C1 [Wu, S. V.; Chen, M. C.; Go, V. L. W.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Excellence Pancreat Dis, Los Angeles, CA 90095 USA. [Wu, S. V.; Tache, Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2014 VL 43 IS 8 BP 1423 EP 1423 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6GO UT WOS:000344362600384 ER PT J AU Sullivan, DR Ganzini, L Lopez-Chavez, A Slatore, CG AF Sullivan, Donald R. Ganzini, Linda Lopez-Chavez, Ariel Slatore, Christopher G. TI Association of patient characteristics with chemotherapy receipt among depressed and non-depressed patients with non-small cell lung cancer SO PSYCHO-ONCOLOGY LA English DT Article DE Depression; Lung Cancer; Epidemiology; Treatment Receipt; Race ID RACIAL-DIFFERENCES; DISPARITIES; TRENDS; COMORBIDITY; OUTCOMES; IMPACT; AGE C1 [Sullivan, Donald R.; Ganzini, Linda; Slatore, Christopher G.] Portland VA Med Ctr, Portland, OR USA. [Sullivan, Donald R.; Slatore, Christopher G.] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA. [Ganzini, Linda] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Lopez-Chavez, Ariel] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97201 USA. [Slatore, Christopher G.] Portland VA Med Ctr, Sect Pulm & Crit Care Med, Portland, OR USA. RP Sullivan, DR (reprint author), 3710 SW US Vet Hosp Rd,R&D 66, Portland, OR 97239 USA. EM sullivad@ohsu.edu OI Sullivan, Donald/0000-0003-3266-3389; Slatore, Christopher/0000-0003-0958-8122 FU NCATS NIH HHS [UL1 TR000128, UL1TR000128]; NHLBI NIH HHS [5 T32 HL083808-05-32, T32 HL083808] NR 18 TC 1 Z9 1 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD NOV PY 2014 VL 23 IS 11 BP 1318 EP 1322 DI 10.1002/pon.3528 PG 5 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AS4JX UT WOS:000344242500016 PM 24771684 ER PT J AU Tracy, M Morgenstern, H Zivin, K Aiello, AE Galea, S AF Tracy, Melissa Morgenstern, Hal Zivin, Kara Aiello, Allison E. Galea, Sandro TI Traumatic event exposure and depression severity over time: results from a prospective cohort study in an urban area SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY LA English DT Article DE Depression; Traumatic events; Stressful events; Violence; Injuries ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL COMORBIDITY SURVEY; POPULATION-BASED COHORT; PRIMARY-CARE PATIENTS; LIFE EVENTS; GENERAL-POPULATION; MAJOR DEPRESSION; MENTAL-HEALTH; RISK-FACTORS; SOCIAL SUPPORT AB Purpose A substantial proportion of adults experience traumatic events each year, yet little is known about the effects of different types of traumatic events on depression severity over time. We prospectively assessed the effects of traumatic event exposure during a 1-year period on changes in depression severity during that period among a representative sample of adults living in Detroit, Michigan in the United States. Methods We used data from 1,054 participants in the first two waves of the Detroit Neighborhood Health Study (2008-2010). Depression severity was measured with the Patient Health Questionnaire-9 (PHQ-9). Negative binomial regression was used to estimate the effect of traumatic event exposure on depression severity at Wave 2, adjusting for Wave 1 PHQ-9 score and potential confounders. Results The mean depression severity score at Wave 2 among those exposed to at least one traumatic event during follow-up was 1.71 times higher than among those with no traumatic event exposure [95 % confidence interval (CI) 1.27-2.29]. Also positively associated with depression severity at Wave 2 (vs. no traumatic events) were assaultive violence (mean ratio 2.49, 95 % CI 1.41-4.38), injuries and other directly experienced shocking events (mean ratio 2.59, 95 % CI 1.62-3.82), and three or more traumatic events (mean ratio 2.58, 95 % CI 1.62-4.09). Conclusions Violence, injuries, and other directly experienced traumatic events increase depression severity and may be useful targets for interventions to alleviate the burden of depression in urban areas. C1 [Tracy, Melissa; Galea, Sandro] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA. [Tracy, Melissa; Morgenstern, Hal; Aiello, Allison E.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Morgenstern, Hal] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. [Morgenstern, Hal] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA. [Zivin, Kara] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. [Zivin, Kara] US Dept Vet Affairs, Ann Arbor, MI 48113 USA. RP Tracy, M (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, 722 W 168th St,Room 515, New York, NY 10032 USA. EM mt2682@columbia.edu FU National Institutes of Health [DA022720, DA022720-S1, MH088283, MH078152, MH082729] FX This study was supported by the National Institutes of Health (Grants DA022720, DA022720-S1, MH088283, MH078152, and MH082729). NR 121 TC 4 Z9 4 U1 5 U2 14 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0933-7954 EI 1433-9285 J9 SOC PSYCH PSYCH EPID JI Soc. Psychiatry Psychiatr. Epidemiol. PD NOV PY 2014 VL 49 IS 11 BP 1769 EP 1782 DI 10.1007/s00127-014-0884-2 PG 14 WC Psychiatry SC Psychiatry GA AS1UM UT WOS:000344067300009 PM 24816599 ER PT J AU Dhaliwal, G Sehgal, NL AF Dhaliwal, Gurpreet Sehgal, Niraj L. TI Demystify Leadership in Order to Cultivate It SO ACADEMIC MEDICINE LA English DT Editorial Material C1 [Dhaliwal, Gurpreet; Sehgal, Niraj L.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Sehgal, Niraj L.] Univ Calif San Francisco, Ctr Hlth Profess, San Francisco, CA USA. RP Dhaliwal, G (reprint author), San Francisco VA Med Ctr, 4150 Clement St 111, San Francisco, CA 94121 USA. EM gurpreet.dhaliwal@ucsf.edu NR 3 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD NOV PY 2014 VL 89 IS 11 BP 1441 EP 1441 DI 10.1097/ACM.0000000000000489 PG 1 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA AR9MC UT WOS:000343897500012 PM 25350336 ER PT J AU McDonald, CC Curry, AE Kandadai, V Sommers, MS Winston, FK AF McDonald, Catherine C. Curry, Allison E. Kandadai, Venk Sommers, Marilyn S. Winston, Flaura K. TI Comparison of teen and adult driver crash scenarios in a nationally representative sample of serious crashes SO ACCIDENT ANALYSIS AND PREVENTION LA English DT Article DE Teen drivers; Adult drivers; Crash-contributing factors; Crash scenarios; Risk factors; Traffic safety ID RISKY DRIVING BEHAVIOR; NOVICE DRIVERS; PASSENGERS AB Motor vehicle crashes are the leading cause of death and acquired disability during the first four decades of life. While teen drivers have the highest crash risk, few studies examine the similarities and differences in teen and adult driver crashes. We aimed to: (1) identify and compare the most frequent crash scenarios integrated information on a vehicle's movement prior to crash, immediate pre-crash event, and crash configuration for teen and adult drivers involved in serious crashes, and (2) for the most frequent scenarios, explore whether the distribution of driver critical errors differed for teens and adult drivers. We analyzed data from the National Motor Vehicle Crash Causation Survey, a nationally representative study of serious crashes conducted by the U.S. National Highway Traffic Safety Administration from 2005 to 2007. Our sample included 642 16- to 19-year-old and 1167 35- to 54-year-old crash-involved drivers (weighted n = 296,482 and 439,356, respectively) who made a critical error that led to their crash's critical pre-crash event (i.e., event that made the crash inevitable). We estimated prevalence ratios (PR) and 95% confidence intervals (CI) to compare the relative frequency of crash scenarios and driver critical errors. The top five crash scenarios among teen drivers, accounting for 37.3% of their crashes, included: (1) going straight, other vehicle stopped, rear end; (2) stopped in traffic lane, turning left at intersection, turn into path of other vehicle; (3) negotiating curve, off right edge of road, right roadside departure; (4) going straight, off right edge of road, right roadside departure; and (5) stopped in lane, turning left at intersection, turn across path of other vehicle. The top five crash scenarios among adult drivers, accounting for 33.9% of their crashes, included the same scenarios as the teen drivers with the exception of scenario (3) and the addition of going straight, crossing over an intersection, and continuing on a straight path. For two scenarios ((1) and (3) above), teens were more likely than adults to make a critical decision error (e.g., traveling too fast for conditions). Our findings indicate that among those who make a driver critical error in a serious crash, there are few differences in the scenarios or critical driver errors for teen and adult drivers. (C) 2014 Elsevier Ltd. All rights reserved. C1 [McDonald, Catherine C.; Sommers, Marilyn S.] Univ Penn, Sch Nursing, Ctr Global Womens Hlth, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. [McDonald, Catherine C.; Curry, Allison E.; Kandadai, Venk; Winston, Flaura K.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA. [Curry, Allison E.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Winston, Flaura K.] Univ Penn, Perelman Sch Med, Div Gen Pediat, Philadelphia, PA 19104 USA. [Winston, Flaura K.] Childrens Hosp Philadelphia, Natl Sci Fdn Ctr Child Injury Prevent Studies, Philadelphia, PA 19104 USA. RP McDonald, CC (reprint author), Univ Penn, Sch Nursing, Ctr Global Womens Hlth, Ctr Hlth Equ Res, Claire Fagin Hall,418 Curie Blvd, Philadelphia, PA 19104 USA. EM mcdonalc@nursing.upenn.edu; currya@email.chop.edu; kandadaiv@email.chop.edu; ssommer@nursing.upenn.edu; flaura@mail.med.upenn.edu NR 31 TC 7 Z9 7 U1 2 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0001-4575 EI 1879-2057 J9 ACCIDENT ANAL PREV JI Accid. Anal. Prev. PD NOV PY 2014 VL 72 BP 302 EP 308 DI 10.1016/j.aap.2014.07.016 PG 7 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA AR8SC UT WOS:000343843700030 PM 25103321 ER PT J AU Beidas, RS Edmunds, J Ditty, M Watkins, J Walsh, L Marcus, S Kendall, P AF Beidas, Rinad S. Edmunds, Julie Ditty, Matthew Watkins, Jessica Walsh, Lucia Marcus, Steven Kendall, Philip TI Are Inner Context Factors Related to Implementation Outcomes in Cognitive-Behavioral Therapy for Youth Anxiety? SO ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH LA English DT Article DE Evidence-based practice; Inner context; Implementation outcomes ID MENTAL-HEALTH; RANDOMIZED-TRIAL; ORGANIZATIONAL READINESS; DISSEMINATION TRIAL; TREATMENT INTEGRITY; CHILDHOOD ANXIETY; CONSULTATION; CLINICIAN; STRATEGIES; SERVICES AB Among the challenges facing the mental health field are the dissemination and implementation of evidence-based practices. The present study investigated the relationships between inner context variables (i.e., adopter characteristics and individual perceptions of intra-organizational factors) and two implementation outcomes-independently rated therapist fidelity on a performance-based role-play (i.e., adherence and skill) and self-reported penetration of cognitive behavioral therapy for youth anxiety following training. A significant relationship was found between inner context variables and fidelity. Specifically, adopter characteristics were associated with adherence and skill; individual perceptions of intra-organizational factors were associated with adherence. Inner context variables were not associated with penetration. Future directions are discussed. C1 [Beidas, Rinad S.; Walsh, Lucia] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Edmunds, Julie] Judge Baker Childrens Ctr, Ctr Effect Child Therapy, Boston, MA USA. [Ditty, Matthew; Marcus, Steven] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Watkins, Jessica] Bryn Mawr Coll, Bryn Mawr, PA 19010 USA. [Marcus, Steven] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Kendall, Philip] Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA. RP Beidas, RS (reprint author), Univ Penn, Perelman Sch Med, Dept Psychiat, 3535 Market St,3015, Philadelphia, PA 19104 USA. EM rbeidas@upenn.edu FU NIMH NIH HHS [F31 MH083333, MH063747, K23 MH099179, MH083333, MH086436, MH099179, R01 MH063747, R25 MH080916, U01 MH063747] NR 62 TC 8 Z9 8 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0894-587X EI 1573-3289 J9 ADM POLICY MENT HLTH JI Adm. Policy. Ment. Health PD NOV PY 2014 VL 41 IS 6 BP 788 EP 799 DI 10.1007/s10488-013-0529-x PG 12 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AS0UW UT WOS:000343994900009 PM 24202067 ER PT J AU Wang, S Luo, XD Barnes, D Sano, M Yaffe, K AF Wang, Sophia Luo, Xiaodong Barnes, Deborah Sano, Mary Yaffe, Kristine TI Physical Activity and Risk of Cognitive Impairment Among Oldest-Old Women SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Cognitive aging; cohort studies; dementia; physical activity; oldest-old ID ALZHEIMERS-DISEASE; EXECUTIVE FUNCTION; DEMENTIA; PREVALENCE; AGE; ASSOCIATION; EXERCISE; DECLINE; COHORT; ADULTS AB Objectives: Physical activity may reduce the risk of cognitive decline in the elderly, but its effects among the oldest-old (i.e., those aged 85 years and older) are not well known. Our study assessed the association between very late-life physical activity and 5-year risk of mild cognitive impairment (MCI) or dementia and neuropsychological test performance among oldest-old women. Methods: This prospective study was conducted at three sites. Participants included 1,249 women (mean [standard deviation] age: 83.3 [2.8] years). Baseline physical activity was measured by self-reported blocks walked per week and analyzed according to tertile. Five years later, surviving participants who were 85 years and older (oldest-old) completed neuropsychological testing and underwent adjudication of clinical cognitive status (normal, MCI, or dementia). All analyses were adjusted for baseline age, education, cognition, depression, body mass index, hypertension, smoking, and coronary artery disease. Results: Compared with women in the lowest tertile, women in the highest tertile were less likely to develop dementia (13.0% versus 23.2%; multivariate adjusted odds ratio: 0.54 [95% confidence interval: 0.36-0.82]). However, risk of MCI was not associated with physical activity. Physical activity was also associated with higher performance 5 years later on tests of global cognition, category fluency, and executive function but not phonemic fluency, memory, or attention. Conclusions: Higher level of very late-life physical activity was associated with a lower risk of subsequent dementia in oldest-old women. These findings support future studies for late-life physical activity interventions for the prevention of dementia among oldest-old women. C1 [Wang, Sophia; Barnes, Deborah; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Wang, Sophia; Barnes, Deborah; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Luo, Xiaodong; Sano, Mary] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Luo, Xiaodong; Sano, Mary] Vet Affairs Med Ctr, Bronx, NY USA. [Barnes, Deborah; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. RP Wang, S (reprint author), Langley Porter Neuropsychiat Inst, 401 Parnassus Ave,GPP 0984, San Francisco, CA 94103 USA. EM sophia.wang@ucsf.edu FU VA Neurosciences Research fellowship; Mount Sinai Alzheimer's Disease Research Center award from National Institute of Aging (NIA) [P50AG005138-27]; National Center for Research Resources' Clinical and Translational Science Award [UL1RR029887]; NIA [K24 AG 031155]; Alzheimer's Association; APA/Lilly Resident Research Award; [AG05407]; [AR35582]; [AG05394]; [AR3354]; [AR35583]; [R01 AG005407]; [R01 AG027576-22]; [2 R01 AG005394-22A1]; [2R01 AG027574-22A1]; [5R01AG026720-04] FX Data collection and sharing for SOF and SOF-WISE are supported by grants AG05407, AR35582, AG05394, AR3354, AR35583, R01 AG005407, R01 AG027576-22, 2 R01 AG005394-22A1, 2R01 AG027574-22A1, and 5R01AG026720-04. The study was coordinated by the University of California at San Francisco, and the SOF data are disseminated by the University of California at San Francisco. This study was also supported in part by a VA Neurosciences Research fellowship (S. W.), Mount Sinai Alzheimer's Disease Research Center award P50AG005138-27 from the National Institute of Aging (NIA) (X. L., M. S.), UL1RR029887 from the National Center for Research Resources' Clinical and Translational Science Award (M. S.), grant K24 AG 031155 from the NIA and an Independent Investigator Award from the Alzheimer's Association (KY). Dr. Wang also received the APA/Lilly Resident Research Award for this work. NR 40 TC 7 Z9 7 U1 0 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD NOV PY 2014 VL 22 IS 11 BP 1149 EP 1157 DI 10.1016/j.jagp.2013.03.002 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AR8YG UT WOS:000343856600011 PM 23831179 ER PT J AU Sultzer, DL Leskin, LP Melrose, RJ Harwood, DG Narvaez, TA Ando, TK Mandelkern, MA AF Sultzer, David L. Leskin, Lorraine P. Melrose, Rebecca J. Harwood, Dylan G. Narvaez, Theresa A. Ando, Timothy K. Mandelkern, Mark A. TI Neurobiology of Delusions, Memory, and Insight in Alzheimer Disease SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Alzheimer disease; delusions; insight; memory; FDG-PET; cerebral metabolism ID NEUROBEHAVIORAL RATING-SCALE; REGIONAL CORTICAL METABOLISM; CEREBRAL-BLOOD-FLOW; BEHAVIORAL DISTURBANCES; PSYCHIATRIC-SYMPTOMS; COGNITIVE DEFICITS; NATIONAL INSTITUTE; PSYCHOTIC SYMPTOMS; IMPAIRED INSIGHT; WORKING-MEMORY AB Objective: Delusional thoughts are common among patients with Alzheimer disease (AD) and may be conceptually linked to memory deficits (cannot recall accurate information, which leads to inaccurate beliefs) and poor insight (unable to appreciate the illogic of beliefs). This study's goals were to examine the clinical associations among delusions, memory deficits, and poor insight; explore neurobiologic correlates for these symptoms; and identify shared mechanisms. Methods: In a cross-sectional analysis, 88 outpatients with AD (mean Mini-Mental State Exam score: 19.3) were studied. Delusional thoughts were assessed with the Neuropsychiatric Inventory, level of inaccurate insight was assessed with the Neurobehavioral Rating Scale, and memory was assessed with the Mattis Dementia Rating Scale memory subscale. F-18-fluorodeoxyglucose positron emission tomography was used to measure regional cortical metabolism. Relationships between clinical ratings and regional cortical metabolic activity (voxel-based) were assessed using SPM2. Results: Patients with delusions had lower Dementia Rating Scale memory subscale scores. Neurobehavioral Rating Scale inaccurate insight scores were no different in those with and without delusions. Cortical metabolic activity was lower in the right lateral frontal cortex, orbitofrontal cortex, and bilateral temporal cortex in patients with delusions. Low cortical metabolic activity in the right lateral, inferior, and medial temporal cortex was associated with poorer memory. This region partially overlapped the region of hypometabolism associated with delusions. In contrast, low cortical metabolic activity in bilateral medial frontal cortex was associated with poor insight. Conclusion: Delusions in AD are associated with dysfunction in specific frontal and temporal cortical regions. Delusions are partially clinically and neurobiologically linked to memory deficits but not to poor insight. C1 [Sultzer, David L.; Leskin, Lorraine P.; Melrose, Rebecca J.; Harwood, Dylan G.; Narvaez, Theresa A.; Ando, Timothy K.] VA Greater Los Angeles Healthcare Syst, Brain Behav & Aging Res Ctr, Los Angeles, CA 90073 USA. [Mandelkern, Mark A.] VA Greater Los Angeles Healthcare Syst, Nucl Med Serv, Los Angeles, CA 90073 USA. [Sultzer, David L.; Melrose, Rebecca J.; Harwood, Dylan G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. RP Sultzer, DL (reprint author), VA Greater Los Angeles Healthcare Syst, Brain Behav & Aging Res Ctr, 11301 Wilshire Blvd,116AE, Los Angeles, CA 90073 USA. EM dsultzer@ucla.edu FU Department of Veterans Affairs; National Institute of Mental Health [R01MH56031]; Eli Lilly FX Supported in part by the Department of Veterans Affairs (Merit Review Award to DLS; Career Development Award to RJM) and the National Institute of Mental Health (R01MH56031).; Dr. Sultzer has received research support from Eli Lilly and has served as a consultant to Otsuka Pharmaceutical and Eli Lilly. NR 59 TC 6 Z9 6 U1 6 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD NOV PY 2014 VL 22 IS 11 BP 1346 EP 1355 DI 10.1016/j.jagp.2013.06.005 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AR8YG UT WOS:000343856600030 PM 24021220 ER PT J AU Welsh, MM Federinko, SP Burnett, DG Gackstetter, GD Boyko, EJ Seelig, AD Wells, TS Hooper, TI AF Welsh, Marleen M. Federinko, Susan P. Burnett, Daniel G. Gackstetter, Gary D. Boyko, Edward J. Seelig, Amber D. Wells, Timothy S. Hooper, Tomoko I. TI Deployment-Related Depression Screening, 2001-2008 Comparing Clinical Versus Research Surveys SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; MILITARY SERVICE MEMBERS; HEALTH-CARE UTILIZATION; MILLENNIUM COHORT; US MILITARY; SMALLPOX VACCINATION; COMBAT DEPLOYMENT; ENROLLMENT; IMPACT; AFGHANISTAN AB Background: Potential adverse mental health effects of deployment, including depression, are an ongoing concern. Although a previous study assessed under-reporting of depression on post-deployment health assessments compared to anonymous surveys, those results were not examined at the individual level to identify demographic or military factors that may be associated with unwillingness to report depression symptoms. Purpose: To compare self-reported depression symptoms on post-deployment health assessments with responses to the same depression questions on a research survey. Methods: This cross-sectional study analyzed depression screening responses from 2001 to 2008 from participants of the Millennium Cohort Study, a longitudinal military cohort study, who completed a post-deployment health assessment within 30 days of a research survey. Kappa statistics and percent positive and negative agreement were calculated. Demographic and military characteristics associated with discordant screening results were examined. Initial analyses were performed in 2011, with additional analyses in 2013. Results: Moderate agreement (kappa=0.464) was observed between paired survey responses. A higher proportion of active duty members, the unmarried, and new accessions into military service endorsed depression symptoms on the research survey but not the military-linked survey. In stratified analyses, agreement was higher in Reserve/National Guard members than active duty (kappa=0.561 vs 0.409). New active duty accessions showed lower agreement (kappa=0.388), as did unmarried active duty participants (kappa=0.304). Conclusions: Deployment health surveys are important tools for identifying returning service members experiencing depression symptoms. However, these findings suggest that ongoing stigma and barriers to appropriate follow-up mental health care remain to be addressed in the military setting. (C) 2014 American Journal of Preventive Medicine. All rights reserved. C1 [Welsh, Marleen M.; Federinko, Susan P.; Burnett, Daniel G.; Hooper, Tomoko I.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA. [Gackstetter, Gary D.] Analyt Serv Inc, Falls Church, VA USA. [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Seelig, Amber D.] Naval Hlth Res Ctr, Deployment Hlth Res Dept, San Diego, CA USA. [Wells, Timothy S.] Optum, Ann Arbor, MI USA. RP Welsh, MM (reprint author), Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Room A1040H,4301 Jones Bridge Rd, Bethesda, MD 20814 USA. EM marleen.welsh.ctr@usuhs.edu OI Boyko, Edward/0000-0002-3695-192X FU Management Information Division, U.S. Defense Manpower Data Center (Seaside CA); Military Operational Medicine Research Program; U.S. Army Medical Research and Materiel Command; Military Operational Medicine Research Program, U.S. Army Medical Research and Materiel Command (Fort Detrick MD) FX We would like to thank the entire Millennium Cohort Study Team from the Deployment Health Research Department, Naval Health Research Center, San Diego CA, for their support, as well as the Millennium Cohort Study co-investigators for their leadership. We are also indebted to the Millennium Cohort Study participants, without whom these analyses would not be possible. We appreciate the support from the Management Information Division, U.S. Defense Manpower Data Center (Seaside CA), Military Operational Medicine Research Program, and U.S. Army Medical Research and Materiel Command.; The Millennium Cohort Study is funded through the Military Operational Medicine Research Program, U.S. Army Medical Research and Materiel Command (Fort Detrick MD). Resources from the Veterans Affairs Puget Sound Health Care System supported Dr. Boyko's involvement in this research. NR 26 TC 2 Z9 2 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2014 VL 47 IS 5 BP 531 EP 540 DI 10.1016/j.amepre.2014.07.036 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AR6DP UT WOS:000343673800001 PM 25241198 ER PT J AU Lehavot, K Browne, KC Simpson, TL AF Lehavot, Keren Browne, Kendall C. Simpson, Tracy L. TI Examining Sexual Orientation Disparities in Alcohol Misuse Among Women Veterans SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE; MENTAL-HEALTH; PHYSICAL ABUSE; MINORITY VETERANS; TRAUMA EXPOSURE; FEMALE VETERANS; BINGE DRINKING; UNITED-STATES; CHILD-ABUSE AB Background: Alcohol misuse is a significant health concern among women veterans, especially among lesbian and bisexual veterans. Mediators that might explain alcohol disparities between heterosexual and sexual minority veterans have not yet been identified. Purpose: To examine the role of civilian and military traumas and mental health symptoms (i.e., depression, post-traumatic stress disorder) in explaining sexual orientation disparities in alcohol misuse between sexual minority and heterosexual women veterans across the U.S. Methods: Women veterans were recruited using Internet methods to participate in an online, anonymous, national survey (N=699, 37% lesbian or bisexual) from February to May 2013. Path analysis was used to examine a model wherein sexual orientation both directly and indirectly predicted alcohol misuse through trauma exposures and mental health symptoms. Data were analyzed in November 2013. Results: Findings indicated significant disparities in alcohol misuse among women veterans by sexual orientation, with indirect effects via childhood trauma, physical victimization in adulthood both during the military and as a civilian, and depressive and post-traumatic stress disorder symptoms. Conclusions: Lesbian and bisexual women veterans reported higher rates of some trauma exposures and mental health symptoms than their heterosexual counterparts, partly accounting for their higher rates of alcohol misuse. Interventions that attend to both victimization and drinking among this population are needed, as well as future research that addresses other factors influencing alcohol misuse. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Lehavot, Keren; Browne, Kendall C.; Simpson, Tracy L.] Univ Washington, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98195 USA. [Simpson, Tracy L.] Univ Washington, Ctr Excellence Substance Abuse Treatment & Educ, Seattle, WA 98195 USA. [Lehavot, Keren; Browne, Kendall C.; Simpson, Tracy L.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Lehavot, Keren; Browne, Kendall C.; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Lehavot, K (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way S-116-POC, Seattle, WA 98108 USA. EM klehavot@uw.edu FU VISN-20 Mental Illness Research, Education, and Clinical Center; VA CSR&D Career Development Award [CX000867]; Advanced Fellowship Program in Mental Illness Research and Treatment FX This research was supported by a research grant to K. Lehavot and T. Simpson from the VISN-20 Mental Illness Research, Education, and Clinical Center. Dr. Lehavot's effort was supported by a VA CSR&D Career Development Award (CX000867). This material is the result of work supported by resources from the U.S. Department of Veterans Affairs Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, and the Veterans Affairs Puget Sound Health Care System, Seattle WA. The views expressed in this article are those of the authors and do not represent the views of the Department of Veterans Affairs or the U.S. government. NR 55 TC 5 Z9 6 U1 3 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2014 VL 47 IS 5 BP 554 EP 562 DI 10.1016/j.amepre.2014.07.002 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AR6DP UT WOS:000343673800003 PM 25241197 ER PT J AU Thomadsen, B Nath, R Bateman, FB Farr, J Glisson, C Islam, MK LaFrance, T Moore, ME Xu, XG Yudelev, M AF Thomadsen, Bruce Nath, Ravinder Bateman, Fred B. Farr, Jonathan Glisson, Cal Islam, Mohammad K. LaFrance, Terry Moore, Mary E. Xu, X. George Yudelev, Mark TI POTENTIAL HAZARD DUE TO INDUCED RADIOACTIVITY SECONDARY TO RADIOTHERAPY: THE REPORT OF TASK GROUP 136 OF THE AMERICAN ASSOCIATION OF PHYSICISTS IN MEDICINE SO HEALTH PHYSICS LA English DT Review DE accelerators, medical; exposure, occupational; radiation risk; radiation therapy ID NEUTRON-THERAPY FACILITY; RADIATION PROTECTION ASPECTS; ENERGY LINEAR-ACCELERATOR; ACTIVATION PRODUCTS; PROTON THERAPY; MULTILEAF COLLIMATOR; STAFF PROTECTION; DOSE-EQUIVALENT; LAYER-STACKING; SAFETY SURVEY AB External-beam radiation therapy mostly uses high-energy photons (x-rays) produced by medical accelerators, but many facilities now use proton beams, and a few use fast-neutron beams. High-energy photons offer several advantages over lower-energy photons in terms of better dose distributions for deep-seated tumors, lower skin dose, less sensitivity to tissue heterogeneities, etc. However, for beams operating at or above 10 MV, some of the materials in the accelerator room and the radiotherapy patient become radioactive due primarily to photonuclear reactions and neutron capture, exposing therapy staff and patients to unwanted radiation dose. Some recent advances in radiotherapy technology require treatments using a higher number of monitor units and monitor-unit rates for the same delivered dose, and compared to the conventional treatment techniques and fractionation schemes, the activation dose to personnel can be substantially higher. Radiotherapy treatments with proton and neutron beams all result in activated materials in the treatment room. In this report, the authors review critically the published literature on radiation exposures from induced radioactivity in radiotherapy. They conclude that the additional exposure to the patient due to induced radioactivity is negligible compared to the overall radiation exposure as a part of the treatment. The additional exposure to the staff due to induced activity from photon beams is small at an estimated level of about 1 to 2 mSv y(-1). This is well below the allowed occupational exposure limits. Therefore, the potential hazard to staff from induced radioactivity in the use of high-energy x-rays is considered to be low, and no specific actions are considered necessary or mandatory. However, in the spirit of the "As Low as Reasonably Achievable (ALARA)" program, some reasonable steps are recommended that can be taken to reduce this small exposure to an even lower level. The dose reduction strategies suggested should be followed only if these actions are considered reasonable and practical in the individual clinics. Therapists working with proton beam and neutron beam units handle treatment devices that do become radioactive, and they should wear extremity monitors and make handling apertures and boluses their last task upon entering the room following treatment. Personnel doses from neutron-beam units can approach regulatory limits depending on the number of patients and beams, and strategies to reduce doses should be followed. C1 [Thomadsen, Bruce] Univ Wisconsin, Dept Med Phys, Madison, WI 53706 USA. [Nath, Ravinder] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA. [Bateman, Fred B.] NIST, Radiat Phys Div, Gaithersburg, MD 20899 USA. [Farr, Jonathan] St Jude Childrens Res Hosp, Dept Radiol Sci, Div Radiat Oncol, Memphis, TN 38105 USA. [Glisson, Cal] Loma Linda Univ, Off Radiat Safety, Loma Linda, CA 92354 USA. [Islam, Mohammad K.] Princess Margaret Hosp, Dept Radiat Phys, Toronto, ON M5G 2M9, Canada. [LaFrance, Terry] Baystate Hlth Syst Inc, Med Phys Radiat Safety Dept, Springfield, MA 01199 USA. [Moore, Mary E.] Philadelphia VA Med Ctr, Radiat Safety Off, Philadelphia, PA 19104 USA. [Xu, X. George] Rensselaer Polytech Inst, Program Nucl Engn & Engn Phys, Troy, NY 12180 USA. [Yudelev, Mark] Ted B Wahby Canc Ctr, Mt Clemens, MI 48043 USA. RP Thomadsen, B (reprint author), Univ Wisconsin, Dept Med Phys, Wisconsin Inst Med Res 1005, 1111 Highland Ave, Madison, WI 53705 USA. EM brthomad@wisc.edu NR 72 TC 3 Z9 3 U1 1 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0017-9078 EI 1538-5159 J9 HEALTH PHYS JI Health Phys. PD NOV PY 2014 VL 107 IS 5 BP 442 EP 460 DI 10.1097/HP.0000000000000139 PG 19 WC Environmental Sciences; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA AR7QF UT WOS:000343773700009 PM 25271934 ER PT J AU Williams, DL Mazefsky, CA Walker, JD Minshew, NJ Goldstein, G AF Williams, Diane L. Mazefsky, Carla A. Walker, Jon D. Minshew, Nancy J. Goldstein, Gerald TI Associations Between Conceptual Reasoning, Problem Solving, and Adaptive Ability in High-functioning Autism SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE Autism; Conceptual reasoning; Problem solving; Adaptive behavior; Cognitive ID DIAGNOSTIC OBSERVATION SCHEDULE; SOCIAL-SKILLS INTERVENTIONS; DEVELOPMENTAL DISORDERS; SPECTRUM DISORDERS; IMPAIRED MEMORY; YOUNG-ADULTS; CHILDREN; INDIVIDUALS; BEHAVIOR; DYSFUNCTION AB The Abstract thinking is generally highly correlated with problem-solving ability which is predictive of better adaptive functioning. Measures of conceptual reasoning, an ecologically-valid laboratory measure of problem-solving, and a report measure of adaptive functioning in the natural environment, were administered to children and adults with and without autism. The individuals with autism had weaker conceptual reasoning ability than individuals with typical development of similar age and cognitive ability. For the autism group, their flexible thinking scores were significantly correlated with laboratory measures of strategy formation and rule shifting and with reported overall adaptive behavior but not socialization scores. Therefore, in autism, flexibility of thought is potentially more important for adaptive functioning in the natural environment than conceptual reasoning or problem-solving. C1 [Williams, Diane L.] Duquesne Univ, Dept Speech Language Pathol, Pittsburgh, PA 15219 USA. [Mazefsky, Carla A.; Minshew, Nancy J.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Walker, Jon D.; Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Minshew, Nancy J.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr, Pittsburgh, PA 15240 USA. EM Ggold@nb.net RI Williams, Diane/B-4128-2017 FU NICHD NIH HHS [HD35469]; NIDCD NIH HHS [K23DC006691] NR 56 TC 4 Z9 4 U1 3 U2 13 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 EI 1573-3432 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD NOV PY 2014 VL 44 IS 11 SI SI BP 2908 EP 2920 DI 10.1007/s10803-014-2190-y PG 13 WC Psychology, Developmental SC Psychology GA AR6XK UT WOS:000343724000022 PM 25099486 ER PT J AU O'Leary, TJ AF O'Leary, Timothy J. TI Reflecting on My Time as Editor-in-Chief SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Editorial Material C1 US Dept Vet Affairs, Washington, DC 20420 USA. RP O'Leary, TJ (reprint author), US Dept Vet Affairs, Washington, DC 20420 USA. NR 3 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2014 VL 16 IS 6 BP 593 EP 594 DI 10.1016/j.jmoldx.2014.09.001 PG 2 WC Pathology SC Pathology GA AR7YZ UT WOS:000343794200001 PM 25307753 ER PT J AU O'Leary, TJ AF O'Leary, Timothy J. TI Regulating Laboratory-Developed Tests SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Editorial Material ID LOCALIZED PROSTATE-CANCER; RETRACTED ARTICLE. SEE; RADICAL PROSTATECTOMY; INTERVENTION; PIVOT C1 US Dept Vet Affairs, Washington, DC 20420 USA. RP O'Leary, TJ (reprint author), US Dept Vet Affairs, Washington, DC 20420 USA. NR 19 TC 0 Z9 1 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2014 VL 16 IS 6 BP 595 EP 598 DI 10.1016/j.jmoldx.2014.09.002 PG 4 WC Pathology SC Pathology GA AR7YZ UT WOS:000343794200002 PM 25307754 ER PT J AU Liu, XH Joshi, SK Ravishankar, B Laron, D Kim, HT Feeley, BT AF Liu, Xuhui Joshi, Sunil K. Ravishankar, Bharat Laron, Dominique Kim, Hubert T. Feeley, Brian T. TI Upregulation of transforming growth factor-beta signaling in a rat model of rotator cuff tears SO JOURNAL OF SHOULDER AND ELBOW SURGERY LA English DT Article DE Massive rotator cuff tear; transforming growth factor-beta; fibrosis ID SUPRASCAPULAR NERVE INJURY; SKELETAL-MUSCLE; FATTY INFILTRATION; MESENCHYMAL TRANSITION; ARTHROSCOPIC REPAIR; INTERVAL SLIDES; SCAR FORMATION; ATROPHY; FIBROSIS; SMAD2 AB Background: Muscle atrophy, fatty infiltration, and fibrosis of the muscle have been described as important factors governing outcome after rotator cuff injury and repair. Muscle fibrosis is also thought to have a role in determining muscle compliance at the time of surgery. The transforming growth factor-beta (TGF-beta) pathways are highly conserved pathways that exert a potent level of control over muscle gene expression and are critical regulators of fibrosis in multiple organ systems. It has been shown that TGF-beta can regulate important pathways of muscle atrophy, including the Akt/mammalian target of rapamycin pathway. The purpose of this study was to evaluate the expression of TGF-beta and its downstream effectors of fibrosis after a massive rotator cuff tear (RCT) in a previously established rat model. Methods: To simulate a massive RCT, infraspinatus and supraspinatus tenotomy and suprascapular nerve transection were performed on Sprague-Dawley rats with use of a validated model. Two and 6 weeks after surgery, supraspinatus muscles were harvested to study alterations in TGF-beta signaling by Western blotting, quantitative polymerase chain reaction, and histologic analysis. Results: There was a significant increase in fibrosis in the rotator cuff muscle after RCT in our animal model. There was a concomitant increase in TGF-beta gene and protein expression at both 2 and 6 weeks after RCT. Evaluation of the TGF-beta signaling pathway revealed an increase in SMAD2 activation but not in SMAD3. There was an increase in profibrotic markers collagen I, collagen III, and alpha-smooth muscle actin. Conclusions: TGF-beta signaling is significantly upregulated in rat supraspinatus muscles after RCTs. (C) 2014 Journal of Shoulder and Elbow Surgery Board of Trustees. C1 [Liu, Xuhui; Joshi, Sunil K.; Ravishankar, Bharat; Kim, Hubert T.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. [Liu, Xuhui; Joshi, Sunil K.; Ravishankar, Bharat; Laron, Dominique; Kim, Hubert T.; Feeley, Brian T.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94158 USA. RP Feeley, BT (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, 1500 Owens Ave,Box 3004, San Francisco, CA 94158 USA. EM feeleyb@orthosurg.ucsf.edu FU Orthopaedic Research and Education Foundation; National Institutes of Health [NIH R03AR060871] FX Funding was provided by a grant from the Orthopaedic Research and Education Foundation (Young Investigator Grant) and the National Institutes of Health (NIH R03AR060871). NR 34 TC 3 Z9 3 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1058-2746 J9 J SHOULDER ELB SURG JI J. Shoulder Elbow Surg. PD NOV PY 2014 VL 23 IS 11 BP 1709 EP 1716 DI 10.1016/j.jse.2014.02.029 PG 8 WC Orthopedics; Sport Sciences; Surgery SC Orthopedics; Sport Sciences; Surgery GA AR8DF UT WOS:000343805000021 PM 24875732 ER PT J AU Walker, KL Kirillova, O Gillespie, SE Hsiao, D Pishchalenko, V Pai, AK Puro, JE Plumley, R Kudyakov, R Hu, WM Allisany, A McBurnie, M Kurtz, SE Hazlehurst, BL AF Walker, Kari L. Kirillova, Olga Gillespie, Suzanne E. Hsiao, David Pishchalenko, Valentyna Pai, Akshatha Kalsanka Puro, Jon E. Plumley, Robert Kudyakov, Rustam Hu, Weiming Allisany, Art McBurnie, MaryAnn Kurtz, Stephen E. Hazlehurst, Brian L. TI Using the CER Hub to ensure data quality in a multi-institution smoking cessation study SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID CLINICAL-RESEARCH; INFORMATICS; RECORDS AB Comparative effectiveness research (CER) studies involving multiple institutions with diverse electronic health records (EHRs) depend on high quality data. To ensure uniformity of data derived from different EHR systems and implementations, the CER Hub informatics platform developed a quality assurance (QA) process using tools and data formats available through the CER Hub. The QA process, implemented here in a study of smoking cessation services in primary care, used the `emrAdapter' tool programmed with a set of quality checks to query large samples of primary care encounter records extracted in accord with the CER Hub common data framework. The tool, deployed to each study site, generated error reports indicating data problems to be fixed locally and aggregate data sharable with the central site for quality review. Across the CER Hub network of six health systems, data completeness and correctness issues were prevalent in the first iteration and were considerably improved after three iterations of the QA process. A common issue encountered was incomplete mapping of local EHR data values to those defined by the common data framework. A highly automated and distributed QA process helped to ensure the correctness and completeness of patient care data extracted from EHRs for a multi-institution CER study in smoking cessation. C1 [Walker, Kari L.; Kirillova, Olga; Gillespie, Suzanne E.; Hu, Weiming; Allisany, Art; McBurnie, MaryAnn; Hazlehurst, Brian L.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR 97227 USA. [Hsiao, David; Pishchalenko, Valentyna] Kaiser Permanente Hawaii, Ctr Hlth Res, Honolulu, HI USA. [Pai, Akshatha Kalsanka] Emory Univ, Atlanta, GA 30322 USA. [Puro, Jon E.] OCHIN Inc, Portland, OR USA. [Plumley, Robert] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Kudyakov, Rustam] Baylor Hlth Care Syst, Ctr Clin Innovat, Dallas, TX USA. [Kurtz, Stephen E.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Hazlehurst, BL (reprint author), Kaiser Permanente Northwest, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA. EM Brian.hazlehurst@kpchr.org FU Agency for Health Care Research and Quality (AHRQ), US Department of Health and Human Services [R01HS019828] FX This research, and the CER Hub project (http://www.cerhub.org), is funded by grant R01HS019828 (Hazlehurst, PI) from the Agency for Health Care Research and Quality (AHRQ), US Department of Health and Human Services. NR 21 TC 2 Z9 2 U1 3 U2 4 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1067-5027 EI 1527-974X J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD NOV PY 2014 VL 21 IS 6 BP 1129 EP 1135 DI 10.1136/amiajnl-2013-002629 PG 7 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA AR7RJ UT WOS:000343776700029 PM 24993545 ER PT J AU Wander, PL Fahrenbruch, CE Rea, TD AF Wander, P. L. Fahrenbruch, C. E. Rea, T. D. TI The dispatcher assisted resuscitation trial: Indirect benefits of emergency research SO RESUSCITATION LA English DT Article DE Cardiac arrest; Waiver of consent; Ethics; Hawthorne effect; Epidemiology ID HOSPITAL CARDIAC-ARREST; ASSOCIATION; SURVIVAL AB Objective: Conduct of emergency research under waiver of consent produces special challenges. Moreover, the act of performing research may have unintended effects, potentially beneficial or detrimental. The Dispatcher-Assisted Randomized Trial (DART) was designed to compare 2 types of dispatcher cardiopulmonary (CPR) instruction, but not intended to affect the proportion of arrest victims that received bystander CPR. We sought to determine whether odds of receiving bystander CPR were higher during DART than during the periods before and after. Methods: We conducted an observational cohort study of 8626 adults who suffered non-traumatic out-of-hospital cardiac arrest prior to emergency medical services (EMS) arrival in greater King County, Washington, between January 1, 1999, and December 31, 2011. Bystander CPR status was assessed through review of dispatch recordings and EMS reports to classify any bystander CPR (any B-CPR), and further categorized as bystander CPR with or without dispatcher assistance (DA-CPR and B-CPR, no DA). We used multivariable logistic regression to evaluate odds of B-CPR before, during, and after DART. Results: The proportions receiving any B- CPR were 52% before DART (1817/3468), 59% during DART (2093/3527), and 54% after DART (885/1631). Compared to the period before DART, odds of receiving any B- CPR were higher during DART (OR = 1.35, 95% CI = 1.23-1.49), but no different after (OR = 1.10, 0.98-1.24). Compared to the before period, odds of DA-CPR were higher during DART (OR = 1.79, 1.59-2.02) but no different after (OR = 0.94, 0.80-1.10). Conclusions: Odds of bystander CPR were higher during the trial, an increase related to higher likelihood of DA-CPR. The finding suggests a possible indirect community-wide benefit due to the interventional trial. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 [Wander, P. L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Wander, P. L.; Rea, T. D.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Fahrenbruch, C. E.; Rea, T. D.] Publ Hlth Seattle & King Cty, Emergency Med Serv Div, Seattle, WA USA. [Wander, P. L.] VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA 98108 USA. RP Wander, PL (reprint author), Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. EM lwander@u.washington.edu OI Wander, Pandora/0000-0003-3671-1464 FU NHLBI NIH HHS [T32 HL007902] NR 16 TC 1 Z9 1 U1 2 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0300-9572 J9 RESUSCITATION JI Resuscitation PD NOV PY 2014 VL 85 IS 11 BP 1594 EP 1598 DI 10.1016/j.resuscitation.2014.08.026 PG 5 WC Critical Care Medicine; Emergency Medicine SC General & Internal Medicine; Emergency Medicine GA AR8LQ UT WOS:000343827100035 PM 25195982 ER PT J AU Quiroga, MJ Carroll, DW Brown, TM AF Quiroga, Martha J. Carroll, David W. Brown, Thomas M. TI Ascorbate- and Zinc-Responsive Parkinsonism SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE vitamins; psychiatry; Parkinson disease; nutrition; central nervous system ID CENTRAL-NERVOUS-SYSTEM; VITAMIN-C; MATRIX METALLOPROTEINASES; HEMODIALYSIS-PATIENTS; DISEASE; SCURVY; ACID; DEFICIENCY; EXCRETION; REQUIREMENTS AB Objective: To report a case of Parkinsonisnn rapidly responsive to intravenous replacement of vitamin C and zinc. Case Summary: A 66-year-old man with Parkinsonisnn, pleural effusion, and bipolar disorder was found to have low serum vitamin C and zinc levels. Intravenous replacement of these micronutrients led to resolution of the movement disorder in less than 24 hours. Discussion: Parkinsonism has been associated with vitamin C deficiency, and recent cases of scurvy complicated by Parkinsonisnn have responded well to intravenous replacement of vitamin C. In this case, deficiency of zinc may have contributed to the development of a movement disorder. The likely pathophysiology of, and treatment recommendations for, Parkinsonism linked to deficiencies of vitamin C and zinc are reviewed. Conclusions: Whereas vitamin C has a strong link with Parkinsonism, the potential role of zinc has only been suspected. This case report highlights some of the potential links between zinc deficiency and Parkinsonism. C1 [Quiroga, Martha J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. [Carroll, David W.; Brown, Thomas M.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78229 USA. RP Brown, TM (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM thomas.brown5@va.gov NR 43 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1060-0280 EI 1542-6270 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD NOV PY 2014 VL 48 IS 11 BP 1515 EP 1520 DI 10.1177/1060028014545356 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AR1PE UT WOS:000343356300015 PM 25070397 ER PT J AU Baker, JF Ostergaard, M George, M Shults, J Emery, P Baker, DG Conaghan, PG AF Baker, Joshua F. Ostergaard, Mikkel George, Michael Shults, Justine Emery, Paul Baker, Daniel G. Conaghan, Philip G. TI Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1-2 years SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID ACTIVE RHEUMATOID-ARTHRITIS; NECROSIS-FACTOR-ALPHA; METHOTREXATE THERAPY; DISEASE-ACTIVITY; JOINT DAMAGE; GO-FORWARD; DOUBLE-BLIND; PHASE-III; GOLIMUMAB; ASSOCIATION AB Introduction Greater body mass index (BMI) has been associated with less radiographic progression in rheumatoid arthritis (RA). We evaluated the association between BMI and joint damage progression as measured by X-ray and MRI. Methods 1068 subjects with RA from two clinical trials of golimumab (GO-BEFORE and GO-FORWARD) had radiographs performed at weeks 0, 52 and 104 and evaluated using the van der Heijde-Sharp (vdHS) scoring system. Contrast-enhanced MRIs of the dominant wrist and hand were obtained at weeks 0, 12, 24, 52 and 104. Multivariable logistic regression evaluated the risk of radiographic progression for each BMI category (<25, 25-30, >30 kg/m(2)). Within GO-BEFORE, piecewise, robust generalised estimating equations marginal models assessed the probability of MRI erosion progression for each BMI category. Multivariable linear regression models assessed baseline associations between BMI and bone oedema (a precursor of bone erosion). Results Higher BMI category was associated with a lower probability of progression in vdHS score at weeks 52 and 104 independent of potential confounders. Higher BMI was also independently associated with a lower probability of progression in MRI erosion score over 2 years. Subjects with greater BMI demonstrated less bone oedema independent of differences in other disease severity measures, including MRI synovitis in the same joints. Conclusions Greater BMI is associated with a lower risk of progression on X-ray and MRI over 2 years. Subjects with greater BMI also demonstrate less bone oedema at baseline. Greater BMI may indicate a less aggressive RA phenotype and aid in risk stratification. C1 [Baker, Joshua F.] Philadelphia Vet Affairs Med Ctr, Div Rheumatol, Philadelphia, PA USA. [Baker, Joshua F.; George, Michael] Univ Penn, Sch Med, Div Rheumatol, Philadelphia, PA 19104 USA. [Baker, Joshua F.; Shults, Justine] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Ostergaard, Mikkel] Glostrup Cty Hosp, Copenhagen Ctr Arthrit Res, Ctr Rheumatol & Spine Dis, Copenhagen, Denmark. [Ostergaard, Mikkel] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark. [Emery, Paul; Conaghan, Philip G.] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England. [Emery, Paul; Conaghan, Philip G.] Chapel Allerton Hosp, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England. [Baker, Daniel G.] Janssen Res & Dev LLC, Spring House, PA USA. RP Baker, JF (reprint author), Hosp Univ Penn, Div Rheumatol, Dept Med, 8 Penn Tower Bldg,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM bakerjo@uphs.upenn.edu FU Veterans Affairs Clinical Science Research and Development Career Development Award; Arthritis Research UK FX JFB is supported by a Veterans Affairs Clinical Science Research and Development Career Development Award. PGC is funded in part by a grant from Arthritis Research UK. This ancillary study did not receive additional funding. NR 23 TC 23 Z9 23 U1 0 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD NOV PY 2014 VL 73 IS 11 BP 1923 EP 1928 DI 10.1136/annrheumdis-2014-205544 PG 6 WC Rheumatology SC Rheumatology GA AR0ZR UT WOS:000343308200012 PM 25091439 ER PT J AU Baddley, JW Winthrop, KL Chen, L Liu, LY Grijalva, CG Delzell, E Beukelman, T Patkar, NM Xie, FL Saag, KG Herrinton, LJ Solomon, DH Lewis, JD Curtis, JR AF Baddley, John W. Winthrop, Kevin L. Chen, Lang Liu, Liyan Grijalva, Carlos G. Delzell, Elizabeth Beukelman, Timothy Patkar, Nivedita M. Xie, Fenglong Saag, Kenneth G. Herrinton, Lisa J. Solomon, Daniel H. Lewis, James D. Curtis, Jeffrey R. TI Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID SERIOUS BACTERIAL-INFECTIONS; FACTOR-ALPHA ANTAGONISTS; RHEUMATOID-ARTHRITIS; GRANULOMATOUS INFECTIONS; PNEUMOCYSTIS PNEUMONIA; MYCOBACTERIAL DISEASES; ANTIBODY THERAPY; BRITISH-SOCIETY; RISK-FACTORS; INFLIXIMAB AB Objectives To determine among patients with autoimmune diseases in the USA whether the risk of non-viral opportunistic infections (OI) was increased among new users of tumour necrosis factor a inhibitors (TNFI), when compared to users of non-biological agents used for active disease. Methods We identified new users of TNFI among cohorts of rheumatoid arthritis (RA), inflammatory bowel disease and psoriasis-psoriatic arthritis-ankylosing spondylitis patients during 1998-2007 using combined data from Kaiser Permanente Northern California, two pharmaceutical assistance programmes for the elderly, Tennessee Medicaid and US Medicaid/Medicare programmes. We compared incidence of non-viral OI among new TNFI users and patients initiating nonbiological disease-modifying antirheumatic drugs (DMARD) overall and within each disease cohort. Cox regression models were used to compare propensity-score and steroid-adjusted OI incidence between new TNFI and non-biological DMARD users. Results Within a cohort of 33 324 new TNFI users we identified 80 non-viral OI, the most common of which was pneumocystosis (n=16). In the combined cohort, crude rates of non-viral OI among new users of TNFI compared to those initiating non-biological DMARD was 2.7 versus 1.7 per 1000-person-years (aHR 1.6, 95% CI 1.0 to 2.6). Baseline corticosteroid use was associated with non-viral OI (aHR 2.5, 95% CI 1.5 to 4.0). In the RA cohort, rates of non-viral OI among new users of infliximab were higher when compared to patients newly starting non-biological DMARD (aHR 2.6, 95% CI 1.2 to 5.6) or new etanercept users (aHR 2.9, 95% CI 1.5 to 5.4). Conclusions In the USA, the rate of non-viral OI was higher among new users of TNFI with autoimmune diseases compared to non-biological DMARD users. C1 [Baddley, John W.; Chen, Lang; Delzell, Elizabeth; Beukelman, Timothy; Patkar, Nivedita M.; Xie, Fenglong; Saag, Kenneth G.; Curtis, Jeffrey R.] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Baddley, John W.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Winthrop, Kevin L.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Liu, Liyan; Herrinton, Lisa J.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Grijalva, Carlos G.] Vanderbilt Univ, Dept Med, Nashville, TN USA. [Solomon, Daniel H.] Harvard Univ, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Lewis, James D.] Univ Penn, Perlman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Baddley, JW (reprint author), Univ Alabama Birmingham, Dept Med, Div Infect Dis, 1900 Univ Blvd,229 Tinsley Harrison Tower, Birmingham, AL 35294 USA. EM jbaddley@uab.edu FU US Food and Drug Administration (FDA); US Department of Health and Human Services (DHHS); Agency for Healthcare Research and Quality [U18 HS17919]; Agency for Healthcare Research and Quality (AHRQ) [1K08HS017552-01]; National Institutes of Health [AR053351]; AHRQ [R01HS018517]; NIH via the University of Alabama at Birmingham Center for Clinical and Translational Science [5KL2 RR025776-03]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [5P60AR56116] FX This work was supported by the US Food and Drug Administration (FDA), US Department of Health and Human Services (DHHS) and the Agency for Healthcare Research and Quality, grant U18 HS17919. KLW's work on this manuscript was funded by an Agency for Healthcare Research and Quality (AHRQ) grant (1K08HS017552-01). JRC receives support from the National Institutes of Health (AR053351) and AHRQ (R01HS018517). TB was supported by NIH grant 5KL2 RR025776-03 via the University of Alabama at Birmingham Center for Clinical and Translational Science. CGG received support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, grant 5P60AR56116. The authors are indebted to the Tennessee Bureau of TennCare of the Department of Finance and Administration, which provided the Tennessee Medicare data. NR 34 TC 25 Z9 25 U1 2 U2 8 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD NOV PY 2014 VL 73 IS 11 BP 1942 EP 1948 DI 10.1136/annrheumdis-2013-203407 PG 7 WC Rheumatology SC Rheumatology GA AR0ZR UT WOS:000343308200015 PM 23852763 ER PT J AU Kemmerly, T Kaunitz, JD AF Kemmerly, Thomas Kaunitz, Jonathan D. TI Gastroduodenal mucosal defense SO CURRENT OPINION IN GASTROENTEROLOGY LA English DT Review DE autophagy; gastrointestinal defense; innate immune system; mucins; toll-like receptors ID OXIDATIVE STRESS; EPITHELIAL-CELLS; DENDRITIC CELLS; EXPRESSION; ACID; MICE; HOMEOSTASIS; DYSFUNCTION; INFECTION; P38-ALPHA AB Purpose of review To review recent developments in the field of gastroduodenal mucosal defense. Recent findings Research in the field of gastroduodenal mucosal defense has focused on continued elucidation of molecular mechanisms that protect the mucosa and influence healing at the cellular level. Review of literature over the past year reveals that familiar proteins and mediators, such as nitric oxide, toll-like receptors, nucleotide-binding oligomerization domain-containing proteins (NOD2), beta-defensins, macrophages, dendritic cells, mucins, autophagy, and the influence of aging and diet, are still subjects of study, but also brings into light new processes and mediators, such as dual oxidases, defense against radiation injuries, and novel proteins such as ZBP-89. Summary These new published findings contribute to our overall understanding of gastroduodenal defense and suggest innovative avenues of future research and possible novel therapeutic targets. C1 [Kemmerly, Thomas] Cedars Sinai Med Residency Program, Los Angeles, CA USA. [Kaunitz, Jonathan D.] Greater Los Angeles Vet Affairs Healthcare Syst, WLAVA Med Ctr, Los Angeles, CA USA. [Kaunitz, Jonathan D.] UCLA Sch Med, Dept Med, Los Angeles, CA USA. [Kaunitz, Jonathan D.] UCLA Sch Med, Dept Surg, Los Angeles, CA USA. [Kaunitz, Jonathan D.] CURE Digest Dis Res Ctr, Dept Med, Los Angeles, CA USA. [Kaunitz, Jonathan D.] Brentwood Biomed Res Inst, Los Angeles, CA USA. RP Kaunitz, JD (reprint author), West Los Angeles VAMC, Bldg 114,Room 217E, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU NIH/NIDDK; DVA; Boehringer-Ingelheim Pharmaceuticals GmbH FX Grant Support: NIH/NIDDK, DVA, and Boehringer-Ingelheim Pharmaceuticals GmbH. NR 33 TC 3 Z9 3 U1 0 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0267-1379 EI 1531-7056 J9 CURR OPIN GASTROEN JI Curr. Opin. Gastroenterol. PD NOV PY 2014 VL 30 IS 6 BP 583 EP 588 DI 10.1097/MOG.0000000000000124 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AR5NZ UT WOS:000343632400010 PM 25229259 ER PT J AU Villasana, LE Westbrook, GL Schnell, E AF Villasana, L. E. Westbrook, G. L. Schnell, E. TI Neurologic impairment following closed head injury predicts post-traumatic neurogenesis SO EXPERIMENTAL NEUROLOGY LA English DT Article DE Closed head injury; Traumatic brain injury; Adult neurogenesis; Hippocampus; Neurologic severity score ID TRAUMATIC BRAIN-INJURY; ADULT HIPPOCAMPAL NEUROGENESIS; GLASGOW COMA SCALE; DENTATE GYRUS; GRANULE CELLS; NEURONAL DIFFERENTIATION; ABERRANT NEUROGENESIS; COGNITIVE RECOVERY; RATS; PROLIFERATION AB In the mammalian hippocampus, neurogenesis persists into adulthood, and increased generation of newborn neurons could be of clinical benefit following concussive head injuries. Post-traumatic neurogenesis has been well documented using "open" traumatic brain injury (TBI) models in rodents: however, human TBI most commonly involves closed head injury. Here we used a closed head injury (CHI) model to examine post-traumatic hippocampal neurogenesis in mice. All mice were subjected to the same CHI protocol, and a gross-motor based injury severity score was used to characterize neurologic impairment 1 h after the injury. When analyzed 2 weeks later, post-traumatic neurogenesis was significantly increased only in mice with a high degree of transient neurologic impairment immediately after injury. This increase was associated with an early increase in c-fos activity, and subsequent reactive astrocytosis and microglial activation in the dentate gyrus. Our results demonstrate that the initial degree of neurologic impairment after closed head injury predicts the induction of secondary physiologic and pathophysiologic processes, and that animals with severe neurologic impairment early after injury manifest an increase in post-traumatic neurogenesis in the absence of gross anatomic pathology. Published by Elsevier Inc. C1 [Villasana, L. E.; Schnell, E.] OHSU, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA. [Westbrook, G. L.] OHSU, Vollum Inst, Portland, OR 97239 USA. [Schnell, E.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Schnell, E (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,P3ANES, Portland, OR 97239 USA. EM schneler@ohsu.edu FU Department of Veteran's Affairs Career Development Award (CDA-2); National Institute of General Medical Sciences [T32-GM082770]; National Institute of Mental Health [R01-MH046613]; National Institutes of Health for the OHSU Imaging Center [P30-NS061800] FX We would like to thank Nee lay Pandit for constructing the closed-head weight drop device and for assistance generating pilot data for this study, and to Dr. Stefanie Kaech-Petrie for assistance with imaging. Funding for the present work was provided by a Department of Veteran's Affairs Career Development Award (CDA-2) to Dr. Schnell, a National Institute of General Medical Sciences T32-GM082770 to Dr. Villasana, a National Institute of Mental Health R01-MH046613 to Dr. Westbrook, and a National Institutes of Health P30-NS061800 for the OHSU Imaging Center. NR 50 TC 2 Z9 2 U1 1 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 EI 1090-2430 J9 EXP NEUROL JI Exp. Neurol. PD NOV PY 2014 VL 261 BP 156 EP 162 DI 10.1016/j.expneurol.2014.05.016 PG 7 WC Neurosciences SC Neurosciences & Neurology GA AR4AX UT WOS:000343531500016 PM 24861442 ER PT J AU Zamani, P Jacobs, DR Segers, P Duprez, DA Brumback, L Kronmal, RA Lilly, SM Townsend, RR Budoff, M Lima, JA Hannan, P Chirinos, JA AF Zamani, Payman Jacobs, David R., Jr. Segers, Patrick Duprez, Daniel A. Brumback, Lyndia Kronmal, Richard A. Lilly, Scott M. Townsend, Raymond R. Budoff, Matthew Lima, Joao A. Hannan, Peter Chirinos, Julio A. TI Reflection Magnitude as a Predictor of Mortality The Multi-Ethnic Study of Atherosclerosis SO HYPERTENSION LA English DT Article DE arteries; atherosclerosis; mortality ID INCIDENT CARDIOVASCULAR EVENTS; LEFT-VENTRICULAR MASS; ANKLE-BRACHIAL INDEX; PRESSURE WAVE-FORM; ARTERIAL STIFFNESS; LOADING SEQUENCE; SYSTOLIC PRESSURE; RELAXATION; MESA; DISEASE AB Arterial wave reflections have been associated with mortality in an ethnically homogenous Asian population. It is unknown whether this association is present in a multiethnic population or whether it is independent of subclinical atherosclerosis. We hypothesized that reflection magnitude (defined as the ratio of the amplitude of the backward wave [P-b] to that of the forward wave [P-f]) is associated with all-cause mortality in a large multiethnic adult community-based sample. We studied 5984 participants enrolled in the Multi-Ethnic Study of Atherosclerosis who had analyzable arterial tonometry waveforms. During 9.8 +/- 1.7 years of follow-up, 617 deaths occurred, of which 134 (22%) were adjudicated cardiovascular deaths. In Cox proportional hazards models, each 10% increase in reflection magnitude was associated with a 31% increased risk for all-cause mortality (hazard ratio [HR]=1.31; 95% confidence interval [CI]=1.11-1.55; P=0.001). This relationship persisted after adjustment for various confounders and for markers of subclinical atherosclerosis (HR=1.23; 95% CI=1.01-1.51; P=0.04), including the coronary calcium score, ankle-brachial index, common carotid intima-media thickness, and ascending thoracic aortic Agatston score. P-b was independently associated with all-cause mortality in a similarly adjusted model (HR per 10 mm Hg increase in P-b =2.18; 95% CI=1.21-3.92; P=0.009). Reflection magnitude (HR=1.71; 95% CI=1.06-2.77; P=0.03) and P-b (HR=5.02; 95% CI=1.29-19.42; P=0.02) were mainly associated with cardiovascular mortality. In conclusion, reflection magnitude is independently associated with all-cause mortality in a multiethnic population initially free of clinically evident cardiovascular disease. This relationship persists after adjustment for a comprehensive set of markers of subclinical atherosclerosis. C1 [Zamani, Payman; Chirinos, Julio A.] Hosp Univ Penn, Div Cardiovasc Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Zamani, Payman; Chirinos, Julio A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Jacobs, David R., Jr.; Hannan, Peter] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Duprez, Daniel A.] Univ Minnesota, Sch Med, Div Cardiol, Minneapolis, MN 55455 USA. [Segers, Patrick] Univ Ghent, IBiTech, iMinds Future Hlth Dept, B-9000 Ghent, Belgium. [Brumback, Lyndia; Kronmal, Richard A.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. [Lilly, Scott M.] Ohio State Univ, Div Cardiovasc Med, Heart & Vasc Ctr, Columbus, OH 43210 USA. [Townsend, Raymond R.] Univ Penn, Div Nephrol Hypertens, Perelman Sch Med, Philadelphia, PA 19104 USA. [Budoff, Matthew] Los Angeles Biomed Res Inst, Torrance, CA USA. [Lima, Joao A.] Johns Hopkins Univ Hosp, Div Cardiol, Baltimore, MD 21287 USA. RP Zamani, P (reprint author), Hosp Univ Penn, Div Cardiovasc Med, 3400 Spruce St,8 Gates, Philadelphia, PA 19104 USA. EM pzamani@upenn.edu RI Lilly, Scott/K-3620-2013 OI Lilly, Scott/0000-0002-2597-6806 FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95169]; National Institutes of Aging grant [1R21AG0411802-01]; Institute for Translational Medicine and Therapeutics of the University of Pennsylvania from the National Center for Research Resources [UL1RR024134]; [RR-024156]; [5-T32-HL007843-17] FX This research as supported by contracts N01-HC-95159 through N01-HC-95169 from the National Heart, Lung, and Blood Institute and RR-024156, as well as National Institutes of Aging grant 1R21AG0411802-01 (J.A.C.). Dr Zamani is supported, in part, by the Institute for Translational Medicine and Therapeutics of the University of Pennsylvania (grant number UL1RR024134 from the National Center for Research Resources) and by 5-T32-HL007843-17. NR 30 TC 18 Z9 18 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X EI 1524-4563 J9 HYPERTENSION JI Hypertension PD NOV PY 2014 VL 64 IS 5 BP 958 EP + DI 10.1161/HYPERTENSIONAHA.114.03855 PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AR4ZB UT WOS:000343593700013 PM 25259746 ER PT J AU Chirinos, JA Rietzschel, ER Shiva-Kumar, P De Buyzere, ML Zamani, P Claessens, T Geraci, S Konda, P De Bacquer, D Akers, SR Gillebert, TC Segers, P AF Chirinos, Julio A. Rietzschel, Ernst R. Shiva-Kumar, Prithvi De Buyzere, Marc L. Zamani, Payman Claessens, Tom Geraci, Salvatore Konda, Prasad De Bacquer, Dirk Akers, Scott R. Gillebert, Thierry C. Segers, Patrick TI Effective Arterial Elastance Is Insensitive to Pulsatile Arterial Load SO HYPERTENSION LA English DT Article DE arterial load; characteristic impedance; effective arterial elastance; total arterial compliance; ventricular-arterial coupling; wave reflections ID PRESERVED EJECTION FRACTION; VARYING MYOCARDIAL STRESS; LEFT-VENTRICULAR MASS; PULSE-WAVE VELOCITY; HEART-FAILURE; SYSTOLIC PRESSURE; NONINVASIVE EVALUATION; DIASTOLIC FUNCTION; CONVERTING-ENZYME; AORTIC STIFFNESS AB Effective arterial elastance (E-A) was proposed as a lumped parameter that incorporates pulsatile and resistive afterload and is increasingly being used in clinical studies. Theoretical modeling studies suggest that E-A is minimally affected by pulsatile load, but little human data are available. We assessed the relationship between E-A and arterial load determined noninvasively from central pressure-flow analyses among middle-aged adults in the general population (n=2367) and a diverse clinical population of older adults (n=193). In a separate study, we investigated the sensitivity of E-A to changes in pulsatile load induced by isometric exercise (n=73). The combination of systemic vascular resistance and heart rate predicted 95.6% and 97.8% of the variability in E-A among middle-aged and older adults, respectively. E-A demonstrated a quasi-perfect linear relationship with the ratio of systemic vascular resistance/heart period (middle-aged adults, R=0.972; older adults, R=0.99; P<0.0001). Aortic characteristic impedance, total arterial compliance, reflection magnitude, and timing accounted together for <1% of the variability in E-A in either middle-aged or older adults. Despite pronounced changes in pulsatile load induced by isometric exercise, changes in E-A were not independently associated with changes pulsatile load but were rather a nearly perfect linear function of the ratio of systemic vascular resistance/heart period (R=0.99; P<0.0001). Our findings demonstrate that E-A is simply a function of systemic vascular resistance and heart rate and is negligibly influenced by (and insensitive to) changes in pulsatile afterload in humans. Its current interpretation as a lumped parameter of pulsatile and resistive afterload should thus be reassessed. C1 [Chirinos, Julio A.; Zamani, Payman] Perelman Sch Med, Dept Med, Philadelphia, PA USA. [Chirinos, Julio A.; Zamani, Payman] Hosp Univ Penn, Philadelphia, PA 19104 USA. [Chirinos, Julio A.; Shiva-Kumar, Prithvi; Geraci, Salvatore; Akers, Scott R.] Philadelphia VA Med Ctr, Dept Med, Philadelphia, PA USA. [Rietzschel, Ernst R.; De Buyzere, Marc L.; De Bacquer, Dirk] Ghent Univ Hosp, Dept Cardiovasc Dis, Ghent, Belgium. [Rietzschel, Ernst R.] Univ Ghent, Dept Publ Hlth, B-9000 Ghent, Belgium. [Claessens, Tom] Univ Ghent, Dept Ind Technol & Construct, B-9000 Ghent, Belgium. [Claessens, Tom; Segers, Patrick] Univ Ghent, Inst Biomed Technol, iMinds Future Hlth Dept, B-9000 Ghent, Belgium. RP Chirinos, JA (reprint author), Univ Penn, Philadelphia VA Med Ctr, Dept Med, 3800 Woodland Ave,Rm 8B111, Philadelphia, PA 19104 USA. EM Julio.chirinos@uphs.upenn.edu OI Gillebert, Thierry/0000-0002-3832-919X FU Fonds voor Wetenschappelijk Onderzoek Viaanderen research grants [G.0427.03, FWO G.0838.10]; [1R21AG043802-01] FX This research was funded by Fonds voor Wetenschappelijk Onderzoek Viaanderen research grants G.0427.03 and FWO G.0838.10 (for the Asklepios Study) and 1R21AG043802-01 (J.A. Chirinos) NR 47 TC 10 Z9 11 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0194-911X EI 1524-4563 J9 HYPERTENSION JI Hypertension PD NOV PY 2014 VL 64 IS 5 BP 1022 EP + DI 10.1161/HYPERTENSIONAHA.114.03696 PG 18 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AR4ZB UT WOS:000343593700020 PM 25069668 ER PT J AU Parker-Autry, CY Gleason, JL Griffin, RL Markland, AD Richter, HE AF Parker-Autry, Candace Y. Gleason, Jonathan L. Griffin, Russell L. Markland, Alayne D. Richter, Holly E. TI Vitamin D deficiency is associated with increased fecal incontinence symptoms SO INTERNATIONAL UROGYNECOLOGY JOURNAL LA English DT Article DE Vitamin D; Pelvic floor; Fecal incontinence ID RANDOMIZED CONTROLLED-TRIAL; PELVIC FLOOR DISORDERS; CALCIUM SUPPLEMENTATION; MUSCLE-TISSUE; HEALTH; WOMEN; PREVALENCE; RECEPTOR; OUTCOMES; ADULTS AB Introduction and hypothesis Vitamin D is an important micronutrient in muscle function. We hypothesize that vitamin D deficiency may contribute to fecal incontinence (FI) symptoms by affecting the anal continence mechanism. Our goal was to characterize the association of vitamin D deficiency as a variable affecting FI symptoms and its impact on health-related quality of life (HR-QoL). Methods This case-control study assessed women seen at a tertiary-care referral center. Participants were identified as having had a serum vitamin D level obtained within a year of their visit: cases were women presenting for care for FI symptoms; controls were women without any pelvic floor symptoms presenting to the same clinical site for general gynecologic care. Cases completed the Modified Manchester Health Questionnaire (MMHQ) and the Fecal Incontinence Severity Index to measure symptom severity and burden on QoL. Results Among the 31 cases and 81 controls, no demographic or medical differences existed. Women with FI had lower vitamin D levels (mean 29.2 +/- 12.3 cases vs. 35 +/- 14.1 ng/ml controls p=0.04). The odds of vitamin D deficiency were higher in women with FI compared with controls [odds ratio (OR) 2.77, 95 % confidence interval (CI) 1.08-7.09]. Among cases, women with vitamin D deficiency (35 %) had higher MMHQ scores, indicating greater FI symptom burden [51.3 +/- 29.3 (vitamin D deficient) vs. 30 +/- 19.5 (vitamin D sufficiency), p=0.02]. No differences were noted for FI severity, p=0.07. Conclusions Vitamin D deficiency is prevalent in women with fecal incontinence and may contribute to patient symptom burden. C1 [Parker-Autry, Candace Y.] Wake Forest Univ, Bowman Gray Sch Med, Dept Obstet & Gynecol, Winston Salem, NC 27103 USA. [Gleason, Jonathan L.] Caril Clin, Div Female Pelv Med & Reconstruct Surg, Dept Obstet & Gynecol, Roanoke, VA USA. [Griffin, Russell L.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA. [Markland, Alayne D.] Univ Alabama Birmingham, Dept Vet Affairs, Div Gerontol Geriatr & Palliat Care, Birmingham VA Med Ctr,Dept Med, Birmingham, AL USA. [Richter, Holly E.] Univ Alabama Birmingham, Dept Obstet & Gynecol, Div Urogynecol & Pelv Reconstruct Surg, Birmingham, AL 35294 USA. RP Parker-Autry, CY (reprint author), 4th Floor Watlington Hall,Med Ctr Blvd, Winston Salem, NC 27157 USA. EM cparkera@wakehealth.edu OI Markland, Alayne/0000-0002-6567-6744 FU National Center for Advancing Translational Research of the National Institutes of Health [UL1TR00165]; National Institute of Diabetes and Digestive and Kidney Diseases [2K24-DK068389] FX Research reported in this publication was supported by the National Center for Advancing Translational Research of the National Institutes of Health under award number UL1TR00165 and by National Institute of Diabetes and Digestive and Kidney Diseases 2K24-DK068389 to Holly E. Richter, PhD, MD. NR 26 TC 1 Z9 1 U1 1 U2 5 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-3462 EI 1433-3023 J9 INT UROGYNECOL J JI Int. Urogynecol. J. PD NOV PY 2014 VL 25 IS 11 BP 1483 EP 1489 DI 10.1007/s00192-014-2389-7 PG 7 WC Obstetrics & Gynecology; Urology & Nephrology SC Obstetrics & Gynecology; Urology & Nephrology GA AR5XQ UT WOS:000343655000006 PM 24807423 ER PT J AU Nielson, JL Guandique, CF Liu, AW Burke, DA Lash, AT Moseanko, R Hawbecker, S Strand, SC Zdunowski, S Irvine, KA Brock, JH Nout-Lomas, YS Gensel, JC Anderson, KD Segal, MR Rosenzweig, ES Magnuson, DS Whittemore, SR McTigue, DM Popovich, PG Rabchevsky, AG Scheff, SW Steward, O Courtine, G Edgerton, VR Tuszynski, MH Beattie, MS Bresnahan, JC Ferguson, AR AF Nielson, Jessica L. Guandique, Cristian F. Liu, Aiwen W. Burke, Darlene A. Lash, A. Todd Moseanko, Rod Hawbecker, Stephanie Strand, Sarah C. Zdunowski, Sharon Irvine, Karen-Amanda Brock, John H. Nout-Lomas, Yvette S. Gensel, John C. Anderson, Kim D. Segal, Mark R. Rosenzweig, Ephron S. Magnuson, David S. K. Whittemore, Scott R. McTigue, Dana M. Popovich, Phillip G. Rabchevsky, Alexander G. Scheff, Stephen W. Steward, Oswald Courtine, Gregoire Edgerton, V. Reggie Tuszynski, Mark H. Beattie, Michael S. Bresnahan, Jacqueline C. Ferguson, Adam R. TI Development of a Database for Translational Spinal Cord Injury Research SO JOURNAL OF NEUROTRAUMA LA English DT Article DE monkeys; rodents; bioinformatics; translation; syndromics ID TRAUMATIC BRAIN-INJURY; INDEPENDENCE MEASURE; WALKING INDEX; TIME LIMITS; RECOVERY; SCALE; VALIDITY; MULTICENTER; RELIABILITY; COMPRESSION AB Efforts to understand spinal cord injury (SCI) and other complex neurotrauma disorders at the pre-clinical level have shown progress in recent years. However, successful translation of basic research into clinical practice has been slow, partly because of the large, heterogeneous data sets involved. In this sense, translational neurological research represents a "big data" problem. In an effort to expedite translation of pre-clinical knowledge into standards of patient care for SCI, we describe the development of a novel database for translational neurotrauma research known as Visualized Syndromic Information and Outcomes for Neurotrauma-SCI (VISION-SCI). We present demographics, descriptive statistics, and translational syndromic outcomes derived from our ongoing efforts to build a multi-center, multi-species pre-clinical database for SCI models. We leveraged archived surgical records, postoperative care logs, behavioral outcome measures, and histopathology from approximately 3000 mice, rats, and monkeys from pre-clinical SCI studies published between 1993 and 2013. The majority of animals in the database have measures collected for health monitoring, such as weight loss/gain, heart rate, blood pressure, postoperative monitoring of bladder function and drug/fluid administration, behavioral outcome measures of locomotion, and tissue sparing postmortem. Attempts to align these variables with currently accepted common data elements highlighted the need for more translational outcomes to be identified as clinical endpoints for therapeutic testing. Last, we use syndromic analysis to identify conserved biological mechanisms of recovery after cervical SCI between rats and monkeys that will allow for more-efficient testing of therapeutics that will need to be translated toward future clinical trials. C1 [Nielson, Jessica L.; Guandique, Cristian F.; Liu, Aiwen W.; Beattie, Michael S.; Bresnahan, Jacqueline C.; Ferguson, Adam R.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, Dept Neurol Surg, San Francisco, CA 94110 USA. [Burke, Darlene A.; Magnuson, David S. K.; Whittemore, Scott R.] Univ Louisville, Kentucky Spinal Cord Injury Res Ctr, Dept Neurol Surg, Louisville, KY 40292 USA. [Lash, A. Todd] Ohio State Univ, Off Res Off Responsible Res Practices, Columbus, OH 43210 USA. [Moseanko, Rod; Hawbecker, Stephanie; Strand, Sarah C.] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA. [Zdunowski, Sharon; Edgerton, V. Reggie] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA USA. [Irvine, Karen-Amanda] Univ Calif San Francisco, Dept Neurol, San Francisco VA Med Ctr, San Francisco, CA 94110 USA. [Brock, John H.; Rosenzweig, Ephron S.; Tuszynski, Mark H.] Univ Calif San Diego, Dept Neurosci, Ctr Neural Repair, La Jolla, CA 92093 USA. [Nout-Lomas, Yvette S.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Clin Sci, Ft Collins, CO 80523 USA. [Gensel, John C.; Rabchevsky, Alexander G.; Scheff, Stephen W.] Univ Kentucky, Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA. [Anderson, Kim D.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA. [Segal, Mark R.] Univ Calif San Francisco, Dept Epidemiol & Biostat, Ctr Bioinformat & Mol Biostat, San Francisco, CA 94110 USA. [McTigue, Dana M.; Popovich, Phillip G.] Ohio State Univ, Dept Neurosci, Ctr Brain & Spinal Cord Repair, Columbus, OH 43210 USA. [Scheff, Stephen W.] Univ Kentucky, Dept Anat & Neurobiol, Sanders Brown Ctr Aging, Lexington, KY 40536 USA. [Steward, Oswald] Univ Calif Irvine, Dept Anat & Neurobiol, Reeve Irvine Res Ctr, Irvine, CA 92717 USA. [Steward, Oswald] Univ Calif Irvine, Dept Neurobiol & Behav, Reeve Irvine Res Ctr, Irvine, CA USA. [Steward, Oswald] Univ Calif Irvine, Dept Neurosurg, Reeve Irvine Res Ctr, Irvine, CA USA. [Courtine, Gregoire] Swiss Fed Inst Technol, Ctr Neuroprosthet, CH-1015 Lausanne, Switzerland. [Courtine, Gregoire] Swiss Fed Inst Technol, Brain Mind Inst, CH-1015 Lausanne, Switzerland. [Tuszynski, Mark H.] Vet Adm Med Ctr, La Jolla, CA USA. RP Ferguson, AR (reprint author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA. EM adam.ferguson@ucsf.edu OI Steward, Oswald/0000-0001-7069-8756; Nielson, Jessica/0000-0002-3677-3959; courtine, gregoire/0000-0002-5744-4142; Nout-Lomas, Yvette/0000-0001-6583-2308; Magnuson, David/0000-0003-3816-3676; , John/0000-0001-8980-108X FU NIH [R01NS067092, F32NS079030, R01NS038079, R01NS042291, R01NS031193, R01NS032000]; Craig H. Neilsen Foundation [224308]; Wings for Life [WFLUS008/12]; NYS CoRE [CO19772, R21 AG032518, R01 NS052292, P01 RR15576, P30 GM103507, R01 NS073584, R01 NS045734, R01 NS089324, R01 NS059776, P30-NS045758, P01NS010165]; Veterans Administration; Kentucky Spinal Cord and Head Injury Research Trust; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Research for Cure; Roman Reed Spinal Cord Injury Research Fund of the State of California; Craig H. Neilsen Foundation; American Paralysis Association; Paralyzed Veterans of America; Christopher and Dana Reeve Foundation; [NIH-N01-NS-3-2353]; [NIH-NO1-NS-3-2354] FX The authors thank, in alphabetical order, Rochelle Deibert, Crystal Forrider, Jenny Haefeli, J. Russell Huie, Amity Lin, Brandon Miller, Vladimir Muraru, Ellen Stuck, AmyTovar, Montina J. Van Meter, and Sergio Veiga for their technical assistance and fruitful discussions regarding database development. This work was supported by NIH grants R01NS067092 (to A. R. F.) and F32NS079030 (to J. L. N.); Craig H. Neilsen Foundation 224308, and Wings for Life WFLUS008/12. Primary data collection was supported by NIH grants R01NS038079, R01NS042291, R01NS031193, and R01NS032000; NYS CoRE CO19772, R21 AG032518, R01 NS052292, P01 RR15576, P30 GM103507, R01 NS073584, R01 NS045734, R01 NS089324, R01 NS059776, P30-NS045758, P01NS010165, NIH-N01-NS-3-2353, and NIH-NO1-NS-3-2354 contract (Facilities of Research Excellence in Spinal Cord Injury), the Veterans Administration, the Kentucky Spinal Cord and Head Injury Research Trust, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, Research for Cure, the Roman Reed Spinal Cord Injury Research Fund of the State of California, the Craig H. Neilsen Foundation, the American Paralysis Association, Paralyzed Veterans of America, and the Christopher and Dana Reeve Foundation. NR 35 TC 12 Z9 12 U1 2 U2 18 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD NOV 1 PY 2014 VL 31 IS 21 BP 1789 EP 1799 DI 10.1089/neu.2014.3399 PG 11 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA AR0TW UT WOS:000343285300004 PM 25077610 ER PT J AU Kim, SH Steele, JW Lee, SW Clemenson, GD Carter, TA Treuner, K Gadient, R Wedel, P Glabe, C Barlow, C Ehrlich, ME Gage, FH Gandy, S AF Kim, S. H. Steele, J. W. Lee, S. W. Clemenson, G. D. Carter, T. A. Treuner, K. Gadient, R. Wedel, P. Glabe, C. Barlow, C. Ehrlich, M. E. Gage, F. H. Gandy, S. TI Proneurogenic Group II mGluR antagonist improves learning and reduces anxiety in Alzheimer A beta oligomer mouse SO MOLECULAR PSYCHIATRY LA English DT Article ID ADULT HIPPOCAMPAL NEUROGENESIS; GLUTAMATE-RECEPTOR ANTAGONIST; AMYLOID-BETA; TRANSGENIC MICE; COGNITIVE IMPAIRMENT; CELL-PROLIFERATION; DENTATE GYRUS; DISEASE; MGS0039; NEURONS AB Proneurogenic compounds have recently shown promise in some mouse models of Alzheimer's pathology. Antagonists at Group II metabotropic glutamate receptors (Group II mGluR: mGlu(2), mGlu(3)) are reported to stimulate neurogenesis. Agonists at those receptors trigger gamma secretase-inhibitor-sensitive biogenesis of A beta 42 peptides from isolated synaptic terminals, which is selectively suppressed by antagonist pretreatment. We have assessed the therapeutic potential of chronic pharmacological inhibition of Group II mGluR in Dutch APP (Alzheimer's amyloid precursor protein E693Q) transgenic mice that accumulate Dutch amyloid-beta (A beta) oligomers but never develop A beta plaques. BCI-838 is a clinically well-tolerated, orally bioavailable, investigational prodrug that delivers to the brain BCI-632, the active Group II mGluR antagonist metabolite. Dutch A beta-oligomer forming APP transgenic mice (APP E693Q) were dosed with BCI-838 for 3 months. Chronic treatment with BCI-838 was associated with reversal of transgene-related amnestic behavior, reduction in anxiety, reduction in levels of brain A beta monomers and oligomers, and stimulation of hippocampal neurogenesis. Group II mGluR inhibition may offer a unique package of relevant properties as an Alzheimer's disease therapeutic or prophylactic by providing both attenuation of neuropathology and stimulation of repair. C1 [Kim, S. H.; Steele, J. W.; Ehrlich, M. E.; Gandy, S.] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, Dept Neurol, New York, NY 10029 USA. [Lee, S. W.; Clemenson, G. D.; Gage, F. H.] Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA. [Carter, T. A.; Treuner, K.; Gadient, R.; Wedel, P.; Barlow, C.] BrainCells, San Diego, CA USA. [Glabe, C.] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA. [Ehrlich, M. E.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA. [Gandy, S.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Gandy, S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Gandy, S (reprint author), James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM samuel.gandy@va.gov FU BrightFocus Foundation; Alzheimer's Art Quilt Initiative Award; Cure Alzheimer's Fund Stem Cell Consortium; VA MERIT Review Awards [I01BX000348, I01RX000684]; Gideon and Sarah Gartner Foundation; Louis B Mayer Foundation; National Institute of General Medical Sciences [T32GM062754]; James S McDonnell Foundation; Mathers Foundation; Ellison Foundation; NINDS; NIMH; NIA; JPB Foundation [BCI-838, BCI-632] FX We thank J Bonet and A Morant for assistance with mouse colony management and ML Gage for editorial comments. SHK was supported by BrightFocus Foundation and by an Alzheimer's Art Quilt Initiative Award to MEE. SG was supported by Cure Alzheimer's Fund Stem Cell Consortium, VA MERIT Review Awards I01BX000348 and I01RX000684, the Gideon and Sarah Gartner Foundation and the Louis B Mayer Foundation. JWS was a trainee in the Integrated Pharmacological Sciences Training Program supported by grant T32GM062754 from the National Institute of General Medical Sciences. This work was also supported by the James S McDonnell Foundation, Mathers Foundation, Ellison Foundation, NINDS, NIMH, NIA and JPB Foundation (FHG). BCI-838 and BCI-632 are proprietary compounds that must be obtained through a Material Transfer Agreement with Taisho Pharmaceutical. BCI-838 and BCI- 632 for this research were obtained through a Material Transfer Agreement with BrainCells, Inc. NR 53 TC 11 Z9 11 U1 2 U2 11 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD NOV PY 2014 VL 19 IS 11 BP 1235 EP 1242 DI 10.1038/mp.2014.87 PG 8 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA AR5ZT UT WOS:000343662300013 PM 25113378 ER PT J AU Chen, LJ Na, R Ran, QT AF Chen, Liuji Na, Ren Ran, Qitao TI Enhanced defense against mitochondrial hydrogen peroxide attenuates age-associated cognition decline SO NEUROBIOLOGY OF AGING LA English DT Article DE Alzheimer's disease; Brain aging; Mitochondria; Oxidative stress; Beta-amyloid; Peroxiredoxin 3; Mitochondrial H2O2 ID TRANSGENIC MOUSE MODEL; ALZHEIMERS-DISEASE; A-BETA; OXIDATIVE STRESS; ANTIOXIDANT DEFENSE; MEMORY DEFICITS; DNA-DAMAGE; TRANSCRIPTION; DYSFUNCTION; PROTEIN AB Increased mitochondrial hydrogen peroxide (H2O2) is associated with Alzheimer's disease and brain aging. Peroxiredoxin 3 (Prdx3) is the key mitochondrial antioxidant defense enzyme in detoxifying H2O2. To investigate the importance of mitochondrial H2O2 in age-associated cognitive decline, we compared cognition between aged (17-19 months) APP transgenic mice and APP/Prdx3 double transgenic mice (dTG) and between old (24 months) wild-type mice and Prdx3 transgenic mice (TG). Compared with aged APP mice, aged dTG mice showed improved cognition that was correlated with reduced brain amyloid beta levels and decreased amyloid beta production. Old TG mice also showed significantly increased cognitive ability compared with old wild-type mice. Both aged dTG mice and old TG mice had reduced mitochondrial oxidative stress and increased mitochondrial function. Moreover, CREB signaling, a signaling pathway important for cognition was enhanced in both aged dTG mice and old TG mice. Thus, our results indicate that mitochondrial H2O2 is a key culprit of age-associated cognitive impairment, and that a reduction of mitochondrial H2O2 could improve cognition by maintaining mitochondrial health and enhancing CREB signaling. Published by Elsevier Inc. C1 [Chen, Liuji; Na, Ren; Ran, Qitao] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Ran, Qitao] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Res & Dev Serv, San Antonio, TX USA. RP Ran, QT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM ran@uthscsa.edu FU U.S. Department of Veteran Affairs; Alzheimer's Association FX The study was supported by a Merit Review Award from the U.S. Department of Veteran Affairs and an Investigator Initiated Research Grant from Alzheimer's Association to Qitao Ran. NR 39 TC 8 Z9 8 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD NOV PY 2014 VL 35 IS 11 BP 2552 EP 2561 DI 10.1016/j.neurobiolaging.2014.05.007 PG 10 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA AR2LX UT WOS:000343419800016 PM 24906890 ER PT J AU Hall, DA Bennett, DA Filley, CM Shah, RC Kluger, B Ouyang, B Berry-Kravis, E AF Hall, Deborah A. Bennett, David A. Filley, Christopher M. Shah, Raj C. Kluger, Benzi Ouyang, Bichun Berry-Kravis, Elizabeth TI Fragile X gene expansions are not associated with dementia SO NEUROBIOLOGY OF AGING LA English DT Article DE FMR1; Fragile X; Alzheimer's disease ID TREMOR/ATAXIA-SYNDROME FXTAS; DISEASE AB The purpose of this study was to determine the frequency of fragile X mental retardation 1 (FMR1) premutation size expansions in individuals with Alzheimer's disease (AD) and other cognitive disorders compared with control subjects. FMR1 genetic screening was completed in patients being seen in a neurobehavioral or AD clinics. Appropriate controls were also collected. A second cohort was a community based, autopsy confirmed, sample of individuals with normal cognitive function, mild cognitive impairment, or AD. There was not an increased frequency of FMR1 expansions in individuals with cognitive disorders, including AD, compared with control subjects. (C) 2014 Elsevier Inc. All rights reserved. C1 [Hall, Deborah A.; Ouyang, Bichun; Berry-Kravis, Elizabeth] Rush Univ, Dept Neurol Sci, Chicago, IL 60611 USA. [Bennett, David A.; Shah, Raj C.] Rush Univ, Rush Alzheimers Dis Ctr, Chicago, IL 60611 USA. [Filley, Christopher M.; Kluger, Benzi] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO USA. [Filley, Christopher M.; Kluger, Benzi] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO USA. [Filley, Christopher M.] Denver Vet Affairs Med Ctr, Dept Neurol, Denver, CO USA. [Berry-Kravis, Elizabeth] Rush Univ, Dept Pediat, Chicago, IL 60611 USA. [Berry-Kravis, Elizabeth] Rush Univ, Dept Biochem, Chicago, IL 60611 USA. RP Hall, DA (reprint author), Rush Univ, Dept Neurol Sci, 1725 West Harrison St,Suite 755, Chicago, IL 60611 USA. EM Deborah_A_Hall@rush.edu FU National Institute of Neurological Disorders and Stroke [K23NS052487]; National Institute on Aging [P30AG10161, R01AG15819] FX This study was funded by the National Institute of Neurological Disorders and Stroke K23NS052487 (Deborah Hall) and National Institute on Aging P30AG10161 and R01AG15819 (David Bennett). NR 5 TC 5 Z9 5 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD NOV PY 2014 VL 35 IS 11 BP 2637 EP 2638 DI 10.1016/j.neurobiolaging.2014.04.027 PG 2 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA AR2LX UT WOS:000343419800024 PM 24958193 ER PT J AU Hatano, T Funayama, M Kubo, SI Mata, IF Oji, Y Mori, A Zabetian, CP Waldherr, SM Yoshino, H Oyama, G Shimo, Y Fujimoto, KI Oshima, H Kunii, Y Yabe, H Mizuno, Y Hattori, N AF Hatano, Taku Funayama, Manabu Kubo, Shin-ichiro Mata, Ignacio F. Oji, Yutaka Mori, Akio Zabetian, Cyrus P. Waldherr, Sarah M. Yoshino, Hiroyo Oyama, Genko Shimo, Yasushi Fujimoto, Ken-ichi Oshima, Hirokazu Kunii, Yasuto Yabe, Hirooki Mizuno, Yoshikuni Hattori, Nobutaka TI Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease SO NEUROBIOLOGY OF AGING LA English DT Article DE Parkinson's disease; LRRK2; p.R1441G; Asia; Intrafamilial clinical heterogeneity ID R1441G MUTATION; HAPLOTYPE ANALYSIS; GENETIC-ANALYSIS; G2019S; NEUROPATHOLOGY; PATHOLOGY; CARRIERS; DARDARIN AB Leucine-rich repeat kinase 2 (LRRK2) is a causative gene of autosomal dominant familial Parkinson's disease (PD). We screened for LRRK2 mutations in 3 frequently reported exons (31, 41, and 48) in our cohort of 871 Japanese patients with PD (430 with sporadic PD and 441 probands with familial PD). Direct sequencing analysis of LRRK2 revealed 1 proband (0.11%) with a p.R1441G mutation, identified for the first time in Asian countries, besides frequently reported substitutions including, the p.G2019S mutation (0.11%) and p.G2385R variant (11.37%). Several studies have suggested that the LRRK2 p.R1441G mutation, which is highly prevalent in the Basque country, is extremely rare outside of northern Spain. Further analysis of family members of the proband with the p.R1441G mutation revealed that her mother and first cousin shared the same mutation and parkinsonism. Haplotype analysis revealed a different haplotype from that of the original Spanish families. Our patients demonstrated levodopa-responsive parkinsonism with intrafamilial clinical heterogeneity. This is the first report of familial PD because of the LRRK2 p.R1441G mutation in Asia. (C) 2014 Elsevier Inc. All rights reserved. C1 [Hatano, Taku; Funayama, Manabu; Kubo, Shin-ichiro; Oji, Yutaka; Mori, Akio; Oyama, Genko; Shimo, Yasushi; Mizuno, Yoshikuni; Hattori, Nobutaka] Juntendo Univ, Dept Neurol, Sch Med, Tokyo 1138421, Japan. [Funayama, Manabu; Yoshino, Hiroyo; Hattori, Nobutaka] Juntendo Univ, Grad Sch Med, Res Inst Dis Old Age, Tokyo 1138421, Japan. [Shimo, Yasushi] Juntendo Univ, Dept Res & Therapeut Movement Disorders, Sch Med, Tokyo 1138421, Japan. [Mata, Ignacio F.; Zabetian, Cyrus P.; Waldherr, Sarah M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Mata, Ignacio F.; Zabetian, Cyrus P.; Waldherr, Sarah M.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Fujimoto, Ken-ichi] Jichi Idai Stn Brain Clin, Fukuoka, Tochigi, Japan. [Oshima, Hirokazu; Kunii, Yasuto; Yabe, Hirooki] Fukushima Med Univ, Dept Neuropsychiat, Fukushima, Japan. RP Hatano, T (reprint author), Juntendo Univ, Dept Neurol, Sch Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan. EM thatano@juntendo.ac.jp; nhattori@juntendo.ac.jp RI Funayama, Manabu/E-6485-2013 OI Funayama, Manabu/0000-0002-7412-3631; Zabetian, Cyrus/0000-0002-7739-4306 FU Strategic Research Foundation; KAKENHI [24390224, 25461290]; Japanese Ministry of Education, Culture, Sports, Science and Technology [23111003, 25129707]; Parkinson's Disease Foundation, United States; National Institutes of Health, United States [R01 NS065070, P50 NS062684] FX The authors thank Dr Hideo Mori (Juntendo Koshigaya Hospital) and all the participants in this study. This work was supported by a Strategic Research Foundation Grant-in-Aid Project for Private Universities, Grants-in-Aid for Scientific Research (KAKENHI) (to Nobutaka Hattori, 24390224 and to Taku Hatano, 25461290) and a Grant-in-Aid for Scientific Research on Innovative Areas (to Nobutaka Hattori, 23111003 and to Manabu Funayama, 25129707) from the Japanese Ministry of Education, Culture, Sports, Science and Technology. This work was also supported by grants from the Parkinson's Disease Foundation, United States and the National Institutes of Health, United States (R01 NS065070 and P50 NS062684). Appendix A. Supplementary dataSupplementary Video 1. Supplementary Video 2. NR 31 TC 2 Z9 2 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD NOV PY 2014 VL 35 IS 11 AR 2656.e17 DI 10.1016/j.neurobiolaging.2014.05.025 PG 7 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA AR2LX UT WOS:000343419800029 PM 24973808 ER PT J AU Rao, MN Chau, A Madden, E Inslicht, S Talbot, L Richards, A O'Donovan, A Ruoff, L Grunfeld, C Neylan, TC AF Rao, Madhu N. Chau, Alanna Madden, Erin Inslicht, Sabra Talbot, Lisa Richards, Anne O'Donovan, Aoife Ruoff, Leslie Grunfeld, Carl Neylan, Thomas C. TI Hyperinsulinemic response to oral glucose challenge in individuals with posttraumatic stress disorder SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Oral glucose; tolerance test; Hyperinsulinemia; Insulin resistance; Glucose metabolism; Sleep; Posttraumatic stress; disorder; Adipocytokines; Diabetes mellitus ID TYPE-2 DIABETES-MELLITUS; ADMINISTERED PTSD SCALE; INSULIN-RESISTANCE; METABOLIC SYNDROME; PHYSICAL ILLNESS; URINARY CORTISOL; SEX-DIFFERENCES; CO-MORBIDITY; PRIMARY-CARE; ADIPONECTIN AB Background: Posttraumatic stress disorder (PTSD) is associated with a 2-4 fold increased risk of developing Type 2 diabetes mellitus. However, detailed assessments of glucose metabolism and insulin secretion in a study designed to minimize confounders are lacking. Furthermore, few studies examine potential mechanisms involved. We analyzed data from a case control study of medically healthy, medication-free adults to determine whether individuals with PTSD had abnormal glucose or insulin response to oral glucose tolerance test (OGTT) compared to controls. Secondarily, we assessed potential mediators such as steep, cortisol and adiponectin. Methods: Data was analyzed from 92 age and gender-matched subjects (44 PTSD, 48 controls). Chronic PTSD was diagnosed using the Structured Clinical Interview for DSM-IV and Clinician Administered PTSD Scale. Subjects underwent 75-g OGTT, actigraphy and sleep diary (to quantify sleep duration), polysomnography (to assess slow wave sleep [SWS] and delta power), and overnight blood sampling (for cortisol and adiponectin). Results: At baseline, individuals with PTSD had mildly increased insulin levels (by 19%, compared to controls, p = 0.048) that was mediated primarily by weight. In response to OGTT, the PTSD group had higher levels of insulin at 120 min (by 44%, p = 0.03) and insulin AUC (by 43%, p = 0.015) compared to controls, after adjusting for confounders. Glucose levels were similar in the two groups. Although self-reported sleep duration, SWS, and delta power differed between PTSD subjects and controls, they did not mediate the effects of PTSD status on insulin response. Conclusion: In this case control study, individuals with PTSD had a hyperinsulinemic response to oral glucose challenge compared to controls, suggestive of insulin resistance. Published by Elsevier Ltd. C1 [Rao, Madhu N.; Madden, Erin; Inslicht, Sabra; Talbot, Lisa; Richards, Anne; O'Donovan, Aoife; Ruoff, Leslie; Grunfeld, Carl; Neylan, Thomas C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Rao, Madhu N.; Grunfeld, Carl] Univ Calif San Francisco, Dept Med, Div Endocrinol & Metab, San Francisco, CA USA. [Chau, Alanna] Albert Einstein Coll Med, New York, NY USA. [Madden, Erin] Northern Calif Inst Res & Educ, San Francisco, CA USA. [Inslicht, Sabra; Talbot, Lisa; Richards, Anne; O'Donovan, Aoife; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Rao, MN (reprint author), San Francisco VA Med Ctr, 111F,4150 Clement St, San Francisco, CA 94121 USA. EM Madhu.Rao@usf.edu FU NIH [R01MH073978, K23HL096832, R34MH077667]; NIH GCRC [UL1 RR024131]; Mental Illness Research and Education Clinical Center of the US Veterans Health Administration; Department of Defense; Department of Veterans Affairs FX This research was supported by NIH grants R01MH073978, K23HL096832 and R34MH077667, NIH GCRC grant UL1 RR024131 and grant funding from the Mental Illness Research and Education Clinical Center of the US Veterans Health Administration. Dr. Neylan reported receiving study medication from Actelion for a study funded by the Department of Defense and receiving study medication from Glaxo Smith Kline for a study funded by the Department of Veterans Affairs. The funding agencies had no role in the collection or analysis of the data or in the preparation of this manuscript. NR 59 TC 5 Z9 5 U1 0 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD NOV PY 2014 VL 49 BP 171 EP 181 DI 10.1016/j.psyneuen.2014.07.006 PG 11 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA AR1KA UT WOS:000343342900019 PM 25108160 ER PT J AU Sharma, M Zhang, MJ Zhong, XB Abidi, MH Akpek, G Bacher, U Callander, NS Dispenzieri, A Freytes, CO Fung, HC Gale, RP Gasparetto, C Gibson, J Holmberg, LA Kindwall-Keller, TL Klumpp, TR Krishnan, AY Landau, HJ Lazarus, HM Lonial, S Maiolino, A Marks, DI Mehta, P Med, JRM Nishihori, T Olsson, R Ramanathan, M Roy, V Savani, BN Schouten, HC Scott, E Tay, J To, LB Vesole, DH Vogl, DT Hari, P AF Sharma, Manish Zhang, Mei-Jie Zhong, Xiaobo Abidi, Muneer H. Akpek, Goerguen Bacher, Ulrike Callander, Natalie S. Dispenzieri, Angela Freytes, Cesar O. Fung, Henry C. Gale, Robert Peter Gasparetto, Cristina Gibson, John Holmberg, Leona A. Kindwall-Keller, Tamila L. Klumpp, Thomas R. Krishnan, Amrita Y. Landau, Heather J. Lazarus, Hillard M. Lonial, Sagar Maiolino, Angelo Marks, David I. Mehta, Paulette Med, Joseph R. Mikhael Nishihori, Taiga Olsson, Richard Ramanathan, Muthalagu Roy, Vivek Savani, Bipin N. Schouten, Harry C. Scott, Emma Tay, Jason To, Luen Bik Vesole, David H. Vogl, Dan T. Hari, Parameswaran TI Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Myeloma; Older patients; Autologous transplantation ID STEM-CELL TRANSPLANTATION; PREDNISONE PLUS THALIDOMIDE; RANDOMIZED CONTROLLED-TRIAL; DIAGNOSED MULTIPLE-MYELOMA; SINGLE-CENTER EXPERIENCE; ELDERLY-PATIENTS; HEMATOLOGIC MALIGNANCIES; COMORBIDITY INDEX; INITIAL TREATMENT; ORAL MELPHALAN AB Autologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed less often in people >70 years old than in people <= 70 years old. We analyzed 11,430 AHCT recipients for plasma cell myeloma prospectively reported to the Center for International Blood and Marrow Transplant Research between 2008 and 2011, representing the majority of US AHCT activity during this period. Survival (OS) was compared in 3 cohorts: ages 18 to 59 years (n = 5818), 60 to 69 years (n = 4666), and >70 years (n = 946). Median OS was not reached for any cohort. In multivariate analysis, increasing age was associated with mortality (P = .0006). Myeloma-specific mortality was similar among cohorts at 12%, indicating an age-related effect on nonmyeloma mortality. Analyses were performed in a representative subgroup comparing relapse rate, progression-free survival (PFS), and nonrelapse mortality (NRM). One-year NRM was 0% for age >70 years and 2% for other ages (P = not significant). The three-year relapse rate was 56% in age 18 to 59 years, 61% in age 60 to 69 years, and 63% age >70 (P = not significant). Three-year PFS was similar at 42% in age 18 to 59 years, 38% in age 60 to 69 years, and 33% in age >70 years (P = not significant). Postrelapse survival was significantly worse for the older cohort (P = .03). Older subjects selected for AHCT derived similar antimyeloma benefit without worse NRM, relapse rate, or PFS. (C) 2014 American Society for Blood and Marrow Transplantation. C1 [Sharma, Manish] Thomas Jefferson Univ, Dept Med Oncol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA. [Zhang, Mei-Jie; Zhong, Xiaobo; Hari, Parameswaran] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Zhang, Mei-Jie] Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. [Abidi, Muneer H.] Wayne State Univ, Dept Med, Karmanos Canc Inst, Detroit, MI 48202 USA. [Akpek, Goerguen] Banner MD Anderson Canc Ctr, Gilbert, AZ USA. [Bacher, Ulrike] Univ Hamburg, Dept Stem Cell Transplantat, Hamburg, Germany. [Bacher, Ulrike] MLL Munich Leukemia Lab, Munich, Germany. [Callander, Natalie S.] Univ Wisconsin Hosp & Clin, Bone Marrow Transplant Program, Madison, WI 53792 USA. [Dispenzieri, Angela] Mayo Clin, Dept Hematol, Rochester, MN USA. [Freytes, Cesar O.] South Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX USA. [Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Fung, Henry C.] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA. [Gale, Robert Peter] Univ London Imperial Coll Sci Technol & Med, Div Expt Med, Dept Med, Hematol Res Ctr, London, England. [Gasparetto, Cristina] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Gibson, John] Royal Prince Alfred Hosp, Inst Haematol, Camperdown, NSW 2050, Australia. [Holmberg, Leona A.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Kindwall-Keller, Tamila L.] Univ Virginia, Dept Med, Charlottesville, VA USA. [Klumpp, Thomas R.] Temple Bone Marrow Transplant Program, Dept Med, Philadelphia, PA USA. [Krishnan, Amrita Y.] City Hope Natl Med Ctr, Dept Hematol Oncol, Duarte, CA 91010 USA. [Landau, Heather J.] Mem Sloan Kettering Canc Ctr, Dept Med, Bone Marrow Transplantat Serv, New York, NY 10021 USA. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Dept Med, Cleveland, OH USA. [Lonial, Sagar] Emory Univ Hosp, Dept Med, Atlanta, GA 30322 USA. [Maiolino, Angelo] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil. [Marks, David I.] Univ Hosp Bristol, NHS Trust, Bristol, Avon, England. [Mehta, Paulette] Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA. [Mehta, Paulette] Univ Arkansas Med Sci, Dept Med, Little Rock, AR 72205 USA. [Med, Joseph R. Mikhael] Mayo Clin Arizona, Dept Hematol Oncol, Phoenix, AZ USA. [Med, Joseph R. Mikhael] Phoenix Childrens Hosp, Phoenix, AZ USA. [Nishihori, Taiga] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Blood & Marrow Transplantat, Tampa, FL 33682 USA. [Nishihori, Taiga] Res Inst, Tampa, FL USA. [Olsson, Richard] Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden. [Olsson, Richard] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden. [Ramanathan, Muthalagu] UMass Mem Med Ctr, Dept Hematol Malignancies Bone Marrow Transplant, Worcester, MA USA. [Roy, Vivek] Mayo Clin, Dept Med, Blood & Marrow Transplant Program, Jacksonville, FL 32224 USA. [Savani, Bipin N.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA. [Schouten, Harry C.] Acad Ziekenhuis, Maastricht, Netherlands. [Scott, Emma] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Tay, Jason] Univ Ottawa, Ottawa, ON, Canada. [To, Luen Bik] Royal Adelaide Hosp, Adelaide, SA, Australia. [Vesole, David H.] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Vogl, Dan T.] Univ Penn, Med Ctr, Dept Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA. RP Hari, P (reprint author), Med Coll Wisconsin, Div Hematol & Oncol, Ctr Int Blood & Marrow Transplant Res, 9200 W Wisconsin Ave,Suite C5500, Milwaukee, WI 53226 USA. EM phari@mcw.edu OI Abidi, Muneer/0000-0002-9936-6031; Olsson, Richard/0000-0001-5970-2128; Dispenzieri, Angela/0000-0001-8780-9512; Hari, Parameswaran/0000-0002-8800-297X FU National Cancer Institute [U24-CA076518]; National Institute of Allergy and Infectious Diseases; NHLBI [5U10HL069294]; NCI [5U10HL069294]; Health Resources and Services Administration [HHSH250201200016C]; Office of Naval Research [N00014-12-1-0142, N00014-13-1-0039]; Actinium Pharmaceuticals; Allos Therapeutics, Inc.; Amgen, Inc.; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc.; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children's Foundation; Kiadis Pharma; Leukemia & Lymphoma Society; Medac GmbH; Medical College of Wisconsin; Merck Co., Inc.; Millennium: The Takeda Oncology Co.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; Remedy Informatics; Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; Terumo BCT; Teva Neuroscience, Inc.; Texas Instruments Inc.; University of Minnesota; University of Utah; WellPoint, Inc; National Heart, Lung and Blood Institute (NHLBI); ROSWELL PARK CANCER INSTITUTE FX The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA076518 from the National Cancer Institute, the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases; a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration; two Grants N00014-12-1-0142 and N00014-13-1-0039 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; *Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. ROSWELL PARK CANCER INSTITUTE; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children's Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co., Inc.; Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *Terumo BCT; *Teva Neuroscience, Inc.; *Texas Instruments Inc.; University of Minnesota; University of Utah; and *WellPoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration or any other agency of the US Government. NR 39 TC 15 Z9 15 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD NOV PY 2014 VL 20 IS 11 BP 1796 EP 1803 DI 10.1016/j.bbmt.2014.07.013 PG 8 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AR1SG UT WOS:000343364300021 PM 25046833 ER PT J AU Spira, AP Chen-Edinboro, LP Wu, MN Yaffe, K AF Spira, Adam P. Chen-Edinboro, Lenis P. Wu, Mark N. Yaffe, Kristine TI Impact of sleep on the risk of cognitive decline and dementia SO CURRENT OPINION IN PSYCHIATRY LA English DT Review DE amyloid; apnea; cognitive decline; dementia; sleep ID ALZHEIMERS-DISEASE PATHOGENESIS; UNITED-STATES; DEPRIVATION; HYPOXIA; QUALITY; MARKERS; INFLAMMATION; DISTURBANCE; POPULATION; EXPRESSION AB Purpose of review Trouble falling or staying asleep, poor sleep quality, and short or long sleep duration are gaining attention as potential risk factors for cognitive decline and dementia, including Alzheimer's disease. Sleep-disordered breathing has also been linked to these outcomes. Here, we review recent observational and experimental studies investigating the effect of poor sleep on cognitive outcomes and Alzheimer's disease, and discuss possible mechanisms. Recent findings Observational studies with self-report and objective sleep measures (e. g. wrist actigraphy, polysomnography) support links between disturbed sleep and cognitive decline. Several recently published studies demonstrate associations between sleep variables and measures of Alzheimer's disease pathology, including cerebrospinal fluid measures of A beta and PET measures of A beta deposition. In addition, experimental studies suggest that sleep loss alters cerebrospinal fluid A beta dynamics, decrements in slow-wave sleep may decrease the clearance of A beta from the brain, and hypoxemia characteristic of sleep-disordered breathing increases A beta production. Summary Findings indicate that poor sleep is a risk factor for cognitive decline and Alzheimer's disease. Although mechanisms underlying these associations are not yet clear, healthy sleep appears to play an important role in maintaining brain health with age, and may play a key role in Alzheimer's disease prevention. C1 [Spira, Adam P.; Chen-Edinboro, Lenis P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. [Spira, Adam P.] Johns Hopkins Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD USA. [Wu, Mark N.] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA. [Wu, Mark N.] Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Spira, AP (reprint author), 624 N Broadway,Hampton House,Rm 794, Baltimore, MD 21205 USA. EM aspira@jhu.edu OI Chen-Edinboro, Lenis/0000-0002-8927-4256 FU National Institute on Aging [1K01AG033195]; National Institute of Mental Health Psychiatric Epidemiology Training Program [T32MH014592]; Burroughs-Wellcome Fund Career Award for Medical Scientists; Alzheimer's Association New Investigator Award; NIH [1R01NS079584, K24AG031155, R01 AG026720] FX Adam Spira is supported in part by a Mentored Research Scientist Development Award (1K01AG033195) from the National Institute on Aging.; Lenis Chen-Edinboro is supported by the National Institute of Mental Health Psychiatric Epidemiology Training Program (T32MH014592).; Mark Wu is supported by NIH 1R01NS079584, a Burroughs-Wellcome Fund Career Award for Medical Scientists, and an Alzheimer's Association New Investigator Award.; Kristine Yaffe is supported in part by NIH K24AG031155 and R01 AG026720. Kristine Yaffe has served on data safety monitoring boards for Takeda and the NIH, and received honoraria from Novartis and Pfizer. NR 50 TC 11 Z9 12 U1 3 U2 43 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7367 EI 1473-6578 J9 CURR OPIN PSYCHIATR JI Curr. Opin. Psychiatr. PD NOV PY 2014 VL 27 IS 6 BP 478 EP 483 DI 10.1097/YCO.0000000000000106 PG 6 WC Psychiatry SC Psychiatry GA AQ8AM UT WOS:000343042700016 PM 25188896 ER PT J AU Sittig, DF Gonzalez, D Singh, H AF Sittig, Dean F. Gonzalez, Daniel Singh, Hardeep TI Contingency planning for electronic health record-based care continuity: A survey of recommended practices SO INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS LA English DT Article DE Electronic health records ID SAFETY AB Background: Reliable health information technology (HIT) in general, and electronic health record systems (EHRs) in particular are essential to a high-performing healthcare system. When the availability of EHRs are disrupted, alternative methods must be used to maintain the continuity of healthcare. Methods: We developed a survey to assess institutional practices to handle situations when EHRs were unavailable for use (downtime preparedness). We used literature reviews and expert opinion to develop items that assessed the implementation of potentially useful practices. We administered the survey to U.S.-based healthcare institutions that were members of a professional organization that focused on collaboration and sharing of HIT-related best practices among its members. All members were large integrated health systems. Results: We received responses from SO of the 59 (84%) member institutions. Nearly all (96%) institutions reported at least one unplanned downtime (of any length) in the last 3 years and 70% had at least one unplanned downtime greater than 8 h in the last 3 years. Three institutions reported that one or more patients were injured as a result of either a planned or unplanned downtime. The majority of institutions (70-85%) had implemented a portion of the useful practices we identified, but very few practices were followed by all organizations. Conclusions: Unexpected downtimes related to EHRs appear to be fairly common among institutions in our survey. Most institutions had only partially implemented comprehensive contingency plans to maintain safe and effective healthcare during unexpected EHRs downtimes. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 [Sittig, Dean F.] Univ Texas Houston, Sch Biomed Informat, Houston, TX 77030 USA. [Sittig, Dean F.] Univ Texas Houston, Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX 77030 USA. [Gonzalez, Daniel] St Lukes Episcopal Hlth Syst, Dept Clin Effectiveness & Performance Measurement, Houston, TX USA. [Singh, Hardeep] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston VA HSR&D Ctr Innovat, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Sittig, DF (reprint author), Univ Texas Houston, Mem Hermann Ctr Healthcare Qual & Safety, 6410 Fannin St,UTPB 1100-43, Houston, TX 77030 USA. EM dean.f.sittig@uth.tmc.edu FU Houston VA Health Services Research 8.7 Development Center of Innovation [GIN 13-413] FX Dr. Singh is partially supported by the Houston VA Health Services Research 8.7 Development Center of Innovation (GIN 13-413). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. NR 30 TC 11 Z9 11 U1 0 U2 8 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1386-5056 EI 1872-8243 J9 INT J MED INFORM JI Int. J. Med. Inform. PD NOV PY 2014 VL 83 IS 11 BP 797 EP 804 DI 10.1016/j.ijmedinf.2014.07.007 PG 8 WC Computer Science, Information Systems; Health Care Sciences & Services; Medical Informatics SC Computer Science; Health Care Sciences & Services; Medical Informatics GA AQ8VL UT WOS:000343114700002 PM 25200197 ER PT J AU Khan, N Almukhtar, RM AF Khan, N. Almukhtar, R. M. TI Letter: predictors of severe disease in ulcerative colitis - the same or different in Crohn's disease? Authors' reply SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Letter C1 [Khan, N.] Univ Penn, Dept Med, Gastroenterol Sect, Perelman Sch Med, Philadelphia, PA 19104 USA. [Khan, N.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Khan, N.] Southeast Louisiana Vet Hlth Care Syst, Gastroenterol Sect, New Orleans, LA USA. [Almukhtar, R. M.] Louisiana State Univ, Hlth Sci Ctr, Dept Epidemiol, New Orleans, LA USA. [Almukhtar, R. M.] Tulane Univ, Hlth Sci Ctr, Dept Internal Med, Sect Gastroenterol & Hepatol, New Orleans, LA 70118 USA. RP Khan, N (reprint author), Univ Penn, Dept Med, Gastroenterol Sect, Perelman Sch Med, Philadelphia, PA 19104 USA. EM nkhan2@tulane.edu NR 5 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 EI 1365-2036 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD NOV PY 2014 VL 40 IS 9 BP 1121 EP 1122 DI 10.1111/apt.12948 PG 2 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA AQ6EU UT WOS:000342903400020 PM 25280262 ER PT J AU Haroutunian, V Katsel, P Roussos, P Davis, KL Altshuler, LL Bartzokis, G AF Haroutunian, V. Katsel, P. Roussos, P. Davis, K. L. Altshuler, L. L. Bartzokis, G. TI Myelination, Oligodendrocytes, and Serious Mental Illness SO GLIA LA English DT Review DE white matter; astrocyte; microglia; GSK-3; metabolic; RAS; apolipoprotein; degeneration; MRI ID CENTRAL-NERVOUS-SYSTEM; 2',3'-CYCLIC NUCLEOTIDE 3'-PHOSPHODIESTERASE; GLYCOGEN-SYNTHASE KINASE-3; WHITE-MATTER; BIPOLAR DISORDER; CHRONIC-SCHIZOPHRENIA; INTRACORTICAL MYELIN; HEALTHY-INDIVIDUALS; SUSCEPTIBILITY GENE; COGNITIVE DECLINE AB Historically, the human brain has been conceptually segregated from the periphery and further dichotomized into gray matter (GM) and white matter (WM) based on the whitish appearance of the exceptionally high lipid content of the myelin sheaths encasing neuronal axons. These simplistic dichotomies were unfortunately extended to conceptually segregate neurons from glia, cognition from behavior, and have been codified in the separation of clinical and scientific fields into medicine, psychiatry, neurology, pathology, etc. The discrete classifications have helped obscure the importance of continual dynamic communication between all brain cell types (neurons, astrocytes, microglia, oligodendrocytes, and precursor (NG2) cells) as well as between brain and periphery through multiple signaling systems. The signaling systems range from neurotransmitters to insulin, angiotensin, and multiple kinases such a glycogen synthase kinase 3 (GSK-3) that together help integrate metabolism, inflammation, and myelination processes and orchestrate the development, plasticity, maintenance, and repair that continually optimize function of neural networks. A more comprehensive, evolution-based, systems biology approach that integrates brain, body, and environmental interactions may ultimately prove more fruitful in elucidating the complexities of human brain function. The historic focus on neurons/GM is rebalanced herein by highlighting the importance of a systems-level understanding of the interdependent age-related shifts in both central and peripheral homeostatic mechanisms that can lead to remarkably prevalent and devastating neuropsychiatric diseases. Herein we highlight the role of glia, especially the most recently evolved oligodendrocytes and the myelin they produce, in achieving and maintaining optimal brain function. The human brain undergoes exceptionally protracted and pervasive myelination (even throughout its GM) and can thus achieve and maintain the rapid conduction and synchronous timing of neural networks on which optimal function depends. The continuum of increasing myelin vulnerability resulting from the human brain's protracted myelination underlies underappreciated communalities between different disease phenotypes ranging from developmental ones such as schizophrenia (SZ) and bipolar disorder (BD) to degenerative ones such as Alzheimer's disease (AD). These shared vulnerabilities also expose significant yet underexplored opportunities for novel treatment and prevention approaches that have the potential to considerably reduce the tremendous burden of neuropsychiatric disease. C1 [Haroutunian, V.; Katsel, P.; Roussos, P.; Davis, K. L.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Haroutunian, V.; Davis, K. L.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Haroutunian, V.; Roussos, P.] MIRECC JJ Peters VA Med Ctr, Bronx, NY USA. [Altshuler, L. L.; Bartzokis, G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Altshuler, L. L.; Bartzokis, G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. [Altshuler, L. L.; Bartzokis, G.] Greater Los Angeles VA Healthcare Syst, West Los Angeles, CA USA. RP Bartzokis, G (reprint author), 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA. EM gbar@ucla.edu RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239 FU NIH [MH0266029, MH064673, AG027342]; Research and Psychiatry Services of the Department of Veterans Affairs; Litwin Foundation; RCS Foundation FX Grant sponsor: NIH; Grant numbers: MH0266029; MH064673; AG027342; Grant sponsor: Research and Psychiatry Services of the Department of Veterans Affairs, and the Litwin and RCS Foundations. NR 95 TC 42 Z9 44 U1 6 U2 46 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-1491 EI 1098-1136 J9 GLIA JI Glia PD NOV PY 2014 VL 62 IS 11 SI SI BP 1856 EP 1877 DI 10.1002/glia.22716 PG 22 WC Neurosciences SC Neurosciences & Neurology GA AQ4YF UT WOS:000342806800008 PM 25056210 ER PT J AU van de Giessen, E Rosell, DR Thompson, JL Xu, XY Girgis, RR Ehrlich, Y Slifstein, M Abi-Dargham, A Siever, LJ AF van de Giessen, Elsmarieke Rosell, Daniel R. Thompson, Judy L. Xu, Xiaoyan Girgis, Ragy R. Ehrlich, Yosefa Slifstein, Mark Abi-Dargham, Anissa Siever, Larry J. TI Serotonin transporter availability in impulsive aggressive personality disordered patients: A PET study with [C-11]DASB SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Impulsive aggression; Intermittent explosive disorder; Serotonin transporter; Positron emission tomography; Anterior cingulate cortex; Callousness ID INTERMITTENT EXPLOSIVE DISORDER; POSITRON-EMISSION-TOMOGRAPHY; MAJOR DEPRESSION; HUMAN BRAIN; PROACTIVE AGGRESSION; GLUCOSE-METABOLISM; AMINE METABOLITES; RECEPTOR-BINDING; VALIDITY; BEHAVIOR AB Serotonin (5-HT) has consistently been implicated in the pathophysiology of impulsive aggression. In the current study, we tested the hypothesis that 5-HT transporter (5-HTT) binding is reduced in the anterior cingulate cortex (ACC) in impulsive aggressive patients. Additionally, we characterized pathological personality dimensions, with a specific focus on callousness (i.e. emotional indifference, a facet of psychopathy). Callousness is putatively positively correlated with presynaptic 5-HT, and thus could potentially confound the hypothesized negative relation between 5-HTT levels and trait aggression. We determined 5-HTT binding with positron emission tomography and [[C-11]DASB in 29 patients with intermittent explosive disorder (IED-IR) and 30 controls. We assessed group differences in 5-HTT binding in the pregenual ACC, amygdala and subcortical regions and examined correlations between 5-HTT binding and clinical measures. There were no significant differences in 5-HTT binding between IED-IR patients and controls. Trait callousness exhibited a significant, positive correlation with ACC 5-HTT availability. Among IED-IR patients, a trend-level negative partial correlation was observed between trait aggression and ACC 5-HTT availability, while covarying for callousness and age. Exploratory analyses revealed a significant negative correlation between state aggression levels and 5-HTT availability in subcortical regions, namely striatum and thalamus. We did not confirm our hypothesis of lower ACC 5-HTT availability in impulsive aggressive patients, however, the positive correlation between callousness and ACC 5-HTT availability likely played a confounding role. Subtypes of aggression (e.g., reactive vs. proactive aggression), which are differentially associated with pathological personality dimensions such as callousness, may contribute to variability between 5-HT functioning and aggression. (C) 2014 Elsevier Ltd. All rights reserved. C1 [van de Giessen, Elsmarieke; Thompson, Judy L.; Xu, Xiaoyan; Girgis, Ragy R.; Slifstein, Mark; Abi-Dargham, Anissa] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA. [van de Giessen, Elsmarieke; Thompson, Judy L.; Xu, Xiaoyan; Girgis, Ragy R.; Slifstein, Mark; Abi-Dargham, Anissa] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Rosell, Daniel R.; Ehrlich, Yosefa; Siever, Larry J.] Med Ctr, James J Peters Dept Vet Affairs, Bronx, NY 10468 USA. [Rosell, Daniel R.; Ehrlich, Yosefa; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Siever, LJ (reprint author), Med Ctr, James J Peters Dept Vet Affairs, 130 West Kingsbridge Rd,Room 6A-44, Bronx, NY 10468 USA. EM larry.siever@va.gov RI Girgis, Ragy/N-3271-2016 FU National Institute of Mental Health [MH63875]; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [MO1-RR-00071]; Nederlandse Organisatie voor Wetenschappelijk Onderzoek [825.12.009] FX This research was supported by Grant MH63875 from the National Institute of Mental Health to Larry J. Siever. This publication was made possible by Grant Number MO1-RR-00071 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NCRR or NIH. Elsmarieke van de Giessen is supported by a Rubicon grant from the Nederlandse Organisatie voor Wetenschappelijk Onderzoek (825.12.009). NR 64 TC 5 Z9 5 U1 3 U2 21 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD NOV PY 2014 VL 58 BP 147 EP 154 DI 10.1016/j.jpsychires.2014.07.025 PG 8 WC Psychiatry SC Psychiatry GA AQ5RL UT WOS:000342866200021 PM 25145808 ER PT J AU Wightman, A Young, B Bradford, M Dick, A Healey, P McDonald, R Smith, J AF Wightman, Aaron Young, Bessie Bradford, Miranda Dick, Andre Healey, Patrick McDonald, Ruth Smith, Jodi TI Prevalence and outcomes of renal transplantation in children with intellectual disability SO PEDIATRIC TRANSPLANTATION LA English DT Article DE renal transplant; intellectual disability; ethics; nephrology; outcomes ID KIDNEY-TRANSPLANTATION; MENTAL-RETARDATION; CANDIDATES AB To describe the prevalence and outcomes of renal transplantation in children with ID we performed a retrospective cohort analysis of all children receiving a first kidney-alone transplant in the UNOS dataset from 2008 to 2011. Recipients with definite, probable, and without ID were compared using chi-square tests. Kaplan-Meier curves were constructed for patient and graft survival. Cox proportional hazard models were used to estimate the association between ID and graft failure and patient survival. Over the study period, 332 children with definite (117) or probable (215) ID underwent first renal transplant, accounting for 16% of all first pediatric renal transplants (n=2076). Children with definite ID were not significantly different from children without ID with respect to sex, ethnicity, or prevalence of acute rejection. ID was associated with increased likelihood of deceased donor source. ID was not significantly associated with decreased graft or patient survival. In this first large-scale study, up to 16% of first pediatric renal transplants were performed in children with ID. Short-term graft and patient survival after transplant were equivalent between children with and without ID. Further research is needed to examine long-term outcomes of transplant in this population. C1 [Wightman, Aaron] Univ Wisconsin, Sch Med & Publ Hlth, Div Nephrol, Dept Pediat, Madison, WI 53792 USA. [Young, Bessie] Univ Washington, Sch Med, Dept Med, Div Nephrol,VA Puget Sound Healthcare Syst,Kidney, Seattle, WA 98195 USA. [Bradford, Miranda] Seattle Childrens Res Inst, Ctr Clin & Translat Res, Seattle, WA USA. [Dick, Andre; Healey, Patrick] Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA. [McDonald, Ruth; Smith, Jodi] Univ Washington, Sch Med, Dept Pediat, Div Nephrol, Seattle, WA 98195 USA. RP Wightman, A (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Div Nephrol, Dept Pediat, Mail Code 4108,600 Highland Ave, Madison, WI 53792 USA. EM wightman@pediatrics.wisc.edu OI Wightman, Aaron/0000-0003-0167-0420 FU NIH [5 T32 DK007662]; National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000423] FX Dr. Wightman was supported in part by NIH training grant: 5 T32 DK007662. Dr. Young was supported by resources from the VA Puget Sound Health Care System, Seattle, Washington. Support was provided by the National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR000423). The content is solely the responsibility of the authors and does not necessarily represent the official views of Veterans Affairs or the National Institutes of Health. NR 11 TC 10 Z9 10 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1397-3142 EI 1399-3046 J9 PEDIATR TRANSPLANT JI Pediatr. Transplant. PD NOV PY 2014 VL 18 IS 7 BP 714 EP 719 DI 10.1111/petr.12339 PG 6 WC Pediatrics; Transplantation SC Pediatrics; Transplantation GA AQ5KT UT WOS:000342848100021 PM 25135680 ER PT J AU Boninger, ML Wechsler, LR Stein, J AF Boninger, Michael L. Wechsler, Lawrence R. Stein, Joel TI Robotics, Stem Cells, and Brain-Computer Interfaces in Rehabilitation and Recovery from Stroke Updates and Advances SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Stroke; Stem Cells; Robotics; Rehabilitation; Brain-Computer Interfaces AB Objective: The aim of this study was to describe the current state and latest advances in robotics, stem cells, and brain-computer interfaces in rehabilitation and recovery for stroke. Design: The authors of this summary recently reviewed this work as part of a national presentation. The article represents the information included in each area. Results: Each area has seen great advances and challenges as products move to market and experiments are ongoing. Conclusions: Robotics, stem cells, and brain-computer interfaces all have tremendous potential to reduce disability and lead to better outcomes for patients with stroke. Continued research and investment will be needed as the field moves forward. With this investment, the potential for recovery of function is likely substantial. C1 [Boninger, Michael L.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, 3471 5th Ave Suite 201, Pittsburgh, PA 15213 USA. [Boninger, Michael L.] VA Pittsburgh Hlth Care Syst, Human Engn Res Lab, Pittsburgh, PA USA. [Wechsler, Lawrence R.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Stein, Joel] Columbia Univ Coll Phys & Surg, Dept Rehabil & Regenerat Med, New York, NY 10032 USA. [Stein, Joel] Weill Cornell Med Coll, Div Rehabil Med, New York, NY USA. RP Boninger, ML (reprint author), Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, 3471 5th Ave Suite 201, Pittsburgh, PA 15213 USA. OI Boninger, Michael/0000-0001-6966-919X FU NIA NIH HHS [P30 AG024827]; NINDS NIH HHS [R01 NS072342] NR 30 TC 2 Z9 2 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0894-9115 EI 1537-7385 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD NOV PY 2014 VL 93 IS 11 SU 3 BP S145 EP S154 DI 10.1097/PHM.0000000000000128 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA V44IV UT WOS:000209743600008 PM 25313662 ER PT J AU Moran-Santa Maria, MM Flanagan, J Brady, K AF Moran-Santa Maria, Megan M. Flanagan, Julianne Brady, Kathleen TI Ovarian Hormones and Drug Abuse SO CURRENT PSYCHIATRY REPORTS LA English DT Article DE Progesterone; Estrogen; Substance use disorders; Menstrual cycle; Estrous cycle; Addiction ID NICOTINIC ACETYLCHOLINE-RECEPTORS; MENSTRUAL-CYCLE; FEMALE RATS; SEX-DIFFERENCES; GENDER-DIFFERENCES; COCAINE-SEEKING; SMOKED COCAINE; INDUCED REINSTATEMENT; SMOKING-CESSATION; LUTEAL PHASES AB There are significant gender differences in course, symptomology, and treatment of substance use disorders. In general data from clinical and preclinical studies of substance use disorders suggest that women are more vulnerable than men to the deleterious consequences of drug use at every phase of the addiction process. In addition data from epidemiologic studies suggest that the gender gap in the prevalence of substance use is narrowing particularly among adolescence. Therefore, understanding the role of estrogen and progesterone in mediating responses to drugs of abuse is of critical importance to women's health. In this review we will discuss findings from clinical and preclinical studies of 1) reproductive cycle phase; 2) endogenous ovarian hormones; and 3) hormone replacement on responses to stimulants, nicotine, alcohol, opioids, and marijuana. In addition, we discuss data from recent studies that have advanced our understanding of the neurobiologic mechanisms that interact with estrogen and progesterone to mediate drug-seeking behavior. C1 [Moran-Santa Maria, Megan M.; Flanagan, Julianne; Brady, Kathleen] Med Univ S Carolina, Dept Psychiat & Behav Neurosci, Clin Neurosci Div, Charleston, SC 29425 USA. [Brady, Kathleen] Ralph H Johnson VAMC, Charleston, SC 29401 USA. RP Moran-Santa Maria, MM (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Neurosci, Clin Neurosci Div, 125 Doughty St, Charleston, SC 29425 USA. EM moranm@musc.edu FU NIH NIDA/ORWH [P50 DA016511]; NIH/NICHD [K12 HD055885] FX Megan M. Moran-Santa Maria has received grants from NIH NIDA/ORWH (Co-I on P50 DA016511 "Sex and Gender Factors Affecting Women's Health") and NIH/NICHD (K12 HD055885 Recipient "Impact of ovarian hormones on brain activity in cocaine-dependent women during exposure to psychosocial stress"). NR 86 TC 4 Z9 4 U1 2 U2 31 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 EI 1535-1645 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD NOV PY 2014 VL 16 IS 11 AR 511 DI 10.1007/s11920-014-0511-7 PG 8 WC Psychiatry SC Psychiatry GA AQ0AX UT WOS:000342444800018 PM 25224609 ER PT J AU Donahue, JJ Goranson, AC McClure, KS Van Male, LM AF Donahue, John J. Goranson, Anders C. McClure, Kelly S. Van Male, Lynn M. TI Emotion dysregulation, negative affect, and aggression: A moderated, multiple mediator analysis SO PERSONALITY AND INDIVIDUAL DIFFERENCES LA English DT Article DE Emotion regulation; Physical aggression; Negative affect; Sex differences ID NATIONAL-COMORBIDITY-SURVEY; GENDER-DIFFERENCES; PROACTIVE AGGRESSION; DISORDERS; ANGER; METAANALYSIS; VALIDATION; AVOIDANCE; CHILDHOOD; ANXIETY AB Research on violence has highlighted the role of trait negative affect in reactive aggressive behavior. Emotion dysregulation is a multidimensional construct reflecting maladaptive ways in which a person experiences and responds to emotional states, and has also been empirically linked to aggression. This study sought to test the hypothesis that multiple facets of emotion dysregulation would mediate the relationship between negative affect and physical aggression in a nonclinical sample. An additional aim was to examine the moderating effect of sex in the relationship between negative affect and aggression, and whether mediators differ as a function of sex. Three-hundred and eighteen participants completed measures of physical aggression, difficulties in emotion regulation, and negative affect. Results showed that sex moderated the relationship between negative affect and physical aggression, and emotion dysregulation fully mediated the relationship between these variables in both males and females. While difficulty inhibiting impulsive behavior when distressed was a significant mediator across sexes, difficulties with emotional awareness demonstrated a mediation effect only in males. Findings provide preliminary support for the facets of emotion dysregulation that are important in understanding the negative affect physical aggression association in males and females. Published by Elsevier Ltd. C1 [Donahue, John J.; Goranson, Anders C.] Portland VA Med Ctr, VISN NW MIRECC 20, Portland, OR 97207 USA. [McClure, Kelly S.] La Salle Univ, Dept Psychol, Philadelphia, PA 19141 USA. [Van Male, Lynn M.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Occupat Hlth Strateg Healthcare Grp 10P3D, VHA CO,Off Publ Hlth,Dept Psychiat, Portland, OR 97207 USA. RP Donahue, JJ (reprint author), Portland VA Med Ctr, VISN NW MIRECC 20, POB 1034, Portland, OR 97207 USA. EM jdonahue81@gmail.com NR 32 TC 6 Z9 6 U1 1 U2 60 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0191-8869 J9 PERS INDIV DIFFER JI Pers. Individ. Differ. PD NOV PY 2014 VL 70 BP 23 EP 28 DI 10.1016/j.paid.2014.06.009 PG 6 WC Psychology, Social SC Psychology GA AO6NO UT WOS:000341469000005 ER PT J AU Mostaghel, EA Morgan, A Zhang, XT Marck, BT Xia, J Hunter-Merrill, R Gulati, R Plymate, S Vessella, RL Corey, E Higano, CS Matsumoto, AM Montgomery, RB Nelson, PS AF Mostaghel, Elahe A. Morgan, Andrew Zhang, Xiaotun Marck, Brett T. Xia, Jing Hunter-Merrill, Rachel Gulati, Roman Plymate, Stephen Vessella, Robert L. Corey, Eva Higano, Celestia S. Matsumoto, Alvin M. Montgomery, R. Bruce Nelson, Peter S. TI Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis SO PLOS ONE LA English DT Article ID INCREASED SURVIVAL; HORMONAL-THERAPY; CARCINOMA; DIHYDROTESTOSTERONE; TESTOSTERONE; PROGRESSION; ABIRATERONE; RESISTANCE; ENZALUTAMIDE; INDEPENDENCE AB Background: Factors influencing differential responses of prostate tumors to androgen receptor (AR) axis-directed therapeutics are poorly understood, and predictors of treatment efficacy are needed. We hypothesized that the efficacy of inhibiting DHT ligand synthesis would associate with intra-tumoral androgen ratios indicative of relative dependence on DHT-mediated growth. Methods: We characterized two androgen-sensitive prostate cancer xenograft models after androgen suppression by castration in combination with the SRD5A inhibitor, dutasteride, as well as a panel of castration resistant metastases obtained via rapid autopsy. Results: In LuCaP35 tumors (intra-tumoral T: DHT ratio 2: 1) dutasteride suppressed DHT to 0.02 ng/gm and prolonged survival vs. castration alone (337 vs. 152 days, HR 2.8, p = 0.0015). In LuCaP96 tumors (T: DHT 10: 1), survival was not improved despite similar DHT reduction (0.02 ng/gm). LuCaP35 demonstrated higher expression of steroid biosynthetic enzymes maintaining DHT levels (5-fold higher SRD5A1, 41 fold higher, 99-fold higher RL-HSD, p<0.0001 for both), reconstitution of intra-tumoral DHT (to similar to 30% of untreated tumors), and similar to 2 fold increased expression of full length AR. In contrast, LuCaP96 demonstrated higher levels of steroid catabolizing enzymes (6.9-fold higher AKR1C2, 3000-fold higher UGT2B15, p = 0.002 and p<0.0001 respectively), persistent suppression of intra-tumoral DHT, and 6-8 fold induction of full length AR and the ligand independent V7 AR splice variant. Human metastases demonstrated bio-active androgen levels and AR full length and AR splice-variant expression consistent with the range observed in xenografts. Conclusions: Intrinsic differences in basal steroidogenesis, as well as variable expression of full length and splice-variant AR, associate with response and resistance to pre-receptor AR ligand suppression. Expression of steroidogenic enzymes and AR isoforms may serve as potential biomarkers of sensitivity to potent AR-axis inhibition and should be validated in additional models. C1 [Mostaghel, Elahe A.; Morgan, Andrew; Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Mostaghel, Elahe A.; Marck, Brett T.; Plymate, Stephen; Higano, Celestia S.; Matsumoto, Alvin M.; Montgomery, R. Bruce; Nelson, Peter S.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Zhang, Xiaotun; Vessella, Robert L.; Corey, Eva] Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. [Marck, Brett T.; Plymate, Stephen; Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Xia, Jing; Hunter-Merrill, Rachel; Gulati, Roman] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. RP Mostaghel, EA (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA. EM emostagh@fhcrc.org FU Prostate Cancer Foundation Career Development Award; Challenge Award; Damon Runyon Genentech-Clinical Investigator Award [C-40-08]; NIH grant [1K23 CA122820-01]; DOD New Investigator Award [W81XWH-10-1-0228]; GlaxoSmithKline; NIH/NCI Pacific Northwest Prostate Cancer SPORE [P50CA97186]; Department of Veterans Affairs; [1RC1 CA146849]; [PC093509]; [PO1 CA 85859] FX Prostate Cancer Foundation Career Development Award (E. A. M.) and Challenge Award (E. A. M., S. P., R. L. V., A. M. M., R. B. M., P.S.N.), Damon Runyon Genentech-Clinical Investigator Award C-40-08 (E. A. M.), NIH grant 1K23 CA122820-01 (E. A. M.), DOD New Investigator Award W81XWH-10-1-0228 (E. A. M.); GlaxoSmithKline (A. M. and P.S.N.); 1RC1 CA146849 (P.S.N.); PC093509 (P.S.N.); PO1 CA 85859 (J.X., R. G., R. V., P.S.N.); the NIH/NCI Pacific Northwest Prostate Cancer SPORE P50CA97186 (J.X., R. H., R. G., P.S.N., R. V.); and the Department of Veterans Affairs (B. T. M., S. P. and A. M. M.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 39 TC 2 Z9 3 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 30 PY 2014 VL 9 IS 10 AR e111545 DI 10.1371/journal.pone.0111545 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AX2HU UT WOS:000346765000069 PM 25356728 ER PT J AU Miranda, M Walker, RH Bustamante, ML AF Miranda, Marcelo Walker, Ruth H. Bustamante, M. L. TI Electronic message ataxia in multiple system atrophy SO NEUROLOGY LA English DT Editorial Material C1 [Miranda, Marcelo] Clin Las Condes, Dept Neurol, Santiago, Chile. [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. [Bustamante, M. L.] Univ Chile, Fac Med, Santiago, Chile. RP Miranda, M (reprint author), Clin Las Condes, Dept Neurol, Santiago, Chile. EM marcelomirandac@gmail.com RI Bustamante, Maria Leonor/H-3728-2014 OI Bustamante, Maria Leonor/0000-0001-9071-2463 NR 2 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD OCT 28 PY 2014 VL 83 IS 18 BP 1677 EP 1677 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AT3RU UT WOS:000344852200020 PM 25349273 ER PT J AU Singh, JA Lu, X Ibrahim, S Cram, P AF Singh, Jasvinder A. Lu, Xin Ibrahim, Said Cram, Peter TI Trends in and disparities for acute myocardial infarction: an analysis of Medicare claims data from 1992 to 2010 SO BMC MEDICINE LA English DT Article DE Myocardial infarction; MI; Disparity; Outcomes; Race; Sex; Mortality; PCI; Hospitalization rates ID AMERICAN-HEART-ASSOCIATION; QUALITY-OF-CARE; FEE-FOR-SERVICE; ETHNIC-DIFFERENCES; UNITED-STATES; MORTALITY; SEX; BENEFICIARIES; DISEASE; REVASCULARIZATION AB Background: It is unknown whether previously reported disparities for acute myocardial infarction (AMI) by race and sex have declined over time. Methods: We used Medicare Part A administrative data files for 1992 to 2010 to evaluate changes in per-capita hospitalization rates for AMI, rates of revascularization (percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG)), and 30-day mortality for four distinct patient subcohorts: black women; black men; white women; and white men, adjusted for age, comorbidities and year using logistic regression. Results: The study sample consisted of 4,045,267 AMI admissions between the years 1992 and 2010 (166,660 black women; 116,201 black men; 1,870,816 white women; 1,891,590 white men). AMI hospitalization rates differed significantly in 1992 to 1993 among black women (61.6 hospitalizations per 10,000 Medicare enrollees), black men (73.2 hospitalizations), white women (72.0 hospitalizations) and white men (113.2 hospitalizations) (P < 0.0001). By 2009 to 2010 AMI hospitalization rates had declined substantially in all cohorts but disparities remained with significantly lower hospitalization rates among women and blacks compared to men and whites, respectively (P < 0.0001). In multivariable-adjusted analyses, despite narrowing of the differences between cohorts over time, disparities in AMI hospitalization rates by race and sex remained statistically significant in 2009 to 2010 (P < 0.001). In 1992 to 1993 and 2009 to 2010, rates of PCI within 30-days of AMI differed significantly among black women (8.6% in 1992 to 1993; 24.2% in 2009 to 2010), black men (10.4% and 32.6%), white women (12.8% and 30.5%), and white men (16.1% and 40.7%) (P < 0.0001). In multivariable-adjusted analyses, racial disparities in procedure utilization appeared somewhat larger and sex-based disparities remained significant. Unadjusted 30-day mortality after AMI in 1992 to 1993 for black women, black men, white women and white men was 20.4%, 17.9%, 23.1% and 19.5%, respectively (P < 0.0001); in 2009 to 2010 mortality was 17.1%, 15.3%, 18.2% and 16.2%, respectively (P < 0.0001). In adjusted analyses, racial differences in mortality declined over time but differences by sex (higher mortality for women) persisted. Conclusions: Disparities in AMI have declined modestly, but remain a problem, particularly with respect to patient sex. C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Med Serv, Birmingham, AL 35294 USA. [Lu, Xin] Univ Iowa, Carver Coll Med, Dept Internal Med, Div Gen Internal Med, Iowa City, IA 52242 USA. [Lu, Xin] City Vet Adm Med Ctr, CADRE, Iowa City, IA 52242 USA. [Ibrahim, Said] Perelman Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA 19104 USA. [Cram, Peter] Univ Hlth Network, Div Gen Internal Med & Geriatr, Toronto, ON M5G 2C4, Canada. [Cram, Peter] Mt Sinai Hosp, Toronto, ON M5G 2C4, Canada. [Cram, Peter] Univ Toronto, Fac Med, Toronto, ON, Canada. RP Singh, JA (reprint author), Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Med Serv, 510 S 20th St,Fac Off Tower 805B, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com FU NHLBI [R01 HL085347]; NIA at the NIH [R01 AG033035]; National Institute of Aging, National Cancer Institute, Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs); NIAMS [AR062133]; Department of Veterans Affairs; National Institute of Arthritis and Musculoskeletal and Skin Diseases [K24AR055259] FX This work is also funded in part by R01 HL085347 from NHLBI and R01 AG033035 from NIA at the NIH. JAS is supported by research grants from National Institute of Aging, National Cancer Institute, Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs), and the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA. PC is supported by a K24 award from NIAMS (AR062133) and by the Department of Veterans Affairs. Dr. Ibrahim is supported by Grant Number K24AR055259 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. NR 35 TC 13 Z9 13 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1741-7015 J9 BMC MED JI BMC Med. PD OCT 24 PY 2014 VL 12 AR 190 DI 10.1186/s12916-014-0190-6 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA AT4FE UT WOS:000344894400001 PM 25341547 ER PT J AU Wilhelm, CJ Hashimoto, JG Roberts, ML Sonmez, MK Wiren, KM AF Wilhelm, C. J. Hashimoto, J. G. Roberts, M. L. Sonmez, M. K. Wiren, K. M. TI UNDERSTANDING THE ADDICTION CYCLE: A COMPLEX BIOLOGY WITH DISTINCT CONTRIBUTIONS OF GENOTYPE VS. SEX AT EACH STAGE SO NEUROSCIENCE LA English DT Article DE prefrontal cortex; ethanol; sexual dimorphism; inflammation; astrocytes; low level response to alcohol ID GENE COEXPRESSION NETWORKS; HIPPOCAMPAL SLICE CULTURES; ALCOHOL-USE DISORDERS; GENDER-DIFFERENCES; ETHANOL WITHDRAWAL; BRAIN-DAMAGE; MICROGLIAL ACTIVATION; ALVEOLAR MACROPHAGE; RETINOIC ACID; MOUSE-BRAIN AB Ethanol abuse can lead to addiction, brain damage and premature death. The cycle of alcohol addiction has been described as a composite consisting of three stages: intoxication, withdrawal and craving/abstinence. There is evidence for contributions of both genotype and sex to alcoholism, but an understanding of the biological underpinnings is limited. Utilizing both sexes of genetic animal models with highly divergent alcohol withdrawal severity, Withdrawal Seizure-Resistant (WSR) and Withdrawal Seizure-Prone (WSP) mice, the distinct contributions of genotype/phenotype and of sex during addiction stages on neuroadaptation were characterized. Transcriptional profiling was performed to identify expression changes as a consequence of chronic intoxication in the medial prefrontal cortex. Significant expression differences were identified on a single platform and tracked over a behaviorally relevant time course that covered each stage of alcohol addiction; i.e., after chronic intoxication, during peak withdrawal, and after a defined period of abstinence. Females were more sensitive to ethanol with higher fold expression differences. Bioinformatics showed a strong effect of sex on the data structure of expression profiles during chronic intoxication and at peak withdrawal irrespective of genetic background. However, during abstinence, differences were observed instead between the lines/phenotypes irrespective of sex. Confirmation of identified pathways showed distinct inflammatory signaling following intoxication at peak withdrawal, with a pro-inflammatory phenotype in females but overall suppression of immune signaling in males. Combined, these results suggest that each stage of the addiction cycle is influenced differentially by sex vs. genetic background and support the development of stage- and sex-specific therapies for alcohol withdrawal and the maintenance of sobriety. Published by Elsevier Ltd. on behalf of IBRO. C1 [Wilhelm, C. J.; Hashimoto, J. G.; Roberts, M. L.; Wiren, K. M.] Dept Vet Affairs Med Ctr, Portland, OR 97239 USA. [Wilhelm, C. J.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Hashimoto, J. G.; Wiren, K. M.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Sonmez, M. K.] Oregon Hlth & Sci Univ, Ctr Spoken Language Understanding, Portland, OR 97239 USA. RP Wilhelm, CJ (reprint author), Portland VA Med Ctr, Res Serv, 3710 SW Vet Hosp Rd, Portland, OR 97239 USA. EM wilhelmc@ohsu.edu FU Department of Veterans Affairs [BX001172, BX001294]; NIH/NIAAA [R01AA021468]; National Institute on Alcohol Abuse and Alcoholism [P60AA010760, R24AA020245] FX This research was supported by grants from the Department of Veterans Affairs (BX001172 (KMW) and BX001294 (CJW)) and from the NIH/NIAAA (R01AA021468 (KMW)). Additionally, this material is the result of work supported with resources and the use of facilities at the Portland VA Medical Center (KMW). We also acknowledge support from National Institute on Alcohol Abuse and Alcoholism for the Portland Alcohol Research Center (P60AA010760) and for the maintenance of colonies of WSR and WSP mice (R24AA020245) used in the present studies and thank Melissa Andrew for assistance with the vapor exposure procedure and Casia Wardzala for comments provided after careful reading of the manuscript. NR 107 TC 7 Z9 7 U1 3 U2 23 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 EI 1873-7544 J9 NEUROSCIENCE JI Neuroscience PD OCT 24 PY 2014 VL 279 BP 168 EP 186 DI 10.1016/j.neuroscience.2014.08.041 PG 19 WC Neurosciences SC Neurosciences & Neurology GA AR5ON UT WOS:000343633800015 PM 25194791 ER PT J AU Cockerham, LR Siliciano, JD Sinclair, E O'Doherty, U Palmer, S Yukl, SA Strain, MC Chomont, N Hecht, FM Siliciano, RF Richman, DD Deeks, SG AF Cockerham, Leslie R. Siliciano, Janet D. Sinclair, Elizabeth O'Doherty, Una Palmer, Sarah Yukl, Steven A. Strain, Matt C. Chomont, Nicolas Hecht, Frederick M. Siliciano, Robert F. Richman, Douglas D. Deeks, Steven G. TI CD4(+) and CD8(+) T Cell Activation Are Associated with HIV DNA in Resting CD4(+) T Cells SO PLOS ONE LA English DT Article ID SUPPRESSIVE ANTIRETROVIRAL THERAPY; IMMUNE ACTIVATION; VIRAL PERSISTENCE; INFECTED PATIENTS; RESERVOIR; SIZE; REPLICATION; INTEGRATION; LYMPHOCYTES; EXPRESSION AB The association between the host immune environment and the size of the HIV reservoir during effective antiretroviral therapy is not clear. Progress has also been limited by the lack of a well-accepted assay for quantifying HIV during therapy. We examined the association between multiple measurements of HIV and T cell activation (as defined by markers including CD38, HLA-DR, CCR5 and PD-1) in 30 antiretroviral-treated HIV-infected adults. We found a consistent association between the frequency of CD4(+) and CD8(+) T cells expressing HLA-DR and the frequency of resting CD4(+) T cells containing HIV DNA. This study highlights the need to further examine this relationship and to better characterize the biology of markers commonly used in HIV studies. These results may also have implications for reactivation strategies. C1 [Cockerham, Leslie R.; Hecht, Frederick M.; Deeks, Steven G.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA 94143 USA. [Siliciano, Janet D.; Siliciano, Robert F.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Sinclair, Elizabeth] Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA. [O'Doherty, Una] Univ Penn, Philadelphia, PA 19104 USA. [Palmer, Sarah] Westmead Millennium Inst Med Res, Westmead, NSW, Australia. [Palmer, Sarah] Univ Sydney, Sydney, NSW 2006, Australia. [Palmer, Sarah] Karolinska Inst, Stockholm, Sweden. [Yukl, Steven A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Strain, Matt C.; Richman, Douglas D.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA. [Richman, Douglas D.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Chomont, Nicolas] Vaccine & Gene Therapy Inst Florida, Port St Lucie, FL USA. [Siliciano, Robert F.] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA. RP Cockerham, LR (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA 94143 USA. EM leslie.cockerham@ucsf.edu FU ARCHE Collaborative Research Grant from the Foundation for AIDS Research [amFAR 108165-50-RGRL]; Martin Delaney CARE and DARE Collaboratories (NIH) [AI096113, 1U19AI096109]; NIH [43222]; Howard Hughes Medical Institute; Department of Veterans Affairs; James Pendleton Charitable Trust; National Institutes of Health [AI080193, AI74621, AI69432-S]; CFAR [AI306214]; Department of Veterans Affairs (VA Career Development Award) [1 IK2 CX000520-01]; NIAID [RO1AIO87145, K24AIO69994]; UCSF/Gladstone CFAR [P30 AIO27763]; UCSF Clinical and Translational Research Institute Clinical Research Center [UL 1 RR024131]; Center for AIDS Prevention Studies [P30 MH62246] FX This work was supported by an ARCHE Collaborative Research Grant from the Foundation for AIDS Research (amFAR 108165-50-RGRL), by the Martin Delaney CARE and DARE Collaboratories (NIH grants AI096113 and 1U19AI096109), and by NIH grant 43222 (RFS), and by the Howard Hughes Medical Institute (RFS). For MCS and DDR, this work was supported by the Department of Veterans Affairs, the James Pendleton Charitable Trust, National Institutes of Health (AI080193, AI74621, AI69432-S), and CFAR grant AI306214. For SAY, this work was supported by the Department of Veterans Affairs (VA Career Development Award 1 IK2 CX000520-01). The UCSF SCOPE cohort was supported in part by the NIAID (RO1AIO87145, K24AIO69994), the UCSF/Gladstone CFAR (P30 AIO27763), the UCSF Clinical and Translational Research Institute Clinical Research Center (UL 1 RR024131) and the Center for AIDS Prevention Studies (P30 MH62246). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 39 TC 17 Z9 17 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 23 PY 2014 VL 9 IS 10 AR e110731 DI 10.1371/journal.pone.0110731 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AR5ZY UT WOS:000343662800051 PM 25340755 ER PT J AU Cowansage, KK Shuman, T Dillingham, BC Chang, A Golshani, P Mayford, M AF Cowansage, Kiriana K. Shuman, Tristan Dillingham, Blythe C. Chang, Allene Golshani, Peyman Mayford, Mark TI Direct Reactivation of a Coherent Neocortical Memory of Context SO NEURON LA English DT Article ID MULTIPLE TRACE THEORY; RETROSPLENIAL CORTEX; FEAR MEMORY; SPATIAL MEMORY; DORSAL HIPPOCAMPUS; CONJUNCTIVE REPRESENTATIONS; TEMPORARY INACTIVATION; CONDITIONED-STIMULUS; RETROGRADE-AMNESIA; ASSOCIATIVE MEMORY AB Declarative memories are thought to be stored within anatomically distributed neuronal networks requiring the hippocampus; however, it is unclear how neocortical areas participate in memory at the time of encoding. Here, we use a c-fos-based genetic tagging system to selectively express the channelrhodopsin variant, ChEF, and optogenetically reactivate a specific neural ensemble in retrosplenial cortex (RSC) engaged by context fear conditioning. Artificial stimulation of RSC was sufficient to produce both context-specific behavior and downstream cellular activity commensurate with natural experience. Moreover, optogenetically but not contextually elicited responses were insensitive to hippocampal inactivation, suggesting that although the hippocampus is needed to coordinate activation by sensory cues, a higher-order cortical framework can independently subserve learned behavior, even shortly after learning. C1 [Cowansage, Kiriana K.; Dillingham, Blythe C.; Chang, Allene; Mayford, Mark] Scripps Res Inst, Dorris Neurosci Ctr, Dept Mol & Cellular Neurosci, La Jolla, CA 92037 USA. [Dillingham, Blythe C.] Univ Calif Los Angeles, Kellogg Sch Sci & Technol, Los Angeles, CA 90095 USA. [Shuman, Tristan; Golshani, Peyman] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Golshani, Peyman] UCLA Integrat Ctr Learning & Memory, Los Angeles, CA 90073 USA. [Golshani, Peyman] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Mayford, M (reprint author), Scripps Res Inst, Dorris Neurosci Ctr, Dept Mol & Cellular Neurosci, 10550 North Torrey Pines Rd,DNC 202, La Jolla, CA 92037 USA. EM mmayford@scripps.edu FU NIH [R01MH057368-15, R01DA028300-03, 5T32NS007101-35] FX This work was supported by NIH funding awards R01MH057368-15 and R01DA028300-03 (to M.M.) and 5T32NS007101-35 (to T.S.). We are grateful to Roger Tsien for providing the ChEF construct used to generate this mouse and to Peter Cameron for contributing the mRNA probes used in fos-CatFISH experiments. We also thank Anton Maximov and Denise Cai for providing helpful discussion and comments on the manuscript. NR 67 TC 39 Z9 40 U1 3 U2 20 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0896-6273 EI 1097-4199 J9 NEURON JI Neuron PD OCT 22 PY 2014 VL 84 IS 2 BP 432 EP 441 DI 10.1016/j.neuron.2014.09.022 PG 10 WC Neurosciences SC Neurosciences & Neurology GA AS3HI UT WOS:000344167900021 PM 25308330 ER PT J AU Velez, JCQ Janech, MG Hicks, MP Morinelli, TA Rodgers, J Self, SE Arthur, JM Fitzgibbon, WR AF Velez, Juan Carlos Q. Janech, Michael G. Hicks, Megan P. Morinelli, Thomas A. Rodgers, Jessalyn Self, Sally E. Arthur, John M. Fitzgibbon, Wayne R. TI Lack of Renoprotective Effect of Chronic Intravenous Angiotensin-(1-7) or Angiotensin-(2-10) in a Rat Model of Focal Segmental Glomerulosclerosis SO PLOS ONE LA English DT Article ID FAWN-HOODED RAT; HYPERTENSIVE-RATS; KIDNEY-DISEASE; FLUID CONCENTRATIONS; ENDOTHELIAL-CELLS; MASS-SPECTROMETRY; ANESTHETIZED RATS; AT(2) RECEPTORS; RENAL-DISEASE; RENIN AB Unopposed angiotensin (Ang) II-mediated cellular effects may lead to progressive glomerulosclerosis. While Ang-II can be locally generated in the kidneys, we previously showed that glomerular podocytes primarily convert Ang-I, the precursor of Ang-II, to Ang-(1-7) and Ang-(2-10), peptides that have been independently implicated in biological actions opposing those of Ang-II. Therefore, we hypothesized that Ang-(1-7) and Ang-(2-10) could be renoprotective in the fawn-hooded hypertensive rat, a model of focal segmental glomerulosclerosis. We evaluated the ability of 8-12 week-long intravenous administration of either Ang-(1-7) or Ang-(2-10) (100-400 ng/kg/min) to reduce glomerular injury in uni-nephrectomized fawn-hooded hypertensive rats, early or late in the disease. Vehicle-treated rats developed hypertension and lesions of focal segmental glomerulosclerosis. No reduction in glomerular damage was observed, as measured by either 24-hour urinary protein excretion or histological examination of glomerulosclerosis, upon Ang-(1-7) or Ang-(2-10) administration, regardless of peptide dose or disease stage. On the contrary, when given at 400 ng/kg/min, both peptides induced a further increase in systolic blood pressure. Content of Ang peptides was measured by parallel reaction monitoring in kidneys harvested at sacrifice. Exogenous administration of Ang-(1-7) and Ang-(2-10) did not lead to a significant increase in their corresponding intrarenal levels. However, the relative abundance of Ang-(1-7) with respect to Ang-II was increased in kidney homogenates of Ang-(1-7)-treated rats. We conclude that chronic intravenous administration of Ang-(1-7) or Ang-(2-10) does not ameliorate glomerular damage in a rat model of focal segmental glomerulosclerosis and may induce a further rise in blood pressure, potentially aggravating glomerular injury. C1 [Velez, Juan Carlos Q.; Janech, Michael G.; Hicks, Megan P.; Morinelli, Thomas A.; Rodgers, Jessalyn; Arthur, John M.; Fitzgibbon, Wayne R.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Velez, Juan Carlos Q.; Arthur, John M.] Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Charleston, SC USA. [Self, Sally E.] Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA. RP Velez, JCQ (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. EM velezj@musc.edu RI Velez, Juan Carlos/N-3782-2016 OI Janech, Michael/0000-0002-3202-4811 FU National Institute of Diabetes and Digestive and Kidney Diseases of the National Institute of Health [DK080944]; American Recovery and Reinvestment Act [DK080944]; Nephcure Foundation; Dialysis Clinics Incorporated FX This work was partially funded by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institute of Health (DK080944) (JCV), American Recovery and Reinvestment Act supplement to DK080944 (MPH and WRF), and The Nephcure Foundation (MGJ), and Dialysis Clinics Incorporated (JCV and TAM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 2 Z9 2 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 22 PY 2014 VL 9 IS 10 AR e110083 DI 10.1371/journal.pone.0110083 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AR6DY UT WOS:000343674800024 PM 25337950 ER PT J AU Luo, YC Cai, XN Liu, SC Wang, S Nold-Petry, CA Nold, MF Bufler, P Norris, D Dinarello, CA Fujita, M AF Luo, Yuchun Cai, Xiangna Liu, Sucai Wang, Sen Nold-Petry, Claudia A. Nold, Marcel F. Bufler, Philip Norris, David Dinarello, Charles A. Fujita, Mayumi TI Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE tolerance; skin inflammation; allergic contact dermatitis ID REGULATORY T-CELLS; CONTACT HYPERSENSITIVITY; LANGERHANS CELLS; IN-VIVO; MICE; INNATE; TOLERANCE; MEMBERS; DIFFERENTIATION; ACTIVATION AB IL-1 family member IL-37 limits innate inflammation in models of colitis and LPS-induced shock, but a role in adaptive immunity remains unknown. Here, we studied mice expressing human IL-37b isoform (IL-37tg) subjected to skin contact hypersensitivity (CHS) to dinitrofluorobenzene. CHS challenge to the hapten was significantly decreased in IL-37tg mice compared with wild-type (WT) mice (-61%; P < 0.001 at 48 h). Skin dendritic cells (DCs) were present and migrated to lymph nodes after antigen uptake in IL-37tg mice. When hapten-sensitized DCs were adoptively transferred to WT mice, antigen challenge was greatly impaired in mice receiving DCs from IL-37tg mice compared with those receiving DCs from WT mice (-60%; P < 0.01 at 48 h). In DCs isolated from IL-37tg mice, LPS-induced increase of MHC II and costimulatory molecule CD40 was reduced by 51 and 31%, respectively. In these DCs, release of IL-1 beta, IL-6, and IL-12 was reduced whereas IL-10 secretion increased (37%). Consistent with these findings, DCs from IL-37tg mice exhibited a lower ability to stimulate syngeneic and allogeneic naive T cells as well as antigen-specific T cells and displayed enhanced induction of T regulatory (Treg) cells (86%; P < 0.001) in vitro. Histological analysis of CHS skin in mice receiving hapten-sensitized DCs from IL-37tg mice revealed a marked reduction in CD8(+) T cells (-74%) but an increase in Treg cells (2.6-fold). Together, these findings reveal that DCs expressing IL-37 are tolerogenic, thereby impairing activation of effector T-cell responses and inducing Treg cells. IL-37 thus emerges as an inhibitor of adaptive immunity. C1 [Luo, Yuchun; Cai, Xiangna; Liu, Sucai; Wang, Sen; Norris, David; Fujita, Mayumi] Univ Colorado Denver, Dept Dermatol, Aurora, CO 80045 USA. [Dinarello, Charles A.] Univ Colorado Denver, Dept Med, Aurora, CO 80045 USA. [Cai, Xiangna; Wang, Sen] Shantou Univ, Coll Med, Affiliated Hosp 1, Dept Plast & Reconstruct Surg, Shantou City 515041, Peoples R China. [Nold-Petry, Claudia A.; Nold, Marcel F.] Monash Univ, Monash Inst Med Res, Ritchie Ctr, Melbourne, Vic 3800, Australia. [Bufler, Philip] Univ Munich, Childrens Hosp, D-80539 Munich, Germany. [Norris, David; Fujita, Mayumi] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Dinarello, CA (reprint author), Univ Colorado Denver, Dept Med, Aurora, CO 80045 USA. EM cdinarello@mac.com; mayumi.fujita@ucdenver.edu OI Nold, Marcel/0000-0001-9682-4618; Nold, Claudia/0000-0002-7439-3834 FU National Institutes of Health (NIH) [P30CA046934, P30AR057212]; NIH [P30AR057212, AI-15614]; Veterans Affairs Merit Review Award; Interleukin Foundation; Cancer League of Colorado; Tadamitsu Research Fund FX We thank Alistaire S. Acosta and Karen Helm [supported by National Institutes of Health (NIH) Grants P30CA046934 and P30AR057212], Laura Hoaglin (supported by NIH Grant P30AR057212), and Tania Azam for assisting with experiments, and Kasey Couts, PhD, and Zili Zhai, PhD, for critically reviewing the manuscript. This study was supported in part by research grants from the Veterans Affairs Merit Review Award (to M. F.), Interleukin Foundation (to M. F.), Cancer League of Colorado (to M. F.), Tadamitsu Research Fund (to M. F.), and NIH Pilot Grants P30AR057212 (to M. F.) and AI-15614 (to C.A.D.). NR 38 TC 35 Z9 41 U1 0 U2 8 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD OCT 21 PY 2014 VL 111 IS 42 BP 15178 EP 15183 DI 10.1073/pnas.1416714111 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AR0YN UT WOS:000343302600059 PM 25294929 ER PT J AU Backhus, LM Farjah, F Varghese, TK Cheng, AM Zhou, XH Wood, DE Kessler, L Zeliadt, SB AF Backhus, Leah M. Farjah, Farhood Varghese, Thomas K. Cheng, Aaron M. Zhou, Xiao-Hua Wood, Douglas E. Kessler, Larry Zeliadt, Steven B. TI Appropriateness of Imaging for Lung Cancer Staging in a National Cohort SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; MEDICARE BENEFICIARIES; BREAST-CANCER; BRONCHOGENIC-CARCINOMA; BONE METASTASES; UNITED-STATES; PET-CT; COST; CRITERIA(R); PROSTATE AB Purpose Optimizing evidence-based care to improve quality is a critical priority in the United States. We sought to examine adherence to imaging guideline recommendations for staging in patients with locally advanced lung cancer in a national cohort. Methods We identified 3,808 patients with stage IIB, IIIA, or IIIB lung cancer by using the national Department of Veterans Affairs (VA) Central Cancer Registry (2004-2007) and linked these patients to VA and Medicare databases to examine receipt of guideline-recommended imaging based on National Comprehensive Cancer Network and American College of Radiology Appropriateness Criteria. Our primary outcomes were receipt of guideline-recommended brain imaging and positron emission tomography (PET) imaging. We also examined rates of overuse defined as combined use of bone scintigraphy (BS) and PET, which current guidelines recommend against. All imaging was assessed during the period 180 days before and 180 days after diagnosis. Results Nearly 75% of patients received recommended brain imaging, and 60% received recommended PET imaging. Overuse of BS and PET occurred in 25% of patients. More advanced clinical stage and later year of diagnosis were the only clinical or demographic factors associated with higher rates of guideline-recommended imaging after adjusting for covariates. We observed considerable regional variation in recommended PET imaging and overuse of combined BS and PET. Conclusion Receipt of guideline-recommended imaging is not universal. PET appears to be underused overall, whereas BS demonstrates continued overuse. Wide regional variation suggests that these findings could be the result of local practice patterns, which may be amenable to provider education efforts such as Choosing Wisely. (C) 2014 by American Society of Clinical Oncology C1 [Backhus, Leah M.; Zhou, Xiao-Hua; Zeliadt, Steven B.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Backhus, Leah M.; Farjah, Farhood; Varghese, Thomas K.; Cheng, Aaron M.; Wood, Douglas E.; Kessler, Larry; Zeliadt, Steven B.] Univ Washington, Seattle, WA 98195 USA. RP Backhus, LM (reprint author), Univ Washington, Dept Surg, Div Cardiothorac Surg, 1959 NE Pacific St, Seattle, WA 98195 USA. EM lbackhus@u.washington.edu FU Department of Veterans Affairs [IIR 07-235-2]; National Cancer Institute [NCI 1RC2CA148433] FX Supported by Grants No. IIR 07-235-2 from the Department of Veterans Affairs and No. NCI 1RC2CA148433 from the National Cancer Institute. NR 40 TC 4 Z9 4 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD OCT 20 PY 2014 VL 32 IS 30 BP 3428 EP U266 DI 10.1200/JCO.2014.55.6589 PG 9 WC Oncology SC Oncology GA AR9GJ UT WOS:000343880800014 PM 25245440 ER PT J AU Fling, BW Dutta, GG Schlueter, H Cameron, MH Horak, FB AF Fling, Brett W. Dutta, Geetanjali Gera Schlueter, Heather Cameron, Michelle H. Horak, Fay B. TI Associations between proprioceptive neural pathway structural connectivity and balance in people with multiple sclerosis SO FRONTIERS IN HUMAN NEUROSCIENCE LA English DT Article DE somatosensory cortex; somatosensory disorders; white matter pathways; diffusion tensor imaging; diffusion tensor tractography; proprioception ID SUBJECT DIFFUSION DATA; WHITE-MATTER; POSTURAL CONTROL; SOMATOSENSORY INFORMATION; SPATIAL STATISTICS; VOXELWISE ANALYSIS; BRAIN; POSTUROGRAPHY; GAIT; REHABILITATION AB Mobility and balance impairments are a hallmark of multiple sclerosis (MS), affecting nearly half of patients at presentation and resulting in decreased activity and participation, falls, injuries, and reduced quality of life. A growing body of work suggests that balance impairments in people with mild MS are primarily the result of deficits in proprioception, the ability to determine body position in space in the absence of vision. A better understanding of the pathophysiology of balance disturbances in MS is needed to develop evidence-based rehabilitation approaches. The purpose of the current study was to (1) map the cortical proprioceptive pathway in vivo using diffusion-weighted imaging and (2) assess associations between proprioceptive pathway white matter microstructural integrity and performance on clinical and behavioral balance tasks. We hypothesized that people with MS (PwMS) would have reduced integrity of cerebral proprioceptive pathways, and that reduced white matter microstructure within these tracts would be strongly related to proprioceptive-based balance deficits. We found poorer balance control on proprioceptive-based tasks and reduced white matter microstructural integrity of the cortical proprioceptive tracts in PwMS compared with age-matched healthy controls (HC). Microstructural integrity of this pathway in the right hemisphere was also strongly associated with proprioceptive-based balance control in PwMS and controls. Conversely, while white matter integrity of the right hemisphere's proprioceptive pathway was significantly correlated with overall balance performance in HC, there was no such relationship in PwMS. These results augment existing literature suggesting that balance control in PwMS may become more dependent upon (1) cerebellar-regulated proprioceptive control, (2) the vestibular system, and/or (3) the visual system. C1 [Fling, Brett W.; Dutta, Geetanjali Gera; Schlueter, Heather; Cameron, Michelle H.; Horak, Fay B.] Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, Portland, OR 97239 USA. [Fling, Brett W.; Cameron, Michelle H.; Horak, Fay B.] Portland VA Med Ctr, Portland, OR USA. RP Fling, BW (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM fling@ohsu.edu FU National Multiple Sclerosis Society [PI: FG 2018-A-1, RG 5273A1/T, PI: MB 0011, PI: FG 2058-A-1]; Medical Research Foundation of Oregon; N.L. Tartar Research Fund FX We thank the volunteers for participating in this study and the Multiple Sclerosis Center of Oregon for referring patients. We are also grateful to Catherine Tallman for assistance in data analysis. This work was supported by grants from the National Multiple Sclerosis Society (Brett W. Fling, PI: FG 2018-A-1; RG 5273A1/T) and (Fay B. Horak, PI: MB 0011). Additional support was provided by the Medical Research Foundation of Oregon (Brett W. Fling, PI) and the N.L. Tartar Research Fund (Brett W. Fling, PI). Grant awarded by the National Multiple Sclerosis Society (Geetanjali Gera Dutta, PI: FG 2058-A-1). Additional support by the Medical Research Foundation of Oregon (Geetanjali Gera Dutta, PI). NR 79 TC 8 Z9 8 U1 2 U2 18 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1662-5161 J9 FRONT HUM NEUROSCI JI Front. Hum. Neurosci. PD OCT 20 PY 2014 VL 8 AR UNSP 814 DI 10.3389/fnhum.2014.00814 PG 11 WC Neurosciences; Psychology SC Neurosciences & Neurology; Psychology GA AR2GU UT WOS:000343402600001 PM 25368564 ER PT J AU Shah, MM Steele, EA White, KP Wilson, DJ AF Shah, Manjool M. Steele, Eric A. White, Kevin P. Wilson, David J. TI Syringoid eccrine carcinoma of the eyelid presenting as cicatricial entropion SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY LA English DT Letter ID MICROCYSTIC ADNEXAL CARCINOMA; SYRINGOMATOUS CARCINOMA; ORBIT C1 [Shah, Manjool M.; Steele, Eric A.; Wilson, David J.] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, Portland, OR 97239 USA. [Steele, Eric A.] Portland VA Med Ctr, Portland, OR 97201 USA. [White, Kevin P.] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97203 USA. RP Steele, EA (reprint author), Casey Eye Inst, Dept Ophthalmol, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU IJO PRESS PI XI AN PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA SN 2222-3959 EI 2227-4898 J9 INT J OPHTHALMOL-CHI JI Int. J. Ophthalmol. PD OCT 18 PY 2014 VL 7 IS 5 BP 912 EP 913 DI 10.3980/j.issn.2222-3959.2014.05.31 PG 2 WC Ophthalmology SC Ophthalmology GA AR0PD UT WOS:000343272900031 PM 25349816 ER PT J AU Das, F Bera, A Ghosh-Choudhury, N Abboud, HE Kasinath, BS Choudhury, GG AF Das, Falguni Bera, Amit Ghosh-Choudhury, Nandini Abboud, Hanna E. Kasinath, Balakuntalam S. Choudhury, Goutam Ghosh TI TGF beta-Induced Deptor Suppression Recruits mTORC1 and Not mTORC2 to Enhance Collagen I (alpha 2) Gene Expression SO PLOS ONE LA English DT Article ID MESANGIAL CELL HYPERTROPHY; PLASMINOGEN-ACTIVATOR INHIBITOR-1; SMOOTH-MUSCLE-CELLS; DIABETIC-NEPHROPATHY; MAMMALIAN TARGET; HIGH GLUCOSE; CALCINEURIN INHIBITORS; MESENCHYMAL TRANSITION; RAPAMYCIN COMPLEXES; SIGNAL-TRANSDUCTION AB Enhanced TGF beta activity contributes to the accumulation of matrix proteins including collagen I (alpha 2) by proximal tubular epithelial cells in progressive kidney disease. Although TGF beta rapidly activates its canonical Smad signaling pathway, it also recruits noncanonical pathway involving mTOR kinase to regulate renal matrix expansion. The mechanism by which chronic TGF beta treatment maintains increased mTOR activity to induce the matrix protein collagen I (alpha 2) expression is not known. Deptor is an mTOR interacting protein that suppresses mTOR activity in both mTORC1 and mTORC2. In proximal tubular epithelial cells, TGF beta reduced deptor levels in a time-dependent manner with concomitant increase in both mTORC1 and mTORC2 activities. Expression of deptor abrogated activity of mTORC1 and mTORC2, resulting in inhibition of collagen I (alpha 2) mRNA and protein expression via transcriptional mechanism. In contrast, neutralization of endogenous deptor by shRNAs increased activity of both mTOR complexes and expression of collagen I (alpha 2) similar to TGF beta treatment. Importantly, downregulation of deptor by TGF beta increased the expression of Hif1 alpha by increasing translation of its mRNA. TGF beta-induced deptor downregulation promotes Hif1 alpha binding to its cognate hypoxia responsive element in the collagen I (alpha 2) gene to control its protein expression via direct transcriptional mechanism. Interestingly, knockdown of raptor to specifically block mTORC1 activity significantly inhibited expression of collagen I (alpha 2) and Hif1 alpha while inhibition of rictor to prevent selectively mTORC2 activation did not have any effect. Critically, our data provide evidence for the requirement of TGF beta-activated mTORC1 only by deptor downregulation, which dominates upon the bystander mTORC2 activity for enhanced expression of collagen I (alpha 2). Our results also suggest the presence of a safeguard mechanism involving deptor-mediated suppression of mTORC1 activity against developing TGF beta-induced renal fibrosis. C1 [Das, Falguni; Bera, Amit; Abboud, Hanna E.; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [Ghosh-Choudhury, Nandini; Abboud, Hanna E.; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, VA Res, San Antonio, TX USA. RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu FU National Institutes of Health [RO1 DK50190]; Veterans Administration Research Service Merit Review [5I01BX000926]; Veterans Administration Senior Research Career Scientist Award; National Institutes of Health; VA Merit Review grants FX This work was supported by National Institutes of Health RO1 DK50190 and Veterans Administration Research Service Merit Review 5I01BX000926 grants to GGC. GGC is a recipient of Veterans Administration Senior Research Career Scientist Award. HEA is supported by National Institutes of Health. NGC and BSK are supported by VA Merit Review grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 83 TC 5 Z9 5 U1 3 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 15 PY 2014 VL 9 IS 10 AR e109608 DI 10.1371/journal.pone.0109608 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AX2IH UT WOS:000346766200044 PM 25333702 ER PT J AU Chattergoon, NN Louey, S Stork, PJ Giraud, GD Thornburg, KL AF Chattergoon, N. N. Louey, S. Stork, P. J. Giraud, G. D. Thornburg, K. L. TI Unexpected maturation of PI3K and MAPK-ERK signaling in fetal ovine cardiomyocytes SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE fetal heart; cardiomyocyte proliferation; thyroid hormone; MAPK; PI3K ID THYROID-HORMONE RECEPTOR; CELL-CYCLE ACTIVITY; CARDIAC MYOCYTES; DNA-SYNTHESIS; SHEEP FETUS; REGULATED KINASE; RAT MYOCARDIUM; NEONATAL-RAT; CROSS-TALK; C-FOS AB In the first two-thirds of gestation, ovine fetal cardiomyocytes undergo mitosis to increase cardiac mass and accommodate fetal growth. Thereafter, some myocytes continue to proliferate while others mature and terminally differentiate into binucleated cells. At term (145 days gestational age; dGA) about 60% of cardiomyocytes become binucleated and exit the cell cycle under hormonal control. Rising thyroid hormone (T-3) levels near term (135 dGA) inhibit proliferation and stimulate maturation. However, the degree to which intracellular signaling patterns change with age in response to T-3 is unknown. We hypothesized that in vitro activation of ERK, Akt, and p70(S6K) by two regulators of cardiomyocyte cell cycle activity, T-3 and insulin like growth factor-1 (IGF-1), would be similar in cardiomyocytes at gestational ages 100 and 135 dGA. IGF-1 and T-3 each independently stimulated phosphorylation of ERK, Akt, and p70(S6K) in cells at both ages. In the younger myocytes, the phosphorylation of ERK and Akt was reduced in the presence of IGF-1 and T-3. However, the same hormone combination led to a dramatic twofold increase in the phosphorylation of these signaling proteins in the 135 dGA cardiomyocytes-even in cells that were not proliferating. In the older cells, both mono- and binucleated cells were affected. In conclusion, fetal ovine cardiomyocytes undergo profound maturation-related changes in signaling in response to T-3 and IGF-1, but not to either factor alone. Differences in age-related response are likely to be related to milestones in fetal cardiac development as the myocardium prepares for ex utero life. C1 [Chattergoon, N. N.; Louey, S.; Stork, P. J.; Giraud, G. D.; Thornburg, K. L.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Ctr Dev Hlth, Portland, OR 97239 USA. [Louey, S.; Giraud, G. D.; Thornburg, K. L.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. [Stork, P. J.] Oregon Hlth & Sci Univ, Vollum Inst Adv Biomed Res, Portland, OR 97239 USA. [Giraud, G. D.] Portland VA Med Ctr, Portland, OR USA. RP Chattergoon, NN (reprint author), Oregon Hlth & Sci Univ, 3303 SW Bond Ave,CH15H, Portland, OR 97239 USA. EM chatterg@ohsu.edu FU National Institutes of Health [P01-HD-34430, R37-NS-045737, R01-HL-102763]; M. Lowell Edwards Endowment; National Heart, Lung, and Blood Institute [T32-HL-094294] FX This study was supported by National Institutes of Health Grants P01-HD-34430, R37-NS-045737, and R01-HL-102763. K. L. Thornburg was supported by the M. Lowell Edwards Endowment. N. N. Chattergoon was supported by National Heart, Lung, and Blood Institute Training Grant T32-HL-094294. NR 50 TC 7 Z9 7 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 EI 1522-1539 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD OCT 15 PY 2014 VL 307 IS 8 BP H1216 EP H1225 DI 10.1152/ajpheart.00833.2013 PG 10 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA AR0EY UT WOS:000343242400014 PM 25128174 ER PT J AU Bauer, KA Perez, KK Forrest, GN Goff, DA AF Bauer, Karri A. Perez, Katherine K. Forrest, Graeme N. Goff, Debra A. TI Review of Rapid Diagnostic Tests Used by Antimicrobial Stewardship Programs SO CLINICAL INFECTIOUS DISEASES LA English DT Review DE antimicrobial stewardship; rapid diagnostic test; outcomes; costs ID IN-SITU HYBRIDIZATION; POLYMERASE-CHAIN-REACTION; BLOOD-STREAM INFECTIONS; STAPHYLOCOCCUS-AUREUS BACTEREMIA; CLOSTRIDIUM-DIFFICILE INFECTION; GRAM-NEGATIVE BACTEREMIA; FLIGHT MASS-SPECTROMETRY; SEPTIC SHOCK; IMPACT; THERAPY AB Rapid microbiologic tests provide opportunities for antimicrobial stewardship programs to improve antimicrobial use and clinical and economic outcomes. Standard techniques for identification of organisms require at least 48-72 hours for final results, compared with rapid diagnostic tests that provide final organism identification within hours of growth. Importantly, rapid microbiologic tests are considered "game changers" and represent a significant advancement in the management of infectious diseases. This review focuses on currently available rapid diagnostic tests and, importantly, the impact of rapid testing in combination with antimicrobial stewardship on patient outcomes. C1 [Bauer, Karri A.; Goff, Debra A.] Ohio State Univ, Wexner Med Ctr, Dept Pharm, Columbus, OH 43210 USA. [Perez, Katherine K.] Houston Methodist Hosp, Dept Pharm, Houston, TX USA. [Perez, Katherine K.] Houston Methodist Hosp, Dept Pathol & Genom Med, Houston, TX USA. [Perez, Katherine K.] Houston Methodist Res Inst, Ctr Outcomes Res, Houston, TX USA. [Forrest, Graeme N.] Portland VA Med Ctr, Div Infect Dis, Portland, OR USA. RP Goff, DA (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Pharm, Doan Hall,410 W 10th Ave,Rm 368, Columbus, OH 43210 USA. EM debbie.goff@osumc.edu FU Cubist Pharmaceuticals FX This article appears as part of a supplement titled "Antimicrobial Stewardship: Patients Over Process," sponsored by Cubist Pharmaceuticals. NR 42 TC 32 Z9 33 U1 3 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2014 VL 59 SU 3 BP S134 EP S145 DI 10.1093/cid/ciu547 PG 12 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AR2KZ UT WOS:000343415900008 PM 25261540 ER PT J AU Forrest, GN Van Schooneveld, TC Kullar, R Schulz, LT Duong, P Postelnick, M AF Forrest, Graeme N. Van Schooneveld, Trevor C. Kullar, Ravina Schulz, Lucas T. Phu Duong Postelnick, Michael TI Use of Electronic Health Records and Clinical Decision Support Systems for Antimicrobial Stewardship SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE antimicrobial stewardship; clinical decision support system; electronic health record ID ORDER ENTRY SYSTEMS; ACUTE RESPIRATORY-INFECTIONS; RANDOMIZED CONTROLLED-TRIAL; INTENSIVE-CARE-UNIT; ANTIBIOTIC-TREATMENT; MEDICAL-RECORD; IMPACT; PROGRAM; SUSCEPTIBILITY; IMPLEMENTATION AB Electronic health records (EHRs) and clinical decision support systems (CDSSs) have the potential to enhance antimicrobial stewardship. Numerous EHRs and CDSSs are available and have the potential to enable all clinicians and antimicrobial stewardship programs (ASPs) to more efficiently review pharmacy, microbiology, and clinical data. Literature evaluating the impact of EHRs and CDSSs on patient outcomes is lacking, although EHRs with integrated CDSSs have demonstrated improvements in clinical and economic outcomes. Both technologies can be used to enhance existing ASPs and their implementation of core ASP strategies. Resolution of administrative, legal, and technical issues will enhance the acceptance and impact of these systems. EHR systems will increase in value when manufacturers include integrated ASP tools and CDSSs that do not require extensive commitment of information technology resources. Further research is needed to determine the true impact of current systems on ASP and the ultimate goal of improved patient outcomes through optimized antimicrobial use. C1 [Forrest, Graeme N.] Portland VA Med Ctr, Div Infect Dis, Portland, OR 97239 USA. [Van Schooneveld, Trevor C.] Univ Nebraska Med Ctr, Omaha, NE USA. [Kullar, Ravina; Phu Duong] Cubist Pharmaceut, Global Med Affairs, Lexington, MA USA. [Schulz, Lucas T.] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. [Postelnick, Michael] NW Mem Hosp, Chicago, IL 60611 USA. RP Forrest, GN (reprint author), Portland VA Med Ctr, Div Infect Dis, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM forrestg@ohsu.edu FU Cubist Pharmaceuticals FX This article appears as part of a supplement titled "Antimicrobial Stewardship: Patients Over Process," sponsored by Cubist Pharmaceuticals. NR 64 TC 16 Z9 16 U1 1 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2014 VL 59 SU 3 BP S122 EP S133 DI 10.1093/cid/ciu565 PG 12 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AR2KZ UT WOS:000343415900007 PM 25261539 ER PT J AU Lo Re, V Tate, JP Lim, JK Fiellin, DA Justice, AC AF Lo Re, Vincent, III Tate, Janet P. Lim, Joseph K. Fiellin, David A. Justice, Amy C. TI High Levels of Alcohol Consumption Increase the Risk of Advanced Hepatic Fibrosis in HIV/Hepatitis C Virus-Coinfected Patients: A Sex-Based Analysis Using Transient Elastography at Enrollment in the HEPAVIH ANRS CO13 Cohort Reply SO CLINICAL INFECTIOUS DISEASES LA English DT Letter C1 [Lo Re, Vincent, III] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Lo Re, Vincent, III] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Tate, Janet P.; Lim, Joseph K.; Justice, Amy C.] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA. [Tate, Janet P.; Lim, Joseph K.; Fiellin, David A.; Justice, Amy C.] Yale Univ, Sch Med, New Haven, CT USA. [Fiellin, David A.; Justice, Amy C.] Yale Univ, Sch Publ Hlth, Yale Ctr Interdisciplinary Res AIDS, New Haven, CT USA. RP Lo Re, V (reprint author), Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, 836 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM vincentl@mail.med.upenn.edu RI Lo Re, Vincent/N-7817-2015 NR 2 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2014 VL 59 IS 8 DI 10.1093/cid/ciu528 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AR2KG UT WOS:000343413200026 ER PT J AU Jarvie, JL Whooley, MA Regan, MC Sin, NL Cohen, BE AF Jarvie, Jennifer L. Whooley, Mary A. Regan, Mathilda C. Sin, Nancy L. Cohen, Beth E. TI Effect of Physical Activity Level on Biomarkers of Inflammation and Insulin Resistance Over 5 Years in Outpatients With Coronary Heart Disease (from the Heart and Soul Study) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID QUALITY-OF-LIFE; DEPRESSIVE SYMPTOMS; CONSTRUCT-VALIDITY; CHOLESTEROL; MEN; FITNESS; COHORT; WOMEN AB Higher levels of physical activity are associated with lower rates of coronary heart disease (CHD). Previous studies have suggested that this is due partly to lower levels of inflammation and insulin resistance. The aim of this study was to determine whether physical activity level was associated with inflammation or insulin resistance during a 5-year period in outpatients with known CHD. A total of 656 participants from the Heart and Soul Study, a prospective cohort study of outpatients with documented CHD, were evaluated. Self-reported physical activity frequency was assessed at baseline and after 5 years of follow-up. Participants were.classified as low versus high activity at each visit, yielding 4 physical activity groups: stable low activity, decreasing activity (high at baseline to low at year 5), increasing activity (low at baseline to high at year 5), and stable high activity. Year 5 markers of inflammation (C-reactive protein [CRP], interleulen-6, and fibrinogen) and insulin resistance (insulin, glucose, and glycated hemoglobin) were compared across the 4 activity groups. After 5 years of follow-up, higher activity was associated with lower mean levels of all biomarkers. In the fully adjusted regression models, CRP, interleukin-6, and glucose remained independently associated with physical activity frequency (log CRP, p for trend across activity groups = 0.03; log interleukin-6, p for trend = 0.01; log glucose, p for trend = 0.003). Subjects with stable high activity typically had the lowest levels of biomarkers. In conclusion, in this novel population of outpatients with known CHD followed for 5 years, higher physical activity frequency was independently associated with lower levels of CRP, interleukin-6, and glucose. (C) 2014 Elsevier Inc. All rights reserved. C1 [Jarvie, Jennifer L.; Whooley, Mary A.; Cohen, Beth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Whooley, Mary A.; Regan, Mathilda C.; Cohen, Beth E.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Sin, Nancy L.] Penn State Univ, Ctr Hlth Aging, University Pk, PA 16802 USA. RP Cohen, BE (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM beth.cohen@ucsf.edu OI /0000-0003-2519-7797 FU National Heart, Lung, and Blood Institute, Bethesda, Maryland [K23 HL 09476]; American Heart Association, Dallas, Texas [12CRP11810021]; National Institute on Aging, Bethesda, Maryland [T32 AG000212]; Department of Veterans Affairs, Washington, District of Columbia; National Heart, Lung, and Blood Institute [R01 HL079235]; American Federation for Aging Research (Paul Beeson Scholars Program), New York, New York; Robert Wood Johnson Foundation (Faculty Scholars Program), Princeton, New Jersey; Ischemia Research and Education Foundation, South San Francisco, California; Nancy Kirwan Heart Research Fund, San Francisco, California FX Dr. Cohen was supported by Grant K23 HL 09476 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland, and Grant 12CRP11810021 from the American Heart Association, Dallas, Texas. Dr.. Sin was supported by Institutional Training Grant T32 AG000212 from the National Institute on Aging, Bethesda, Maryland. The Heart and Soul Study was funded by the Department of Veterans Affairs, Washington, District of Columbia; grant R01 HL079235 from the National Heart, Lung, and Blood Institute; the American Federation for Aging Research (Paul Beeson Scholars Program), New York, New York; the Robert Wood Johnson Foundation (Faculty Scholars Program), Princeton, New Jersey; the Ischemia Research and Education Foundation, South San Francisco, California; and the Nancy Kirwan Heart Research Fund, San Francisco, California. NR 20 TC 7 Z9 8 U1 0 U2 4 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD OCT 15 PY 2014 VL 114 IS 8 BP 1192 EP 1197 DI 10.1016/j.amjcard.2014.07.036 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ7TE UT WOS:000343021300010 PM 25173442 ER PT J AU Fatemi, O Yuriditsky, E Tsioufis, C Tsachris, D Morgan, T Basile, J Bigger, T Cushman, W Goff, D Soliman, EZ Thomas, A Papademetriou, V AF Fatemi, Omid Yuriditsky, Eugene Tsioufis, Costas Tsachris, Demetrios Morgan, Timothy Basile, Jan Bigger, Thomas Cushman, William Goff, David Soliman, Elsayed Z. Thomas, Abraham Papademetriou, Vasilios TI Impact of Intensive Glycemic Control on the Incidence of Atrial Fibrillation and Associated Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID INDEPENDENT RISK; ACCORD TRIAL; HYPOGLYCEMIA; METAANALYSIS; DISEASE; COHORT AB Atrial fibrillation (AF) is prevalent in patients with type 2 diabetes mellitus (DM) and is associated with markers of poor glycemic control; however, the impact of glycemic control on incident AF and outcomes is unknown. The aims of this study were to prospectively evaluate if intensive glycemic control in patients with DM affects incident AF and to evaluate morbidity and mortality in patients with DM and incident AF. A total of 10,082 patients with DM from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) cohort were studied in a randomized, double-blind fashion. Participants were randomized to an intensive therapeutic strategy targeting a glycated hemoglobin level of <6.0% or a standard strategy targeting a glycated hemoglobin level of 7.0% to 7.9%. Incident AF occurred in 159 patients (1.58%) over the follow-up period, at a rate of 5.9 per 1,000 patient-years in the intensive-therapy group and a rate of 6.37 per 1,000 patient-years in the standard-therapy group (p = 0.52). In a multivariate model, predictors of incident AF were age, weight, diastolic blood pressure, heart rate, and heart failure history. Patients with DM and new-onset AF had a hazard ratio of 2.65 for all-cause mortality (95% confidence interval 1.8 to 3.86, p <0.0001), a hazard ratio of 2.1 for myocardial infarction (95% confidence interval 1.33 to 3.31, p = 0.0015), and a hazard ratio of 3.80 for the development of heart failure (95% confidence interval 2.48 to 5.84, p <0.0001). In conclusion, intensive glycemic control did not affect the rate of new-onset AF. Patients with DM and incident AF had an increased risk for morbidity and mortality compared with those without AF. (C) 2014 Elsevier Inc. All rights reserved. C1 [Fatemi, Omid; Yuriditsky, Eugene] Washington Hosp Ctr, Washington, DC 20010 USA. [Fatemi, Omid; Yuriditsky, Eugene; Papademetriou, Vasilios] Georgetown Univ Hosp, Washington, DC 20007 USA. [Fatemi, Omid; Yuriditsky, Eugene; Papademetriou, Vasilios] Washington DC Vet Med Ctr, Washington, DC USA. [Tsioufis, Costas; Tsachris, Demetrios] Univ Athens, Hippokrat Hosp, Athens, Greece. [Morgan, Timothy; Soliman, Elsayed Z.] Wake Forest Baptist Med Ctr, Winston Salem, NC USA. [Basile, Jan] Med Univ S Carolina, Charleston, SC 29425 USA. [Basile, Jan] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Bigger, Thomas] Columbia Univ, Med Ctr, New York, NY USA. [Cushman, William] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA. [Goff, David] Colorado Sch Publ Hlth, Aurora, CO USA. [Thomas, Abraham] Henry Ford Hlth Syst, Detroit, MI USA. RP Yuriditsky, E (reprint author), Washington Hosp Ctr, Washington, DC 20010 USA. EM eugene.yuriditsky@gmail.com OI Yuriditsky, Eugene/0000-0003-2263-9297; Thomas, Abraham/0000-0002-3941-1195; Papademetriou, Vasilios/0000-0002-2882-2757 FU National Heart, Lung, and Blood Institute, Bethesda, Maryland [Y01 HC001010] FX This study was funded by the National Heart, Lung, and Blood Institute (grant number Y01 HC001010), Bethesda, Maryland (ClinicalTrials.gov identifier NCT00000620). NR 27 TC 21 Z9 21 U1 1 U2 9 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD OCT 15 PY 2014 VL 114 IS 8 BP 1217 EP 1222 DI 10.1016/j.amjcard.2014.07.045 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AQ7TE UT WOS:000343021300015 PM 25159234 ER PT J AU Neuman, MD Wirtalla, C Werner, RM AF Neuman, Mark D. Wirtalla, Christopher Werner, Rachel M. TI Association Between Skilled Nursing Facility Quality Indicators and Hospital Readmissions SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID POST-ACUTE CARE; OF-CARE; RACIAL DISPARITIES; MEDICAID PAYMENT; HOME RESIDENTS; FOR-PROFIT; DEFICIENCIES; REHOSPITALIZATION; PROGRAM; COST AB IMPORTANCE Hospital readmissions are common, costly, and potentially preventable. Little is known about the association between available skilled nursing facility (SNF) performance measures and the risk of hospital readmission. OBJECTIVE To measure the association between SNF performance measures and hospital readmissions among Medicare beneficiaries receiving postacute care at SNFs in the United States. DESIGN AND PARTICIPANTS Using national Medicare data on fee-for-service Medicare beneficiaries discharged to a SNF after an acute care hospitalization between September 1, 2009, and August 31, 2010, we examined the association between SNF performance on publicly available metrics (SNF staffing intensity, health deficiencies identified through site inspections, and the percentages of SNF patients with delirium, moderate to severe pain, and new or worsening pressure ulcers) and the risk of readmission or death 30 days after discharge to a SNF. Adjusted analyses controlled for patient case mix, SNF facility factors, and the discharging hospital. MAIN OUTCOMES AND MEASURES Readmission to an acute care hospital or death within 30 days of the index hospital discharge. RESULTS Of 1 530 824 patients discharged, 357 752 (23.3%; 99% CI, 23.3%-23.5%) were readmitted or died within 30 days; 72 472 died within 30 days (4.7%; 99% CI, 4.7%-4.8%), and 321 709 were readmitted (21.0%; 99% CI, 20.9%-21.1%). The unadjusted risk of readmission or death was lower at SNFs with better staffing ratings and better facility inspection ratings. [GRAPHICS] Adjustment for patient factors, SNF facility factors, and the discharging hospital attenuated these associations; we observed small differences in the adjusted risk of readmission or death according to SNF facility inspection ratings. Other measures did not predict clinically meaningful differences in the adjusted risk of readmission or death. CONCLUSIONS AND RELEVANCE Among fee-for-service Medicare beneficiaries discharged to a SNF after an acute care hospitalization, available performance measures were not consistently associated with differences in the adjusted risk of readmission or death. Copyright 2014 American Medical Association. All rights reserved. C1 [Neuman, Mark D.] Univ Penn, Dept Anesthesiol & Crit Care, Perelman Sch Med, Philadelphia, PA 19104 USA. [Neuman, Mark D.; Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Wirtalla, Christopher; Werner, Rachel M.] Univ Penn, Div Gen Internal Med, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. RP Neuman, MD (reprint author), Univ Penn, Dept Anesthesiol & Crit Care, Perelman Sch Med, 423 Guardian Dr,1119A Blockley Hall, Philadelphia, PA 19104 USA. EM neumanm@mail.med.upenn.edu FU National Institute on Aging [K08AG043548, R01 AG034182] FX This work was supported by grants from the National Institute on Aging (grant K08AG043548 to Dr Neuman; grant R01 AG034182 to Dr Werner). NR 36 TC 20 Z9 20 U1 3 U2 13 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 15 PY 2014 VL 312 IS 15 BP 1542 EP 1551 DI 10.1001/jama.2014.13513 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA AQ7HL UT WOS:000342983200018 PM 25321909 ER PT J AU Rogers, T Milkman, KL Volpp, KG AF Rogers, Todd Milkman, Katherine L. Volpp, Kevin G. TI Commitment Devices to Improve Unhealthy Behaviors Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Rogers, Todd] Harvard Univ, Harvard Kennedy Sch, Boston, MA 02115 USA. [Milkman, Katherine L.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] UPENN Ctr Hlth Incent & Behav Econ, Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Volpp, KG (reprint author), Univ Penn, Philadelphia VA Med Ctr, Perelman Sch Med, 423 Guardian Dr, Philadelphia, PA 19104 USA. EM volpp70@exchange.upenn.edu NR 1 TC 0 Z9 0 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 15 PY 2014 VL 312 IS 15 BP 1592 EP 1593 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA AQ7HL UT WOS:000342983200031 PM 25321920 ER PT J AU Bera, A Das, F Ghosh-Choudhury, N Kasinath, BS Abboud, HE Choudhury, GG AF Bera, Amit Das, Falguni Ghosh-Choudhury, Nandini Kasinath, Balakuntalam S. Abboud, Hanna E. Choudhury, Goutam Ghosh TI microRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKK beta-mTORC1 axis to regulate renal cancer cell invasion SO EXPERIMENTAL CELL RESEARCH LA English DT Article DE Renal carcinoma; miR-21; Akt kinase; mTOR ID NF-KAPPA-B; TUMOR-SUPPRESSOR PDCD4; INITIATION-FACTOR 4A; KIDNEY CANCER; MAMMALIAN TARGET; BREAST-CANCER; TRANSFORMATION SUPPRESSOR; HEPATOCELLULAR-CARCINOMA; PROGRAMMED CELL-DEATH-4; MICRORNA EXPRESSION AB Renal cancer metastasis may result from oncogenic forces that contribute to the primary tumor. We have recently identified microRNA-21 as an oncogenic driver of renal cancer cells. The mechanism by which miR-21 controls renal cancer cell invasion is poorly understood. We show that miR-21 directly downregulates the proapoptotic protein PDCD4 to increase migration and invasion of ACHN and 786-O renal cancer cells as a result of phosphorylation/activation of Akt and IKK beta, which activate NF kappa B-dependent transcription. Constitutively active (CA) Akt or CA IKK beta blocks PDCD4-mediated inhibition and restores renal cancer cell migration and invasion. PDCD4 inhibits mTORC1 activity, which was reversed by CA IKK beta. Moreover, CA mTORC1 restores cell migration and invasion inhibited by PDCD4 and dominant negative IKK beta. Moreover, PDCD4 negatively regulates mTORC2-dependent Akt phosphorylation upstream of this cascade. We show that PDCD4 forms a complex with rictor, an exclusive component of mTORC2, and that this complex formation is reduced in renal cancer cells due to increased miR-21 expression resulting in enhanced phospholylation of Akt. Thus our results identify a previously unrecognized signaling node where high miR-21 levels reduce rictor PDCD4 interaction to increase phosphorylation of Akt and contribute to metastatic fitness of renal cancer cells. (C) 2014 Elsevier Inc. All rights reserved. C1 [Ghosh-Choudhury, Nandini; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Vet Adm Res Serv, San Antonio, TX USA. [Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Bera, Amit; Das, Falguni; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu FU VA Research Service Merit Review [5101BX000926, 5101BX000150]; NIH [RO1 DK50190]; VA Senior Research Career Scientist Award; VA Research Service grants; Cancer Therapy and Research Center at San Antonio FX The results described in this manuscript are the work supported by VA Research Service Merit Review 5101BX000926 and NIH RO1 DK50190 grants to GGC. GGC is a recipient of VA Senior Research Career Scientist Award. BSI and HEA are supported by NIH and VA Research Service grants (BSI and HEA). NGC is supported by VA Research Service Merit Review 5101BX000150 grant and a pilot grant from Cancer Therapy and Research Center at San Antonio. NR 129 TC 16 Z9 20 U1 0 U2 5 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4827 EI 1090-2422 J9 EXP CELL RES JI Exp. Cell Res. PD OCT 15 PY 2014 VL 328 IS 1 BP 99 EP 117 DI 10.1016/j.yexcr.2014.06.022 PG 19 WC Oncology; Cell Biology SC Oncology; Cell Biology GA AQ1KK UT WOS:000342540100008 PM 25016284 ER PT J AU Hsieh, CL Niemi, EC Wang, SH Lee, CC Bingham, D Zhang, JS Cozen, ML Charo, I Huang, EJ Liu, JL Nakamura, MC AF Hsieh, Christine L. Niemi, Erene C. Wang, Sarah H. Lee, Chih Cheng Bingham, Deborah Zhang, Jiasheng Cozen, Myrna L. Charo, Israel Huang, Eric J. Liu, Jialing Nakamura, Mary C. TI CCR2 Deficiency Impairs Macrophage Infiltration and Improves Cognitive Function after Traumatic Brain Injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE brain injury; CCR2; chemotaxis; inflammation; macrophage ID CHEMOKINE RECEPTOR CCR2; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; NEUROPATHIC PAIN; MOUSE MODEL; HIPPOCAMPAL NEUROGENESIS; MONOCYTE RECRUITMENT; CRANIAL IRRADIATION AB Traumatic brain injury (TBI) provokes inflammatory responses, including a dramatic rise in brain macrophages in the area of injury. The pathway(s) responsible for macrophage infiltration of the traumatically injured brain and the effects of macrophages on functional outcomes are not well understood. C-C-chemokine receptor 2 (CCR2) is known for directing monocytes to inflamed tissues. To assess the role of macrophages and CCR2 in TBI, we determined outcomes in CCR2-deficient (Ccr2(-/-)) mice in a controlled cortical impact model. We quantified brain myeloid cell numbers post-TBI by flow cytometry and found that Ccr2(-/-) mice had greatly reduced macrophage numbers (similar to 80-90% reduction) early post-TBI, compared with wild-type mice. Motor, locomotor, and cognitive outcomes were assessed. Lack of Ccr2 improved locomotor activity with less hyperactivity in open field testing, but did not affect anxiety levels or motor coordination on the rotarod three weeks after TBI. Importantly, Ccr2(-/-) mice demonstrated greater spatial learning and memory, compared with wildtype mice eight weeks after TBI. Although there was no difference in the volume of tissue loss, Ccr2(-/-) mice had significantly increased neuronal density in the CA1-CA3 regions of the hippocampus after TBI, compared with wild-type mice. These data demonstrate that Ccr2 directs the majority of macrophage homing to the brain early after TBI and indicates that Ccr2 may facilitate harmful responses. Lack of Ccr2 improves functional recovery and neuronal survival. These results suggest that therapeutic blockade of CCR2-dependent responses may improve outcomes following TBI. C1 [Hsieh, Christine L.; Niemi, Erene C.; Wang, Sarah H.; Nakamura, Mary C.] San Francisco VA Med Ctr, Immunol Sect, San Francisco, CA 94121 USA. [Lee, Chih Cheng; Bingham, Deborah; Liu, Jialing] San Francisco VA Med Ctr, Dept Neurol Surg, San Francisco, CA 94121 USA. [Zhang, Jiasheng; Huang, Eric J.] San Francisco VA Med Ctr, Pathol Serv, San Francisco, CA 94121 USA. [Cozen, Myrna L.] San Francisco VA Med Ctr, Ctr Liver, San Francisco, CA 94121 USA. [Hsieh, Christine L.; Niemi, Erene C.; Wang, Sarah H.; Cozen, Myrna L.; Charo, Israel; Nakamura, Mary C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Lee, Chih Cheng; Bingham, Deborah; Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA. [Zhang, Jiasheng; Huang, Eric J.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA. [Charo, Israel] Gladstone Inst Cardiovasc Dis, San Francisco, CA USA. RP Hsieh, CL (reprint author), San Francisco VA Med Ctr, Immunol Sect, 4150 Clement St,111-R Bldg 2,Room 500, San Francisco, CA 94121 USA. EM Christine.Hsieh@ucsf.edu RI Liu, Jialing/A-8627-2012 OI Liu, Jialing/0000-0003-4420-4382; Huang, Eric/0000-0002-5381-3801 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Career Development Award-2; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; Russell/Engelman Center for Arthritis Research FX The authors thank Ruby Gribi of the San Francisco VA Flow Cytometry core, Ivy Hsieh and Sherry Kamiya of the San Francisco VA Cell Imaging core for their dedication and contributions to this project. This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Career Development Award-2 to CLH. MCN is supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Merit Award and by the Russell/Engelman Center for Arthritis Research. With tremendous gratitude, we acknowledge Dr. William E. Seaman for helpful discussions and an insightful review of this manuscript. NR 80 TC 23 Z9 24 U1 1 U2 11 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD OCT 15 PY 2014 VL 31 IS 20 BP 1677 EP 1688 DI 10.1089/neu.2013.3252 PG 12 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA AP8BF UT WOS:000342302200001 PM 24806994 ER PT J AU Maddox, TM Stanislawski, MA O'Donnell, C Plomondon, ME Bradley, SM Ho, PM Tsai, TT Shroff, AR Speiser, B Jesse, RJ Rumsfeld, JS AF Maddox, Thomas M. Stanislawski, Maggie A. O'Donnell, Colin Plomondon, Mary E. Bradley, Steven M. Ho, P. Michael Tsai, Thomas T. Shroff, Adhir R. Speiser, Bernadette Jesse, Robert J. Rumsfeld, John S. TI Patient Access and 1-Year Outcomes of Percutaneous Coronary Intervention Facilities With and Without On-Site Cardiothoracic Surgery Insights From the Veterans Affairs (VA) Clinical Assessment, Reporting, and Tracking (CART) Program SO CIRCULATION LA English DT Article DE angioplasty; registries; stents; surgery ID CARDIOVASCULAR DATA REGISTRY; CARDIAC-SURGERY; RISK; HOSPITALS; PCI; PREDICTION; THERAPY; CENTERS AB Background-The safety of percutaneous coronary intervention (PCI) at medical facilities without on-site cardiothoracic (CT) surgery has been established in clinical trials. However, the comparative effectiveness of this strategy in real-world practice, including impact on patient access and outcomes, is uncertain. The Veterans Affairs (VA) health care system has used this strategy, with strict quality oversight, since 2005, and can provide insight into this question. Methods and Results-Among 24 387 patients receiving PCI at VA facilities between October 2007 and September 2010, 6616 (27.1%) patients underwent PCI at facilities (n=18) without on-site CT surgery. Patient drive time (as a proxy for access), procedural complications, 1-year mortality, myocardial infarction, and rates of subsequent revascularization procedures were compared by facility. Results were stratified by procedural indication (ST-segment-elevation myocardial infarction versus non-ST-segment-elevation myocardial infarction/unstable angina versus elective) and PCI volume. With the inclusion of PCI facilities without on-site CT surgery, median drive time for patients treated at those facilities decreased by 90.8 minutes (P<0.001). Procedural need for emergent coronary artery bypass graft and mortality rates were low and similar between facilities. Adjusted 1-year mortality and myocardial infarction rates were similar between facilities (hazard ratio in PCI facilities without relative to those with on-site CT surgery, 1.02; 95% confidence interval, 0.87-1.2), and not modified by either PCI indication or PCI volume. Subsequent revascularization rates were higher at sites without on-site CT surgery facilities (hazard ratio, 1.21; 95% confidence interval, 1.03-1.42). Conclusions-This study suggests that providing PCI facilities without on-site CT surgery in an integrated health care system with quality oversight improves patient access without compromising procedural or 1-year outcomes. C1 [Maddox, Thomas M.; Stanislawski, Maggie A.; O'Donnell, Colin; Plomondon, Mary E.; Bradley, Steven M.; Ho, P. Michael; Tsai, Thomas T.; Rumsfeld, John S.] VA Eastern Colorado Hlth Care Syst, Denver, CO 80220 USA. [Maddox, Thomas M.; Stanislawski, Maggie A.; O'Donnell, Colin; Plomondon, Mary E.; Ho, P. Michael; Tsai, Thomas T.; Rumsfeld, John S.] Univ Colorado, Sch Med, Denver, CO USA. [Tsai, Thomas T.] Kaiser Permanente Colorado, Denver, CO USA. [Shroff, Adhir R.; Speiser, Bernadette] Jesse Brown VA Med Ctr, Chicago, IL USA. [Jesse, Robert J.] Vet Hlth Adm, US Dept Vet Affairs, Washington, DC USA. RP Maddox, TM (reprint author), VA Eastern Colorado Hlth Care Syst, Cardiol 111B,1055 Clermont St, Denver, CO 80220 USA. EM thomas.maddox@va.gov FU Department of Veterans Affairs Health Services Research and Development career development awards FX Drs Maddox and Bradley are supported by the Department of Veterans Affairs Health Services Research and Development career development awards. The views in this manuscript are the authors' own and do not necessarily reflect those of the US Department of Veterans Affairs. NR 20 TC 4 Z9 4 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD OCT 14 PY 2014 VL 130 IS 16 BP 1383 EP 1391 DI 10.1161/CIRCULATIONAHA.114.009713 PG 9 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AR9DS UT WOS:000343872700014 PM 25189215 ER PT J AU Camus, M Jensen, DM Matthews, JD Ohning, GV Kovacs, TO Jutabha, R Ghassemi, KA Machicado, GA Dulai, GS AF Camus, Marine Jensen, Dennis M. Matthews, Jason D. Ohning, Gordon V. Kovacs, Thomas O. Jutabha, Rome Ghassemi, Kevin A. Machicado, Gustavo A. Dulai, Gareth S. TI Epistaxis in end stage liver disease masquerading as severe upper gastrointestinal hemorrhage SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Epistaxis; Upper gastrointestinal bleeding; End stage liver disease; Cirrhosis; Nasogastric tube; Liver transplantation; Digestive bleeding; Nasal packing; Coagulopathy ID INTENSIVE-CARE-UNIT; CIRRHOTIC-PATIENTS; SURVIVAL; HEMATEMESIS; OUTCOMES; MODEL AB AIM: To describe the prevalence, diagnosis, treatment, and outcomes of end stage liver disease (ESLD) patients with severe epistaxis thought to be severe upper gastrointestinal hemorrhage (UGIH). METHODS: This observational single center study included all consecutive patients with ESLD and epistaxis identified from consecutive subjects hospitalized with suspected UGIH and prospectively enrolled in our databases of severe UGIH between 1998 and 2011. RESULTS: A total of 1249 patients were registered for severe UGIH in the data basis, 461 (36.9%) were cirrhotics. Epistaxis rather than UGIH was the bleeding source in 20 patients. All patients had severe coagulopathy. Epistaxis was initially controlled in all cases. Fifteen (75%) subjects required posterior nasal packing and 2 (10%) embolization in addition to correction of coagulopathy. Five (25%) patients died in the hospital, 12 (60%) received orthotopic liver transplantation (OLT), and 3 (15%) were discharged without OLT. The mortality rate was 63% in patients without OLT. CONCLUSION: Severe epistaxis in patients with ESLD is (1) a diagnosis of exclusion that requires upper endoscopy to exclude severe UGIH; and (2) associated with a high mortality rate in patients not receiving OLT. (C) 2014 Baishideng Publishing Group Inc. All rights reserved. C1 [Camus, Marine; Jensen, Dennis M.; Ohning, Gordon V.; Kovacs, Thomas O.; Jutabha, Rome; Ghassemi, Kevin A.; Machicado, Gustavo A.; Dulai, Gareth S.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, CURE Hemostasis Res Grp, Los Angeles, CA 90095 USA. [Camus, Marine; Jensen, Dennis M.; Kovacs, Thomas O.; Jutabha, Rome; Ghassemi, Kevin A.; Machicado, Gustavo A.; Dulai, Gareth S.] Univ Calif Los Angeles, Ronald Reagan Med Ctr, Div Digest Dis, Los Angeles, CA 90095 USA. [Camus, Marine] Univ Paris 07, AP HP, Lariboisiere Hosp, Dept Gastroenterol, F-75010 Paris, France. [Jensen, Dennis M.; Ohning, Gordon V.; Kovacs, Thomas O.; Machicado, Gustavo A.; Dulai, Gareth S.] VA Greater Angeles Healthcare Syst, Div Gastroenterol, Los Angeles, CA 90095 USA. [Matthews, Jason D.] Hunterdon Gastrointestinal Associates, Flemington, NJ 08822 USA. RP Camus, M (reprint author), Lariboisiere Hosp, AP HP, Dept Gastroenterol, 2 Rue Ambroise Pare, F-75010 Paris, France. EM marine.camus@gmail.com FU National Institutes of Health [41301]; Veteran Administration Clinical Merit Review Grant; Philippe Foundation Grant FX Supported by National Institutes of Health, No. 41301; Veteran Administration Clinical Merit Review Grant, to Dr Dennis M Jensen; and Philippe Foundation Grant, to Dr. Marine Camus NR 15 TC 0 Z9 0 U1 0 U2 1 PU BAISHIDENG PUBLISHING GROUP INC PI PLEASANTON PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA SN 1007-9327 EI 2219-2840 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD OCT 14 PY 2014 VL 20 IS 38 BP 13993 EP 13998 DI 10.3748/wjg.v20.i38.13993 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AR9GU UT WOS:000343882100037 PM 25320538 ER PT J AU Hoffman, JR Kanzaria, HK AF Hoffman, Jerome R. Kanzaria, Hemal K. TI Intolerance of error and culture of blame drive medical excess SO BMJ-BRITISH MEDICAL JOURNAL LA English DT Editorial Material ID DEFENSIVE MEDICINE; CLINICAL-PRACTICE; MALPRACTICE; CARE; HEALTH; PHYSICIANS; REFORM; COSTS; ASSOCIATION; SPECIALTY AB Jerome R Hoffman and Hemal K Kanzaria argue that efforts to reduce overdiagnosis and overtreatment should focus on changing professional and public attitudes towards medical error and uncertainty C1 [Hoffman, Jerome R.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Kanzaria, Hemal K.] Univ Calif Los Angeles, Robert Wood Johnson Fdn Clin Scholars Program, US Dept Vet Affairs, Ctr Emergency Med, Los Angeles, CA 90024 USA. RP Hoffman, JR (reprint author), Univ Calif Los Angeles, Los Angeles, CA 90024 USA. EM jrh@ucla.edu NR 36 TC 19 Z9 19 U1 0 U2 8 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BMJ-BRIT MED J JI BMJ-British Medical Journal PD OCT 14 PY 2014 VL 349 AR g5702 DI 10.1136/bmj.g5702 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA AR7NT UT WOS:000343767300001 PM 25315302 ER PT J AU Felker, GM Teerlink, JR Butler, J Hernandez, AF Miller, AB Cotter, G Davison, BA Filippatos, G Greenberg, BH Ponikowski, P Voors, AA Hua, TA Severin, TM Unemori, E Metra, M AF Felker, G. Michael Teerlink, John R. Butler, Javed Hernandez, Adrian F. Miller, Alan B. Cotter, Gad Davison, Beth A. Filippatos, Gerasimos Greenberg, Barry H. Ponikowski, Piotr Voors, Adriaan A. Hua, Tsushung A. Severin, Thomas M. Unemori, Elaine Metra, Marco TI Effect of Serelaxin on Mode of Death in Acute Heart Failure Results From the RELAX-AHF Study SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE cause of death; heart failure; relaxin; sudden cardiac death ID LEFT-VENTRICULAR DYSFUNCTION; MYOCARDIAL-INFARCTION; TRIAL; RISK; OUTCOMES AB BACKGROUND Little is known about mode of death after acute heart failure (AHF) hospitalization. In the RELAX-AHF (Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure) study, serelaxin, the recombinant form of human relaxin-2, reduced post-discharge mortality at 180 days in selected patients with AHF. OBJECTIVES The goal of this study was to assess the effect of serelaxin on specific modes of death in patients with AHF. METHODS The RELAX-AHF study randomized 1,161 patients with AHF to 48 h of therapy with intravenous serelaxin or placebo. Patients were followed for vital status through 180 days. A blinded clinical events committee reviewed all deaths and adjudicated a cause of death on the basis of pre-specified criteria. Cox proportional hazard models were used to assess the effect of serelaxin on each mode of death, on the basis of pre-specified groupings of mode of death. RESULTS There were 107 deaths (9.3%): 37 (35%) due to HF, 25 (23%) due to sudden death, 15 (14%) due to other cardiovascular (CV) causes, 19 (18%) due to non-CV causes, and 11 (10%) classified as unknown. The treatment effect of serelaxin was most pronounced on other CV deaths (hazard ratio [HR]: 0.29; 95% CI: 0.12 to 0.73; p = 0.005) and sudden death (HR: 0.46; 95% CI: 0.20 to 1.07; p = 0.065). There was no apparent impact of serelaxin treatment on HF deaths or non-CV deaths. CONCLUSIONS In the RELAX-AHF study, the effects of serelaxin on mortality were primarily driven by reduction in mortality from other CV causes and sudden death, without apparent impact on HF deaths. (Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure [RELAX-AHF]; C1 [Felker, G. Michael; Hernandez, Adrian F.] Duke Univ, Sch Med, Div Cardiol, Durham, NC USA. [Felker, G. Michael; Hernandez, Adrian F.] Duke Univ, Med Ctr, Duke Heart Ctr, Durham, NC 27710 USA. [Teerlink, John R.] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Butler, Javed] Emory Univ, Div Cardiol, Atlanta, GA 30322 USA. [Miller, Alan B.] Univ Florida, Div Cardiol, Jacksonville, FL USA. [Cotter, Gad; Davison, Beth A.] Momentum Res Inc, Durham, NC USA. [Filippatos, Gerasimos] Athens Univ Hosp, Dept Cardiol, Attikon, Greece. [Greenberg, Barry H.] Univ Calif San Diego, Div Cardiol, San Diego, CA 92103 USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Dept Cardiol, Wroclaw, Poland. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Ek, Dept Cardiol, Groningen, Netherlands. [Hua, Tsushung A.] Novartis Pharmaceut, E Hanover, NJ USA. [Severin, Thomas M.] Novartis Pharma AG, Basel, Switzerland. [Unemori, Elaine] Corthera Inc, San Carlos, CA USA. [Metra, Marco] Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Brescia, Italy. RP Felker, GM (reprint author), Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA. EM michael.felker@duke.edu RI Lainscak, Mitja/F-3237-2015; Ponikowski, Piotr/O-6454-2015; Hernandez, Adrian F./A-7818-2016 OI Ponikowski, Piotr/0000-0002-3391-7064; Davison, Beth/0000-0003-2374-6449; Hernandez, Adrian F./0000-0003-3387-9616 FU Novartis; Amgen; Bayer; BG Medicine; CardioCell; Celladon; Gambro; GE Healthcare; Medtronic; Ono Pharmaceutical; Takeda; Trevena; Zensun; St. Jude Medical; BioControl; Pfizer; Respicardia; Merck; NovaCardia; Sorbent Therapeutics; Corthera; ChanRx; Cardio3; Servier Laboratories FX Drs. Felker and Teerlink have received consulting fees and research grants from Novartis. Dr. Butler has received consulting fees from Novartis, Amgen, Bayer, BG Medicine, CardioCell, Celladon, Gambro, GE Healthcare, Medtronic, Ono Pharmaceutical, Takeda, Trevena, and Zensun. Drs. Hernandez, Filippatos, Greenberg, Ponikowski, and Voors have received consulting fees from Novartis. Dr. Miller has received consulting fees from Novartis, St. Jude Medical, BioControl, Pfizer, Bayer, Respicardia, and Celladon. Drs. Cotter and Davison are employees of Momentum Research, which provided consulting and trial management services to Novartis and received research funding from Merck, NovaCardia, Sorbent Therapeutics, Trevena, Corthera, Novartis, ChanRx, Amgen, and Cardio3. Drs. Hua and Severin are employees of Novartis Pharma AG. Dr. Unemori is a former employee of Corthera, Inc. (a Novartis company). Dr. Metra has received consulting fees from Novartis, Bayer, and Servier Laboratories. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 21 TC 19 Z9 20 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD OCT 14 PY 2014 VL 64 IS 15 BP 1591 EP 1598 DI 10.1016/j.jacc.2014.05.071 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AR3EK UT WOS:000343470400009 PM 25301463 ER PT J AU Horan, WP Wynn, JK Mathis, I Miller, GA Green, MF AF Horan, William P. Wynn, Jonathan K. Mathis, Ian Miller, Gregory A. Green, Michael F. TI Approach and Withdrawal Motivation in Schizophrenia: An Examination of Frontal Brain Asymmetric Activity SO PLOS ONE LA English DT Article ID PSYCHIATRIC RATING-SCALE; EEG-ALPHA ASYMMETRY; AVOIDANCE MOTIVATION; INDIVIDUAL-DIFFERENCES; BEHAVIORAL ACTIVATION; EMOTION REGULATION; QUALITY-ASSURANCE; AFFECTIVE STYLE; DEPRESSION; ANXIETY AB Although motivational disturbances are common in schizophrenia, their neurophysiological and psychological basis is poorly understood. This electroencephalography (EEG) study examined the well-established motivational direction model of asymmetric frontal brain activity in schizophrenia. According to this model, relative left frontal activity in the resting EEG reflects enhanced approach motivation tendencies, whereas relative right frontal activity reflects enhanced withdrawal motivation tendencies. Twenty-five schizophrenia outpatients and 25 healthy controls completed resting EEG assessments of frontal asymmetry in the alpha frequency band (8-12 Hz), as well as a self-report measure of behavioral activation and inhibition system (BIS/BAS) sensitivity. Patients showed an atypical pattern of differences from controls. On the EEG measure patients failed to show the left lateralized activity that was present in controls, suggesting diminished approach motivation. On the self-report measure, patients reported higher BIS sensitivity than controls, which is typically interpreted as heightened withdrawal motivation. EEG asymmetry scores did not significantly correlate with BIS/BAS scores or with clinical symptom ratings among patients. The overall pattern suggests a motivational disturbance in schizophrenia characterized by elements of both diminished approach and elevated withdrawal tendencies. C1 [Horan, William P.; Wynn, Jonathan K.; Mathis, Ian; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Horan, William P.; Wynn, Jonathan K.; Mathis, Ian; Miller, Gregory A.; Green, Michael F.] Univ Calif Los Angeles, Los Angeles, CA USA. RP Horan, WP (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. EM horan@ucla.edu RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 FU NARSAD; NIMH [MH043292, MH065707] FX This work received support from a NARSAD Young Investigator Award (WPH), NIMH Grant MH043292 (MFG), and NIMH Grant MH065707 (MFG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 56 TC 5 Z9 5 U1 4 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 13 PY 2014 VL 9 IS 10 AR e110007 DI 10.1371/journal.pone.0110007 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AQ9WZ UT WOS:000343210300084 PM 25310340 ER PT J AU Yi, X Yuan, DF Farr, SA Banks, WA Poon, CD Kabanov, AV AF Yi, Xiang Yuan, Dongfen Farr, Susan A. Banks, William A. Poon, Chi-Duen Kabanov, Alexander V. TI Pluronic modified leptin with increased systemic circulation, brain uptake and efficacy for treatment of obesity SO JOURNAL OF CONTROLLED RELEASE LA English DT Article; Proceedings Paper CT 11th International Nanomedicine and Drug Delivery Symposium (NanoDDS) CY OCT 25-27, 2013 CL San Diego, CA DE Leptin; Pluronic block copolymer; Protein-polymer conjugation; Brain pharmacokinetics; Blood-brain barrier; Obesity ID MODIFIED SUPEROXIDE-DISMUTASE; SECONDARY STRUCTURE ANALYSES; GLYCOL-MODIFIED PROTEINS; RECOMBINANT HUMAN LEPTIN; WEIGHT-LOSS; POLY(ETHYLENE GLYCOL); MONOCLONAL-ANTIBODY; FOOD-INTAKE; PEG-OB; BARRIER AB Modification of hydrophilic proteins with amphiphilic block copolymers capable of crossing cell membranes is a new strategy to improve protein delivery to the brain. Leptin, a candidate for the treatment of epidemic obesity, has failed in part because of impairment in its transport across the blood-brain barrier (BBB) that develops with obesity. We posit that modification of leptin with poly(ethylene oxide)-b-poly(propylene oxide)-b-poly (ethylene oxide), Pluronic P85 (P85) might permit this protein to penetrate the BBB independently of its transporter, thereby overcoming peripheral leptin resistance. Here we report that peripherally administered leptin-P85 conjugates exhibit biological activity by reducing food intake in mouse models of obesity (ob/ob, and diet-induced obese mouse). We further generated two new leptin-P85 conjugates: one, Lep (ss)-P85 (L), containing one P85 chain and another, Lep(ss)-P85(H), containing multiple P85 chains. We report data on their purification, analytical characterization, peripheral and brain pharmacokinetics (PK). Lep(ss)-P85(L) crosses the BBB using the leptin transporter, and exhibits improved peripheral PK along with increased accumulation in the brain compared to unmodified leptin. Lep(ss)-P85(H) also has improved peripheral PK but in a striking difference to the first conjugate penetrates the BBB independently of the leptin transporter via a non-saturable mechanism. The results demonstrate that leptin analogs can be developed through chemical modification of the native leptin with P85 to overcome leptin resistance at the level of the BBB, thus improving the potential for the treatment of obesity. (C) 2014 Elsevier B.V. All rights reserved. C1 [Yi, Xiang; Yuan, Dongfen; Kabanov, Alexander V.] Univ N Carolina, Eshelman Sch Pharm, Ctr Nanotechnol Drug Delivery, Chapel Hill, NC 27599 USA. [Yi, Xiang; Yuan, Dongfen; Kabanov, Alexander V.] Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA. [Farr, Susan A.] St Louis Univ, Res & Dev, VA Med Ctr, Sch Med, St Louis, MI USA. [Farr, Susan A.] St Louis Univ, Div Geriatr, Sch Med, St Louis, MI USA. [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Banks, William A.] Univ Washington, Div Gerontol & Geriatr Med, Dept Med, Sch Med, Seattle, WA 98108 USA. [Poon, Chi-Duen] Univ N Carolina, Ctr Res Comp, Chapel Hill, NC 27599 USA. [Kabanov, Alexander V.] Moscow MV Lomonosov State Univ, Fac Chem, Moscow 119899, Russia. RP Yi, X (reprint author), Univ N Carolina, Ctr Nanotechnol Drug Delivery, UNC Eshelman Sch Pharm, Chapel Hill, NC 27599 USA. EM xiang_yi@unc.edu; kabanov@unc.edu FU NCI NIH HHS [P30 CA016086, CA016086]; NINDS NIH HHS [R01 NS051334] NR 56 TC 10 Z9 11 U1 1 U2 28 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-3659 EI 1873-4995 J9 J CONTROL RELEASE JI J. Control. Release PD OCT 10 PY 2014 VL 191 SI SI BP 34 EP 46 DI 10.1016/j.jconrel.2014.05.044 PG 13 WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy SC Chemistry; Pharmacology & Pharmacy GA AP7SA UT WOS:000342275800005 PM 24881856 ER PT J AU Walker, RJ Gebregziabher, M Martin-Harris, B Egede, LE AF Walker, Rebekah J. Gebregziabher, Mulugeta Martin-Harris, Bonnie Egede, Leonard E. TI Relationship between social determinants of health and processes and outcomes in adults with type 2 diabetes: validation of a conceptual framework SO BMC ENDOCRINE DISORDERS LA English DT Article DE Diabetes; Social determinants; Socioeconomic; Psychological; Glycemic control; Conceptual framework ID GLYCEMIC CONTROL; SELF-CARE; PSYCHOMETRIC PROPERTIES; SOCIOECONOMIC POSITION; SCALE; METAANALYSIS; VALIDITY; SUPPORT; QUESTIONNAIRE; DEPRESSION AB Background: The aim of this study was to empirically validate a conceptual framework and elucidate the pathways linking social determinants of health to outcomes in individuals with type 2 diabetes. Methods: 615 adults were recruited from adult primary care clinics in the southeastern United States. The model was estimated using path analysis to determine if socioeconomic (education, employment, income) and psychosocial (fatalism, self-efficacy, depression, diabetes distress, serious psychological distress, social support, and perceived stress) factors would independently predict glycemic control or be associated with mediator/moderators of self-care, access to care, and processes of care. Covariates were gender, age, race and health literacy. Results: The final model (chi2 (15) = 17.68, p = 0.28; RMSEA = 0.02, CFI = 0.99) showed lower glycemic control was directly associated with less hours worked (r = 0.13, p = 0.002), more fatalistic attitudes (r = -0.09, p = 0.03), more self-efficacy (r = -0.30, p < 0.001), and less diabetes distress (r = 0.12, p = 0.03), with the majority of total effects being direct. Significant paths associated self-care with diabetes distress (r = -0.14, p = 0.01) and perceived stress (r = -0.15, p = .001); access to care with income (r = 0.08, p = 0.03), diabetes distress (r = -0.21, p < 0.001) and social support (r = 0.08, p = 0.03); and processes of care with income (r = -0.11, p = 0.03), social support (r = 0.10, p = 0.04), and perceived stress (r = 0.10, p = 0.04). The paths explained 76% of the variance in the model. Conclusions: Consistent with the conceptual framework, social determinants were associated with glycemic control through a direct association and mediators/moderators of self-care, access to care and processes of care. This study provides the first validation of a conceptual framework for the relationship between socioeconomic and psychological components of social determinants of health and diabetes outcomes. C1 [Walker, Rebekah J.; Gebregziabher, Mulugeta; Egede, Leonard E.] Ralph H Johnson VAMC, Charleston VA HSR&D COIN, Hlth Equ & Rural Outreach Innovat Ctr HEROIC, Charleston, SC 29401 USA. [Walker, Rebekah J.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Walker, Rebekah J.; Martin-Harris, Bonnie] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta] Med Univ S Carolina, Dept Med, Div Publ Hlth Sci, Charleston, SC 29425 USA. [Martin-Harris, Bonnie] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Ralph H Johnson VAMC, Charleston VA HSR&D COIN, Hlth Equ & Rural Outreach Innovat Ctr HEROIC, Charleston, SC 29401 USA. EM egedel@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU National Institute of Diabetes and Digestive and Kidney Disease [K24DK093699-01] FX This study was supported by Grant K24DK093699-01 from The National Institute of Diabetes and Digestive and Kidney Disease (PI: Leonard Egede). NR 45 TC 8 Z9 8 U1 4 U2 20 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6823 J9 BMC ENDOCR DISORD JI BMC Endocr. Disord. PD OCT 9 PY 2014 VL 14 AR 82 DI 10.1186/1472-6823-14-82 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AT1PD UT WOS:000344705000001 PM 25298071 ER PT J AU Kaminer, Y Gordon, AJ AF Kaminer, Yifrah Gordon, Adam J. TI It Is Getting Late Here Early: Youth Substance Abuse Theory and Practice SO SUBSTANCE ABUSE LA English DT Editorial Material C1 [Kaminer, Yifrah] Univ Connecticut, Ctr Hlth, Dept Psychiat, Alcohol Res Ctr, Farmington, CT 06032 USA. [Kaminer, Yifrah] Univ Connecticut, Ctr Hlth, Dept Pediat, Alcohol Res Ctr, Farmington, CT USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA 15240 USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA 15240 USA. [Gordon, Adam J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. RP Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, CHERP, Univ Dr C,Bldg 30, Pittsburgh, PA 15240 USA. EM adam.gordon@va.gov NR 12 TC 3 Z9 3 U1 0 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PD OCT 2 PY 2014 VL 35 IS 4 SI SI BP 329 EP 330 DI 10.1080/08897077.2014.956023 PG 2 WC Substance Abuse SC Substance Abuse GA AW3MO UT WOS:000346191100001 PM 25148071 ER PT J AU Abdel-Mohsen, M Deng, XT Danesh, A Liegler, T Jacobs, ES Rauch, A Ledergerber, B Norris, PJ Gunthard, HF Wong, JK Pillai, SK AF Abdel-Mohsen, Mohamed Deng, Xutao Danesh, Ali Liegler, Teri Jacobs, Evan S. Rauch, Andri Ledergerber, Bruno Norris, Philip J. Guenthard, Huldrych F. Wong, Joseph K. Pillai, Satish K. TI Role of MicroRNA Modulation in the Interferon-alpha/Ribavirin Suppression of HIV-1 In Vivo SO PLOS ONE LA English DT Article ID PERSISTENT LCMV INFECTION; C VIRUS; ANTIRETROVIRAL ACTIVITY; PEGINTERFERON ALPHA-2A; RESTRICTION FACTORS; CELLULAR MICRORNAS; ELITE SUPPRESSORS; GENE-EXPRESSION; CELLS; APOPTOSIS AB Background: Interferon-alpha (IFN-alpha) treatment suppresses HIV-1 viremia and reduces the size of the HIV-1 latent reservoir. Therefore, investigation of the molecular and immunologic effects of IFN-alpha may provide insights that contribute to the development of novel prophylactic, therapeutic and curative strategies for HIV-1 infection. In this study, we hypothesized that microRNAs (miRNAs) contribute to the IFN-alpha-mediated suppression of HIV-1. To inform the development of novel miRNA-based antiretroviral strategies, we investigated the effects of exogenous IFN-alpha treatment on global miRNA expression profile, HIV-1 viremia, and potential regulatory networks between miRNAs and cell-intrinsic anti-HIV-1 host factors in vivo. Methods: Global miRNA expression was examined in longitudinal PBMC samples obtained from seven HIV/HCV-coinfected, antiretroviral therapy-naive individuals before, during, and after pegylated interferon-alpha/ribavirin therapy (IFN-alpha/RBV). We implemented novel hybrid computational-empirical approaches to characterize regulatory networks between miRNAs and anti-HIV-1 host restriction factors. Results: miR-422a was the only miRNA significantly modulated by IFN-alpha/RBV in vivo (p < 0.0001, paired t test; FDR < 0.037). Our interactome mapping revealed extensive regulatory involvement of miR-422a in p53-dependent apoptotic and pyroptotic pathways. Based on sequence homology and inverse expression relationships, 29 unique miRNAs may regulate anti-HIV-1 restriction factor expression in vivo. Conclusions: The specific reduction of miR-422a is associated with exogenous IFN-alpha treatment, and likely contributes to the IFN-alpha suppression of HIV-1 through the enhancement of anti-HIV-1 restriction factor expression and regulation of genes involved in programmed cell death. Moreover, our regulatory network analysis presents additional candidate miRNAs that may be targeted to enhance anti-HIV-1 restriction factor expression in vivo. C1 [Abdel-Mohsen, Mohamed; Liegler, Teri; Norris, Philip J.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Abdel-Mohsen, Mohamed; Deng, Xutao; Danesh, Ali; Jacobs, Evan S.; Norris, Philip J.; Pillai, Satish K.] Blood Syst Res Inst, San Francisco, CA 94118 USA. [Rauch, Andri] Univ Hosp Bern, Dept Infect Dis, CH-3010 Bern, Switzerland. [Rauch, Andri] Univ Bern, Bern, Switzerland. [Ledergerber, Bruno; Guenthard, Huldrych F.] Univ Zurich, Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland. [Norris, Philip J.; Pillai, Satish K.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. [Wong, Joseph K.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Pillai, SK (reprint author), Blood Syst Res Inst, San Francisco, CA 94118 USA. EM satish.pillai@ucsf.edu RI SHCS, int. coll. A/G-4083-2011; Infektiologie, USZ/A-6921-2011; SHCS, all/G-4072-2011; Ledergerber, Bruno/B-5656-2009; gunthard, huldrych/F-1724-2011 OI Ledergerber, Bruno/0000-0002-6881-4401; gunthard, huldrych/0000-0002-1142-6723 FU National Institutes of Health [1K01DA024654]; University of California, San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research [P30 AI027763]; Swiss HIV Cohort Study Project [594]; Swiss National Science Foundation [324730-130865, 33CS30-134277]; Swiss HIV Cohort Study Research Foundation FX This study was supported by grants from the National Institutes of Health 1K01DA024654, and the University of California, San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research (grant number P30 AI027763). Additional support was provided by Swiss HIV Cohort Study Project 594 and Swiss National Science Foundation Grant 324730-130865. The Swiss HIV Cohort Study is supported by Swiss National Science Foundation Grant 33CS30-134277 and the Swiss HIV Cohort Study Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 63 TC 3 Z9 3 U1 0 U2 33 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 2 PY 2014 VL 9 IS 10 AR e109220 DI 10.1371/journal.pone.0109220 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AQ2BX UT WOS:000342591500077 PM 25275557 ER PT J AU Anderson, CE Stewart, L AF Anderson, Cristan E. Stewart, Lygia TI Hyperbilirubinemia and complicated acute cholecystitis: improving preoperative diagnostic strategies SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT 100th Annual Clinical Congress of the American-College-of-Surgeons CY OCT 26-30, 2014 CL San Francisco, CA SP Amer Coll Surg C1 San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2014 VL 219 IS 4 SU S BP E114 EP E114 PG 1 WC Surgery SC Surgery GA CR1UU UT WOS:000361111400273 ER PT J AU Gibbs, VC Pelletreau, B Wiebe, R AF Gibbs, Verna C. Pelletreau, Barbara Wiebe, Robert TI Large-scale system-wide success with an ACCOUNTing process to eliminate surgical sponge retention SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT 100th Annual Clinical Congress of the American-College-of-Surgeons CY OCT 26-30, 2014 CL San Francisco, CA SP Amer Coll Surg C1 Dign Hlth, San Francisco, CA USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2014 VL 219 IS 4 SU S BP E35 EP E36 PG 2 WC Surgery SC Surgery GA CR1UU UT WOS:000361111400078 ER PT J AU Gunnar, WP Wilson, MA Smith, T AF Gunnar, William P. Wilson, Mark A. Smith, Tracy TI Three year analysis of the surgical complexity model in the Veterans Health Administration (VHA) SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT 100th Annual Clinical Congress of the American-College-of-Surgeons CY OCT 26-30, 2014 CL San Francisco, CA SP Amer Coll Surg C1 [Gunnar, William P.; Wilson, Mark A.; Smith, Tracy] US Dept Vet Affairs, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2014 VL 219 IS 4 SU S BP E141 EP E142 PG 2 WC Surgery SC Surgery GA CR1UU UT WOS:000361111400340 ER PT J AU Zimmet, J Kaiser, E Tseng, E Shunk, K AF Zimmet, Jeffrey Kaiser, Erhard Tseng, Elaine Shunk, Kendrick TI Successful Percutaneous Management of Partial Avulsion of the Native Aortic Valve Complex Complicating Transcatheter Aortic Valve Replacement SO JOURNAL OF INVASIVE CARDIOLOGY LA English DT Article DE balloon aortic valvuloplasty; aortic valve stenosis ID HIGH-RISK; VALVULOPLASTY; IMPLANTATION; RUPTURE AB This is the first reported case of partial aortic valve and annulus rupture during transcatheter aortic valve replacement, and its successful management through percutaneous means. It stresses the fact that even severe procedural complications can often be treated by a heart team endovascularly, without requiring sternotomy. C1 [Zimmet, Jeffrey] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Tseng, Elaine] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Zimmet, Jeffrey] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Kaiser, Erhard] Kardiol Privatarztpraxis, Frankfurt, Germany. RP Zimmet, J (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Cardiol 111C, San Francisco, CA 94121 USA. EM Jeffrey.Zimmet@va.gov FU Edwards Lifesciences; University of California; Coulter Foundation; Siemens Medical Systems; TransAortic Medical Inc. FX The authors have completed and returned the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Zimmet reports no disclosures. Dr Kaiser reports personal fees from Edwards Lifesciences. Dr Tseng reports grants from University of California and the Coulter Foundation. Dr Shunk reports a grant from Siemens Medical Systems and consulting fees from TransAortic Medical Inc. NR 11 TC 0 Z9 0 U1 0 U2 0 PU H M P COMMUNICATIONS PI MALVERN PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA SN 1042-3931 EI 1557-2501 J9 J INVASIVE CARDIOL JI J. Invasive Cardiol. PD OCT PY 2014 VL 26 IS 10 BP E137 EP E140 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CN1SH UT WOS:000358199900002 PM 25274870 ER PT J AU Womack, JA Chang, CCH So-Armah, KA Alcorn, C Baker, JV Brown, ST Budoff, M Butt, AA Gibert, C Goetz, MB Gottdiener, J Gottlieb, S Justice, AC Leaf, D McGinnis, K Rimland, D Rodriguez-Barradas, MC Sico, J Skanderson, M Tindle, H Tracy, RP Warner, A Freiberg, MS AF Womack, Julie A. Chang, Chung-Chou H. So-Armah, Kaku A. Alcorn, Charles Baker, Jason V. Brown, Sheldon T. Budoff, Matthew Butt, Adeel A. Gibert, Cynthia Goetz, Matthew Bidwell Gottdiener, John Gottlieb, Stephen Justice, Amy C. Leaf, David McGinnis, Kathleen Rimland, David Rodriguez-Barradas, Maria C. Sico, Jason Skanderson, Melissa Tindle, Hilary Tracy, Russell P. Warner, Alberta Freiberg, Matthew S. TI HIV Infection and Cardiovascular Disease in Women SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE AIDS; CVD risk factors; Women ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACUTE MYOCARDIAL-INFARCTION; CORONARY-HEART-DISEASE; IMMUNE ACTIVATION; RISK-FACTORS; HEALTH; VETERANS; COHORT; ATHEROSCLEROSIS; POPULATION AB Background-HIV infection is associated with increased risk of cardiovascular disease (CVD) in men. Whether HIV is an independent risk factor for CVD in women has not yet been established. Methods and Results-We analyzed data from the Veterans Aging Cohort Study on 2187 women (32% HIV infected [HIV+]) who were free of CVD at baseline. Participants were followed from their first clinical encounter on or after April 01, 2003 until a CVD event, death, or the last follow-up date (December 31, 2009). The primary outcome was CVD (acute myocardial infarction [AMI], unstable angina, ischemic stroke, and heart failure). CVD events were defined using clinical data, International Classification of Diseases, Ninth Revision, Clinical Modification codes, and/or death certificate data. We used Cox proportional hazards models to assess the association between HIV and incident CVD, adjusting for age, race/ethnicity, lipids, smoking, blood pressure, diabetes, renal disease, obesity, hepatitis C, and substance use/abuse. Median follow-up time was 6.0 years. Mean age at baseline of HIV+ and HIV uninfected (HIV-) women was 44.0 versus 43.2 years (P<0.05). Median time to CVD event was 3.1 versus 3.7 years (P=0.11). There were 86 incident CVD events (53%, HIV+): AMI, 13%; unstable angina, 8%; ischemic stroke, 22%; and heart failure, 57%. Incident CVD/1000 person-years was significantly higher among HIV+ (13.5; 95% confidence interval [CI]= 10.1, 18.1) than HIV- women (5.3; 95% CI=3.9, 7.3; P<0.001). HIV+ women had an increased risk of CVD, compared to HIV- (hazard ratio=2.8; 95% CI=1.7, 4.6; P<0.001). Conclusions-HIV is associated with an increased risk of CVD in women. C1 [Womack, Julie A.] Yale Univ, Sch Nursing, West Haven, CT 06516 USA. [Chang, Chung-Chou H.; Butt, Adeel A.; Tindle, Hilary] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Chang, Chung-Chou H.; Alcorn, Charles] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [So-Armah, Kaku A.; Justice, Amy C.; Sico, Jason] Yale Univ, Sch Med, New Haven, CT USA. [Baker, Jason V.] Univ Minnesota, Dept Med, Hennepin Cty Med Ctr, Minneapolis, MN 55455 USA. [Brown, Sheldon T.] James J Peters VA Med Ctr, Bronx, NY USA. [Brown, Sheldon T.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Budoff, Matthew] Harbor UCLA Med Ctr, Los Angeles, CA USA. [Budoff, Matthew] Los Angeles Biomed Res Inst, Los Angeles, CA USA. [Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Butt, Adeel A.] Sheikh Khalifa Med City, Abu Dhabi, U Arab Emirates. [Gibert, Cynthia] VA Med Ctr, Washington, DC USA. [Gibert, Cynthia] George Washington Univ, Sch Med, Washington, DC USA. [Goetz, Matthew Bidwell; Leaf, David; Warner, Alberta] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Goetz, Matthew Bidwell; Leaf, David; Warner, Alberta] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Gottdiener, John; Gottlieb, Stephen] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Justice, Amy C.; McGinnis, Kathleen; Sico, Jason; Skanderson, Melissa] Vet Affairs Connecticut Hlth Care Syst, West Haven Vet Adm Med Ctr, West Haven, CT USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Tracy, Russell P.] Univ Vermont, Coll Med, Burlington, VT USA. [Freiberg, Matthew S.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. RP Womack, JA (reprint author), Yale Univ, Sch Nursing, Yale Univ West Campus,POB 27399,300 Heffernan Dr, West Haven, CT 06516 USA. EM julie.womack@yale.edu OI Butt, Adeel/0000-0002-1118-1826 FU Yale Center for Clinical Investigation and the Clinical and Translational Science Award from the National Center for Research Resources of the National Institutes of Health (NIH) [UL1 RR024139]; National Institute of Nursing Research of the National Institutes of Health (NIH) [K01 NR013437]; National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) [HL095136]; National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health (NIH) [AA013566-10, AA020790, AA020794] FX This work was supported by the Yale Center for Clinical Investigation and the Clinical and Translational Science Award Grant No. UL1 RR024139 from the National Center for Research Resources; National Institute of Nursing Research Grant No. K01 NR013437; National Heart, Lung and Blood Institute Grant No. HL095136; and the National Institute on Alcohol Abuse and Alcoholism Grant Nos. AA013566-10, AA020790, and AA020794, all components of the National Institutes of Health (NIH). NR 26 TC 20 Z9 20 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD OCT PY 2014 VL 3 IS 5 AR e001035 DI 10.1161/JAHA.114.001035 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CM0VL UT WOS:000357396800013 PM 25324353 ER PT J AU Agarwal, A Carey, A Traer, E Tyner, J Bagby, GC Druker, BJ AF Agarwal, Anupriya Carey, Alyssa Traer, Elie Tyner, Jeffrey Bagby, Grover C. Druker, Brian J. TI Targeted suppression of interleukin-1 signaling inhibits growth of primary human acute myeloid leukemia cells SO CANCER RESEARCH LA English DT Meeting Abstract CT 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 05-09, 2014 CL San Diego, CA SP Amer Assoc Canc Res C1 [Agarwal, Anupriya; Carey, Alyssa; Traer, Elie; Bagby, Grover C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA. [Tyner, Jeffrey] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Knight Canc Inst, Portland, OR 97201 USA. [Bagby, Grover C.] Portland VA Med Ctr, Portland, OR 97201 USA. [Druker, Brian J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. [Druker, Brian J.] Howard Hughes Med Inst, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT 1 PY 2014 VL 74 IS 19 SU S MA 5248 DI 10.1158/1538-7445.AM2014-5248 PG 2 WC Oncology SC Oncology GA CB8VR UT WOS:000349910204198 ER PT J AU Chiyomaru, T Fukuhara, S Saini, S Majid, S Deng, G Shahryary, V Chang, I Tanaka, Y Enokida, H Nakagawa, M Dahiya, R Yamamura, S AF Chiyomaru, Takeshi Fukuhara, Shinichiro Saini, Sharanjot Majid, Shahana Deng, Guoren Shahryary, Varahram Chang, Inik Tanaka, Yuichiro Enokida, Hideki Nakagawa, Masayuki Dahiya, Rajvir Yamamura, Soichiro TI Long noncoding RNA HOTAIR is targeted and regulated by microRNA-141 in renal carcinoma cells SO CANCER RESEARCH LA English DT Meeting Abstract CT 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 05-09, 2014 CL San Diego, CA SP Amer Assoc Canc Res C1 [Chiyomaru, Takeshi; Fukuhara, Shinichiro; Saini, Sharanjot; Majid, Shahana; Deng, Guoren; Shahryary, Varahram; Chang, Inik; Tanaka, Yuichiro; Dahiya, Rajvir; Yamamura, Soichiro] San Francisco VA Med Ctr, San Francisco, CA USA. [Enokida, Hideki; Nakagawa, Masayuki] Kagoshima Univ, Kagoshima 890, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT 1 PY 2014 VL 74 IS 19 SU S MA 4357 DI 10.1158/1538-7445.AM2014-4357 PG 1 WC Oncology SC Oncology GA CB8VR UT WOS:000349910202333 ER PT J AU Katiyar, SK Singh, T Vaid, M AF Katiyar, Santosh K. Singh, Tripti Vaid, Mudit TI Dietary grape seed proanthocyanidins inhibit UV-induced immune suppression by targeting the development of regulatory T cells in mice SO CANCER RESEARCH LA English DT Meeting Abstract CT 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 05-09, 2014 CL San Diego, CA SP Amer Assoc Canc Res C1 [Katiyar, Santosh K.; Singh, Tripti; Vaid, Mudit] Univ Alabama Birmingham, Birmingham, AL USA. [Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT 1 PY 2014 VL 74 IS 19 SU S MA 1239 DI 10.1158/1538-7445.AM2014-1239 PG 1 WC Oncology SC Oncology GA CB8UN UT WOS:000349906900477 ER PT J AU Liu, G Sprenger, C Wu, PJ Sun, SH Uo, T Haugk, K Epilepsia, KS Plymate, S AF Liu, Gang Sprenger, Cynthia Wu, Pin-Jou Sun, Shihua Uo, Takuma Haugk, Kathleen Epilepsia, Kathryn Soriano Plymate, Stephen TI Phospho-MED1 mediates the transcriptional regulation of AR splice variants in castration-resistant prostate cancer SO CANCER RESEARCH LA English DT Meeting Abstract CT 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 05-09, 2014 CL San Diego, CA SP Amer Assoc Canc Res C1 [Liu, Gang; Sprenger, Cynthia; Wu, Pin-Jou; Sun, Shihua; Uo, Takuma; Epilepsia, Kathryn Soriano; Plymate, Stephen] Univ Washington, Seattle, WA 98195 USA. [Haugk, Kathleen] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT 1 PY 2014 VL 74 IS 19 SU S MA 2324 DI 10.1158/1538-7445.AM2014-2324 PG 1 WC Oncology SC Oncology GA CB8UN UT WOS:000349906903045 ER PT J AU Merrick, DT Edwards, MG Franklin, WA Sugita, M Friedman, M Miller, YE Dwyer-Nield, L Tennis, M Choo, K Hickey, G Adriaan, V Heasley, L Bunn, PA Geraci, M Keith, RL Nemenoff, R AF Merrick, Daniel T. Edwards, Michael G. Franklin, Wilbur A. Sugita, Michio Friedman, Micah Miller, York E. Dwyer-Nield, Lori Tennis, Meredith Choo, Kevin Hickey, Greg Adriaan, van Bokhoven Heasley, Lynn Bunn, Paul A. Geraci, Mark Keith, Robert L. Nemenoff, Raphael TI Gene expression analysis of persistent and regressive bronchial dysplasia identifies polo-like kinase 1 (PLK1) and epoxide hydrolase 3 (EPHX3) as potential mediators of malignant progression SO CANCER RESEARCH LA English DT Meeting Abstract CT 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 05-09, 2014 CL San Diego, CA SP Amer Assoc Canc Res C1 [Merrick, Daniel T.; Friedman, Micah; Miller, York E.; Dwyer-Nield, Lori; Choo, Kevin; Keith, Robert L.] Denver VAMC, Denver, CO USA. [Edwards, Michael G.; Franklin, Wilbur A.; Sugita, Michio; Tennis, Meredith; Hickey, Greg; Adriaan, van Bokhoven; Heasley, Lynn; Bunn, Paul A.; Geraci, Mark; Nemenoff, Raphael] Univ Colorado, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT 1 PY 2014 VL 74 IS 19 SU S MA 231 DI 10.1158/1538-7445.AM2014-231 PG 2 WC Oncology SC Oncology GA CB8UN UT WOS:000349906903029 ER PT J AU Mirkheshti, N Song, C Chatterjee, B AF Mirkheshti, Nooshin Song, Chung Chatterjee, Bandana TI The antibiotic salinomycin cotargets two pivotal pathways in prostate cancer SO CANCER RESEARCH LA English DT Meeting Abstract CT 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 05-09, 2014 CL San Diego, CA SP Amer Assoc Canc Res C1 [Mirkheshti, Nooshin; Song, Chung] UT Hlth Sci Ctr San Antonio, San Antonio, TX USA. [Chatterjee, Bandana] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT 1 PY 2014 VL 74 IS 19 SU S MA 3312 DI 10.1158/1538-7445.AM2014-3312 PG 1 WC Oncology SC Oncology GA CB8VR UT WOS:000349910200312 ER PT J AU Morgan, T Meyskens, FL Hoefs, J Hu, KQ Hassanein, T Boyer, TD Pimstone, NR Osann, K Gonzalez, R Rodriguez, LM AF Morgan, Timothy Meyskens, Frank L. Hoefs, John Hu, Ke-Qin Hassanein, Tarek Boyer, Thomas D. Pimstone, Neville R. Osann, Kathy Gonzalez, Rachel Rodriguez, L. M. TI SAMe versus placebo for the reduction of serum AFP in patients with hepatitis C cirrhosis and moderately elevated AFP: A randomized, placebo-controlled, double-blind phase II trial SO CANCER RESEARCH LA English DT Meeting Abstract CT 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 05-09, 2014 CL San Diego, CA SP Amer Assoc Canc Res C1 [Morgan, Timothy; Meyskens, Frank L.; Hoefs, John; Hu, Ke-Qin; Osann, Kathy] Univ Calif Irvine, Orange, CA 92668 USA. [Hassanein, Tarek] Univ Calilfornia San Diego, San Diego, CA USA. [Boyer, Thomas D.] Univ Arizona Hlth Sci Ctr, Tucson, AZ USA. [Pimstone, Neville R.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Gonzalez, Rachel] VA Long Beach Healthcare Syst, Long Beach, CA USA. [Rodriguez, L. M.] Natl Canc Inst DCP GOCRG, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT 1 PY 2014 VL 74 IS 19 SU S MA 3247 DI 10.1158/1538-7445.AM2014-3247 PG 1 WC Oncology SC Oncology GA CB8VR UT WOS:000349910200248 ER PT J AU Mysore, VS Nickols, NG Szablowski, J Dervan, P Lichtenstein, A Frost, PJ AF Mysore, Veena S. Nickols, Nicholas G. Szablowski, Jerzy Dervan, Peter Lichtenstein, Alan Frost, Patrick J. TI Targeting hypoxia-mediated gene transcription with a novel polyamide drug designed to disrupt the HIF1 alpha/beta heterodimer binding overcomes resistance to hypoxia in myeloma cell lines SO CANCER RESEARCH LA English DT Meeting Abstract CT 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 05-09, 2014 CL San Diego, CA SP Amer Assoc Canc Res C1 [Mysore, Veena S.; Lichtenstein, Alan; Frost, Patrick J.] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. [Nickols, Nicholas G.] Univ Calif Los Angeles, Los Angeles, CA USA. [Szablowski, Jerzy; Dervan, Peter] CALTECH, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT 1 PY 2014 VL 74 IS 19 SU S MA 5132 DI 10.1158/1538-7445.AM2014-5132 PG 1 WC Oncology SC Oncology GA CB8VR UT WOS:000349910204085 ER PT J AU Peng, HZ Farrooji, MTZ Osborne, MJ Prokop, JW McDonald, PC Karar, J Hou, ZY He, M Kebebew, E Orntoft, T Herlyn, M Caton, AJ Fredericks, W Malkowicz, B Paterno, CS Carolin, AS Speicher, DW Skordalakes, E Huang, QH Dedhar, SS Borden, KLB Rauscher, FJ AF Peng, Hongzhuang Farrooji, Mehdi Taleb Zadeh Osborne, Michael J. Prokop, Jeremy W. McDonald, Paul C. Karar, Jayashree Hou, Zhaoyuan He, Mei Kebebew, Electron Orntoft, Torben Herlyn, Meenhard Caton, Andrew J. Fredericks, William Malkowicz, Bruce Paterno, Christopher S. Carolin, Alexandra S. Speicher, David W. Skordalakes, Emmanuel Huang, Qihong Dedhar, Shoukat S. Borden, Katherine L. B. Rauscher, Frank J. TI LIMD2 is a small LIM-only protein overexpressed in metastatic lesions which regulates cell motility and tumor progression by directly binding to and activating the integrin-linked-kinase SO CANCER RESEARCH LA English DT Meeting Abstract CT 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 05-09, 2014 CL San Diego, CA SP Amer Assoc Canc Res C1 [Peng, Hongzhuang; Karar, Jayashree; Hou, Zhaoyuan; Herlyn, Meenhard; Caton, Andrew J.; Paterno, Christopher S.; Carolin, Alexandra S.; Speicher, David W.; Skordalakes, Emmanuel; Huang, Qihong; Rauscher, Frank J.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA. [Farrooji, Mehdi Taleb Zadeh; Osborne, Michael J.] Univ Montreal, Inst Res Immunol & Canc, Dept Pathol & Cell Biol, Montreal, PQ, Canada. [Prokop, Jeremy W.] Med Coll Wisconsin, Human Mol & Genet Ctr, Milwaukee, WI USA. [McDonald, Paul C.; Dedhar, Shoukat S.] British Columbia Canc Res Ctr, Dept Integrat Oncol, Vancouver, BC V5Z 1L3, Canada. [He, Mei; Kebebew, Electron] NCI, Ctr Canc Res, Bethesda, MD 20892 USA. [Orntoft, Torben] Aarhus Univ Hosp, Skejby, Denmark. [Fredericks, William; Malkowicz, Bruce] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA. [Fredericks, William; Malkowicz, Bruce] Vet Affairs Med Ctr, Philadelphia, PA USA. [Borden, Katherine L. B.] Univ Montreal, Inst Res Immunol & Canc, Dept Pathol & Cell Biol, Vancouver, PQ, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT 1 PY 2014 VL 74 IS 19 SU S MA 992 DI 10.1158/1538-7445.AM2014-992 PG 2 WC Oncology SC Oncology GA CB8UN UT WOS:000349906905460 ER PT J AU Sun, Y Coleman, I Plymate, S Nelson, P AF Sun, Yu Coleman, Ilsa Plymate, Stephen Nelson, Peter TI DNA damage response in quiescent fibroblasts elicits a distinct secretory program and confers acquired resistance to cancer therapies SO CANCER RESEARCH LA English DT Meeting Abstract CT 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 05-09, 2014 CL San Diego, CA SP Amer Assoc Canc Res C1 [Sun, Yu; Plymate, Stephen] Univ Washington, VA Puget Sound Healthcare Syst, Seattle, WA 98195 USA. [Coleman, Ilsa; Nelson, Peter] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT 1 PY 2014 VL 74 IS 19 SU S MA 184 DI 10.1158/1538-7445.AM2014-184 PG 1 WC Oncology SC Oncology GA CB8UN UT WOS:000349906900181 ER PT J AU Vaid, M Katiyar, SK AF Vaid, Mudit Katiyar, Santosh K. TI Bioactive proanthocyanidins from grape seeds inhibit cigarette smoke condensate-enhanced invasion of human non-small cell lung cancer cells by targeting NADPH oxidase and epithelial-mesenchymal transition SO CANCER RESEARCH LA English DT Meeting Abstract CT 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 05-09, 2014 CL San Diego, CA SP Amer Assoc Canc Res C1 [Vaid, Mudit; Katiyar, Santosh K.] Univ Alabama Birmingham, Birmingham, AL USA. [Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT 1 PY 2014 VL 74 IS 19 SU S MA 1240 DI 10.1158/1538-7445.AM2014-1240 PG 1 WC Oncology SC Oncology GA CB8UN UT WOS:000349906900478 ER PT J AU Young, MR Noble, PW Weisbart, RH Hansen, JE AF Young, Melissa R. Noble, Philip W. Weisbart, Richard H. Hansen, James E. TI Targeting K-ras mutant cancer cells with a lupus anti-guanosine antibody SO CANCER RESEARCH LA English DT Meeting Abstract CT 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 05-09, 2014 CL San Diego, CA SP Amer Assoc Canc Res C1 [Young, Melissa R.; Noble, Philip W.; Hansen, James E.] Yale Univ Sch Med, New Haven, CT USA. [Weisbart, Richard H.] Vet Affairs Greater Los Angeles Hlth Care Syst, Sepulveda, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT 1 PY 2014 VL 74 IS 19 SU S MA 654 DI 10.1158/1538-7445.AM2014-654 PG 1 WC Oncology SC Oncology GA CB8UN UT WOS:000349906905116 ER PT J AU Singh, JA Khanna, P Aquino-Beaton, C Persselin, JE Duffy, E Elashoff, D Khanna, D AF Singh, Jasvinder A. Khanna, Puja Aquino-Beaton, Cleopatra Persselin, Jay E. Duffy, Erin Elashoff, David Khanna, Dinesh TI Racial Differences in Quality of Life in Patients with Gout SO QUALITY OF LIFE RESEARCH LA English DT Meeting Abstract C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Khanna, Puja] Univ Michigan, Ann Arbor, MI 48109 USA. [Aquino-Beaton, Cleopatra; Persselin, Jay E.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Duffy, Erin; Elashoff, David] Univ Calif Los Angeles, Los Angeles, CA USA. [Khanna, Dinesh] Univ Cincinnati, Cincinnati, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 EI 1573-2649 J9 QUAL LIFE RES JI Qual. Life Res. PD OCT PY 2014 VL 23 SU 1 MA 2025 BP 107 EP 107 PG 1 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CF6XJ UT WOS:000352699800275 ER PT J AU D'Aiuto, L Zhi, Y Das, DK Wilcox, MR Johnson, JW McClain, L MacDonald, ML Di Maio, R Schurdak, ME Piazza, P Viggiano, L Sweet, R Kinchington, PR Bhattacharjee, AG Yolken, R Nimgaonka, VL AF D'Aiuto, Leonardo Zhi, Yun Das, Dhanjit Kumar Wilcox, Madeleine R. Johnson, Jon W. McClain, Lora MacDonald, Matthew L. Di Maio, Roberto Schurdak, Mark E. Piazza, Paolo Viggiano, Luigi Sweet, Robert Kinchington, Paul R. Bhattacharjee, Ayantika G. Yolken, Robert Nimgaonka, Vishwajit L. TI Large-scale generation of human iPSC-derived neural stem cells/early neural progenitor cells and their neuronal differentiation SO ORGANOGENESIS LA English DT Article DE high-throughput screening; induced pluripotent stem cells (iPSCs); neural progenitor cells; neural stem cells; neuronal differentiation ID IN-VITRO DIFFERENTIATION; CORTICAL-NEURONS; DISEASE; PROGRESSION; MODULATION; PROTEIN; SOX1 AB Induced pluripotent stem cell (iPSC)-based technologies offer an unprecedented opportunity to perform high-throughput screening of novel drugs for neurological and neurodegenerative diseases. Such screenings require a robust and scalable method for generating large numbers of mature, differentiated neuronal cells. Currently available methods based on differentiation of embryoid bodies (EBs) or directed differentiation of adherent culture systems are either expensive or are not scalable. We developed a protocol for large-scale generation of neuronal stem cells (NSCs)/early neural progenitor cells (eNPCs) and their differentiation into neurons. Our scalable protocol allows robust and cost-effective generation of NSCs/eNPCs from iPSCs. Following culture in neurobasal medium supplemented with B27 and BDNF, NSCs/eNPCs differentiate predominantly into vesicular glutamate transporter 1 (VGLUT1) positive neurons. Targeted mass spectrometry analysis demonstrates that iPSC-derived neurons express ligand-gated channels and other synaptic proteins and whole-cell patch-clamp experiments indicate that these channels are functional. The robust and cost-effective differentiation protocol described here for large-scale generation of NSCs/eNPCs and their differentiation into neurons paves the way for automated high-throughput screening of drugs for neurological and neurodegenerative diseases. C1 [D'Aiuto, Leonardo; Zhi, Yun; Das, Dhanjit Kumar; McClain, Lora; MacDonald, Matthew L.; Sweet, Robert; Bhattacharjee, Ayantika G.; Nimgaonka, Vishwajit L.] Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA 15260 USA. [Zhi, Yun] Tsinghua Univ, Sch Med, Dept Pharmacol & Pharmaceut Sci, Beijing 100084, Peoples R China. [Das, Dhanjit Kumar] Natl Inst Res Reprod Hlth, Genet Res Ctr, Bombay, Maharashtra, India. [Wilcox, Madeleine R.; Johnson, Jon W.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA USA. [Wilcox, Madeleine R.; Johnson, Jon W.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA. [McClain, Lora; Nimgaonka, Vishwajit L.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. [Di Maio, Roberto] Univ Pittsburgh, Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA USA. [Di Maio, Roberto] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Di Maio, Roberto] Ri MED Fdn, Palermo, Italy. [Schurdak, Mark E.] Univ Pittsburgh, Drug Discovery Inst, Pittsburgh, PA USA. [Piazza, Paolo] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15260 USA. [Viggiano, Luigi] Univ Bari Aldo Moro, Dept Biol, Bari, Italy. [Sweet, Robert] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Kinchington, Paul R.] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA. [Kinchington, Paul R.] Univ Pittsburgh, Dept Mol Genet & Biochem, Pittsburgh, PA USA. [Yolken, Robert] Johns Hopkins Univ, Sch Med, Dept Pediat, Stanley Div Neurovirol, Baltimore, MD 21205 USA. RP Nimgaonka, VL (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA 15260 USA. EM VishwajitNL@upmc.edu RI Di Maio, Roberto/G-1788-2015 FU NIH [MH63480, MH045817, MH071533]; Stanley Medical Research Foundation [07R-1712]; Ri.MED; China Scholarship Council; Indo-US Science & Technology Forum (IUSSTF); [P30CA047904] FX This project was funded from NIH grants MH63480 and MH045817, and MH071533, by Stanley Medical Research Foundation 07R-1712, and by the Ri.MED. We also thank China Scholarship Council for providing a fellowship to YZ and thank Indo-US Science & Technology Forum (IUSSTF) for providing a fellowship to DKD. The Biomedical Mass Spectrometry Center and UPCI Cancer Biomarker Facility are supported in part by award P30CA047904. NR 33 TC 7 Z9 7 U1 4 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1547-6278 EI 1555-8592 J9 ORGANOGENESIS JI Organogenesis PD OCT-DEC PY 2014 VL 10 IS 4 BP 365 EP 377 DI 10.1080/15476278.2015.1011921 PG 13 WC Biochemistry & Molecular Biology; Developmental Biology; Engineering, Biomedical SC Biochemistry & Molecular Biology; Developmental Biology; Engineering GA CF5QI UT WOS:000352611600004 PM 25629202 ER PT J AU Singh, H McGregor, JC Nigro, SJ Higginson, A Larsen, GC AF Singh, Harleen McGregor, Jessina C. Nigro, Sarah J. Higginson, Amy Larsen, Greg C. TI Evaluation of Collaborative Therapy Review to Improve Care of Heart Failure Patients SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID CARDIOLOGY PRACTICES; ADULTS; HF; MANAGEMENT; DISEASE; TRIAL AB Objectives As more demands are placed on primary care providers, new innovative models are required to optimize heart failure (HF) care. The purpose of this study was to evaluate a collaborative therapy review (CTR) program that was implemented to improve guideline-based therapy among HF outpatients. Study Design and Methods We screened patient lists of 18 PCPs at the Portland Veterans Affairs Medical Center to identify patients with an ICD-9 code for HF. The charts of patients with ejection fractions (EFs) <40% were then abstracted in more detail. The CTR team reviewed each patient and provided specific guideline-based recommendations. The team then gave specific recommendations to providers through the electronic medical record system. We categorized recommendations relating to drug or device therapies, or need for laboratory testing, and calculated provider acceptance rates by recommendation type. Results Of the 641 patients reviewed, 156 patients had detailed chart reviews. We found opportunities for improvement in care in 70 (45%) patients who received 100 recommendations. Among the 100 recommendations, 62 (55%) were for guideline-based drugs, 12 (17%) were for consideration of device therapy, and 26 (24%) were to update lab tests or echocardiograms. Eighty percent of the recommendations were acted on within 90 days. Conclusions The CTR program was able to facilitate guideline-based management for HF patients by identifying treatment gaps and making specific guideline-based recommendations to PCPs. While further evaluations are needed, this approach may serve as an efficient method of leveraging the expertise of specialty-trained clinicians to optimize patient care. C1 [Singh, Harleen; McGregor, Jessina C.; Nigro, Sarah J.; Higginson, Amy] Oregon Hlth & Sci Univ, Oregon State Univ, Coll Pharm, Portland, OR 97239 USA. [Larsen, Greg C.] Portland VA Med Ctr, Portland, OR USA. RP Singh, H (reprint author), Oregon Hlth & Sci Univ, Oregon State Univ, Coll Pharm, 3303 SW Bond Ave,CH12C, Portland, OR 97239 USA. EM singhh@ohsu.edu NR 17 TC 0 Z9 0 U1 0 U2 2 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD OCT PY 2014 VL 20 IS 10 BP E425 EP + PG 10 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CD3QX UT WOS:000350995900001 PM 25414980 ER PT J AU Sargoy, A Barnes, S Brecha, NC Muller, LPD AF Sargoy, Allison Barnes, Steven Brecha, Nicholas C. Mueller, Luis Perez De Sevilla TI Immunohistochemical and Calcium Imaging Methods in Wholemount Rat Retina SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS LA English DT Article DE Neuroscience; Issue 92; immunohistochemistry; antibody; fluo-4; calcium imaging; ganglion cells; retina; rat ID FLUORESCENT PROTEIN EXPRESSION; GANGLION-CELL LAYER; MOUSE RETINA; AMACRINE CELLS; MAMMALIAN RETINA; DIVALENT-CATIONS; CENTRAL NEURONS; MECHANISMS; RECEPTORS; RESPONSES AB In this paper we describe the tools, reagents, and the practical steps that are needed for: 1) successful preparation of wholemount retinas for immunohistochemistry and, 2) calcium imaging for the study of voltage gated calcium channel (VGCC) mediated calcium signaling in retinal ganglion cells. The calcium imaging method we describe circumvents issues concerning non-specific loading of displaced amacrine cells in the ganglion cell layer. C1 [Sargoy, Allison; Barnes, Steven; Brecha, Nicholas C.; Mueller, Luis Perez De Sevilla] Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90024 USA. [Barnes, Steven; Brecha, Nicholas C.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Barnes, Steven] Dalhousie Univ, Dept Phys & Biophys, Halifax, NS B3H 3J5, Canada. [Barnes, Steven] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS B3H 3J5, Canada. [Brecha, Nicholas C.] Univ Calif Los Angeles, Dept Neurobiol, CURE Digest Dis Res Ctr, Jules Stein Eye Inst,David Geffen Sch Med,Dept Me, Los Angeles, CA USA. RP Muller, LPD (reprint author), Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90024 USA. EM luisperez@mednet.ucla.edu FU U.S. Army Medical Research & Materiel Command (USAMRMC); Telemedicine & Advanced Technology Research Center (TATRC), at Fort Detrick, MD [W81XWH-10-2-0077]; NIH [EY04067]; VA Merit Review FX We thank Dr. S. Stella and Helen Vuong for contributions to the calcium imaging protocol. We thank Dr. K. Sheets for filming the interview scenes. We thank Dr. Arlene Hirano for her comments on the manuscript. This research and development project was conducted by the authors at the David Geffen School of Medicine at UCLA and is made possible by a contract agreement that was awarded and administered by the U.S. Army Medical Research & Materiel Command (USAMRMC) and the Telemedicine & Advanced Technology Research Center (TATRC), at Fort Detrick, MD under Contract Number: W81XWH-10-2-0077. Support for these studies also came from NIH EY04067 and a VA Merit Review (NB). NCB is a VA Career Research Scientist. NR 38 TC 2 Z9 2 U1 0 U2 1 PU JOURNAL OF VISUALIZED EXPERIMENTS PI CAMBRIDGE PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA SN 1940-087X J9 JOVE-J VIS EXP JI J. Vis. Exp. PD OCT PY 2014 IS 92 AR e51396 DI 10.3791/51396 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CB0GF UT WOS:000349303100006 PM 25349920 ER PT J AU Kranzler, HR Feinn, R Gelernter, J Pond, T Covault, J AF Kranzler, Henry R. Feinn, Richard Gelernter, Joel Pond, Timothy Covault, Jonathan TI Topiramate's Reduction of Body Mass Index in Heavy Drinkers: Lack of Moderation by a GRIK1 Polymorphism SO EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY LA English DT Article DE body mass index; heavy drinkers; pharmacogenetics; topiramate; weight loss ID RANDOMIZED CONTROLLED-TRIAL; ALCOHOL DEPENDENCE; WEIGHT-LOSS; NEURONS; CURRENTS; RELEASE AB Topiramate, which interacts with multiple neurotransmitter and enzyme systems, is approved by the Food and Drug Administration to treat seizure disorder, prevent migraine, and (in combination with phentermine) reduce weight. Topiramate has also been shown in multiple studies to reduce heavy drinking. The authors found that topiramate 200 mg/day significantly reduced heavy drinking in heavy drinkers with a treatment goal of reduced drinking (Kranzler et al., 2014). Further, in the European American (EA) subsample (n = 122), a single nucleotide polymorphism (rs2832407) in GRIK1, which encodes the GluK1 subunit of the kainate receptor, moderated the effect on heavy drinking days. Here the authors examined the effects of topiramate on body mass index (BMI) and the moderating effect of rs2832407 in the EA subsample from Kranzler et al. (2014). Across the 12 weeks of treatment, BMI was reduced by 1.2 kg/m2 (p < .001) in the topiramate group but was unchanged in the placebo group. There was no evidence of moderation by rs2832407 of topiramate's effects on BMI. Controlling for changes in drinking and other potential confounders did not alter the findings. These results suggest that the effect of topiramate on drinking behavior, in which the GluK1-containing kainate receptor appears to play a key role, can be dissociated from its effect on weight, the specific mechanism of which remains to be determined. C1 [Kranzler, Henry R.; Pond, Timothy] Univ Penn, Perelman Sch Med, Ctr Studies Addict, Dept Psychiat, Philadelphia, PA 19104 USA. [Kranzler, Henry R.] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr VISN4, Philadelphia, PA USA. [Feinn, Richard] Quinnipiac Univ, Dept Med Sci, Frank Netter Sch Med, Hamden, CT USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Gelernter, Joel] Vet Affairs Connecticut, West Haven, CT USA. [Covault, Jonathan] Univ Connecticut, Sch Med, Alcohol Res Ctr, Dept Psychiat, Storrs, CT USA. RP Kranzler, HR (reprint author), Univ Penn, Perelman Sch Med, Treatment Res Ctr, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM kranzler@mail.med.upenn.edu FU National Institutes of Health [P60 AA03510, K24 AA13736]; VISN 4 Mental Illness Research, Education, and Clinical Center of the Philadelphia Veterans Affairs Medical Center; AbbVie; Ethypharm; Lilly; Lundbeck; Pfizer FX This study was supported by National Institutes of Health Grants P60 AA03510 and K24 AA13736 and by the VISN 4 Mental Illness Research, Education, and Clinical Center of the Philadelphia Veterans Affairs Medical Center. The funding sources had no role other than financial support. The authors acknowledge the assistance in the conduct of this study provided by the staff of the Clinical Research and Evaluation Unit at the University of Connecticut Health Center and the Treatment Research Center of the University of Pennsylvania Perelman School of Medicine. Henry R. Kranzler has been a consultant or advisory board member for the following pharmaceutical companies: Alkermes, Lilly, Lundbeck, Pfizer, and Roche. He is also a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which is supported by AbbVie, Ethypharm, Lilly, Lundbeck, and Pfizer. www.clinicaltrials.govregistration#NCT00626925. NR 25 TC 1 Z9 1 U1 0 U2 0 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1064-1297 EI 1936-2293 J9 EXP CLIN PSYCHOPHARM JI Exp. Clin. Psychopharmacol. PD OCT PY 2014 VL 22 IS 5 BP 419 EP 423 DI 10.1037/a0037309 PG 5 WC Psychology, Biological; Psychology, Clinical; Pharmacology & Pharmacy; Psychiatry SC Psychology; Pharmacology & Pharmacy; Psychiatry GA AZ6EF UT WOS:000348310700005 PM 24978347 ER PT J AU Sullivan, MP Griffiths, GG Sohlberg, MM AF Sullivan, Michael P. Griffiths, Gina G. Sohlberg, Mckay Moore TI Effect of Posttraumatic Stress on Study Time in a Task Measuring Four Component Processes Underlying Text-Level Reading SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH LA English DT Article DE posttraumatic stress; attention; processing speed; reading comprehension ID ATTENTIONAL CONTROL-THEORY; WORKING-MEMORY CAPACITY; TEST ANXIETY; COGNITIVE PERFORMANCE; MIND; COMPREHENSION; DISORDER AB Purpose: To investigate the effect of combat-related posttraumatic stress disorder (PTSD) on 4 components underlying text-level reading comprehension. Method: A group of 17 veterans with PTSD and 17 matched control participants took part. An experimental task required participants to read and study 3-sentence paragraphs describing semantic features associated with real and unreal objects. Each paragraph was followed by true-false statements that assessed knowledge access, text memory, inference, and integration. Results: The results revealed that the PTSD group took significantly longer than the control group to study the paragraphs. Although there was no group difference in test statement accuracy, the PTSD group also took significantly longer to respond to the test statements. Conclusions: Overall, the results provide evidence for the control theory of attention but suggest that more direct measures of task-irrelevant processing during text-level reading are needed. More important, the results begin to lay a foundation for developing not only diagnostic but also intervention strategies. C1 [Sullivan, Michael P.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. [Griffiths, Gina G.; Sohlberg, Mckay Moore] Univ Oregon, Eugene, OR 97403 USA. RP Sullivan, MP (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. EM sullivan@ohsu.edu FU National Science Foundation [1012947] FX This work was supported by National Science Foundation Grant 1012947. NR 48 TC 3 Z9 3 U1 0 U2 2 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA SN 1092-4388 EI 1558-9102 J9 J SPEECH LANG HEAR R JI J. Speech Lang. Hear. Res. PD OCT PY 2014 VL 57 IS 5 BP 1731 EP 1739 DI 10.1044/2014_JSLHR-L-13-0238 PG 9 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA AZ4NZ UT WOS:000348200500012 PM 24686914 ER PT J AU Soriano, ER Acosta-Felquer, ML Luong, P Caplan, L AF Roberto Soriano, Enrique Laura Acosta-Felquer, Maria Luong, Phat Caplan, Liron TI Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY LA English DT Article DE NLM MeSH terms; Arthritis; Psoriatic; Spondylitis; Ankylosing; Therapeutics; Biological therapies ID PLACEBO-CONTROLLED TRIAL; REFRACTORY ANKYLOSING-SPONDYLITIS; OPEN-LABEL TRIAL; ORAL PHOSPHODIESTERASE-4 INHIBITOR; EVIDENCE-BASED RECOMMENDATIONS; MODIFYING ANTIRHEUMATIC DRUGS; SYSTEMATIC LITERATURE SEARCH; RANDOMIZED CONTROLLED-TRIALS; DECREASED CLINICAL-RESPONSE; ASAS CONSENSUS STATEMENT AB This manuscript focuses on the pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis - including ankylosing spondylitis using traditional biologic and non-biologic disease-modifying antirheumatic drugs. Early treatment of psoriatic arthritis and axial spondyloarthritis/ankylosing spondylitis as well as the treat-to-target concept receive particular attention. This review also surveys recent national and international guidelines for the treatment of both psoriatic arthritis and couches practice recommendations for axial spondyloarthritis/ankylosing spondylitis within the context of various international guidelines. Published by Elsevier Ltd. C1 [Roberto Soriano, Enrique; Laura Acosta-Felquer, Maria] Hosp Italiano Buenos Aires, Internal Med Serv, Rheumatol Unit, Buenos Aires, DF, Argentina. [Roberto Soriano, Enrique; Laura Acosta-Felquer, Maria] Inst Univ, Caba, Argentina. [Luong, Phat; Caplan, Liron] Denver Vet Affairs Hosp, Rheumatol Sect, Aurora, CO 80045 USA. [Luong, Phat; Caplan, Liron] Univ Colorado, Sch Med, Aurora, CO 80045 USA. RP Caplan, L (reprint author), Denver Vet Affairs Hosp, Rheumatol Sect, 1775 Aurora Court,B115, Aurora, CO 80045 USA. EM enrique.soriano@hospitalitaliano.org.ar; marial.acosta@hospitalitaliano.org.ar; phat.luong@va.gov; liron.caplan@ucdenver.edu FU U.S. Department of Veterans Affairs (VA) FX All authors acknowledge that they have no financial and personal relationships with other people or organizations that could inappropriately influence the content of this article. This project received no specific function. Dr. Caplan is supported by the U.S. Department of Veterans Affairs (VA); however, the VA had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 99 TC 4 Z9 4 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1521-6942 EI 1521-1770 J9 BEST PRACT RES CL RH JI Best Pract. Res. Clin. Rheumatol. PD OCT PY 2014 VL 28 IS 5 BP 793 EP 806 DI 10.1016/j.berh.2014.10.011 PG 14 WC Rheumatology SC Rheumatology GA AZ1PC UT WOS:000348009600011 PM 25488785 ER PT J AU Gamble, T Stanton, J Greene, E Taylor, J Pack, AP Shelus, V Tolley, EE Brown, ST El-Sadr, W AF Gamble, Theresa Stanton, Jill Greene, Elizabeth Taylor, Jamilah Pack, Allison P. Shelus, Victoria Tolley, Elizabeth E. Brown, Sheldon T. El-Sadr, Wafaa CA HPTN 065 Study Team TI Unanticipated Impact of Financial Incentives on HIV Patients and Providers: Findings from a Qualitative Substudy (HPTN 065) SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Symposium on HIV Research for Prevention (HIV R4P) CY OCT 28-31, 2014 CL Cape Town, SOUTH AFRICA C1 [Gamble, Theresa; Stanton, Jill; Greene, Elizabeth; Taylor, Jamilah; Pack, Allison P.; Shelus, Victoria; Tolley, Elizabeth E.] FHI 360, Durham, NC USA. [Brown, Sheldon T.] James J Peters VA Med Ctr, Bronx, NY USA. [El-Sadr, Wafaa] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY USA. [El-Sadr, Wafaa] Harlem Hosp Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT 1 PY 2014 VL 30 SU 1 MA P06.02 BP A104 EP A104 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AT2OO UT WOS:000344774401067 ER PT J AU LaFemina, MJ Sutherland, KM Bentley, T Gonzales, LW Allen, L Chapin, CJ Rokkam, D Sweerus, KA Dobbs, LG Ballard, PL Frank, JA AF LaFemina, Michael J. Sutherland, Katherine M. Bentley, Trevor Gonzales, Linda W. Allen, Lennell Chapin, Cheryl J. Rokkam, Deepti Sweerus, Kelly A. Dobbs, Leland G. Ballard, Philip L. Frank, James A. TI Claudin-18 Deficiency Results in Alveolar Barrier Dysfunction and Impaired Alveologenesis in Mice SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY LA English DT Article DE claudins; tight junctions; bronchopulmonary dysplasia; lung injury ID CHRONIC LUNG-DISEASE; TIGHT JUNCTION STRANDS; BRONCHOPULMONARY DYSPLASIA; EPITHELIAL-CELLS; II CELLS; EXPRESSION; GENE; FIBROSIS; PROTEIN; INJURY AB Claudins are a family of transmembrane proteins that are required for tight junction formation. Claudin (CLDN)-18.1, the only known lung-specific tight junction protein, is the most abundant claudin in alveolar epithelial type (AT) 1 cells, and is regulated by lung maturational agonists and inflammatory mediators. To determine the function of CLDN18 in the alveolar epithelium, CLDN18 knockout (KO) mice were generated and studied by histological, biochemical, and physiological approaches, in addition to whole-genome microarray. Alveolar epithelial barrier function was assessed after knockdown of CLDN18 in isolated lung cells. CLDN18 levels were measured by quantitative PCR in lung samples from fetal and postnatal human infants. We found that CLDN18 deficiency impaired alveolar epithelial barrier function in vivo and in vitro, with evidence of increased paracellular permeability and architectural distortion at AT1-AT1 cell junctions. Although CLDN18 KO mice were born without evidence of a lung abnormality, histological and gene expression analysis at Postnatal Day 3 and Week 4 identified impaired alveolarization. CLDN18 KO mice also had evidence of postnatal lung injury, including acquired AT1 cell damage. Human fetal lungs at 23-24 weeks gestational age, the highest-risk period for developing bronchopulmonary dysplasia, a disease of impaired alveolarization, had significantly lower CLDN18 expression relative to postnatal lungs. Thus, CLDN18 deficiency results in epithelial barrier dysfunction, injury, and impaired alveolarization in mice. Low expression of CLDN18 in human fetal lungs supports further investigation into a role for this tight junction protein in bronchopulmonary dysplasia. C1 [LaFemina, Michael J.; Sutherland, Katherine M.; Sweerus, Kelly A.; Dobbs, Leland G.; Frank, James A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Allen, Lennell; Chapin, Cheryl J.; Dobbs, Leland G.; Ballard, Philip L.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA. [LaFemina, Michael J.; Frank, James A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Bentley, Trevor; Rokkam, Deepti; Frank, James A.] Northern Calif Inst Res & Educ, San Francisco, CA USA. [Gonzales, Linda W.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA. RP LaFemina, MJ (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 111D, San Francisco, CA 94121 USA. EM michael.lafemina@ucsf.edu FU Fisher Fellowship within the Nina Ireland Lung Disease Program; T32 Multidisciplinary Training Program in Lung Diseases [HL007185]; Sandler Asthma Basic Research Center Functional Genomics Core Facility; National Institutes of Health (NIH)/National Center for Research Resources University of California San Francisco-Clinical & Translational Science Institute [UL1 RR024131]; NIH [U01HG004085]; [HL088440]; [K08HL116647]; [HL24075] FX This work was supported by HL088440 (J.A.F.), K08HL116647 (M.J.L.), HL24075 (P.L.B., L.G.D.), a Parker B. Francis Fellowship (M.J.L.), the Fisher Fellowship within the Nina Ireland Lung Disease Program (M.J.L.), and T32 Multidisciplinary Training Program in Lung Diseases HL007185 (K.M.S.). Microarray work was supported in part by the Sandler Asthma Basic Research Center Functional Genomics Core Facility and National Institutes of Health (NIH)/National Center for Research Resources University of California San Francisco-Clinical & Translational Science Institute grant UL1 RR024131. NIH grants to Velocigene at Regeneron Inc. (U01HG004085) and the CSD Consortium of Children's Hospital Oakland Research Institute (CHORI), Sanger Institute, and University of California Davis (U01HG004080) funded the generation of gene-targeted ES cells for 8,500 genes in the trans-NIH Knock-Out Mouse Project (KOMP) Program and archived and distributed by the KOMP Repository at University of California Davis and CHORI (U42RR024244). NR 42 TC 15 Z9 15 U1 0 U2 3 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1044-1549 EI 1535-4989 J9 AM J RESP CELL MOL JI Am. J. Respir. Cell Mol. Biol. PD OCT PY 2014 VL 51 IS 4 BP 550 EP 558 DI 10.1165/rcmb.2013-0456OC PG 9 WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System GA AY2KK UT WOS:000347418700009 PM 24787463 ER PT J AU Basu, P Shah, N Aloysius, M Lee, D Gress, F AF Basu, Patrick Shah, Niraj Aloysius, Mark Lee, David Gress, Frank TI Novel Colonoscopy Preparation of Organic Coconut Water With Miralax (R) and Dulcolax (R) in Split Doses for Decompensated Cirrhotics. A Randomized, Double-Blinded, Open-Labelled, Clinical Pilot Single-Centered Observational Study: COSMIC Study SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Basu, Patrick; Gress, Frank] Columbia Sch Phys & Surg, New York, NY USA. [Aloysius, Mark; Lee, David] Kings Cty Hosp Med Ctr, Brooklyn, NY USA. [Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 1890 BP S560 EP S560 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383102285 ER PT J AU Basu, P Shah, N Aloysius, M AF Basu, Patrick Shah, Niraj Aloysius, Mark TI Simeprevir and Sofosbuvir With Modified Doses of Ribavirin (RBV) Therapy on Telaprevir-Experienced, Coinfected (With HIV) Cirrhotics With Chronic Hepatitis C (CHC): A Randomized, Open-Label, Clinical Pilot Study, STOP C, Interim Results SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Basu, Patrick] Columbia Sch Phys & Surg, New York, NY USA. [Aloysius, Mark] Kings Cty Hosp Med Ctr, New York, NY USA. [Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 606 BP S177 EP S177 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383100599 ER PT J AU Basu, P Shah, N Aloysius, M Brown, R AF Basu, Patrick Shah, Niraj Aloysius, Mark Brown, Robert TI Role of Intravenous N-Acetyl Cysteine (NAC) With Steroids in Acute Alcoholic Hepatitis With High Morbidity Score: A Randomized, Open-Label, Prospective Clinical Trial: Renaissance Trial SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Basu, Patrick; Brown, Robert] Columbia Sch Phys & Surg, New York, NY USA. [Aloysius, Mark] Kings Cty Hosp Med Ctr, New York, NY USA. [Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 603 BP S176 EP S176 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383100596 ER PT J AU Basu, P Shah, N Aloysius, M Brown, R AF Basu, Patrick Shah, Niraj Aloysius, Mark Brown, Robert TI Trial Role of Mycophenolate Mofetil (MMF) in Steroid Nonresponsive Severe Acute Alcoholic Hepatitis: A Randomized, Open-Label, Placebo-Controlled Prospective Clinical Pilot Trial-MASH SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Basu, Patrick; Brown, Robert] Columbia Sch Phys & Surg, New York, NY USA. [Aloysius, Mark] Kings Cty Hosp Med Ctr, New York, NY USA. [Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 602 BP S176 EP S176 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383100595 ER PT J AU Basu, P Shah, N Aloysius, M Brown, R AF Basu, Patrick Shah, Niraj Aloysius, Mark Brown, Robert TI Berberine With Alfa Lipoic Acid (ALA) in Non-alcoholic Steatohepatitis: A Randomized Double-Blinded Placebo Control Trial: A Clinical Pilot: The Banish Trial SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Basu, Patrick; Brown, Robert] Columbia Sch Phys & Surg, New York, NY USA. [Aloysius, Mark] Kings Cty Hosp Med Ctr, New York, NY USA. [Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 599 BP S175 EP S175 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383100592 ER PT J AU Chen, TC Cruz, G Sellin, J Hou, J AF Chen, Tien-Chun Cruz, Guillermina Sellin, Joseph Hou, Jason TI Food Avoidance and Use of Dietary Supplements Among Patients With Inflammatory Bowel Disease SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Chen, Tien-Chun; Cruz, Guillermina] Baylor Coll Med, Houston, TX 77030 USA. [Sellin, Joseph] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Hou, Jason] Baylor Coll Med, Ctr Innovat Qual Effectiveness & Safety IQuESt, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 1715 BP S507 EP S507 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383102111 ER PT J AU Diamond, S Sonnenberg, A AF Diamond, Sarah Sonnenberg, Amnon TI Game Theory in Repetitive Ingestion of Foreign Bodies SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Diamond, Sarah] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 2234 BP S648 EP S648 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383102588 ER PT J AU DSouza, S Enestvedt, B Pavic, B Holub, J Rodriguez, S AF DSouza, Sharlene Enestvedt, Brintha Pavic, Brian Holub, Jennifer Rodriguez, Sarah Betsy TI Nationwide Utilization of Endoscopic Ultrasound SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Pavic, Brian; Rodriguez, Sarah Betsy] Oregon Clin West, Portland, OR USA. [Enestvedt, Brintha; Holub, Jennifer] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [DSouza, Sharlene] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 1956 BP S579 EP S579 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383102351 ER PT J AU Hashash, J Chedid, V Habib-Bein, N Francis, F AF Hashash, Jana Chedid, Victor Habib-Bein, Nadia Francis, Fadi TI Unusual Cause of Gastric Outlet Obstruction SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Hashash, Jana; Chedid, Victor] Univ Pittsburgh, Med Ctr, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA. [Habib-Bein, Nadia; Francis, Fadi] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 1157 BP S344 EP S344 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383101383 ER PT J AU Jain, V Sharma, D Simeunovic, K Gavrancic, T Jubbal, S Ramasamy, V Anklesaria, A AF Jain, Varun Sharma, Deepak Simeunovic, Kosana Gavrancic, Tatjana Jubbal, Sandeep Ramasamy, Vimala Anklesaria, Ava TI Colon Cancer With Gastric Invasion Resulting in Gastric Outlet Obstruction: An Uncommon Presentation of Locally Advanced Colorectal Cancer That Was Successfully Treated With Surgical Resection SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Jain, Varun; Sharma, Deepak; Simeunovic, Kosana; Gavrancic, Tatjana; Jubbal, Sandeep; Anklesaria, Ava] James J Peters VA Med Ctr, Icahn Sch Med Mt Sinai, Bronx, NY USA. [Ramasamy, Vimala] North Cent Bronx Hosp, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 1388 BP S411 EP S411 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383101614 ER PT J AU Jain, V Sharma, D Marcus, S Brau, N AF Jain, Varun Sharma, Deepak Marcus, Sonja Brau, Norbert TI Spontaneous Clearance of Chronic HCV Infection: An Unusual Phenomenon SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Jain, Varun; Sharma, Deepak; Marcus, Sonja; Brau, Norbert] James J Peters VA Med Ctr, Icahn Sch Med Mt Sinai Bronx, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 1337 BP S392 EP S392 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383101563 ER PT J AU Jain, V Sharma, D Gavrancic, T Anklesaria, A Ramasamy, V White, S Iliev, A AF Jain, Varun Sharma, Deepak Gavrancic, Tatjana Anklesaria, Ava Ramasamy, Vimala White, Sherrie Iliev, Andrey TI An Unusual Cause of Partial Small Bowel Obstruction in a Young Male With HTLV-1 SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Ramasamy, Vimala; White, Sherrie; Iliev, Andrey] North Cent Bronx Hosp, Bronx, NY USA. [Jain, Varun; Sharma, Deepak; Gavrancic, Tatjana; Anklesaria, Ava] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 1096 BP S325 EP S326 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383101322 ER PT J AU Jain, V Sharma, D Ramasamy, V Anklesaria, A Goswami, G AF Jain, Varun Sharma, Deepak Ramasamy, Vimala Anklesaria, Ava Goswami, Gayotri TI A Case of Exenatide-Induced Recurrent Pancreatitis Despite Withdrawl of Drug Therapy SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Jain, Varun; Sharma, Deepak; Anklesaria, Ava] James J Peters VA Med Ctr, Icahn Sch Med Mt Sinai Bronx, Bronx, NY USA. [Ramasamy, Vimala; Goswami, Gayotri] North Cent Bronx Hosp, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 977 BP S291 EP S291 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383101209 ER PT J AU Malaty, H Sansgiry, S Hou, J AF Malaty, Hoda Sansgiry, Shubhada Hou, Jason TI Time Trends, Clinical Characteristics, and Risk Factors of Chronic Anal Fissure Among a National Cohort of Patients With Inflammatory Bowel Disease SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Malaty, Hoda; Hou, Jason] Baylor Coll Med, Houston, TX 77030 USA. [Sansgiry, Shubhada] VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 1625 BP S481 EP S482 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383102021 ER PT J AU Rao, BB Click, B Codario, R AF Rao, Bhavana Bhagya Click, Benjamin Codario, Ronald TI Successful Management of Refractory Noninsulinoma Pancreatogenous Hypoglycemia Syndrome With Gastric Bypass Reversal: A Case Report SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Rao, Bhavana Bhagya; Click, Benjamin] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Codario, Ronald] VA Pittsburgh Healthcare Syst, Univ Drive Div, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 1037 BP S309 EP S309 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383101263 ER PT J AU Sharma, D Jain, V Jubbal, S Ramasamy, V Anklesaria, A Bogdanovic, Z AF Sharma, Deepak Jain, Varun Jubbal, Sandeep Ramasamy, Vimala Anklesaria, Ava Bogdanovic, Zoran TI Rare Case of End-Stage Gastric Signet Cell Adenocarcinoma that Metastasized to the Colon SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Sharma, Deepak; Jain, Varun; Jubbal, Sandeep; Anklesaria, Ava] Icahn Sch Med Mt Sinai Bronx, James J Peters VA Med Ctr, Bronx, NY USA. [Ramasamy, Vimala; Bogdanovic, Zoran] North Cent Bronx Hosp, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 882 BP S259 EP S259 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383101117 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Ruling In and Out a Source of Gastrointestinal Bleeding SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 1864 BP S551 EP S551 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383102259 ER PT J AU Sonnenberg, A Turner, K Genta, R AF Sonnenberg, Amnon Turner, Kevin Genta, Robert TI Ethnic Distribution of Microscopic Colitis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. [Turner, Kevin; Genta, Robert] Miraca Life Sci Res Inst, Irving, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 690 BP S200 EP S200 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383100681 ER PT J AU Whitman, C Arnold, C Patel, H Scopel, J Martinez, B Reid, M Spiegel, B AF Whitman, Cynthia Arnold, Corey Patel, Haridarshan Scopel, Justin Martinez, Bibiana Reid, Mark Spiegel, Brennan TI Managing Opioid-Induced Constipation: Perceptions and Misconceptions From the Online Community SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Whitman, Cynthia; Martinez, Bibiana] Cedars Sinai Med Ctr CORE, Beverly Hills, CA USA. [Arnold, Corey] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Patel, Haridarshan] Takeda Pharmaceut Int Inc, Global Outcomes & Epidemiol Res, Deerfield, IL USA. [Scopel, Justin] Takeda Pharmaceut Int Inc, US Med Affairs, Deerfield, IL USA. [Reid, Mark] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Spiegel, Brennan] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 2218 BP S643 EP S644 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383102572 ER PT J AU Yen, E Sonnenberg, A Genta, R AF Yen, Eugene Sonnenberg, Amnon Genta, Robert TI Higher Prevalence of Celiac Disease in Patients With Microscopic Colitis: Results From a Large Pathology Database SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 79th Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 17-22, 2014 CL Philadelphia, PA SP Amer Coll Gastroenterol C1 [Yen, Eugene] NorthShore Univ HealthSyst, Evanston, IL USA. [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. [Genta, Robert] Miraca Life Sci Res Inst, Irving, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 SU 2 MA 713 BP S207 EP S207 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS6OR UT WOS:000344383100704 ER PT J AU Baker, J Conaghan, PG Emery, P Baker, D Ostergaard, M AF Baker, Joshua Conaghan, Philip G. Emery, Paul Baker, Daniel Ostergaard, Mikkel TI Early MRI Endpoints Provide a Valid Measure of Structural Damage While Reducing Study Duration and Participant Numbers in Rheumatoid Arthritis Clinical Trials. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Baker, Joshua] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Conaghan, Philip G.] Univ Leeds, Leeds, W Yorkshire, England. [Conaghan, Philip G.; Emery, Paul] NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England. [Emery, Paul] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England. [Baker, Daniel] Janseen R&D, Spring House, PA USA. Copenhagen Univ Hosp Glostrup, Copenhagen Ctr Arthrit Res, Glostrup, Denmark. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 1891 BP S832 EP S832 PG 1 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384904041 ER PT J AU Baker, J Cannon, GW Ibrahim, S Haroldsen, C Caplan, L Mikuls, TR AF Baker, Joshua Cannon, Grant W. Ibrahim, Said Haroldsen, Candace Caplan, Liron Mikuls, Ted R. TI Predictors of Long-Term Changes in Body Mass Index in Rheumatoid Arthritis. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Baker, Joshua] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Cannon, Grant W.] Salt Lake City VA, Salt Lake City, UT USA. [Cannon, Grant W.; Haroldsen, Candace] Univ Utah, Salt Lake City, UT USA. [Ibrahim, Said] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Caplan, Liron] Denver VA, Aurora, CO USA. [Caplan, Liron] Univ Colorado, Sch Med, Aurora, CO USA. [Mikuls, Ted R.] Omaha VA Med Ctr, Omaha, NE USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 1392 BP S614 EP S614 PG 1 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384903016 ER PT J AU Battistone, MJ Barker, AM Grotzke, MP Beck, JP Quan, A Hose, M Seligman, V Ravenell, R Pavuluri, P Roberts, WN Pioro, M Fisher, N Osting, V Prihar, B Hackman, J Kirsh, S Cannon, GW AF Battistone, Michael J. Barker, Andrea M. Grotzke, Marissa P. Beck, J. Peter Quan, Anna Hose, Michal Seligman, Victoria Ravenell, Roneka Pavuluri, Pushpa Roberts, W. Neal Pioro, Mathilde Fisher, Nancy Osting, Vanessa Prihar, Betty Hackman, Joanne Kirsh, Susan Cannon, Grant W. TI The Musculoskeletal Mini-Residency Collaborative Network: A National Department of Veterans Affairs Interdisciplinary and Interprofessional Educational Innovation for Primary Care Providers. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Battistone, Michael J.; Barker, Andrea M.; Grotzke, Marissa P.; Beck, J. Peter; Cannon, Grant W.] Salt Lake City VA, Salt Lake City, UT USA. [Battistone, Michael J.; Barker, Andrea M.; Grotzke, Marissa P.; Beck, J. Peter; Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA. [Quan, Anna; Hose, Michal] San Diego VA, San Diego, CA USA. [Seligman, Victoria] Denver VA Med Ctr, Denver, CO USA. [Ravenell, Roneka; Pavuluri, Pushpa; Roberts, W. Neal] Louisville VA, Louisville, KY USA. [Pioro, Mathilde; Fisher, Nancy] Cleveland VA, Cleveland, OH USA. [Osting, Vanessa; Prihar, Betty] Tampa VA, Tampa, FL USA. [Hackman, Joanne; Kirsh, Susan] VHA Cent Off, Patient Care Serv, Off Specialty Care Transformat, Washington, DC USA. RI Beck, James Peter/F-9407-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 2001 BP S878 EP S879 PG 2 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384904151 ER PT J AU Berman, N Dunham, JS Baker, J Vivino, FB AF Berman, Nicola Dunham, Jonathan S. Baker, Joshua Vivino, Frederick B. TI Risk of Cervical Root and Incisal Caries in Patients with Sjogren's Syndrome. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Berman, Nicola] Penn Hosp, Philadelphia, PA 19107 USA. [Dunham, Jonathan S.] Univ Penn, Philadelphia, PA 19104 USA. [Baker, Joshua] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Vivino, Frederick B.] Penn Presbyt Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 2545 BP S1112 EP S1113 PG 2 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384905222 ER PT J AU Bethel, M Bailey, L Weaver, F Le, B Burns, S Svircev, J Heggeness, M Carbone, L AF Bethel, Monique Bailey, Lauren Weaver, Frances Le, Brian Burns, Stephen Svircev, Jelena Heggeness, Michael Carbone, Laura TI Surgical Compared with Nonsurgical Management of Fractures in Men with Chronic Spinal Cord Injury. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Bethel, Monique; Le, Brian] Georgia Regents Univ, Augusta, GA USA. [Bailey, Lauren; Weaver, Frances] Edward Hines Jr VA Hosp, Chicago, IL USA. [Burns, Stephen; Svircev, Jelena] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Heggeness, Michael] Univ Kansas, Sch Med, Kansas City, KS USA. [Carbone, Laura] Charlie Norwood VA Med Ctr, Augusta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 2106 BP S921 EP S921 PG 1 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384904255 ER PT J AU Bledsoe, C Davis, LA Tran, V Keniston, A Caplan, L Quinzanos, I Hirsh, JM AF Bledsoe, Carol Davis, Lisa A. Tran, Vivian Keniston, Angela Caplan, Liron Quinzanos, Itziar Hirsh, Joel M. TI Patients' Interpretations of Rheumatoid Arthritis Model Disease States in a Safety-Net Rheumatology Clinic SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Bledsoe, Carol] E Carolina Univ, Brody Sch Med, Greenville, NC USA. [Davis, Lisa A.] Denver VAMC, Aurora, CO USA. [Davis, Lisa A.; Caplan, Liron; Quinzanos, Itziar] Univ Colorado, Sch Med, Aurora, CO USA. [Tran, Vivian; Keniston, Angela; Hirsh, Joel M.] Denver Hlth & Hosp Author, Denver, CO USA. [Caplan, Liron] Denver VA, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 2386 BP S1039 EP S1040 PG 2 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384905064 ER PT J AU Domsic, RT Nihtyanova, SI Lucas, M Wisniewski, SR Fine, MJ Kwoh, CK Denton, CP Medsger, TA AF Domsic, Robyn T. Nihtyanova, Svetlana I. Lucas, Mary Wisniewski, Stephen R. Fine, Michael J. Kwoh, C. Kent Denton, Christopher P. Medsger, Thomas A., Jr. TI Development and External Validation of a Five-Year Mortality Risk Stratification Tool for Early Diffuse Systemic Sclerosis Patients. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Domsic, Robyn T.; Lucas, Mary; Fine, Michael J.; Medsger, Thomas A., Jr.] Univ Pittsburgh, Pittsburgh, PA USA. [Nihtyanova, Svetlana I.] Royal Free & Univ Coll Med Sch, London WC1E 6BT, England. [Wisniewski, Stephen R.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Fine, Michael J.] VA Pittsburgh Healthcare, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Kwoh, C. Kent] Univ Arizona, Arthrit Ctr, Tucson, AZ USA. [Denton, Christopher P.] Royal Free & Univ Coll Med Sch, Ctr Rheumatol, London WC1E 6BT, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 2997 BP S1310 EP S1310 PG 1 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384906231 ER PT J AU Feldon, M Sikora, KA Harley, JB Huggins, JL Brunner, HI Kaufman, KM AF Feldon, Michal Sikora, Keith A. Harley, John B. Huggins, Jennifer L. Brunner, Hermine I. Kaufman, Kenneth M. TI Whole Exome Sequencing Analysis Performed on a Patient with Fibroblastic Rheumatism. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Feldon, Michal; Sikora, Keith A.; Huggins, Jennifer L.; Kaufman, Kenneth M.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Med Ctr, US Dept Vet Affairs, Cincinnati, OH 45229 USA. [Brunner, Hermine I.] PRCSG, Cincinnati, OH USA. [Kaufman, Kenneth M.] Univ Cincinnati, Cincinnati, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 83 BP S35 EP S35 PG 1 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384900084 ER PT J AU Hamilton, J Li, J Wu, Q Yang, PA Luo, B Li, H Randall, T Bradley, JE Taylor, JJ Mountz, JD Hsu, HC AF Hamilton, Jennie Li, Jun Wu, Qi Yang, PingAr Luo, Bao Li, Hao Randall, Troy Bradley, John Edwin Taylor, Justin J. Mountz, John D. Hsu, Hui-Chen TI B-Cell Autoepitope and Tetramer Analysis Reveals Expansion of Apoptotic Autoantigen La and snRNP Reactive B Cells in BXD2 Mice. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Hamilton, Jennie; Li, Jun; Wu, Qi; Yang, PingAr; Luo, Bao; Li, Hao; Randall, Troy; Bradley, John Edwin; Hsu, Hui-Chen] Univ Alabama Birmingham, Birmingham, AL USA. [Taylor, Justin J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 2872 BP S1255 EP S1255 PG 1 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384906107 ER PT J AU Le, B Bethel, M Bailey, L Weaver, F Burns, S Svircev, J Heggeness, M Carbone, L AF Le, Brian Bethel, Monique Bailey, Lauren Weaver, Frances Burns, Stephen Svircev, Jelena Heggeness, Michael Carbone, Laura TI Nonsurgical Treatment Patterns in Patients with Chronic Spinal Cord Injury. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Le, Brian; Bethel, Monique] Georgia Regents Univ, Augusta, GA USA. [Bailey, Lauren; Weaver, Frances] Edward Hines Jr VA Hosp, Chicago, IL USA. [Burns, Stephen; Svircev, Jelena] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Heggeness, Michael] Univ Kansas, Sch Med, Kansas City, KS USA. [Carbone, Laura] Charlie Norwood VA Med Ctr, Augusta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 2105 BP S921 EP S921 PG 1 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384904254 ER PT J AU Munroe, ME Young, KA Fessler, J Fife, D Kamen, DL Guthridge, JM Niewold, TB Weisman, MH Ishimori, ML Wallace, DJ Karp, DR Harley, JB Gilkeson, GS Norris, JM James, JA AF Munroe, Melissa E. Young, Kendra A. Fessler, Jennifer Fife, Dustin Kamen, Diane L. Guthridge, Joel M. Niewold, Timothy B. Weisman, Michael H. Ishimori, Mariko L. Wallace, Daniel J. Karp, David R. Harley, John B. Gilkeson, Gary S. Norris, Jill M. James, Judith A. TI Elevated Levels of Soluble Inflammatory Mediators and Lupus-Specific Connective Tissue Disease Questionnaire Scores Discern Unaffected First Degree Relatives of Lupus Patients from Unaffected Individuals Not Related to Lupus Patients. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Munroe, Melissa E.; Fessler, Jennifer; Fife, Dustin; Guthridge, Joel M.; James, Judith A.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [Young, Kendra A.; Norris, Jill M.] Colorado Sch Publ Hlth, Aurora, CO USA. [Kamen, Diane L.; Gilkeson, Gary S.] Med Univ S Carolina, Charleston, SC 29425 USA. [Niewold, Timothy B.] Mayo Clin, Rochester, MN USA. [Weisman, Michael H.; Ishimori, Mariko L.; Wallace, Daniel J.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Karp, David R.] UT Southwestern Med Ctr, Dallas, TX USA. [Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 2880 BP S1258 EP S1258 PG 1 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384906115 ER PT J AU Myung, G Harada, ND Fong, SL Aquino-Beaton, C Fang, MA AF Myung, Gihyun Harada, Nancy D. Fong, Stephanie L. Aquino-Beaton, Cleopatra Fang, Meika A. TI Characterization of Social Stigma in Rheumatic Diseases and Correlation with Quality of Life and Medication Adherence. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Myung, Gihyun] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Harada, Nancy D.] Univ Calif Los Angeles, David Geffen Sch Med, Long Beach, CA USA. [Fong, Stephanie L.; Fang, Meika A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Aquino-Beaton, Cleopatra] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 2107 BP S921 EP S922 PG 2 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384904256 ER PT J AU Patel, R Mikuls, TR Richards, JS Cannon, GW Kerr, GS Davis, LA Caplan, L Baker, JF AF Patel, Ruchika Mikuls, Ted R. Richards, J. Steuart Cannon, Grant W. Kerr, Gail S. Davis, Lisa A. Caplan, Liron Baker, Joshua F. TI Prevalence of Cardiovascular Disease in US Veterans with Rheumatoid Arthritis and Hepatitis C Infection. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Patel, Ruchika; Baker, Joshua F.] Univ Penn, Philadelphia, PA 19104 USA. [Patel, Ruchika] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Mikuls, Ted R.] Omaha VA Med Ctr, Omaha, NE USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Richards, J. Steuart] Washington DC VA, Washington, DC USA. [Richards, J. Steuart] Georgetown Univ, Washington, DC USA. [Cannon, Grant W.] Salt Lake City VA, Salt Lake City, UT USA. [Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA. [Kerr, Gail S.] Washington DC VAMC, Georgetown, DC USA. [Kerr, Gail S.] Howard Univ, Washington, DC 20059 USA. [Davis, Lisa A.] Denver VAMC, Aurora, CO USA. [Davis, Lisa A.; Caplan, Liron] Univ Colorado, Sch Med, Aurora, CO USA. [Caplan, Liron] Denver VA, Aurora, CO USA. [Baker, Joshua F.] Philadelphia VAMC, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 1372 BP S604 EP S605 PG 2 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384902476 ER PT J AU Quinzanos, I Luong, P Bobba, S Richards, JS Majithia, V Davis, LA Caplan, L AF Quinzanos, Itziar Luong, Phat Bobba, Sushmitha Richards, J. Steuart Majithia, Vikas Davis, Lisa A. Caplan, Liron TI Validation of Modified Disease Activity and Functional Status Questionnaires in Spondyloarthritis. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Quinzanos, Itziar; Luong, Phat] Denver VA Med Ctr, Denver, CO USA. [Bobba, Sushmitha] Dept Vet Affairs, Denver, CO USA. [Richards, J. Steuart] Washington DC VA, Washington, DC USA. [Richards, J. Steuart] Georgetown Univ, Washington, DC USA. [Majithia, Vikas] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. [Davis, Lisa A.] Denver VAMC, Aurora, CO USA. [Davis, Lisa A.; Caplan, Liron] Univ Colorado, Sch Med, Aurora, CO USA. [Caplan, Liron] Denver VA, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 2570 BP S1123 EP S1124 PG 2 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384905247 ER PT J AU Robinson, ES Okawa, J Feng, R Payne, AS Werth, VP AF Robinson, Elizabeth S. Okawa, Joyce Feng, Rui Payne, Aimee S. Werth, Victoria P. TI The Incidence of Zoster in Patients with Cutaneous Lupus Erythematosus and Dermatomyositis Is Increased Compared to the Average US Population. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Robinson, Elizabeth S.; Werth, Victoria P.] Vet Affairs Med Ctr, Philadelphia, PA USA. [Okawa, Joyce; Feng, Rui; Payne, Aimee S.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 2206 BP S961 EP S961 PG 1 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384904352 ER PT J AU Solow, EB Yu, F Thiele, GM Sokolove, J Robinson, WH Pruhs, ZM Michaud, K Erickson, AR Sayles, H Kerr, GS Gaffo, AL Caplan, L Davis, LA Cannon, GW Reimold, AM Baker, J Schwab, P Anderson, D Mikuls, TR AF Solow, E. Blair Yu, Fang Thiele, Geoffrey M. Sokolove, Jeremy Robinson, William H. Pruhs, Zachary M. Michaud, Kaleb Erickson, Alan R. Sayles, Harlan Kerr, Gail S. Gaffo, Angelo L. Caplan, Liron Davis, Lisa A. Cannon, Grant W. Reimold, Andreas M. Baker, Joshua Schwab, Pascale Anderson, Daniel Mikuls, Ted R. TI Vascular Calcifications on Hand and Wrist Radiographs Are Associated with Cardiovascular Risk Factors, Antigen-Specific Anti-Citrullinated Protein Antibodies, and Mortality in Rheumatoid Arthritis. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Solow, E. Blair] UT Southwestern Med Ctr, Dallas, TX USA. [Yu, Fang; Thiele, Geoffrey M.; Pruhs, Zachary M.; Michaud, Kaleb; Erickson, Alan R.; Sayles, Harlan; Anderson, Daniel; Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Thiele, Geoffrey M.; Pruhs, Zachary M.; Michaud, Kaleb; Erickson, Alan R.; Sayles, Harlan; Anderson, Daniel; Mikuls, Ted R.] Omaha VA Med Ctr, Omaha, NE USA. [Sokolove, Jeremy] VA Palo Alto Healthcare Syst, Palo Alto, CA USA. [Sokolove, Jeremy; Robinson, William H.] Stanford Univ, Palo Alto, CA 94304 USA. [Robinson, William H.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Kerr, Gail S.] Georgetown & Howard Univ, Washington DC VAMC, Washington, DC USA. [Gaffo, Angelo L.] Birmingham VA Med Ctr, Birmingham, AL USA. [Gaffo, Angelo L.] Univ Alabama Birmingham, Birmingham, AL USA. [Caplan, Liron; Davis, Lisa A.] Denver VAMC, Aurora, CO USA. [Caplan, Liron; Davis, Lisa A.] Univ Colorado, Sch Med, Aurora, CO USA. [Cannon, Grant W.] Salt Lake City VA, Salt Lake City, UT USA. [Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA. [Reimold, Andreas M.] Dallas VA, Dallas, TX USA. [Reimold, Andreas M.] Univ Texas Southwestern, Dallas, TX USA. [Baker, Joshua] Univ Penn, Philadelphia, PA 19104 USA. [Baker, Joshua] Philadelphia VAMC, Philadelphia, PA 19104 USA. [Schwab, Pascale] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 840 BP S370 EP S371 PG 2 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384901384 ER PT J AU Sullivan, B Guzman, R Russell, CB Arnold, G Boedigheimer, M Ma, C Chung, J Werth, VP Martin, DA AF Sullivan, Barbara Guzman, Roberto Russell, Christopher B. Arnold, Greg Boedigheimer, Michael Ma, Connie Chung, James Werth, Victoria P. Martin, David A. TI Molecular, Cellular and Histopathologic Assessment of Baseline Characteristics of Sixteen Subjects with Discoid Lupus Erythematosus Prior to Treatment with AMG 811 (anti-IFN gamma). SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Sullivan, Barbara; Guzman, Roberto; Arnold, Greg; Boedigheimer, Michael; Ma, Connie; Chung, James] Amgen Inc, Thousand Oaks, CA USA. [Russell, Christopher B.; Martin, David A.] Amgen Inc, Seattle, WA USA. [Werth, Victoria P.] Vet Affairs Med Ctr, Philadelphia, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 1646 BP S725 EP S726 PG 2 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384903270 ER PT J AU Thiyagarajan, T Molano, I Nowling, TK AF Thiyagarajan, Thirumagal Molano, Ivan Nowling, Tamara K. TI The Role of Fli1 in Lupus T Cell Function and Nephritis. SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Thiyagarajan, Thirumagal; Molano, Ivan; Nowling, Tamara K.] Med Univ S Carolina, Charleston, SC 29425 USA. [Nowling, Tamara K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 2741 BP S1198 EP S1199 PG 2 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384905418 ER PT J AU Thiyagarajan, T Siskind, L Oates, J Drake, R Nowling, TK AF Thiyagarajan, Thirumagal Siskind, Leah Oates, Jim Drake, Richard Nowling, Tamara K. TI Dysfunction of Glycosphingolipid Metabolism in Lupus Nephritis SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Thiyagarajan, Thirumagal; Oates, Jim; Drake, Richard; Nowling, Tamara K.] Med Univ S Carolina, Charleston, SC 29425 USA. [Siskind, Leah] Univ Louisville, Louisville, KY 40292 USA. [Nowling, Tamara K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 SU 10 SI SI MA 661 BP S288 EP S289 PG 2 WC Rheumatology SC Rheumatology GA AS6PK UT WOS:000344384901205 ER PT J AU Everett, CJ AF Everett, Charles J. TI Commentary on nephropathy and longitudinal studies of diabetes, and dioxins, furans, and dioxin-like PCBs SO ENVIRONMENTAL RESEARCH LA English DT Editorial Material C1 US Dept Vet Affairs, Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Everett, CJ (reprint author), US Dept Vet Affairs, Ralph H Johnson VA Med Ctr, 109 Bee St,Mail Code 151, Charleston, SC 29401 USA. EM Charles.Everett@va.gov NR 1 TC 0 Z9 2 U1 1 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 EI 1096-0953 J9 ENVIRON RES JI Environ. Res. PD OCT PY 2014 VL 134 SI SI BP 8 EP 8 DI 10.1016/j.envres.2014.06.020 PG 1 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA AX3CB UT WOS:000346817100002 PM 25042030 ER PT J AU Mavandadi, S Dobkin, R Mamikonyan, E Sayers, S Ten Have, T Weintraub, D AF Mavandadi, Shahrzad Dobkin, Roseanne Mamikonyan, Eugenia Sayers, Steven Ten Have, Thomas Weintraub, Daniel TI Benefit Finding and Relationship Quality in Parkinson's Disease: A Pilot Dyadic Analysis of Husbands and Wives SO JOURNAL OF FAMILY PSYCHOLOGY LA English DT Article DE chronic disease; Parkinson's disease; marital relationship; psychosocial support systems caregiving ID STAGE BREAST-CANCER; MARITAL QUALITY; POSTTRAUMATIC GROWTH; CAREGIVER-BURDEN; SOCIAL SUPPORT; YOUNG-ONSET; SATISFACTION; HEALTH; DEPRESSION; EXPERIENCE AB Parkinson's disease (PD) significantly impacts both patients' and spouses' emotional and physical health. However, despite the importance of social relationships for wellbeing, few studies have examined relationship quality and their correlates in individuals with PD and their partners. Specifically, no known studies have examined the association between benefit finding, or the experience of personal growth and other positive changes in the face of a stressor, and perceived marital quality. To address these gaps in the field, 25 married couples participated in a cross-sectional, pilot study. Patients were veterans diagnosed with idiopathic PD receiving care at the Philadelphia VA Medical Center. Each patient and spouse independently completed self-reported measures of sociodemographics, physical and mental wellbeing, caregiver burden, marital quality, and perceived benefits associated with having PD. Actor-partner interdependence models revealed that, after adjusting for covariates, greater perceived benefits from either having PD or living with a spouse with PD was associated with greater marital quality, both for that individual and their partner. Thus, perceiving positive consequences, such as personal growth, as a result of personally having PD or living with a spouse with PD is related to greater marital quality for both members of the marital dyad. Findings may inform individual and couples-based interventions that address the value of benefit finding and incorporate other techniques of positive reappraisal. C1 [Mavandadi, Shahrzad; Sayers, Steven; Weintraub, Daniel] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Mavandadi, Shahrzad; Mamikonyan, Eugenia; Sayers, Steven; Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Dobkin, Roseanne] Rutgers Robert Wood Johnson Med Sch, Dept Psychiat, New Brunswick, NJ USA. [Ten Have, Thomas] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. RP Mavandadi, S (reprint author), 3900 Woodland Ave,116A, Philadelphia, PA 19104 USA. EM Shahrzad.Mavandadi@va.gov NR 41 TC 3 Z9 3 U1 2 U2 10 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0893-3200 EI 1939-1293 J9 J FAM PSYCHOL JI J. Fam. Psychol. PD OCT PY 2014 VL 28 IS 5 BP 728 EP 734 DI 10.1037/a0037847 PG 7 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA AX4FE UT WOS:000346888300017 PM 25180468 ER PT J AU Morone, NE Greco, CM AF Morone, Natalia E. Greco, Carol M. TI Adapting Mindfulness Meditation for the Older Adult SO MINDFULNESS LA English DT Editorial Material ID LOW-BACK-PAIN C1 [Morone, Natalia E.] Univ Pittsburgh, Sch Med, Geriatr Res Educ & Clin Ctr, Dept Med,Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA. [Greco, Carol M.] Univ Pittsburgh, Sch Med, Dept Psychiat, Ctr Integrat Med,Med Ctr, Pittsburgh, PA 15213 USA. RP Morone, NE (reprint author), Univ Pittsburgh, Sch Med, Geriatr Res Educ & Clin Ctr, Dept Med,Vet Affairs Pittsburgh Healthcare Syst, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM moronene@upmc.edu NR 7 TC 0 Z9 0 U1 0 U2 8 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1868-8527 EI 1868-8535 J9 MINDFULNESS JI Mindfulness PD OCT PY 2014 VL 5 IS 5 BP 610 EP 612 DI 10.1007/s12671-014-0297-z PG 3 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AX0IB UT WOS:000346635000016 ER PT J AU Bachhuber, MA Saloner, B Cunningham, CO Barry, CL AF Bachhuber, Marcus A. Saloner, Brendan Cunningham, Chinazo O. Barry, Colleen L. TI Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010 SO JAMA INTERNAL MEDICINE LA English DT Article ID CHRONIC NONCANCER PAIN; MARIJUANA USE; DRUG-USE; YOUNG-ADULTS; ABUSE; WITHDRAWAL; DEPENDENCE; PATTERNS; DEATHS; COHORT AB IMPORTANCE Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mortality related to opioid analgesics in states that have enacted them. OBJECTIVE To determine the association between the presence of state medical cannabis laws and opioid analgesic overdose mortality. DESIGN, SETTING, AND PARTICIPANTS A time-series analysis was conducted of medical cannabis laws and state-level death certificate data in the United States from 1999 to 2010; all 50 states were included. EXPOSURES Presence of a law establishing a medical cannabis program in the state. MAIN OUTCOMES AND MEASURES Age-adjusted opioid analgesic overdose death rate per 100 000 population in each state. Regression models were developed including state and year fixed effects, the presence of 3 different policies regarding opioid analgesics, and the state-specific unemployment rate. RESULTS Three states (California, Oregon, and Washington) had medical cannabis laws effective prior to 1999. Ten states (Alaska, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Mexico, Rhode Island, and Vermont) enacted medical cannabis laws between 1999 and 2010. States with medical cannabis laws had a 24.8% lower mean annual opioid overdose mortality rate (95% CI, -37.5% to -9.5%; P = .003) compared with states without medical cannabis laws. Examination of the association between medical cannabis laws and opioid analgesic overdose mortality in each year after implementation of the law showed that such laws were associated with a lower rate of overdose mortality that generally strengthened over time: year 1 (-19.9%; 95% CI, -30.6% to -7.7%; P = .002), year 2 (-25.2%; 95% CI, -40.6% to -5.9%; P = .01), year 3 (-23.6%; 95% CI, -41.1% to -1.0%; P = .04), year 4 (-20.2%; 95% CI, -33.6% to -4.0%; P = .02), year 5 (-33.7%; 95% CI, -50.9% to -10.4%; P = .008), and year 6 (-33.3%; 95% CI, -44.7% to -19.6%; P < .001). In secondary analyses, the findings remained similar. CONCLUSIONS AND RELEVANCE Medical cannabis laws are associated with significantly lower state-level opioid overdose mortality rates. Further investigation is required to determine how medical cannabis laws may interact with policies aimed at preventing opioid analgesic overdose. C1 [Bachhuber, Marcus A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Bachhuber, Marcus A.] Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, Philadelphia, PA 19104 USA. [Bachhuber, Marcus A.; Saloner, Brendan; Barry, Colleen L.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Saloner, Brendan] Univ Penn, Robert Wood Johnson Hlth & Soc Scholars Program, Philadelphia, PA 19104 USA. [Cunningham, Chinazo O.] Montefiore Med Ctr, Albert Einstein Coll Med, Div Gen Internal Med, Bronx, NY 10467 USA. [Barry, Colleen L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. RP Bachhuber, MA (reprint author), Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, 423 Guardian Dr,1303-A Blockley Hall, Philadelphia, PA 19104 USA. EM marcus.bachhuber@gmail.com OI Bachhuber, Marcus/0000-0002-5610-8382 FU National Institutes of Health (NIH) [R01DA032110, R25DA023021]; Center for AIDS Research at the Albert Einstein College of Medicine; Montefiore Medical Center grant [NIH AI-51519]; Robert Wood Johnson Foundation Health and Society Scholars Program; Philadelphia Veterans Affairs Medical Center; Robert Wood Johnson Foundation Clinical Scholars Program FX This work was funded by National Institutes of Health (NIH) grants R01DA032110 and R25DA023021 and the Center for AIDS Research at the Albert Einstein College of Medicine and Montefiore Medical Center grant NIH AI-51519. Dr Saloner received funding support from the Robert Wood Johnson Foundation Health and Society Scholars Program. Dr Bachhuber received funding support from the Philadelphia Veterans Affairs Medical Center and the Robert Wood Johnson Foundation Clinical Scholars Program. NR 42 TC 67 Z9 68 U1 5 U2 38 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD OCT PY 2014 VL 174 IS 10 BP 1668 EP 1673 DI 10.1001/jamainternmed.2014.4005 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA AU9JS UT WOS:000345909100029 PM 25154332 ER PT J AU Schopfer, DW Takemoto, S Allsup, K Helfrich, CD Ho, PM Forman, DE Whooley, MA AF Schopfer, David W. Takemoto, Steven Allsup, Kelly Helfrich, Christian D. Ho, P. Michael Forman, Daniel E. Whooley, Mary A. TI Cardiac Rehabilitation Use Among Veterans With Ischemic Heart Disease SO JAMA INTERNAL MEDICINE LA English DT Letter ID PERFORMANCE-MEASURES; ASSOCIATION; DELIVERY C1 [Schopfer, David W.; Takemoto, Steven; Whooley, Mary A.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Allsup, Kelly; Forman, Daniel E.] Vet Affairs Boston Healthcare Syst, New England Geriatr Res Educ & Clin Ctr, Boston, MA USA. [Helfrich, Christian D.] Vet Affairs Puget Sound Healthcare Syst, Northwest Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. [Ho, P. Michael] Denver Vet Affairs Med Ctr, Div Cardiol, Denver, CO USA. [Ho, P. Michael] Univ Colorado, Div Cardiol, Dept Med, Hlth Sci Ctr, Denver, CO 80262 USA. [Forman, Daniel E.] Vet Affairs Boston Healthcare Syst, Div Cardiovasc Med, Boston, MA USA. [Forman, Daniel E.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA. [Forman, Daniel E.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Schopfer, DW (reprint author), San Francisco VA Med Ctr, 4150 Clement St 111A1, San Francisco, CA 94121 USA. EM david.schopfer@gmail.com RI Helfrich, Christian/D-2382-2016 OI Helfrich, Christian/0000-0002-9827-4768; Schopfer, David/0000-0002-7244-9857 NR 5 TC 3 Z9 3 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD OCT PY 2014 VL 174 IS 10 BP 1687 EP 1689 DI 10.1001/jamainternmed.2014.3441 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA AU9JS UT WOS:000345909100033 PM 25133868 ER PT J AU Schmajuk, G Bozic, KJ Yazdany, J AF Schmajuk, Gabriela Bozic, Kevin J. Yazdany, Jinoos TI Using Medicare Data to Understand Low-Value Health Care: The Case of Intra-articular Hyaluronic Acid Injections SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Schmajuk, Gabriela; Yazdany, Jinoos] Univ Calif San Francisco, Dept Med & Rheumatol, San Francisco, CA 94143 USA. [Schmajuk, Gabriela] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Bozic, Kevin J.] Univ Calif San Francisco, Dept Orthoped Surg, San Francisco, CA 94143 USA. [Bozic, Kevin J.] Philip R Lee Inst Hlth Policy Studies, San Francisco, CA USA. RP Schmajuk, G (reprint author), San Francisco VA Med Ctr, Dept Med & Rheumatol, 4150 Clement St,Mail Stop 111R, San Francisco, CA 94121 USA. EM gabriela.schmajuk@ucsf.edu FU NIAMS NIH HHS [K23 AR063770, K23 AR060259] NR 7 TC 8 Z9 8 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD OCT PY 2014 VL 174 IS 10 BP 1702 EP 1704 DI 10.1001/jamainternmed.2014.3926 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA AU9JS UT WOS:000345909100044 PM 25156406 ER PT J AU Santucci, AK Singer, LT Wisniewski, SR Luther, JF Eng, HF Dills, JL Sit, DKY Hanusa, BH Wisner, KL AF Santucci, Aimee K. Singer, Lynn T. Wisniewski, Stephen R. Luther, James F. Eng, Heather F. Dills, John L. Sit, Dorothy K. Y. Hanusa, Barbara H. Wisner, Katherine L. TI Impact of Prenatal Exposure to Serotonin Reuptake Inhibitors or Maternal Major Depressive Disorder on Infant Developmental Outcomes SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID ANTIDEPRESSANT DRUGS; SSRI ANTIDEPRESSANTS; ANTENATAL ANXIETY; FOLLOW-UP; IN-UTERO; PREGNANCY; CHILDREN; BEHAVIORS; NEWBORN; HEALTH AB Objective: To examine the impact of prenatal exposure to both serotonin reuptake inhibitors (SRIs; during any trimester) and maternal major depressive disorder (MDD; by DSM-IV criteria) on infant functioning. We hypothesized that infants with prenatal exposure to SRIs or MDD would have lower psychomotor, mental, and behavioral scores compared with nonexposed infants. Method: This longitudinal study included 166 mother-infant dyads: 68 with prenatal MDD/SRI (n = 41) or MDD/no SRI exposure (n = 27) and 98 nonexposed controls. Maternal depression and SRI exposure assessments were completed at or as near to 20, 30, and 36 prenatal weeks and 12, 26, 52, and 78 weeks postpartum as feasible. Infants were evaluated with the Bayley Scales of Infant Development, Second Edition, including the psychomotor (Psychomotor Development Index; PDI), cognitive (Mental Development Index; MDI), and behavioral (Behavioral Rating Scale; BRS) components. Study assessments occurred between 2003 and 2009. Results: Neither prenatal exposure to MDD/SRI nor MDD/no SRI significantly impacted overall PDI, MDI, or BRS scores. However, we observed a significant SRI exposure by time interaction for the PDI (P = .038). MDD/SRI exposure was associated with lower PDI scores at 26 (mean = 97.0) and 52 weeks (mean = 92.9) compared with nonexposed infants (mean = 101.4 and 100.5). This difference was no longer significant at the 78-week assessment. Conclusions: Consistent with previous studies, we found no impact of prenatal MDD/SRI exposure on MDI scores. Less favorable PDI scores were observed in the first year; notably, these scores remained well within the normative range. The effects of prenatal MDD/SRI exposure on motor functioning may be transitory. A longitudinal pattern of poor developmental outcomes has not been established. (C) Copyright 2014 Physicians Postgraduate Press, Inc. C1 [Santucci, Aimee K.] St Jude Childrens Res Hosp, Dept Epidemiol & Canc Control, Memphis, TN 38105 USA. [Singer, Lynn T.] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA. [Singer, Lynn T.] Case Western Reserve Univ, Dept Psychiat, Cleveland, OH 44106 USA. [Singer, Lynn T.] Case Western Reserve Univ, Dept Psychol, Cleveland, OH 44106 USA. [Singer, Lynn T.] Case Western Reserve Univ, Dept Environm Hlth Sci, Cleveland, OH 44106 USA. [Wisniewski, Stephen R.; Luther, James F.; Dills, John L.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Sit, Dorothy K. Y.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Hanusa, Barbara H.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA. [Hanusa, Barbara H.] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA USA. [Wisner, Katherine L.] Northwestern Univ, Asher Ctr Study & Treatment Depress Disorders, Chicago, IL 60611 USA. [Wisner, Katherine L.] Northwestern Univ, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Wisner, Katherine L.] Northwestern Univ, Dept Obstet & Gynecol, Chicago, IL 60611 USA. RP Santucci, AK (reprint author), St Jude Childrens Res Hosp, 262 Danny Thomas Pl,Mail Stop 735, Memphis, TN 38105 USA. EM aimee.santucci@stjude.org OI Wisniewski, Stephen/0000-0002-3877-9860 FU National Institute of Mental Health [5R01 MH60335, 5K23MH082114-05]; Clinical Research Training Program at Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania - National Institute of Mental Health [T32 MH16804-22] FX This research was supported by National Institute of Mental Health grant 5R01 MH60335 (Project investigator: Dr Wisner). The corresponding author (Dr Santucci) was supported by the Clinical Research Training Program (T32 MH16804-22) at Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, funded by National Institute of Mental Health while this research was conducted. Dr Sit was supported by 5K23MH082114-05 (Project investigator: Dr Sit) funded by National Institute of Mental Health. This work was conducted within Women's Behavioral HealthCARE, Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania. Drs Santucci, Hanusa, and Wisner have relocated. NR 40 TC 10 Z9 10 U1 1 U2 8 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD OCT PY 2014 VL 75 IS 10 BP 1088 EP 1095 DI 10.4088/JCP.13m08902 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AU4CT UT WOS:000345557300024 PM 25373117 ER PT J AU Klingensmith, K Tsai, J Mota, N Southwick, SM Pietrzak, RH AF Klingensmith, Katherine Tsai, Jack Mota, Natalie Southwick, Steven M. Pietrzak, Robert H. TI Military Sexual Trauma in US Veterans: Results From the National Health and Resilience in Veterans Study SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; POSTTRAUMATIC-STRESS-DISORDER; WOMEN VETERANS; DSM-IV; ASSAULT; PREVALENCE; PTSD; QUESTIONNAIRE; VALIDATION; SYMPTOMATOLOGY AB Objective: To evaluate the prevalence of military sexual trauma (MST) among US veterans, identify sociodemographic and military characteristics of MST, and examine the relationships between MST and psychiatric comorbidities, functioning/quality of life, and mental health treatment utilization. Method: Data were analyzed from the National Health and Resilience in Veterans Study, a contemporary, nationally representative survey of 1,484 US veterans conducted September-October 2013. Poststratification weights were applied to analyses to permit generalizability of results to the US veteran population. Outcomes measured include history of MST, trauma histories, lifetime and current DSM-IV mental disorders, functioning and quality of life, and utilization of mental health treatment. Results: The overall prevalence of MST was 7.6% and was higher among female than male veterans (32.4% vs 4.8%) and younger than older veterans (22.8% among veterans aged 18-29 years vs 4.5% among veterans aged 60+ years). After adjustment for sociodemographic and military characteristics, MST was associated with elevated rates of current major depressive disorder, posttraumatic stress disorder, and generalized anxiety disorder (adjusted odds ratio [aOR] range, 2.19-3.12); past history of suicide attempt (aOR - 2.78) and current suicidal ideation (aOR = 2.19); and decreased mental and cognitive functioning and quality of life (Cohen d, 0.23-0.38). MST was also associated with increased current utilization of psychotropic medication (aOR = 3.70) and psychotherapy or counseling (aOR = 2.41), independent of psychiatric morbidities. Conclusions: 7.6% of US veterans screen positive for MST, with substantially higher rates among female and younger veterans. MST is associated with elevated rates of several psychiatric morbidities and suicidality, reduced functioning and quality of life, and increased mental health treatment utilization, independent of other sociodemographic, military, and mental health factors. These results suggest that MST is prevalent among US veterans and associated with elevated health burden. Findings can help inform efforts to identify at-risk veterans and characterize the concomitant health burden and needs associated with MST in this population. (C) Copyright 2014 Physicians Postgraduate Press, Inc. C1 [Klingensmith, Katherine; Tsai, Jack; Southwick, Steven M.; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Tsai, Jack] US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA. [Mota, Natalie] Univ Manitoba, Dept Psychol, Winnipeg, MB R3T 2N2, Canada. [Southwick, Steven M.; Pietrzak, Robert H.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, West Haven, CT USA. RP Pietrzak, RH (reprint author), Yale Univ, US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Sch Med,Dept Psychiat,VA Connecticut Healthcare S, 950 Campbell Ave 151E, West Haven, CT 06516 USA. EM robert.pietrzak@yale.edu FU US Department of Veterans Affairs National Center for Posttraumatic Stress Disorder FX This study was supported by the US Department of Veterans Affairs National Center for Posttraumatic Stress Disorder and a private donation. NR 41 TC 12 Z9 12 U1 3 U2 26 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD OCT PY 2014 VL 75 IS 10 BP E1133 EP E1139 DI 10.4088/JCP.14m09244 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AU4CT UT WOS:000345557300005 PM 25373123 ER PT J AU Levine, DA Walter, JM AF Levine, Deborah A. Walter, James M. TI Response to "Index Event Bias: Problems with Eliminating the Paradox" SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES LA English DT Letter C1 [Levine, Deborah A.] Univ Michigan Hlth Syst, Dept Internal Med, Ann Arbor, MI 48109 USA. [Levine, Deborah A.] VA Ann Arbor Healthcare Syst, Ann Arbor, MI 48105 USA. [Walter, James M.] Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA. [Walter, James M.] San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Levine, DA (reprint author), Univ Michigan Hlth Syst, Dept Internal Med, Ann Arbor, MI 48109 USA. EM s.sep@mumc.nl NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1052-3057 EI 1532-8511 J9 J STROKE CEREBROVASC JI J. Stroke Cerebrovasc. Dis. PD OCT PY 2014 VL 23 IS 9 BP 2464 EP 2465 DI 10.1016/j.jstrokecerebrovasdis.2014.06.028 PG 3 WC Neurosciences; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA AU5MA UT WOS:000345649900041 PM 25194741 ER PT J AU Hunt, KJ Kistner-Griffin, E Spruill, I Teklehaimanot, AA Garvey, WT Sale, M Fernandes, J AF Hunt, Kelly J. Kistner-Griffin, Emily Spruill, Ida Teklehaimanot, Abeba A. Garvey, W. Timothy Sale, Michele Fernandes, Jyotika TI Cardiovascular Risk in Gullah African Americans with High Familial Risk of Type 2 Diabetes Mellitus: Project SuGAR SO SOUTHERN MEDICAL JOURNAL LA English DT Article DE African Americans; community-based participatory research; diabetes complications; public health; secondary prevention ID NUCLEAR-MAGNETIC-RESONANCE; CORONARY-ARTERY-DISEASE; DENSITY-LIPOPROTEIN PARTICLES; NUTRITION EXAMINATION SURVEY; IMPAIRED GLUCOSE-TOLERANCE; INSULIN-RESISTANCE; METABOLIC SYNDROME; ATHEROSCLEROSIS RISK; UNITED-STATES; NATIONAL-HEALTH AB Objectives: To determine the prevalence of cardiovascular disease, levels of cardiovascular risk factors, and extent of preventive care in Gullah African Americans with a high familial risk of type 2 diabetes mellitus. Methods: Between 1995 and 2003, 1321 Gullah African Americans with a high prevalence of diabetes mellitus from the South Carolina Sea Islands consented to and enrolled in the Sea Islands Genetic African American Registry (Project SuGAR). A cross-sectional analysis of cardiometabolic risk, preventive care, and self-reported cardiovascular disease was conducted. Results: Cardiometabolic risk factor levels were high and vascular disease was prevalent. Among the subjects with diabetes mellitus, the mean disease duration was 10.5 years; approximately one-third reported reduced vision or blindness; and >80% reported numbness, pain, or burning in their feet. Preventive diabetes carewas limited, with <60%, <25%, and <40% seeing an ophthalmologist, podiatrist, and dentist, respectively, within the past year. Only 54.4% of women and 39.3% of men reported daily glucose monitoring. Conclusions: As the largest existing study of Gullah individuals, our study offers insight into not only the level of cardiovascular risk in this population but also the pathophysiological mechanisms central to ancestral differences in cardiometabolic risk in the broader African American population. C1 [Hunt, Kelly J.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC 29401 USA. Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35233 USA. Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA 22903 USA. RP Hunt, KJ (reprint author), Med Univ S Carolina, Dept Publ Hlth Sci, 135 Cannon St,Suite 302,POB 25 0835, Charleston, SC 29425 USA. EM huntke@musc.edu FU Sea Islands Genetics Network [R01 DK084350]; National Institute on Minority Health and Health Disparities [R01-MD004251]; South Carolina Center of Biomedical Research Excellence in Oral Health [P20 RR017696]; National Institutes of Health; Department of Veterans Affairs; National Institute of Diabetes and Digestive and Kidney Diseases; Merck; AstraZeneca; Weight Watchers FX The project was supported by the Sea Islands Genetics Network R01 DK084350 (M.S.); a grant from the National Institute on Minority Health and Health Disparities (R01-MD004251); a South Carolina Center of Biomedical Research Excellence in Oral Health Project P20 RR017696 (J.F., subaward); and the study from which the data originated, Project SuGAR (W.T.G., Sea Islands Genetic African American Registry, W.M. Keck Foundation and American Diabetes Association).; K.J.H. has received grants from the National Institutes of Health and the Department of Veterans Affairs. E.K.G. has received grants from the National Institutes of Health. A.A.T. has received grants from the National Institutes of Health. I.S. has received a grant from the National Institute of Diabetes and Digestive and Kidney Diseases. W.T.G. has been a consultant to Daiichi-Sankyo, Liposcience, Eisai, Vivus, Novo Nordisk, Janssen, Bristol-Myers Squibb, AstraZeneca, Takeda Pharmaceuticals, and Boehringer-Ingelheim; he has provided expert testimony to the Federal Trade Commission; he has grants or grants pending from Merck, AstraZeneca, and Weight Watchers; he has served on the speakers' bureaus of Merck and Eisai; he has developed educational presentations for Pri-Med, CME Incite, and Vindico. M.S. and J.F. have no financial relationships to disclose and no conflicts of interest to report. NR 52 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 EI 1541-8243 J9 SOUTH MED J JI South.Med.J. PD OCT PY 2014 VL 107 IS 10 BP 607 EP 614 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA AU6WZ UT WOS:000345743400002 PM 25279862 ER PT J AU Kopacz, MS McCarten, JM Pollitt, MJ AF Kopacz, Marek S. McCarten, Janet M. Pollitt, Michael J. TI VHA Chaplaincy Contact with Veterans at Increased Risk of Suicide SO SOUTHERN MEDICAL JOURNAL LA English DT Article DE chaplains; military veterans; suicide ID HELP-SEEKING; CARE; MORTALITY; SERVICES; PTSD AB Objectives: To examine the extent to which chaplains interact with military veterans at increased risk of suicide and select characteristics related to those at-risk veterans who present for chaplaincy services. Methods: The nationwide network of chaplains affiliated with the Veterans Health Administration (n = 990) was e-mailed a letter inviting those who have contact with at-risk veterans to complete a survey. This letter included an Internet link, connecting respondents to an online survey collection service. One hundred eighteen chaplains (11.91%) responded to the survey. Results: More than half of the respondents reported that veterans at increased risk of suicide constitute either <5% or 5% to 10% of the overall population of veterans under their care. At-risk veterans are most often identified based on open admission of suicidal behavior or red flags in their treatment file. Veterans typically do not look for chaplains from their own faith tradition, will seek care from >1 chaplain, and present at a moderate-to-high level of risk. Conclusions: The present study finds that some at-risk veterans look to chaplains for supportive services. The findings also allow for opportunities for future research. C1 [Kopacz, Marek S.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA. US Dept Vet Affairs, Natl Chaplain Ctr, Hampton, VA USA. RP Kopacz, MS (reprint author), US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM marek.kopacz@va.gov NR 39 TC 6 Z9 6 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 EI 1541-8243 J9 SOUTH MED J JI South.Med.J. PD OCT PY 2014 VL 107 IS 10 BP 661 EP 664 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA AU6WZ UT WOS:000345743400013 PM 25279873 ER PT J AU Lehrner, A Allen, NE AF Lehrner, Amy Allen, Nicole E. TI Construct Validity of the Conflict Tactics Scales: A Mixed-Method Investigation of Women's Intimate Partner Violence SO PSYCHOLOGY OF VIOLENCE LA English DT Article DE assessment; Conflict Tactics Scales; intimate partner violence; mixed-methods; play; women ID DATING VIOLENCE; PHYSICAL AGGRESSION; COURTSHIP VIOLENCE; COLLEGE-STUDENTS; RELIABILITY; COUPLES; SYMMETRY; CONTEXT; FORMS; PLAY AB Objective: The Conflict Tactics Scales 2 (CTS; Straus, Hamby, Boney-McCoy, & Sugarman, 1996) is the most widely used measure of intimate partner violence (IPV), and it consistently indicates high rates of IPV by young women in dating relationships. However, the CTS has been criticized for not assessing the context of the acts it measures. This study undertook a mixed-method investigation of women's IPV, incorporating both the CTS and in-depth interviews, to contextualize women's CTS reports of their use of violence against dating partners. Method: Four hundred seventy-six female undergraduates who had been in a heterosexual dating relationship in the past year completed the CTS. Women were then purposively recruited for follow-up interviews in a balanced design across 4 groups defined by self-reports of IPV perpetration on the CTS, ranging from none to severe and/or frequent violence. Thirty-four women completed interviews. Results: Although women's CTS reports were consistent with rates reported in the literature, there were discrepancies with the interview data. Findings indicate that women report endorsing acts of playful wrestling/fighting (i.e., "roughhousing") and mock violence on the CTS, and that such behavior is common among undergraduate women. The directionality of IPV identified by the CTS was also inconsistent with interview data. Conclusions: The CTS may potentially miscategorize acts and individuals and inflate estimates of the frequency and severity of women's IPV in young, dating, nonclinical samples. Research and clinical implications include the need for clearer definitions of the construct of IPV and the development of alternative or complementary assessment measures. C1 [Lehrner, Amy] James J Peters VA Med Ctr, Bronx, NY USA. [Allen, Nicole E.] Univ Illinois, Dept Psychol, Urbana, IL 61801 USA. RP Lehrner, A (reprint author), James J Peters Vet Affairs Med Ctr, Mental Hlth Patient Care Ctr, 526 OOMH PTSD 116-A,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM amy.lehrner@va.gov NR 55 TC 8 Z9 8 U1 2 U2 12 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 2152-0828 EI 2152-081X J9 PSYCHOL VIOLENCE JI Psychol. Violence PD OCT PY 2014 VL 4 IS 4 SI SI BP 477 EP 490 DI 10.1037/a0037404 PG 14 WC Psychology, Clinical; Criminology & Penology; Family Studies SC Psychology; Criminology & Penology; Family Studies GA AU6GD UT WOS:000345700800009 ER PT J AU Levy, BR Pilver, CE Pietrzak, RH AF Levy, Becca R. Pilver, Corey E. Pietrzak, Robert H. TI Lower prevalence of psychiatric conditions when negative age stereotypes are resisted SO SOCIAL SCIENCE & MEDICINE LA English DT Article DE Aging; Age stereotypes; Mental health; Stress; Suicide; Anxiety; Posttraumatic stress disorder; Veterans ID SELF-PERCEPTIONS; MALE VETERANS; WAR VETERANS; PRIMARY-CARE; SUICIDE; HEALTH; DEPRESSION; ANXIETY; EXPECTATIONS; RESILIENCE AB Older military veterans are at greater risk for psychiatric disorders than same-aged non-veterans. However, little is known about factors that may protect older veterans from developing these disorders. We considered whether an association exists between the potentially stress-reducing factor of resistance to negative age stereotypes and lower prevalence of the following outcomes among older veterans: suicidal ideation, anxiety, and posttraumatic stress disorder (PTSD). Participants consisted of 2031 veterans, aged 55 or older, who were drawn from the National Health and Resilience in Veterans Study, a nationally representative survey of American veterans. The prevalence of all three outcomes was found to be significantly lower among participants who fully resisted negative age stereotypes, compared to those who fully accepted them: suicidal ideation, 5.0% vs. 30.1%; anxiety, 3.6% vs. 34.9%; and PTSD, 2.0% vs. 18.5%, respectively. The associations followed a graded linear pattern and persisted after adjustment for relevant covariates, including age, combat experience, personality, and physical health. These findings suggest that developing resistance to negative age stereotypes could provide older individuals with a path to greater mental health. (C) 2014 Published by Elsevier Ltd. C1 [Levy, Becca R.] Yale Univ, Sch Publ Hlth, Social & Behav Sci Div, New Haven, CT 06520 USA. [Pilver, Corey E.] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT 06520 USA. [Pietrzak, Robert H.] Yale Univ, US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, VA Connecticut Healthcare Syst,Sch Med, West Haven, CT 06516 USA. [Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA. RP Levy, BR (reprint author), Yale Univ, Sch Publ Hlth, Social & Behav Sci Div, 60 Coll St, New Haven, CT 06520 USA. EM becca.levy@yale.edu FU Becca Levy from the National Institute on Aging [R01AG023993]; National Heart, Lung and Blood Institute [R01HL089314]; National Institute of Mental Health [5-T32-MH01423537] FX This research was supported by grants to Becca Levy from the National Institute on Aging (R01AG023993), and the National Heart, Lung and Blood Institute (R01HL089314). Corey Pilver was supported by a National Institute of Mental Health postdoctoral fellowship (5-T32-MH01423537). The National Health and Resilience in Veterans Study and Robert Pietrzak were supported by the United States Department of Veterans Affairs National Center for Posttraumatic Stress Disorder. NR 30 TC 6 Z9 6 U1 2 U2 17 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD OCT PY 2014 VL 119 BP 170 EP 174 DI 10.1016/j.socscimed.2014.06.046 PG 5 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA AU2YI UT WOS:000345480000020 PM 25189737 ER PT J AU Jensen, JD Delcambre, MR Nguyen, G Sami, N AF Jensen, J. Daniel Delcambre, Macey Renault Nguyen, Gloria Sami, Naveed TI Biologic Therapy with or Without Topical Treatment in Psoriasis: What Does the Current Evidence Say? SO AMERICAN JOURNAL OF CLINICAL DERMATOLOGY LA English DT Article ID SEVERE PLAQUE PSORIASIS; PROPIONATE SPRAY 0.05-PERCENT; ADD-ON THERAPY; CALCIPOTRIOL OINTMENT; COMBINATION THERAPY; OPEN-LABEL; MODERATE; MULTICENTER; EFFICACY; ETANERCEPT AB Biologic therapy represents a relatively new class of drugs which have revolutionized the treatment of psoriasis and are used with increasing frequency in order to control this chronic, systemic inflammatory disease. However, it is unclear what role there is for combination therapy of biologics with traditional topical agents. The purpose of this article is to assess the literature on the role of topical agents as adjuvants to biological treatments in the treatment of psoriasis and identify areas for further research. A MEDLINE search was performed in order to identify English-language publications from 1996 to 2014 examining combination biologic therapy with topical medications in the treatment of psoriasis. Data from these clinical studies are summarized and the outcomes are discussed. In general, the addition of adjuvant topical therapy to systemic biologic therapy allowed for a reduction in dosage and side effects of both agents, maintenance of initial response to biologics, treatment of recalcitrant lesions in partial responders, and potential acceleration of response to biologic therapies. The current data, though limited, suggest that using topical therapies as adjunct treatment to biologics is a well tolerated and effective means of controlling psoriasis and improving quality of life for patients. However, the treating physician should remain attentive to signs of adverse events and seek opportunities to reduce the dose or treatment frequency during chronic use. C1 [Jensen, J. Daniel] Univ Alabama, Dept Dermatol, South Birmingham, AL 35294 USA. [Delcambre, Macey Renault] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA. [Nguyen, Gloria] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA. [Sami, Naveed] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Sami, N (reprint author), Univ Alabama, Dept Dermatol, EFH 414,1530 3rd Ave, South Birmingham, AL 35294 USA. EM nsami@uab.edu NR 33 TC 1 Z9 1 U1 1 U2 4 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 1175-0561 EI 1179-1888 J9 AM J CLIN DERMATOL JI Am. J. Clin. Dermatol. PD OCT PY 2014 VL 15 IS 5 BP 379 EP 385 DI 10.1007/s40257-014-0089-1 PG 7 WC Dermatology SC Dermatology GA AT0BN UT WOS:000344602100001 PM 25027461 ER PT J AU Johnson, DA Barkun, AN Cohen, LB Dominitz, JA Kaltenbach, T Martel, M Robertson, DJ Boland, CR Giardello, FM Lieberman, DA Levin, TR Rex, DK AF Johnson, David A. Barkun, Alan N. Cohen, Larry B. Dominitz, Jason A. Kaltenbach, Tonya Martel, Myriam Robertson, Douglas J. Boland, C. Richard Giardello, Frances M. Lieberman, David A. Levin, Theodore R. Rex, Douglas K. TI Optimizing Adequacy of Bowel Cleansing for Colonoscopy: Recommendations From the US Multi-Society Task Force on Colorectal Cancer SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Review ID ORAL SODIUM-PHOSPHATE; RANDOMIZED CONTROLLED-TRIAL; POLYETHYLENE-GLYCOL SOLUTION; ELECTROLYTE LAVAGE SOLUTION; PLUS ASCORBIC-ACID; INVESTIGATOR-BLINDED TRIAL; HIGH-DOSE SENNA; INCREASE SCREENING COLONOSCOPY; ADENOMA DETECTION RATE; CLEAR LIQUID DIET AB Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States (1). Colonoscopy can prevent CRC by the detection and removal of precancerous lesions. In addition to CRC screening and surveillance, colonoscopy is used widely for the diagnostic evaluation of symptoms and other positive CRC screening tests. Regardless of indication, the success of colonoscopy is linked closely to the adequacy of preprocedure bowel cleansing. Unfortunately, up to 20-25% of all colonoscopies are reported to have an inadequate bowel preparation (2,3). The reasons for this range from patient-related variables such as compliance with preparation instructions and a variety of medical conditions that make bowel cleansing more difficult to unit-specific factors (eg, extended wait times aft er scheduling of colonoscopy) (4). Adverse consequences of ineffective bowel preparation include lower adenoma detection rates, longer procedural time, lower cecal intubation rates, increased electrocautery risk, and shorter intervals between examinations (3,5-7). Bowel preparation formulations intended for precolonoscopy cleansing are assessed based on their efficacy, safety, and tolerability. Lack of specific organ toxicity is considered to be a prerequisite for bowel preparations. Between cleansing efficacy and tolerability, however, the consequences of inadequate cleansing suggest that efficacy should be a higher priority than tolerability. Consequently, the choice of a bowel cleansing regimen should be based on cleansing efficacy first and patient tolerability second. However, efficacy and tolerability are closely interrelated. For example, a cleansing agent that is poorly tolerated and thus not fully ingested may not achieve an adequate cleansing. The goals of this consensus document are to provide expert, evidence-based recommendations for clinicians to optimize colonoscopy preparation quality and patient safety. Recommendations are provided using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) scoring system, which weighs the strength of the recommendation and the quality of the evidence (8). C1 [Johnson, David A.] Eastern VA Med Sch, Norfolk, VA 23507 USA. [Barkun, Alan N.; Martel, Myriam] McGill Univ, Ctr Hlth, Montreal, PQ, Canada. [Cohen, Larry B.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Dominitz, Jason A.] Univ Washington, Seattle, WA 98195 USA. [Kaltenbach, Tonya] Stanford Univ, Sch Med, Vet Affairs Palo Alto, Palo Alto, CA 94304 USA. [Robertson, Douglas J.] VA Med Ctr, Portland, OR USA. [Robertson, Douglas J.] Geisel Sch Med Dartmouth, White River Jct, VT USA. [Boland, C. Richard] Baylor Univ, Med Ctr, Dallas, TX USA. [Giardello, Frances M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Lieberman, David A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Levin, Theodore R.] Kaiser Permanente Med Ctr, Walnut Creek, CA USA. [Rex, Douglas K.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. RP Johnson, DA (reprint author), Eastern VA Med Sch, Norfolk, VA 23507 USA. EM dajevms@aol.com OI Dominitz, Jason/0000-0002-8070-7086 FU Boston Scientific and Cook; Salix; Olympus America, Inc; Braintree Laboratories and Ferring Pharmaceuticals; Given Imaging; Olympus America Corp FX These authors disclose the following: David Johnson has served as a consultant and clinical investigator for Epigenomics, as a consultant for Given Imaging, and as a clinical investigator for Exact Sciences; A. Barkun has served as a consultant for Olympus, Inc, and Pendopharm, Inc, and has received clinical research support from Boston Scientific and Cook; L. B. Cohen has served as a consultant and on the speaker's bureau and received research support from Salix, and as a consultant for Braintree; T. Kaltenbach has been a research grant recipient and consultant for Olympus America, Inc, D.J. Robertson has served as a consultant for Given Imaging; D. A. Lieberman has served on the scientific advisory boards for Exact Sciences, Given Imaging, and Roche, and as a consultant for MOTUS; and D. K. Rex has received research support and served as a consultant for Braintree Laboratories and Ferring Pharmaceuticals, Given Imaging, and Olympus America Corp, has served as a consultant for Epigenomics and Exact Sciences, and has served on the speaker's bureau for Boston Scientific, Inc. The remaining authors disclose no conflicts. NR 252 TC 32 Z9 32 U1 3 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 IS 10 BP 1528 EP 1545 DI 10.1038/ajg.2014.272 PG 18 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS7UM UT WOS:000344460100005 PM 25223578 ER PT J AU Ford, AC Quigley, EMM Lacy, BE Lembo, AJ Saito, YA Schiller, LR Soffer, EE Spiegel, BMR Moayyedi, P AF Ford, Alexander C. Quigley, Eamonn M. M. Lacy, Brian E. Lembo, Anthony J. Saito, Yuri A. Schiller, Lawrence R. Soffer, Edy E. Spiegel, Brennan M. R. Moayyedi, Paul TI Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; LACTOBACILLUS-PLANTARUM 299V; QUALITY-OF-LIFE; SIGNIFICANTLY REDUCES SYMPTOMS; PLACEBO-CONTROLLED-TRIAL; DOUBLE-BLIND; CLINICAL-TRIAL; FERMENTED MILK; FECAL MICROBIOTA; PRIMARY-CARE AB OBJECTIVES: Irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC) are functional bowel disorders. Evidence suggests that disturbance in the gastrointestinal microbiota may be implicated in both conditions. We performed a systematic review and meta-analysis to examine the efficacy of prebiotics, probiotics, and synbiotics in IBS and CIC. METHODS: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (up to December 2013). Randomized controlled trials (RCTs) recruiting adults with IBS or CIC, which compared prebiotics, probiotics, or synbiotics with placebo or no therapy, were eligible. Dichotomous symptom data were pooled to obtain a relative risk (RR) of remaining symptomatic after therapy, with a 95% confidence interval (CI). Continuous data were pooled using a standardized or weighted mean difference with a 95% CI. RESULTS: The search strategy identified 3,216 citations. Forty-three RCTs were eligible for inclusion. The RR of IBS symptoms persisting with probiotics vs. placebo was 0.79 (95% CI 0.70-0.89). Probiotics had beneficial effects on global IBS, abdominal pain, bloating, and flatulence scores. Data for prebiotics and synbiotics in IBS were sparse. Probiotics appeared to have beneficial effects in CIC (mean increase in number of stools per week = 1.49; 95% CI = 1.02-1.96), but there were only two RCTs. Synbiotics also appeared beneficial (RR of failure to respond to therapy = 0.78; 95% CI 0.67-0.92). Again, trials for prebiotics were few in number, and no definite conclusions could be drawn. CONCLUSIONS: Probiotics are effective treatments for IBS, although which individual species and strains are the most beneficial remains unclear. Further evidence is required before the role of prebiotics or synbiotics in IBS is known. The efficacy of all three therapies in CIC is also uncertain. C1 [Ford, Alexander C.] St James Univ Hosp, Leeds Gastroenterol Inst, Leeds LS9 7TF, W Yorkshire, England. [Ford, Alexander C.] Univ Leeds, Leeds Inst Biomed & Clin Sci, Leeds, W Yorkshire, England. [Quigley, Eamonn M. M.] Houston Methodist Hosp, Dept Med, Div Gastroenterol & Hepatol, Houston, TX USA. [Lacy, Brian E.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. [Lembo, Anthony J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Saito, Yuri A.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA. [Schiller, Lawrence R.] Baylor Univ, Med Ctr, Digest Hlth Associates Texas, Dallas, TX USA. [Soffer, Edy E.] Univ So Calif, Div Gastroenterol Cedars Sinai, Los Angeles, CA USA. [Spiegel, Brennan M. R.] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA. [Moayyedi, Paul] McMaster Univ, Hlth Sci Ctr, Div Gastroenterol, Hamilton, ON, Canada. RP Ford, AC (reprint author), St James Univ Hosp, Leeds Gastroenterol Inst, Room 125,4th Floor,Bexley Wing,Beckett St, Leeds LS9 7TF, W Yorkshire, England. EM alexf12399@yahoo.com RI Ford, Alexander/K-5491-2012; Moayyedi, Paul/M-6178-2014 OI Ford, Alexander/0000-0001-6371-4359; Moayyedi, Paul/0000-0002-3616-9292 FU American College of Gastroenterology FX This work was supported by American College of Gastroenterology. NR 72 TC 91 Z9 97 U1 13 U2 70 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2014 VL 109 IS 10 BP 1547 EP 1561 DI 10.1038/ajg.2014.202 PG 15 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS7UM UT WOS:000344460100007 PM 25070051 ER PT J AU Kaup, AR Drummond, SPA Eyler, LT AF Kaup, Allison R. Drummond, Sean P. A. Eyler, Lisa T. TI Brain Functional Correlates of Working Memory: Reduced Load-Modulated Activation and Deactivation in Aging without Hyperactivation or Functional Reorganization SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE Aging; Working memory; Cognition; Functional neuroimaging; fMRI; Individual differences ID AGE-RELATED DIFFERENCES; ADULT LIFE-SPAN; PERFORMANCE; FMRI; RECRUITMENT; MODEL; PET AB We aimed to identify brain functional correlates of working memory performance in aging, in hopes of facilitating understanding of mechanisms that promote better versus worse working memory in late-life. Among 64 healthy adults, aged 23 to 78, we examined the relationship between age, working memory performance, and brain functional response during task performance. We focused on the association between working memory load-modulated functional response and individual differences in performance and whether these function-performance relationships differed with age. As expected, older age was associated with poorer working memory performance. Older age was also associated with reduced load-modulated activation including in bilateral prefrontal and parietal regions and left caudate as well as reduced deactivation including in the medial prefrontal cortex. Contrary to findings of hyperactivation in aging, we found no evidence of increased activation with older age. Positive associations identified between brain response and performance did not differ with age. Our findings suggest that the neural mechanisms underlying better versus worse working memory performance are age-invariant across adulthood, and argue against a pattern of functional reorganization in aging. Results are discussed within the broader literature, in which significant heterogeneity in findings between studies has been common. C1 [Kaup, Allison R.] Univ Calif San Francisco, San Francisco VA Med Ctr, Sierra Pacific Mental Illness Res Educ & Clin Ctr, San Francisco, CA 94143 USA. [Kaup, Allison R.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Kaup, Allison R.] Univ Calif San Francisco, San Diego State Univ, Joint Doctoral Program Clin Psychol, San Francisco, CA 94143 USA. [Drummond, Sean P. A.] VA San Diego Hlth Care Syst, Psychol Serv, San Diego, CA USA. [Drummond, Sean P. A.; Eyler, Lisa T.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Eyler, Lisa T.] Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA. [Eyler, Lisa T.] VA San Diego Healthcare Syst, Mental Illness Res Educ & Clin Ctr, San Diego, CA USA. RP Kaup, AR (reprint author), San Francisco VA Med Ctr, 4150 Clement St,116H, San Francisco, CA 94121 USA. EM allison.kaup@ucsf.edu FU NIMH T-32 Fellowship in Geriatric Mental Health [T32 MH019934]; [R01 MH083968]; [R01 AG024506] FX This study was funded by R01 MH083968 awarded to Dr. Eyler, R01 AG024506 awarded to Dr. Drummond, and the NIMH T-32 Fellowship in Geriatric Mental Health (T32 MH019934) awarded to Dilip V. Jeste, M.D. Infrastructure support was provided to one of the studies by the VA San Diego Center for Excellence in Stress and Mental Health. Writing of this manuscript was supported by Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment, the Medical Research Service of the San Francisco Veterans Affairs Medical Center, and the Department of Veterans Affairs Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC). The authors have no conflicts of interest to disclose. NR 20 TC 4 Z9 4 U1 3 U2 5 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 EI 1469-7661 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD OCT PY 2014 VL 20 IS 9 BP 945 EP 950 DI 10.1017/S1355617714000824 PG 6 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA AT4YD UT WOS:000344947600008 PM 25263349 ER PT J AU Evangelista, KV Hahn, B Wunder, EA Ko, AI Haake, DA Coburn, J AF Evangelista, Karen V. Hahn, Beth Wunder, Elsio A., Jr. Ko, Albert I. Haake, David A. Coburn, Jenifer TI Identification of Cell-Binding Adhesins of Leptospira interrogans SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID OUTER-MEMBRANE PROTEINS; PATHOGENIC LEPTOSPIRA; EXTRACELLULAR-MATRIX; BORRELIA-BURGDORFERI; PHAGE DISPLAY; TREPONEMA-PALLIDUM; YERSINIA-PSEUDOTUBERCULOSIS; ENDOTHELIAL-CELLS; INVASIN PROTEIN; CULTURED-CELLS AB Leptospirosis is a globally distributed bacterial infectious disease caused by pathogenic members of the genus Leptospira. Infection can lead to illness ranging from mild and non-specific to severe, with jaundice, kidney and liver dysfunction, and widespread endothelial damage. The adhesion of pathogenic Leptospira species (spp.), the causative agent of leptospirosis, to host tissue components is necessary for infection and pathogenesis. While it is well-established that extracellular matrix (ECM) components play a role in the interaction of the pathogen with host molecules, we have shown that pathogenic Leptospira interrogans binds to host cells more efficiently than to ECM components. Using in vitro phage display to select for phage clones that bind to EA. hy926 endothelial cells, we identified the putative lipoproteins LIC10508 and LIC13411, and the conserved hypothetical proteins LIC12341 and LIC11574, as candidate L. interrogans sv. Copenhageni st. Fiocruz L1-130 adhesins. Recombinant LIC11574, but not its L. biflexa homologue LBF1629, exhibited dose-dependent binding to both endothelial and epithelial cells. In addition, LIC11574 and LIC13411 bind to VE-cadherin, an endothelial cell receptor for L. interrogans. Extraction of bacteria with the non-ionic detergent Triton X-114 resulted in partitioning of the candidate adhesins to the detergent fraction, a likely indication that these proteins are outer membrane localized. All candidate adhesins were recognized by sera obtained from leptospirosis patients but not by sera from healthy individuals as assessed by western blot. This work has identified bacterial adhesins that are potentially involved in L. interrogans infection of the mammalian host, and through cadherin binding, may contribute to dissemination and vascular damage. Our findings may be of value in leptospirosis control and prevention, with the bacterial adhesins potentially serving as targets for development of diagnostics, therapeutics, and vaccines. C1 [Evangelista, Karen V.; Coburn, Jenifer] Med Coll Wisconsin, Grad Program Microbiol Immunol & Mol Genet, Milwaukee, WI 53226 USA. [Hahn, Beth; Coburn, Jenifer] Med Coll Wisconsin, Dept Med, Div Infect Dis, Milwaukee, WI 53226 USA. [Wunder, Elsio A., Jr.; Ko, Albert I.] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA. [Haake, David A.] VA Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. [Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. RP Evangelista, KV (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. EM jcoburn@mcw.edu RI Ko, Albert/P-2343-2015; Wunder, Elsio/C-2733-2013 OI Ko, Albert/0000-0001-9023-2339; FU National Institutes of Health [R21 AI077560, R56 AI087835,, R21 AI093509, R01 AI 034431, R01 AI 052473, R01 TW009504, U01 AI088752]; Veterans Affairs Merit Review award FX This work was supported by National Institutes of Health grants R21 AI077560, R56 AI087835, and R21 AI093509 to JC, R01 AI 034431 to DAH, R01 AI 052473, R01 TW009504, and U01 AI088752 to AIK, and by a Veterans Affairs Merit Review award to DAH. None of the funders had any role in the design or analysis of experiments, the preparation of the manuscript, or the decision to publish. NR 75 TC 7 Z9 7 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2014 VL 8 IS 10 AR e3215 DI 10.1371/journal.pntd.0003215 PG 14 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AS9WJ UT WOS:000344589000033 PM 25275630 ER PT J AU Witchell, TD Eshghi, A Nally, JE Hof, R Boulanger, MJ Wunder, EA Ko, AI Haake, DA Cameron, CE AF Witchell, Timothy D. Eshghi, Azad Nally, Jarlath E. Hof, Rebecca Boulanger, Martin J. Wunder, Elsio A., Jr. Ko, Albert I. Haake, David A. Cameron, Caroline E. TI Post-translational Modification of LipL32 during Leptospira interrogans Infection SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID OUTER-MEMBRANE; PATHOGENIC LEPTOSPIRA; RICKETTSIA-PROWAZEKII; PROTEOMIC ANALYSIS; CALCIUM-BINDING; PLASMA FIBRONECTIN; MASS-SPECTROMETRY; SURFACE PROTEIN; ANTIGEN; LIPOPROTEIN AB Background: Leptospirosis, a re-emerging disease of global importance caused by pathogenic Leptospira spp., is considered the world's most widespread zoonotic disease. Rats serve as asymptomatic carriers of pathogenic Leptospira and are critical for disease spread. In such reservoir hosts, leptospires colonize the kidney, are shed in the urine, persist in fresh water and gain access to a new mammalian host through breaches in the skin. Methodology/Principal Findings: Previous studies have provided evidence for post-translational modification (PTM) of leptospiral proteins. In the current study, we used proteomic analyses to determine the presence of PTMs on the highly abundant leptospiral protein, LipL32, from rat urine-isolated L. interrogans serovar Copenhageni compared to in vitro-grown organisms. We observed either acetylation or tri-methylation of lysine residues within multiple LipL32 peptides, including peptides corresponding to regions of LipL32 previously identified as epitopes. Intriguingly, the PTMs were unique to the LipL32 peptides originating from in vivo relative to in vitro grown leptospires. The identity of each modified lysine residue was confirmed by fragmentation pattern analysis of the peptide mass spectra. A synthetic peptide containing an identified tri-methylated lysine, which corresponds to a previously identified LipL32 epitope, demonstrated significantly reduced immunoreactivity with serum collected from leptospirosis patients compared to the peptide version lacking the tri-methylation. Further, a subset of the identified PTMs are in close proximity to the established calcium-binding and putative collagen-binding sites that have been identified within LipL32. Conclusions/Significance: The exclusive detection of PTMs on lysine residues within LipL32 from in vivo-isolated L. interrogans implies that infection-generated modification of leptospiral proteins may have a biologically relevant function during the course of infection. Although definitive determination of the role of these PTMs must await further investigations, the reduced immune recognition of a modified LipL32 epitope suggests the intriguing possibility that LipL32 modification represents a novel mechanism of immune evasion within Leptospira. C1 [Witchell, Timothy D.; Eshghi, Azad; Hof, Rebecca; Boulanger, Martin J.; Cameron, Caroline E.] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC, Canada. [Nally, Jarlath E.] Univ Coll Dublin, Sch Vet Med, Dublin 2, Ireland. [Wunder, Elsio A., Jr.; Ko, Albert I.] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA. [Wunder, Elsio A., Jr.; Ko, Albert I.] Brazilian Minist Hlth, Oswaldo Cruz Fdn, Goncalo Moniz Res Ctr, Salvador, BA, Brazil. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. [Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Witchell, TD (reprint author), Univ Victoria, Dept Biochem & Microbiol, Victoria, BC, Canada. EM caroc@uvic.ca RI Ko, Albert/P-2343-2015; Wunder, Elsio/C-2733-2013 OI Ko, Albert/0000-0001-9023-2339; FU Natural Sciences and Engineering Research Council of Canada [327186]; Canada Research Chair Program; Michael Smith Foundation for Health Research Scholar Program; Science Foundation Ireland [05/YI/B696]; Research Stimulus Fund (Department of Agriculture, Food & Marine, Ireland) [06/363]; Veterans Affairs Merit Review award; Public Health Service from the National Institute of Allergy and Infectious Diseases [AI-034431]; Natural History of Leptospirosis [R01AI052473]; Ecoepidemiology of Leptospirosis [R01TW009504]; Disease Determinants of Urban Leptospirosis [U01AI088752]; Natural Sciences and Engineering Research Council (NSERC) FX This research was supported by a Discovery Grant from the Natural Sciences and Engineering Research Council of Canada (327186; CEC), the Canada Research Chair Program (CEC) and the Michael Smith Foundation for Health Research Scholar Program (CEC). This research was also funded in part by Science Foundation Ireland award 05/YI/B696 (JEN), The Research Stimulus Fund (06/363 Department of Agriculture, Food & Marine, Ireland; JEN), Veterans Affairs Merit Review award (DAH), Public Health Service grant AI-034431 from the National Institute of Allergy and Infectious Diseases (DAH), and grants R01AI052473 (Natural History of Leptospirosis; AIK and EAW), R01TW009504 (Ecoepidemiology of Leptospirosis; AIK and EAW) and U01AI088752 (Disease Determinants of Urban Leptospirosis; AIK and EAW). MJB is supported by an operating grant from the Natural Sciences and Engineering Research Council (NSERC) and by the Canada Research Chair program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 53 TC 6 Z9 6 U1 3 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2014 VL 8 IS 10 AR e3280 DI 10.1371/journal.pntd.0003280 PG 9 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AS9WJ UT WOS:000344589000078 PM 25356675 ER PT J AU Patel, MS Lypson, ML Miller, DD Davis, MM AF Patel, Mitesh S. Lypson, Monica L. Miller, D. Douglas Davis, Matthew M. TI A Framework for Evaluating Student Perceptions of Health Policy Training in Medical School SO ACADEMIC MEDICINE LA English DT Editorial Material ID EDUCATION; CARE AB Problem Nearly half of graduating medical students in the United States report that medical school provides inadequate instruction in topics related to health policy. Although most medical schools report some form of policy education, there lacks a standard for teaching core concepts and evaluating student satisfaction. Approach Responses to the Association of American Medical College's Medical School Graduation Questionnaire were obtained for the years 2007-2008 and 2011-2012 and mapped to domains of training in health policy curricula for four domains: systems and principles; value and equity; quality and safety; and politics and law. Chi-square tests were used to test differences among unadjusted temporal trends. Multiple logistic regression models were fit to the outcome variables and adjusted for student characteristics, student preferences, and medical school characteristics. Outcomes Compared with 2007-2008, students' perceptions of training in 2011-2012 increased on a relative basis by 11.7% for components within systems and principles, 2.8% for quality and safety, and 6.8% for value and equity. Components within politics and law had a composite decline of 4.8%. Multiple logistic regression models found higher odds of reporting satisfaction with training over time for all components within the domains of systems and principles, quality and safety, and value and equity (P < .01), with the exception of medical economics. Next Steps Medical student perceptions of training in health policy improved over time. Causal factors for these trends require further study. Despite improvement, nearly 40% of graduating medical students still report inadequate instruction in health policy. C1 [Patel, Mitesh S.] Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA. [Patel, Mitesh S.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Lypson, Monica L.] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Lypson, Monica L.] Vet Affairs Healthcare Syst, Ann Arbor, MI USA. [Miller, D. Douglas] Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada. [Davis, Matthew M.] Univ Michigan Hlth Syst, Ann Arbor, MI USA. [Davis, Matthew M.] Univ Michigan, Gerald R Ford Sch Publ Policy, Ann Arbor, MI 48109 USA. RP Patel, MS (reprint author), 423 Guardian Dr,1303B Blockley Hall, Philadelphia, PA 19104 USA. EM mpatel@upenn.edu FU Department of Veterans Affairs; Robert Wood Johnson Foundation FX Dr. Patel was supported by the Department of Veterans Affairs and the Robert Wood Johnson Foundation. NR 5 TC 4 Z9 4 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD OCT PY 2014 VL 89 IS 10 BP 1375 EP 1379 DI 10.1097/ACM.0000000000000408 PG 5 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA AR9LQ UT WOS:000343896100023 PM 25006706 ER PT J AU Schultz, CL Mitra, N Schapira, MM Lambert, MP AF Schultz, Corinna L. Mitra, Nandita Schapira, Marilyn M. Lambert, Michele P. TI Influence of the American Society of Hematology Guidelines on the Management of Newly Diagnosed Childhood Immune Thrombocytopenia SO JAMA PEDIATRICS LA English DT Article ID PEDIATRIC-HEMATOLOGY/ONCOLOGY; INTRAVENOUS IMMUNOGLOBULIN; NATURAL-HISTORY; PURPURA; CHILDREN; HEMORRHAGE; ADULTS; TRENDS; CARE; ITP AB IMPORTANCE In 2011, the American Society of Hematology (ASH) published updated guidelines for the management of childhood immune thrombocytopenia (ITP) recommending management with observation alone when there are mild or no bleeding symptoms, regardless of platelet count. Little is known about practice patterns of newly diagnosed ITP in the United States. OBJECTIVE To understand the impact of management recommendations on practice patterns. DESIGN, SETTING, AND PARTICIPANTS Retrospective medical record review in the Children's Hospital of Philadelphia, a large, urban, pediatric tertiary care hospital in Philadelphia, Pennsylvania. The study involved 311 pediatric patients with newly diagnosed ITP managed between January 1, 2007, and December 31, 2012. MAIN OUTCOMES AND MEASURES Management type (observation alone vs pharmacotherapy) was determined via medical record review and electronic pharmacy data at diagnosis and within 6 months after diagnosis. RESULTS Overall, 44.7% of patients were managed with observation alone at diagnosis, with a significant increase from 34.9% in 2007-2010 to 49.2% in 2011 (P<.02) and 71.1% in 2012 (P<.001). Of those treated, 99% were treated with intravenous immunoglobulin. In multivariable logistic regression, younger age (odds ratio, 0.92; 95% CI, 0.87-0.99), lower platelet count (odds ratio, 0.86; 95% CI, 0.83-0.89), and earlier period (2007-2010) of diagnosis (odds ratio, 0.17; 95% CI, 0.09-0.34) were significantly associated with increased odds of pharmacologic management. During 2010-2012, 20.8% of patients were also treated within 6 months after diagnosis. There was no significant difference by year or initial management type in those who received this later pharmacotherapy. Additionally, 19.6% of patients had documented bleeding symptoms beyond cutaneous bruising or petechiae at diagnosis. Intracranial hemorrhage at diagnosis was rare (0.6%). CONCLUSIONS AND RELEVANCE We demonstrated a significant practice change in the management of newly diagnosed ITP at a pediatric care tertiary care hospital in the United States surrounding revision of the ASH management guidelines for childhood ITP. Our experience supports adoption of observation alone for a proportion of patients with newly diagnosed childhood ITP. This form of management did not lead to an increase in later treatment or an increase in delayed bleeding symptoms. C1 [Schultz, Corinna L.; Lambert, Michele P.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Mitra, Nandita] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Mitra, Nandita; Schapira, Marilyn M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.; Lambert, Michele P.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Schultz, CL (reprint author), Dept Hematol, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM schultzc1@email.chop.edu FU Division of Hematology, The Children's Hospital of Philadelphia FX This study was supported by the Division of Hematology, The Children's Hospital of Philadelphia. NR 24 TC 5 Z9 7 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD OCT PY 2014 VL 168 IS 10 AR e142214 DI 10.1001/jamapediatrics.2014.2214 PG 7 WC Pediatrics SC Pediatrics GA AT1NC UT WOS:000344699800002 PM 25288142 ER PT J AU Richman, JS Itani, KMF Deierhoi, RJ Henderson, WG Hawn, MT AF Richman, Joshua S. Itani, Kamal M. F. Deierhoi, Rhiannon J. Henderson, William G. Hawn, Mary T. TI Improved Outcomes Associated With a Revised Quality Measure for Continuing Perioperative beta-Blockade SO JAMA SURGERY LA English DT Article ID MAJOR NONCARDIAC SURGERY; SURGICAL CARE; POSTOPERATIVE MORTALITY; RISK ADJUSTMENT; CARDIAC RISK; PROGRAM; WITHDRAWAL AB IMPORTANCE The Surgical Care Improvement Project perioperative beta-blocker (BB) (SCIP-BB) continuation measure was revised in 2012 to incorporate inpatient BB continuation after discharge from the postanesthesia care unit. OBJECTIVE To determine whether adherence to the original or revised SCIP-BB measure is associated with decreased adverse events. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study using national Veterans Affairs patient-level data on adherence to the original SCIP-BB measure and inpatient BB continuation for operations between July 2006 and August 2009. METHODS Data for SCIP-BB measure adherence, inpatient BB continuation, and patient and procedure risk variables were used to estimate the associations between adherence to the original and revised SCIP-BB measures and outcomes of major adverse cardiovascular or cerebrovascular events (MACCEs) and their components of cardiovascular events, cerebrovascular events, and 30-day mortality. In addition to unadjusted estimates, propensity score matching and bootstrapping were used to estimate the associations and generate 95% CIs. MAIN OUTCOMES AND MEASURES Major adverse cardiovascular or cerebrovascular events. RESULTS Of 14 420 nonemergent operations with at least 2 postoperative inpatient days, 13 170 (91.3%) adhered to the original SCIP-BB measure, and 480 (3.3%) experienced a MACCE. Propensity score-matched analyses showed that adherence to the original SCIP-BB measure was not associated with MACCEs (odds ratio [OR], 1.00; 95% CI, 0.66-1.54) but was associated with increased cerebrovascular events (OR, 3.01; 95% CI, 1.00-10.07). Adherence to the revised SCIP-BB measure occurred in 11 597 (80.4%), and in matched analysis adherence was associated with decreased MACCEs (OR, 0.75; 95% CI, 0.57-0.95), cardiovascular events (OR, 0.66; 95% CI, 0.46-0.93), and 30-day mortality (OR, 0.74; 95% CI, 0.53-0.98). Adherence to the revised SCIP-BB measure was not associated with increased cerebrovascular events (OR, 1.22; 95% CI, 0.62-2.38). CONCLUSIONS AND RELEVANCE Adherence to the original SCIP-BB measure was associated with increased cerebrovascular events but not improved cardiovascular event outcomes. beta-Blocker continuation consistent with the revised SCIP-BB measure is associated with reduced MACCEs, cardiovascular events, and 30-day mortality. These data provide a cautionary tale of implementing performance measures before they have been rigorously tested. Although the observed associations between adherence to the revised SCIP-BB measure and outcomes are promising, they should be evaluated in the postimplementation period. C1 [Richman, Joshua S.; Deierhoi, Rhiannon J.; Hawn, Mary T.] Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL 35294 USA. [Richman, Joshua S.; Deierhoi, Rhiannon J.; Hawn, Mary T.] Univ Alabama Birmingham, Dept Surg, Sect Gastrointestinal Surg, Birmingham, AL USA. [Itani, Kamal M. F.] Boston Univ, Dept Surg, Vet Affairs Boston Hlth Care Syst, Boston, MA 02215 USA. [Itani, Kamal M. F.] Harvard Univ, Sch Med, Boston, MA USA. [Henderson, William G.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Henderson, William G.] Univ Colorado, Hlth Outcomes Program, Aurora, CO USA. [Henderson, William G.] Univ Colorado, Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. RP Richman, JS (reprint author), Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit, 1922 Seventh Ave S,Kracke Bldg 428, Birmingham, AL 35294 USA. EM jrichman@uab.edu FU VA Health Services Research and Development Career Development Award [CDA2 09-014-3]; VA Health Services Research and Development program [PPO 10-296] FX Dr Richman was supported by VA Health Services Research and Development Career Development Award CDA2 09-014-3. This study was funded by grant PPO 10-296 from the VA Health Services Research and Development program. NR 18 TC 4 Z9 4 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD OCT PY 2014 VL 149 IS 10 BP 1031 EP 1037 DI 10.1001/jamasurg.2014.351 PG 7 WC Surgery SC Surgery GA AS0SC UT WOS:000343987300009 PM 25141795 ER PT J AU Greenstein, RJ Cameron, DW Brown, ST AF Greenstein, Robert John Cameron, D. W. Brown, Sheldon T. TI "Add-on" is scientifically more accurate than "Placebo control" in multiple Inflammatory Bowel Disease (IBD) trials SO JOURNAL OF CROHNS & COLITIS LA English DT Letter DE Crohn's disease; Ulcerative colitis; Clinical trials; Placebo; Anti-inflammatory; Immunemodulators ID AVIUM SUBSPECIES PARATUBERCULOSIS C1 [Greenstein, Robert John; Brown, Sheldon T.] James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA. [Cameron, D. W.] Ottawa Hosp Res Inst, Ottawa, ON, Canada. RP Greenstein, RJ (reprint author), James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA. OI Cameron, Bill/0000-0002-0090-3539 NR 5 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1873-9946 EI 1876-4479 J9 J CROHNS COLITIS JI J. Crohns Colitis PD OCT 1 PY 2014 VL 8 IS 10 BP 1334 EP 1335 DI 10.1016/j.crohns.2014.03.015 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS2RU UT WOS:000344128100025 PM 24768214 ER PT J AU Marcum, ZA Hanlon, JT Strotmeyer, ES Newman, AB Shorr, RI Simonsick, EM Bauer, DC Boudreau, R Donohue, JM Perera, S AF Marcum, Zachary A. Hanlon, Joseph T. Strotmeyer, Elsa S. Newman, Anne B. Shorr, Ronald I. Simonsick, Eleanor M. Bauer, Douglas C. Boudreau, Robert Donohue, Julie M. Perera, Subashan CA Hlth Aging & Body Composition Stud TI Gastroprotective Agent Underuse in High-Risk Older Daily Nonsteroidal Anti-Inflammatory Drug Users over Time SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE nonsteroidal anti-inflammatory drug; older adults; gastroprotection ID COX-2 INHIBITORS; NSAIDS; CARE; OSTEOARTHRITIS; PREVENTION; ELDERS AB ObjectivesTo examine whether older adults taking nonsteroidal anti-inflammatory drugs (NSAIDs) decreased the underuse of gastroprotective agents over time. DesignBefore-and-after study. SettingHealth, Aging and Body Composition Study. ParticipantsDaily users of a NSAID (prescription and over the counter (OTC)) at visits in 2002-03 (preperiod; n=404) and 2006-07 (postperiod; n=172). The sample had a meanstandard deviation age of 78.22.7 at the preperiod visit and 81.92.7 at the postperiod visit. The majority were white and female and had 12 or more years of education. MeasurementsUnderusers were defined as persons taking nonselective NSAIDs who were at risk of peptic ulcer disease (PUD; because of current warfarin or glucocorticoid use or history of PUD) and not using a proton pump inhibitor (PPI) or persons taking cyclooxygenase 2 (COX-2) selective NSAIDs and aspirin who were at risk of PUD (having at least one risk factor) and not using a PPI. ResultsDaily NSAID use decreased from 17.6% to 11.3% (P<.001), and gastroprotective agent underuse decreased from 23.5% to 15.1% (P=.008). Controlling for important covariates, having prescription insurance was somewhat protective against underuse in the preperiod (adjusted odds ratio (AOR)=0.78, 95% confidence interval (CI)=0.46-1.34; P=.37), but more so and significantly in the postperiod (AOR=0.41, 95% CI=0.18-0.93; P=.03). Having prescription insurance was more protective in the post- than in the preperiod (less gastroprotective agent underuse; adjusted ratio of OR=0.53, 95% CI=0.22-1.29; P=.16), but this increased protection was not statistically significant. ConclusionIn older daily NSAID users at high risk of PUD, having prescription insurance and adequate gastroprotective use was more common in the post- than in the preperiod. C1 [Marcum, Zachary A.; Hanlon, Joseph T.; Newman, Anne B.; Perera, Subashan] Univ Pittsburgh, Div Geriatr Med, Sch Med, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.; Strotmeyer, Elsa S.; Newman, Anne B.; Boudreau, Robert] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res, Pittsburgh, PA USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Shorr, Ronald I.] Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Gainesville, FL 32608 USA. [Simonsick, Eleanor M.] NIA, Intramural Res Program, Baltimore, MD 21224 USA. [Bauer, Douglas C.] Univ Calif San Francisco, Sch Med, Dept Med, Div Gen Internal Med, San Francisco, CA USA. [Boudreau, Robert; Perera, Subashan] Univ Pittsburgh, Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15213 USA. [Donohue, Julie M.] Univ Pittsburgh, Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15213 USA. RP Marcum, ZA (reprint author), Univ Pittsburgh, Div Geriatr Med, Sch Med, 3471 Fifth Ave,Suite 500, Pittsburgh, PA 15213 USA. EM zam12@pitt.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150; Strotmeyer, Elsa/0000-0002-4093-6036; Boudreau, Robert/0000-0003-0162-5187; Donohue, Julie/0000-0003-2418-6017 FU Intramural NIH HHS; NIA NIH HHS [N01-AG-6-2106, K07 AG033174, K07AG033174, N01-AG-6-2101, N01-AG-6-2103, P30 AG024827, P30AG024827, R01 AG027017, R01 AG028050, R01AG027017, R01AG028050, T32 AG021885]; NINR NIH HHS [R01 NR012459] NR 19 TC 3 Z9 3 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2014 VL 62 IS 10 BP 1923 EP 1927 DI 10.1111/jgs.13066 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AS6QA UT WOS:000344386400015 PM 25284702 ER PT J AU Hanlon, JT Semla, TP Schmader, KE AF Hanlon, Joseph T. Semla, Todd P. Schmader, Kenneth E. TI Medication Misadventures in Older Adults: Literature from 2013 SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE medication errors; adverse drug events; age; pharmacoepidemiology ID SERUM ANTICHOLINERGIC ACTIVITY; RANDOMIZED-CONTROLLED-TRIAL; DRUG; POPULATION; HYDROCHLOROTHIAZIDE; CHLORTHALIDONE; ASSOCIATIONS; PEOPLE; BURDEN; RISK AB The objective of this paper is to review articles published in 2013 examining drug-related problems in the elderly and comment on their potential impact on clinical practice. To identify articles, we did a systematic search of the English-language literature restricted to those aged 65+from January 2013 to December 2013 using Medline and Google Scholar and a combination of the following search terms: drug-related problems, medication-related problems, medication errors, suboptimal prescribing, inappropriate prescribing, underutilization, polypharmacy, medication monitoring, medication dispensing, medication administration, medication adherence, adverse drug events, and adverse drug withdrawal events. A manual search of major general medicine and clinical pharmacology journals was also conducted to identify additional articles. A total of 51 articles were identified of which 20 were chosen to highlight. Three were annotated and critiqued and the additional 17 articles were summarized in an appendix. One article reported the results of a randomized controlled trial that showed that a pharmacist intervention successfully reduced suboptimal prescribing in older hospital patients. Another paper from this group previously reported data from the same study showing that the intervention also reduced medication related readmissions to the hospital. An observational study compared the use of two thiazide diuretics in older outpatients. They found that chlorthalidone was more likely to cause hypokalemia than hydrochlorothiazide. Finally, in a randomized controlled trial a pharmacist intervention resulted in the reduction of anticholinergic burden but did result in an improvement in cognition. These studies highlight that medication errors and adverse drug events continue to be important issues for health care professionals caring for older adults. C1 [Hanlon, Joseph T.] Univ Pittsburgh, Div Geriatr, Dept Med, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Biomed Informat, Sch Med, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Sch Publ Hlth, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Geriatr Pharmaceut Outcomes & Gero Informat Res &, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Semla, Todd P.] Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL USA. [Semla, Todd P.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA. [Semla, Todd P.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Schmader, Kenneth E.] Duke Univ, Med Ctr, Sch Med, Div Geriatr,Dept Med, Durham, NC 27710 USA. [Schmader, Kenneth E.] Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. RP Hanlon, JT (reprint author), Univ Pittsburgh, Dept Geriatr Med, Kaufman Med Bldg,Suite 514,3471 5th Ave, Pittsburgh, PA 15213 USA. EM jth14@pitt.edu FU NIA NIH HHS [R01AG027017, K07 AG033174, K07AG033174, P30 AG024827, P30 AG028716, P30AG024827, P30AG028716, R01 AG027017, R01 AG037451, R01AG037451, T32 AG021885] NR 18 TC 2 Z9 3 U1 2 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2014 VL 62 IS 10 BP 1950 EP 1953 DI 10.1111/jgs.13026 PG 4 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AS6QA UT WOS:000344386400020 PM 25333528 ER PT J AU Edes, T Kinosian, B Vuckovic, NH Nichols, LO Becker, MM Hossain, M AF Edes, Thomas Kinosian, Bruce Vuckovic, Nancy H. Nichols, Linda Olivia Becker, Margaret Mary Hossain, Monir TI Better Access, Quality, and Cost for Clinically Complex Veterans with Home-Based Primary Care SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE frail elders; policy; home care services; chronic disease; patient-centered care ID RISK ADJUSTMENT; MEDICARE; FRAIL; MODEL AB In successfully reducing healthcare expenditures, patient goals must be met and savings differentiated from cost shifting. Although the Department of Veterans Affairs (VA) Home Based Primary Care (HBPC) program for chronically ill individuals has resulted in cost reduction for the VA, it is unknown whether cost reduction results from restricting services or shifting costs to Medicare and whether HBPC meets patient goals. Cost projection using a hierarchical condition category (HCC) model adapted to the VA was used to determine VA plus Medicare projected costs for 9,425 newly enrolled HBPC recipients. Projected annual costs were compared with observed annualized costs before and during HBPC. To assess patient perspectives of care, 31 veterans and caregivers were interviewed from three representative programs. During HBPC, Medicare costs were 10.8% lower than projected, VA plus Medicare costs were 11.7% lower than projected, and combined hospitalizations were 25.5% lower than during the period without HBPC. Patients reported high satisfaction with HBPC team access, education, and continuity of care, which they felt contributed to fewer exacerbations, emergency visits, and hospitalizations. HBPC improves access while reducing hospitalizations and total cost. Medicare is currently testing the HBPC approach through the Independence at Home demonstration. C1 [Edes, Thomas] US Dept Vet Affairs, Off Clin Operat & Management, Washington, DC USA. [Kinosian, Bruce] Univ Penn, Sch Med, Div Geriatr, Philadelphia, PA 19104 USA. [Kinosian, Bruce] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Kinosian, Bruce] Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. [Kinosian, Bruce] Philadelphia Vet Affairs Med Ctr, Geriatr & Extended Care Data Anal Ctr, Philadelphia, PA USA. [Vuckovic, Nancy H.] Intel Corp, Hlth Strategies & Solut, Portland, OR USA. [Nichols, Linda Olivia] Vet Affairs Med Ctr, Caregiver Ctr, Memphis, TN USA. [Nichols, Linda Olivia] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA. [Becker, Margaret Mary] US Dept Vet Affairs, Vet Affairs New England Healthcare Syst, Vet Integrated Serv Network 1, Bedford, MA USA. [Hossain, Monir] US Dept Vet Affairs, Off Assistant Deputy Secretary Hlth Policy & Plan, Field Off, Medicare & Medicaid Anal Ctr, Braintree, MA USA. RP Edes, T (reprint author), Dept Vet Affairs, 810 Vermont Ave NW, Washington, DC 20420 USA. EM thomas.edes@va.gov NR 25 TC 25 Z9 25 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2014 VL 62 IS 10 BP 1954 EP 1961 DI 10.1111/jgs.13030 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AS6QA UT WOS:000344386400021 PM 25333529 ER PT J AU Merlin, JS Turan, JM Herbey, I Westfall, AO Starrels, JL Kertesz, SG Saag, MS Ritchie, CS AF Merlin, Jessica S. Turan, Janet M. Herbey, Ivan Westfall, Andrew O. Starrels, Joanna L. Kertesz, Stefan G. Saag, Michael S. Ritchie, Christine S. TI Aberrant Drug-Related Behaviors: A Qualitative Analysis of Medical Record Documentation in Patients Referred to an HIV/Chronic Pain Clinic SO PAIN MEDICINE LA English DT Article DE HIV; Aberrant Behavior; Opioid; Misuse ID CHRONIC NONCANCER PAIN; OPIOID-PRESCRIBING PRACTICES; CHRONIC NONMALIGNANT PAIN; HIV-INFECTED PATIENTS; PRIMARY-CARE; REPORTED OUTCOMES; THERAPY; MANAGEMENT; ABUSE; COHORT AB BackgroundDue to rising rates of opioid addiction and overdose among individuals on chronic opioid therapy, aberrant drug-related behaviors (ADRBs) are an important and challenging issue. Our objective was to qualitatively investigate the documentation of ADRBs in the medical record. MethodsManually abstracted provider notes from an HIV primary care clinic were analyzed using content analysis methods. ResultsCategories of ADRBs identified included patients requesting opioids, obtaining nonprescribed opioids, and becoming emotional about opioids. We also identified several types of provider language used when documenting ADRBs, including purely descriptive language and emotional language such as labeling, frustration, and concern, and responses such as setting conditions for opioid prescription and action-oriented language. ConclusionsThe impact of including emotional language in the medical record is unknown. Development of instruments that can be used to facilitate ADRB documentation, as well as evidence-based approaches to addressing ADRBs, is needed. C1 [Merlin, Jessica S.; Herbey, Ivan; Westfall, Andrew O.; Saag, Michael S.] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Turan, Janet M.] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA. [Kertesz, Stefan G.] Univ Alabama Birmingham, Div Prevent Med, Dept Med, Birmingham, AL 35294 USA. [Starrels, Joanna L.] Albert Einstein Coll Med, Div Gen Internal Med, Bronx, NY 10467 USA. [Starrels, Joanna L.] Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA. [Kertesz, Stefan G.] Birmingham VA Med Ctr, Birmingham, AL USA. [Ritchie, Christine S.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ritchie, Christine S.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Ritchie, Christine S.] Jewish Home San Francisco Ctr Res Aging, San Francisco, CA USA. RP Merlin, JS (reprint author), Univ Alabama Birmingham, Dept Med, Div Infect Dis, BBRB 222,1530 3rd Ave S, Birmingham, AL 35294 USA. EM jmerlin@uab.edu FU University of Alabama at Birmingham (UAB) Center for AIDS Research CFAR; NIH [P30 A1027767]; NIAID; NCI; NICHD; NHLBI; NIDA; NIMH; NIA; FIC; OAR FX This research was supported by the University of Alabama at Birmingham (UAB) Center for AIDS Research CFAR, an NIH-funded program (P30 A1027767) that was made possible by the following institutes: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, and OAR. NR 40 TC 2 Z9 2 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD OCT PY 2014 VL 15 IS 10 BP 1724 EP 1733 DI 10.1111/pme.12533 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA AS4KO UT WOS:000344244800008 PM 25138608 ER PT J AU Arfianti, E Barn, V Haigh, WG Ioannou, GN Teoh, N Farrell, G AF Arfianti, E. Barn, V. Haigh, W. G. Ioannou, G. N. Teoh, N. Farrell, G. TI Exercise slows growth of dysplastic hepatocytes by improving insulin sensitivity and enhancing DNA damage surveillance pathways in mice genetically predisposed to obesity and diabetes SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY LA English DT Meeting Abstract C1 [Arfianti, E.; Barn, V.; Teoh, N.; Farrell, G.] Canberra Hosp, ANU Med Sch, Liver Res Grp, Garran, ACT, Australia. [Haigh, W. G.; Ioannou, G. N.] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Seattle, WA USA. [Haigh, W. G.; Ioannou, G. N.] Univ Washington, Seattle, WA 98195 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0815-9319 EI 1440-1746 J9 J GASTROEN HEPATOL JI J. Gastroenterol. Hepatol. PD OCT PY 2014 VL 29 SU 2 SI SI BP 1 EP 1 DI 10.1111/jgh.12736_2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AR9AM UT WOS:000343863000002 ER PT J AU Garrido, MM AF Garrido, Melissa M. TI Propensity Scores: A Practical Method for Assessing Treatment Effects in Pain and Symptom Management Research SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Propensity score; treatment effect; causality; randomized controlled trial; palliative care ID MENTAL-HEALTH-CARE; CAUSAL INFERENCE; MEDICAL-RESEARCH; OLDER-ADULTS; MODEL; PRINCIPLES; BALLOON; TRIALS; COSTS AB When conducting research on pain and symptom management interventions for seriously ill individuals, randomized controlled trials are not always feasible or ethical to conduct. Secondary analyses of observational data sets that include information on treatments experienced and outcomes for individuals who did and did not receive a given treatment can be conducted, but confounding because of selection bias can obscure the treatment effect in which one is interested. Propensity scores provide a way to adjust for observable characteristics that differ between treatment and comparison groups. This article provides conceptual guidance in addition to an empirical example to illustrate two areas of propensity score analysis that often lead to confusion in practice: covariate selection and interpretation of resultant treatment effects. Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine. C1 [Garrido, Melissa M.] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Garrido, Melissa M.] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. RP Garrido, MM (reprint author), James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, 4A-17,130 W, Bronx, NY USA. OI Garrido, Melissa/0000-0002-8986-3536 FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [11-201/CDP 12-255]; National Palliative Care Research Center FX Dr. Garrido is supported by a Career Development Award from the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (CDA 11-201/CDP 12-255). The views expressed in this article are those of the author and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. government. Data collection for this study was supported by a Junior Faculty Career Development Award from the National Palliative Care Research Center. The author declares no conflicts of interest. NR 25 TC 10 Z9 10 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD OCT PY 2014 VL 48 IS 4 BP 711 EP 718 DI 10.1016/j.jpainsymman.2014.05.014 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AR8YF UT WOS:000343856500022 PM 24937162 ER PT J AU Pruitt, LD Luxton, DD Shore, P AF Pruitt, Larry D. Luxton, David D. Shore, Peter TI Additional Clinical Benefits of Home-Based Telemental Health Treatments SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article DE telemental health; home-based; telehealth; telemedicine; telecommunications ID SOCIAL SUPPORT; TELEPSYCHIATRIC CONSULTATION; MENTAL-ILLNESS; PRIMARY-CARE; FOLLOW-UP; TELEHEALTH; OUTCOMES; SATISFACTION; TELEMEDICINE; VETERANS AB Home-based telemental health (HBTMH) has several important benefits for both patients and clinical practitioners including improved access to services, convenience, flexibility, and potential cost savings. HBTMH also has the potential to offer additional clinical benefits that are not realized with traditional in-office alternatives. Through a review of the empirical literature, this article presents and evaluates evidence of the clinical benefits and limitations of HBTMH. Particular topics include treatment attendance and satisfaction, social support, access to contextual information, patient and practitioner safety, and concerns about privacy and stigma. By making use of commonly available communication technologies, HBTMH affords opportunities to bridge gaps in care to meet current and future mental health care needs. C1 [Pruitt, Larry D.; Luxton, David D.] Natl Ctr Telehealth & Technol, Tacoma, WA 98431 USA. [Luxton, David D.] Univ Washington, Sch Med, Seattle, WA USA. [Shore, Peter] Portland VA Med Ctr, Portland, OR USA. [Shore, Peter] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. RP Pruitt, LD (reprint author), Natl Ctr Telehealth & Technol, 9933 W Hayes St, Tacoma, WA 98431 USA. EM Larry.d.pruitt21.ctr@mail.mil OI Pruitt, Larry/0000-0001-6925-7830 NR 59 TC 6 Z9 6 U1 3 U2 11 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 EI 1939-1323 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD OCT PY 2014 VL 45 IS 5 BP 340 EP 346 DI 10.1037/a0035461 PG 7 WC Psychology, Multidisciplinary SC Psychology GA AR9BU UT WOS:000343866900007 ER PT J AU Oktay, J Nedjat-Haiem, F Davis, C AF Oktay, Julianne Nedjat-Haiem, Frances Davis, Cindy TI Implementing Distress Screening: Social Workers' Experiences SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Oktay, Julianne] Univ Maryland, Baltimore, MD 21201 USA. [Nedjat-Haiem, Frances] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Davis, Cindy] Univ Tennessee, Knoxville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD OCT PY 2014 VL 23 SU 3 SI SI MA P1-0199 BP 239 EP 239 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AS0YX UT WOS:000344003700357 ER PT J AU Fan, VS Locke, ER Diehr, P Wilsdon, A Enright, P Yende, S Avdalovic, M Barr, G Kapur, VK Thomas, R Krishnan, JA Lovasi, G Thielke, S AF Fan, Vincent S. Locke, Emily R. Diehr, Paula Wilsdon, Anthony Enright, Paul Yende, Sachin Avdalovic, Mark Barr, Graham Kapur, Vishesh K. Thomas, Rachel Krishnan, Jerry A. Lovasi, Gina Thielke, Stephen TI Disability and Recovery of Independent Function in Obstructive Lung Disease: The Cardiovascular Health Study SO RESPIRATION LA English DT Article DE Chronic airflow obstruction; Activities of daily living; Disability ID AIR-FLOW OBSTRUCTION; PULMONARY-DISEASE; OLDER-ADULTS; PHYSICAL-ACTIVITY; CONTROLLED-TRIAL; COPD; REHABILITATION; EXERCISE; OUTCOMES; STATES AB Background: Chronic obstructive lung disease frequently leads to disability. Older patients may experience transitions between states of disability and independence over time. Objective: To identify factors associated with transition between states of disability and independent function in obstructive lung disease. Methods: We analyzed data on 4,394 participants in the Cardiovascular Health Study who completed prebronchodilator spirometry. We calculated the 1-year probability of developing and resolving impairment in >= 1 instrumental activity of daily living (IADL) or >= 1 activity of daily living (ADL) using transition probability analysis. We identified factors associated with resolving disability using relative risk (RR) regression. Results: The prevalence of IADL impairment was higher with moderate (23.9%) and severe (36.9%) airflow obstruction compared to normal spirometry (22.5%; p < 0.001). Among participants with severe airflow obstruction, 23.5% recovered independence in IADLs and 40.5% recovered independence in ADLs. In the adjusted analyses, airflow obstruction predicted the development of IADL, but not ADL impairment. Participants with severe airflow obstruction were less likely to resolve IADL impairment [RR 0.67 and 95% confidence interval (CI) 0.49-0.94]. Compared to the most active individuals (i.e. who walked >= 28 blocks per week), walking less was associated with a decreased likelihood of resolving IADL impairment (7-27 blocks: RR 0.81 and 95% CI 0.69-0.86 and < 7 blocks: RR 0.73 and 95% CI 0.61-0.86). Increased strength (RR 1.16 and 95% CI 1.05-1.29) was associated with resolving IADL impairment. Conclusions: Disability is common in older people, especially in those with severe airflow obstruction. Increased physical activity and muscle strength are associated with recovery. Research is needed on interventions to improve these factors among patients with obstructive lung disease and disability. (C) 2014 S. Karger AG, Basel C1 [Fan, Vincent S.; Locke, Emily R.; Thomas, Rachel] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Fan, Vincent S.; Kapur, Vishesh K.] Univ Washington, Dept Med, Seattle, WA USA. [Diehr, Paula; Wilsdon, Anthony] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Thielke, Stephen] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Diehr, Paula] Univ Arizona, Tucson, AZ USA. [Yende, Sachin] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA. [Avdalovic, Mark] Univ Calif Davis, Div Pulm & Crit Care, Sacramento, CA 95817 USA. [Barr, Graham] Columbia Univ, Med Ctr, New York, NY USA. [Lovasi, Gina] Columbia Univ, Dept Epidemiol, New York, NY USA. [Krishnan, Jerry A.] Univ Illinois Hosp & Hlth Sci Syst, Chicago, IL USA. RP Fan, VS (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-152, Seattle, WA 98108 USA. EM Vincent.fan@va.gov RI Lovasi, Gina/C-2781-2009 OI Lovasi, Gina/0000-0003-2613-9599; Kapur, Vishesh/0000-0002-5417-1097 FU Merck; Glaxo-Smith Kline; Novartis; National Institutes of Health (NIH; US-EPA); Alpha1 Foundation; NIH; Department of Veterans Affairs (VA); PCORI; VA Puget Sound Health Care System, Seattle, Washington, USA FX Dr. Avdalovic received research support from Merck, Glaxo-Smith Kline and Novartis. Dr. Barr received grants or contracts from the National Institutes of Health (NIH; US-EPA) and the Alpha1 Foundation; in-kind contribution from Cenestra Health, travel reimbursement from Boeringher Ingleheim and royalties from UpToDate. Dr. Fan received grants from the NIH and Department of Veterans Affairs (VA) and has served as a consultant to Uptake Medical. Dr. Krishnan received grants from the NIH and PCORI and royalties from UpToDate. No other authors have any financial interests to report, and none of the authors report any conflicts of interest with the material in the manuscript. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of VA or the United States government. This material is the result of work supported by resources from the VA Puget Sound Health Care System, Seattle, Washington, USA. NR 46 TC 1 Z9 1 U1 2 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0025-7931 EI 1423-0356 J9 RESPIRATION JI Respiration PD OCT PY 2014 VL 88 IS 4 BP 329 EP 338 DI 10.1159/000363772 PG 10 WC Respiratory System SC Respiratory System GA AR8IS UT WOS:000343819400011 PM 25228204 ER PT J AU Stamp, LK Merriman, TR Barclay, ML Singh, JA Roberts, RL Wright, DFB Dalbeth, N AF Stamp, Lisa K. Merriman, Tony R. Barclay, Murray L. Singh, Jasvinder A. Roberts, Rebecca L. Wright, Daniel F. B. Dalbeth, Nicola TI Impaired response or insufficient dosage?-Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout SO SEMINARS IN ARTHRITIS AND RHEUMATISM LA English DT Review DE Gout; Allopurinol; Oxypurinol; Drug resistance ID URATE-LOWERING THERAPY; XANTHINE-OXIDASE; SERUM URATE; ALDEHYDE OXIDASE; HYPERURICEMIA; OXYPURINOL; DISEASE; BENZBROMARONE; TRANSPORTER; POPULATION AB Objectives: Gout is one of the most common forms of arthritis. It is well established that urate-lowering therapy that aims for a serum urate less than at least 0.36 mmol/l (6 mg/dl) is required for the successful management of gout. Allopurinol, a xanthine oxidase (XO) inhibitor, is the most commonly used urate-lowering therapy. However, many patients fail to achieve the target serum urate on allopurinol; these patients can be considered to have "inadequate response" to allopurinol. Herein, we examine the potential mechanisms and implications of inadequate response to allopurinol. Methods: The literature was reviewed for potential causes for failure to reach target serum urate in patients receiving allopurinol. Results: The two most common causes of inadequate response to allopurinol are poor adherence and under-dosing of allopurinol. Adherent patients who fail to achieve target serum urate on standard doses of allopurinol form a group that could be considered to be "partially resistant" to allopurinol. There are four potential mechanisms for partial allopurinol resistance: decreased conversion of allopurinol to oxypurinol; increased renal excretion of oxypurinol; abnormality in XO structure and/or function such that oxypurinol is rendered less effective and/or drug interactions. Conclusions: It is important to determine the reasons for failure to achieve treatment targets with allopurinol, particularly as newer agents become available. The knowledge of the mechanisms for inadequate response may help guide the clinician towards making a therapeutic choice that is more likely to result in achieving the serum urate target. (C) 2014 Elsevier Inc. All rights reserved. C1 [Stamp, Lisa K.] Univ Otago, Dept Med, Christchurch 8140, New Zealand. [Merriman, Tony R.] Univ Otago, Dept Biochem, Dunedin, New Zealand. [Barclay, Murray L.] Christchurch Hosp, Dept Clin Pharmacol, Christchurch, New Zealand. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Div Rheumatol, Birmingham, AL USA. [Roberts, Rebecca L.] Univ Otago, Dept Surg Sci, Dunedin, New Zealand. [Wright, Daniel F. B.] Univ Otago, Sch Pharm, Dunedin, New Zealand. [Dalbeth, Nicola] Univ Auckland, Dept Med, Auckland, New Zealand. RP Stamp, LK (reprint author), Univ Otago, Dept Med, POB 4345, Christchurch 8140, New Zealand. EM lisa.stamp@cdhb.health.nz OI Merriman, Tony/0000-0003-0844-8726 FU Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) [U19 HS021110]; National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) [P50 AR060772, U34 AR062891]; National Institute of Aging (NIA) [U01 AG018947]; National Cancer Institute (NCI) [U10 CA149950]; Patient Centered Outcomes Research Institute (PCORI) [CE-1304-6631]; Division of Rheumatology at the University of Alabama at Birmingham FX This article is the result of work supported by a grant from the Division of Rheumatology at the University of Alabama at Birmingham. JAS is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110, National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891, National Institute of Aging (NIA) U01 AG018947, National Cancer Institute (NCI) U10 CA149950, the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama and research contract CE-1304-6631 from the Patient Centered Outcomes Research Institute (PCORI). NR 31 TC 11 Z9 13 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0049-0172 EI 1532-866X J9 SEMIN ARTHRITIS RHEU JI Semin. Arthritis Rheum. PD OCT PY 2014 VL 44 IS 2 BP 170 EP 174 DI 10.1016/j.semarthrit.2014.05.007 PG 5 WC Rheumatology SC Rheumatology GA AR8WM UT WOS:000343852200007 PM 24925693 ER PT J AU Kanzaria, HK Probst, MA Ponce, NA Hsia, RY AF Kanzaria, Hemal K. Probst, Marc A. Ponce, Ninez A. Hsia, Renee Y. TI The association between advanced diagnostic imaging and ED length of stay SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article; Proceedings Paper CT Meeting of the Society-for-Academic-Emergency-Medicine (SAEM) CY MAY 13-17, 2014 CL Dallas, TX SP Soc Acad Emergency Med ID EMERGENCY-DEPARTMENT PATIENTS; NATIONALLY REPRESENTATIVE SAMPLE; MEDICAL-CARE SURVEY; TRENDS; VISITS; CT; RADIATION; RISK AB Objective: There has been a rise in advanced diagnostic imaging (ADI) use in the emergency department (ED). Increased utilization may contribute to longer length of stay (LOS), but prior reports have not considered improved methods for modeling skewed LOS data. Methods: The 2010 National Hospital Ambulatory Medical Care Survey data were analyzed by 5 common ED chief complaints. Generalized linear model (GLM) was compared to quantile and ordinary least squares (OLS) regression to evaluate the association between ADI and ED LOS. Receipt of computed tomography or magnetic resonance imaging was the primary exposure. Emergency department LOS was the primary outcome. Results: Of the 33,685 ED visits analyzed, 17% involved ADI. The median LOS for patients without ADI was 138 minutes compared to 252 minutes for those who received ADI. Overall, GLM offered the most unbiased estimates, although it provided similar adjusted point estimates to OLS for the marginal change in LOS associated with ADI. The effect of imaging differed by LOS quantile, especially for patients with abdominal pain, fever, and back symptoms. Conclusions: Generalized linear model offered an improved modeling approach compared to OLS and quantile regression. Consideration of such techniques may facilitate a more complete view of the effect of ADI on ED LOS. Published by Elsevier Inc. C1 [Kanzaria, Hemal K.] Univ Calif Los Angeles, Ctr Emergency Med, US Dept Vet Affairs, Robert Wood Johnson Fdn Clin Scholars program, Los Angeles, CA 90024 USA. [Probst, Marc A.] Mt Sinai Med Ctr, Dept Emergency Med, New York, NY 10029 USA. [Ponce, Ninez A.] Univ Calif Los Angeles, UCLA Ctr Hlth Policy Res, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90024 USA. [Hsia, Renee Y.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Emergency Med, San Francisco, CA 94143 USA. RP Kanzaria, HK (reprint author), Univ Calif Los Angeles, Ctr Emergency Med, US Dept Vet Affairs, Robert Wood Johnson Fdn Clin Scholars program, 10940 Wilshire Blvd,Suite 710, Los Angeles, CA 90024 USA. EM hkanzaria@mednet.ucla.edu OI Ponce, Ninez/0000-0001-5151-6718 FU NCRR NIH HHS [KL2RR024130]; NHLBI NIH HHS [5 K12 HL109005] NR 37 TC 5 Z9 5 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 EI 1532-8171 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD OCT PY 2014 VL 32 IS 10 BP 1253 EP 1258 DI 10.1016/j.ajem.2014.07.038 PG 6 WC Emergency Medicine SC Emergency Medicine GA AR1BU UT WOS:000343316000018 PM 25176565 ER PT J AU Karlin, BE Cross, G AF Karlin, Bradley E. Cross, Gerald TI Enhancing Access, Fidelity, and Outcomes in the National Dissemination of Evidence-Based Psychotherapies SO AMERICAN PSYCHOLOGIST LA English DT Editorial Material ID COGNITIVE-BEHAVIORAL THERAPY; HEALTH-CARE-SYSTEM; VETERANS; IMPLEMENTATION; DEPRESSION C1 [Karlin, Bradley E.] Educ Dev Ctr Inc, New York, NY 10014 USA. [Karlin, Bradley E.] Johns Hopkins Univ, Baltimore, MD 21218 USA. [Cross, Gerald] US Dept Vet Affairs, Cent Off, Washington, DC USA. RP Karlin, BE (reprint author), Educ Dev Ctr Inc, 96 Morton St,7th Floor, New York, NY 10014 USA. EM bkarlin@edc.org NR 12 TC 3 Z9 3 U1 0 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0003-066X EI 1935-990X J9 AM PSYCHOL JI Am. Psychol. PD OCT PY 2014 VL 69 IS 7 BP 709 EP 711 DI 10.1037/a0037384 PG 4 WC Psychology, Multidisciplinary SC Psychology GA AS1AZ UT WOS:000344010000011 PM 25265301 ER PT J AU Germain, A Richardson, R Stocker, R Mammen, O Hall, M Bramoweth, AD Begley, A Rode, N Frank, E Haas, G Buysse, DJ AF Germain, Anne Richardson, Robin Stocker, Ryan Mammen, Oommen Hall, Martica Bramoweth, Adam D. Begley, Amy Rode, Noelle Frank, Ellen Haas, Gretchen Buysse, Daniel J. TI Treatment for insomnia in combat-exposed OEF/OIF/OND Military Veterans: Preliminary, randomized controlled trial SO BEHAVIOUR RESEARCH AND THERAPY LA English DT Article DE Military Veterans; Insomnia; Stimulus control; Sleep restriction; Education ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL THERAPY; SLEEP QUALITY INDEX; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; SELF-HELP TREATMENT; PTSD CHECKLIST PCL; PSYCHOMETRIC PROPERTIES; PSYCHIATRIC-DISORDERS; OLDER-ADULTS AB Chronic insomnia is highly prevalent among military personnel returning from Iraq and Afghanistan. We evaluated the effects of a military version of a brief behavioral treatment of insomnia (BBTI-MV) compared to an information only control (IC) condition in combat-exposed Veterans of Operations Enduring/Iraqi Freedom or Operation New Dawn (OEF/OIF/OND) on insomnia, sleep quality, and daytime symptoms of anxiety and depression. Forty OEF/OIF/OND Veterans (Mean age = 38.4 years old, s.d. =11.69; 85% men; 77.5% white) were randomized to one of two conditions. BBTI-MV consisted of two in-person sessions and two telephone contacts delivered over four weeks, and included personalized recommendations to reduce insomnia. The IC condition also consisted of 2 in-person sessions two telephone contacts delivered over four weeks, and Veterans were encouraged to read written information about sleep-promoting behaviors. The Insomnia Severity Index, Pittsburgh Sleep Quality Index, PTSD Checklist, and Beck Depression and Anxiety Inventories were completed at baseline, post-treatment, and at the six-month follow-up. Both interventions were associated with clinically significant improvements in insomnia, although the magnitude of improvements in sleep and rates of treatment response and remission were greater for BBTI-MV compared to IC from pre- to post-treatment. Both BBTI-MV and the provision of information were associated with clinically significant improvements in insomnia among Veterans. Despite the preliminary nature of the findings and limitations inherent to small controlled trials, the findings suggest that both approaches may provide viable options in a stepped-care approach to the treatment of insomnia in retuning combat-exposed Veterans. Larger, confirmatory effectiveness trials are required. ClinicalTrials.gov Identifier: NCT00840255. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Germain, Anne; Mammen, Oommen; Hall, Martica; Bramoweth, Adam D.; Frank, Ellen; Haas, Gretchen; Buysse, Daniel J.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. [Richardson, Robin; Stocker, Ryan; Begley, Amy; Rode, Noelle] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA. [Bramoweth, Adam D.; Haas, Gretchen] VA Pittsburgh Healthcare Syst, VISN4 Mental Illness Res Educ & Clin Ctr MIRECC, Pittsburgh, PA USA. RP Germain, A (reprint author), 3811 OHara St,Sterling Plaza, Pittsburgh, PA 15213 USA. EM germax@upmc.edu RI Hall, Martica/D-2809-2012 OI Hall, Martica/0000-0003-0642-2098 FU NCRR NIH HHS [UL1 RR024153, UL1RR024153]; NIA NIH HHS [P01 AG020677, P01AG020677]; NIMH NIH HHS [MH080696, R34 MH080696] NR 75 TC 7 Z9 7 U1 0 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0005-7967 EI 1873-622X J9 BEHAV RES THER JI Behav. Res. Ther. PD OCT PY 2014 VL 61 BP 78 EP 88 DI 10.1016/j.brat.2014.07.016 PG 11 WC Psychology, Clinical SC Psychology GA AR1NB UT WOS:000343350800009 PM 25194223 ER PT J AU Cooke, CR Feemster, LC Wiener, RS O'Neil, ME Slatore, CG AF Cooke, Colin R. Feemster, Laura C. Wiener, Renda Soylemez O'Neil, Maya E. Slatore, Christopher G. TI Aggressiveness of Intensive Care Use Among Patients With Lung Cancer in the Surveillance, Epidemiology, and End Results-Medicare Registry SO CHEST LA English DT Article ID OF-LIFE CARE; POPULATION; OUTCOMES; BENEFICIARIES; TRENDS; UNITS AB BACKGROUND: Approximately 65% of elderly patients with lung cancer who are admitted to the ICU will die within 6 months. Efforts to improve end-of-life care for this population must first understand the patient factors that underlie admission to the ICU. METHODS: We performed a retrospective cohort study examining all fee-for-service inpatient claims in the Surveillance, Epidemiology, and End Results (SEER)-Medicare registry for elderly patients (aged. 65 years) who had received a diagnosis of lung cancer between 1992 and 2005 and who were hospitalized for reasons other than resection of their lung cancer. We calculated yearly rates of ICU admission per 1,000 hospitalizations via room and board codes or International Classification of Diseases, Ninth Revision, Clinical Modification and diagnosis-related group codes for mechanical ventilation, stratified the rates by receipt of mechanical ventilation and ICU type (medical/surgical/cardiac vs intermediate), and compared these rates over time. RESULTS: A total of 175,756 patients with lung cancer in SEER were hospitalized for a reason other than surgical resection of their tumor during the study period, 49,373 (28%) of whom had at least one ICU stay. The rate of ICU admissions per 1,000 hospitalizations increased over the study period from 140.7 in 1992 to 201.7 in 2005 (P < .001). The majority of the increase in ICU admissions (per 1,000 hospitalizations) between 1992 and 2005 occurred among patients who were not mechanically ventilated (118.2 to 173.3, P < .001) and among those who were in intermediate ICUs (20.0 to 61.9, P < .001), but increased only moderately in medical/surgical/cardiac units (120.7 to 139.9, P < .001). CONCLUSIONS: ICU admission for patients with lung cancer increased over time, mostly among patients without mechanical ventilation who were largely cared for in intermediate ICUs. C1 [Cooke, Colin R.] Univ Michigan, Ctr Healthcare Outcomes & Policy, Inst Healthcare Innovat & Policy, Div Pulm & Crit Care Med,Michigan Ctr Integrat Re, Ann Arbor, MI 48109 USA. [Feemster, Laura C.] VA Puget Sound Healthcare Syst, Div Pulm & Crit Care Med, Seattle, WA USA. [Feemster, Laura C.] Univ Washington, Sch Med, Seattle, WA USA. [Wiener, Renda Soylemez] Boston Univ, Sch Med, Boston, MA 02118 USA. [Wiener, Renda Soylemez] Edith Nourse Rogers Mem VA Hosp, Bedford, MA USA. [O'Neil, Maya E.; Slatore, Christopher G.] Portland VA Med Ctr, Hlth Serv Res, Portland, OR USA. [O'Neil, Maya E.; Slatore, Christopher G.] Portland VA Med Ctr, Hlth Serv Dev, Portland, OR USA. [Slatore, Christopher G.] Portland VA Med Ctr, Sect Pulm & Crit Care Med, Portland, OR USA. [Slatore, Christopher G.] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA. RP Cooke, CR (reprint author), Univ Michigan, Ctr Healthcare Outcomes & Policy, 2800 Plymouth Rd,Bldg 16,Room 127W, Ann Arbor, MI 48109 USA. EM cookecr@umich.edu OI Cooke, Colin/0000-0001-9713-5371; Wiener, Renda/0000-0001-7712-2135; Slatore, Christopher/0000-0003-0958-8122 FU Agency for Healthcare Research and Quality [K08 HS020672]; National Cancer Institute [K07 CA138772]; National Heart, Lung and Blood Institute [K23 HL111116]; Department of Veterans Affairs FX This work was supported in part by the Agency for Healthcare Research and Quality [Grant K08 HS020672 to Dr Cooke], the National Cancer Institute [Grant K07 CA138772 to Dr Wiener], the National Heart, Lung and Blood Institute [Grant K23 HL111116 to Dr Feemster], and the Department of Veterans Affairs [to Drs Wiener and Feemster]. NR 26 TC 9 Z9 9 U1 1 U2 4 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2014 VL 146 IS 4 BP 916 EP 923 DI 10.1378/chest.14-0477 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AR4QD UT WOS:000343570400020 PM 25117058 ER PT J AU Bowler, RP Kim, V Regan, E Williams, AAA Santorico, SA Make, BJ Lynch, DA Hokanson, JE Washko, GR Bercz, P Soler, X Marchetti, N Criner, GJ Ramsdell, J Han, MK Demeo, D Anzueto, A Comellas, A Crapo, JD Dransfield, M Wells, JM Hersh, CP MacIntyre, N Martinez, F Nath, HP Niewoehner, D Sciurba, F Sharafkhaneh, A Silverman, EK van Beek, EJR Wilson, C Wendt, C Wise, RA AF Bowler, Russell P. Kim, Victor Regan, Elizabeth Williams, Andre A. A. Santorico, Stephanie A. Make, Barry J. Lynch, David A. Hokanson, John E. Washko, George R. Bercz, Peter Soler, Xavier Marchetti, Nathaniel Criner, Gerard J. Ramsdell, Joe Han, MeiLan K. Demeo, Dawn Anzueto, Antonio Comellas, Alejandro Crapo, James D. Dransfield, Mark Wells, J. Michael Hersh, Craig P. MacIntyre, Neil Martinez, Fernando Nath, Hrudaya P. Niewoehner, Dennis Sciurba, Frank Sharafkhaneh, Amir Silverman, Edwin K. van Beek, Edwin J. R. Wilson, Carla Wendt, Christine Wise, Robert A. CA COPDGene Investigators TI Prediction of Acute Respiratory Disease in Current and Former Smokers With and Without COPD SO CHEST LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; GASTROESOPHAGEAL-REFLUX SYMPTOMS; EARLY-ONSET COPD; QUALITY-OF-LIFE; FAMILIAL AGGREGATION; ACUTE EXACERBATIONS; GENDER-DIFFERENCES; UNITED-STATES; LUNG-FUNCTION; PREVALENCE AB BACKGROUND: The risk factors for acute episodes of respiratory disease in current and former smokers who do not have COPD are unknown. METHODS: Eight thousand two hundred forty-six non-Hispanic white and black current and former smokers in the Genetic Epidemiology of COPD (COPDGene) cohort had longitudinal follow-up (LFU) every 6 months to determine acute respiratory episodes requiring antibiotics or systemic corticosteroids, an ED visit, or hospitalization. Negative binomial regression was used to determine the factors associated with acute respiratory episodes. A Cox proportional hazards model was used to determine adjusted hazard ratios (HRs) for time to first episode and an acute episode of respiratory disease risk score. RESULTS: At enrollment, 4,442 subjects did not have COPD, 658 had mild COPD, and 3,146 had moderate or worse COPD. Nine thousand three hundred three acute episodes of respiratory disease and 2,707 hospitalizations were reported in LFU (3,044 acute episodes of respiratory disease and 827 hospitalizations in those without COPD). Major predictors included acute episodes of respiratory disease in year prior to enrollment (HR, 1.20; 95% CI, 1.15-1.24 per exacerbation), airflow obstruction (HR, 0.94; 95% CI, 0.91-0.96 per 10% change in % predicted FEV1), and poor health-related quality of life (HR, 1.07; 95% CI, 1.06-1.08 for each 4-unit increase in St. George's Respiratory Questionnaire score). Risks were similar for those with and without COPD. CONCLUSIONS: Although acute episode of respiratory disease rates are higher in subjects with COPD, risk factors are similar, and at a population level, there are more episodes in smokers without COPD. C1 [Bowler, Russell P.; Regan, Elizabeth; Williams, Andre A. A.; Make, Barry J.; Lynch, David A.; Crapo, James D.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA. [Wilson, Carla] Natl Jewish Hlth, Div Biostat & Bioinformat, Denver, CO 80206 USA. [Santorico, Stephanie A.] Univ Colorado Denver, Dept Math & Stat Sci, Denver, CO USA. [Kim, Victor; Bercz, Peter; Marchetti, Nathaniel; Criner, Gerard J.] Temple Univ, Sect Pulm & Crit Care Med, Dept Med, Philadelphia, PA 19122 USA. [Hokanson, John E.] Univ Colorado, Dept Med, Aurora, CO USA. [Hokanson, John E.] Univ Colorado, Dept Epidemiol, Aurora, CO USA. [Washko, George R.; Demeo, Dawn; Hersh, Craig P.; Silverman, Edwin K.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care, Channing Div Network Med, Boston, MA 02115 USA. [Soler, Xavier; Ramsdell, Joe] Univ Calif San Diego, Dept Med, Div Pulm & Crit Care Med, La Jolla, CA 92093 USA. [Han, MeiLan K.; Martinez, Fernando] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, Dept Med, San Antonio, TX 78229 USA. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Comellas, Alejandro] Univ Iowa, Iowa City, IA USA. [Dransfield, Mark; Wells, J. Michael; Nath, Hrudaya P.] Univ Alabama Birmingham, Birmingham, AL USA. [MacIntyre, Neil] Duke Univ, Med Ctr, Durham, NC USA. [Niewoehner, Dennis; Wendt, Christine] Univ Minnesota, Minneapolis, MN USA. [Sciurba, Frank] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Sharafkhaneh, Amir] Baylor Coll Med, Houston, TX 77030 USA. [van Beek, Edwin J. R.] Univ Edinburgh, Clin Res Imaging Ctr, Edinburgh, Midlothian, Scotland. [Wise, Robert A.] Johns Hopkins Univ, Baltimore, MD USA. RP Bowler, RP (reprint author), Natl Jewish Hlth, Dept Med, 1400 Jackson St,Room K715a, Denver, CO 80206 USA. EM Bowlerr@njhealth.org RI Coxson, Harvey/A-9861-2017 OI Coxson, Harvey/0000-0001-5750-9711; Comellas, Alejandro/0000-0003-1521-7520; Curtis, Jeffrey/0000-0001-5191-4847; Foreman, Marilyn/0000-0002-9405-7475 FU National Heart, Lung and Blood Institute [R01 HL 08 9856, R01 HL 08 9897]; National Center for Research Resources/National Institutes of Health [UL1 RR025780]; National Institute of Nursing Research [NR013377] FX This study was supported by the National Heart, Lung and Blood Institute [Grants R01 HL 08 9856 and R01 HL 08 9897], National Center for Research Resources/National Institutes of Health [Grant UL1 RR025780], and National Institute of Nursing Research [NR013377]. NR 39 TC 21 Z9 21 U1 0 U2 12 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2014 VL 146 IS 4 BP 941 EP 950 DI 10.1378/chest.13-2946 PG 10 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AR4QD UT WOS:000343570400023 PM 24945159 ER PT J AU Livio, S Strockbine, NA Panchalingam, S Tennant, SM Barry, EM Marohn, ME Antonio, M Hossain, A Mandomando, I Ochieng, JB Oundo, JO Qureshi, S Ramamurthy, T Tamboura, B Adegbola, RA Hossain, MJ Saha, D Sen, S Faruque, AS Alonso, PL Breiman, RF Zaidi, AKM Sur, D Sow, SO Berkeley, LY O'Reilly, CE Mintz, ED Biswas, K Cohen, D Farag, TH Nasrin, D Wu, YK Blackwelder, WC Kotloff, KL Nataro, JP Levine, MM AF Livio, Sofie Strockbine, Nancy A. Panchalingam, Sandra Tennant, Sharon M. Barry, Eileen M. Marohn, Mark E. Antonio, Martin Hossain, Anowar Mandomando, Inacio Ochieng, John B. Oundo, Joseph O. Qureshi, Shahida Ramamurthy, Thandavarayan Tamboura, Boubou Adegbola, Richard A. Hossain, Mohammed Jahangir Saha, Debasish Sen, Sunil Faruque, Abu Syed Golam Alonso, Pedro L. Breiman, Robert F. Zaidi, Anita K. M. Sur, Dipika Sow, Samba O. Berkeley, Lynette Y. O'Reilly, Ciara E. Mintz, Eric D. Biswas, Kousick Cohen, Dani Farag, Tamer H. Nasrin, Dilruba Wu, Yukun Blackwelder, William C. Kotloff, Karen L. Nataro, James P. Levine, Myron M. TI Shigella Isolates From the Global Enteric Multicenter Study Inform Vaccine Development SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE serotyping; Shigella; shigellosis; vaccines ID SHIGA BACILLUS DYSENTERY; FLEXNERI 2A; DIARRHEAL DISEASE; ORAL IMMUNIZATION; DEVELOPING-COUNTRIES; ENTEROTOXIN GENES; SERUM ANTIBODIES; YOUNG-CHILDREN; O-ANTIGEN; IN-VITRO AB Background. Shigella, a major diarrheal disease pathogen worldwide, is the target of vaccine development. The Global Enteric Multicenter Study (GEMS) investigated burden and etiology of moderate-to-severe diarrheal disease in children aged <60 months and matched controls without diarrhea during 3 years at 4 sites in Africa and 3 in Asia. Shigella was 1 of the 4 most common pathogens across sites and age strata. GEMS Shigella serotypes are reviewed to guide vaccine development. Methods. Subjects' stool specimens/rectal swabs were transported to site laboratories in transport media and plated onto xylose lysine desoxycholate and MacConkey agar. Suspect Shigella colonies were identified by biochemical tests and agglutination with antisera. Shigella isolates were shipped to the GEMS Reference Laboratory (Baltimore, MD) for confirmation and serotyping of S. flexneri; one-third of isolates were sent to the Centers for Disease Control and Prevention for quality control. Results. Shigella dysenteriae and S. boydii accounted for 5.0% and 5.4%, respectively, of 1130 Shigella case isolates; S. flexneri comprised 65.9% and S. sonnei 23.7%. Five serotypes/subserotypes comprised 89.4% of S. flexneri, including S. flexneri 2a, S. flexneri 6, S. flexneri 3a, S. flexneri 2b, and S. flexneri 1b. Conclusions. A broad-spectrum Shigella vaccine must protect against S. sonnei and 15 S. flexneri serotypes/subserotypes. A quadrivalent vaccine with O antigens from S. sonnei, S. flexneri 2a, S. flexneri 3a, and S. flexneri 6 can provide broad direct coverage against these most common serotypes and indirect coverage against all but 1 (rare) remaining subserotype through shared S. flexneri group antigens. C1 [Livio, Sofie; Panchalingam, Sandra; Tennant, Sharon M.; Barry, Eileen M.; Marohn, Mark E.; Sen, Sunil; Berkeley, Lynette Y.; Farag, Tamer H.; Nasrin, Dilruba; Wu, Yukun; Blackwelder, William C.; Kotloff, Karen L.; Nataro, James P.; Levine, Myron M.] Univ Maryland Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA. [Strockbine, Nancy A.] Ctr Dis Control & Prevent, Escherichia & Shigella Reference Unit, Enter Dis Lab Branch, Atlanta, GA USA. [Strockbine, Nancy A.; O'Reilly, Ciara E.; Mintz, Eric D.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Antonio, Martin; Adegbola, Richard A.; Hossain, Mohammed Jahangir; Saha, Debasish] Med Res Council Unit United Kingdom, Fajara, Gambia. [Hossain, Anowar; Faruque, Abu Syed Golam] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Mandomando, Inacio; Alonso, Pedro L.] Ctr Invest Saude Manhica, Manhica, Mozambique. [Mandomando, Inacio; Breiman, Robert F.] Univ Barcelona, Hosp Clinic, Ctr Recerca Salut Int Barcelona, E-08007 Barcelona, Spain. [Ochieng, John B.; Oundo, Joseph O.; Breiman, Robert F.] Ctr Dis Control & Prevent, Kenya Med Res Inst, Kisumu, Kenya. [Qureshi, Shahida; Zaidi, Anita K. M.] Aga Khan Univ, Dept Paediat & Child Hlth, Karachi, Pakistan. [Ramamurthy, Thandavarayan; Sur, Dipika] Natl Inst Cholera & Enter Dis, Kolkata, India. [Tamboura, Boubou; Sow, Samba O.] Ctr Dev Vaccins Mali, Bamako, Mali. [Breiman, Robert F.] US Ctr Dis Control & Prevent, Global Dis Detect Div, Kenya Off, Nairobi, Kenya. [Sur, Dipika] PATH, New Delhi, India. [Berkeley, Lynette Y.] US FDA, Rockville, MD 20857 USA. [Biswas, Kousick] US Dept Vet Affairs, Cooperat Studies Program Coordinating Ctr, Perry Point, MD USA. [Cohen, Dani] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, Ramat Aviv, Israel. RP Levine, MM (reprint author), Univ Maryland Sch Med, Ctr Vaccine Dev, 685 West Baltimore St, Baltimore, MD 21201 USA. EM mlevine@medicine.umaryland.edu FU Bill & Melinda Gates Foundation [38774] FX This work was supported by grant 38774 from the Bill & Melinda Gates Foundation to M. M. L. NR 46 TC 52 Z9 53 U1 1 U2 17 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2014 VL 59 IS 7 BP 933 EP 941 DI 10.1093/cid/ciu468 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AR2JY UT WOS:000343411900005 PM 24958238 ER PT J AU Lo Re, V Wang, L Devine, S Baser, O Olufade, T AF Lo Re, Vincent, III Wang, Li Devine, Scott Baser, Onur Olufade, Temitope TI Hepatic Decompensation in Patients With HIV/Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) Triple Infection Versus HIV/HCV Coinfection and the Effect of Anti-HBV Nucleos(t)ide Therapy SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material DE end-stage liver disease; hepatic decompensation; hepatitis B; hepatitis C; HIV ID HUMAN-IMMUNODEFICIENCY-VIRUS; VETERANS AGING COHORT; VIRAL-HEPATITIS; HIV-INFECTION; AFFAIRS; EVENTS; SYSTEM; CARE AB The incidence rate of hepatic decompensation was higher in patients with human immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C virus (HCV) triple infection than in those with HIV/HCV coinfection (24.1 vs 10.8 events per 1000 person-years; hazard ratio [HR], 1.89; 95% confidence interval [CI], 1.12-3.18). Compared with HIV/HCV-infected patients, the rate of decompensation was increased among HIV/HBV/HCV-infected patients receiving no anti-HBV therapy (HR, 2.48; 95% CI, 1.37-4.49) but not among those who did receive such therapy (HR, 1.09; 95% CI,.40-2.97) C1 [Lo Re, Vincent, III] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Lo Re, Vincent, III] Univ Penn, Perelman Sch Med, Penn Ctr AIDS Res, Philadelphia, PA 19104 USA. [Lo Re, Vincent, III] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Lo Re, Vincent, III] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. [Wang, Li; Baser, Onur] STATinMED Res, Analyt Res, Dallas, TX USA. [Devine, Scott; Olufade, Temitope] Merck Sharpe & Dohme Corp, US Outcomes Res, Whitehouse Stn, NJ USA. [Baser, Onur] MEF Univ, Dept Econ Adm & Social Sci, Istanbul, Turkey. RP Lo Re, V (reprint author), Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, 836 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM vincentl@mail.med.upenn.edu RI Lo Re, Vincent/N-7817-2015 NR 25 TC 4 Z9 4 U1 1 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2014 VL 59 IS 7 BP 1027 EP 1031 DI 10.1093/cid/ciu476 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AR2JY UT WOS:000343411900019 PM 24944235 ER PT J AU Katon, J Mattocks, K Zephyrin, L Reiber, G Yano, EM Callegari, L Schwarz, EB Goulet, J Shaw, J Brandt, C Haskell, S AF Katon, Jodie Mattocks, Kristin Zephyrin, Laurie Reiber, Gayle Yano, Elizabeth M. Callegari, Lisa Schwarz, Eleanor Bimla Goulet, Joseph Shaw, Jonathan Brandt, Cynthia Haskell, Sally TI Gestational Diabetes and Hypertensive Disorders of Pregnancy Among Women Veterans Deployed in Service of Operations in Afghanistan and Iraq SO JOURNAL OF WOMENS HEALTH LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; HEALTH-CARE; GENDER-DIFFERENCES; MENTAL-HEALTH; UNITED-STATES; RISK-FACTORS; PREECLAMPSIA; DEPRESSION; DIAGNOSES; MELLITUS AB Objective: To determine the prevalence of gestational diabetes (GDM) and hypertensive disorders of pregnancy (HDP) among women Veterans using Department of Veterans Affairs (VA) maternity benefits previously deployed in service of Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND), and whether pregnancy complications were associated with VA use following delivery. Methods: We identified the study population through linkage with the Department of Defense roster and VA administrative and clinical data. GDM and HDP were identified by International Classification of Diseases, Ninth Revision codes in VA inpatient or outpatient files. Similarly, we constructed a nationally representative sample of deliveries from the Nationwide Inpatient Sample. We calculated standardized incidence ratios (SIR) adjusted for age and year of delivery to compare rates of GDM and HDP. Proportional hazards regression was used to determine whether pregnancy complications were associated with use of VA following delivery. Results: Between 2001 and 2010, 2,288 women OEF/OIF/OND Veterans used VA maternity benefits; 5.2% had GDM and 9.6% had HDP. Compared with women delivering in the United States, women OEF/OIF/OND Veterans using VA maternity benefits had higher risk of developing GDM (SIR: 1.40; 95% confidence interval [CI] 1.16, 1.68) and HDP (SIR: 1.32; 95% CI 1.15, 1.51). Among women OEF/OIF/OND Veterans using VA maternity benefits, GDM (HR 1.01, 95% CI 0.83, 1.24) and HDP (HR 1.07, 95% CI 0.92, 1.25) were not associated with use of VA following delivery. Conclusions: Non-VA providers should be aware of their patients' Veteran status and the associated elevated risk for pregnancy complications. Within VA, focused efforts to optimize Veterans' preconception and postpartum health are needed. C1 [Katon, Jodie; Reiber, Gayle; Callegari, Lisa] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, HSR&D, Seattle, WA USA. [Katon, Jodie; Zephyrin, Laurie; Haskell, Sally] Off Womens Hlth Serv, VA Cent Off, Washington, DC USA. [Katon, Jodie; Reiber, Gayle; Callegari, Lisa] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Reiber, Gayle] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Mattocks, Kristin] VA Cent Western Massachusetts, Leeds, MA USA. [Mattocks, Kristin] Univ Massachusetts, Sch Med, Worcester, MA USA. [Zephyrin, Laurie] New York Harbor VA Healthcare Syst, New York, NY USA. [Zephyrin, Laurie] NYU, Dept Obstet & Gynecol, Langone Med Ctr, New York, NY 10016 USA. [Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, Los Angeles, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Callegari, Lisa] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Schwarz, Eleanor Bimla] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Schwarz, Eleanor Bimla] Univ Pittsburgh, Dept Obstet & Gynecol, Pittsburgh, PA USA. [Schwarz, Eleanor Bimla] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Goulet, Joseph] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Haskell, Sally] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Goulet, Joseph; Brandt, Cynthia; Haskell, Sally] VA Connecticut Healthcare Syst, West Haven, CT USA. [Shaw, Jonathan] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Shaw, Jonathan] Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA. RP Katon, J (reprint author), VA Med Ctr, 1660 South Columbian Way S-152, Seattle, WA 98108 USA. EM jkaton@u.washington.edu OI Goulet, Joseph/0000-0002-0842-804X FU U.S. Department of Veteran Affairs, Office of Research and Development, Health Services Research and Development [DHI 07-065-2]; Office of Academic Affiliations' Associated Health Postdoctoral Fellowship [TPP 61-026]; VA Health Services Research and Development (HSR&D) Senior Career Scientist Award [RCS 98-353]; VA HSR&D Career Scientist Award [RCS 05-195] FX This material is based on work supported by the U.S. Department of Veteran Affairs, Office of Research and Development, Health Services Research and Development (DHI 07-065-2), an Office of Academic Affiliations' Associated Health Postdoctoral Fellowship to Dr. Katon (#TPP 61-026), a VA Health Services Research and Development (HSR&D) Senior Career Scientist Award to Dr. Reiber (grant RCS 98-353) and a VA HSR&D Career Scientist Award to Dr. Yano (grant RCS 05-195). The authors would like to thank Norman Silliker and Melissa Skanderson, at VA Connecticut Healthcare System, West Haven, CT, and Jeff Rodenbaugh, at VA Puget Sound Health Care System, for their work managing the data. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 52 TC 5 Z9 5 U1 1 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD OCT 1 PY 2014 VL 23 IS 10 BP 792 EP 800 DI 10.1089/jwh.2013.4681 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA AR0DT UT WOS:000343237900005 PM 25090022 ER PT J AU Gupta, A Mayer, EA Sanmiguel, CP Van Horn, J Tillisch, K Labus, JS AF Gupta, Arpana Mayer, Emeran A. Sanmiguel, Claudia P. Van Horn, John Tillisch, Kirsten Labus, Jennifer S. TI Morphological and Diffuse Tensor Imaging-Based Brain Signatures Discriminate Obese and Overweight from Lean Subjects: Examining Sex Differences Within the Brain SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Gupta, Arpana; Mayer, Emeran A.; Sanmiguel, Claudia P.; Tillisch, Kirsten; Labus, Jennifer S.] Univ Calif Los Angeles, Ingest Behav & Obes Program, Gail & Gerald Oppenheimer Family Ctr Neurobiol St, Los Angeles, CA USA. [Gupta, Arpana; Mayer, Emeran A.; Sanmiguel, Claudia P.; Tillisch, Kirsten; Labus, Jennifer S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Gupta, Arpana; Mayer, Emeran A.; Sanmiguel, Claudia P.; Tillisch, Kirsten; Labus, Jennifer S.] Univ Calif Los Angeles, Div Digest Dis, Los Angeles, CA USA. [Mayer, Emeran A.] Univ Calif Los Angeles, Ahmanson Lovelace Brain Mapping Ctr, Los Angeles, CA USA. [Van Horn, John] Univ So Calif, Keck Sch Med, Inst Neuroimaging & Informat, Los Angeles, CA 90033 USA. [Tillisch, Kirsten] Greater Los Angeles Healthcare Syst, US Dept Vet Affairs, Integrat Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD OCT 1 PY 2014 VL 23 IS 10 MA P-30 BP 860 EP 860 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA AR0DT UT WOS:000343237900044 ER PT J AU Thompson, JL Rosell, DR Slifstein, M Girgis, RR Xu, XY Ehrlich, Y Kegeles, LS Hazlett, EA Abi-Dargham, A Siever, LJ AF Thompson, Judy L. Rosell, Daniel R. Slifstein, Mark Girgis, Ragy R. Xu, Xiaoyan Ehrlich, Yosefa Kegeles, Lawrence S. Hazlett, Erin A. Abi-Dargham, Anissa Siever, Larry J. TI Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [C-11]NNC112 SO PSYCHOPHARMACOLOGY LA English DT Article DE Schizotypal personality disorder; Schizophrenia; PET; Dopamine; Prefrontal cortex; Working memory ID IN-VIVO BINDING; NEUROPSYCHOLOGICAL PERFORMANCE; SCHIZOPHRENIA SPECTRUM; NAIVE PATIENTS; D-1 RECEPTORS; TASK; SPECIFICITY; SELECTIVITY; TOMOGRAPHY; IMPAIRMENT AB Schizotypal personality disorder (SPD) is associated with working memory (WM) impairments that are similar to those observed in schizophrenia. Imaging studies have suggested that schizophrenia is associated with alterations in dopamine D1 receptor availability in the prefrontal cortex (PFC) that may be related to the WM impairments that characterize this disorder. The aim of this study was to characterize prefrontal D1 receptor availability and its relation to WM performance in SPD. We used positron emission tomography (PET) and the radiotracer [C-11]NNC112 with 18 unmedicated SPD and 21 healthy control participants; as an index of D1 receptor availability, binding potential (BP) measures (BPF, BPND, and BPP) were calculated for prefrontal and striatal subregions. To assess WM, SPD participants completed the 2-back and Paced Auditory Serial Addition Test (PASAT). There were no significant group differences in PFC BP. BPF and BPP in the medial PFC were significantly negatively related to PASAT performance (r (s) = -0.551, p = .022 and r (s) = -0.488, p = .047, respectively), but BP was not related to 2-back performance. In contrast to what has been found in schizophrenia, SPD was not associated with significant alterations in prefrontal D1 receptor availability. Similar to previous schizophrenia findings, however, higher prefrontal D1 receptor availability was associated with poorer WM performance (as measured by the PASAT) in SPD. These findings suggest that schizophrenia and SPD may share a common pathophysiological feature related to prefrontal dopamine functioning that contributes to WM dysfunction, but that in SPD, alterations in D1 may occur only in a subset of individuals and/or to an extent that is minor relative to what occurs in schizophrenia. C1 [Thompson, Judy L.; Slifstein, Mark; Girgis, Ragy R.; Xu, Xiaoyan; Kegeles, Lawrence S.; Abi-Dargham, Anissa] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA. [Rosell, Daniel R.; Ehrlich, Yosefa; Hazlett, Erin A.; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Rosell, Daniel R.; Ehrlich, Yosefa; Hazlett, Erin A.; Siever, Larry J.] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Kegeles, Lawrence S.; Abi-Dargham, Anissa] Columbia Univ Coll Phys & Surg, Dept Radiol, New York, NY 10032 USA. [Thompson, Judy L.] Rutgers State Univ, Sch Hlth Related Profess, Scotch Plains, NJ 07076 USA. RP Thompson, JL (reprint author), Rutgers State Univ, Sch Hlth Related Profess, 1776 Raritan Rd, Scotch Plains, NJ 07076 USA. EM judy.thompson@rutgers.edu RI Girgis, Ragy/N-3271-2016 FU US Department of Veterans Affairs [7609-028]; National Institute of Mental Health [MH56140]; Veterans Affairs VISN 3 Mental Illness Research, Education and Clinical Center (MIRECC) FX We thank the research participants of this study and express gratitude for the expert assistance of Rawad Ayoub, Jennifer Bae, Felipe Castillo, John Castrillon, Elizabeth Hackett, Elisabeth Iskander, Olga Kambalov, and Ethan Rothstein. This work was supported by a Merit Review grant (7609-028) from the US Department of Veterans Affairs to Larry J. Siever, by grant MH56140 from the National Institute of Mental Health to Larry J. Siever, and by the Veterans Affairs VISN 3 Mental Illness Research, Education and Clinical Center (MIRECC). NR 39 TC 2 Z9 2 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 EI 1432-2072 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD OCT PY 2014 VL 231 IS 21 BP 4231 EP 4240 DI 10.1007/s00213-014-3566-6 PG 10 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA AR6WO UT WOS:000343721600014 PM 24781514 ER PT J AU Barshes, NR Rodriguez-Barradas, MC Bechara, CF Pisimisis, G Young, EJ Kougias, P AF Barshes, Neal R. Rodriguez-Barradas, Maria C. Bechara, Carlos F. Pisimisis, George Young, Edward J. Kougias, Panos TI Microbial Isolates and Their Antimicrobial Susceptibilities in Inframalleolar Foot Infections SO SURGICAL INFECTIONS LA English DT Article ID SURGICAL SERIES; OSTEOMYELITIS; ULCERS AB Background: Foot infections are especially common among diabetic individuals and often contribute to limb loss. We investigated the microbiology of foot infections in our hospital to further understand the microbes involved and to assist in identifying potential empiric oral antibiotic regimens for foot infections. Methods: All moderate/severe inframalleolar foot infections that were drained surgically at a single center during a single calendar year were included. Initial isolates obtained intra-operatively were reviewed. Results: A total of 39 patients underwent operative drainage, of whom 34 (87%) had diabetes mellitus. Fifty-two total specimens were obtained, consisting of 26 fluid swabs, 12 soft-tissue specimens, and 11 bone specimens. Nineteen (49%) of the specimens were obtained from toe wounds, 16 (41%) from forefoot wounds, two (5%) from midfoot wounds, and two (5%) from heel wounds. Most specimens (71%) were polymicrobial, yielding a mean of 2.2 isolates. In all, 100 individual isolates, encompassing 39 different bacterial organisms, were identified (55 gram-positive aerobes, 33 gram-negative aerobes, 11 anaerobes, and one fungus). Enterococcus species and Staphylococcus aureus were the most common bacteria, each representing 13% of isolates. Only 9% of isolates were methicillin-resistant S. aureus. Obtaining multiple specimens (e.g., both fluid and tissue) increased the yield for identification of organisms. Oral antibiotics provided adequate coverage for gram-positive organisms but not for gram-negative organisms. Conclusions: Foot infections are typically polymicrobial and may involve a wide variety of microbes. Initial gram-stain results could be used to choose better initial empiric antimicrobial therapy for such infections. C1 [Barshes, Neal R.; Bechara, Carlos F.; Pisimisis, George; Kougias, Panos] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E Debakey Dept Surg, Houston, TX 77030 USA. [Rodriguez-Barradas, Maria C.; Young, Edward J.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. RP Barshes, NR (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E Debakey Dept Surg, Div Vasc & Endovasc Surg, 2002 Holcombe Blvd OCL 112, Houston, TX 77030 USA. EM nbarshes@bcm.tmc.edu NR 8 TC 2 Z9 2 U1 0 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-2964 EI 1557-8674 J9 SURG INFECT JI Surg. Infect. PD OCT 1 PY 2014 VL 15 IS 5 BP 585 EP 591 DI 10.1089/sur.2013.126 PG 7 WC Infectious Diseases; Surgery SC Infectious Diseases; Surgery GA AR0AO UT WOS:000343224800019 PM 24827989 ER PT J AU Karasawa, H Yakabi, S Wang, L Stengel, A Rivier, J Tache, Y AF Karasawa, Hiroshi Yakabi, Seiichi Wang, Lixin Stengel, Andreas Rivier, Jean Tache, Yvette TI Brain somatostatin receptor 2 mediates the dipsogenic effect of central somatostatin and cortistatin in rats: role in drinking behavior SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE angiotensin receptor 1; brain; cortistatin; somatostatin agonists; water intake ID CENTRAL-NERVOUS-SYSTEM; FOOD-ASSOCIATED DRINKING; GROWTH-HORMONE; WATER-INTAKE; OCTAPEPTIDE ANALOG; CONTAINING NEURONS; CIRCADIAN-RHYTHMS; SUBFORNICAL ORGAN; BINDING-AFFINITY; RING SIZE AB Intracerebroventricular injection of stable somatostatin (SST) agonists stimulates food and water intake in rats. We investigated the receptor subtype(s) involved in the dipsogenic effect of intracerebroventricular injection of SST agonists, mechanisms of action, and role. In nonfasted and non-water-deprived male rats with chronic intracerebroventricular cannula, intake of water without food or food without water was monitored separately to avoid any interactions compared with intracerebroventricular vehicle. SST-14 and cortistatin (CST-14) (1 mu g/rat icv) increased water intake by 3.1- and 2.7-fold, respectively, while both peptides did not alter food intake at 1 h postinjection in the light phase. By contrast, the stable pan-somatostatin agonist ODT8-SST (1 mu g/rat icv) increased both water and food intake by 4.9- and 3.7-fold, respectively. S-346-011, a selective receptor 2 (sst(2)) agonist (1 mu g/rat icv) induced water ingestion, while sst(1) or sst(4) agonist, injected under the same conditions, did not. The sst(2) antagonist S-406-028 (1 mu g/rat icv) prevented the 1-h water intake induced by intracerebroventricular ODT8-SST and CST-14. Losartan (100 mu g/rat icv), an angiotensin receptor 1 (AT(1)) antagonist, completely blocked the water consumption induced by intracerebroventricular ODT8-SST, whereas intracerebroventricular injection of S-406-028 did not modify the intracerebroventricular ANG II-induced dipsogenic response. The sst(2) antagonist reduced by 40% the increase of the 3-h water intake in the early dark phase. These data indicate that SST-14 and CST-14 interact with sst(2) to exert a potent dipsogenic effect, which is mediated downstream by angiotensin-AT1 signaling. These data also indicate that sst(2) activation by brain SST-14 and/or CST-14 may play an important role in the regulation of drinking behavior. C1 [Karasawa, Hiroshi; Yakabi, Seiichi; Wang, Lixin; Stengel, Andreas; Tache, Yvette] Univ Calif Los Angeles, Dept Med, CURE Digest Dis Ctr, Div Digest Dis, Los Angeles, CA 90024 USA. [Karasawa, Hiroshi; Yakabi, Seiichi; Wang, Lixin; Stengel, Andreas; Tache, Yvette] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Rivier, Jean] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA USA. RP Tache, Y (reprint author), Bldg 115,Rm 117B,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [P30-DK-41303, R01-30110]; Veterans Administration Research Career Scientist Award FX This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Grants P30-DK-41303 (Animal Core, to Y. Tache and L. Wang), and R01-30110, and by the Veterans Administration Research Career Scientist Award (to Y. Tache). NR 64 TC 2 Z9 2 U1 1 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 EI 1522-1490 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD OCT 1 PY 2014 VL 307 IS 7 BP R793 EP R801 DI 10.1152/ajpregu.00248.2014 PG 9 WC Physiology SC Physiology GA AQ9XZ UT WOS:000343214000004 PM 25031229 ER PT J AU Do, C Barnes, JL Tan, CY Wagner, B AF Do, Catherine Barnes, Jeffrey L. Tan, Chunyan Wagner, Brent TI Type of MRI contrast, tissue gadolinium, and fibrosis SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE gadolinium/adverse effects; magnetic resonance imaging/adverse effects; nephrogenic fibrosing dermopathy; skin diseases; animals; fibrosis ID NEPHROGENIC SYSTEMIC FIBROSIS; KIDNEY-DISEASE; AGENTS; BIODISTRIBUTION; DERMOPATHY; SKIN; CONSEQUENCES; FIBROBLASTS; GADOTERIDOL; GADODIAMIDE AB It has been presupposed that the thermodynamic stability constant (K-therm) of gadolinium-based MRI chelates relate to the risk of precipitating nephrogenic systemic fibrosis. The present study compared low-K-therm gadodiamide with high-K-therm gadoteridol in cultured fibroblasts and rats with uninephrectomies. Gadolinium content was assessed using scanning electron microscopy equipped with energy-dispersive X-ray spectroscopy in paraffin-embedded tissues. In vitro, fibroblasts demonstrated dose-dependent fibronectin generation, transforming growth factor-beta production, and expression of activated myofibroblast stress fiber protein alpha-smooth muscle actin. There were negligible differences with respect to toxicity or proliferation between the two contrast agents. In the rodent model, gadodiamide treatment led to greater skin fibrosis and dermal cellularity than gadoteridol. In the kidney, both contrast agents led to proximal tubule vacuolization and increased fibronectin accumulation. Despite large detectable gadolinium signals in the spleen, skin, muscle, and liver from the gadodiamide-treated group, contrast-induced fibrosis appeared to be limited to the skin and kidney. These findings support the hypothesis that low-Ktherm chelates have a greater propensity to elicit nephrogenic systemic fibrosis and demonstrate that certain tissues are resistant to these effects. C1 [Do, Catherine; Barnes, Jeffrey L.; Tan, Chunyan] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Barnes, Jeffrey L.; Wagner, Brent] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Wagner, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, 7703 Floyd Curl Dr,MC 7882, San Antonio, TX 78229 USA. EM wagnerb@uthscsa.edu OI Wagner, Brent/0000-0002-7063-0142 FU Veterans Administration VISN 17 New Investigator Award; Veterans Administration Career Development Award; Veterans Administration BLR&D Merit Review Award [I01 BX001958]; National Institute of Diabetes and Digestive and Kidney Disease Grant [DK-102085] FX This work was supported by a Veterans Administration VISN 17 New Investigator Award (to B. Wagner), a Veterans Administration Career Development Award (to B. Wagner), Veterans Administration BLR&D Merit Review Award I01 BX001958 (to B. Wagner), and National Institute of Diabetes and Digestive and Kidney Disease Grant DK-102085. NR 40 TC 11 Z9 11 U1 1 U2 8 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD OCT 1 PY 2014 VL 307 IS 7 BP F844 EP F855 DI 10.1152/ajprenal.00379.2014 PG 12 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA AR0CE UT WOS:000343231600010 PM 25100280 ER PT J AU Wei, Y Liao, Y Zavilowitz, B Ren, J Liu, W Chan, P Rohatgi, R Estilo, G Jackson, EK Wang, WH Satlin, LM AF Wei, Yuan Liao, Yi Zavilowitz, Beth Ren, Jin Liu, Wen Chan, Pokman Rohatgi, Rajeev Estilo, Genevieve Jackson, Edwin K. Wang, Wen-Hui Satlin, Lisa M. TI Angiotensin II type 2 receptor regulates ROMK- like K+ channel activity in the renal cortical collecting duct during high dietary K+ adaptation SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE angiotensin II; angiotensin II type 2 receptor; cortical collecting duct; renal outer medullary potassium channel; protein kinase A ID DEPENDENT PROTEIN-KINASE; NITRIC-OXIDE SYNTHASE; AT(2) RECEPTOR; RAT-KIDNEY; APICAL MEMBRANE; TYROSINE KINASE; GENE-EXPRESSION; MESSENGER-RNA; TUBULE; PHOSPHATASE AB The kidney adjusts K+ excretion to match intake in part by regulation of the activity of apical K+ secretory channels, including renal outer medullary K+ (ROMK)-like K+ channels, in the cortical collecting duct (CCD). ANG II inhibits ROMK channels via the ANG II type 1 receptor (AT(1)R) during dietary K+ restriction. Because AT(1)Rs and ANG II type 2 receptors (AT(2)Rs) generally function in an antagonistic manner, we sought to characterize the regulation of ROMK channels by the AT(2)R. Patchclamp experiments revealed that ANG II increased ROMK channel activity in CCDs isolated from high-K+ (HK)-fed but not normal K+ (NK)-fed rats. This response was blocked by PD-123319, an AT(2)R antagonist, but not by losartan, an AT(1)R antagonist, and was mimicked by the AT(2)R agonist CGP-42112. Nitric oxide (NO) synthase is present in CCD cells that express ROMK channels. Blockade of NO synthase with N-nitro-L-arginine methyl ester and free NO with 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide potassium salt completely abolished ANG II-stimulated ROMK channel activity. NO enhances the synthesis of cGMP, which inhibits phosphodiesterases (PDEs) that normally degrade cAMP; cAMP increases ROMK channel activity. Pretreatment of CCDs with IBMX, a broad-spectrum PDE inhibitor, or cilostamide, a PDE3 inhibitor, abolished the stimulatory effect of ANG II on ROMK channels. Furthermore, PKA inhibitor peptide, but not an activator of the exchange protein directly activated by cAMP (Epac), also prevented the stimulatory effect of ANG II. We conclude that ANG II acts at the AT(2)R to stimulate ROMK channel activity in CCDs from HK-fed rats, a response opposite to that mediated by the AT(1)R in dietary K+-restricted animals, via a NO/cGMP pathway linked to a cAMPPKA-PKA pathway. C1 [Wei, Yuan; Zavilowitz, Beth; Liu, Wen; Rohatgi, Rajeev; Satlin, Lisa M.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA. [Rohatgi, Rajeev; Estilo, Genevieve; Satlin, Lisa M.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Chan, Pokman] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Ren, Jin; Jackson, Edwin K.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Ren, Jin; Jackson, Edwin K.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA. [Wei, Yuan; Wang, Wen-Hui] New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA. [Rohatgi, Rajeev] James J Peters Vet Affairs Med Ctr, Dept Med, Bronx, NY USA. [Wei, Yuan; Liao, Yi] NYU, Med Ctr, Dept Cell Biol, New York, NY 10016 USA. RP Wei, Y (reprint author), NYU, Med Ctr, Dept Cell Biol, 550 First Ave, New York, NY 10016 USA. EM yuan.wei@nyumc.org FU American Heart Association Scientist Development [0530092N]; NIH [DK-47402, DK-38470, DK-51391, P30-DK-079307]; Department of Veterans Affairs Merit Review [1I01BX000388] FX This work was supported by American Heart Association Scientist Development Grant 0530092N (to Y. Wei). W. H. Wang was supported by NIH Grant DK-47402, and L. M. Satlin was supported by NIH Grants DK-38470 and DK-51391. L. M. Satlin and E. K. Jackson were further supported by NIH Grant P30-DK-079307 (Pittsburgh Center for Kidney Research). R. Rohatgi was supported by Department of Veterans Affairs Merit Review 1I01BX000388. NR 66 TC 7 Z9 7 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD OCT 1 PY 2014 VL 307 IS 7 BP F833 EP F843 DI 10.1152/ajprenal.00141.2014 PG 11 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA AR0CE UT WOS:000343231600009 PM 25100281 ER PT J AU Yu, GY Herazo-Maya, JD Nukui, T Romkes, M Parwani, A Juan-Guardela, BM Robertson, J Gauldie, J Siegfried, JM Kaminski, N Kass, DJ AF Yu, Guoying Herazo-Maya, Jose D. Nukui, Tomoko Romkes, Marjorie Parwani, Anil Juan-Guardela, Brenda M. Robertson, Jennifer Gauldie, Jack Siegfried, Jill M. Kaminski, Naftali Kass, Daniel J. TI Matrix Metalloproteinase-19 Promotes Metastatic Behavior In Vitro and Is Associated with Increased Mortality in Non-Small Cell Lung Cancer SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE MMP19; epithelial-mesenchymal transition; metastasis; non-small cell lung cancer; miR-30 ID IDIOPATHIC PULMONARY-FIBROSIS; TUMOR-MICROENVIRONMENT; HEMOPEXIN DOMAIN; PROSTATE-CANCER; EXPRESSION; INVASION; ANGIOGENESIS; PROGRESSION; SIGNATURES; MICRORNA AB Rationale: Lung cancer is the leading cause of cancer death in both men and women in the United States and worldwide. Matrix metalloproteinases (MMPs) have been implicated in the development and progression of lung cancer, but their role in the molecular pathogenesis of lung cancer remains unclear. We have found that MMP19, a relatively novel member of the MMP family, is overexpressed in lung tumors when compared with control subjects. Objectives: To test the hypothesis that MMP19 plays a significant role in the development and progression of non-small cell lung cancer (NSCLC). Methods: We have analyzed lung cancer gene expression data, immunostained lung tumors for MMP19, and performed in vitro assays to test the effects of MMP19 in NSCLC cells. Measurements and Main Results: We found that MMP19 gene and protein expression is increased in lung cancer tumors compared with adjacent and histologically normal lung tissues. In three independent datasets, increased MMP19 gene expression conferred a poorer prognosis in NSCLC. In vitro, we found that overexpression of MMP19 promotes epithelial-mesenchymal transition, migration, and invasiveness in multiple NSCLC cell lines. Overexpression of MMP19 with a mutation at the catalytic site did not impair epithelial-mesenchymal transition or expression of prometastasis genes. We also found that miR-30 isoforms, a microRNA family predicted to target MMP19, is markedly down-regulated in human lung cancer and regulates MMP19 expression. Conclusions: Taken together, these findings suggest that MMP19 is associated with the development and progression of NSCLC and may be a potential biomarker of disease severity and outcome. C1 [Yu, Guoying; Herazo-Maya, Jose D.; Juan-Guardela, Brenda M.; Kaminski, Naftali] Yale Univ, Sch Med, Sect Pulm Crit Care & Sleep Med, New Haven, CT USA. [Nukui, Tomoko; Romkes, Marjorie] Univ Pittsburgh, Div Hematol & Oncol, Pittsburgh, PA USA. [Kass, Daniel J.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA. [Kass, Daniel J.] Univ Pittsburgh, Dorothy P & Richard P Simmons Ctr Interstitial Lu, Dept Med, Pittsburgh, PA USA. [Parwani, Anil] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. [Robertson, Jennifer; Gauldie, Jack] McMaster Univ, Dept Pathol & Lab Med, Hamilton, ON, Canada. [Siegfried, Jill M.] Univ Minnesota, Dept Pharmacol, Minneapolis, MN USA. [Kass, Daniel J.] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. RP Kass, DJ (reprint author), UPMC Montefiore, NW 628,3459 Fifth Ave, Pittsburgh, PA 15213 USA. EM kassd2@upmc.edu OI Kaminski, Naftali/0000-0001-5917-4601 FU Dorothy P. and Richard P. Simmons Endowed Chair for Pulmonary Research; National Institutes of Health [R01HL107883, P30CA047904]; Lung Cancer Genomics project, University of Pittsburgh Medical Center FX Supported by the Dorothy P. and Richard P. Simmons Endowed Chair for Pulmonary Research; National Institutes of Health grants R01HL107883 and P30CA047904; and the Lung Cancer Genomics project, University of Pittsburgh Medical Center. NR 58 TC 7 Z9 8 U1 0 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD OCT 1 PY 2014 VL 190 IS 7 BP 780 EP 790 DI 10.1164/rccm.201310-1903OC PG 11 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AQ7TS UT WOS:000343022700012 PM 25250855 ER PT J AU Pantoja, JL Ge, L Zhang, ZH Morrel, WG Guccione, JM Grossi, EA Ratcliffe, MB AF Pantoja, Joe Luis Ge, Liang Zhang, Zhihong Morrel, William G. Guccione, Julius M. Grossi, Eugene A. Ratcliffe, Mark B. TI Posterior Papillary Muscle Anchoring Affects Remote Myofiber Stress and Pump Function: Finite Element Analysis SO ANNALS OF THORACIC SURGERY LA English DT Article ID ISCHEMIC MITRAL REGURGITATION; POSTEROLATERAL MYOCARDIAL-INFARCTION; LEFT-VENTRICLE; DILATED CARDIOMYOPATHY; VALVE ANNULOPLASTY; HEART-FAILURE; REPAIR; MODEL; REVASCULARIZATION; BORDERZONE AB Background. The role of posterior papillary muscle anchoring (PPMA) in the management of chronic ischemic mitral regurgitation (CIMR) is controversial. We studied the effect of anchoring point direction and relocation displacement on left ventricular (LV) regional myofiber stress and pump function. Methods. Previously described finite element models of sheep 16 weeks after posterolateral myocardial infarction (MI) were used. True-sized mitral annuloplasty (MA) ring insertion plus different PPM anchoring techniques were simulated. Anchoring points tested included both commissures and the central anterior mitral annulus; relocation displacement varied from 10% to 40% of baseline diastolic distance from the PPM to the anchor points on the annulus. For each reconstruction scenario, myofiber stress in the MI, border zone, and remote myocardium as well as pump function were calculated. Results. PPMA caused reductions in myofiber stress at end-diastole and end-systole in all regions of the left ventricle that were proportional to the relocation displacement. Although stress reduction was greatest in the MI region, it also occurred in the remote region. The maximum 40% displacement caused a slight reduction in LV pump function. However, with the correction of regurgitation by MA plus PPMA, there was an overall increase in forward stroke volume. Finally, anchoring point direction had no effect on myofiber stress or pump function. Conclusions. PPMA reduces remote myofiber stress, which is proportional to the absolute distance of relocation and independent of anchoring point. Aggressive use of PPMA techniques to reduce remote myofiber stress may accelerate reverse LV remodeling without impairing LV function. (C) 2014 by The Society of Thoracic Surgeons C1 Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. Univ Calif San Francisco, Dept Bioengn, San Francisco, CA USA. Univ Calif San Francisco, Sch Med, San Francisco, CA USA. Vet Affairs Med Ctr, San Francisco, CA 94121 USA. NYU, Dept Cardiothorac Surg, New York, NY USA. New York Harbor Vet Affairs Med Ctr, New York, NY USA. RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA. EM mark.ratcliffe@med.va.gov OI Morrel, William/0000-0001-6371-1094; GROSSI, eugene/0000-0002-2066-7035 FU National Institutes of Health [R01-HL-63348]; AHA [13MSRF17090108] FX This study was supported by National Institutes of Health grant R01-HL-63348 (MBR) and by AHA grant 13MSRF17090108. This support is gratefully acknowledged. NR 37 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD OCT PY 2014 VL 98 IS 4 BP 1355 EP 1362 DI 10.1016/j.athoracsur.2014.04.077 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA AQ9DM UT WOS:000343143400037 PM 25130075 ER PT J AU Yazdany, J Tonner, C Schmajuk, G Lin, GA Trivedi, AN AF Yazdany, Jinoos Tonner, Chris Schmajuk, Gabriela Lin, Grace A. Trivedi, Amal N. TI Receipt of Glucocorticoid Monotherapy Among Medicare Beneficiaries With Rheumatoid Arthritis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID MODIFYING ANTIRHEUMATIC DRUGS; HEALTH ADMINISTRATIVE DATABASES; EULAR RECOMMENDATIONS; ELDERLY-PATIENTS; ET-AL; CARE; MANAGEMENT; ARTICLE; UPDATE; SAFETY AB Objective. Using disease-modifying antirheumatic drugs (DMARDs) improves outcomes in rheumatoid arthritis (RA) and is a nationally endorsed quality measure. We investigated the prevalence and predictors of receiving glucocorticoids alone for the treatment of RA in a nationwide sample of Medicare beneficiaries. Methods. Among individuals ages >= 65 years with RA enrolled in the Part D prescription drug benefit in 2009, we compared those with >= 1 DMARD claim to those receiving glucocorticoid monotherapy, defined as no DMARD claim and an annual glucocorticoid supply of >= 180 days or an annual dose of >= 900 mg of prednisone or equivalent. We fit multivariable models to determine the sociodemographic and clinical factors associated with glucocorticoid monotherapy. Results. Of 8,125 beneficiaries treated for RA, 10.2% (n = 825) received glucocorticoids alone. Beneficiaries with low incomes were more likely to receive glucocorticoids alone (12.3%; 95% confidence interval [95% CI] 10.9-13.8% versus 9.4%; 95% CI 8.6-10.1%), as were those living in certain US regions. More physician office visits and hospitalizations were associated with glucocorticoid monotherapy. Individuals who had no contact with a rheumatologist were significantly more likely to receive glucocorticoids alone (17.5%; 95% CI 16.0-19.0% versus 8.5%; 95% CI 7.4-9.5% for those with no rheumatology visits versus 1-4 visits). Conclusion. Approximately 1 in 10 Medicare beneficiaries treated for RA received glucocorticoids without DMARDs in 2009. Compared to DMARD users, glucocorticoid users were older, had lower incomes, were more likely to live in certain US regions, and were less likely to have seen a rheumatologist, suggesting persistent gaps in quality of care despite expanded drug coverage under Part D. C1 [Yazdany, Jinoos; Tonner, Chris] San Francisco Gen Hosp, San Francisco, CA 94110 USA. [Yazdany, Jinoos; Tonner, Chris; Schmajuk, Gabriela; Lin, Grace A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Schmajuk, Gabriela] San Francisco VA Med Ctr, San Francisco, CA USA. [Trivedi, Amal N.] Providence VA Med Ctr, Providence, RI USA. [Trivedi, Amal N.] Brown Univ, Providence, RI 02912 USA. RP Yazdany, J (reprint author), Univ Calif San Francisco, Div Rheumatol, Box 0920, San Francisco, CA 94143 USA. EM jinoos.yazdany@ucsf.edu FU National Institute of Arthritis and Musculoskeletal and Skin Diseases [K23-AR-060259, P60-AR-053308]; University of California, San Francisco Resource Evaluation and Allocation Committee Grant Program; Rosalind Russell Medical Research Center for Arthritis; Informed Medical Decisions Foundation FX Supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases (awards K23-AR-060259, P60-AR-053308), the University of California, San Francisco Resource Evaluation and Allocation Committee Grant Program, and the Rosalind Russell Medical Research Center for Arthritis.; Dr. Lin has received consulting fees, speaking fees, and/or honoraria (less than $10,000) from Informed Medical Decisions Foundation. NR 28 TC 4 Z9 4 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD OCT PY 2014 VL 66 IS 10 BP 1447 EP 1455 DI 10.1002/acr.22312 PG 9 WC Rheumatology SC Rheumatology GA AQ7PP UT WOS:000343011800003 PM 25244314 ER PT J AU Thapa, D Meng, P Bedolla, RG Reddick, RL Kumar, AP Ghosh, R AF Thapa, Dinesh Meng, Peng Bedolla, Roble G. Reddick, Robert L. Kumar, Addanki P. Ghosh, Rita TI NQO1 Suppresses NF-kappa B-p300 Interaction to Regulate Inflammatory Mediators Associated with Prostate Tumorigenesis SO CANCER RESEARCH LA English DT Article ID NF-KAPPA-B; NAD(P)HQUINONE OXIDOREDUCTASE 1; IKK-ALPHA; OXIDATIVE STRESS; TRANSGENIC ADENOCARCINOMA; ANDROGEN DEPRIVATION; GENE-EXPRESSION; CANCER CELLS; P53; THERAPY AB NADPH reductase NAD(P) H: quinone oxidoreductase 1 (NQO1) is needed to maintain a cellular pool of antioxidants, and this enzyme may contribute to tumorigenesis on the basis of studies in NQO1-deficient mice. In this work, we sought deeper insights into how NQO1 contributes to prostate carcinogenesis, a setting in which oxidative stress and inflammation are established contributors to disease development and progression. In the TRAMP mouse model of prostate cancer, NQO1 was highly expressed in tumor cells. NQO1 silencing in prostate cancer cells increased levels of nuclear IKK alpha and NF-kappa B while decreasing the levels of p53, leading to interactions between NF-kappa B and p300 that reinforce survival signaling. Gene expression analysis revealed upregulation of a set of immune-associated transcripts associated with inflammation and tumorigenesis in cells in which NQO1 was attenuated, with IL8 confirmed functionally in cell culture as one key NQO1-supported cytokine. Notably, NQO1-silenced prostate cancer cells were more resistant to androgen deprivation. Furthermore, NQO1 inhibition increased migration, including under conditions of androgen deprivation. These results reveal a molecular link between NQO1 expression and proinflammatory cytokine signaling in prostate cancer. Furthermore, our results suggest that altering redox homeostasis through NQO1 inhibition might promote androgen-independent cell survival via opposing effects on NF-kappa B and p53 function. (C) 2014 AACR. C1 [Thapa, Dinesh; Meng, Peng; Bedolla, Roble G.; Kumar, Addanki P.; Ghosh, Rita] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Urol, San Antonio, TX 78229 USA. [Reddick, Robert L.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Pathol, San Antonio, TX 78229 USA. [Reddick, Robert L.; Kumar, Addanki P.; Ghosh, Rita] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. [Kumar, Addanki P.; Ghosh, Rita] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Pharmacol, San Antonio, TX 78229 USA. [Kumar, Addanki P.; Ghosh, Rita] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Mol Med, San Antonio, TX 78229 USA. [Kumar, Addanki P.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Ghosh, R (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Urol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM ghoshr@uthscsa.edu FU [5R01CA149516]; [CTSA UL1 TR000149]; [1R01AT7448]; [CPRIT PDF RP101491] FX This work was supported by 5R01CA149516 (R. Ghosh), CTSA UL1 TR000149 (R. Ghosh), 1R01AT7448 (to A.P. Kumar), and CPRIT PDF RP101491 (D. Thapa). NR 49 TC 10 Z9 11 U1 2 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT 1 PY 2014 VL 74 IS 19 BP 5644 EP 5655 DI 10.1158/0008-5472.CAN-14-0562 PG 12 WC Oncology SC Oncology GA AQ8WP UT WOS:000343118900028 PM 25125658 ER PT J AU Phillips, LS Ratner, RE Buse, JB Kahn, SE AF Phillips, Lawrence S. Ratner, Robert E. Buse, John B. Kahn, Steven E. TI We Can Change the Natural History of Type 2 Diabetes SO DIABETES CARE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; INTENSIVE INSULIN THERAPY; LIFE-STYLE INTERVENTION; PREVENTION PROGRAM OUTCOMES; RANDOMIZED CONTROLLED-TRIAL; BETA-CELL DYSFUNCTION; ALL-CAUSE MORTALITY; 10-YEAR FOLLOW-UP; GLYCEMIC CONTROL; CLINICAL INERTIA AB As diabetes develops, we currently waste the first similar to 10 years of the natural history. If we found prediabetes and early diabetes when they first presented and treated them more effectively, we could prevent or delay the progression of hyperglycemia and the development of complications. Evidence for this comes from trials where lifestyle change and/or glucose-lowering medications decreased progression from prediabetes to diabetes. After withdrawal of these interventions, there was no "catch-up"-cumulative development of diabetes in the previously treated groups remained less than in control subjects. Moreover, achieving normal glucose levels even transiently during the trials was associated with a substantial reduction in subsequent development of diabetes. These findings indicate that we can change the natural history through routine screening to find prediabetes and early diabetes, combined with management aimed to keep glucose levels as close to normal as possible, without hypoglycemia. We should also test the hypothesis with a randomized controlled trial. C1 [Phillips, Lawrence S.] Atlanta VA Med Ctr, Decatur, GA 30033 USA. [Phillips, Lawrence S.] Emory Univ Sch Med, Div Endocrinol & Metab, Dept Med, Atlanta, GA USA. [Ratner, Robert E.] Amer Diabet Assoc, Alexandria, VA USA. [Buse, John B.] Univ North Carolina Sch Med, Dept Med, Div Endocrinol & Metab, Chapel Hill, NC USA. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Kahn, Steven E.] Univ Washington Sch Med, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA USA. RP Phillips, LS (reprint author), Atlanta VA Med Ctr, Decatur, GA 30033 USA. EM lawrence.phillips@emory.edu OI Kahn, Steven/0000-0001-7307-9002 FU National Institutes of Health [DK066204, UL1 RR025008]; VA award HSRD IIR [07-138]; Cystic Fibrosis Foundation [PHILLI12A0]; National Center for Advancing Translational Sciences [UL1TR000083]; U.S. Department of Veterans Affairs; ADA; [P30 DK017047] FX This work was supported in part by National Institutes of Health awards DK066204 and UL1 RR025008, VA award HSR&D IIR 07-138, and a Cystic Fibrosis Foundation award PHILLI12A0 (L.S.P.); the National Center for Advancing Translational Sciences (UL1TR000083) (J.B.B.); P30 DK017047 (S.E.K.); the U.S. Department of Veterans Affairs (L.S.P. and S.E.K.); and the ADA (R.E.R.). NR 80 TC 11 Z9 11 U1 0 U2 7 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2014 VL 37 IS 10 BP 2668 EP 2676 DI 10.2337/dc14-0817 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AR4UM UT WOS:000343582400018 PM 25249668 ER PT J AU Anderson, RJ Bahn, GD Emanuele, NV Marks, JB Duckworth, WC AF Anderson, Robert J. Bahn, Gideon D. Emanuele, Nicholas V. Marks, Jennifer B. Duckworth, William C. CA VADT Study Grp TI Blood Pressure and Pulse Pressure Effects on Renal Outcomes in the Veterans Affairs Diabetes Trial (VADT) SO DIABETES CARE LA English DT Article ID CHRONIC KIDNEY-DISEASE; GLYCEMIC CONTROL; GLUCOSE CONTROL; COMPLICATIONS; MORTALITY; MELLITUS; RISK AB OBJECTIVE Blood pressure (BP) control for renal protection is essential for patients with type 2 diabetes. Our objective in this analysis of Veterans Affairs Diabetes Trial (VADT) data was to learn whether on-study systolic BP (SBP), diastolic BP (DBP), and pulse pressure (PP) affected renal outcomes measured as albumin-to-creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR). RESEARCH DESIGN AND METHODS The VADT was a prospective, randomized study of 1,791 veterans with type 2 diabetes to determine whether intensive glucose control prevented major cardiovascular events. In this post hoc study, time-varying covariate survival analyses and hazard ratios (HR) were used to determine worsening of renal outcomes. RESULTS Compared with SBP 105-129 mmHg, the risk of ACR worsening increased significantly for SBP 130-139 mmHg (HR 1.88 [95% CI 1.28-2.77]; P = 0.001) and for SBP >= 140 mmHg (2.51 [1.66-3.78]; P < 0.0001). Compared with a PP range of 40-49 mmHg, PP < 40 was associated with significantly lowered risk of worsening ACR (0.36 [0.15-0.87]; P = 0.022) and PP >= 60 with significantly increased risk (2.38 [1.58-3.59]; P < 0.0001). Analyses of BP ranges associated with eGFR worsening showed significantly increased risk with rising baseline SBP and an interaction effect between SBP >= 140 mmHg and on-study A1C. These patients were 15% more likely than those with SBP <140 mmHg to experience eGFR worsening (1.15 [1.00-1.32]; P = 0.045) for each 1% (10.9 mmol/mol) A1C increase. CONCLUSIONS SBP >= 130 mmHg and PP >60 mmHg were associated with worsening ACR. The results suggest that treatment of SBP to <130 mmHg may lessen ACR worsening. The interaction between SBP >= 140 mmHg and A1C suggests that the effect of glycemic control on reducing progression of renal disease may be greater in hypertensive patients. C1 [Anderson, Robert J.] Vet Affairs Med Ctr, Omaha, NE 68105 USA. [Bahn, Gideon D.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Cooperat Studies Program, Coordinating Ctr, Hines, IL 60141 USA. [Emanuele, Nicholas V.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. [Emanuele, Nicholas V.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Med Serv, Hines, IL 60141 USA. [Marks, Jennifer B.] Vet Affairs Med Ctr, Endocrinol Sect, Med Serv, Miami, FL 33125 USA. [Duckworth, William C.] Vet Affairs Med Ctr, Res Serv, Phoenix, AZ USA. RP Anderson, RJ (reprint author), Vet Affairs Med Ctr, Omaha, NE 68105 USA. EM robert.anderson4@va.gov FU Veterans Affairs Cooperative Studies Program, Department of Veterans Affairs Office of Research and Development; American Diabetes Association; National Eye Institute of the National Institutes of Health FX This study was supported by the Veterans Affairs Cooperative Studies Program, Department of Veterans Affairs Office of Research and Development. Additional support was received from the American Diabetes Association and the National Eye Institute of the National Institutes of Health. NR 24 TC 4 Z9 5 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2014 VL 37 IS 10 BP 2782 EP 2788 DI 10.2337/dc14-0284 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AR4UM UT WOS:000343582400032 PM 25048382 ER PT J AU Lipkin, EW Schwartz, AV Anderson, AM Davis, C Johnson, KC Gregg, EW Bray, GA Berkowitz, R Peters, AL Hodges, A Lewis, C Kahn, SE AF Lipkin, Edward W. Schwartz, Ann V. Anderson, Andrea M. Davis, Cralen Johnson, Karen C. Gregg, Edward W. Bray, George A. Berkowitz, Robert Peters, Anne L. Hodges, Amelia Lewis, Cora Kahn, Steven E. CA Look AHEAD Res Grp TI The Look AHEAD Trial: Bone Loss at 4-Year Follow-up in Type 2 Diabetes SO DIABETES CARE LA English DT Article ID X-RAY ABSORPTIOMETRY; OBESE OLDER-ADULTS; LIFE-STYLE INTERVENTION; WEIGHT-LOSS; MINERAL DENSITY; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; LUMBAR SPINE; EXERCISE; ROSIGLITAZONE AB OBJECTIVE To determine whether an intensive lifestyle intervention (ILI) designed to sustain weight loss and improve physical fitness in overweight or obese persons with type 2 diabetes was associated with bone loss after 4 years of follow-up. RESEARCH DESIGN AND METHODS This randomized controlled trial of intensive weight loss compared an ILI with a diabetes support and education (DSE) group among 1,309 overweight or obese subjects. Bone mineral density was assessed at baseline and after 1 year and 4 years of intervention. RESULTS ILI was effective in producing significant weight loss (5.3% vs. 1.8% in ILI and DSE, respectively; P < 0.01) and increased fitness (6.4% vs. -0.8%) at year 4. Inmen, ILI participants had a greater rate of bone loss during the first year (-1.66% vs. -0.09% per year in ILI and DSE, respectively). Differences between groups were diminished by one-half after 4 years (-0.88% vs. -0.05% per year in ILI and DSE, respectively) but remained significant (P < 0.01). The difference in rate of hip bone loss between groups over 4 years was related to increased weight loss in ILI. Among women, the rate of bone loss did not differ between ILI and DSE after 4 years. CONCLUSIONS A 4-year weight loss intervention was significantly associated with a modest increase in bone loss at the hip in men but not in women. C1 [Lipkin, Edward W.; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. [Lipkin, Edward W.; Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Schwartz, Ann V.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Anderson, Andrea M.; Davis, Cralen; Hodges, Amelia] Wake Forest Univ Hlth Sci, Div Publ Hlth Sci, Dept Biostat Sci, Winston Salem, NC USA. [Johnson, Karen C.] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. [Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Bray, George A.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA. [Berkowitz, Robert] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Peters, Anne L.] Univ So Calif, Keck Sch Med, Dept Med, Div Endocrinol, Los Angeles, CA 90033 USA. [Lewis, Cora] Univ Alabama Birmingham, Dept Prevent Med, Birmingham, AL USA. RP Lipkin, EW (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. EM ewl@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002 FU Department of Health and Human Services through National Institutes of Health [DK-57136, DK-57149, DK-56990, DK-57177, DK-57171, DK-57151, DK-57182, DK-57131, DK-57002, DK-57078, DK57154, DK-57178, DK-57219, DK-57008, DK-57135, DK-56992]; Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases; Johns Hopkins Medical Institutions Bayview General Clinical Research Center (GCRC) [M01-RR-02719]; Massachusetts General Hospital Mallinckrodt GCRC; Massachusetts Institute of Technology GCRC [M01-RR-01066]; University of Colorado Health Sciences Center GCRC [M01-RR-00051]; Clinical Nutrition Research Unit [P30-DK-48520]; University of Tennessee at Memphis GCRC [M01-RR-0021140]; University of Pittsburgh GCRC [M01-RR-000056]; Clinical Translational Research Center - Clinical and Translational Science Award [UL1-RR-024153]; National Institutes of Health [DK-046204]; VA Puget Sound Health Care System Medical Research Service; Department of Veterans Affairs; Frederic C. Bartter GCRC [M01-RR-01346] FX This study is supported by the Department of Health and Human Services through the following cooperative agreements from the National Institutes of Health: DK-57136, DK-57149, DK-56990, DK-57177, DK-57171, DK-57151, DK-57182, DK-57131, DK-57002, DK-57078, DK57154, DK-57178, DK-57219, DK-57008, DK-57135, and DK-56992. The following federal agencies have contributed support: National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; Office of Research on Women's Health; and the Centers for Disease Control and Prevention. This research was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. The Indian Health Service (IHS) provided personnel, medical oversight, and use of facilities. The opinions expressed in this article are those of the authors and do not necessarily reflect the views of the IHS or other funding sources.; Additional support was received from The Johns Hopkins Medical Institutions Bayview General Clinical Research Center (GCRC) (M01-RR-02719), the Massachusetts General Hospital Mallinckrodt GCRC and the Massachusetts Institute of Technology GCRC (M01-RR-01066), the University of Colorado Health Sciences Center GCRC (M01-RR-00051) and Clinical Nutrition Research Unit (P30-DK-48520), the University of Tennessee at Memphis GCRC (M01-RR-0021140), the University of Pittsburgh GCRC (M01-RR-000056), the Clinical Translational Research Center funded by a Clinical and Translational Science Award (UL1-RR-024153) and a National Institutes of Health grant (DK-046204), the VA Puget Sound Health Care System Medical Research Service, the Department of Veterans Affairs, and the Frederic C. Bartter GCRC (M01-RR-01346). NR 36 TC 5 Z9 5 U1 1 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2014 VL 37 IS 10 BP 2822 EP 2829 DI 10.2337/dc14-0762 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AR4UM UT WOS:000343582400037 PM 25048381 ER PT J AU Kornblit, B Maloney, DG Storer, BE Maris, MB Vindelov, L Hari, P Langston, AA Pulsipher, MA Bethge, WA Chauncey, TR Lange, T Petersen, FB Hubel, K Woolfrey, AE Flowers, MED Storb, R Sandmaier, BM AF Kornblit, Brian Maloney, David G. Storer, Barry E. Maris, Michael B. Vindelov, Lars Hari, Parameswaran Langston, Amelia A. Pulsipher, Michael A. Bethge, Wolfgang A. Chauncey, Thomas R. Lange, Thoralf Petersen, Finn B. Huebel, Kai Woolfrey, Ann E. Flowers, Mary E. D. Storb, Rainer Sandmaier, Brenda M. TI A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation SO HAEMATOLOGICA LA English DT Article ID VERSUS-HOST-DISEASE; STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; TOTAL-BODY IRRADIATION; LOW-DOSE METHOTREXATE; GVHD PROPHYLAXIS; COMPARING METHOTREXATE; CYCLOSPORINE; COMBINATION; RISK AB The study is a randomized phase II trial investigating graft-versus-host disease prophylaxis after non-myeloablative (90 mg/m(2) fludarabine and 2 Gy total body irradiation) human leukocyte antigen matched unrelated donor transplantation. Patients were randomized as follows: arm 1 - tacrolimus 180 days and mycophenolate mofetil 95 days (n=69); arm 2 - tacrolimus 150 days and mycophenolate mofetil 180 days (n=71); arm 3 - tacrolimus 150 days, mycophenolate mofetil 180 days and sirolimus 80 days (n=68). All patients had sustained engraftment. Grade II-IV acute graft-versus-host disease rates in the 3 arms were 64%, 48% and 47% at Day 150, respectively (arm 3 vs. arm 1 (hazard ratio 0.62; P=0.04). Owing to the decreased incidence of acute graft-versus-host disease, systemic steroid use was lower at Day 150 in arm 3 (32% vs. 55% in arm 1 and 49% in arm 2; overall P=0.009 by hazard ratio analysis). The Day 150 incidence of cytomegalovirus reactivation was lower in arm 3 (arm 1, 54%; arm 2, 47%; arm 3, 22%; overall P=0.002 by hazard ratio analysis). Non-relapse mortality was comparable in the three arms at two years (arm 1, 26%; arm 2, 23%; arm 3, 18%). Toxicity rates and other outcome measures were similar between the three arms. The addition of sirolimus to tacrolimus and mycophenolate mofetil is safe and associated with lower incidence of acute graft-versus-host disease and cytomegalovirus reactivation. C1 [Kornblit, Brian; Maloney, David G.; Storer, Barry E.; Woolfrey, Ann E.; Flowers, Mary E. D.; Storb, Rainer; Sandmaier, Brenda M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Maloney, David G.; Woolfrey, Ann E.; Flowers, Mary E. D.; Storb, Rainer; Sandmaier, Brenda M.] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA. [Storer, Barry E.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Maris, Michael B.] Colorado Blood Canc Inst, Denver, CO USA. [Vindelov, Lars] Univ Copenhagen, Rigshosp, DK-1168 Copenhagen, Denmark. [Hari, Parameswaran] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Langston, Amelia A.] Emory Univ, Atlanta, GA 30322 USA. [Pulsipher, Michael A.] Univ Utah, Sch Med, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA. [Bethge, Wolfgang A.] Univ Tubingen, Med Ctr, Tubingen, Germany. [Chauncey, Thomas R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Lange, Thoralf] Univ Leipzig, D-04109 Leipzig, Germany. [Petersen, Finn B.] LDS Hosp, Salt Lake City, UT USA. [Huebel, Kai] Univ Cologne, Cologne, Germany. RP Sandmaier, BM (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA. EM bsandmai@fhcrc.org OI Hari, Parameswaran/0000-0002-8800-297X FU National Institutes of Health, Bethesda, MD [CA018029, CA015704]; Danish Cancer Society [DP08135, R56-A2960-12-S2]; Froken Amalie Jorgensens Mindelegat; Anders Hasselbalchs Fond; Lundbeck Foundation [R32-A2730]; Rigshospitalet FX Research funding was provided by the National Institutes of Health, Bethesda, MD, grants, CA018029 and CA015704. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health nor its subsidiary Institutes and Centers. BK was supported by a fellowship from the Danish Cancer Society (DP08135), Froken Amalie Jorgensens Mindelegat and Anders Hasselbalchs Fond. Research funding for LV was provided by the Danish Cancer Society (R56-A2960-12-S2), the Lundbeck Foundation (R32-A2730) and Rigshospitalet. NR 40 TC 12 Z9 12 U1 0 U2 3 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD OCT 1 PY 2014 VL 99 IS 10 BP 1624 EP 1631 DI 10.3324/haematol.2014.108340 PG 8 WC Hematology SC Hematology GA AQ7ZC UT WOS:000343038500027 PM 25085357 ER PT J AU Garrido, MM Kelley, AS Paris, J Roza, K Meier, DE Morrison, RS Aldridge, MD AF Garrido, Melissa M. Kelley, Amy S. Paris, Julia Roza, Katherine Meier, Diane E. Morrison, R. Sean Aldridge, Melissa D. TI Methods for Constructing and Assessing Propensity Scores SO HEALTH SERVICES RESEARCH LA English DT Article DE Observational data/quasi-experiments; administrative data uses; patient outcomes/function ID VARIABLE SELECTION; CAUSAL INFERENCE; BALANCE; MODELS; SERVICES; BIAS; CARE AB Objectives. To model the steps involved in preparing for and carrying out propensity score analyses by providing step-by-step guidance and Stata code applied to an empirical dataset. Study Design. Guidance, Stata code, and empirical examples are given to illustrate (1) the process of choosing variables to include in the propensity score; (2) balance of propensity score across treatment and comparison groups; (3) balance of covariates across treatment and comparison groups within blocks of the propensity score; (4) choice of matching and weighting strategies; (5) balance of covariates after matching or weighting the sample; and (6) interpretation of treatment effect estimates. Empirical Application. We use data from the Palliative Care for Cancer Patients (PC4C) study, a multisite observational study of the effect of inpatient palliative care on patient health outcomes and health services use, to illustrate the development and use of a propensity score. Conclusions. Propensity scores are one useful tool for accounting for observed differences between treated and comparison groups. Careful testing of propensity scores is required before using them to estimate treatment effects. C1 [Garrido, Melissa M.; Kelley, Amy S.; Morrison, R. Sean; Aldridge, Melissa D.] James J Peters VA Med Ctr, GRECC, Bronx, NY 10468 USA. [Garrido, Melissa M.; Kelley, Amy S.; Paris, Julia; Roza, Katherine; Meier, Diane E.; Morrison, R. Sean; Aldridge, Melissa D.] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Meier, Diane E.] Icahn Sch Med Mt Sinai, Ctr Adv Palliat Care, New York, NY 10029 USA. [Morrison, R. Sean] Hertzberg Palliat Care Inst, Natl Palliat Care Res Ctr, New York, NY USA. RP Garrido, MM (reprint author), James J Peters VA Med Ctr, GRECC, Bronx, NY 10468 USA. EM melissa.garrido@mssm.edu FU NCI/NINR [5R01CA116227]; National Palliative Care Research Center; Department of Veterans Affairs HSRD CDA [11-201/CDP 12-255]; National Institute on Aging [1K23AG040774-01A1, K24 AG022345]; American Federation for Aging Research; Doris Duke Charitable Foundation Clinical Research Program FX Joint Acknowledgment/Disclosure Statement: This work was funded by NCI/NINR 5R01CA116227 (PI: Diane E. Meier) and partially supported by the National Palliative Care Research Center. Dr. Garrido is supported by Department of Veterans Affairs HSR&D CDA 11-201/CDP 12-255, Dr. Kelley is supported by National Institute on Aging (1K23AG040774-01A1) and the American Federation for Aging Research, Ms. Paris and Ms. Roza are supported by the Doris Duke Charitable Foundation Clinical Research Program, and Dr. Morrison is supported by a Mid-Career Investigator Award in Patient Oriented Research from the National Institute on Aging (K24 AG022345). Dr. Meier directs the Center to Advance Palliative Care, and Dr. Morrison directs the National Center for Palliative Care Research. The authors wish to thank Peter May and two anonymous reviewers for helpful comments on previous drafts of this paper. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 44 TC 62 Z9 64 U1 1 U2 30 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD OCT PY 2014 VL 49 IS 5 BP 1701 EP 1720 DI 10.1111/1475-6773.12182 PG 20 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AQ7OA UT WOS:000343006400017 PM 24779867 ER PT J AU Li, PL Fujimoto, K Bourguingnon, L Yukl, S Deeks, S Wong, JK AF Li, Peilin Fujimoto, Katsuya Bourguingnon, Lilly Yukl, Steven Deeks, Steven Wong, Joseph K. TI Exogenous and endogenous hyaluronic acid reduces HIV infection of CD4(+) T cells SO IMMUNOLOGY AND CELL BIOLOGY LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN-KINASE-C; SEXUAL TRANSMISSION; CD44; INHIBITOR; OPPORTUNITIES; PROLIFERATION; PROPAGATION; ACTIVATION; RECEPTORS AB Preventing mucosal transmission of HIV is critical to halting the HIV epidemic. Novel approaches to preventing mucosal transmission are needed. Hyaluronic acid (HA) is a major extracellular component of mucosa and the primary ligand for the cell surface receptor CD44. CD44 enhances HIV infection of CD4(+) T cells, but the role of HA in this process is not clear. To study this, virions were generated with CD44 (HIVCD44) or without CD44 (HIVmock). Exogenous HA reduced HIV infection of unstimulated CD4(+) T cells in a CD44-dependent manner. Conversely, hyaluronidase-mediated reduction of endogenous HA on the cell surface enhanced HIV binding to and infection of unstimulated CD4(+) T cells. Exogenous HA treatment reduced activation of protein kinase C alpha via CD44 on CD4(+) T cells during infection with HIVCD44. These results reveal new roles for HA during the interaction of HIV with CD4(+) T cells that may be relevant to mucosal HIV transmission and could be exploitable as a future strategy to prevent HIV infection. C1 [Li, Peilin; Fujimoto, Katsuya; Bourguingnon, Lilly; Yukl, Steven; Wong, Joseph K.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Li, Peilin; Yukl, Steven; Deeks, Steven; Wong, Joseph K.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. RP Li, PL (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, 4150 Clement St, San Francisco, CA 94121 USA. EM Peilin.li@ucst.edu FU National Institutes of Health [1R21AI104445-01A1, R56AI091573-01]; Department of Veterans Affairs [1 IK2 CX000520-01, 5101 BX001048] FX This work was supported by the National Institutes of Health (grants 1R21AI104445-01A1 (PL) and R56AI091573-01 (JKW)), and the Department of Veterans Affairs (1 IK2 CX000520-01 (SY) and Merit Review Award 5101 BX001048 (JKW)). NR 53 TC 4 Z9 4 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0818-9641 EI 1440-1711 J9 IMMUNOL CELL BIOL JI Immunol. Cell Biol. PD OCT PY 2014 VL 92 IS 9 BP 770 EP 780 DI 10.1038/icb.2014.50 PG 11 WC Cell Biology; Immunology SC Cell Biology; Immunology GA AR2BI UT WOS:000343388000008 PM 24957217 ER PT J AU Marcocci, C Bollerslev, J Khan, AA Shoback, DM AF Marcocci, Claudio Bollerslev, Jens Khan, Aliya Aziz Shoback, Dolores Marie TI Medical Management of Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID MILD PRIMARY HYPERPARATHYROIDISM; VITAMIN-D DEFICIENCY; PARATHYROID CELL-PROLIFERATION; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; CALCIUM INTAKE; SERUM-CALCIUM; ORAL ALENDRONATE; CONTROLLED-TRIAL; CINACALCET HCL AB Objective: Asymptomatic primary hyperparathyroidism (PHPT) is a common clinical problem. The only available definitive therapy is parathyroidectomy, which is appropriate to consider in all patients. The purpose of this report is to provide an update on calcium and vitamin D supplementation and medical management for those patients with PHPT who cannot or do not want to undergo surgery. Methods: Questions were developed by the International Task Force on PHPT. A comprehensive literature search was undertaken, and relevant articles published between 2008 and 2013 were reviewed in detail. The questions were addressed by the panel of experts, and consensus was established at the time of the workshop. Conclusions: The recommended calcium intake in patients with PHPT should follow guidelines established for all individuals. It is not recommended to limit calcium intake in patients with PHPT who do not undergo surgery. Patients with low serum 25-hydroxyvitamin D should be repleted with doses of vitamin D aiming to bring serum 25-hydroxyvitamin D levels to >= 50 nmol/L (20 ng/mL) at a minimum, but a goal of >= 75 nmol/L (30 ng/mL) also is reasonable. Pharmacological approaches are available and should be reserved for those patients in whom it is desirable to lower the serum calcium, increase BMD, or both. For the control of hypercalcemia, cinacalcet is the treatment of choice. Cinacalcet reduces serum calcium concentrations to normal in many cases, but has only a modest effect on serum PTH levels. However, bone mineral density (BMD) does not change. To improve BMD, bisphosphonate therapy is recommended. The best evidence is for the use of alendronate, which improves BMD at the lumbar spine without altering the serum calcium concentration. To reduce the serum calcium and improve BMD, combination therapy with both agents is reasonable, but strong evidence for the efficacy of that approach is lacking. C1 [Marcocci, Claudio] Univ Pisa, Dept Clin & Expt Med, I-56124 Pisa, Italy. Univ Hosp Pisa, Endocrine Unit 2, I-56124 Pisa, Italy. [Bollerslev, Jens] Univ Oslo, Sect Specialized Endocrinol, Oslo Univ Hosp, Rikshosp, N-0027 Oslo, Norway. Univ Oslo, Fac Med, N-0027 Oslo, Norway. [Khan, Aliya Aziz] McMaster Univ, Dept Med, Div Endocrinol, Hamilton, ON L8N 4A6, Canada. [Khan, Aliya Aziz] McMaster Univ, Dept Med, Div Geriatr, Hamilton, ON L8N 4A6, Canada. [Shoback, Dolores Marie] Univ Calif San Francisco, Endocrine Res Unit, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. RP Marcocci, C (reprint author), Univ Pisa, Endocrine Unit 2, Dept Clin & Expt Med, Via Paradisa 2, I-56124 Pisa, Italy. FU Amgen; NPS; Merck; Lilly FX Disclosure Summary: C.M., J.B., and D.M.S. have nothing to declare. A.A.K. received research funds from Amgen, NPS, and Merck and advisory board and speaker fees from Amgen, Merck, and Lilly. NR 70 TC 27 Z9 28 U1 1 U2 5 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD OCT PY 2014 VL 99 IS 10 BP 3607 EP 3618 DI 10.1210/jc.2014-1417 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AR2NC UT WOS:000343423300058 PM 25162668 ER PT J AU DeFronzo, RA Tripathy, D Abdul-Ghani, M Musi, N Gastaldelli, A AF DeFronzo, Ralph A. Tripathy, Devjit Abdul-Ghani, Muhammad Musi, Nicolas Gastaldelli, Amalia TI The Disposition Index Does Not Reflect beta-Cell Function in IGT Subjects Treated With Pioglitazone SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; TYPE-2 DIABETIC-PATIENTS; INSULIN-SECRETION; DOSE-RESPONSE; SENSITIVITY; CLEARANCE; METABOLISM; PREVENTION; RESISTANCE; INTOLERANCE AB Aims and Hypothesis: The insulin secretion/insulin resistance (IR) (disposition) index (Delta I/Delta G divided by IR, where Delta is change from baseline, I is insulin, and G is glucose) is commonly used as a measure of beta-cell function. This relationship is curvilinear and becomes linear when log transformed. Delta I is determined by 2 variables: insulin secretion rate (ISR) and metabolic clearance of insulin. We postulated that the characteristic curvilinear relationship would be lost if Delta plasma C-peptide (Delta CP) (instead of Delta plasma insulin) was plotted against insulin sensitivity. Methods: A total of 441 individuals with impaired glucose tolerance (IGT) from ACT NOW received an oral glucose tolerance test and were randomized to pioglitazone or placebo for 2.4 years. Results: Pioglitazone reduced IGT conversion to diabetes by 72% (P <.0001). Delta I/Delta G vs the Matsuda index of insulin sensitivity showed the characteristic curvilinear relationship. However, when Delta CP/Delta G or Delta ISR/Delta G was plotted against the Matsuda index, the curvilinear relationship was completely lost. This discordance was explained by 2 distinct physiologic effects that altered plasma insulin response in opposite directions: 1) increased ISR and 2) augmented metabolic clearance of insulin. The net result was a decline in the plasma insulin response to hyperglycemia during the oral glucose tolerance test. These findings demonstrate a physiologic control mechanism wherein the increase in ISR ensures adequate insulin delivery into the portal circulation to suppress hepatic glucose production while delivering a reduced but sufficient amount of insulin to peripheral tissues to maintain the pioglitazone-mediated improvement in insulin sensitivity without excessive hyperinsulinemia. Conclusions: These results demonstrate the validity of the disposition index when relating the plasma insulin response to insulin sensitivity but underscore the pitfall of this index when drawing conclusions about beta-cell function, because insulin secretion declined despite an increase in the plasma insulin response. C1 [DeFronzo, Ralph A.; Tripathy, Devjit; Abdul-Ghani, Muhammad; Musi, Nicolas; Gastaldelli, Amalia] Texas Diabet Inst, San Antonio, TX 78229 USA. [DeFronzo, Ralph A.; Tripathy, Devjit; Abdul-Ghani, Muhammad; Musi, Nicolas; Gastaldelli, Amalia] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [DeFronzo, Ralph A.; Tripathy, Devjit] South Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX 78229 USA. [Gastaldelli, Amalia] Inst Clin Physiol, Cardiometab Risk Unit, I-56124 Pisa, Italy. RP DeFronzo, RA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, San Antonio, TX 78229 USA. EM albarado@uthscsa.edu RI Gastaldelli, Amalia/H-3319-2014 OI Gastaldelli, Amalia/0000-0003-2594-1651 FU Takeda Pharmaceuticals North America FX This study was supported by an investigator-initiated and unrestricted research grant from Takeda Pharmaceuticals North America. Takeda played no role in the study design, data collection/analysis, or manuscript preparation/review. NR 26 TC 4 Z9 5 U1 0 U2 3 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD OCT PY 2014 VL 99 IS 10 BP 3774 EP 3781 DI 10.1210/jc.2014-1515 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AR2NC UT WOS:000343423300079 PM 24937535 ER PT J AU Gelman, SK Freund, KB Shah, VP Sarraf, D AF Gelman, Susan K. Freund, K. Bailey Shah, Vinnie P. Sarraf, David TI THE PEARL NECKLACE SIGN A Novel Spectral Domain Optical Coherence Tomography Finding in Exudative Macular Disease SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article DE neovascular age-related macular degeneration; Coats disease; diabetic macular edema; exudative maculopathy; hard exudate; lipid; retinal arterial macroaneurysm; spectral domain optical coherence tomography ID RETINAL VEIN OCCLUSION; HYPERREFLECTIVE FOCI; SD-OCT; DEGENERATION; EDEMA; ASSOCIATION; DETACHMENT; SPACES; LAYER AB Purpose:To report a novel spectral domain optical coherence tomography finding in exudative macular disease, called the pearl necklace sign.Methods:A retrospective case series of 21 eyes (20 patients) with chronic exudative maculopathy resulting from age-related macular degeneration, diabetic macular edema, branch retinal vein occlusion, retinal arterial macroaneurysm, and Coats disease. Spectral domain optical coherence tomography images were carefully evaluated and correlated with color fundus photography, near-infrared reflectance, and fluorescein angiography.Results:A unique spectral domain optical coherence tomography macular finding of hyperreflective dots in a contiguous ring around the inner wall of cystoid spaces in the outer plexiform layer of the retina that the authors refer to as the pearl necklace sign was seen in all patients. Visual acuity ranged from 20/30 to hand motions. The cystoid spaces and the hyperreflective dots resolved in certain cases after anti-vascular endothelial growth factor therapy and/or focal macular laser, but tended to recur.Conclusion:Because the pearl necklace configuration can be found adjacent to hard exudates in the outer plexiform layer, the authors speculate that the hyperreflective material is composed of lipoproteins or lipid-laden macrophages. This novel spectral domain optical coherence tomography sign gives further insight into the development and progression of hard lipoprotein exudates in exudative maculopathy. C1 [Gelman, Susan K.; Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90095 USA. [Gelman, Susan K.; Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Freund, K. Bailey; Shah, Vinnie P.] Vitreous Retina Macula Consultants New York, New York, NY USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM dsarraf@ucla.edu OI Freund, K. Bailey/0000-0002-7888-9773 FU Genentech, Inc; Regeneron Pharmaceuticals, Inc; Heidelberg Engineering; Optos plc; Regeneron Pharmaceuticals, Inc (IST grant) FX Financial disclosures are as follows: KBF: Genentech, Inc (advisor); Regeneron Pharmaceuticals, Inc (advisor); Heidelberg Engineering (advisor); Optos plc (advisor); DS: Heidelberg Engineering (speaker), Regeneron Pharmaceuticals, Inc (IST grant). NR 29 TC 7 Z9 7 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD OCT PY 2014 VL 34 IS 10 BP 2088 EP 2095 DI 10.1097/IAE.0000000000000207 PG 8 WC Ophthalmology SC Ophthalmology GA AQ8BX UT WOS:000343048200030 PM 25020214 ER PT J AU Baker, JF Pullman-Mooar, S Ibrahim, S AF Baker, Joshua F. Pullman-Mooar, Sally Ibrahim, Said TI Management of rheumatoid arthritis Incorporating patient perceptions and objective measures SO RHEUMATOLOGY LA English DT Editorial Material ID DISEASE-ACTIVITY C1 [Baker, Joshua F.; Pullman-Mooar, Sally] Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA. [Baker, Joshua F.] Univ Penn, Div Epidemiol, Philadelphia, PA 19104 USA. [Baker, Joshua F.; Pullman-Mooar, Sally] Philadelphia VA Med Ctr, Div Rheumatol, Philadelphia, PA USA. [Ibrahim, Said] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Baker, JF (reprint author), Univ Penn, Div Rheumatol, Hosp Univ Penn, 8 Penn Tower Bldg,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM bakerjo@uphs.upenn.edu FU NIAMS NIH HHS [K24 AR055259] NR 10 TC 2 Z9 3 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-0324 EI 1462-0332 J9 RHEUMATOLOGY JI RHEUMATOLOGY PD OCT PY 2014 VL 53 IS 10 BP 1721 EP 1722 PG 2 WC Rheumatology SC Rheumatology GA AR2MU UT WOS:000343422400001 PM 24505124 ER PT J AU Singh, JA Lewallen, DG AF Singh, Jasvinder A. Lewallen, David G. TI Predictors of pain medication use for arthroplasty pain after revision total knee arthroplasty SO RHEUMATOLOGY LA English DT Article DE total knee replacement; pain medication; narcotic; NSAIDs; predictors; revision TKA; opioid ID QUALITY-OF-LIFE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TOTAL HIP-ARTHROPLASTY; INPATIENT REHABILITATION; UNITED-STATES; POOR PAIN; OUTCOMES; NSAIDS; RISK; REPLACEMENT AB Objective. Our objective was to study the use of pain medications for persistent knee pain and their predictors after revision total knee arthroplasty (TKA). Methods. We examined whether demographic (gender, age) and clinical characteristics [BMI, co-morbidity measured by the Deyo-Charlson index (a 5-point increase), anxiety and depression] predict the use of NSAIDs and narcotic pain medications 2 and 5 years after revision TKA. Multivariable logistic regression adjusted for these predictors as well as operative diagnosis, American Society of Anesthesiologists class and distance from the medical centre. Results. A total of 1533 patients responded to the 2-year questionnaire and 881 responded to the 5-year questionnaire. NSAID use was reported by 13.4% (206/1533) of patients at 2 years and 16.7% (147/881) at 5 years. Narcotic medication use was reported by 5.4% (83/1533) of patients at 2 years and 5.9% (52/881) at 5 years. Significant predictors of the use of NSAIDs for index TKA pain at 2 and 5 years were age >60-70 years [odds ratio (OR) 0.62 (95% CI 0.39, 0.98) and 0.46 (0.25, 0.85)] compared with age <= 60 years and a higher Deyo-Charlson index [OR 0.51 (95% CI 0.28, 0.93)] per 5-point increase at 5-year after revision TKA. Significant predictors of narcotic pain medication use for index TKA pain were age >60-70 years [OR 0.41 (0.21, 0.78)] and >70-80 years [0.40 (95% CI 0.22, 0.73)] at 2 years and depression [OR 4.58 (95% CI 1.58, 13.18)] at 5 years. Conclusion. Younger age and depression were risk factors for the use of NSAIDs and narcotic pain medications for index TKA pain at 2- and 5-years after revision TKA. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA. [Singh, Jasvinder A.; Lewallen, David G.] Univ Alabama Birmingham, Dept Med, Sch Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Lewallen, David G.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Dept Med, Sch Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Mayo Clinic Orthopedic Surgery research funds, National Institutes of Health (NIH) Clinical Translational Science Award [1 KL2 RR024151-01]; Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs); National Institute of Aging; National Cancer Institute FX Funding: This material is the result of work supported by research grants from the Mayo Clinic Orthopedic Surgery research funds, National Institutes of Health (NIH) Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research) and the resources and use of facilities at the Birmingham VA Medical Center, Birmingham, AL, USA. J.A.S. is also supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs), National Institute of Aging and National Cancer Institute. NR 37 TC 6 Z9 6 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-0324 EI 1462-0332 J9 RHEUMATOLOGY JI RHEUMATOLOGY PD OCT PY 2014 VL 53 IS 10 BP 1752 EP 1758 DI 10.1093/rheumatology/ket443 PG 7 WC Rheumatology SC Rheumatology GA AR2MU UT WOS:000343422400008 PM 24459220 ER PT J AU Driver, TH Shlipak, MG Katz, R Goldenstein, L Sarnak, MJ Hoofnagle, AN Siscovick, DS Kestenbaum, B de Boer, IH Ix, JH AF Driver, Todd H. Shlipak, Michael G. Katz, Ronit Goldenstein, Leonard Sarnak, Mark J. Hoofnagle, Andrew N. Siscovick, David S. Kestenbaum, Bryan de Boer, Ian H. Ix, Joachim H. TI Low Serum Bicarbonate and Kidney Function Decline: The Multi-Ethnic Study of Atherosclerosis (MESA) SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Serum bicarbonate; metabolic acidosis; chronic kidney disease (CKD); kidney function; renal disease; disease progression; kidney disease trajectory ID GLOMERULAR-FILTRATION-RATE; DIETARY ACID LOAD; METABOLIC-ACIDOSIS; CKD; DISEASE; ABNORMALITIES; ASSOCIATION; MORTALITY; OUTCOMES AB Background: Among populations with established chronic kidney disease (CKD), metabolic acidosis is associated with more rapid progression of kidney disease. The association of serum bicarbonate concentrations with early declines in kidney function is less clear. Study Design: Retrospective cohort study. Setting & Participants: 5,810 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) with a baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m(2) using the CKD-EPI (CKD Epidemiology Collaboration) creatinine-cystatin C equation. Predictors: Serum bicarbonate concentrations. Outcomes: Rapid kidney function decline (eGFR decline > 5% per year) and incident reduced eGFR (eGFR < 60 mL/min/1.73 m(2) with minimum rate of eGFR loss of 1 mL/min/1.73 m(2) per year). Results: Average bicarbonate concentration was 23.2 +/- 1.8 mEq/L. 1,730 (33%) participants had rapid kidney function decline, and 487 had incident reduced eGFR during follow-up. Each 1-SD lower baseline bicarbonate concentration was associated with 12% higher adjusted odds of rapid kidney function decline (95% CI, 6%-20%) and higher risk of incident reduced eGFR (adjusted incidence rate ratio, 1.11; 95% CI, 1.03-1.20) in models adjusting for demographics, baseline eGFR, albuminuria, and CKD risk factors. The OR for the associations of bicarbonate level, 21 mEq/L relative to 23-24 mEq/L was 1.35 (95% CI, 1.05-1.73) for rapid kidney function decline, and the incidence rate ratio was 1.16 (95% CI, 0.83-1.62) for incident reduced eGFR. Limitations: Cause of metabolic acidosis cannot be determined in this study. Conclusions: Lower serum bicarbonate concentrations are associated independently with rapid kidney function decline independent of eGFR or albuminuria in community-living persons with baseline eGFR. 60 mL/min/1.73 m(2). If confirmed, our findings suggest that metabolic acidosis may indicate either early kidney disease that is not captured by eGFR or albuminuria or may have a causal role in the development of eGFR, 60 mL/min/1.73 m(2). (C) 2014 by the National Kidney Foundation, Inc. C1 [Driver, Todd H.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Gen Internal Med, San Francisco, CA USA. [Katz, Ronit; Hoofnagle, Andrew N.; Siscovick, David S.; Kestenbaum, Bryan; de Boer, Ian H.] Univ Washington, Div Nephrol, Kidney Res Inst, Seattle, WA USA. [Goldenstein, Leonard; Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, San Diego, CA 92161 USA. [Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. [Siscovick, David S.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Siscovick, David S.] Univ Washington, Dept Med, Seattle, WA USA. [Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Ix, Joachim H.] Univ Calif San Diego, Dept Family & Prevent Med, Div Prevent Med, San Diego, CA 92161 USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA USA. RP Ix, JH (reprint author), Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, 3350 La Jolla Village Dr,Mail Code 111-H, San Diego, CA 92161 USA. EM joeix@ucsd.edu FU National Institute on Aging [5R01AG027002-07]; National Institute of Diabetes and Digestive and Kidney Diseases [1R01DK098234-01A1]; UCSF-CTSI [TL1 TR000144]; National Heart, Lung, and Blood Institute; National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169]; National Center for Research Resources [UL1-TR-000040, UL1-TR-001079]; Clinical and Translational Science Award [UL1-RR-024156] FX Support: Drs Shlipak and Sarnak are supported by grant 5R01AG027002-07 from the National Institute on Aging; Drs Ix and Shlipak, by grant 1R01DK098234-01A1 from the National Institute of Diabetes and Digestive and Kidney Diseases; and Dr Driver, by grant TL1 TR000144 from UCSF-CTSI. MESA and the MESA SHARe project are conducted and supported by the National Heart, Lung, and Blood Institute in collaboration with MESA investigators; support for MESA is provided by contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, and N01-HC-95169 from the National Heart, Lung, and Blood Institute: by grants UL1-TR-000040 and UL1-TR-001079 from the National Center for Research Resources, and Clinical and Translational Science Award UL1-RR-024156. None of the funding agencies had any role in the study design, collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication. NR 28 TC 24 Z9 25 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD OCT PY 2014 VL 64 IS 4 BP 534 EP 541 DI 10.1053/j.ajkd.2014.05.008 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA AQ4CN UT WOS:000342739900012 PM 24953891 ER PT J AU Goldenstein, L Driver, TH Fried, LF Rifkin, DE Patel, KV Yenchek, RH Harris, TB Kritchevsky, SB Newman, AB Sarnak, MJ Shlipak, MG Ix, JH AF Goldenstein, Leonard Driver, Todd H. Fried, Linda F. Rifkin, Dena E. Patel, Kushang V. Yenchek, Robert H. Harris, Tamara B. Kritchevsky, Stephen B. Newman, Anne B. Sarnak, Mark J. Shlipak, Michael G. Ix, Joachim H. CA Hlth ABC Study Investigators TI Serum Bicarbonate Concentrations and Kidney Disease Progression in Community-Living Elders: The Health, Aging, and Body Composition (Health ABC) Study SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article ID GLOMERULAR-FILTRATION-RATE; INJURY MOLECULE-1 KIM-1; METABOLIC-ACIDOSIS; SODIUM-BICARBONATE; FUNCTION DECLINE; LIPOCALIN NGAL; RENAL BIOPSY; OLDER-ADULTS; CKD; RISK AB Background: In populations with prevalent chronic kidney disease (CKD), lower serum bicarbonate levels are associated with more rapid CKD progression, but whether lower bicarbonate levels also are associated with risk of incident estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m 2 and CKD progression among community-living persons with predominantly preserved kidney function is unknown. Study Design: Longitudinal observational cohort study. Setting & Participants: Well-functioning community-living elders aged 70-79 years at inception. Predictor: Serum bicarbonate level measured at the time of collection by arterialized venous blood sample using an arterial blood gas analyzer. Outcomes: Change in eGFR over 7 years, and new eGFR, 60 mL/min/1.73 m(2) with a rate of loss of at least 1 mL/min/1.73 m(2) per year. Measurements: Linear and logistic regressions were used to evaluate associations of baseline serum bicarbonate level with change in eGFR and incident eGFR < 60 mL/min/1.73 m(2). Results: At baseline, mean eGFR was 84 +/- 16 (SD) mL/min/1.73 m(2), and serum bicarbonate level was 25.2 +/- 1.9 mmol/L. Compared with participants with higher bicarbonate concentrations (23.0-28.0 mmol/L), those with bicarbonate concentrations < 23 mmol/L (n = 85 [8%]) lost eGFR 0.55 (95% CI, 0.13-0.97) mL/min/1.73 m(2) per year faster inmodels adjusted for demographics, CKDrisk factors, baseline eGFR, and urinealbumin-creatinine ratio. Among the 989 (92%) participantswith baseline eGFRs > 60 mL/min/1.73 m(2), 252 (25%) developed incident eGFRs < 60 mL/min/1.73 m(2) at follow-up. Adjusting for the same covariates, participants with bicarbonate concentrations, 23 mmol/L had nearly 2-fold greater odds of incident eGFRs < 60 mL/min/1.73 m(2) (OR, 1.72; 95% CI, 0.97-3.07) compared with those with higher bicarbonate concentrations. Limitations: Only 2 measurements of kidney function separated by 7 years and loss to follow-up due to intervening mortality in this elderly population. Conclusions: Lower serum bicarbonate concentrations are associated independently with decline in eGFR and incident eGFR < 60 mL/min/1.73 m(2) in community-living older persons. If confirmed, serum bicarbonate levels may give insight into kidney tubule health in persons with preserved eGFRs and suggest a possible new target for intervention to prevent CKD development. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. C1 [Goldenstein, Leonard; Rifkin, Dena E.; Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, San Diego, CA 92161 USA. [Goldenstein, Leonard; Rifkin, Dena E.; Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA USA. [Driver, Todd H.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Fried, Linda F.] Vet Affairs Hosp, Nephrol Sect, Pittsburgh, PA USA. [Fried, Linda F.] Univ Pittsburgh, Dept Med, Div Nephrol, Pittsburgh, PA USA. [Fried, Linda F.; Newman, Anne B.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Rifkin, Dena E.; Ix, Joachim H.] Univ Calif San Diego, Dept Family & Prevent Med, Div Prevent Med, San Diego, CA 92161 USA. [Patel, Kushang V.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. [Yenchek, Robert H.] Univ Utah, Dept Med, Div Nephrol, Salt Lake City, UT 84112 USA. [Harris, Tamara B.] NIA, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA. [Kritchevsky, Stephen B.] Wake Forest Sch Med, Sticht Ctr Aging, Winston Salem, NC USA. [Sarnak, Mark J.] Tufts Med Ctr, Dept Med, Div Nephrol, Boston, MA USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Ix, JH (reprint author), Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, 3350 La Jolla Village Dr,Mail Code 111-H, San Diego, CA 92161 USA. EM joeix@ucsd.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU National Institute of Diabetes and Digestive and Kidney Diseases [R01DK098234, T32DK069263]; National Institute on Aging [R01AG 027002, R01-AG028050, N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; National Institute of Nursing Research [R01-NR012459]; National Institutes of Health, NIA FX This research was supported by the National Institute of Diabetes and Digestive and Kidney Diseases by grants R01DK098234 (Drs Ix and Shlipak) and T32DK069263 (Dr Goldenstein); the National Institute on Aging by grants R01AG 027002 (Dr Sarnak) and R01-AG028050 (Dr Strotmeyer) and contracts N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106; the National Institute of Nursing Research by grant R01-NR012459 (Dr Albert); and the Intramural Research Program of the National Institutes of Health, NIA. The funders of this study had no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication. NR 33 TC 16 Z9 17 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD OCT PY 2014 VL 64 IS 4 BP 542 EP 549 DI 10.1053/j.ajkd.2014.05.009 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA AQ4CN UT WOS:000342739900013 PM 24953890 ER PT J AU Lang, JS Scherzer, R Tien, PC Parikh, CR Anastos, K Estrella, MM Abraham, AG Sharma, A Cohen, MH Butch, AW Nowicki, M Grunfeld, C Shlipak, MG AF Lang, Joshua Scherzer, Rebecca Tien, Phyllis C. Parikh, Chirag R. Anastos, Kathryn Estrella, Michelle M. Abraham, Alison G. Sharma, Anjali Cohen, Mardge H. Butch, Anthony W. Nowicki, Marek Grunfeld, Carl Shlipak, Michael G. TI Serum Albumin and Kidney Function Decline in HIV-Infected Women SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Albumin; kidney function; HIV (human immunodeficiency virus); incident reduced estimated; glomerular filtration rate (eGFR); albuminuria; disease trajectory; chronic kidney disease (CKD) progression ID ALL-CAUSE MORTALITY; CYSTATIN-C; DIALYSIS PATIENTS; INTERAGENCY HIV; RENAL-DISEASE; RISK-FACTORS; INFLAMMATION; PROGRESSION; HYPOALBUMINEMIA; INDIVIDUALS AB Background: Serum albumin concentrations are a strong predictor of mortality and cardiovascular disease in human immunodeficiency virus (HIV)-infected individuals. We studied the longitudinal associations between serum albumin levels and kidney function decline in a population of HIV-infected women. Study Design: Retrospective cohort analysis. Setting & Participants: Study participants were recruited from the Women's Interagency HIV Study (WIHS), a large observational study designed to understand risk factors for the progression of HIV infection in women living in urban communities. 908 participants had baseline assessment of kidney function and 2 follow-up measurements over an average of 8 years. Predictor: The primary predictor was serum albumin concentration. Outcomes: We examined annual change in kidney function. Secondary outcomes included rapid kidney function decline and incident reduced estimated glomerular filtration rate (eGFR). Measurements: Kidney function decline was determined by cystatin C-based (eGFR(cys)) and creatinine-based eGFR (eGFR(cr)) at baseline and follow-up. Each model was adjusted for kidney disease and HIV-related risk factors using linear and relative risk regression. Results: After multivariate adjustment, each 0.5-g/dL decrement in baseline serum albumin concentration was associated with a 0.56-mL/min faster annual decline in eGFR(cys) (P < 0.001), which was attenuated only slightly to 0.55 mL/min/1.73 m(2) after adjustment for albuminuria. Results were similar whether using eGFR(cys) or eGFR(cr). In adjusted analyses, each 0.5-g/dL lower baseline serum albumin level was associated with a 1.71-fold greater risk of rapid kidney function decline (P < 0.001) and a 1.72-fold greater risk of incident reduced eGFR (P < 0.001). Limitations: The cohort is composed of only female participants from urban communities within the United States. Conclusions: Lower serum albumin levels were associated strongly with kidney function decline and incident reduced eGFRs in HIV-infected women independent of HIV disease status, body mass index, and albuminuria. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Lang, Joshua; Tien, Phyllis C.; Grunfeld, Carl; Shlipak, Michael G.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Scherzer, Rebecca] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Tien, Phyllis C.; Grunfeld, Carl; Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Parikh, Chirag R.] Yale Univ, Dept Med, Nephrol Sect, New Haven, CT 06520 USA. [Parikh, Chirag R.] Yale Univ, Program Appl Translat Res, New Haven, CT USA. [Anastos, Kathryn] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Anastos, Kathryn] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [Estrella, Michelle M.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Abraham, Alison G.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Sharma, Anjali] Suny Downstate Med Ctr, Dept Med, Div Infect Dis, Brooklyn, NY 11203 USA. [Cohen, Mardge H.] Stroger Hosp, Dept Med, Chicago, IL USA. [Cohen, Mardge H.] Rush Univ, Dept Med, Chicago, IL 60612 USA. [Butch, Anthony W.] Univ Calif Los Angeles, Clin Immunol Res Lab, Los Angeles, CA USA. [Nowicki, Marek] Univ So Calif, Los Angeles, CA USA. RP Shlipak, MG (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 111A1, San Francisco, CA 94121 USA. EM michael.shlipak@ucsf.edu FU National Institute on Aging [1R03AG034871-01, 5R01AG034853-04] FX Support: This study was supported by the National Institute on Aging (grants 1R03AG034871-01 [Principal Investigator (PI), Dr Shlipak] and 5R01AG034853-04 [PI, Dr Shlipak]). NR 26 TC 1 Z9 1 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD OCT PY 2014 VL 64 IS 4 BP 584 EP 591 DI 10.1053/j.ajkd.2014.05.015 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA AQ4CN UT WOS:000342739900018 PM 25059222 ER PT J AU Johansen, KL Dalrymple, LS Delgado, C Kaysen, GA Kornak, J Grimes, B Chertow, GM AF Johansen, Kirsten L. Dalrymple, Lorien S. Delgado, Cynthia Kaysen, George A. Kornak, John Grimes, Barbara Chertow, Glenn M. TI Comparison of Self-report-Based and Physical Performance-Based Frailty Definitions Among Patients Receiving Maintenance Hemodialysis SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Frailty; physical performance; self-reported function; hemodialysis; physical activity; physical function; end-stage renal disease (ESRD) ID STAGE RENAL-DISEASE; BODY-COMPOSITION; WOMENS HEALTH; OLDER-ADULTS; PHENOTYPE; MORTALITY; CONSENSUS AB Background: A well-accepted definition of frailty includes measurements of physical performance, which may limit its clinical utility. Study Design: In a cross-sectional study, we compared prevalence and patient characteristics based on a frailty definition that uses self-reported function to the classic performance-based definition and developed a modified self-report-based definition. Setting & Participants: Prevalent adult patients receiving hemodialysis in 14 centers around San Francisco and Atlanta in 2009-2011. Index Tests: Self-report-based frailty definition in which a score lower than 75 on the Physical Function scale of the 36-Item Short Form Health Survey (SF-36) was substituted for gait speed and grip strength in the classic definition; modified self-report definition with optimized Physical Function score cutoff points derived in a development (one-half) cohort and validated in the other half. Reference Test: Performance-based frailty defined as 3 of the following: weight loss, weakness, exhaustion, low physical activity, and slow gait speed. Results: 387 (53%) patients were frail based on self-reported function, of whom 209 (29% of the cohort) met the performance-based definition. Only 23 (3%) met the performance-based definition of frailty only. The self-report definition had 90% sensitivity, 64% specificity, 54% positive predictive value, 93% negative predictive value, and 72.5% overall accuracy. Intracellular water per kilogram of body weight and serum albumin, prealbumin, and creatinine levels were highest among nonfrail individuals, intermediate among those who were frail by self-report, and lowest among those who also were frail by performance. Age, percentage of body fat, and C-reactive protein level followed an opposite pattern. The modified self-report definition had better accuracy (84%; 95% CI, 79%-89%) and superior specificity (88%) and positive predictive value (67%). Limitations: Our study did not address prediction of outcomes. Conclusions: Patients who meet the self-report-based but not the performance-based definition of frailty may represent an intermediate phenotype. A modified self-report definition can improve the accuracy of a questionnaire-based method of defining frailty. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Johansen, Kirsten L.; Dalrymple, Lorien S.; Delgado, Cynthia; Kaysen, George A.; Kornak, John; Grimes, Barbara; Chertow, Glenn M.] US Renal Data Syst, Nutr Special Studies Ctr, San Francisco, CA USA. [Johansen, Kirsten L.; Delgado, Cynthia] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94121 USA. [Johansen, Kirsten L.; Delgado, Cynthia] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA. [Johansen, Kirsten L.; Kornak, John; Grimes, Barbara] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. [Dalrymple, Lorien S.; Kaysen, George A.] Univ Calif Davis, Univ Calif San Francisco, Div Nephrol, Davis, CA 95616 USA. [Chertow, Glenn M.] Stanford Univ, Sch Med, Div Nephrol, Palo Alto, CA 94304 USA. RP Johansen, KL (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Nephrol Sect, 111J,4150 Clement St, San Francisco, CA 94121 USA. EM kirsten.johansen@ucsf.edu FU National Institutes of Health [N01-DK-0005, K23 DK093584] FX Support: This work was supported by the National Institutes of Health (contract N01-DK-0005 to Dr Johansen and K23 DK093584 to Dr Dalrymple). The interpretation and reporting of the data presented here are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government. NR 19 TC 18 Z9 18 U1 0 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD OCT PY 2014 VL 64 IS 4 BP 600 EP 607 DI 10.1053/j.ajkd.2014.03.016 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA AQ4CN UT WOS:000342739900020 PM 24793033 ER PT J AU Deodhar, A Reveille, JD van den Bosch, F Braun, J Burgos-Vargas, R Caplan, L Clegg, DO Colbert, RA Gensler, LS van der Heijde, D van der Horst-Bruinsma, IE Inman, RD Maksymowych, WP Mease, PJ Raychaudhuri, S Reimold, A Rudwaleit, M Sieper, J Weisman, MH Landewe, RBM AF Deodhar, Atul Reveille, John D. van den Bosch, Filip Braun, Juergen Burgos-Vargas, Ruben Caplan, Liron Clegg, Daniel O. Colbert, Robert A. Gensler, Lianne S. van der Heijde, Desiree van der Horst-Bruinsma, Irene E. Inman, Robert D. Maksymowych, Walter P. Mease, Philip J. Raychaudhuri, Siba Reimold, Andreas Rudwaleit, Martin Sieper, Joachim Weisman, Michael H. Landewe, Robert B. M. TI The Concept of Axial Spondyloarthritis SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID SOCIETY CLASSIFICATION CRITERIA; PLACEBO-CONTROLLED TRIAL; ANKYLOSING-SPONDYLITIS; DIAGNOSTIC-CRITERIA; DOUBLE-BLIND; SPONDYLARTHRITIS; EFFICACY; SAFETY; PREVALENCE C1 [Deodhar, Atul] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [van den Bosch, Filip] Ghent Univ Hosp, Ghent, Belgium. [Braun, Juergen] Rheumazentrum Ruhrgebiet, Herne, Germany. [Burgos-Vargas, Ruben] Hosp Gen Mexico City, Mexico City, DF, Mexico. [Burgos-Vargas, Ruben] Univ Nacl Autonoma Mexico, Mexico City 04510, DF, Mexico. [Caplan, Liron] Univ Colorado, Denver, CO 80202 USA. [Caplan, Liron] Denver VA Med Ctr, Denver, CO USA. [Clegg, Daniel O.] Univ Utah, Med Ctr, Salt Lake City, UT USA. [Colbert, Robert A.] NIAMSD, NIH, Bethesda, MD 20892 USA. [Gensler, Lianne S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [van der Heijde, Desiree] Leiden Univ, Med Ctr, Leiden, Netherlands. [van der Horst-Bruinsma, Irene E.] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands. [Inman, Robert D.] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada. [Inman, Robert D.] Univ Toronto, Toronto, ON, Canada. [Maksymowych, Walter P.] Alberta Heritage Fdn Med Res, Edmonton, AB, Canada. [Maksymowych, Walter P.] Univ Alberta, Edmonton, AB, Canada. [Mease, Philip J.] Seattle Rheumatol Associates, Seattle, WA USA. [Raychaudhuri, Siba] Univ Calif Davis, Sacramento, CA 95817 USA. [Reimold, Andreas] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Rudwaleit, Martin; Sieper, Joachim] Charite, Campus Benjamin Franklin, D-13353 Berlin, Germany. [Weisman, Michael H.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Landewe, Robert B. M.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands. [Landewe, Robert B. M.] Univ Amsterdam, Amsterdam, Netherlands. RP Deodhar, A (reprint author), Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, OP09,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM deodhara@ohsu.edu FU UCB; Novartis; AbbVie; Pfizer; MSD; Amgen; Celgene; AbbVie (Abbott); Bristol-Myers Squibb; Boehringer; Celltrion; Centocor; Chugai; EBEWE Pharma; Medac; MSD (Schering-Plough); Mundipharma; Pfizer (Wyeth); Roche; Sanofi-Aventis; Janssen; AstraZeneca; Augunex; Covagen; Daiichi; Eli Lilly; Galapagos NV; GlaxoSmithKline; Janssen Biologics; Merck; Novo Nordisk; Otsuka; Vertex; Quest; Biogen Idec; Crescendo; Genentech; Lilly; Abbott; Wyeth FX Dr. Deodhar has received consulting fees, speaking fees, and/or honoraria from UCB, Novartis, AbbVie, Pfizer, and MSD (less than $10,000 each), has served as an expert witness on behalf of UCB and AbbVie, and has received research grants from UCB, AbbVie, Novartis, Pfizer, and Amgen. Dr. van den Bosch has received consulting fees, speaking fees, and/or honoraria from AbbVie, Celgene, MSD, Pfizer, and UCB (less than $10,000 each). Dr. Braun has received consulting fees, speaking fees, and/or honoraria from AbbVie (Abbott), Amgen, Bristol-Myers Squibb, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, and UCB (less than $10,000 each). Dr. Burgos-Vargas has received consulting fees, speaking fees, and/or honoraria from AbbVie, Bristol-Myers Squibb, Janssen, Pfizer, Roche, and UCB (less than $10,000 each). Dr. Clegg has received consulting fees, speaking fees, and/or honoraria from Abbott (less than $10,000). Dr. Gensler has received consulting fees from UCB and AbbVie (less than $10,000 each). Dr. van der Heijde has received consulting fees, speaking fees, and/or honoraria from AbbVie, Amgen, AstraZeneca, Augunex, Bristol-Myers Squibb, Celgene, Chugai, Covagen, Daiichi, Eli Lilly, Galapagos NV, GlaxoSmithKline, Janssen Biologics, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Vertex (less than $10,000 each) and is the director of Imaging Rheumatology BV. Dr. Inman has received consulting fees from AbbVie, Amgen, Janssen, Pfizer, and UCB (less than $10,000 each). Dr. Maksymowych has received consulting fees, speaking fees, and/or honoraria from Pfizer, Eli Lilly, Merck, Janssen, and Quest (less than $10,000 each) and from AbbVie and UCB (more than $10,000 each). Dr. Mease has received consulting fees, speaking fees, and/or honoraria from Biogen Idec, Celgene, Covagen, Crescendo, Genentech, Janssen, Lilly, Merck, Novartis, and Vertex (less than $10,000 each) and from AbbVie, Amgen, Bristol-Myers Squibb, Pfizer, and UCB (more than $10,000 each). Dr. Raychaudhuri has received speaking fees or honoraria from Abbott, Amgen, and UCB (less than $10,000 each). Dr. Reimold has received consulting fees, speaking fees, and/or honoraria from UCB (less than $10,000). Dr. Rudwaleit has received consulting fees, speaking fees, and/or honoraria from AbbVie, Bristol-Myers Squibb, MSD, Pfizer, Roche, UCB, and Janssen (less than $10,000 each) and has served as an expert witness on behalf of UCB. Dr. Sieper has received consulting fees, speaking fees, and/or honoraria from AbbVie, Pfizer, Merck, UCB, and Novartis (less than $10,000 each). Dr. Weisman has received consulting fees from UCB (less than $10,000). Dr. Landewe has received consulting fees, speaking fees, and/or honoraria from AbbVie, Pfizer, UCB, Amgen, Wyeth, Merck, Novartis, and Janssen (less than $10,000 each) and is director of Rheumatology Consultancy BV. NR 23 TC 28 Z9 30 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2014 VL 66 IS 10 BP 2649 EP 2656 DI 10.1002/art.38776 PG 8 WC Rheumatology SC Rheumatology GA AQ4DZ UT WOS:000342744300001 PM 25154344 ER PT J AU Rasmussen-Torvik, LJ Stallings, SC Gordon, AS Almoguera, B Basford, MA Bielinski, SJ Brautbar, A Brilliant, MH Carrell, DS Connolly, JJ Crosslin, DR Doheny, KF Gallego, CJ Gottesman, O Kim, DS Leppig, KA Li, R Lin, S Manzi, S Mejia, AR Pacheco, JA Pan, V Pathak, J Perry, CL Peterson, JF Prows, CA Ralston, J Rasmussen, LV Ritchie, MD Sadhasivam, S Scott, SA Smith, M Vega, A Vinks, AA Volpi, S Wolf, WA Bottinger, E Chisholm, RL Chute, CG Haines, JL Harley, JB Keating, B Holm, IA Kullo, IJ Jarvik, GP Larson, EB Manolio, T McCarty, CA Nickerson, DA Scherer, SE Williams, MS Roden, DM Denny, JC AF Rasmussen-Torvik, L. J. Stallings, S. C. Gordon, A. S. Almoguera, B. Basford, M. A. Bielinski, S. J. Brautbar, A. Brilliant, M. H. Carrell, D. S. Connolly, J. J. Crosslin, D. R. Doheny, K. F. Gallego, C. J. Gottesman, O. Kim, D. S. Leppig, K. A. Li, R. Lin, S. Manzi, S. Mejia, A. R. Pacheco, J. A. Pan, V. Pathak, J. Perry, C. L. Peterson, J. F. Prows, C. A. Ralston, J. Rasmussen, L. V. Ritchie, M. D. Sadhasivam, S. Scott, S. A. Smith, M. Vega, A. Vinks, A. A. Volpi, S. Wolf, W. A. Bottinger, E. Chisholm, R. L. Chute, C. G. Haines, J. L. Harley, J. B. Keating, B. Holm, I. A. Kullo, I. J. Jarvik, G. P. Larson, E. B. Manolio, T. McCarty, C. A. Nickerson, D. A. Scherer, S. E. Williams, M. S. Roden, D. M. Denny, J. C. TI Design and Anticipated Outcomes of the eMERGE-PGx Project: A Multicenter Pilot for Preemptive Pharmacogenomics in Electronic Health Record Systems SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Article ID GENOME-WIDE ASSOCIATION; MEDICAL-RECORDS; PERSONALIZED MEDICINE; GENETIC-VARIANTS; RESEARCH NETWORK; AFRICAN-AMERICANS; EXTRACTION SYSTEM; PHENOME-WIDE; IMPLEMENTATION; CONSORTIUM AB We describe here the design and initial implementation of the eMERGE-PGx project. eMERGE-PGx, a partnership of the Electronic Medical Records and Genomics Network and the Pharmacogenomics Research Network, has three objectives: (i) to deploy PGRNseq, a next-generation sequencing platform assessing sequence variation in 84 proposed pharmacogenes, in nearly 9,000 patients likely to be prescribed drugs of interest in a 1- to 3-year time frame across several clinical sites; (ii) to integrate well-established clinically validated pharmacogenetic genotypes into the electronic health record with associated clinical decision support and to assess process and clinical outcomes of implementation; and (iii) to develop a repository of pharmacogenetic variants of unknown significance linked to a repository of electronic health record-based clinical phenotype data for ongoing pharmacogenomics discovery. We describe site-specific project implementation and anticipated products, including genetic variant and phenotype data repositories, novel variant association studies, clinical decision support modules, clinical and process outcomes, approaches to managing incidental findings, and patient and clinician education methods. C1 [Rasmussen-Torvik, L. J.; Rasmussen, L. V.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. [Stallings, S. C.] Vanderbilt Inst Clin & Translat Res, Nashville, TN USA. [Gordon, A. S.; Crosslin, D. R.; Kim, D. S.; Nickerson, D. A.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Almoguera, B.; Connolly, J. J.; Keating, B.] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA. [Bielinski, S. J.] Mayo Clin, Dept Hlth Sci Res, Div Epidemiol, Rochester, MN USA. [Brautbar, A.; Brilliant, M. H.] Marshfield Clin Res Fdn, Ctr Human Genet, Marshfield, WI USA. [Carrell, D. S.; Leppig, K. A.; Ralston, J.; Larson, E. B.] Grp Hlth Res Inst, Seattle, WA USA. [Doheny, K. F.] Johns Hopkins Univ, Sch Med, Inst Med Genet, Ctr Inherited Dis Res, Baltimore, MD USA. [Gallego, C. J.; Jarvik, G. P.] Univ Washington, Div Med Genet, Seattle, WA 98195 USA. [Gottesman, O.; Mejia, A. R.; Bottinger, E.] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA. [Li, R.; Volpi, S.; Manolio, T.] NHGRI, Div Genom Med, Bethesda, MD 20892 USA. [Lin, S.] Marshfield Clin Res Fdn, Biomed Informat Res Ctr, Marshfield, WI USA. [Manzi, S.; Perry, C. L.; Wolf, W. A.] Boston Childrens Hosp, Div Genet & Genom, Boston, MA USA. [Pacheco, J. A.; Pan, V.; Smith, M.; Chisholm, R. L.] Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Chicago, IL 60611 USA. [Pathak, J.] Mayo Clin, Dept Hlth Sci Res, Div Biomed Stat & Informat, Rochester, MN USA. [Peterson, J. F.; Denny, J. C.] Vanderbilt Univ, Med Ctr, Dept Biomed Informat & Med, Nashville, TN USA. [Prows, C. A.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Human Genet, Cincinnati, OH 45229 USA. [Ritchie, M. D.] Penn State Univ, Dept Biochem & Mol Biol, State Coll, PA USA. [Sadhasivam, S.] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH 45229 USA. [Sadhasivam, S.; Vinks, A. A.; Harley, J. B.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA. [Scott, S. A.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. Icahn Sch Med Mt Sinai, Mt Sinai Fac Practice Associates Primary Care Pro, New York, NY 10029 USA. [Prows, C. A.; Vinks, A. A.] Cincinnati Childrens Hosp Med Ctr, Div Clin Pharmacol, Cincinnati, OH 45229 USA. [Wolf, W. A.; Holm, I. A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Chute, C. G.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA. [Haines, J. L.] Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA. [Harley, J. B.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [Harley, J. B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Holm, I. A.] Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA USA. [Kullo, I. J.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA. [McCarty, C. A.] Essentia Inst Rural Hlth, Duluth, MN USA. [Scherer, S. E.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA. [Williams, M. S.] Geisinger Hlth Syst, Genom Med Inst, Danville, PA USA. [Roden, D. M.] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA. [Roden, D. M.; Denny, J. C.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA. RP Rasmussen-Torvik, LJ (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. EM ljrtorvik@northwestern.edu RI Bielinski, Suzette/A-2238-2009 OI Bielinski, Suzette/0000-0002-2905-5430; Pan, Vivian/0000-0002-1666-9273; Rasmussen, Luke/0000-0002-4497-8049 FU Cincinnati Children's Hospital Medical Center/Harvard [U01HG006828]; Children's Hospital of Philadelphia [U01HG006830]; Essentia Institute of Rural Health [U01HG006389]; Geisinger Clinic [U01HG006382]; Group Health Cooperative [U01HG006375]; University of Washington [U01HG006375]; Mayo Clinic [U01HG006379]; Icahn School of Medicine at Mount Sinai [U01HG006380]; Northwestern University [U01HG006388]; Vanderbilt University [U01HG006378]; Vanderbilt serving as the coordinating center [U01HG006385]; Deep Resequencing Resources of the Pharmacogenomic Research Network [U01 HL069757, U19 GM61388, U01 GM097119]; National Human Genome Research Institute [5U01HG006507]; Mayo Clinic Center for Individualized Medicine; National Institutes of Health (Pharmacogenomics Research Network) [U19 GM61388]; Rochester Epidemiology Project [R01 GM28157, U01 HG005137, R01 CA138461, R01 AG034676]; Pharmacogenomics of Arrhythmia Therapy PGRN site grant from the National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute [U19 HL65262]; [U01HG004438]; [HL069757] FX The eMERGE Network was funded through the following grants: U01HG006828 (Cincinnati Children's Hospital Medical Center/Harvard); U01HG006830 (Children's Hospital of Philadelphia); U01HG006389 (Essentia Institute of Rural Health); U01HG006382 (Geisinger Clinic); U01HG006375 (Group Health Cooperative and the University of Washington); U01HG006379 (Mayo Clinic)); U01HG006380 (Icahn School of Medicine at Mount Sinai); U01HG006388 (Northwestern University); U01HG006378 (Vanderbilt University); and U01HG006385 (Vanderbilt serving as the coordinating center). The development of the PGRN-Seq platform was supported by the Deep Resequencing Resources of the Pharmacogenomic Research Network: U01 HL069757, U19 GM61388, and U01 GM097119. The activities being performed at Johns Hopkins Center for Inherited Disease Research and Johns Hopkins DNA Diagnostic Lab are funded by grant U01HG004438. This work is also supported by grant (HL069757). One list of actionable genes was generated with funding from the National Human Genome Research Institute, 5U01HG006507. At Mayo Clinic this work was also supported in part by Mayo Clinic Center for Individualized Medicine and National Institutes of Health grants U19 GM61388 (the Pharmacogenomics Research Network), R01 GM28157, U01 HG005137, R01 CA138461, and R01 AG034676 (the Rochester Epidemiology Project). At Vanderbilt University, the work was also supported by the Pharmacogenomics of Arrhythmia Therapy PGRN site grant from the National Institute of General Medical Sciences and the National Heart, Lung, and Blood Institute (U19 HL65262), which also supports the site's participation in the Translational Pharmacogenetics Program and the Clinical Pharmacogenetics Implementation Consortium. NR 47 TC 55 Z9 56 U1 4 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-9236 EI 1532-6535 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD OCT PY 2014 VL 96 IS 4 BP 482 EP 489 DI 10.1038/clpt.2014.137 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AQ3FN UT WOS:000342675400027 PM 24960519 ER PT J AU Li, XF Shorter, D Kosten, TR AF Li, Xiaofan Shorter, Daryl Kosten, Thomas R. TI Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies SO EXPERT OPINION ON PHARMACOTHERAPY LA English DT Editorial Material DE barriers; buprenorphine; integrated treatment model; office-based; opioid dependence ID INJECTION DEPOT FORMULATION; RANDOMIZED CONTROLLED-TRIAL; DAY DOSING REGIMENS; PRIMARY-CARE; IMPLEMENTING BUPRENORPHINE; PRESCRIBING BUPRENORPHINE; SUBLINGUAL BUPRENORPHINE; SUBSTITUTION TREATMENT; METHADONE-MAINTENANCE; TREATMENT OUTCOMES AB Introduction: Buprenorphine follows the success of methadone as another milestone in the history of treatment for opioid addiction. Buprenorphine can be used in an office-based setting where it is clearly effective, highly accepted by patients and has a favorable safety profile and less abuse potential. However, the adoption of buprenorphine treatment has been slow in the USA. Areas covered: This article first reviews the history of medication-assisted opioid addiction treatment and the current epidemic opioid addiction, followed by a review of the efficacy, pharmacology and clinical prescription of buprenorphine in office-based care. We then explore the possible barriers in using buprenorphine and the ways to overcome these barriers, including new formulations, educational programs and policy regulations that strike a balance between accessibility and reducing diversion. Expert opinion: Buprenorphine can align addiction treatment with treatments for other chronic medical illnesses. However, preventing diversion will require graduate and continuing medical education and integrated care models for delivery of buprenorphine to those in need. C1 [Li, Xiaofan] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Shorter, Daryl] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Div Alcohol & Addict Psychiat, Houston, TX 77030 USA. RP Shorter, D (reprint author), Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Michael E DeBakey Vet Affairs Med Ctr, 1 Baylor Plaza, Houston, TX 77030 USA. EM shorter@bcm.edu FU CSRD VA [IK2 CX000946] NR 85 TC 4 Z9 4 U1 4 U2 20 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1465-6566 EI 1744-7666 J9 EXPERT OPIN PHARMACO JI Expert Opin. Pharmacother. PD OCT PY 2014 VL 15 IS 15 BP 2263 EP 2275 DI 10.1517/14656566.2014.955469 PG 13 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AQ5UP UT WOS:000342874400012 PM 25171726 ER PT J AU Kullgren, JT Harkins, KA Bellamy, SL Gonzales, A Tao, YY Zhu, JS Volpp, KG Asch, DA Heisler, M Karlawish, J AF Kullgren, Jeffrey T. Harkins, Kristin A. Bellamy, Scarlett L. Gonzales, Amy Tao, Yuanyuan Zhu, Jingsan Volpp, Kevin G. Asch, David A. Heisler, Michele Karlawish, Jason TI A Mixed-Methods Randomized Controlled Trial of Financial Incentives and Peer Networks to Promote Walking Among Older Adults SO HEALTH EDUCATION & BEHAVIOR LA English DT Article DE behavioral economics; eHealth; financial incentives; older adults; walking ID IMPROVE WARFARIN ADHERENCE; INCREASE PHYSICAL-ACTIVITY; HEALTH OUTCOMES; WEIGHT-LOSS; SUPPORT; PEDOMETER; PEOPLE; METAANALYSIS; POPULATIONS; MANAGEMENT AB Background. Financial incentives and peer networks could be delivered through eHealth technologies to encourage older adults to walk more. Methods. We conducted a 24-week randomized trial in which 92 older adults with a computer and Internet access received a pedometer, daily walking goals, and weekly feedback on goal achievement. Participants were randomized to weekly feedback only (Comparison), entry into a lottery with potential to earn up to $200 each week walking goals were met (Financial Incentive), linkage to four other participants through an online message board (Peer Network), or both interventions (Combined). Main outcomes were the proportion of days walking goals were met during the 16-week intervention and 8-week follow-up. We conducted a content analysis of messages posted by Peer Network and Combined arm participants. Results. During the 16-week intervention, there were no differences in the proportion of days walking goals were met in the Financial Incentive (39.7%; p = .78), Peer Network (24.9%; p = .08), and Combined (36.0%; p = .77) arms compared with the Comparison arm (36.0%). During 8 weeks of follow-up, the proportion of days walking goals were met was lower in the Peer Network arm (18.7%; p = .025) but not in the Financial Incentive (29.3%; p = .50) or Combined (24.8%; p = .37) arms, relative to the Comparison arm (34.5%). Messages posted by participants focused on barriers to walking and provision of social support. Conclusions. Financial incentives and peer networks delivered through eHealth technologies did not result in older adults walking more. C1 [Kullgren, Jeffrey T.; Heisler, Michele] VA Ann Arbor Healthcare Syst, Ann Arbor, MI 48113 USA. [Kullgren, Jeffrey T.; Heisler, Michele] Univ Michigan, Ann Arbor, MI 48109 USA. [Harkins, Kristin A.; Bellamy, Scarlett L.; Tao, Yuanyuan; Zhu, Jingsan; Volpp, Kevin G.; Asch, David A.; Karlawish, Jason] Univ Penn, Philadelphia, PA 19104 USA. [Bellamy, Scarlett L.; Tao, Yuanyuan; Zhu, Jingsan; Volpp, Kevin G.; Asch, David A.; Karlawish, Jason] Ctr Hlth Incent & Behav Econ, Leonard Davis Inst Hlth Econ, Philadelphia, PA USA. [Bellamy, Scarlett L.; Tao, Yuanyuan; Zhu, Jingsan; Volpp, Kevin G.; Asch, David A.; Karlawish, Jason] Penn CMU Roybal P30 Ctr Behav Econ & Hlth, Philadelphia, PA USA. [Gonzales, Amy] Indiana Univ, Bloomington, IN USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Kullgren, JT (reprint author), VA Ann Arbor Healthcare Syst, VA Ctr Clin Management Res, POB 130170, Ann Arbor, MI 48113 USA. EM jkullgre@med.umich.edu RI Heisler, Michele/B-5774-2015 OI Heisler, Michele/0000-0002-6889-2063 FU National Institute on Aging (Multi PIs Volpp and Asch) [RC2103282621]; Department of Veterans Affairs; Robert Wood Johnson Foundation FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Grant RC2103282621 from the National Institute on Aging (Multi PIs Volpp and Asch). Support was also provided by the Department of Veterans Affairs and the Robert Wood Johnson Foundation. NR 46 TC 9 Z9 9 U1 1 U2 15 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1090-1981 EI 1552-6127 J9 HEALTH EDUC BEHAV JI Health Educ. Behav. PD OCT PY 2014 VL 41 SU 1 BP 43S EP 50S DI 10.1177/1090198114540464 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ6MW UT WOS:000342928400006 PM 25274710 ER PT J AU Nevin, DT Morgan, CJ Graham, DY Genta, RM AF Nevin, Daniel T. Morgan, Christopher J. Graham, David Y. Genta, Robert M. TI Helicobacter pylori Gastritis in HIV-Infected Patients: A Review SO HELICOBACTER LA English DT Review DE Epidemiology; Helicobacter pylori; immune response; HIV; AIDS; immunocompromised host ID HUMAN-IMMUNODEFICIENCY-VIRUS; INFLAMMATORY-BOWEL-DISEASE; ACTIVE ANTIRETROVIRAL THERAPY; PEPTIC-ULCER DISEASE; DELTA T-CELLS; LOW-PREVALENCE; POSITIVE PATIENTS; ENDOSCOPIC FINDINGS; SELECTIVE INCREASE; HYGIENE HYPOTHESIS AB BackgroundThe risk factors for acquiring Helicobacter pylori and Human Immunodeficiency Virus (HIV) infections are different: H.pylori is transmitted by gastro- or fecal-oral routes and is associated with low socioeconomic conditions, while HIV is transmitted through sexual intercourse, infected body fluids, and transplacentally. If the host responses to these infections were independent, the prevalence of H.pylori should be similar in HIV-infected and non-infected patients. Yet, several studies have detected a lower prevalence of H.pylori in patients with HIV infection, whereas other studies found either no differences or greater rates of H.pylori infection in HIV-positive subjects. ObjectiveTo review studies that addressed the issue of these two simultaneous infections and attempt to determine whether reliable conclusions can be drawn from this corpus of often contrasting evidence. MethodsElectronic literature search for relevant publications, followed by manual search of additional citations from extracted articles. ResultsThe initial search yielded 44 publications; after excluding case reports, reviews, narrowly focused articles, and duplicate reports, there remained 29 articles, which are the corpus of this review. With one exception, all studies reported higher rates of H.pylori infection in HIV-negative subjects. Five studies also examined the CD4 lymphocyte counts and found an inverse correlation between the degree of immunosuppression and the prevalence of active H.pylori infection. ConclusionsCurrent evidence suggests that it is likely that H.pylori needs a functional immune system to successfully and persistently colonize the human gastric mucosa. C1 [Nevin, Daniel T.; Morgan, Christopher J.; Genta, Robert M.] Miraca Life Sci Res Inst, Irving, TX USA. [Graham, David Y.] Houston VA Med Ctr, Houston, TX USA. [Graham, David Y.] Baylor Coll Med, Houston, TX 77030 USA. RP Genta, RM (reprint author), Miraca Life Sci, 6655 North MacArthur Blvd, Irving, TX 75039 USA. EM robert.genta@utsouthwestern.edu NR 48 TC 4 Z9 6 U1 2 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1083-4389 EI 1523-5378 J9 HELICOBACTER JI Helicobacter PD OCT PY 2014 VL 19 IS 5 BP 323 EP 329 DI 10.1111/hel.12131 PG 7 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA AQ7JK UT WOS:000342989000001 PM 24773336 ER PT J AU Knapp, H Hagedorn, H Anaya, HD AF Knapp, Herschel Hagedorn, Hildi Anaya, Henry D. TI A five-year self-sustainability analysis of nurse-administered HIV rapid testing in Veterans Affairs primary care SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE HIV; AIDS; screening; diagnostic testing; rapid testing; point-of-care ID EMERGENCY-DEPARTMENT; ACCURACY; RISK AB In 2008, nurse-administered HIV oral rapid testing (RT) was introduced at the Veterans Affairs Primary Care Clinic in Downtown Los Angeles. Analysis at five years revealed variable yet increasing rates of HIV RT at that facility despite the fact that no post-launch support was provided by the implementation team. Qualitative interviews among stakeholders conducted at five years revealed the pre-existing implementation practices endemic to this clinic that facilitated this unprecedented success (e.g. history of positive quality improvement implementations, leadership support, clinician involvement at each step of the process to facilitate empowerment, ownership and feasible customisation of the implementation, cohesive communication among clinicians and leadership, training, efficient supply pathway, progressive performance feedback and ongoing encouragement). C1 [Knapp, Herschel; Anaya, Henry D.] US Dept Vet Affairs, Hlth Serv Res & Dev, Los Angeles, CA 90073 USA. [Hagedorn, Hildi] Minneapolis VA Healthcare Syst, QUERI Subst Use Disorders, Minneapolis, MN USA. [Hagedorn, Hildi] Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. RP Knapp, H (reprint author), US Dept Vet Affairs, Hlth Serv Res & Dev, 11301 Wilshire Blvd,111-G Bldg 500,Rm 4681, Los Angeles, CA 90073 USA. EM Herschel.Knapp@va.gov NR 18 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0956-4624 EI 1758-1052 J9 INT J STD AIDS JI Int. J. STD AIDS PD OCT PY 2014 VL 25 IS 12 BP 837 EP 843 DI 10.1177/0956462414521796 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AQ5CO UT WOS:000342821500001 PM 24480848 ER PT J AU Thase, ME AF Thase, Michael E. TI Large-Scale Study Suggests Specific Indicators for Combined Cognitive Therapy and Pharmacotherapy in Major Depressive Disorder SO JAMA PSYCHIATRY LA English DT Editorial Material ID BEHAVIORAL-ANALYSIS SYSTEM; PSYCHOTHERAPY; COMBINATION; NEFAZODONE C1 [Thase, Michael E.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA USA. [Thase, Michael E.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA. RP Thase, ME (reprint author), Mood & Anxiety Disorders Treatment Res Program, 3535 Market St,Ste 670, Philadelphia, PA 19104 USA. EM thase@mail.med.upenn.edu NR 8 TC 2 Z9 2 U1 0 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD OCT PY 2014 VL 71 IS 10 BP 1101 EP 1102 DI 10.1001/jamapsychiatry.2014.1524 PG 2 WC Psychiatry SC Psychiatry GA AQ6DW UT WOS:000342900200003 PM 25142013 ER PT J AU Anyanwu, CO Stewart, CL Werth, VP AF Anyanwu, Cynthia O. Stewart, Campbell L. Werth, Victoria P. TI Thalidomide-Induced Orofacial Neuropathy SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Letter ID CUTANEOUS LUPUS-ERYTHEMATOSUS C1 [Anyanwu, Cynthia O.; Werth, Victoria P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Anyanwu, Cynthia O.; Stewart, Campbell L.; Werth, Victoria P.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. RP Anyanwu, CO (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; National Institutes of Health (NIH) [K24-AR 02207] FX The authors acknowledge the Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development, and the National Institutes of Health (NIH K24-AR 02207) (V.P.W.). NR 9 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-1608 EI 1536-7355 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD OCT PY 2014 VL 20 IS 7 BP 399 EP 400 PG 2 WC Rheumatology SC Rheumatology GA AQ8BJ UT WOS:000343046100015 PM 25275775 ER PT J AU Baskin, DG Hewitt, SM AF Baskin, Denis G. Hewitt, Stephen M. TI Improving the State of the Science of Immunohistochemistry: The Histochemical Society's Standards of Practice SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY LA English DT Editorial Material C1 [Baskin, Denis G.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, R&D Serv, Seattle, WA USA. [Baskin, Denis G.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Hewitt, Stephen M.] NCI, Pathol Lab, Ctr Canc Res, Bethesda, MD 20892 USA. RP Hewitt, SM (reprint author), NCI, Pathol Lab, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA. EM genejock@helix.nih.gov OI Hewitt, Stephen/0000-0001-8283-1788 FU Intramural NIH HHS; NIDDK NIH HHS [P30DK017047, P30 DK017047] NR 2 TC 2 Z9 2 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0022-1554 EI 1551-5044 J9 J HISTOCHEM CYTOCHEM JI J. Histochem. Cytochem. PD OCT PY 2014 VL 62 IS 10 BP 691 EP 692 DI 10.1369/0022155414538453 PG 2 WC Cell Biology SC Cell Biology GA AQ5GU UT WOS:000342836200001 PM 25085896 ER PT J AU Bhatt, SP Wells, JM Dransfield, MT AF Bhatt, Surya P. Wells, J. Michael Dransfield, Mark T. TI Cardiovascular disease in COPD: a call for action SO LANCET RESPIRATORY MEDICINE LA English DT Editorial Material ID OBSTRUCTIVE PULMONARY-DISEASE; CLINICAL-PRACTICE GUIDELINE; AMERICAN-COLLEGE; RISK; MANAGEMENT; EXACERBATIONS; MORTALITY; EVENTS C1 [Bhatt, Surya P.; Wells, J. Michael; Dransfield, Mark T.] Univ Alabama Birmingham, UAB Lung Hlth Ctr, Birmingham, AL 35229 USA. [Wells, J. Michael; Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Bhatt, SP (reprint author), Univ Alabama Birmingham, UAB Lung Hlth Ctr, Birmingham, AL 35229 USA. EM mdrans99@uab.edu NR 15 TC 6 Z9 6 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-2600 J9 LANCET RESP MED JI Lancet Resp. Med. PD OCT PY 2014 VL 2 IS 10 BP 783 EP 785 PG 4 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AQ3KP UT WOS:000342692100014 PM 25298057 ER PT J AU Murugan, R Wen, XY Shah, N Lee, M Kong, L Pike, F Keener, C Unruh, M Finkel, K Vijayan, A Palevsky, PM Paganini, E Carter, M Elder, M Kellum, JA AF Murugan, Raghavan Wen, Xiaoyan Shah, Nilesh Lee, Minjae Kong, Lan Pike, Francis Keener, Christopher Unruh, Mark Finkel, Kevin Vijayan, Anitha Palevsky, Paul M. Paganini, Emil Carter, Melinda Elder, Michele Kellum, John A. CA Biol Markers Recovery Kidney TI Plasma inflammatory and apoptosis markers are associated with dialysis dependence and death among critically ill patients receiving renal replacement therapy SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE acute kidney injury; biomarkers; mortality; renal recovery; renal replacement therapy ID ACUTE KIDNEY INJURY; PREDICT MORTALITY; TRIAL NETWORK; APACHE-II; FAILURE; INTERLEUKIN-6; INTENSITY; SURGERY; SEPSIS; ARF AB Background. Survivors of critical illness complicated by acute kidney injury requiring renal replacement therapy (RRT) are at an increased risk of dialysis dependence and death but the mechanisms are unknown. Methods. In a multicenter, prospective, cohort study of 817 critically ill patients receiving RRT, we examined association between Day 1 plasma inflammatory [interleukin (IL)-1 beta, IL-6, IL-8, IL-10 and IL-18; macrophage migration inhibitory factor (MIF) and tumor necrosis factor]; apoptosis [tumor necrosis factor receptor (TNFR)-I and TNFR-II and death receptor (DR)-5]; and growth factor (granulocyte macrophage colony stimulating factor) biomarkers and renal recovery and mortality at Day 60. Renal recovery was defined as alive and RRT independent. Results. Of 817 participants, 36.5% were RRT independent and 50.8% died. After adjusting for differences in demographics, comorbid conditions; premorbid creatinine; nephrotoxins; sepsis; oliguria; mechanical ventilation; RRT dosing; and severity of illness, increased concentrations of plasma IL-8 and IL-18 and TNFR-I were independently associated with slower renal recovery [adjusted hazard ratio (AHR) range for all markers, 0.70-0.87]. Higher concentrations of IL-6, IL-8, IL-10 and IL-18; MIF; TNFR-I and DR-5 were associated with mortality (AHR range, 1.16-1.47). In an analysis of multiple markers simultaneously, increased IL-8 [AHR, 0.80, 95% confidence interval (95% CI) 0.70-0.91, P < 0.001] and TNFR-I (AHR, 0.63, 95% CI 0.50-0.79, P < 0.001) were associated with slower recovery, and increased IL-8 (AHR, 1.26, 95% CI 1.14-1.39, P < 0.001); MIF (AHR, 1.18, 95% CI 1.08-1.28, P < 0.001) and TNFR-I (AHR, 1.26, 95% CI 1.02-1.56, P < 0.03) were associated with mortality. Conclusions. Elevated plasma concentrations of inflammatory and apoptosis biomarkers are associated with RRT dependence and death. Our data suggest that future interventions should investigate broad-spectrum immune-modulation to improve outcomes. C1 [Murugan, Raghavan; Wen, Xiaoyan; Palevsky, Paul M.; Elder, Michele; Kellum, John A.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Ctr Crit Care Nephrol,CRISMA, Pittsburgh, PA 15260 USA. [Murugan, Raghavan; Wen, Xiaoyan; Shah, Nilesh; Lee, Minjae; Kong, Lan; Pike, Francis; Keener, Christopher; Carter, Melinda; Elder, Michele; Kellum, John A.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness CRI, Pittsburgh, PA USA. [Shah, Nilesh; Pike, Francis; Keener, Christopher] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Lee, Minjae] Univ Texas Hlth Sci Ctr Houston, Ctr Clin & Translat Sci, Houston, TX 77030 USA. [Kong, Lan] Penn State Hershey Coll Med, Div Biostat & Bioinformat, Dept Publ Hlth Sci, Hershey, PA USA. [Unruh, Mark] Univ New Mexico, Div Nephrol, Dept Internal Med, Albuquerque, NM 87131 USA. [Finkel, Kevin] Univ Texas Med Sch Houston, Div Renal Dis & Hypertens, Houston, TX USA. [Vijayan, Anitha] Washington Univ, Div Renal Dis, St Louis, MO USA. [Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Paganini, Emil] Cleveland Clin Fdn, Cleveland, OH 44195 USA. RP Kellum, JA (reprint author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Ctr Crit Care Nephrol,CRISMA, Pittsburgh, PA 15260 USA. EM kellumja@ccm.upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 FU National Institute of Diabetes and Digestive, and Kidney Diseases (NIDDK) [R01DK070910]; National Center For Advancing Translational Sciences of the National Institutes of Health [KL2TR000146]; Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development (CSP) [530]; NIDDK [Y1-DK-3508]; [R01DK083961] FX BioMaRK was supported by a grant (R01DK070910) from the National Institute of Diabetes and Digestive, and Kidney Diseases (NIDDK). Additional support for J.K., X.W. and F.P. was provided by grant (R01DK083961) and for R.M. from the National Center For Advancing Translational Sciences of the National Institutes of Health under Award Number KL2TR000146. The VA/NIH ATN study was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development (CSP #530) and by NIDDK by interagency agreement Y1-DK-3508. NR 38 TC 20 Z9 21 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD OCT PY 2014 VL 29 IS 10 BP 1854 EP 1864 DI 10.1093/ndt/gfu051 PG 11 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA AQ6SE UT WOS:000342943300011 PM 24619058 ER PT J AU Potts, MB Siu, JJ Price, JD Salinas, RD Cho, MJ Ramos, AD Hahn, J Margeta, M Oldham, MC Lim, DA AF Potts, Matthew B. Siu, Jason J. Price, James D. Salinas, Ryan D. Cho, Mathew J. Ramos, Alexander D. Hahn, Junghyun Margeta, Marta Oldham, Michael C. Lim, Daniel A. TI Analysis of Mll1 Deficiency Identifies Neurogenic Transcriptional Modules and Brn4 as a Factor for Direct Astrocyte-to-Neuron Reprogramming SO NEUROSURGERY LA English DT Article DE Astrocytes; Brn4 (Pou3f4); Cell transdifferentiation; Epigenomics; Mll1; Neural stem cells; Neurogenesis ID HUMAN SOMATIC-CELLS; STEM-CELLS; SUBVENTRICULAR ZONE; ADULT BRAIN; POSTNATAL ASTROGLIA; DEFINED FACTORS; IN-VIVO; OLIGODENDROCYTES; EXPRESSION; NETWORK AB BACKGROUND: Mixed lineage leukemia-1 (Mll1) epigenetically regulates gene expression patterns that specify cellular identity in both embryonic development and adult stem cell populations. In the adult mouse brain, multipotent neural stem cells (NSCs) in the subventricular zone generate new neurons throughout life, and Mll1 is required for this postnatal neurogenesis but not for glial cell differentiation. Analysis of Mll1-dependent transcription may identify neurogenic genes useful for the direct reprogramming of astrocytes into neurons. OBJECTIVE: To identify Mll1-dependent transcriptional modules and to determine whether genes in the neurogenic modules can be used to directly reprogram astrocytes into neurons. METHODS: We performed gene coexpression module analysis on microarray data from differentiating wild-type and Mll1-deleted subventricular zone NSCs. Key developmental regulators belonging to the neurogenic modules were overexpressed in Mll1-deleted cells and cultured cortical astrocytes, and cell phenotypes were analyzed by immunocytochemistry and electrophysiology. RESULTS: Transcriptional modules that correspond to neurogenesis were identified in wild-type NSCs. Modules related to astrocytes and oligodendrocytes were enriched in Mll1-deleted NSCs, consistent with their gliogenic potential. Overexpression of genes selected from the neurogenic modules enhanced the production of neurons from Mll1-deleted cells, and overexpression of Brn4 (Pou3f4) in nonneurogenic cortical astroglia induced their transdifferentiation into electrophysiologically active neurons. CONCLUSION: Our results demonstrate that Mll1 is required for the expression of neurogenic but not gliogenic transcriptional modules in a multipotent NSC population and further indicate that specific Mll1-dependent genes may be useful for direct reprogramming strategies. C1 [Potts, Matthew B.; Siu, Jason J.; Price, James D.; Salinas, Ryan D.; Cho, Mathew J.; Ramos, Alexander D.; Lim, Daniel A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA. [Potts, Matthew B.; Siu, Jason J.; Price, James D.; Salinas, Ryan D.; Cho, Mathew J.; Ramos, Alexander D.; Oldham, Michael C.; Lim, Daniel A.] Univ Calif San Francisco, Eli & Edythe Broad Inst Regenerat Med & Stem Cell, San Francisco, CA USA. [Hahn, Junghyun; Margeta, Marta] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA. [Oldham, Michael C.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Lim, Daniel A.] San Francisco VA Med Ctr, Surg Serv, San Francisco, CA USA. RP Lim, DA (reprint author), 35 Med Ctr Way, San Francisco, CA 94143 USA. EM limd@neurosurg.ucsf.edu OI Lim, Daniel/0000-0001-7221-3425; Margeta, Marta/0000-0001-6889-2488 FU VA BSLRD Merit Award [I01 BX000252]; National Institutes of Health [DP2 OD006505, R01-NS073765]; UCSF REAC/CTSI; National Institutes of Health NSRA [F32 NS073173]; UCSF Program for Breakthrough Biomedical Research; Sandler Foundation FX This work was supported by a VA BSLRD Merit Award (I01 BX000252), a National Institutes of Health New Innovator Award (DP2 OD006505), and a UCSF REAC/CTSI pilot award to Dr Lim; National Institutes of Health NSRA (F32 NS073173) to Dr Potts; a National Institutes of Health grant (R01-NS073765) to Dr Margeta; the UCSF Program for Breakthrough Biomedical Research, which is funded in part by the Sandler Foundation, to Dr Oldham; and facilities and resources provided by the San Francisco Veterans Affairs Medical Center. The other authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article. NR 50 TC 5 Z9 5 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-396X EI 1524-4040 J9 NEUROSURGERY JI Neurosurgery PD OCT PY 2014 VL 75 IS 4 BP 472 EP 482 DI 10.1227/NEU.0000000000000452 PG 11 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA AQ3AY UT WOS:000342662300041 PM 24887289 ER PT J AU Walker, RN Utech, A Velez, ME Schwartz, K AF Walker, Renee Nichole Utech, Anne Velez, Maria Eugenia Schwartz, Katie TI Delivered Volumes of Enteral Nutrition Exceed Prescribed Volumes SO NUTRITION IN CLINICAL PRACTICE LA English DT Article DE enteral nutrition; infusion pumps; energy intake ID RECEIVING MECHANICAL VENTILATION; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; ENERGY-EXPENDITURE; ACCURACY; ROUTE; PUMPS AB Background: Enteral nutrition (EN) provisions are typically calculated based on a 24-hour infusion period. However, feedings are often interrupted for daily activities, procedures, or gastrointestinal intolerance. The study's objective was to determine the delivered EN quantities provided to stable hospitalized patients, using cellular time and measured volumes to verify our EN calculation adjustment. Methods: A supply of consecutively numbered ready-to-hang (RTH) EN product was delivered to the bedside of 26 inpatients with established EN tolerance at goal rates on various types of nursing units. The dietitian weighed the volume remaining in the infusing product and recorded the measurement time. On the following days, the dietitian continued to weigh the infusing RTH product and the empty RTH bottles saved by nursing. The primary outcome was the difference between the prescribed and delivered EN provisions, which was calculated with a paired t test. Results: Patients received significantly more calories in the delivered enteral feeding (mean [SD], 1678 [385] kcal) than prescribed calories in the EN order (1489 [246 kcal]; t = 3.736, P = .001), adjusting for observed time. No significant differences were found between nursing units, product, and rate. Conclusion: EN delivered may actually exceed ordered amounts by 5%-21% (mean, 12%) with feeding pump inaccuracy as the primary contributing factor. This differs from what others have found. Our findings support using a volume-based ordering system vs a rate-based ordering system for more accurate EN delivery. C1 [Walker, Renee Nichole; Velez, Maria Eugenia; Schwartz, Katie] Michael E DeBakey Med Ctr, Houston, TX 77030 USA. [Utech, Anne] Vet Hlth Adm, Dept Vet Affairs, Houston, TX USA. [Utech, Anne; Velez, Maria Eugenia] Baylor Coll Med, Houston, TX 77030 USA. RP Walker, RN (reprint author), Michael E DeBakey Med Ctr, 2002 Holcombe Blvd,Rm 4a-340, Houston, TX 77030 USA. EM RNEW00@aol.com NR 13 TC 1 Z9 1 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0884-5336 EI 1941-2452 J9 NUTR CLIN PRACT JI Nutr. Clin. Pract. PD OCT PY 2014 VL 29 IS 5 BP 662 EP 666 DI 10.1177/0884533614529998 PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA AQ5ME UT WOS:000342852500014 PM 25606647 ER PT J AU Suhler, EB Lim, LL Beardsley, RM Giles, TR Pasadhika, S Lee, ST de Saint Sardos, A Butler, NJ Smith, JR Rosenbaum, JT AF Suhler, Eric B. Lim, Lyndell L. Beardsley, Robert M. Giles, Tracy R. Pasadhika, Sirichai Lee, Shelly T. de Saint Sardos, Alexandre Butler, Nicholas J. Smith, Justine R. Rosenbaum, James T. TI Rituximab Therapy for Refractory Scleritis Results of a Phase I/II Dose-Ranging, Randomized, Clinical Trial SO OPHTHALMOLOGY LA English DT Article ID RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; DISEASE; MULTICENTER AB Objective: To determine whether rituximab, a monoclonal antibody against the B-lymphocyte antigen CD20, is effective in the treatment of refractory noninfectious scleritis. Design: Prospective, dose-ranging, randomized, double-masked phase I/II clinical trial. Participants: Twelve patients with noninfectious scleritis refractory to systemic corticosteroid and >= 1 other systemic immunosuppressive agent were enrolled from January 2007 to March 2010. Intervention: Subjects were randomly assigned to 500 (n = 5) or 1000 mg (n = 7) dosing arms of rituximab intravenous infusions (500 or 1000 mg), given at study days 1 and 15. Initial responders with breakthrough inflammation after study week 24 were offered treatment with an additional cycle of 2 open-label rituximab 1000 mg infusions. Main Outcome Measures: Primary outcomes were reduction of inflammation, as measured with a validated scleritis disease grading scale (SGS) and reduction in corticosteroid dose by >= 50%. Patients were characterized as responders to study therapy if >= 1 of these endpoints showed improvement and neither showed evidence of worsening. Secondary outcomes were improvement in visual acuity, reduction in pain, and improvement in patient and physician-reported global health assessment. Results: Of 12 enrolled patients, 9 met the SGS endpoint at or before week 24, and 4 additionally were able to reduce corticosteroid dose by >= 50%. With regard to secondary outcome measures, 11 and 9 patients showed improvement in patient and physician global health scores, respectively, and 7 patients had reduction in pain. Of 9 initial responders, 7 experienced breakthrough inflammation after 24 weeks and were treated with a second cycle of rituximab infusions. Four patients had significant objective or subjective worsening within 8 weeks of receiving rituximab; this event was averted in subsequent patients by treatment with peri-infusional oral corticosteroid. No other significant adverse events were noted. No differences in efficacy, toxicity, or likelihood of retreatment were noted between the dosing arms. Conclusions: Rituximab was effective treatment for 9 of 12 enrolled patients with refractory, noninfectious scleritis at 24 weeks, although 7 required reinfusion with rituximab to maintain inflammatory control. The treatment was well-tolerated, and peri-infusional inflammatory exacerbations were managed successfully with oral corticosteroids. Further long-term studies are warranted to determine the safety and efficacy of rituximab in treating noninfectious scleritis and other ocular inflammatory diseases. (C) 2014 by the American Academy of Ophthalmology. C1 [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Suhler, Eric B.; Lim, Lyndell L.; Beardsley, Robert M.; Giles, Tracy R.; Pasadhika, Sirichai; Lee, Shelly T.; de Saint Sardos, Alexandre; Butler, Nicholas J.; Smith, Justine R.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, Portland, OR 97201 USA. [Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med & Cell & Dev Biol, Portland, OR 97201 USA. [Smith, Justine R.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Dev Biol, Portland, OR 97201 USA. [Lim, Lyndell L.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia. [Smith, Justine R.] Flinders Univ S Australia, Adelaide, SA 5001, Australia. [Rosenbaum, James T.] Devers Eye Inst, Portland, OR USA. RP Suhler, EB (reprint author), Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA. EM suhlere@ohsu.edu OI Lim, Lyndell/0000-0003-2491-685X FU Department of Veterans'Affairs; Genentech (San Francisco, CA); Research to Prevent Blindness grant (unrestricted grant to Casey Eye Institute); Rosenfeld Family Trust; William and Mary Bauman Foundation; Genentech; Abbott/Abbvie; Bristol-Myers-Squibb; EyeGate; LuxBio; Novartis FX E. B. S.: Research Supportd-Department of Veterans'Affairs; Supported in part by Genentech (San Francisco, CA). The funding organization had no role in the design or conduct of this research. Funded by a Research to Prevent Blindness grant (unrestricted grant to Casey Eye Institute), the Rosenfeld Family Trust (J. T. R.), and the William and Mary Bauman Foundation. The OHSU Uveitis Clinic has received research support from Genentech, Abbott/Abbvie, Bristol-Myers-Squibb, EyeGate, LuxBio, and Novartis. NR 23 TC 13 Z9 13 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD OCT PY 2014 VL 121 IS 10 BP 1885 EP 1891 DI 10.1016/j.ophtha.2014.04.044 PG 7 WC Ophthalmology SC Ophthalmology GA AQ3ME UT WOS:000342697300017 PM 24953794 ER PT J AU Tunkel, DE Bauer, CA Sun, GH Rosenfeld, RM Chandrasekhar, SS Cunningham, ER Archer, SM Blakley, BW Carter, JM Granieri, EC Henry, JA Hollingsworth, D Khan, FA Mitchell, S Monfared, A Newman, CW Omole, FS Phillips, CD Robinson, SK Taw, MB Tyler, RS Waguespack, R Whamond, EJ AF Tunkel, David E. Bauer, Carol A. Sun, Gordon H. Rosenfeld, Richard M. Chandrasekhar, Sujana S. Cunningham, Eugene R., Jr. Archer, Sanford M. Blakley, Brian W. Carter, John M. Granieri, Evelyn C. Henry, James A. Hollingsworth, Deena Khan, Fawad A. Mitchell, Scott Monfared, Ashkan Newman, Craig W. Omole, Folashade S. Phillips, C. Douglas Robinson, Shannon K. Taw, Malcolm B. Tyler, Richard S. Waguespack, Richard Whamond, Elizabeth J. TI Clinical Practice Guideline: Tinnitus Executive Summary SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE tinnitus; hearing loss; quality of life; sound therapy; hearing aids; amplification AB The American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) has published a supplement to this issue featuring the new Clinical Practice Guideline: Tinnitus. To assist in implementing the guideline recommendations, this article summarizes the rationale, purpose, and key action statements. The 13 recommendations developed address the evaluation of patients with tinnitus, including selection and timing of diagnostic testing and specialty referral to identify potential underlying treatable pathology. It will then focus on the evaluation and treatment of patients with persistent primary tinnitus, with recommendations to guide the evaluation and measurement of the impact of tinnitus and to determine the most appropriate interventions to improve symptoms and quality of life for tinnitus sufferers. C1 [Tunkel, David E.] Johns Hopkins Outpatient Ctr, Baltimore, MD 21287 USA. [Bauer, Carol A.] So Illinois Univ, Sch Med, Div Otolaryngol Head & Neck Surg, Springfield, IL USA. [Sun, Gordon H.] Partnership Hlth Analyt Res LLC, Los Angeles, CA USA. [Rosenfeld, Richard M.] Suny Downstate Med Ctr, Dept Otolaryngol, Brooklyn, NY 11203 USA. [Chandrasekhar, Sujana S.] New York Otol, New York, NY USA. [Cunningham, Eugene R., Jr.] Head & Neck Surg Fdn, Amer Acad Otolaryngol, Dept Res & Qual Improvement, Alexandria, VA USA. [Archer, Sanford M.] Univ Kentucky, Div Rhinol & Sinus Surg, Lexington, KY USA. [Archer, Sanford M.] Univ Kentucky, Div Facial Plast & Reconstruct Surg, Lexington, KY USA. [Blakley, Brian W.] Univ Manitoba, Dept Otolaryngol, Winnipeg, MB, Canada. [Carter, John M.] Tulane Univ, Dept Otolaryngol, New Orleans, LA 70118 USA. [Granieri, Evelyn C.] Columbia Univ, Div Geriatr Med & Aging, New York, NY USA. [Henry, James A.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR USA. [Hollingsworth, Deena] ENT Specialists Northern Virginia, Falls Church, VA USA. [Khan, Fawad A.] Ochsner Hlth Syst, Kenner, LA USA. [Mitchell, Scott] Mitchell & Cavallo PC, Houston, TX USA. [Monfared, Ashkan] George Washington Univ, Dept Otol & Neurotol, Washington, DC USA. [Newman, Craig W.] Cleveland Clin, Lerner Coll Med, Dept Surg, Cleveland, OH 44106 USA. [Omole, Folashade S.] Morehouse Sch Med, East Point, GA USA. [Phillips, C. Douglas] New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Head & Neck Imaging, New York, NY USA. [Robinson, Shannon K.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Taw, Malcolm B.] Univ Calif Los Angeles, Dept Med, Ctr East West Med, Los Angeles, CA 90024 USA. [Tyler, Richard S.] Univ Iowa, Dept Otolaryngol Head & Neck Surg, Iowa City, IA 52242 USA. [Waguespack, Richard] Univ Alabama Birmingham, Sch Med, Dept Surg, Birmingham, AL 35294 USA. [Whamond, Elizabeth J.] Consumers United Evidence Based Healthcare, Fredericton, NB, Canada. RP Tunkel, DE (reprint author), Johns Hopkins Outpatient Ctr, Room 6231,601 North Caroline St,Rm 6231, Baltimore, MD 21287 USA. EM dtunkel@jhmi.edu OI Phillips, C. Douglas/0000-0003-1773-8899 FU American Academy of Otolaryngology-Head and Neck Surgery Foundation FX American Academy of Otolaryngology-Head and Neck Surgery Foundation. NR 8 TC 5 Z9 5 U1 3 U2 18 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD OCT PY 2014 VL 151 IS 4 BP 533 EP 541 DI 10.1177/0194599814547475 PG 9 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA AQ7HI UT WOS:000342982900004 PM 25274374 ER PT J AU Adamson, B Attridge, RT AF Adamson, Braden Attridge, Russell T. TI Risk factors for resistant pathogens in community-dwelling pneumonia patients from 2001 to 2010. SO PHARMACOTHERAPY LA English DT Meeting Abstract CT Annual Meeting of the American-College-of-Clinical-Pharmacy (ACCP) CY OCT 12-15, 2014 CL Austin, TX SP Amer Coll Clin Pharm C1 [Adamson, Braden] Univ Incarnate Word, Feik Sch Phamracy, Dept Pharm Practice, San Antonio, TX USA. [Attridge, Russell T.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD OCT PY 2014 VL 34 IS 10 MA 314 BP E260 EP E260 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AQ6JF UT WOS:000342916800257 ER PT J AU Lee, TC Attridge, RL Cota, JM Horlen, CK Attridge, RT AF Lee, Tina C. Attridge, Rebecca L. Cota, Jason M. Horlen, Cheryl K. Attridge, Russell T. TI Median potassium increases and the effect of patient-specific factors with potassium supplementation in hospitalized adults. SO PHARMACOTHERAPY LA English DT Meeting Abstract CT Annual Meeting of the American-College-of-Clinical-Pharmacy (ACCP) CY OCT 12-15, 2014 CL Austin, TX SP Amer Coll Clin Pharm C1 [Lee, Tina C.; Cota, Jason M.; Horlen, Cheryl K.] Univ Incarnate Word, Feik Sch Pharm, San Antonio, TX USA. [Attridge, Rebecca L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Attridge, Russell T.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD OCT PY 2014 VL 34 IS 10 MA 294 BP E254 EP E254 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AQ6JF UT WOS:000342916800237 ER PT J AU Trester, M Wang, L Chao, S Maddix, D AF Trester, Marissa Wang, Lorraine Chao, Shirley Maddix, Daniel TI Comparing estimated glomerular filtration rates based on serum creatinine versus serum cystatin C and effect on renal dosing of medications. SO PHARMACOTHERAPY LA English DT Meeting Abstract CT Annual Meeting of the American-College-of-Clinical-Pharmacy (ACCP) CY OCT 12-15, 2014 CL Austin, TX SP Amer Coll Clin Pharm C1 [Trester, Marissa; Wang, Lorraine; Chao, Shirley; Maddix, Daniel] San Francisco VA Med Ctr, Serv Pharm, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD OCT PY 2014 VL 34 IS 10 MA 178 BP E222 EP E223 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AQ6JF UT WOS:000342916800135 ER PT J AU Ikeda, AJ Grabowski, AM Lindsley, A Sadeghi-Demneh, E Reisinger, KD AF Ikeda, Andrea J. Grabowski, Alena M. Lindsley, Alida Sadeghi-Demneh, Ebrahim Reisinger, Kim D. TI A scoping literature review of the provision of orthoses and prostheses in resource-limited environments 2000-2010. Part two: Research and outcomes SO PROSTHETICS AND ORTHOTICS INTERNATIONAL LA English DT Review DE Prosthetics and orthotics in developing countries; developing countries; prosthetics and orthotics services in low-income countries; orthotics; prosthetics ID LOW-INCOME COUNTRIES; TRANS-TIBIAL AMPUTEES; FIELD FOLLOW-UP; PONSETI METHOD; TRANSTIBIAL PROSTHESES; CLUBFOOT DEFORMITY; FEMORAL AMPUTEES; DEVELOPING-WORLD; LIMB AMPUTEES; FEET AB Background: Despite the activities of many orthotic and prosthetic provision organizations in resource-limited environments, there is still a great need and there are several areas for improvement, as identified in Part One of this series. Objectives: Our goal was to examine outcomes and conclusions of research studies to produce an evidence base for determining factors that may lead to successful provision of orthoses and prostheses in resource-limited environments. Study design: Literature review. Methods: We conducted a scoping literature review of all information related to orthotic and prosthetic provision in resource-limited environments published from 2000 to 2010. We extracted measured outcomes reported in all types of articles and analyzed conclusions from research studies. Results: Reported outcomes included durability, cost, satisfaction, use/nonuse of device, amount of utilization, walking speed, discomfort, pain, fit, misalignment, capacity for service provision, number of devices produced or delivered, and number of graduates from training programs. Conclusions: There are many gaps in the evidence base, notably in measuring inclusion, participation, and quality of life for orthosis and prosthesis users in resource-limited environments. There is a paucity of reported outcomes for orthotics. Valid, reliable, and standard methods of data collection and reporting are needed to advance the field and enhance the evidence base. C1 [Ikeda, Andrea J.; Lindsley, Alida; Reisinger, Kim D.] San Francisco State Univ, Whirlwind Wheelchair Int, San Francisco, CA 94132 USA. [Grabowski, Alena M.] Univ Colorado, Dept Integrat Physiol, Boulder, CO 80309 USA. [Sadeghi-Demneh, Ebrahim] Isfahan Univ Med Sci, Orthot & Prosthet Dept, Musculoskeletal Res Ctr, Esfahan, Iran. [Grabowski, Alena M.] US Dept Vet Affairs, Eastern Colorado Healthcare Syst, Denver, CO USA. RP Ikeda, AJ (reprint author), San Francisco State Univ, Whirlwind Wheelchair Int, 1600 Holloway Ave,SCI 251, San Francisco, CA 94132 USA. EM andrea@whirlwindwheelchair.org RI Sadeghi-Demneh, Ebrahim/E-8110-2012 OI Sadeghi-Demneh, Ebrahim/0000-0003-0590-8512; GRABOWSKI, ALENA/0000-0002-4432-618X FU US Department of Education, National Institute on Disability and Rehabilitation Research [H133A090020] FX This work was supported by the US Department of Education, National Institute on Disability and Rehabilitation Research (grant number H133A090020). NR 102 TC 3 Z9 3 U1 4 U2 17 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0309-3646 EI 1746-1553 J9 PROSTHET ORTHOT INT JI Prosthet. Orthot. Int. PD OCT PY 2014 VL 38 IS 5 BP 343 EP 362 DI 10.1177/0309364613490443 PG 20 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA AQ4NG UT WOS:000342774400001 PM 23942758 ER PT J AU Nanyes, DR Junco, SE Taylor, AB Robinson, AK Patterson, NL Shivarajpur, A Halloran, J Hale, SM Kaur, Y Hart, PJ Kim, CA AF Nanyes, David R. Junco, Sarah E. Taylor, Alexander B. Robinson, Angela K. Patterson, Nicolle L. Shivarajpur, Ambika Halloran, Jonathan Hale, Seth M. Kaur, Yogeet Hart, P. John Kim, Chongwoo A. TI Multiple polymer architectures of human polyhomeotic homolog 3 sterile alpha motif SO PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS LA English DT Article DE SAM; Polyhomeotic; Polycomb group; chromatin; polymer ID TUMOR-SUPPRESSOR ACTIVITY; POLYCOMB-GROUP PROTEINS; SAM DOMAIN; SEX-COMB; REPRESSION; GENES; PHC3; SOFTWARE AB The self-association of sterile alpha motifs (SAMs) into a helical polymer architecture is a critical functional component of many different and diverse array of proteins. For the Drosophila Polycomb group (PcG) protein Polyhomeotic (Ph), its SAM polymerization serves as the structural foundation to cluster multiple PcG complexes, helping to maintain a silenced chromatin state. Ph SAM shares 64% sequence identity with its human ortholog, PHC3 SAM, and both SAMs polymerize. However, in the context of their larger protein regions, PHC3 SAM forms longer polymers compared with Ph SAM. Motivated to establish the precise structural basis for the differences, if any, between Ph and PHC3 SAM, we determined the crystal structure of the PHC3 SAM polymer. PHC3 SAM uses the same SAM-SAM interaction as the Ph SAM sixfold repeat polymer. Yet, PHC3 SAM polymerizes using just five SAMs per turn of the helical polymer rather than the typical six per turn observed for all SAM polymers reported to date. Structural analysis suggested that malleability of the PHC3 SAM would allow formation of not just the fivefold repeat structure but also possibly others. Indeed, a second PHC3 SAM polymer in a different crystal form forms a sixfold repeat polymer. These results suggest that the polymers formed by PHC3 SAM, and likely others, are dynamic. The functional consequence of the variable PHC3 SAM polymers may be to create different chromatin architectures. (C) 2014 Wiley Periodicals, Inc. C1 [Nanyes, David R.; Junco, Sarah E.; Taylor, Alexander B.; Robinson, Angela K.; Patterson, Nicolle L.; Shivarajpur, Ambika; Halloran, Jonathan; Hale, Seth M.; Kaur, Yogeet; Hart, P. John; Kim, Chongwoo A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Taylor, Alexander B.; Hart, P. John] Xray Crystallog Core Lab, San Antonio, TX 78229 USA. [Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. RP Kim, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, MSC 7760,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM chong@biochem.uthscsa.edu FU American Heart Association [0830111N]; American Cancer Society [RSG 08 285 01 GMC]; Department of Defense Breast Cancer Research Program [BC075278]; Welch Foundation [AQ-1813, AQ-1399]; NIH [1 F31 GM099418-01A1]; NIH-NCI [P30 CA054174-17] FX Grant sponsor: American Heart Association; Grant number: #0830111N (to C. A. K.); Grant sponsor: American Cancer Society; Grant number: RSG 08 285 01 GMC (to C. A. K.); Grant sponsor: Department of Defense Breast Cancer Research Program; Grant number: BC075278 (to C. A. K.); Grant sponsor: Welch Foundation; Grant numbers: AQ-1813 (to C. A. K.) and AQ-1399 (to P.J.H.); Grant sponsor: NIH; Grant numbers: 1 F31 GM099418-01A1 (to S.E.J.) and NIH-NCI P30 CA054174-17 (to P.J.H). NR 29 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0887-3585 EI 1097-0134 J9 PROTEINS JI Proteins PD OCT PY 2014 VL 82 IS 10 BP 2823 EP 2830 DI 10.1002/prot.24645 PG 8 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA AQ5LC UT WOS:000342849400044 PM 25044168 ER PT J AU Mahaney-Price, AF Hilgeman, MM Davis, LL McNeal, SF Conner, CM Allen, RS AF Mahaney-Price, Ann F. Hilgeman, Michelle M. Davis, Lori L. McNeal, Sandre F. Conner, Charles M. Allen, Rebecca S. TI Living Will Status and Desire for Living Will Help Among Rural Alabama Veterans SO RESEARCH IN NURSING & HEALTH LA English DT Article DE living will; advance care planning; advance directive; end of life; rural; veterans ID ILLNESS RATING-SCALE; OF-LIFE CARE; ADVANCE DIRECTIVE COMPLETION; DECISION-MAKING; MEDICAL-CARE; END; COMMUNICATION; VALIDATION; DISABILITY; ADMISSION AB The purpose of this secondary analysis of data from an earlier intervention study to increase Veterans Administration health care enrollment in rural Alabama veterans was to determine the veterans' living will status, desire for help completing a living will, and relationships between these and demographic, health insurance, health self-report, cumulative illness, disability, and trust characteristics. Baseline data for 201 rural Alabama veterans were extracted from the larger study. Chi-square and t tests were used to analyze group differences in categorical and continuous variables. Logistic regression models were used to determine multivariate associations of variables with living will status and desire for help. Only 13% of participants had living wills. Of those without living wills, 40% expressed a desire for help completing a living will. African Americans were less likely to have living wills than were Caucasians. Participants with more than high school education were more likely to desire help completing living wills than were those with less education. With the exception of moderate-severe respiratory illness, moderate-severe illness was not associated with having a living will. With the exception of moderate-severe vascular illness, moderate-severe illness was not associated with desire for help completing a living will. The racial and educational disparities in living will status and desire for help and the number of participants who desired help completing a living will suggests a need for action to increase advance care planning among rural veterans. (C) 2014 Wiley Periodicals, Inc. C1 [Mahaney-Price, Ann F.] Tuscaloosa VA Med Ctr, Res & Dev Serv, Tuscaloosa, AL 35404 USA. [Hilgeman, Michelle M.] Univ Alabama, Res & Dev Serv, Tuscaloosa VA Med Ctr, Tuscaloosa Res & Educ Adv Corp,Ctr Mental Hlth &, Tuscaloosa, AL USA. [Davis, Lori L.] Tuscaloosa Res & Educ Adv Corp, Tuscaloosa VA Med Ctr, Res & Dev Serv, Tuscaloosa, AL USA. [Davis, Lori L.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [McNeal, Sandre F.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. [Conner, Charles M.] Birmingham VA Med Ctr, Res Dept, Birmingham, AL USA. [Allen, Rebecca S.] Univ Alabama, Ctr Mental Hlth & Aging, Tuscaloosa, AL USA. RP Mahaney-Price, AF (reprint author), Tuscaloosa VA Med Ctr, Res & Dev Serv, 3701 Loop Rd East, Tuscaloosa, AL 35404 USA. EM amparnp@yahoo.com OI Allen, Rebecca Sue/0000-0002-2563-4996 FU Veterans Health Administration Office of Rural Health FX We are grateful for the support of the Veterans Health Administration Office of Rural Health (funding), Lawrence Biro (former VA VISN 7 Director), Maria Andrews, Tuscaloosa VA Medical Center Director, Alan Tyler, former Tuscaloosa VA Medical Center Director, Rica Lewis-Payton, former Birmingham VA Medical Center Director, and VA Research Services at the Tuscaloosa and Birmingham VA Medical Centers. A full list of participating Alabama Veteran Rural Health Initiative investigators and institutions is published elsewhere (see Hilgeman et al., 2014). NR 44 TC 2 Z9 2 U1 2 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0160-6891 EI 1098-240X J9 RES NURS HEALTH JI Res. Nurs. Health PD OCT PY 2014 VL 37 IS 5 BP 379 EP 390 DI 10.1002/nur.21617 PG 12 WC Nursing SC Nursing GA AQ7FB UT WOS:000342976900007 PM 25156143 ER PT J AU Horton, LE Smith, AA Haas, GL AF Horton, Leslie E. Smith, Ashley A. Haas, Gretchen L. TI The nature and timing of social deficits in child and adolescent offspring of parents with schizophrenia: Preliminary evidence for precursors of negative symptoms? SO SCHIZOPHRENIA RESEARCH LA English DT Article DE High-risk; Schizophrenia; Social skills; Premorbid adjustment; Social anhedonia; Social amotivation; Negative symptoms ID ADULT SCHIZOPHRENIA; HIGH-RISK; ABNORMALITIES; ADJUSTMENT; ANHEDONIA AB Children with social dysfunction and a first-degree relative with schizophrenia are at elevated risk for schizophrenia; however, the nature of this dysfunction is unclear. It was hypothesized that familial high-risk (HR) children and adolescents (n = 17) would have social skill deficits relative to healthy controls (HC; n = 35). HR participants had a bimodal distribution of social skill scores (47% excellent; 53% poor). HR participants had worse social skills, assertion and empathy scores, suggesting possible developmental precursors to the social amotivation domain of negative symptoms. Characterizing HR children's social deficits could assist identification of those at risk for schizophrenia. (C) 2014 Elsevier B. V. All rights reserved. C1 [Horton, Leslie E.; Smith, Ashley A.; Haas, Gretchen L.] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA. [Haas, Gretchen L.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Horton, LE (reprint author), Univ Pittsburgh, Med Ctr, 3811 OHara St, Pittsburgh, PA 15213 USA. EM hortonle2@upmc.edu FU NARSAD Independent Investigator Grant [1098]; Department of Psychiatry of the University of Pittsburgh School of Medicine FX This work was supported, in part, by NARSAD Independent Investigator Grant #1098 to the senior author (G. Haas), and infrastructure support funding from the Department of Psychiatry of the University of Pittsburgh School of Medicine. We thank Dr. Matcheri S. Keshavan and Diana Mermon, MS, for their assistance in referral of some of the participants to this study. We thank Shelby Miller, Audrey Brie Latimore, Valerie Michael, and Nicole Pawloski for their assistance in data preparation efforts. NR 17 TC 1 Z9 1 U1 1 U2 12 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD OCT PY 2014 VL 159 IS 1 BP 27 EP 30 DI 10.1016/j.schres.2014.07.007 PG 4 WC Psychiatry SC Psychiatry GA AQ8TY UT WOS:000343107400005 PM 25112161 ER PT J AU Mote, J Minzenberg, MJ Carter, CS Kring, AM AF Mote, Jasmine Minzenberg, Michael J. Carter, C. S. Kring, Ann M. TI Deficits in anticipatory but not consummatory pleasure in people with recent-onset schizophrenia spectrum disorders SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Anhedonia; Anticipatory pleasure; Consummatory pleasure; Psychosis; Schizophrenia ID NEGATIVE SYMPTOMS; ANHEDONIA; SCALE; EXPERIENCE; PSYCHOSIS; INDIVIDUALS; VALIDATION AB The majority of studies examining self-reported anticipatory and consummatory pleasure in schizophrenia, as measured on the Temporal Experience of Pleasure Scale (TEPS), have been conducted on chronically ill people with the disorder. In this study, people with a recent-onset schizophrenia spectrum diagnosis (first psychotic episode within one year of study participation) (n = 88) and people without a schizophrenia spectrum diagnosis (n = 66) were administered the TEPS. People with a schizophrenia spectrum diagnosis reported significantly lower scores of anticipatory, but not consummatory, pleasure on the TEPS compared to the control group. TEPS anticipatory pleasure scores were also significantly, negatively correlated with negative symptoms, but neither TEPS anticipatory nor consummatory pleasure scores were significantly correlated with functioning measures. Our results replicate previous findings with chronically ill people with schizophrenia on the TEPS. (C) 2014 Elsevier B. V. All rights reserved. C1 [Mote, Jasmine; Kring, Ann M.] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA. [Minzenberg, Michael J.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Carter, C. S.] UC Davis Med Ctr, Imaging Res Ctr, Sacramento, CA 95817 USA. RP Mote, J (reprint author), Univ Calif Berkeley, Dept Psychol, 3210 Tolman Hall 1650, Berkeley, CA 94720 USA. EM mote@berkeley.edu; michael.minzenberg@ucsf.edu; cameron.carter@ucdmc.ucdavis.edu; akring@berkeley.edu FU National Institute of Mental Health [5R01MH059883-11]; National Science Foundation [DGE 1106400] FX This work was supported by the National Institute of Mental Health (5R01MH059883-11 to CSC). Jasmine Mote was supported by award number DGE 1106400 from the National Science Foundation. NR 26 TC 11 Z9 11 U1 1 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD OCT PY 2014 VL 159 IS 1 BP 76 EP 79 DI 10.1016/j.schres.2014.07.048 PG 4 WC Psychiatry SC Psychiatry GA AQ8TY UT WOS:000343107400013 PM 25139112 ER PT J AU Reddy, LF Green, MF Rizzo, S Sugar, CA Blanchard, JJ Gur, RE Kring, AM Horan, WP AF Reddy, L. Felice Green, Michael F. Rizzo, Shemra Sugar, Catherine A. Blanchard, Jack J. Gur, Raquel E. Kring, Ann M. Horan, William P. TI Behavioral approach and avoidance in schizophrenia: An evaluation of motivational profiles SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Motivation; Behavioral approach and avoidance; Social anhedonia; Negative symptoms; BIS/BAS ID CLINICAL-ASSESSMENT INTERVIEW; PSYCHIATRIC RATING-SCALE; NEGATIVE SYMPTOMS CAINS; INHIBITION SYSTEMS; EEG ASYMMETRY; MONTE-CARLO; ACTIVATION; ANHEDONIA; PERSONALITY; BIS AB Schizophrenia is associated with motivational deficits that interfere with a wide range of goal directed activities. Despite their clinical importance, our current understanding of these motivational impairments is limited. Furthermore, different types of motivational problems are commonly seen among individuals within the broad diagnosis of schizophrenia. The goal of the current study was to examine whether clinically meaningful subgroups could be identified based on approach and avoidance motivational tendencies. We measured these tendencies in 151 individuals with schizophrenia. Although prior studies demonstrate elevated BIS sensitivity in schizophrenia at the overall group level, none have explored various combinations of BIS/BAS sensitivities within this disorder. Cluster analyses yielded five subgroups with different combinations of low, moderate, or high BIS and BAS. The subgroups had interpretable differences in clinically rated negative symptoms and self-reported anhedonia/socio-emotional attitudes, which were not detectable with the more commonly used linear BIS/BAS scores. Two of the subgroups had significantly elevated negative symptoms but different approach/avoidance profiles: one was characterized by markedly low BIS, low BAS and an overall lack of social approach motivation; the other had markedly high BIS but moderate BAS and elevated social avoidance motivation. The two subgroups with relatively good clinical functioning showed patterns of BAS greater than BIS. Our findings indicate that there are distinct motivational pathways that can lead to asociality in schizophrenia and highlight the value of considering profiles based on combined patterns of BIS and BAS in schizophrenia. Published by Elsevier B.V. C1 [Reddy, L. Felice; Green, Michael F.; Horan, William P.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Reddy, L. Felice; Green, Michael F.; Rizzo, Shemra; Sugar, Catherine A.; Horan, William P.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Rizzo, Shemra; Sugar, Catherine A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90024 USA. [Blanchard, Jack J.] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. [Gur, Raquel E.] Univ Penn, Dept Psychiat, Neuropsychiat Sect, Philadelphia, PA 19104 USA. [Kring, Ann M.] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA. RP Reddy, LF (reprint author), VA Greater Los Angeles Healthcare Syst, MIRECC 210A,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NIH [1R01MH082890, 1R01MH082783, RO1 MH08272, 1R01MH082839, 1R01MH082782] FX This work was supported in part by NIH grant 1R01MH082890 to Dr. Kring, grants 1R01MH082783 and RO1 MH08272 to Dr. Gur, grant 1R01MH082839 to Dr. Blanchard, and grant 1R01MH082782 to Dr. Horan. NR 46 TC 6 Z9 6 U1 5 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD OCT PY 2014 VL 159 IS 1 BP 164 EP 170 DI 10.1016/j.schres.2014.07.047 PG 7 WC Psychiatry SC Psychiatry GA AQ8TY UT WOS:000343107400027 ER PT J AU Gray, BE McMahon, RP Green, MF Seidman, LJ Mesholam-Gately, RI Kern, RS Nuechterlein, KH Keefe, RS Gold, JM AF Gray, Bradley E. McMahon, Robert P. Green, Michael F. Seidman, Larry J. Mesholam-Gately, Raquelle I. Kern, Robert S. Nuechterlein, Keith H. Keefe, Richard S. Gold, James M. TI Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Reliable change; Regression; MCCB; MATRICS ID SCHIZOPHRENIA; REGRESSION AB Objective: Clinicians often need to evaluate the treatment response of an individual person and to know that observed change is true improvement or worsening beyond usual week-to-week changes. This paper gives clinicians tools to evaluate individual changes on the MATRICS Consensus Cognitive Battery (MCCB). We compare three different approaches: a descriptive analysis of MCCB test-retest performance with no intervention, a reliable change index (RCI) approach controlling for average practice effects, and a regression approach. Method: Data were gathered as part of the MATRICS PASS study (Nuechterlein et al., 2008). A total of 159 people with schizophrenia completed the MCCB at baseline and 4 weeks later. Data were analyzed using an RCI and a regression formula establishing confidence intervals. Results: The RCI and regression approaches agree within one point when baseline values are close to the sample mean. However, the regression approach offers more accurate limits for expected change at the tails of the distribution of baseline scores. Conclusions: Although both approaches have their merits, the regression approach provides the most accurate measure of significant change across the full range of scores. As the RCI does not account for regression to the mean and has confidence limits that remain constant across baseline scores, the RCI approach effectively gives narrower confidence limits around an inaccurately predicted average change value. Further, despite the high test-retest reliability of the MCCB, a change in an individual's score must be relatively large to be confident that it is beyond normal month-to-month variation. (C) 2014 Elsevier B. V. All rights reserved. C1 [Gray, Bradley E.; McMahon, Robert P.; Gold, James M.] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Dept Psychiat, Baltimore, MD 21228 USA. [Green, Michael F.; Kern, Robert S.; Nuechterlein, Keith H.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Green, Michael F.; Kern, Robert S.; Nuechterlein, Keith H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Seidman, Larry J.; Mesholam-Gately, Raquelle I.] Harvard Univ, Massachusetts Mental Hlth Ctr, Beth Israel Deaconess Med Ctr, Publ Psychiat Div,Med Sch,Dept Psychiat, Boston, MA 02115 USA. [Keefe, Richard S.] Duke Univ, Sch Med, Dept Psychiat, Durham, NC 27710 USA. RP Gold, JM (reprint author), MPRC, POB 21247, Baltimore, MD 21228 USA. EM jgold@mprc.umaryland.edu FU NIMH [N01MH22006] FX This work was made possible by NIMH contract N01MH22006 provided to the University of California, Los Angeles (Drs. Marder, Green, and Fenton); and an option (Drs. Green and Nuechterlein) to the NIMH MATRICS initiative. NR 12 TC 5 Z9 5 U1 3 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD OCT PY 2014 VL 159 IS 1 BP 182 EP 187 DI 10.1016/j.schres.2014.07.032 PG 6 WC Psychiatry SC Psychiatry GA AQ8TY UT WOS:000343107400030 PM 25156338 ER PT J AU Miller, CB Espie, CA Epstein, DR Friedman, L Morin, CM Pigeon, WR Spielman, AJ Kyle, SD AF Miller, Christopher B. Espie, Colin A. Epstein, Dana R. Friedman, Leah Morin, Charles M. Pigeon, Wilfred R. Spielman, Arthur J. Kyle, Simon D. TI The evidence base of sleep restriction therapy for treating insomnia disorder SO SLEEP MEDICINE REVIEWS LA English DT Review DE Insomnia; Sleep; Cognitive behavioral therapy; Treatment; Psychological intervention; Sleep restriction therapy; Evidence base; Review ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; ECOLOGICAL MOMENTARY ASSESSMENT; PLACEBO-CONTROLLED TRIAL; OLDER-ADULTS; NONPHARMACOLOGIC TREATMENT; COMPARATIVE METAANALYSIS; CLINICAL MANAGEMENT; PRACTICE PARAMETERS; DAYTIME SYMPTOMS AB Sleep restriction therapy is routinely used within cognitive behavioral therapy to treat chronic insomnia. However, the efficacy for sleep restriction therapy as a standalone intervention has yet to be comprehensively reviewed. This review evaluates the evidence for the use of sleep restriction therapy in the treatment of chronic insomnia. The literature was searched using web-based databases, finding 1344 studies. Twenty-one were accessed in full (1323 were deemed irrelevant to this review). Nine were considered relevant and evaluated in relation to study design using a standardized study checklist and levels of evidence. Four trials met adequate methodological strength to examine the efficacy of therapy for chronic insomnia. Weighted effect sizes for self-reported sleep diary measures of sleep onset latency, wake time after sleep onset, and sleep efficiency were moderate-to-large after therapy. Total sleep time indicated a small improvement. Standalone sleep restriction therapy is efficacious for the treatment of chronic insomnia for sleep diary continuity variables. Studies are insufficient to evaluate the full impact on objective sleep variables. Measures of daytime functioning in response to therapy are lacking. Variability in the sleep restriction therapy implementation methods precludes any strong conclusions regarding the true impact of therapy. A future research agenda is outlined. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Miller, Christopher B.] Univ Sydney, Sydney Med Sch, Woolcock Inst Med Res, Ctr Integrated Res & Understanding Sleep, Sydney, NSW 2050, Australia. [Miller, Christopher B.] Univ Glasgow, Inst Neurosci & Psychol, Glasgow G12 8QQ, Lanark, Scotland. [Espie, Colin A.] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford OX1 2JD, England. [Espie, Colin A.] Univ Oxford, Circadian Neurosci Inst, Oxford OX1 2JD, England. [Epstein, Dana R.] Phoenix Vet Affairs Hlth Care Syst, Phoenix, AZ USA. [Epstein, Dana R.] Arizona State Univ, Coll Nursing & Hlth Innovat, Tempe, AZ 85287 USA. [Friedman, Leah] Stanford Univ, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Friedman, Leah] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Morin, Charles M.] Univ Laval, Quebec City, PQ, Canada. [Pigeon, Wilfred R.] Univ Rochester, Med Ctr, Sleep & Neurophysiol Res Lab, Rochester, NY 14627 USA. [Pigeon, Wilfred R.] US Dept Vet Affairs, Ctr Excellence Suicide Prevent, Washington, DC USA. [Spielman, Arthur J.] CUNY City Coll, Cognit Neurosci Doctoral Program, New York, NY USA. [Spielman, Arthur J.] Weill Cornell Med Coll, Ctr Sleep Med, New York, NY USA. [Kyle, Simon D.] Univ Manchester, Sch Psychol Sci, Manchester M13 9PL, Lancs, England. RP Miller, CB (reprint author), Univ Sydney, Sydney Med Sch, Woolcock Inst Med Res, POB M77,Missenden Rd, Sydney, NSW 2050, Australia. EM chris.miller@sydney.edu.au OI Miller, Christopher/0000-0002-2936-7717; Kyle, Simon/0000-0002-9581-5311 FU National Health and Medical Research Council (NHMRC, Australia) Centre for Integrated Research and Understanding of Sleep (CIRUS) [571421]; Sackler Institute of Psychobiological Research (University of Glasgow Sleep Centre, Scotland, UK); Chief Scientist Office (Scotland, UK) [CZG/2/503] FX This research was supported by the National Health and Medical Research Council (NHMRC, Australia) Centre for Integrated Research and Understanding of Sleep (CIRUS), grant no. 571421; the Sackler Institute of Psychobiological Research (University of Glasgow Sleep Centre, Scotland, UK); and the Chief Scientist Office (Scotland, UK) Grant # CZG/2/503. Authors Epstein, Friedman and Pigeon are employees of the United States Department of Veterans Affairs, which supported their work on this manuscript. The authors' views or opinions do not necessarily represent those of the Department of Veterans Affairs or the United States Government. NR 75 TC 11 Z9 11 U1 3 U2 24 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1087-0792 EI 1532-2955 J9 SLEEP MED REV JI Sleep Med. Rev. PD OCT PY 2014 VL 18 IS 5 BP 415 EP 424 DI 10.1016/j.smrv.2014.01.006 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AQ6XB UT WOS:000342956100007 PM 24629826 ER PT J AU Knox, R Brennan-Minnella, AM Lu, FX Yang, DN Nakazawa, T Yamamoto, T Swanson, RA Ferriero, DM Jiang, XN AF Knox, Renatta Brennan-Minnella, Angela M. Lu, Fuxin Yang, Diana Nakazawa, Takanobu Yamamoto, Tadashi Swanson, Raymond A. Ferriero, Donna M. Jiang, Xiangning TI NR2B Phosphorylation at Tyrosine 1472 Contributes to Brain Injury in a Rodent Model of Neonatal Hypoxia-Ischemia SO STROKE LA English DT Article DE Fyn tyrosine kinase; hypoxia-ischemia, brain; NR2B NMDA receptor ID D-ASPARTATE RECEPTOR; NEURONAL CELL-DEATH; NMDA-RECEPTORS; NADPH OXIDASE; ACTIVATION; SUBUNIT; MICE; SUPEROXIDE; LOCALIZATION; 3-KINASE AB Background and Purpose-The NR2B subunit of the N-methyl-d-aspartate (NMDA) receptor is phosphorylated by the Src family kinase Fyn in brain, with tyrosine (Y) 1472 as the major phosphorylation site. Although Y1472 phosphorylation is important for synaptic plasticity, it is unknown whether it is involved in NMDA receptor-mediated excitotoxicity in neonatal brain hypoxia-ischemia (HI). This study was designed to elucidate the specific role of Y1472 phosphorylation of NR2B in neonatal HI in vivo and in NMDA-mediated neuronal death in vitro. Methods-Neonatal mice with a knockin mutation of Y1472 to phenylalanine (YF-KI) and their wild-type littermates were subjected to HI using the Vannucci model. Brains were scored 5 days later for damage using cresyl violet and iron staining. Western blotting and immunoprecipitation were performed to determine NR2B tyrosine phosphorylation. Expression of NADPH oxidase subunits and superoxide production were measured in vivo. NMDA-induced calcium response, superoxide formation, and cell death were evaluated in primary cortical neurons. Results-After neonatal HI, YF-KI mice have reduced expression of NADPH oxidase subunit gp91(phox) and p47(phox) and superoxide production, lower activity of proteases implicated in necrotic and apoptotic cell death, and less brain damage when compared with the wild-type mice. In vitro, YF-KI mutation diminishes superoxide generation in response to NMDA without effect on calcium accumulation and inhibits NMDA and glutamate-induced cell death. Conclusions-Upregulation of NR2B phosphorylation at Y1472 after neonatal HI is involved in superoxide-mediated oxidative stress and contributes to brain injury. C1 [Knox, Renatta; Lu, Fuxin; Yang, Diana; Ferriero, Donna M.; Jiang, Xiangning] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94158 USA. [Knox, Renatta; Ferriero, Donna M.] Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94158 USA. [Knox, Renatta] Univ Calif San Francisco, Med Scientist Training Program, San Francisco, CA 94158 USA. [Brennan-Minnella, Angela M.; Swanson, Raymond A.; Ferriero, Donna M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA. [Brennan-Minnella, Angela M.; Swanson, Raymond A.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94158 USA. [Nakazawa, Takanobu; Yamamoto, Tadashi] Univ Tokyo, Inst Med Sci, Div Oncol, Tokyo, Japan. RP Jiang, XN (reprint author), Univ Calif San Francisco, Dept Pediat, 675 Nelson Rising Lane Room 494, San Francisco, CA 94158 USA. EM xiangning.jiang@ucsf.edu FU National Institute of Neurological Disorders and Stroke [F31NS073145, R21NS059613, RO1NS084057, RO1NS081149, RO1NS33997] FX This work was funded by grants from National Institute of Neurological Disorders and Stroke: F31NS073145 (Dr Knox); R21NS059613 and RO1NS084057 (Dr Jiang); RO1NS081149 (Dr Swanson); and RO1NS33997 (Dr Ferriero). NR 25 TC 7 Z9 7 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD OCT PY 2014 VL 45 IS 10 BP 3040 EP 3047 DI 10.1161/STROKEAHA.114.006170 PG 8 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA AQ4UH UT WOS:000342794700042 PM 25158771 ER PT J AU Thase, ME Kingdon, D Turkington, D AF Thase, Michael E. Kingdon, David Turkington, Douglas TI The promise of cognitive behavior therapy for treatment of severe mental disorders: a review of recent developments SO WORLD PSYCHIATRY LA English DT Article DE Cognitive behavior therapy; adjunctive therapy; severe mental disorders; schizophrenia; major depressive disorders; treatment refractory depression; bipolar disorder ID RANDOMIZED CONTROLLED-TRIAL; CHRONIC DEPRESSION; MAJOR DEPRESSION; ANALYSIS SYSTEM; BIPOLAR DISORDER; CHRONIC FORMS; PSYCHOSIS; PSYCHOTHERAPY; METAANALYSIS; SCHIZOPHRENIA AB Cognitive behavior therapy (CBT), as exemplified by the model of psychotherapy developed and refined over the past 40 years by A. T. Beck and colleagues, is one of the treatments of first choice for ambulatory depressive and anxiety disorders. Over the past several decades, there have been vigorous efforts to adapt CBT for treatment of more severe mental disorders, including schizophrenia and the more chronic and/or treatment refractory mood disorders. These efforts have primarily studied CBT as an adjunctive therapy, i.e., in combination with pharmacotherapy. Given the several limitations of state-of-the-art pharmacotherapies for these severe mental disorders, demonstration of clinically meaningful additive effects for CBT would have important implications for improving public health. This paper reviews the key developments in this important area of therapeutics, providing a summary of the current state of the art and suggesting directions for future research. C1 [Thase, Michael E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Kingdon, David] Univ Southampton, Southampton, Hants, England. [Turkington, Douglas] NTW NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England. RP Thase, ME (reprint author), Univ Penn, Perelman Sch Med, 3535 Market St, Philadelphia, PA 19104 USA. NR 50 TC 16 Z9 17 U1 8 U2 29 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1723-8617 EI 2051-5545 J9 WORLD PSYCHIATRY JI World Psychiatry PD OCT PY 2014 VL 13 IS 3 BP 244 EP 250 DI 10.1002/wps.20149 PG 7 WC Psychiatry SC Psychiatry GA AQ5LR UT WOS:000342851200007 PM 25273290 ER PT J AU Swann, AC AF Swann, Alan C. TI Non-pharmacological and pharmacological treatments act on the same brain SO WORLD PSYCHIATRY LA English DT Editorial Material ID BIPOLAR DISORDERS; DEPRESSION; THERAPY C1 Baylor Coll Med Mental Hlth Care Line, Dept Psychiat & Behav Sci, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Swann, AC (reprint author), Baylor Coll Med Mental Hlth Care Line, Dept Psychiat & Behav Sci, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. NR 11 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1723-8617 EI 2051-5545 J9 WORLD PSYCHIATRY JI World Psychiatry PD OCT PY 2014 VL 13 IS 3 BP 262 EP 264 DI 10.1002/wps.20166 PG 4 WC Psychiatry SC Psychiatry GA AQ5LR UT WOS:000342851200016 PM 25273299 ER PT J AU Wang, CL Davenport, MS Chinnugounder, S Schopp, JG Kani, K Zaidi, S Hippe, DS Paladin, AM Lalwani, N Bhargava, P Bush, WH AF Wang, Carolyn L. Davenport, Matthew S. Chinnugounder, Sankar Schopp, Jennifer G. Kani, Kimia Zaidi, Sadaf Hippe, Dan S. Paladin, Angelisa M. Lalwani, Neeraj Bhargava, Puneet Bush, William H. TI Errors of epinephrine administration during severe allergic-like contrast reactions: lessons learned from a bi-institutional study using high-fidelity simulation testing SO ABDOMINAL IMAGING LA English DT Article DE Epinephrine; Epinephrine error; Contrast reaction; High-fidelity simulation ID RADIOLOGY RESIDENTS; MEDIA REACTIONS; MANAGEMENT; EMERGENCIES; GUIDELINES; INJECTION; FREQUENCY; OVERDOSE; ASTHMA AB To determine the most common errors of epinephrine administration during severe allergic-like contrast reaction management using high-fidelity simulation surrogates. IRB approval and informed consent were obtained for this HIPAA-compliant bi-institutional prospective study of 40 radiology residents, fellows, and faculty who were asked to manage a structured high-fidelity severe allergic-like contrast reaction scenario (i.e., mild hives progressing to mild bronchospasm, then bronchospasm unresponsive to bronchodilators, and finally anaphylactic shock) on an interactive manikin. Intravenous (IV) and intramuscular epinephrine ampules were available to all participants, and the manikin had a functioning intravenous catheter for all scenarios. Video recordings of their performance were reviewed by experts in contrast reaction management, and errors in epinephrine administration were recorded and characterized. No participant (0/40) failed to give indicated epinephrine, but more than half (58% [23/40]) committed an error while doing so. The most common mistake was to administer epinephrine as the first-line treatment for mild bronchospasm (33% [13/40]). Other common errors were to administer IV epinephrine without a subsequent IV saline flush or concomitant IV fluids (25% [10/40]), administer an overdose of epinephrine (8% [3/40]), and administer epinephrine 1:1000 intravenously (8% [3/40]). Epinephrine administration errors are common. Many radiologists fail to administer albuterol as the first-line treatment for mild bronchospasm and fail to flush the IV catheter when administering IV epinephrine. High-fidelity contrast reaction scenarios can be used to identify areas for training improvement. C1 [Wang, Carolyn L.; Chinnugounder, Sankar; Kani, Kimia; Zaidi, Sadaf; Hippe, Dan S.; Paladin, Angelisa M.; Lalwani, Neeraj; Bush, William H.] Univ Washington, Seattle, WA 98195 USA. [Davenport, Matthew S.] Univ Michigan Hlth Syst, Dept Radiol, Ann Arbor, MI 48109 USA. [Schopp, Jennifer G.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Bhargava, Puneet] Univ Washington, Seattle, WA 98108 USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Wang, CL (reprint author), Univ Washington, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA. EM wangcl@uw.edu OI Hippe, Daniel/0000-0003-2427-4404; Bhargava, Puneet/0000-0002-3849-9666 NR 35 TC 3 Z9 3 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0942-8925 EI 1432-0509 J9 ABDOM IMAGING JI Abdom. Imaging PD OCT PY 2014 VL 39 IS 5 BP 1127 EP 1133 DI 10.1007/s00261-014-0141-x PG 7 WC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging SC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging GA AP9TB UT WOS:000342421700021 PM 25237003 ER PT J AU Lamming, DW Mihaylova, MM Katajisto, P Baar, EL Yilmaz, OH Hutchins, A Gultekin, Y Gaither, R Sabatini, DM AF Lamming, Dudley W. Mihaylova, Maria M. Katajisto, Pekka Baar, Emma L. Yilmaz, Omer H. Hutchins, Amanda Gultekin, Yetis Gaither, Rachel Sabatini, David M. TI Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan SO AGING CELL LA English DT Article DE aging; gender dimorphism; longevity; mTORC2; Rictor; Rapamycin ID COMPLEX 2; RAPAMYCIN; MICE; PHOSPHORYLATION; LONGEVITY; EXTENSION; SIROLIMUS; AKT/PKB; GROWTH; PKC AB Rapamycin, an inhibitor of the mechanistic target of rapamycin (mTOR), robustly extends the lifespan of model organisms including mice. We recently found that chronic treatment with rapamycin not only inhibits mTOR complex 1 (mTORC1), the canonical target of rapamycin, but also inhibits mTOR complex 2 (mTORC2) in vivo. While genetic evidence strongly suggests that inhibition of mTORC1 is sufficient to promote longevity, the impact of mTORC2 inhibition on mammalian longevity has not been assessed. RICTOR is a protein component of mTORC2 that is essential for its activity. We examined three different mouse models of Rictor loss: mice heterozygous for Rictor, mice lacking hepatic Rictor, and mice in which Rictor was inducibly deleted throughout the body in adult animals. Surprisingly, we find that depletion of RICTOR significantly decreases male, but not female, lifespan. While the mechanism by which RICTOR loss impairs male survival remains obscure, we find that the effect of RICTOR depletion on lifespan is independent of the role of hepatic mTORC2 in promoting glucose tolerance. Our results suggest that inhibition of mTORC2 signaling is detrimental to males, which may explain in part why interventions that decrease mTOR signaling show greater efficacy in females. C1 [Lamming, Dudley W.; Baar, Emma L.] Univ Wisconsin, Dept Med, Madison, WI 53705 USA. [Lamming, Dudley W.; Baar, Emma L.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Lamming, Dudley W.; Mihaylova, Maria M.; Katajisto, Pekka; Yilmaz, Omer H.; Hutchins, Amanda; Gultekin, Yetis; Gaither, Rachel; Sabatini, David M.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA. [Lamming, Dudley W.; Mihaylova, Maria M.; Katajisto, Pekka; Yilmaz, Omer H.; Hutchins, Amanda; Gultekin, Yetis; Gaither, Rachel; Sabatini, David M.] MIT, Dept Biol, Cambridge, MA 02139 USA. [Lamming, Dudley W.; Mihaylova, Maria M.; Katajisto, Pekka; Yilmaz, Omer H.; Hutchins, Amanda; Gultekin, Yetis; Gaither, Rachel; Sabatini, David M.] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA. [Lamming, Dudley W.; Mihaylova, Maria M.; Katajisto, Pekka; Yilmaz, Omer H.; Hutchins, Amanda; Gultekin, Yetis; Gaither, Rachel; Sabatini, David M.] Broad Inst Harvard & MIT, Seven Cambridge Ctr, Cambridge, MA 02142 USA. [Lamming, Dudley W.; Mihaylova, Maria M.; Katajisto, Pekka; Yilmaz, Omer H.; Hutchins, Amanda; Gultekin, Yetis; Gaither, Rachel; Sabatini, David M.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. RP Lamming, DW (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room C3127 Res 151, Madison, WI 53705 USA. EM dlamming@medicine.wisc.edu; sabatini@wi.mit.edu RI Gultekin, Yetis/H-4194-2013 OI Lamming, Dudley/0000-0002-0079-4467 FU National Institute of Health; UW-Madison School of Medicine and Public Health; UW-Madison Department of Medicine; American Federation for Aging Research; Starr Foundation; Koch Institute Frontier Research Program; Ellison Medical Foundation; NIH/NIA [AG041765]; Damon Runyon Cancer Research Foundation [DRG-2146-13]; American Diabetes Association FX We would like to thank all the members of the Lamming and Sabatini labs. The Lamming lab is supported by a grant from the National Institute of Health and startup funds from the UW-Madison School of Medicine and Public Health and the UW-Madison Department of Medicine. The Sabatini lab is supported by grants from the National Institutes of Health and awards from the American Federation for Aging Research, Starr Foundation, Koch Institute Frontier Research Program, and the Ellison Medical Foundation to D. M. S. D. W. L is supported in part by a K99/R00 Pathway to Independence Award from the NIH/NIA (AG041765). M. M. is a Robert Black Fellow of the Damon Runyon Cancer Research Foundation, DRG-2146-13. P. K was supported by a mentor- based fellowship award from the American Diabetes Association. D. M. S. is an investigator of Howard Hughes Medical Institute. This work was supported using facilities and resources from the William S. Middleton Memorial Veterans Hospital. This work does not represent the views of the Department of Veterans Affairs or the United States Government. NR 32 TC 23 Z9 24 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1474-9718 EI 1474-9726 J9 AGING CELL JI Aging Cell PD OCT PY 2014 VL 13 IS 5 BP 911 EP 917 DI 10.1111/acel.12256 PG 7 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA AQ2PY UT WOS:000342631100015 PM 25059582 ER PT J AU Tuerk, PW AF Tuerk, Peter W. TI Starting From Something: Augmenting Exposure Therapy and Methods of Inquiry SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Editorial Material ID OBSESSIVE-COMPULSIVE DISORDER; POSTTRAUMATIC-STRESS-DISORDER; SOCIAL ANXIETY DISORDER; D-CYCLOSERINE; PROLONGED EXPOSURE; DOUBLE-BLIND; METAANALYSIS; PHOBIA; AUGMENTATION; ENHANCEMENT C1 [Tuerk, Peter W.] Vet Hlth Adm, Ralph H Johnson VA Med Ctr, Charleston, SC 29403 USA. [Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Mil Sci Div, Charleston, SC 29425 USA. RP Tuerk, PW (reprint author), Vet Hlth Adm, Ralph H Johnson VA Med Ctr, Charleston, SC 29403 USA. EM tuerk@musc.edu NR 19 TC 2 Z9 2 U1 2 U2 6 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD OCT PY 2014 VL 171 IS 10 BP 1034 EP 1037 DI 10.1176/appi.ajp.2014.14070880 PG 4 WC Psychiatry SC Psychiatry GA AQ3SM UT WOS:000342713800004 PM 25272341 ER PT J AU Pokharel, Y Nambi, V Martin, SS Hoogeveen, RC Nasir, K Khera, A Wong, ND Jones, PH Boone, J Roberts, AJ Ballantyne, CM Virani, SS AF Pokharel, Yashashwi Nambi, Vijay Martin, Seth S. Hoogeveen, Ron C. Nasir, Khurram Khera, Amit Wong, Nathan D. Jones, Peter H. Boone, Jeffrey Roberts, Arthur J. Ballantyne, Christie M. Virani, Salim S. TI Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players SO ATHEROSCLEROSIS LA English DT Article DE Coronary artery calcium; Carotid artery plaque; Lipoprotein associated phospholipase A(2); National football league; Subclinical atherosclerosis ID INTIMA-MEDIA THICKNESS; ACTIVATING-FACTOR ACETYLHYDROLASE; LOW-DENSITY-LIPOPROTEIN; HEART-DISEASE RISK; MYOCARDIAL-INFARCTION; COMPUTED-TOMOGRAPHY; METABOLIC SYNDROME; ARTERY-DISEASE; A(2) MASS; CALCIUM AB Objectives: Retired National Football League (NFL) players were reported to have high prevalence of cardiovascular risk factors. Lipoprotein Associated Phospholipase A(2) (LpPLA(2)) has shown to be associated with cardiovascular disease in the general population, but it is unknown whether such an association exists in retired NFL players. Our objective was to assess whether LpPLA(2) mass was associated with coronary artery calcium (CAC) and carotid artery plaque (CAP) in retired NFL players. Methods: LpPLA(2) mass was assessed using a dual monoclonal antibody immunoassay. CAC presence was defined as CAC score>0. CAP was defined as focal thickening >= 50% than that of the surrounding vessel wall with a minimal thickness of 1.2 mm on carotid ultrasound. Results: In 832 NFL players, the median (IQR) age and LpPLA2 levels were 54 (45-63) years and 142 (109-181) ng/mL respectively. LpPLA(2) mass was positively correlated with low-density lipoprotein (LDL) cholesterol and high-density lipoprotein cholesterol; negatively correlated with LDL particle concentration and body mass index; and not correlated with high-sensitivity C-reactive protein. CAC was present in 659 (79%) and CAP in 544 (65%) players. In a fully adjusted model, LpPLA(2) was not associated with CAC (ORper 1-SD increase, 0.85; 95% CI 0.71-1.02) or CAP (0.90, 0.75-1.08). LpPLA(2) was also not associated with CAC burden in those with CAC>0. Results were similar when highest and lowest LpPLA(2) tertiles were compared, and also in various subgroups. Conclusion: LpPLA2 mass was not associated with coronary or carotid subclinical atherosclerosis in retired NFL players. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 [Pokharel, Yashashwi; Nambi, Vijay; Hoogeveen, Ron C.; Jones, Peter H.; Ballantyne, Christie M.; Virani, Salim S.] Baylor Coll Med, Dept Med, Sect Cardiovasc Res, Houston, TX 77030 USA. [Pokharel, Yashashwi; Nambi, Vijay; Hoogeveen, Ron C.; Jones, Peter H.; Ballantyne, Christie M.; Virani, Salim S.] Methodist DeBakey Heart & Vasc Ctr, Ctr Cardiovasc Dis Prevent, Houston, TX USA. [Nambi, Vijay; Virani, Salim S.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Martin, Seth S.; Nasir, Khurram] Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Baltimore, MD USA. [Nasir, Khurram] Baptist Hlth Med Grp, Ctr Prevent & Wellness Res, Miami Beach, FL USA. [Nasir, Khurram] Baptist Hlth South Florida, Baptist Cardiovasc Inst, Miami, FL USA. [Nasir, Khurram] Robert Stempel, Dept Epidemiol, W Palm Beach, FL USA. [Nasir, Khurram] Herbert Wertheim Coll Med, Dept Med, Miami, FL USA. [Khera, Amit] Univ Texas SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA. [Wong, Nathan D.] Univ Calif Irvine, Heart Dis Prevent Program, Irvine, CA USA. [Boone, Jeffrey] Boone Heart Inst, Denver, CO USA. [Roberts, Arthur J.] Living Heart Fdn, Little Silver, NJ USA. [Virani, Salim S.] Michael E DeBakey VA Med Ctr Hlth Serv, Res & Dev Ctr Innovat, Hlth Policy Qual & Informat Program, Houston, TX USA. RP Pokharel, Y (reprint author), Baylor Coll Med, Dept Med, Sect Cardiovasc Res, 6565 Fannin St,Suite B160, Houston, TX 77030 USA. EM Yashashwi.pokharel@bcm.edu; vnambi@bcm.edu; smart100@jhmi.edu; ronh@bcm.edu; knasir1@jhmi.edu; Amit.Khera@UTSouthwestern.edu; ndwong@uci.edu; jones@bcm.edu; jeffboonemd@gmail.com; drrobertslhf@gmail.com; cmb@bcm.edu; virani@bcm.edu OI Virani, Salim/0000-0001-9541-6954 FU Pollin Fellowship in Preventive Cardiology; Marie Josee and Henry R. Kravis endowed fellowship; Abbott; Amarin; Amgen; Eli Lilly; GlaxoSmithKline; Genentech; Merck; Novartis; Pfizer; Regeneron; Roche; Sanofi-Synthelabo; NIH; AHA; Department of Veterans Affairs Health Services Research and Development Service Career Development Award; American Heart Association Beginning; American Diabetes Association Clinical Science and Epidemiology Award FX Martin: Supported by the Pollin Fellowship in Preventive Cardiology, as well as the Marie Josee and Henry R. Kravis endowed fellowship. Listed as a co-inventor on pending patent filed by Johns Hopkins University on a novel method for LDL cholesterol estimation.; Ballantyne: Grant/Research Support (All paid to institution, not individual): Abbott, Amarin, Amgen, Eli Lilly, GlaxoSmithKline, Genentech, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi-Synthelabo, NIH, AHA.; Virani: Supported by a Department of Veterans Affairs Health Services Research and Development Service Career Development Award, American Heart Association Beginning Grant-in-Aid, and the American Diabetes Association Clinical Science and Epidemiology Award. NR 43 TC 2 Z9 2 U1 0 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 EI 1879-1484 J9 ATHEROSCLEROSIS JI Atherosclerosis PD OCT PY 2014 VL 236 IS 2 BP 251 EP 256 DI 10.1016/j.atherosclerosis.2014.07.011 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AP9QP UT WOS:000342414700024 PM 25105582 ER PT J AU Wang, XG Jia, YL Spain, R Potsaid, B Liu, JJ Baumann, B Hornegger, J Fujimoto, JG Wu, Q Huang, D AF Wang, Xiaogang Jia, Yali Spain, Rebecca Potsaid, Benjamin Liu, Jonathan J. Baumann, Bernhard Hornegger, Joachim Fujimoto, James G. Wu, Qiang Huang, David TI Optical coherence tomography angiography of optic nerve head and parafovea in multiple sclerosis SO BRITISH JOURNAL OF OPHTHALMOLOGY LA English DT Article ID RETINAL BLOOD-FLOW; AMPLITUDE-DECORRELATION ANGIOGRAPHY; FIBER LAYER; NEURITIS; PARAMETERS AB Aims To investigate swept-source optical coherence tomography (OCT) angiography in the optic nerve head (ONH) and parafoveal regions in patients with multiple sclerosis (MS). Methods Fifty-two MS eyes and 21 healthy control (HC) eyes were included. There were two MS subgroups: 38 MS eyes without an optic neuritis (ON) history (MS -ON), and 14 MS eyes with an ON history (MS +ON). The OCT images were captured by high-speed 1050 nm swept-source OCT. The ONH flow index (FI) and parafoveal FI were quantified from OCT angiograms. Results The mean ONH FI was 0.160 +/- 0.010 for the HC group, 0.156 +/- 0.017 for the MS-ON group, and 0.140 +/- 0.020 for the MS+ON group. The ONH FI of the MS+ON group was reduced by 12.5% compared to HC eyes (p=0.004). A higher percentage of MS+ON eyes had abnormal ONH FI compared to HC patients (43% vs 5%, p=0.01). Mean parafoveal FIs were 0.126 +/- 0.007, 0.127 +/- 0.010, and 0.129 +/- 0.005 for the HC, MS-ON, and MS +ON groups, respectively, and did not differ significantly among them. The coefficient of variation (CV) of intravisit repeatability and intervisit reproducibility were 1.03% and 4.53% for ONH FI, and 1.65% and 3.55% for parafoveal FI. Conclusions Based on OCT angiography, the FI measurement is feasible, highly repeatable and reproducible, and it is suitable for clinical measurement of ONH and parafoveal perfusion. The ONH FI may be useful in detecting damage from ON and quantifying its severity. C1 [Wang, Xiaogang; Jia, Yali; Huang, David] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA. [Wang, Xiaogang; Wu, Qiang] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai 200030, Peoples R China. [Spain, Rebecca] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Neurol, Portland, OR 97239 USA. [Potsaid, Benjamin; Liu, Jonathan J.; Baumann, Bernhard; Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA. [Potsaid, Benjamin; Liu, Jonathan J.; Baumann, Bernhard; Fujimoto, James G.] MIT, Elect Res Lab, Cambridge, MA 02139 USA. [Hornegger, Joachim] Univ Erlangen Nurnberg, Pattern Recognit Lab, D-91054 Erlangen, Germany. [Hornegger, Joachim] Univ Erlangen Nurnberg, SAOT, D-91054 Erlangen, Germany. RP Huang, D (reprint author), Oregon Hlth & Sci Univ, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA. EM bjo@dr-huang.net OI Jia, Yali/0000-0002-2784-1905; Baumann, Bernhard/0000-0001-6419-1932 FU NIH [UL1TR000128, R01 EY023285, R01 EY013516, R01-EY11289, P30EY010572]; AFOSR [FA9550-10-1-0551, FA9550-12-1-0499]; German Research Foundation [DFG-HO-1791/11-1]; Research to Prevent Blindness FX This work was supported by NIH grants: Clinical and Translational Science Award Grant (UL1TR000128), R01 EY023285, R01 EY013516, R01-EY11289, and P30EY010572. Additional supports were AFOSR FA9550-10-1-0551, FA9550-12-1-0499, German Research Foundation DFG-HO-1791/11-1, and a grant from Research to Prevent Blindness. NR 25 TC 29 Z9 31 U1 0 U2 6 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0007-1161 EI 1468-2079 J9 BRIT J OPHTHALMOL JI Br. J. Ophthalmol. PD OCT PY 2014 VL 98 IS 10 BP 1368 EP 1373 DI 10.1136/bjophthalmol-2013-304547 PG 6 WC Ophthalmology SC Ophthalmology GA AQ3HF UT WOS:000342681400014 PM 24831719 ER PT J AU Bonilha, HS Simpson, AN Ellis, C Mauldin, P Martin-Harris, B Simpson, K AF Bonilha, Heather Shaw Simpson, Annie N. Ellis, Charles Mauldin, Patrick Martin-Harris, Bonnie Simpson, Kit TI The One-Year Attributable Cost of Post-stroke Dysphagia SO DYSPHAGIA LA English DT Article DE Deglutition; Deglutition disorders; Dysphagia; Cost; Stroke; Length of stay; Discharge severity ID RACIAL DISPARITIES; ACUTE STROKE; MORTALITY; DATABASE AB With the recent emphasis on evidence-based practice and healthcare reform, understanding the cost of dysphagia management has never been more important. It is helpful for clinicians to understand and objectively report the costs associated with dysphagia when they advocate for their services in this economy. Having carefully estimated cost of illness, inputs are needed for cost-effectiveness analyses that help support the value of treatments. This study sought to address this issue by examining the 1-year cost associated with a diagnosis of dysphagia post-stroke in South Carolina. Furthermore, this study investigated whether ethnicity and residence differences exist in the cost of dysphagia post-stroke. Data on 3,200 patients in the South Carolina Medicare database from 2004 who had ICD-9 codes for ischemic stroke, 434 and 436, were retrospectively included in this study. Differences between persons with and without dysphagia post-stroke were compared with respect to age, gender, ethnicity, mortality, length of stay, comorbidity, rurality, discharge disposition, and cost to Medicare. Univariate analyses and a gamma-distributed generalized linear multivariable model with a log link function were completed. We found that the 1-year cost to Medicare for persons with dysphagia post ischemic stroke was $4,510 higher than that for persons without dysphagia post ischemic stroke when controlling for age, comorbidities, ethnicity, and proportion of time alive. Univariate analysis revealed that rurality, ethnicity, and gender were not statistically significantly different in comparisons of individuals with or without dysphagia post-stroke. Post-stroke dysphagia significantly increases post-stroke medical expenses. Understanding the expenditures associated with post-stroke dysphagia is helpful for optimal allocation and use of resources. Such information is needed to conduct cost-effectiveness studies. C1 [Bonilha, Heather Shaw; Ellis, Charles; Martin-Harris, Bonnie] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Bonilha, Heather Shaw; Martin-Harris, Bonnie] Med Univ S Carolina, Evelyn Trammell Inst Voice & Swallowing, Charleston, SC 29425 USA. [Bonilha, Heather Shaw; Simpson, Annie N.; Martin-Harris, Bonnie] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Simpson, Annie N.; Simpson, Kit] Med Univ S Carolina, Dept Healthcare Leadership & Management, Charleston, SC 29425 USA. [Mauldin, Patrick] Med Univ S Carolina, Dept Med, Div Gen Med & Geriatr, Charleston, SC 29425 USA. [Martin-Harris, Bonnie] Ralph H Johnson VA Med Ctr, VA Ctr Dis Prevent & Hlth Intervent Diverse Popul, Charleston, SC USA. RP Bonilha, HS (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, 77 President St, Charleston, SC 29425 USA. EM bonilhah@musc.edu FU NIH/NCRR, South Carolina Translational Research Institute part of the NIH Clinical Translational Science Award Program [UL1 RR029880] FX Dr. Bonilha's effort on this project was supported by a career development award (NIH/NCRR grant No. UL1 RR029880) from the South Carolina Translational Research Institute part of the NIH Clinical Translational Science Award Program. NR 27 TC 8 Z9 10 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0179-051X EI 1432-0460 J9 DYSPHAGIA JI Dysphagia PD OCT PY 2014 VL 29 IS 5 BP 545 EP 552 DI 10.1007/s00455-014-9543-8 PG 8 WC Otorhinolaryngology SC Otorhinolaryngology GA AQ0TG UT WOS:000342495000003 PM 24948438 ER PT J AU Burke, RE Jones, J Ho, PM Bekelman, DB AF Burke, Robert E. Jones, Jacqueline Ho, P. Michael Bekelman, David B. TI Caregivers' Perceived Roles in Caring for Patients With Heart Failure: What Do Clinicians Need to Know? SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Caregiver; self-management; heart failure; qualitative ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; FAMILY CAREGIVERS; OLDER-ADULTS; INFORMAL CAREGIVERS; ALZHEIMERS-DISEASE; CARE; PROGRAM; HOME; INTERVENTION AB Background: Poor self-management of heart failure (HF) is an essential contributor to poor outcomes. Caregivers are involved in the care of HF patients, but caregiver interventions intended to improve the outcomes of patients have been largely unsuccessful. Improved knowledge of caregivers' desired roles in care may improve future interventions. Methods and Results: This qualitative study of 20 caregivers of BF patients recruited from an academic medical center used a general inductive approach, with insights from role theory, to analyze the data. Caregivers perceived themselves as health care managers and care plan enforcers, advocates for quality of life, and experts in the lived experience of HF at home. However, they encountered role strain (expectations of role exceed ability to perform role) and role conf